{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "\n",
    "from typing import List\n",
    "\n",
    "from collections import Counter\n",
    "from dataclasses import dataclass\n",
    "from dataclasses import field\n",
    "\n",
    "from nltk.tokenize import word_tokenize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "@dataclass\n",
    "class SentCounter:\n",
    "    lengths: Counter = field(default_factory=Counter)\n",
    "    punctuation_marks: Counter = field(default_factory=Counter)\n",
    "    brackets: Counter = field(default_factory=Counter)\n",
    "    long_sents: List = field(default_factory=list)\n",
    "    short_sents: List = field(default_factory=list)\n",
    "    many_punctuations: List = field(default_factory=list)\n",
    "    many_brackets: List = field(default_factory=list)\n",
    "    total: int = 0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "tagged_sent_path = os.path.join('data', 'tagged_sentences')\n",
    "\n",
    "sent_counter = SentCounter()\n",
    "\n",
    "for index in range(1, 1016):\n",
    "    s_i = str(index)\n",
    "    zeros = \"0\" * (4 - len(s_i))\n",
    "    tagged_sent_file = f\"tagged_pubmed20n{zeros + s_i}.json\"\n",
    "    file_path = os.path.join(tagged_sent_path, tagged_sent_file)\n",
    "    with open(file_path, \"r\") as json_file:\n",
    "        file_data = json.load(json_file)\n",
    "    #count = 0\n",
    "    for sent in file_data:\n",
    "        sent_token = word_tokenize(sent[\"sentence\"])\n",
    "        punctuation_marks = 0\n",
    "        number_brackets = 0\n",
    "        for token in sent_token:\n",
    "            if token in \"!;,?.-â€“\":\n",
    "                punctuation_marks += 1\n",
    "            if token in \"()[]{}\":\n",
    "                number_brackets += 1\n",
    "        sent_counter.lengths[f\"{len(sent_token)}\"] += 1\n",
    "        sent_counter.punctuation_marks[f\"{punctuation_marks}\"] += 1\n",
    "        sent_counter.brackets[f\"{number_brackets}\"] += 1\n",
    "        if len(sent_token) >= 200:\n",
    "            sent_counter.long_sents.append(sent)\n",
    "        if len(sent_token) <= 5:\n",
    "            sent_counter.short_sents.append(sent)\n",
    "        if punctuation_marks >= 100:\n",
    "            sent_counter.many_punctuations.append(sent)\n",
    "        if number_brackets >= 50:\n",
    "            sent_counter.many_brackets.append(sent)\n",
    "        sent_counter.total += 1\n",
    "        \n",
    "        #if count <= 1:\n",
    "        #    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"3\": 255,\n",
      "  \"4\": 827,\n",
      "  \"5\": 2145,\n",
      "  \"6\": 4735,\n",
      "  \"7\": 8280,\n",
      "  \"8\": 13107,\n",
      "  \"9\": 19596,\n",
      "  \"10\": 27588,\n",
      "  \"11\": 37387,\n",
      "  \"12\": 47439,\n",
      "  \"13\": 57660,\n",
      "  \"14\": 65820,\n",
      "  \"15\": 74065,\n",
      "  \"16\": 80999,\n",
      "  \"17\": 85405,\n",
      "  \"18\": 88700,\n",
      "  \"19\": 90850,\n",
      "  \"20\": 91936,\n",
      "  \"21\": 92302,\n",
      "  \"22\": 92505,\n",
      "  \"23\": 90599,\n",
      "  \"24\": 89519,\n",
      "  \"25\": 87609,\n",
      "  \"26\": 85590,\n",
      "  \"27\": 82909,\n",
      "  \"28\": 80645,\n",
      "  \"29\": 77904,\n",
      "  \"30\": 75328,\n",
      "  \"31\": 71557,\n",
      "  \"32\": 68073,\n",
      "  \"33\": 65488,\n",
      "  \"34\": 61974,\n",
      "  \"35\": 58401,\n",
      "  \"36\": 54517,\n",
      "  \"37\": 51577,\n",
      "  \"38\": 48399,\n",
      "  \"39\": 45246,\n",
      "  \"40\": 42432,\n",
      "  \"41\": 38701,\n",
      "  \"42\": 36266,\n",
      "  \"43\": 33578,\n",
      "  \"44\": 30872,\n",
      "  \"45\": 28460,\n",
      "  \"46\": 26915,\n",
      "  \"47\": 24412,\n",
      "  \"48\": 22806,\n",
      "  \"49\": 20685,\n",
      "  \"50\": 19060,\n",
      "  \"51\": 17450,\n",
      "  \"52\": 16167,\n",
      "  \"53\": 14862,\n",
      "  \"54\": 13549,\n",
      "  \"55\": 12315,\n",
      "  \"56\": 11530,\n",
      "  \"57\": 10713,\n",
      "  \"58\": 9863,\n",
      "  \"59\": 8976,\n",
      "  \"60\": 8300,\n",
      "  \"61\": 7708,\n",
      "  \"62\": 7147,\n",
      "  \"63\": 6368,\n",
      "  \"64\": 6062,\n",
      "  \"65\": 5511,\n",
      "  \"66\": 5150,\n",
      "  \"67\": 4792,\n",
      "  \"68\": 4410,\n",
      "  \"69\": 4261,\n",
      "  \"70\": 3713,\n",
      "  \"71\": 3494,\n",
      "  \"72\": 3265,\n",
      "  \"73\": 3000,\n",
      "  \"74\": 2900,\n",
      "  \"75\": 2685,\n",
      "  \"76\": 2496,\n",
      "  \"77\": 2316,\n",
      "  \"78\": 2154,\n",
      "  \"79\": 2024,\n",
      "  \"80\": 1809,\n",
      "  \"81\": 1750,\n",
      "  \"82\": 1714,\n",
      "  \"83\": 1493,\n",
      "  \"84\": 1414,\n",
      "  \"85\": 1398,\n",
      "  \"86\": 1257,\n",
      "  \"87\": 1165,\n",
      "  \"88\": 1121,\n",
      "  \"89\": 1034,\n",
      "  \"90\": 978,\n",
      "  \"91\": 953,\n",
      "  \"92\": 876,\n",
      "  \"93\": 773,\n",
      "  \"94\": 772,\n",
      "  \"95\": 749,\n",
      "  \"96\": 710,\n",
      "  \"97\": 651,\n",
      "  \"98\": 659,\n",
      "  \"99\": 562,\n",
      "  \"100\": 550,\n",
      "  \"101\": 529,\n",
      "  \"102\": 515,\n",
      "  \"103\": 444,\n",
      "  \"104\": 421,\n",
      "  \"105\": 390,\n",
      "  \"106\": 420,\n",
      "  \"107\": 343,\n",
      "  \"108\": 359,\n",
      "  \"109\": 317,\n",
      "  \"110\": 373,\n",
      "  \"111\": 322,\n",
      "  \"112\": 313,\n",
      "  \"113\": 251,\n",
      "  \"114\": 269,\n",
      "  \"115\": 282,\n",
      "  \"116\": 239,\n",
      "  \"117\": 204,\n",
      "  \"118\": 219,\n",
      "  \"119\": 191,\n",
      "  \"120\": 182,\n",
      "  \"121\": 182,\n",
      "  \"122\": 190,\n",
      "  \"123\": 171,\n",
      "  \"124\": 166,\n",
      "  \"125\": 167,\n",
      "  \"126\": 140,\n",
      "  \"127\": 149,\n",
      "  \"128\": 150,\n",
      "  \"129\": 150,\n",
      "  \"130\": 151,\n",
      "  \"131\": 106,\n",
      "  \"132\": 125,\n",
      "  \"133\": 116,\n",
      "  \"134\": 104,\n",
      "  \"135\": 110,\n",
      "  \"136\": 93,\n",
      "  \"137\": 98,\n",
      "  \"138\": 105,\n",
      "  \"139\": 86,\n",
      "  \"140\": 72,\n",
      "  \"141\": 79,\n",
      "  \"142\": 72,\n",
      "  \"143\": 65,\n",
      "  \"144\": 82,\n",
      "  \"145\": 66,\n",
      "  \"146\": 60,\n",
      "  \"147\": 69,\n",
      "  \"148\": 61,\n",
      "  \"149\": 54,\n",
      "  \"150\": 51,\n",
      "  \"151\": 55,\n",
      "  \"152\": 54,\n",
      "  \"153\": 60,\n",
      "  \"154\": 50,\n",
      "  \"155\": 36,\n",
      "  \"156\": 39,\n",
      "  \"157\": 45,\n",
      "  \"158\": 34,\n",
      "  \"159\": 34,\n",
      "  \"160\": 25,\n",
      "  \"161\": 42,\n",
      "  \"162\": 40,\n",
      "  \"163\": 34,\n",
      "  \"164\": 44,\n",
      "  \"165\": 37,\n",
      "  \"166\": 42,\n",
      "  \"167\": 31,\n",
      "  \"168\": 31,\n",
      "  \"169\": 24,\n",
      "  \"170\": 32,\n",
      "  \"171\": 25,\n",
      "  \"172\": 27,\n",
      "  \"173\": 32,\n",
      "  \"174\": 23,\n",
      "  \"175\": 22,\n",
      "  \"176\": 23,\n",
      "  \"177\": 25,\n",
      "  \"178\": 19,\n",
      "  \"179\": 28,\n",
      "  \"180\": 19,\n",
      "  \"181\": 22,\n",
      "  \"182\": 24,\n",
      "  \"183\": 11,\n",
      "  \"184\": 15,\n",
      "  \"185\": 18,\n",
      "  \"186\": 19,\n",
      "  \"187\": 21,\n",
      "  \"188\": 17,\n",
      "  \"189\": 14,\n",
      "  \"190\": 15,\n",
      "  \"191\": 15,\n",
      "  \"192\": 10,\n",
      "  \"193\": 10,\n",
      "  \"194\": 8,\n",
      "  \"195\": 13,\n",
      "  \"196\": 15,\n",
      "  \"197\": 14,\n",
      "  \"198\": 12,\n",
      "  \"199\": 7,\n",
      "  \"200\": 13,\n",
      "  \"201\": 8,\n",
      "  \"202\": 10,\n",
      "  \"203\": 9,\n",
      "  \"204\": 9,\n",
      "  \"205\": 6,\n",
      "  \"206\": 8,\n",
      "  \"207\": 5,\n",
      "  \"208\": 7,\n",
      "  \"209\": 8,\n",
      "  \"210\": 8,\n",
      "  \"211\": 10,\n",
      "  \"212\": 5,\n",
      "  \"213\": 7,\n",
      "  \"214\": 7,\n",
      "  \"215\": 9,\n",
      "  \"216\": 5,\n",
      "  \"217\": 14,\n",
      "  \"218\": 12,\n",
      "  \"219\": 5,\n",
      "  \"220\": 7,\n",
      "  \"221\": 5,\n",
      "  \"222\": 6,\n",
      "  \"223\": 2,\n",
      "  \"224\": 10,\n",
      "  \"225\": 6,\n",
      "  \"226\": 12,\n",
      "  \"227\": 6,\n",
      "  \"228\": 3,\n",
      "  \"229\": 2,\n",
      "  \"230\": 4,\n",
      "  \"231\": 6,\n",
      "  \"232\": 5,\n",
      "  \"233\": 4,\n",
      "  \"234\": 4,\n",
      "  \"235\": 9,\n",
      "  \"236\": 3,\n",
      "  \"237\": 3,\n",
      "  \"238\": 4,\n",
      "  \"239\": 1,\n",
      "  \"240\": 5,\n",
      "  \"241\": 4,\n",
      "  \"242\": 4,\n",
      "  \"243\": 2,\n",
      "  \"244\": 5,\n",
      "  \"245\": 6,\n",
      "  \"246\": 1,\n",
      "  \"247\": 4,\n",
      "  \"248\": 6,\n",
      "  \"249\": 3,\n",
      "  \"250\": 2,\n",
      "  \"252\": 2,\n",
      "  \"253\": 2,\n",
      "  \"254\": 1,\n",
      "  \"255\": 3,\n",
      "  \"256\": 1,\n",
      "  \"258\": 3,\n",
      "  \"259\": 4,\n",
      "  \"260\": 3,\n",
      "  \"262\": 1,\n",
      "  \"263\": 6,\n",
      "  \"264\": 1,\n",
      "  \"265\": 1,\n",
      "  \"266\": 1,\n",
      "  \"267\": 2,\n",
      "  \"268\": 1,\n",
      "  \"269\": 1,\n",
      "  \"270\": 2,\n",
      "  \"271\": 1,\n",
      "  \"272\": 2,\n",
      "  \"273\": 2,\n",
      "  \"274\": 8,\n",
      "  \"275\": 2,\n",
      "  \"276\": 5,\n",
      "  \"277\": 2,\n",
      "  \"279\": 1,\n",
      "  \"280\": 2,\n",
      "  \"281\": 3,\n",
      "  \"282\": 3,\n",
      "  \"283\": 3,\n",
      "  \"284\": 1,\n",
      "  \"287\": 1,\n",
      "  \"288\": 1,\n",
      "  \"291\": 1,\n",
      "  \"292\": 1,\n",
      "  \"293\": 1,\n",
      "  \"294\": 4,\n",
      "  \"295\": 2,\n",
      "  \"296\": 1,\n",
      "  \"297\": 1,\n",
      "  \"298\": 2,\n",
      "  \"299\": 1,\n",
      "  \"303\": 1,\n",
      "  \"304\": 3,\n",
      "  \"305\": 1,\n",
      "  \"306\": 2,\n",
      "  \"307\": 1,\n",
      "  \"308\": 1,\n",
      "  \"309\": 1,\n",
      "  \"310\": 1,\n",
      "  \"311\": 2,\n",
      "  \"313\": 2,\n",
      "  \"314\": 1,\n",
      "  \"316\": 2,\n",
      "  \"323\": 2,\n",
      "  \"325\": 2,\n",
      "  \"326\": 1,\n",
      "  \"328\": 1,\n",
      "  \"334\": 1,\n",
      "  \"338\": 2,\n",
      "  \"339\": 1,\n",
      "  \"342\": 1,\n",
      "  \"343\": 1,\n",
      "  \"344\": 1,\n",
      "  \"347\": 1,\n",
      "  \"350\": 1,\n",
      "  \"353\": 1,\n",
      "  \"357\": 1,\n",
      "  \"359\": 1,\n",
      "  \"363\": 1,\n",
      "  \"366\": 1,\n",
      "  \"370\": 1,\n",
      "  \"383\": 2,\n",
      "  \"391\": 1,\n",
      "  \"393\": 1,\n",
      "  \"395\": 1,\n",
      "  \"396\": 1,\n",
      "  \"410\": 1,\n",
      "  \"413\": 1,\n",
      "  \"414\": 1,\n",
      "  \"418\": 1,\n",
      "  \"422\": 1,\n",
      "  \"434\": 1,\n",
      "  \"442\": 1,\n",
      "  \"450\": 1,\n",
      "  \"456\": 1,\n",
      "  \"470\": 1,\n",
      "  \"486\": 1,\n",
      "  \"497\": 1,\n",
      "  \"528\": 1,\n",
      "  \"533\": 1,\n",
      "  \"573\": 1,\n",
      "  \"611\": 1,\n",
      "  \"619\": 1,\n",
      "  \"700\": 1,\n",
      "  \"945\": 1\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "sent_length = {int(key): val for key, val in sent_counter.lengths.items()}\n",
    "print(json.dumps(sent_length, indent=2, sort_keys=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"0\": 2343,\n",
      "  \"1\": 1246927,\n",
      "  \"2\": 585424,\n",
      "  \"3\": 415901,\n",
      "  \"4\": 214316,\n",
      "  \"5\": 114698,\n",
      "  \"6\": 62459,\n",
      "  \"7\": 35638,\n",
      "  \"8\": 21071,\n",
      "  \"9\": 12695,\n",
      "  \"10\": 8338,\n",
      "  \"11\": 5346,\n",
      "  \"12\": 3729,\n",
      "  \"13\": 2497,\n",
      "  \"14\": 1732,\n",
      "  \"15\": 1232,\n",
      "  \"16\": 878,\n",
      "  \"17\": 666,\n",
      "  \"18\": 534,\n",
      "  \"19\": 377,\n",
      "  \"20\": 314,\n",
      "  \"21\": 230,\n",
      "  \"22\": 173,\n",
      "  \"23\": 139,\n",
      "  \"24\": 116,\n",
      "  \"25\": 100,\n",
      "  \"26\": 55,\n",
      "  \"27\": 48,\n",
      "  \"28\": 42,\n",
      "  \"29\": 47,\n",
      "  \"30\": 29,\n",
      "  \"31\": 29,\n",
      "  \"32\": 23,\n",
      "  \"33\": 21,\n",
      "  \"34\": 15,\n",
      "  \"35\": 14,\n",
      "  \"36\": 11,\n",
      "  \"37\": 11,\n",
      "  \"38\": 7,\n",
      "  \"39\": 4,\n",
      "  \"40\": 11,\n",
      "  \"41\": 5,\n",
      "  \"42\": 4,\n",
      "  \"43\": 4,\n",
      "  \"44\": 5,\n",
      "  \"45\": 4,\n",
      "  \"46\": 1,\n",
      "  \"47\": 3,\n",
      "  \"48\": 5,\n",
      "  \"49\": 4,\n",
      "  \"50\": 2,\n",
      "  \"51\": 2,\n",
      "  \"52\": 1,\n",
      "  \"54\": 1,\n",
      "  \"55\": 4,\n",
      "  \"56\": 3,\n",
      "  \"58\": 3,\n",
      "  \"59\": 1,\n",
      "  \"61\": 1,\n",
      "  \"63\": 2,\n",
      "  \"64\": 3,\n",
      "  \"72\": 1,\n",
      "  \"75\": 1,\n",
      "  \"82\": 1,\n",
      "  \"84\": 1,\n",
      "  \"87\": 1,\n",
      "  \"88\": 1,\n",
      "  \"91\": 2,\n",
      "  \"93\": 1,\n",
      "  \"97\": 1,\n",
      "  \"106\": 1,\n",
      "  \"108\": 2,\n",
      "  \"110\": 1,\n",
      "  \"112\": 1,\n",
      "  \"114\": 1,\n",
      "  \"115\": 1,\n",
      "  \"116\": 1,\n",
      "  \"117\": 2,\n",
      "  \"118\": 1,\n",
      "  \"120\": 2,\n",
      "  \"122\": 1,\n",
      "  \"129\": 1,\n",
      "  \"132\": 1,\n",
      "  \"140\": 1,\n",
      "  \"141\": 1,\n",
      "  \"143\": 1,\n",
      "  \"145\": 1,\n",
      "  \"149\": 1,\n",
      "  \"153\": 1,\n",
      "  \"159\": 1,\n",
      "  \"162\": 1,\n",
      "  \"166\": 1,\n",
      "  \"169\": 1,\n",
      "  \"185\": 1,\n",
      "  \"241\": 1\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "sent_punctuations = {int(key): val for key, val in sent_counter.punctuation_marks.items()}\n",
    "print(json.dumps(sent_punctuations, indent=2, sort_keys=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"0\": 1757332,\n",
      "  \"1\": 8970,\n",
      "  \"2\": 523738,\n",
      "  \"3\": 4428,\n",
      "  \"4\": 230344,\n",
      "  \"5\": 2353,\n",
      "  \"6\": 103308,\n",
      "  \"7\": 1365,\n",
      "  \"8\": 49235,\n",
      "  \"9\": 886,\n",
      "  \"10\": 23794,\n",
      "  \"11\": 512,\n",
      "  \"12\": 12807,\n",
      "  \"13\": 287,\n",
      "  \"14\": 6966,\n",
      "  \"15\": 211,\n",
      "  \"16\": 4044,\n",
      "  \"17\": 150,\n",
      "  \"18\": 2535,\n",
      "  \"19\": 79,\n",
      "  \"20\": 1526,\n",
      "  \"21\": 57,\n",
      "  \"22\": 956,\n",
      "  \"23\": 56,\n",
      "  \"24\": 664,\n",
      "  \"25\": 35,\n",
      "  \"26\": 444,\n",
      "  \"27\": 27,\n",
      "  \"28\": 317,\n",
      "  \"29\": 17,\n",
      "  \"30\": 186,\n",
      "  \"31\": 7,\n",
      "  \"32\": 135,\n",
      "  \"33\": 13,\n",
      "  \"34\": 118,\n",
      "  \"35\": 3,\n",
      "  \"36\": 94,\n",
      "  \"37\": 4,\n",
      "  \"38\": 42,\n",
      "  \"39\": 7,\n",
      "  \"40\": 53,\n",
      "  \"41\": 6,\n",
      "  \"42\": 29,\n",
      "  \"43\": 3,\n",
      "  \"44\": 34,\n",
      "  \"45\": 3,\n",
      "  \"46\": 18,\n",
      "  \"47\": 1,\n",
      "  \"48\": 26,\n",
      "  \"49\": 1,\n",
      "  \"50\": 16,\n",
      "  \"51\": 3,\n",
      "  \"52\": 13,\n",
      "  \"54\": 12,\n",
      "  \"55\": 2,\n",
      "  \"56\": 7,\n",
      "  \"58\": 8,\n",
      "  \"60\": 6,\n",
      "  \"62\": 5,\n",
      "  \"64\": 4,\n",
      "  \"65\": 1,\n",
      "  \"66\": 3,\n",
      "  \"68\": 3,\n",
      "  \"69\": 1,\n",
      "  \"70\": 4,\n",
      "  \"71\": 1,\n",
      "  \"72\": 4,\n",
      "  \"74\": 1,\n",
      "  \"76\": 1,\n",
      "  \"78\": 1,\n",
      "  \"80\": 3,\n",
      "  \"84\": 1,\n",
      "  \"88\": 2,\n",
      "  \"92\": 1,\n",
      "  \"96\": 1,\n",
      "  \"98\": 1,\n",
      "  \"102\": 1,\n",
      "  \"112\": 2,\n",
      "  \"126\": 1,\n",
      "  \"162\": 1\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "sent_brackets = {int(key): val for key, val in sent_counter.brackets.items()}\n",
    "print(json.dumps(sent_brackets, indent=2, sort_keys=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2738336"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sent_counter.total"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': 12087878,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abiciximab, acetylcholine chloride, acetylcysteine, alefacept, alemtuzumab, alicaforsen, alteplase, aminopterin, amoxicillin sodium, amphotericin B, anastrozole, argatroban monohydrate, arsenic trioxide, aspirin, atazanavir, atorvastatin, augmerosen, azathioprine; Benzylpenicillin, BMS-284756, botulinum toxin type A, botulinum toxin type B, BQ-123, budesonide, BXT-51072; Calcium folinate, carbamazepine, carboplatin, carmustine, ceftriaxone sodium, cefuroxime axetil, chorionic gonadotropin (human), cimetidine, ciprofloxacin hydrochloride, cisplatin, citalopram hydrobromide, cladribine, clarithromycin, clavulanic acid, clofarabine, clopidogrel hydrogensulfate, clotrimazole, CNI-1493, colesevelam hydrochloride, cyclophosphamide, cytarabine; Dalteparin sodium, daptomycin, darbepoetin alfa, debrisoquine sulfate, dexrazoxane, diaziquone, didanosine, docetaxel, donezepil, doxorubicin hydrochloride liposome injection, DX-9065a; Eberconazole, ecogramostim, eletriptan, enoxaparin sodium, epoetin, epoprostenol sodium, erlizumab, ertapenem sodium, ezetimibe; Fampridine, fenofibrate, filgrastim, fluconazole, fludarabine phosphate, fluorouracil, 5-fluorouracil/epinephrine, fondaparinux sodium, formoterol fumarate; Gabapentin, gemcitabine, gemfibrozil, glatiramer; Heparin sodium, homoharringtonine; Ibuprofen, iloprost, imatinib mesilate, imiquimod, interferon alpha-2b, interferon alpha-2c, interferon-beta; KW-6002; Lamotrigine, lanoteplase, metoprolol tartrate, mitoxantrone hydrochloride; Naproxen sodium, naratriptan, Natalizumab, nelfinavir mesilate, nevirapine, nifedipine, NSC-683864; Oral heparin; Paclitaxel, peginterferon alfa-2b, phenytoin, pimecrolimus, piperacillin, pleconaril, pramipexole hydrochloride, prednisone, pregabalin, progesterone; Rasburicase, ravuconazole, reteplase, ribavirin, rituximab, rizatriptan, rosiglitazone maleate, rotigotine; Semaxanib, sildenafil citrate, simvastatin, stavudine, sumatriptan; Tacrolimus, tamoxifen citrate, tanomastat, tazobactam, telithromycin, tenecteplase, tolafentrine, tolterodine tartrate, triamcinolone acetonide, trimetazidine, troxacitabine; Valproic acid, vancomycin hydrochloride, vincristine, voriconazole, Warfarin sodium; Ximelagatran, Zidovudine, zolmitriptan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['daptomycin',\n",
       "   'natalizumab',\n",
       "   'zolmitriptan',\n",
       "   'clofarabine',\n",
       "   'nelfinavir',\n",
       "   'amoxicillin',\n",
       "   'eletriptan',\n",
       "   'cytarabine',\n",
       "   'rituximab',\n",
       "   'mitoxantrone',\n",
       "   'alteplase',\n",
       "   'fluorouracil',\n",
       "   'gemcitabine',\n",
       "   'carboplatin',\n",
       "   'cimetidine',\n",
       "   'telithromycin',\n",
       "   'ertapenem',\n",
       "   'tenecteplase',\n",
       "   'cladribine',\n",
       "   'imiquimod',\n",
       "   'triamcinolone',\n",
       "   'zidovudine',\n",
       "   'epoetin',\n",
       "   'anastrozole',\n",
       "   'stavudine',\n",
       "   'argatroban',\n",
       "   'fludarabine',\n",
       "   'benzylpenicillin',\n",
       "   'paclitaxel',\n",
       "   'darbepoetin',\n",
       "   'pimecrolimus',\n",
       "   'piperacillin',\n",
       "   'docetaxel',\n",
       "   'clopidogrel',\n",
       "   'simvastatin',\n",
       "   'voriconazole',\n",
       "   'nifedipine',\n",
       "   'enoxaparin',\n",
       "   'tacrolimus',\n",
       "   'imatinib',\n",
       "   'sumatriptan',\n",
       "   'sodium',\n",
       "   'tazobactam',\n",
       "   'ibuprofen',\n",
       "   'phenytoin',\n",
       "   'cisplatin',\n",
       "   'heparin',\n",
       "   'fluconazole',\n",
       "   'glatiramer',\n",
       "   'ciprofloxacin',\n",
       "   'vancomycin',\n",
       "   'clarithromycin',\n",
       "   'fenofibrate',\n",
       "   'tamoxifen',\n",
       "   'atorvastatin',\n",
       "   'calcium',\n",
       "   'carmustine',\n",
       "   'rizatriptan',\n",
       "   'acetonide',\n",
       "   'rosiglitazone',\n",
       "   'metoprolol',\n",
       "   'alefacept',\n",
       "   'dalteparin',\n",
       "   'naratriptan',\n",
       "   'doxorubicin',\n",
       "   'sildenafil',\n",
       "   'alemtuzumab',\n",
       "   'formoterol',\n",
       "   'atazanavir',\n",
       "   'fondaparinux',\n",
       "   'budesonide',\n",
       "   'filgrastim'],\n",
       "  'reaction': ['injection', 'progesterone']},\n",
       " {'pmid': 12092009,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, acarbose, alefacept, alteplase, amisulpride, amoxicillin trihydrate, apomorphine hydrochloride, aprepitant, argatroban monohydrate, aspirin, atenolol; Betamethasone dipropionate, betamethasone valerate, bicalutamide, bleomycin sulfate; Calcium carbonate, candesartan cilexetil, celecoxib, cetirizine hydrochloride, cisplatin, clarithromycin, clavulanate potassium, clomethiazole edisilate, clopidogrel hydrogensulfate, cyclophosphamide, chorionic gonadotropin (human); Dalteparin sodium, desloratadine, dexamethasone, doxorubicin, DPC-083; Efalizumab, efavirenz, enoxaparin sodium, eprosartan mesilate, etanercept, etoposide, ezetimibe; Faropenem daloxate, fenofibrate, fluocinolone acetonide, flutamide, fluvastatin sodium, follitropin beta, fondaparinux sodium; Gabapentin, glibenclamide, goserelin, granisetron hydrochloride; Haloperidol, hydrochlorothiazide; Imiquimod, interferon beta-1a, irbesartan, iseganan hydrochloride; L-758298, lamivudine, lanoteplase, leflunomide, leuprorelin acetate, loratadine, losartan potassium; Melagatran, metformin hydrochloride, methotrexate, metronidazole, micafungin sodium, mitoxantrone hydrochloride; Nelfinavir mesilate, neutral insulin injection, nizatidine; Olopatadine hydrochloride, omeprazole, ondansetron hydrochloride; Pamidronate sodium, paracetamol, paroxetine hydrochloride, perindopril, pimecrolimus, pioglitazone hydrochloride, piroxicam, pleconaril, pralmorelin, pravastatin sodium, prednisolone, prednisone, propofol; Raloxifene hydrochloride, ranpirnase, remifentanil hydrochloride, risedronate sodium, risperidone, rofecoxib, ropinirole hydrochloride, rosuvastatin calcium; Sevoflurane, sildenafil citrate, simvastatin, somatropin; Tacrolimus, tamoxifen citrate, telmisartan, temozolomide, thiopental sodium, tinzaparin sodium, tirofiban hydrochloride, treosulfan, triamcinolone acetonide; Urokinase; Valsartan, vardenafil, vincristine; Warfarin sodium; Ximelagatran; Zidovudine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['prednisolone',\n",
       "   'candesartan',\n",
       "   'ondansetron',\n",
       "   'aprepitant',\n",
       "   'nizatidine',\n",
       "   'imiquimod',\n",
       "   'zidovudine',\n",
       "   'rofecoxib',\n",
       "   'simvastatin',\n",
       "   'haloperidol',\n",
       "   'sodium',\n",
       "   'treosulfan',\n",
       "   'bicalutamide',\n",
       "   'fenofibrate',\n",
       "   'methotrexate',\n",
       "   'efavirenz',\n",
       "   'tirofiban',\n",
       "   'piroxicam',\n",
       "   'loratadine',\n",
       "   'celecoxib',\n",
       "   'atenolol',\n",
       "   'dalteparin',\n",
       "   'sildenafil',\n",
       "   'granisetron',\n",
       "   'micafungin',\n",
       "   'losartan',\n",
       "   'fluvastatin',\n",
       "   'lamivudine',\n",
       "   'risedronate',\n",
       "   'nelfinavir',\n",
       "   'alteplase',\n",
       "   'efalizumab',\n",
       "   'olopatadine',\n",
       "   'metronidazole',\n",
       "   'triamcinolone',\n",
       "   'leuprorelin',\n",
       "   'paroxetine',\n",
       "   'clopidogrel',\n",
       "   'bleomycin',\n",
       "   'sevoflurane',\n",
       "   'acetonide',\n",
       "   'alefacept',\n",
       "   'valsartan',\n",
       "   'amoxicillin',\n",
       "   'abacavir',\n",
       "   'rosuvastatin',\n",
       "   'argatroban',\n",
       "   'pimecrolimus',\n",
       "   'enoxaparin',\n",
       "   'eprosartan',\n",
       "   'tacrolimus',\n",
       "   'cisplatin',\n",
       "   'potassium',\n",
       "   'clarithromycin',\n",
       "   'tamoxifen',\n",
       "   'fluocinolone',\n",
       "   'vardenafil',\n",
       "   'goserelin',\n",
       "   'tinzaparin',\n",
       "   'omeprazole',\n",
       "   'fondaparinux',\n",
       "   'etanercept',\n",
       "   'raloxifene',\n",
       "   'desloratadine',\n",
       "   'pamidronate',\n",
       "   'telmisartan',\n",
       "   'metformin',\n",
       "   'mitoxantrone',\n",
       "   'perindopril',\n",
       "   'pioglitazone',\n",
       "   'hydrochlorothiazide',\n",
       "   'pravastatin',\n",
       "   'flutamide',\n",
       "   'risperidone',\n",
       "   'calcium',\n",
       "   'doxorubicin',\n",
       "   'amisulpride',\n",
       "   'remifentanil',\n",
       "   'irbesartan'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 14571286,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abetimus sodium, adefovir dipivoxil, AGI-1067, alefacept, alemtuzumab, ALVAC-p53, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, Anti-CTLA-4 Mab, AOD-9604, apafant, aprinocarsen sodium, arsenic trioxide; Balaglitazone, BIM-23190, bimatoprost, bortezomib, bosentan, BR-1; Canertinib dihydrochloride, CDP-850, cevimeline hydrochloride, cinacalcet hydrochloride, clenoliximab, clevudine, CN-787; D-003, darusentan, deferasirox, desloratadine dexanabinol, duloxetine hydrochloride; E-5564, edaravone, efaproxiral sodium, elvucitabine emfilermin, EN-101, enfuvirtide, entecavir, epithalon, eplerenone, erlotinib hydrochloride, escitalopram oxalate, esomeprazole magnesium, eszopiclone, etilefrine pivalate hydrochloride etoricoxib, everolimus, exenatide; Fidarestat, fondaparinux sodium; Ganstigmine hydrochloride; Homoharringtonine, HuMax-IL-15, hyperimmune IVIG; Imatinib mesylate, IMC-1C11, Inhaled insulin, irofulven, iseganan hydrochloride, ISIS-14803, ISIS-5132, ivabradine hydrochloride; Keratinocyte growth factor; Lafutidine, lanthanum carbonate, LAS-34475, levocetirizine, liraglutide, LY-307161 SR; Magnesium sulfate, maribavir, melatonin, mycobacterium cell wall complex; NN-414, NO-aspirin, nociceptin, nolomirole hydrochloride; Olmesartan medoxomil oral insulin, ospemifene; PDX, perillyl alcohol, pimecrolimus, pitavastatin calcium, pramlintide acetate, prasterone, pregabalin, PRO-542, PV-701, pyrazoloacridine; R-744, ranelic acid distrontium salt, rasburicase, rDNA insulin, resiniferatoxin, reslizumab, ridogrel, riplizumab ropivacaine, rosuvastatin calcium, roxifiban acetate, ruboxistaurin mesilate hydrate; Satraplatin, Sch-58500, semaxanib, sitaxsentan sodium, SMP-114, SU-6668; Teriparatide, tetrathiomolybdate, tipifarnib, tolvaptan, travoprost, treprostinil sodium; Valdecoxib, valganciclovir hydrochloride, vardenafil hydrochloride hydrate, vatalanib succinate; Ximelagatran; Z-335, ziprasidone hydrochloride, zoledronic acid monohydrate, ZYC-00101.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bimatoprost',\n",
       "   'erlotinib',\n",
       "   'eszopiclone',\n",
       "   'vardenafil',\n",
       "   'eplerenone',\n",
       "   'sodium',\n",
       "   'valganciclovir',\n",
       "   'olmesartan',\n",
       "   'treprostinil',\n",
       "   'calcium',\n",
       "   'exenatide',\n",
       "   'desloratadine',\n",
       "   'bosentan',\n",
       "   'duloxetine',\n",
       "   'bortezomib',\n",
       "   'enfuvirtide',\n",
       "   'pitavastatin',\n",
       "   'magnesium',\n",
       "   'reslizumab',\n",
       "   'alefacept',\n",
       "   'alemtuzumab',\n",
       "   'ropivacaine',\n",
       "   'entecavir',\n",
       "   'lafutidine',\n",
       "   'tolvaptan',\n",
       "   'liraglutide',\n",
       "   'esomeprazole',\n",
       "   'rosuvastatin',\n",
       "   'imatinib',\n",
       "   'everolimus',\n",
       "   'teriparatide',\n",
       "   'travoprost',\n",
       "   'fondaparinux',\n",
       "   'valdecoxib',\n",
       "   'cinacalcet',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 14988742,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaforsen sodium, almotriptan, alpharadin, anakinra, anatumomab mafenatox, ANG-453, anti-CTLA-4 Mab, AP-12009, aprepitant, aripiprazole, arsenic trioxide, astemizole, atlizumab, atomoxetine hydrochloride; Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; Caffeine, CDP-870, cetuximab, cilomilast, ciluprevir, clofarabine, continuous erythropoiesis receptor activator, CP-461; Darbepoetin alfa, deferasirox, desloratadine, desoxyepothilone B, diflomotecan, dolasetron, drotrecogin alfa (activated), duloxetine hydrochloride; ED-71, efalizumab, efaproxiral sodium, EKB-569, eletriptan, EMD-72000, enfuvirtide, erlotinib hydrochloride, escitalopram oxalate, etoricoxib; Fampridine, ferumoxytol, fondaparinux sodium; Gadofosveset sodium, gastrazole, gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride glutamine; hLM609, HSPPC-96, human insulin; IDD-1, imatinib mesylate, indisulam, inhaled insulin, ixabepilone; Keratinocyte growth factor; Lapatinib, laquinimod, LDP-02, LE-SN38, levetiracetam, levosimendan, licofelone, liposomal doxorubicin, liposomal NDDP, lopinavir, lumiracoxib, LY-156735; Morphine hydrochloride, morphine-6-glucuronide, motexafin gadolinium, MS-27-275, MVA-5T4, MVA-Muc1-IL-2; Nemifitide ditriflutate, neridronic acid nitronaproxen, NSC-683864, NSC-703940, NVP-LAF-237; Oblimersen sodium, ocinaplon, oncomyc-NG, OPC-28326, ortataxel, ospemifene; Palonosetron hydrochloride, PEG-filgrastim peginterferon alfa-2(a), peginterferon alfa-2b, pegsunercept, pemetrexed disodium, pregabalin, prilocaine, pyridoxamine; RDP-58, recombinant glucagon-like peptide-1 (7-36) amide, recombinant human ApoA-I milano/phospholipid complex; SB-715992, soblidotin, sodium dichloroacetate, St. John's Wort extract; TAS-102, terfenadine, TG-1024, TG-5001, 4'-Thio-ara-C, tipranavir, topixantrone hydrochloride, trabectedin, transdermal selegiline, trimethoprim, troxacitabine, TT-232; Vatalanib succinate, vinflunine; Ximelagatran; Ziprasidone hydrochloride, Zoledronic acid monohydrate.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['erlotinib',\n",
       "   'clofarabine',\n",
       "   'sodium',\n",
       "   'trimethoprim',\n",
       "   'levetiracetam',\n",
       "   'efalizumab',\n",
       "   'lapatinib',\n",
       "   'gemtuzumab',\n",
       "   'selegiline',\n",
       "   'desloratadine',\n",
       "   'doxorubicin',\n",
       "   'duloxetine',\n",
       "   'enfuvirtide',\n",
       "   'palonosetron',\n",
       "   'anakinra',\n",
       "   'alemtuzumab',\n",
       "   'aripiprazole',\n",
       "   'ozogamicin',\n",
       "   'eletriptan',\n",
       "   'dolasetron',\n",
       "   'imatinib',\n",
       "   'prilocaine',\n",
       "   'aprepitant',\n",
       "   'tipranavir',\n",
       "   'darbepoetin',\n",
       "   'lopinavir',\n",
       "   'fondaparinux',\n",
       "   'cetuximab',\n",
       "   'atomoxetine',\n",
       "   'bevacizumab',\n",
       "   'pemetrexed',\n",
       "   'almotriptan',\n",
       "   'trabectedin',\n",
       "   'gefitinib',\n",
       "   'disodium',\n",
       "   'gadolinium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 15071612,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, l-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, Bi-20, binodenoson, biphasic insulin aspart, bivatuzumab, 186Re-bivatuzumab, BMS-181176, bosentan, botulinum toxin type B, BQ-123, bryostatin 1; Carboxy- amidotriazole, caspofungin acetate, CB-1954, CC-4047, CDP-860, cerivastatin sodium, clevidipine, CTL-102; 3,4-DAP, darbepoetin alfa, decitabine, desloratadine, DHA-paclitaxel, duloxetine hydrochloride; Efalizumab, EGF vaccine, eletriptan, eniluracil, ENMD-0997, eplerenone, eplivanserin, erlosamide, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, eszopiclone, everolimus, exatecan mesilate, exenatide, ezetimibe; Fondaparinux sodium, FR-901228, FTY-720; Gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride; Hexyl insulin M2, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, iodine (I131) tositumomab, ISV-205, ivabradine hydrochloride, ixabepilone; Levetiracetam, levocetirizine, linezolid, liposomal NDDP, lonafarnib, lopinavir, LY-156735; Mafosfamide cyclohexylamine salt, magnesium sulfate, maxacalcitol, meclinertant, melagatran, melatonin, MENT, mepolizumab, micafungin sodium, midostaurin, motexafin gadolinium; Nesiritide, NS-1209, NSC-601316, NSC-683864; Osanetant; Palonosetron hydrochloride, parecoxib sodium, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, pemetrexed disodium, perillyl alcohol, picoplatin, pimecrolimus, pixantrone maleate, plevitrexed, polyglutamate paclitaxel, posurdex, pramlintide acetate, prasterone, pregabalin; Rasburicase, rimonabant hydrochloride, rostaporfin, rosuvastatin calcium; SDZ-SID-791, sibrotuzumab, sorafenib, SU-11248; Tadalafil, targinine, tegaserod maleate, telithromycin, TheraCIM, tigecycline, tiotropium bromide, tipifarnib, tirapazamine, treprostinil sodium; Valdecoxib, Valganciclovir hydrochloride, Vardenafil hydrochloride hydrate; Ximelagatran; Zofenopril calcium, Zoledronic acid monohydrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tadalafil',\n",
       "   'eszopiclone',\n",
       "   'cerivastatin',\n",
       "   'eplerenone',\n",
       "   'vardenafil',\n",
       "   'sodium',\n",
       "   'micafungin',\n",
       "   'levetiracetam',\n",
       "   'efalizumab',\n",
       "   'valganciclovir',\n",
       "   'gemtuzumab',\n",
       "   'treprostinil',\n",
       "   'exenatide',\n",
       "   'calcium',\n",
       "   'desloratadine',\n",
       "   'ertapenem',\n",
       "   'tegaserod',\n",
       "   'bosentan',\n",
       "   'duloxetine',\n",
       "   'mepolizumab',\n",
       "   'magnesium',\n",
       "   'parecoxib',\n",
       "   'palonosetron',\n",
       "   'alemtuzumab',\n",
       "   'aripiprazole',\n",
       "   'ozogamicin',\n",
       "   'caspofungin',\n",
       "   'eletriptan',\n",
       "   'esomeprazole',\n",
       "   'rosuvastatin',\n",
       "   'imatinib',\n",
       "   'everolimus',\n",
       "   'aprepitant',\n",
       "   'paclitaxel',\n",
       "   'darbepoetin',\n",
       "   'tiotropium',\n",
       "   'lopinavir',\n",
       "   'fondaparinux',\n",
       "   'valdecoxib',\n",
       "   'tigecycline',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'pemetrexed',\n",
       "   'telithromycin',\n",
       "   'linezolid',\n",
       "   'gefitinib',\n",
       "   'disodium',\n",
       "   'gadolinium'],\n",
       "  'reaction': ['protein c']},\n",
       " {'pmid': 15319815,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol; Valganciclovir hydrochloride, val-mCyd, vardenafil hydrochloride hydrate, vinflunine, voriconazole; Ximelagatran, XTL-002; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gefitinib',\n",
       "   'desloratadine',\n",
       "   'calcium',\n",
       "   'duloxetine',\n",
       "   'voriconazole',\n",
       "   'lopinavir',\n",
       "   'galiximab',\n",
       "   'azimilide',\n",
       "   'treprostinil',\n",
       "   'sodium',\n",
       "   'telithromycin',\n",
       "   'darbepoetin',\n",
       "   'enfuvirtide',\n",
       "   'tadalafil',\n",
       "   'travoprost',\n",
       "   'alemtuzumab',\n",
       "   'vardenafil',\n",
       "   'parecoxib',\n",
       "   'omalizumab',\n",
       "   'efalizumab',\n",
       "   'fosamprenavir',\n",
       "   'alefacept',\n",
       "   'natalizumab',\n",
       "   'adalimumab',\n",
       "   'tolvaptan',\n",
       "   'frovatriptan',\n",
       "   'bortezomib',\n",
       "   'ertapenem',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'valganciclovir',\n",
       "   'tipranavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'caspofungin',\n",
       "   'dutasteride',\n",
       "   'emtricitabine',\n",
       "   'everolimus',\n",
       "   'doxorubicin',\n",
       "   'rosuvastatin',\n",
       "   'nelfinavir'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 15349141,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: ABI-007, Ad.Egr.TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['aliskiren',\n",
       "   'gefitinib',\n",
       "   'rasagiline',\n",
       "   'teriparatide',\n",
       "   'calcium',\n",
       "   'duloxetine',\n",
       "   'anakinra',\n",
       "   'ciclesonide',\n",
       "   'ramelteon',\n",
       "   'conivaptan',\n",
       "   'lopinavir',\n",
       "   'treprostinil',\n",
       "   'trabectedin',\n",
       "   'sodium',\n",
       "   'reslizumab',\n",
       "   'darbepoetin',\n",
       "   'travoprost',\n",
       "   'alemtuzumab',\n",
       "   'vardenafil',\n",
       "   'efalizumab',\n",
       "   'alefacept',\n",
       "   'eculizumab',\n",
       "   'palonosetron',\n",
       "   'aprepitant',\n",
       "   'tolvaptan',\n",
       "   'exenatide',\n",
       "   'bortezomib',\n",
       "   'gamma-globulin',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'eletriptan',\n",
       "   'clofarabine',\n",
       "   'atazanavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'bimatoprost',\n",
       "   'telbivudine',\n",
       "   'caspofungin',\n",
       "   'everolimus',\n",
       "   'rosuvastatin',\n",
       "   'erlotinib'],\n",
       "  'reaction': ['prostate cancer']},\n",
       " {'pmid': 15538546,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 101M, 166Ho-DOTMP, 3-AP; Abatacept, abetimus sodium, ACR-16, adefovir dipivoxil, alefacept, AMD-070, aminolevulinic acid hexyl ester, anatumomab mafenatox, anti-CTLA-4 MAb, antigastrin therapeutic vaccine, AP-12009, AP-23573, APC-8024, aripiprazole, ATL-962, atomoxetine hydrochloride; Bevacizumab, bimatoprost, bortezomib, bosentan, BR-1; Calcipotriol/betamethasone dipropionate, cinacalcet hydrochloride, clofazimine, colchicine, cold-adapted influenza vaccine trivalent, CRM197; Desloratadine, desoxyepothilone B, diethylhomospermine; Edodekin alfa, efalizumab, elcometrine, eletriptan, enfuvirtide, entecavir, EP-2101, eplerenone, erlotinib hydrochloride, etoricoxib, everolimus, exherin, ezetimibe; Febuxostat, fluorescein lisicol, fosamprenavir calcium, frovatriptan; Hemoglobin raffimer, HSPPC-96, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, IRX-2, istradefylline, IV gamma-globulin, ixabepilone; Kahalalide F; L-759274, levodopa/carbidopa/entacapone, licofelone, lonafarnib, lopinavir, lurtotecan, LY-156735; MAb G250, mecasermin, melatonin, midostaurin, muraglitazar; Nesiritide, nitronaproxen; O6-Benzylguanine, olmesartan medoxomil, olmesartan medoxomil/hydrochlorothiazide, omapatrilat, oral insulin; Parecoxib sodium, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, pemetrexed disodium, peptide YY3-36, PG-CPT, phenoxodiol, pimecrolimus, posaconazole; Rasagiline mesilate, rDNA insulin, RG228, rimonabant hydrochloride, rosuvastatin calcium, rotigotine hydrochloride; S-3304, safinamide mesilate, salcaprozic acid sodium salt, SDZ-SID-791, SGN-30, soblidotin, squalamine; Telmisartan/hydrochlorothiazide, testosterone gel, TF(c)-KLH conjugate vaccine, TH-9507, theraloc, tipifarnib, tocilizumab, travoprost; ValboroPro, valdecoxib, veglin, voriconazole; Ximelagatran.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rasagiline',\n",
       "   'desloratadine',\n",
       "   'abatacept',\n",
       "   'calcium',\n",
       "   'cinacalcet',\n",
       "   'voriconazole',\n",
       "   'lopinavir',\n",
       "   'pemetrexed',\n",
       "   'sodium',\n",
       "   'peptide',\n",
       "   'enfuvirtide',\n",
       "   'travoprost',\n",
       "   'atomoxetine',\n",
       "   'parecoxib',\n",
       "   'olmesartan',\n",
       "   'efalizumab',\n",
       "   'fosamprenavir',\n",
       "   'alefacept',\n",
       "   'aripiprazole',\n",
       "   'frovatriptan',\n",
       "   'bortezomib',\n",
       "   'gamma-globulin',\n",
       "   'tocilizumab',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'bevacizumab',\n",
       "   'eletriptan',\n",
       "   'entecavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'bimatoprost',\n",
       "   'valdecoxib',\n",
       "   'eplerenone',\n",
       "   'everolimus',\n",
       "   'rosuvastatin',\n",
       "   'posaconazole',\n",
       "   'erlotinib'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 15834459,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs:[188Re]-HDD; A-179578, adalimumab, AK-602, albumin interferon alfa, alfimeprase, amelubant, anakinra, anti-CD2 MAb, APD-356, aripiprazole, atvogen; Bimatoprost, bimosiamose, BLP-25, brivaracetam; Caspofungin acetate, cilansetron, CMV vaccine (bivalent), conivaptan hydrochloride, Cypher; Darbepoetin alfa, darifenacin hydrobromide, D-D4FC, decitabine, dnaJP1, doranidazole, dronedarone hydrochloride; Efalizumab, efaproxiral sodium, emtricitabine, Endeavor, entecavir, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, etravirine, ezetimibe; Fampridine, fenretinide, ferumoxtran-10, forodesine hydrochloride; Gantacurium chloride, gemi-floxacin mesilate, Glyminox, GW-501516; HBV-ISS, hepavir B, human insulin, HuMax-CD20, hyaluronic acid, HyCAMP; Icatibant, IDEA-070, IGN-311, imatinib mesylate, insulin detemir, insulin glargine, insulin glulisine; Lapatinib, lasofoxifene tartrate, LB-80380, liarozole fumarate, liposome encapsulated doxorubicin, lumiracoxib, LY-570310; MC-1, melatonin, merimepodib, metanicotine, midostaurin; Natalizumab, nicotine conjugate vaccine, NYVAC-HIV C; Patupilone, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pelitinib, Peru-15, pexelizumab, PHP, pimecrolimus, prednisolone sodium metasulfobenzoate; Recombinant alfa1-antitrypsin (AAT), retigabine, rHA influenza vaccine, rifalazil, rofecoxib, rosiglitazone maleate/Metformin hydrochloride, rostaporfin, rosuvastatin calcium, rubitecan; Selenite sodium, semilente insulin, SMP-797, sorafenib; Talampanel, tenofovir disoproxil fumarate, TER-199, tiotropium bromide, torcetrapib, treprostinil sodium, TTA; ValboroPro, valdecoxib, val-mCyd, valtorcitabine dihydrochloride: XP-828L.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium',\n",
       "   'prednisolone',\n",
       "   'anakinra',\n",
       "   'conivaptan',\n",
       "   'treprostinil',\n",
       "   'sodium',\n",
       "   'darbepoetin',\n",
       "   'brivaracetam',\n",
       "   'retigabine',\n",
       "   'efalizumab',\n",
       "   'aripiprazole',\n",
       "   'natalizumab',\n",
       "   'adalimumab',\n",
       "   'dronedarone',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'entecavir',\n",
       "   'icatibant',\n",
       "   'bimatoprost',\n",
       "   'tiotropium',\n",
       "   'valdecoxib',\n",
       "   'caspofungin',\n",
       "   'lapatinib',\n",
       "   'rofecoxib',\n",
       "   'emtricitabine',\n",
       "   'doxorubicin',\n",
       "   'rosuvastatin',\n",
       "   'erlotinib',\n",
       "   'rosiglitazone'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 16082422,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciclosporin',\n",
       "   'paclitaxel',\n",
       "   'desipramine',\n",
       "   'lapatinib',\n",
       "   'methylprednisolone',\n",
       "   'tiotropium',\n",
       "   'desloratadine',\n",
       "   'pitavastatin',\n",
       "   'filgrastim',\n",
       "   'fluvastatin',\n",
       "   'anakinra',\n",
       "   'etonogestrel',\n",
       "   'voriconazole',\n",
       "   'enfuvirtide',\n",
       "   'atazanavir',\n",
       "   'carmustine',\n",
       "   'paroxetine',\n",
       "   'sodium',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'atorvastatin',\n",
       "   'clopidogrel',\n",
       "   'olmesartan',\n",
       "   'gefitinib',\n",
       "   'icatibant',\n",
       "   'maraviroc',\n",
       "   'fluorouracil',\n",
       "   'docetaxel',\n",
       "   'estramustine',\n",
       "   'cisplatin',\n",
       "   'bevacizumab',\n",
       "   'travoprost',\n",
       "   'mitoxantrone',\n",
       "   'timolol',\n",
       "   'venlafaxine',\n",
       "   'ciclesonide',\n",
       "   'tacrolimus',\n",
       "   'bortezomib',\n",
       "   'busulfan',\n",
       "   'darbepoetin',\n",
       "   'lovastatin',\n",
       "   'famciclovir',\n",
       "   'zidovudine',\n",
       "   'lamivudine',\n",
       "   'calcium',\n",
       "   'prasugrel',\n",
       "   'sirolimus',\n",
       "   'dutasteride',\n",
       "   'aripiprazole',\n",
       "   'lopinavir',\n",
       "   'certolizumab',\n",
       "   'clofarabine',\n",
       "   'cytarabine',\n",
       "   'pravastatin',\n",
       "   'haloperidol',\n",
       "   'alemtuzumab',\n",
       "   'etanercept',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'nelfinavir',\n",
       "   'heparin',\n",
       "   'rosuvastatin',\n",
       "   'ipratropium',\n",
       "   'imatinib',\n",
       "   'efavirenz',\n",
       "   'infliximab',\n",
       "   'eletriptan',\n",
       "   'telithromycin',\n",
       "   'varenicline',\n",
       "   'budesonide',\n",
       "   'fluocinolone',\n",
       "   'atomoxetine',\n",
       "   'rasagiline',\n",
       "   'tegaserod',\n",
       "   'trabectedin',\n",
       "   'rituximab',\n",
       "   'exenatide',\n",
       "   'methotrexate',\n",
       "   'latanoprost',\n",
       "   'treprostinil',\n",
       "   'duloxetine',\n",
       "   'tigecycline',\n",
       "   'acetonide',\n",
       "   'emtricitabine',\n",
       "   'gemcitabine',\n",
       "   'stavudine',\n",
       "   'valdecoxib',\n",
       "   'mitomycin',\n",
       "   'lorazepam',\n",
       "   'tetrasodium',\n",
       "   'adalimumab',\n",
       "   'ritonavir',\n",
       "   'levonorgestrel',\n",
       "   'desvenlafaxine',\n",
       "   'indium',\n",
       "   'bimatoprost',\n",
       "   'fludarabine',\n",
       "   'tadalafil',\n",
       "   'doxorubicin',\n",
       "   'alefacept',\n",
       "   'capecitabine',\n",
       "   'fondaparinux',\n",
       "   'omalizumab',\n",
       "   'simvastatin',\n",
       "   'enoxaparin'],\n",
       "  'reaction': ['prostate cancer']},\n",
       " {'pmid': 16179960,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T 4; NBI-56418, NCX-4016, nesiritide, nicotine conjugate vaccine, NSC-330507; Oglufanide, omalizumab, oxipurinol; Palifermin, palonosetron hydrochloride, parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, PEGylated interferon alfacon-1, perospirone hydrochloride, pimecrolimus, pixantrone maleate, plerixafor hydrochloride, PowderJect lidocaine, pradefovir mesylate, prasterone, pregabalin, Prostvac VF, PT-141, PTC-124, pyridoxamine; QS-21, quercetin; R-126638, R-411, ralfinamide, rasagiline mesilate, rF-PSA, RG-2077, rhThrombin, rimonabant hydrochloride, rofecoxib, rosuvastatin calcium, rotigotine hydrochloride, rV-PSA; S-18886, S-303, seocalcitol, SGN-40, sitaxsentan sodium, SPP-301, St. John's Wort extract; Tadalafil, taxus, telithromycin, tenatoprazole, tenofovir disoproxil fumarate, testosterone MDTS, testosterone transdermal patch, tgAAC-09, TH-9507, thioacetazone, tipifarnib, TQ-1011, trabectedin, travoprost, trimethoprim; Valdecoxib, valganciclovir hydrochloride, valopicitabine, voriconazole; Xcellerated T cells.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['palifermin',\n",
       "   'exenatide',\n",
       "   'gamma-globulin',\n",
       "   'anidulafungin',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'magnesium',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'parecoxib',\n",
       "   'trimethoprim',\n",
       "   'emtricitabine',\n",
       "   'cetuximab',\n",
       "   'valdecoxib',\n",
       "   'travoprost',\n",
       "   'anakinra',\n",
       "   'linezolid',\n",
       "   'esomeprazole',\n",
       "   'bosentan',\n",
       "   'valganciclovir',\n",
       "   'adalimumab',\n",
       "   'plerixafor',\n",
       "   'voriconazole',\n",
       "   'rosuvastatin',\n",
       "   'enfuvirtide',\n",
       "   'rofecoxib',\n",
       "   'atazanavir',\n",
       "   'bimatoprost',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'eletriptan',\n",
       "   'telithromycin',\n",
       "   'palonosetron',\n",
       "   'aprepitant',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'alefacept',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'doxorubicin',\n",
       "   'eplerenone',\n",
       "   'lidocaine',\n",
       "   'atomoxetine',\n",
       "   'fondaparinux',\n",
       "   'dutasteride',\n",
       "   'gefitinib',\n",
       "   'eszopiclone',\n",
       "   'rasagiline',\n",
       "   'aripiprazole',\n",
       "   'icatibant',\n",
       "   'fosamprenavir',\n",
       "   'omalizumab',\n",
       "   'trabectedin',\n",
       "   'lopinavir'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 16636723,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium, mycophenolate mofetil, mycophenolic acid sodium salt; Nitisinone; Omalizumab, omapatrilat, ONYX-015, oxaliplatin; Paclitaxel, paclitaxel nanoparticles, panitumumab, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pertuzumab, phosphatidylcholine-rich phospholipid mixture, pimecrolimus, pioglitazone hydrochloride, pramlintide acetate, prasterone; QR-333; Ranelic acid distrontium salt, ranolazine, rasagiline mesilate, RFB4(dsFv)-PE38, ribavirin, rifabutin, risperidone, rituximab, rofecoxib, rosiglitazone maleate, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; S-236, salmeterol xinafoate, sarizotan hydrochloride, sildenafil, sildenafil citrate, sunitinib malate; Tadalafil, tegaserod maleate, temozolomide, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipifarnib, trabectedin, treprostinil sodium; Vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, vinflunine, virosome influenza vaccine, voriconazole; Zidovudine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['carboplatin',\n",
       "   'ciclosporin',\n",
       "   'fluorouracil',\n",
       "   'paclitaxel',\n",
       "   'docetaxel',\n",
       "   'lapatinib',\n",
       "   'methotrexate',\n",
       "   'haloperidol',\n",
       "   'tiotropium',\n",
       "   'treprostinil',\n",
       "   'drospirenone',\n",
       "   'rosiglitazone',\n",
       "   'clarithromycin',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'trabectedin',\n",
       "   'cisplatin',\n",
       "   'desloratadine',\n",
       "   'magnesium',\n",
       "   'epoetin',\n",
       "   'etanercept',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'panitumumab',\n",
       "   'gadolinium',\n",
       "   'vardenafil',\n",
       "   'gemcitabine',\n",
       "   'cetuximab',\n",
       "   'abatacept',\n",
       "   'fluconazole',\n",
       "   'metformin',\n",
       "   'anakinra',\n",
       "   'pioglitazone',\n",
       "   'salmeterol',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'voriconazole',\n",
       "   'montelukast',\n",
       "   'rofecoxib',\n",
       "   'abacavir',\n",
       "   'lomustine',\n",
       "   'pertuzumab',\n",
       "   'axitinib',\n",
       "   'irinotecan',\n",
       "   'teriparatide',\n",
       "   'sildenafil',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'fludarabine',\n",
       "   'carmustine',\n",
       "   'zidovudine',\n",
       "   'lamivudine',\n",
       "   'amlodipine',\n",
       "   'enalapril',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'tadalafil',\n",
       "   'letrozole',\n",
       "   'alefacept',\n",
       "   'sunitinib',\n",
       "   'erlotinib',\n",
       "   'cinacalcet',\n",
       "   'omalizumab',\n",
       "   'gefitinib',\n",
       "   'rasagiline',\n",
       "   'tegaserod',\n",
       "   'aripiprazole',\n",
       "   'vandetanib',\n",
       "   'risperidone',\n",
       "   'rituximab',\n",
       "   'dicycloverine',\n",
       "   'oxaliplatin'],\n",
       "  'reaction': ['influenza', 'influenza', 'influenza', 'influenza']},\n",
       " {'pmid': 17003851,\n",
       "  'sentence': 'The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'exenatide',\n",
       "   'tiotropium',\n",
       "   'anidulafungin',\n",
       "   'dabigatran',\n",
       "   'treprostinil',\n",
       "   'peptide',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'desloratadine',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'pemetrexed',\n",
       "   'emtricitabine',\n",
       "   'cetuximab',\n",
       "   'fulvestrant',\n",
       "   'anakinra',\n",
       "   'telbivudine',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'valganciclovir',\n",
       "   'voriconazole',\n",
       "   'tolvaptan',\n",
       "   'rosuvastatin',\n",
       "   'adalimumab',\n",
       "   'teriparatide',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'clindamycin',\n",
       "   'alefacept',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'erlotinib',\n",
       "   'eplerenone',\n",
       "   'prasugrel',\n",
       "   'atomoxetine',\n",
       "   'cinacalcet',\n",
       "   'fondaparinux',\n",
       "   'omalizumab',\n",
       "   'gefitinib',\n",
       "   'hydralazine',\n",
       "   'eszopiclone',\n",
       "   'aripiprazole',\n",
       "   'tegaserod',\n",
       "   'vandetanib',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['hepatitis', 'hepatitis c']},\n",
       " {'pmid': 17235418,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, belagenpumatucel-L, beta-lapachone, BHT-3009, BIBW-2992, bremelanotide, BX-471; Casopitant mesylate, cediranib, certolizumab pegol, CH-1504, ChimeriVax-West Nile, clofazimine, CpG-7909, curcumin, Cypher; Dapoxetine hydrochloride, darusentan, diflomotecan, D-methionine, dnaJP1, D-serine, DTPw-HB Hib-MenAC, DTPw-HepB-Hib; E-7010, ecogramostim, edodekin alfa, EGFRvlll peptide vaccine, elcometrine, elcometrine/ethinylestradiol, elsilimomab, enrasentan, ertumaxomab, etalocib sodium, exisulind; Fenretinide, fesoterodine, fingolimod hydrochloride, fontolizumab; Gefitinib, gemtuzumab ozogamicin, ghrelin (human), GV-1001; HTU-PA, human papillomavirus vaccine; Indacaterol, indiplon, interleukin-21, intranasal insulin, irinotecan hydrochloride/floxuridine, ISIS-301012, ispinesib mesylate, ixabepilone; K562/GM-CSF; Lapatinib, L-BLP-25, linezolid, liposome encapsulated paclitaxel, LY-2124275; MC-1, MC-1/lisinopril, MDX-066, melanoma vaccine, MMR-V, multivalent (ACYW) meningitis vaccine; Nilotinib, nobori, nociceptin; Oblimersen sodium, orbofiban acetate, ospemifene; Paliperidone, panitumumab, PEG-filgrastim, PEGylated interferon alfacon-1, perflubutane, pertuzumab, phenserine tartrate, phVEGF-A165, pleconaril, prasugrel, prednisolone sodium metasulfobenzoate; R-411, recombinant malaria vaccine, rhGM-CSF, roflumilast, romidepsin, ruboxistaurin mesilate hydrate; Sirolimus-eluting stent, SR-4554, St. John's Wort extract; Talabostat, Taxus, TGN-255, tifacogin, tiotropium bromide, tolevamer sodium, trabectedin, tretinoin LF; Vatalanib succinate; Yellow fever vaccine, YM-155.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tifacogin',\n",
       "   'paclitaxel',\n",
       "   'lapatinib',\n",
       "   'indacaterol',\n",
       "   'tiotropium',\n",
       "   'peptide',\n",
       "   'nilotinib',\n",
       "   'dapoxetine',\n",
       "   'panitumumab',\n",
       "   'paliperidone',\n",
       "   'linezolid',\n",
       "   'intranasal',\n",
       "   'irinotecan',\n",
       "   'ozogamicin',\n",
       "   'pertuzumab',\n",
       "   'axitinib',\n",
       "   'roflumilast',\n",
       "   'prednisolone',\n",
       "   'sodium',\n",
       "   'azimilide',\n",
       "   'gemtuzumab',\n",
       "   'prasugrel',\n",
       "   'fingolimod',\n",
       "   'gefitinib',\n",
       "   'trabectedin',\n",
       "   'certolizumab',\n",
       "   'cediranib'],\n",
       "  'reaction': ['meningitis', 'malaria']},\n",
       " {'pmid': 17982511,\n",
       "  'sentence': '12B75, 274150; Abacavir sulfate/lamivudine, Abatacept, Ad2/HIF-1alpha, Adalimumab, Adefovir, Adefovir dipivoxil, AGN-201904-Z, AIDSVAX, Albinterferon alfa-2b, Alemtuzumab, Aliskiren fumarate, Alvimopan hydrate, Amlodipine besylate/atorvastatin calcium, Amlodipine besylate/Olmesartan medoxomil, Ammonium tetrathiomolybdate, Amodiaquine, Apaziquone, Aprepitant, Arsenic trioxide, Artesunate/Amodiaquine, Ascorbic acid, Atazanavir sulfate, Atazanavir/ritonavir, Atomoxetine hydrochloride, Atrigel-Leuprolide, Axitinib; Bevacizumab, Binodenoson, Bortezomib, Bovine lactoferrin; Calcipotriol/betamethasone dipropionate, Carisbamate, Certolizumab pegol, Ciclesonide, Conivaptan hydrochloride, CP-690550, CP-751871, Cypher; Dapivirine, Darbepoetin alfa, Darunavir, Dasatinib, del-1 Genemedicine, Denosumab, Desloratadine, Dexlansoprazole, DiabeCell, Drospirenone/ethinylestradiol, DTaP-HepB-IPV, Duloxetine hydrochloride, Dutasteride; Eculizumab, Eldecalcitol, Eletriptan, Emtricitabine, Entecavir, Eritoran tetrasodium, Ertapenem sodium, Escitalopram oxalate, Eslicarbazepine acetate, Esomeprazole magnesium, Estradiol acetate, Eszopiclone, ETEC vaccine, Etoricoxib, Exenatide, Ezetimibe; Fluticasone furoate, Fosmidomycin, Fosmidomycin/clindamycin; Glutamine; Heat Shock Protein 10, Hepatitis B hyperimmunoglobulin, HIV vaccine, Hochuekki-to, Human Albumin, Human papillomavirus vaccine; Immune globulin subcutaneous [human], IMP-321, Interferon omega, ISIS-301012, Istaroxime; Japanese encephalitis virus vaccine; Latanoprost/timolol maleate, Lenalidomide, Linaclotide acetate, Lumiracoxib, LY-517717; Malaria vaccine, MAS-063D, Meningitis B vaccine, Mepolizumab, Methylnaltrexone bromide, Micafungin sodium, MK-0822A, Morphine glucuronide, Morphine hydrochloride, Mycophenolic acid sodium salt; Natalizumab, Nesiritide, Norelgestromin/ethinyl estradiol, NT-201; Oblimersen sodium, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Omalizumab, Otamixaban; Paclitaxel nanoparticles, Panitumumab, Panobinostat, Parathyroid hormone (human recombinant), Parecoxib sodium, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pegvisomant, PI-88, Pimecrolimus, Pneumococcal 7-valent conjugate vaccine, Pneumococcal 9-valent conjugate vaccine, Pneumococcal conjugate vaccine, Poloxamer-188, Prasugrel, Pregabalin, Prulifloxacin; R-109339, Ramipril/amlodipine, Ranolazine, Rasburicase, rHA influenza vaccine, Ro-50-3821, Rosuvastatin calcium, Rotavirus vaccine, Rotigotine, Ruboxistaurin mesilate hydrate; Satavaptan, SC-75416, Solifenacin succinate, Sorafenib, Sugammadex sodium, Sunitinib malate, Synthetic conjugated estrogens B; Tadalafil, Talnetant, Taxus, Tegaserod maleate, Telbivudine, Temsirolimus, Tenofovir disoproxil fumarate, Tetomilast, Tiotropium bromide, Tipifarnib, Tofimilast, Tremelimumab, Trimethoprim; Udenafil, Urocortin 2; Valdecoxib, Vernakalant hydrochloride; XP-828L.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['paclitaxel',\n",
       "   'entecavir',\n",
       "   'exenatide',\n",
       "   'ertapenem',\n",
       "   'denosumab',\n",
       "   'tiotropium',\n",
       "   'conivaptan',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'aliskiren',\n",
       "   'desloratadine',\n",
       "   'magnesium',\n",
       "   'darunavir',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'panitumumab',\n",
       "   'parecoxib',\n",
       "   'trimethoprim',\n",
       "   'pimecrolimus',\n",
       "   'emtricitabine',\n",
       "   'valdecoxib',\n",
       "   'abatacept',\n",
       "   'esomeprazole',\n",
       "   'telbivudine',\n",
       "   'tetrasodium',\n",
       "   'micafungin',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'abacavir',\n",
       "   'axitinib',\n",
       "   'atazanavir',\n",
       "   'globulin',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'temsirolimus',\n",
       "   'ammonium',\n",
       "   'eletriptan',\n",
       "   'linaclotide',\n",
       "   'dexlansoprazole',\n",
       "   'eculizumab',\n",
       "   'aprepitant',\n",
       "   'amlodipine',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'prasugrel',\n",
       "   'atomoxetine',\n",
       "   'olmesartan',\n",
       "   'dutasteride',\n",
       "   'eszopiclone',\n",
       "   'tegaserod',\n",
       "   'omalizumab',\n",
       "   'dasatinib',\n",
       "   'mepolizumab',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['shock',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'encephalitis',\n",
       "   'malaria',\n",
       "   'meningitis',\n",
       "   'influenza']},\n",
       " {'pmid': 18040531,\n",
       "  'sentence': '(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869, Adalimumab, Ad-rh Endostatin, AI-700, Alemtuzumab, Alvimopan hydrate, Amrubicin hydrochloride, AP-12009, Apomab 7.3, Arformoterol tartrate, Aripiprazole, AS-1404, Azacitidine, AZD-0530; Bevacizumab, BHT-3009, Biapenem, Bortezomib, Bosentan, Bremelanotide; CA9-SCAN, Calcitonin gene-related peptide, Canertinib dihydrochloride, Cannabidiol, Carboxyamidotriazole, Caspofungin acetate, Celgosivir, Certolizumab pegol, Cinacalcet hydrochloride, Clevudine, CP-751871, Curcumin, Cx-401, Cypher; Darunavir, Decitabine, Deforolimus, Dexamet, Dipyridamole/prednisolone, Drospirenone, Drospirenone/estradiol, DTPw-HepB-Hib, Duloxetine hydrochloride; Efalizumab, Emtricitabine, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone; Ferumoxtran-10, Ferumoxytol, Fondaparinux sodium, Fosaprepitant dimeglumine; gamma-Hydroxybutyrate sodium, Gefitinib, Genistein, Ghrelin (human), Gimatecan, GM-CSF PMED, Golimumab, gp100 PMED; Imatinib mesylate, Immunoglobulin intravenous (human), IV Gamma-globulin; LA-419, Laropiprant, L-BLP-25, Levodopa/carbidopa/entacapone, Lidocaine/prilocaine, Lopinavir/ritonavir, Lumiracoxib, LY-2076962; Mepolizumab, Methylnaltrexone bromide, Mitiglinide calcium hydrate, Mycophenolic acid sodium salt, Myristyl nicotinate; Natalizumab, Nesiritide, Niacin/lovastatin; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Ozarelix; Palonosetron hydrochloride, Parathyroid hormone (human recombinant), Pazopanib hydrochloride, Pegaptanib octasodium, Pegfilgrastim, Peginterferon alfa- 2a, Peginterferon alfa-2b, Pegvisomant, Pemetrexed disodium, Pexelizumab, Picoplatin, Pimecrolimus, Posaconazole, Pregabalin, PRO-1762, Progesterone caproate, Prulifloxacin; Ramelteon, Ranelic acid distrontium salt, Reparixin, Rosuvastatin calcium; Rotigotine; Satraplatin, Sertraline, Sipuleucel-T, SLIT-cisplatin, SNDX-275, Solifenacin succinate, Sunitinib malate; Tadalafil, Talnetant, Tanespimycin, Taxus, Tegaserod maleate, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate/emtricitabine, Teriparatide, tgAAC-94, Tiotropium bromide, Tocilizumab, Tolvaptan, Trimethoprim; Vardenafil hydrochloride hydrate, Vatalanib succinate, Vinflunine, Voriconazole, VX-680; XL-880; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ramelteon',\n",
       "   'azacitidine',\n",
       "   'gamma-globulin',\n",
       "   'tiotropium',\n",
       "   'drospirenone',\n",
       "   'peptide',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'darunavir',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'trimethoprim',\n",
       "   'pemetrexed',\n",
       "   'emtricitabine',\n",
       "   'abatacept',\n",
       "   'immunoglobulin',\n",
       "   'golimumab',\n",
       "   'fosaprepitant',\n",
       "   'bosentan',\n",
       "   'ofatumumab',\n",
       "   'tolvaptan',\n",
       "   'voriconazole',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'abacavir',\n",
       "   'teriparatide',\n",
       "   'endostatin',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'palonosetron',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'posaconazole',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'erlotinib',\n",
       "   'cinacalcet',\n",
       "   'olmesartan',\n",
       "   'fondaparinux',\n",
       "   'gefitinib',\n",
       "   'pazopanib',\n",
       "   'eszopiclone',\n",
       "   'aripiprazole',\n",
       "   'tegaserod',\n",
       "   'tocilizumab',\n",
       "   'mepolizumab',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 18806898,\n",
       "  'sentence': '(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine, Denosumab, Desloratadine, DMXB-Anabaseine, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Eicosapentaenoic acid/docosahexaenoic acid, Eletriptan, Enzastaurin hydrochloride, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumarate, Fulvestrant; Gefitinib, GM-CSF DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human Fibroblast Growth Factor 1, Hypericin-PVP; Icatibant acetate, Iclaprim, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-IL-2, Lapuleucel-T, Laropiprant, Liposomal doxorubicin, LP-261, Lumiracoxib, LY-518674; MDV-3100, MGCD-0103, Mirabegron, MyoCell; NASHA/Dx, Niacin/laropiprant; O6-Benzylguanine, Ocrelizumab, Olmesartan medoxomil, Omalizumab; P-276-00, Paclitaxel nanoparticles, Paclitaxel nanoparticles, Padoporfin, Paliperidone, PAN-811, Pegaptanib octasodium, Pegfilgrastim, Pemetrexed disodium, PF-00299804, Pimecrolimus, Prasugrel, Pregabalin; Reolysin, Rimonabant, Rivaroxaban, Rosuvastatin calcium; Satraplatin, SCH-697243,Selenite sodium, Silodosin, Sorafenib, Sunitinib malate; Talarozole, Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; Xience V; Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['paclitaxel',\n",
       "   'ipilimumab',\n",
       "   'azacitidine',\n",
       "   'denosumab',\n",
       "   'uracil',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'desloratadine',\n",
       "   'everolimus',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'vardenafil',\n",
       "   'pemetrexed',\n",
       "   'abatacept',\n",
       "   'immunoglobulin',\n",
       "   'fulvestrant',\n",
       "   'paliperidone',\n",
       "   'degarelix',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'rivaroxaban',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'temsirolimus',\n",
       "   'eletriptan',\n",
       "   'varenicline',\n",
       "   'potassium',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'doxorubicin',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'erlotinib',\n",
       "   'prasugrel',\n",
       "   'mirabegron',\n",
       "   'olmesartan',\n",
       "   'dutasteride',\n",
       "   'gefitinib',\n",
       "   'ocrelizumab',\n",
       "   'omalizumab',\n",
       "   'aripiprazole',\n",
       "   'icatibant',\n",
       "   'tocilizumab'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'growth']},\n",
       " {'pmid': 18850047,\n",
       "  'sentence': '(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher; Dalbavancin, Dalcetrapib, Daptomycin, Darapladib, Deferasirox, Deforolimus, Denosumab, DNA-HIV-C, Dovitinib, DR-5001, Dronedarone hydrochloride, DT388IL3; E75, EC-17/EC-90, Ecogramostim, Efungumab, Entecavir, EP HIV-1090, EP-2101, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Faropenem daloxate, Fluticasone furoate, Fondaparinux sodium, Fospropofol disodium, Fulvestrant; Golimumab, GSK-089, GW-590735; HO/03/03, hTERT572, hTERT572Y; Iloperidone; Immunoglobulin intravenous (human), Ispinesib mesylate, Istradefylline, Ixabepilone; JR-031, JX-594; KLH; Laropiprant, Lecozotan hydrochloride, Lenalidomide, Lestaurtinib, Linezolid; MGCD-0103, MK-0646, MVA-BN Measles; NI-0401, Niacin/laropiprant, NSC-719239, NYVAC-C; Ospemifene; Paliperidone palmitate, PAN-811, PCV7, Pegfilgrastim, Peginterferon alfa-2a, PEGirinotecan, Perifosine, Pertuzumab, PF-00299804, Picoplatin, Pimavanserin tartrate, Pitavastatin calcium, Pomalidomide, Prasterone, Pratosartan, Prucalopride, PSMA27/pDOM, Pyridoxal phosphate; QS-21, Quercetin; Rebimastat, Rimonabant, Rolofylline, Romidepsin, Rosuvastatin calcium, RTS,S/SBAS2; SCH-530348, SN-29244, Soblidotin, Sodium dichloroacetate, Solifenacin succinate, Sorafenib, Spheramine, SU-6668, Succinobucol; Taranabant, Taxus, Telaprevir, Telavancin hydrochloride, Telbivudine, Tenofovir disoproxil fumarate, Tigecycline, Tiotropium bromide, Tocilizumab, Triphendiol; UC-781, Udenafil, UNIL-025; V-5 Immunitor, Valsartan/amlodipine besylate, Varenicline tartrate, Velafermin, Vernakalant hydrochloride, Vinflunine, Vitespen, Vorinostat, VX-001; Xience V, XRP-0038; Yttrium Y90 Epratuzumab; Z-360, Ziconotide, Ziprasidone hydrochloride, Zotarolimus, Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'cetuximab',\n",
       "   'vorinostat',\n",
       "   'pegfilgrastim',\n",
       "   'atazanavir',\n",
       "   'certolizumab',\n",
       "   'disodium',\n",
       "   'linezolid',\n",
       "   'alefacept',\n",
       "   'apixaban',\n",
       "   'tigecycline',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'golimumab',\n",
       "   'cediranib',\n",
       "   'pitavastatin',\n",
       "   'sodium',\n",
       "   'denosumab',\n",
       "   'aliskiren',\n",
       "   'fondaparinux',\n",
       "   'bortezomib',\n",
       "   'rosuvastatin',\n",
       "   'dronedarone',\n",
       "   'telbivudine',\n",
       "   'prucalopride',\n",
       "   'tocilizumab',\n",
       "   'daptomycin',\n",
       "   'tiotropium',\n",
       "   'immunoglobulin',\n",
       "   'adalimumab',\n",
       "   'abatacept',\n",
       "   'iloperidone',\n",
       "   'caspofungin',\n",
       "   'paliperidone',\n",
       "   'varenicline',\n",
       "   'fulvestrant',\n",
       "   'calcium',\n",
       "   'pertuzumab',\n",
       "   'dovitinib'],\n",
       "  'reaction': ['measles']},\n",
       " {'pmid': 18985183,\n",
       "  'sentence': 'The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Perillyl alcohol, Perphenazine 4-aminobutyrate, PeviPRO/breast cancer, PF-03814735, PHA-739358, Pimecrolimus, Plitidepsin, Posaconazole, Prasterone, Prasugrel, Pregabalin, Prucalopride, PRX-08066; rAAV2-TNFR:Fc, Ranelic acid distrontium salt, Ranibizumab, rCD154-CLL, Retapamulin, RTS,S/SBAS2, rV-PSA-TRICOM/rF-PSA-TRICOM; SG-2000, Sinecatechins, Sirolimus-eluting stent, Sorafenib, SP-1640, Strontium malonate, Succinobucol, Sunitinib malate; Taxus, Teduglutide, Telavancin hydrochloride, Telbivudine, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ustekinumab; V-5 Immunitor, Voriconazole, Vorinostat; Xience V, XL-184, XL-647, XL-765; Y-39983, Zibotentan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'cetuximab',\n",
       "   'vorinostat',\n",
       "   'irinotecan',\n",
       "   'bevacizumab',\n",
       "   'imatinib',\n",
       "   'anakinra',\n",
       "   'nilotinib',\n",
       "   'disodium',\n",
       "   'teduglutide',\n",
       "   'alefacept',\n",
       "   'dasatinib',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'paclitaxel',\n",
       "   'sunitinib',\n",
       "   'sodium',\n",
       "   'posaconazole',\n",
       "   'denosumab',\n",
       "   'aliskiren',\n",
       "   'darbepoetin',\n",
       "   'bortezomib',\n",
       "   'ciclesonide',\n",
       "   'bazedoxifene',\n",
       "   'telbivudine',\n",
       "   'prucalopride',\n",
       "   'tocilizumab',\n",
       "   'dexlansoprazole',\n",
       "   'brivanib',\n",
       "   'lumiliximab',\n",
       "   'strontium',\n",
       "   'emtricitabine',\n",
       "   'daptomycin',\n",
       "   'ozogamicin',\n",
       "   'aprepitant',\n",
       "   'gefitinib',\n",
       "   'ustekinumab',\n",
       "   'duloxetine',\n",
       "   'azacitidine',\n",
       "   'caspofungin',\n",
       "   'aripiprazole',\n",
       "   'prasugrel',\n",
       "   'voriconazole',\n",
       "   'fulvestrant',\n",
       "   'dutasteride',\n",
       "   'dovitinib',\n",
       "   'aclidinium',\n",
       "   'ranibizumab',\n",
       "   'pemetrexed',\n",
       "   'gemtuzumab',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['fibrin']},\n",
       " {'pmid': 19088949,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: (+)-Dapoxetine hydrochloride, (S)-Tenatoprazole sodium salt monohydrate 19-28z, Acotiamide hydrochloride hydrate, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, Aliskiren fumarate, Asenapine maleate, Axitinib; Bavituximab, Becatecarin, beta-1,3/1,6-Glucan, Bevacizumab, Bremelanotide; Calcipotriol/betamethasone dipropionate, Casopitant mesylate, Catumaxomab, CDX-110, Cediranib, CMD-193, Cositecan; Darinaparsin, Denosumab, DP-b99, Duloxetine hydrochloride; E75, Ecogramostim, Elacytarabine, EMD-273063, EndoTAG-1, Enzastaurin hydrochloride, Eplerenone, Eribulin mesilate, Esomeprazole magnesium, Etravirine, Everolimus, Ezetimibe; Faropenem daloxate, Febuxostat, Fenretinide; Ghrelin (human); I-131 ch-TNT-1/B, I-131-3F8, Iclaprim, Iguratimod, Iloperidone, Imatinib mesylate, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, Ispinesib mesylate, Ixabepilone; Lapatinib ditosylate, Laquinimod sodium, Larotaxel dehydrate, Linezolid, LOR-2040; Mapatumumab, MKC-1, Motesanib diphosphate, Mycophenolic acid sodium salt; NK-012; Olanzapine pamoate, Oncolytic HSV, Ortataxel; Paclitaxel nanoparticles, Paclitaxel poliglumex, Paliperidone palmitate, Panitumumab, Patupilone, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, Picoplatin, Pimavanserin tartrate, Pimecrolimus, Plerixafor hydrochloride, PM-02734, Poly I:CLC, PR1, Prasugrel, Pregabalin, Progesterone caproate, Prucalopride, Pumosetrag hydrochloride; RAV-12, RB-006, RB-007, Recombinant human erythropoietin alfa, Rimonabant, Romidepsin; SAR-109659, Satraplatin, Sodium butyrate; Tadalafil, Talampanel, Tanespimycin, Tarenflurbil, Tariquidar, Taurine, Tecovirimat, Telatinib, Telavancin hydrochloride, Telcagepant, Terameprocol, Tesofensine, Tetrodotoxin, Tezampanel, Tipifarnib, TPI-287, Tremelimumab; Valspodar, Vatalanib succinate, VCL-CB01, vCP1452, Vorinostat; XL-228; Ziprasidone hydrochloride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['esomeprazole',\n",
       "   'vorinostat',\n",
       "   'pegfilgrastim',\n",
       "   'bevacizumab',\n",
       "   'imatinib',\n",
       "   'aflibercept',\n",
       "   'indacaterol',\n",
       "   'linezolid',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'paclitaxel',\n",
       "   'cediranib',\n",
       "   'denosumab',\n",
       "   'sodium',\n",
       "   'aliskiren',\n",
       "   'prucalopride',\n",
       "   'ipilimumab',\n",
       "   'lapatinib',\n",
       "   'magnesium',\n",
       "   'duloxetine',\n",
       "   'iloperidone',\n",
       "   'paliperidone',\n",
       "   'prasugrel',\n",
       "   'tadalafil',\n",
       "   'eplerenone',\n",
       "   'panitumumab',\n",
       "   'plerixafor',\n",
       "   'pertuzumab',\n",
       "   'eribulin',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 20140276,\n",
       "  'sentence': '[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezomib, Bosentan, Briakinumab; Capecitabine, Certolizumab pegol, Cetuximab, Cholecalciferol, Choline fenofibrate, Chorionic gonadotropin (human), Cixutumumab, Clopidogrel, CP-690550 citrate; Dabigatran, Dacetuzumab, Daclizumab, Dapagliflozin, Darbepoetin alfa, Dasatinib, Denosumab; Efavirenz, Elisidepsin, Enoxaparin, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Everolimus, Exenatide; Fenobam, Figitumumab, Filibuvir, Fondaparinux sodium, Fresolimumab; Gefitinib, Golimumab, Golnerminogene pradenovec; Ifosfamide, Imatinib mesylate, Ipilimumab, Ivabradine hydrochloride, Ixabepilone; Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liposomal vincristine, Liraglutide; M-118, Masitinib mesylate, Metformin hydrochloride, Micafungin sodium, Moxifloxacin hydrochloride; Neratinib; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil; Paclitaxel nanoparticles, Palifosfamide lysine, Panobacumab, Panobinostat, Patupilone, Peginterferon alfa-2a, Pegylated arginine deiminase 20000, Piclozotan hydrochloride hydrate, Pixantrone maleate, Prasterone, Prasugrel, Prednisone, Progesterone, Prucalopride, pVGI.1 (VEGF-2); Retigabine, rhFSH, Rituximab, Rivaroxaban, Rosuvastatin calcium; Salinosporamide A, Selumetinib, Sipuleucel-T, Somatropin, Sorafenib, SSR-244738, Sunitinib malate; Tamoxifen citrate, Teduglutide, Telavancin hydrochloride, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tenofovir disoproxil fumarate, Tipifarnib, Tolvaptan, Trastuzumab, Trastuzumab-MCC-DM1, Travoprost, Tremelimumab; Valsartan/amlodipine besylate, Valsartan/amlodipine besylate/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Vandetanib, Vorinostat.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['retigabine',\n",
       "   'amlodipine',\n",
       "   'capecitabine',\n",
       "   'tamoxifen',\n",
       "   'calcium',\n",
       "   'bortezomib',\n",
       "   'paclitaxel',\n",
       "   'dabigatran',\n",
       "   'prasugrel',\n",
       "   'denosumab',\n",
       "   'aflibercept',\n",
       "   'imatinib',\n",
       "   'trastuzumab',\n",
       "   'micafungin',\n",
       "   'liraglutide',\n",
       "   'metformin',\n",
       "   'olmesartan',\n",
       "   'aliskiren',\n",
       "   'lapatinib',\n",
       "   'aprepitant',\n",
       "   'travoprost',\n",
       "   'bevacizumab',\n",
       "   'temsirolimus',\n",
       "   'darbepoetin',\n",
       "   'teduglutide',\n",
       "   'ipilimumab',\n",
       "   'erlotinib',\n",
       "   'exenatide',\n",
       "   'everolimus',\n",
       "   'efavirenz',\n",
       "   'prucalopride',\n",
       "   'certolizumab',\n",
       "   'fenofibrate',\n",
       "   'gefitinib',\n",
       "   'rituximab',\n",
       "   'sunitinib',\n",
       "   'neratinib',\n",
       "   'dasatinib',\n",
       "   'vandetanib',\n",
       "   'sodium',\n",
       "   'golimumab',\n",
       "   'selumetinib',\n",
       "   'moxifloxacin',\n",
       "   'vorinostat',\n",
       "   'cetuximab',\n",
       "   'rivaroxaban',\n",
       "   'eribulin',\n",
       "   'rosuvastatin',\n",
       "   'fondaparinux',\n",
       "   'bosentan',\n",
       "   'telmisartan',\n",
       "   'ofatumumab',\n",
       "   'enoxaparin',\n",
       "   'daclizumab',\n",
       "   'adalimumab',\n",
       "   'clopidogrel',\n",
       "   'tolvaptan'],\n",
       "  'reaction': ['growth', 'progesterone']},\n",
       " {'pmid': 20664824,\n",
       "  'sentence': '[Â¹Â¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[Â¹â¸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin acetate, Cediranib, Cetuximab, ChimeriVax-Dengue, Choriogonadotropin alfa, Cinacalcet hydrochloride, Cizolirtine citrate, Clofarabine, Cocaine conjugate vaccine, CX-717; Darbepoetin alfa, Dasatinib, Decitabine, Denosumab, Desvenlafaxine succinate, Dexamethasone sodium phosphate, Dienogest, Diphencyprone, Doripenem, DTaP-HepB-IPV, Dutasteride; E-7010, Ecallantide, Ecstasy, Eicosapentaenoic acid/docosahexaenoic acid, Emtricitabine, Enfuvirtide, Erlotinib hydrochloride, Eszopiclone, Etonogestrel/ethinyl estradiol, Etoricoxib, Everolimus, Everolimus-eluting coronary stent EVT-201, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumavate, Figitumumab, Filgrastim, Fingolimod hydrochloride, Fluticasone furoate, Fluval P, Fluzone, Fondaparinux sodium, Fulvestrant, Fungichromin; Gamma-hydroxybutyrate sodium, Gefitinib, GHB-01L1, GLY-230, GSK-1349572; Hib-MenCY-TT, Hib-TT, HPV-6/11/16/18, Hydrocodone bitartrate; IC-51, Icatibant acetate, Imatinib mesylate, Immunoglobulin intravenous (human), Indetanib, Influenza A (H1N1) 2009 Monovalent Vaccine, Inhalable human insulin, Insulin glargine, Insulin glulisine, Interferon-beta, Ispinesib mesylate, Ixabepilone; Laromustine, Latanoprost/timolol maleate, L-Citrulline, Lenalidomide, Lexatumumab, Linezolid, Lopinavir/ritonavir, Lutropin alfa; Mapatumumab, MDX-066, MDX-1388, Mepolizumab, Methoxy polyethylene glycol-epoetin-beta, Metreleptin, Micafungin sodium, Mometasone furoate/oxymetazoline hydrochloride, Mx-dnG1, Mycophenolic acid sodium salt; Nabiximols, Natalizumab, Nemonoxacin, Norelgestromin/ethinyl estradiol; Oblimersen sodium, Ocriplasmin, Olmesartan medoxomil, Omacetaxine mepesuccinate; Paclitaxel-eluting stent, Pagoclone, Paliperidone, Panitumumab, Pazopanib hydrochloride, PCV7, Pegaptanib octasodium, Peginterferon alfa-2a, Peginterferon alfa-2b/ ribavirin, Pegvisomant, Pemetrexed disodium, Perifosine, Pimecrolimus, Pitavastatin calcium, Plerixafor hydrochloride, Plitidepsin, Posaconazole, Pregabalin, Progesterone capriate; Raltegravir potassium, Ramucirumab, Ranelic acid distrontium salt, Rasburicase, Recombinant Bet V1, Recombinant human insulin, rhFSH, Rolofylline, Romidepsin, Romiplostim, Rosuvastatin calcium; Sapacitabine, Sevelamer carbonate, Sinecatechins, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, SN-29244, Sorafenib, Sugammadex sodium, Sunitinib malate; Tadalafil, Tafenoquine, Talnetant, Tanezumab, Tapentadol hydrochloride, Tasocitinib citrate, Technosphere/Insulin, Telcagepant, Tenofovir disoproxil fumarate, Teriparatide, Ticagrelor, Tigecycline, Tiotropium bromide, Tipifarnib, Tocilizumab, TS-041; Ulipristal acetate, Urtoxazumab, Ustekinumab; Vandetanib, Varenicline tartrate, Vicriviroc, Voriconazole, Vorinostat, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP; Zoledronic acid monohydrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pimecrolimus',\n",
       "   'denosumab',\n",
       "   'eszopiclone',\n",
       "   'gefitinib',\n",
       "   'icatibant',\n",
       "   'tocilizumab',\n",
       "   'atazanavir',\n",
       "   'sevelamer',\n",
       "   'vorinostat',\n",
       "   'posaconazole',\n",
       "   'aliskiren',\n",
       "   'aflibercept',\n",
       "   'teriparatide',\n",
       "   'paliperidone',\n",
       "   'sunitinib',\n",
       "   'caspofungin',\n",
       "   'mepolizumab',\n",
       "   'cediranib',\n",
       "   'romiplostim',\n",
       "   'olmesartan',\n",
       "   'adalimumab',\n",
       "   'calcium',\n",
       "   'plerixafor',\n",
       "   'omacetaxine',\n",
       "   'immunoglobulin',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'raltegravir',\n",
       "   'pazopanib',\n",
       "   'clofarabine',\n",
       "   'fondaparinux',\n",
       "   'sodium',\n",
       "   'ustekinumab',\n",
       "   'cetuximab',\n",
       "   'cinacalcet',\n",
       "   'vandetanib',\n",
       "   'tigecycline',\n",
       "   'linezolid',\n",
       "   'imatinib',\n",
       "   'voriconazole',\n",
       "   'natalizumab',\n",
       "   'aripiprazole',\n",
       "   'emtricitabine',\n",
       "   'micafungin',\n",
       "   'tiotropium',\n",
       "   'tadalafil',\n",
       "   'fulvestrant',\n",
       "   'ramucirumab',\n",
       "   'fingolimod',\n",
       "   'bevacizumab',\n",
       "   'varenicline',\n",
       "   'rosuvastatin',\n",
       "   'panitumumab',\n",
       "   'everolimus',\n",
       "   'apixaban',\n",
       "   'dutasteride',\n",
       "   'bosentan',\n",
       "   'desvenlafaxine',\n",
       "   'enfuvirtide',\n",
       "   'filgrastim',\n",
       "   'sitagliptin',\n",
       "   'pemetrexed',\n",
       "   'atomoxetine',\n",
       "   'erlotinib',\n",
       "   'darbepoetin',\n",
       "   'pitavastatin',\n",
       "   'disodium',\n",
       "   'potassium',\n",
       "   'cocaine'],\n",
       "  'reaction': ['influenza', 'progesterone']},\n",
       " {'pmid': 21069103,\n",
       "  'sentence': 'Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placarbil, Aripiprazole, ARQ-621, Azelnidipine, Azilsartan medoxomil potassium; Bevacizumab, Biphasic insulin aspart, Bortezomib; Choriogonadotropin alfa, CTS-1027; Dapagliflozin, Dasatinib, Deforolimus, Degarelix acetate, Denufosol tetrasodium, Desvenlafaxine succinate, Dronedarone hydrochloride, Duloxetine hydrochloride, Dutasteride; Enfuvirtide, Entecavir, Etaracizumab, Everolimus, Exenatide, Ezetimibe; Ferric carboxymaltose, Fludarabine, Foretinib; Gefitinib, GFT-505, GSK-256066; HPV-6/11/16/18, HuM195/rGel, HyperAcute-Lung cancer vaccine; I5NP, Imatinib mesylate, Imexon, Insulin detemir, Insulin glargine, Ivabradine hydrochloride; L2G7, Lacosamide, Lapatinib ditosylate, Lenalidomide, Lidocaine/prilocaine, Liposomal vincristine, Liraglutide, Lixivaptan; Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Methoxy polyethylene glycol-epoetin-Î², Mirabegron, Morphine/oxycodone, MR Vaccine, MSC-1936369B, Mycophenolic acid sodium salt; Narlaprevir, N-Desmethylclozapine; Ocriplasmin, Olaparib, Olmesartan medoxomil, Olmesartan medoxomil/azelnidipine, ONO-5334, ONO-8539; Palifermin, Panitumumab, Pardoprunox hydrochloride, PCV7, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pexelizumab, PF-337210, Pitavastatin calcium; Raltegravir potassium, Recombinant interleukin-7, Regadenoson, Reniale, Roflumilast, Rosuvastatin calcium; Safinamide mesilate, SB-1518, SCH-527123, Selumetinib, Sipuleucel-T, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talaporfin sodium, Tanespimycin, Technosphere/Insulin, Telaprevir, Telatinib, Telcagepant, Telmisartan/hydrochlorothiazide, Teriparatide, Testosterone transdermal gel, TH-302, Tiotropium bromide, Tocilizumab, Trabedersen, Tremelimumab; Valsartan/amlodipine besylate, Vernakalant hydrochloride, Visilizumab, Voreloxin, Vorinostat.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tocilizumab',\n",
       "   'gefitinib',\n",
       "   'fludarabine',\n",
       "   'vorinostat',\n",
       "   'duloxetine',\n",
       "   'liraglutide',\n",
       "   'teriparatide',\n",
       "   'sunitinib',\n",
       "   'selumetinib',\n",
       "   'olmesartan',\n",
       "   'calcium',\n",
       "   'amlodipine',\n",
       "   'alemtuzumab',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'palifermin',\n",
       "   'raltegravir',\n",
       "   'dronedarone',\n",
       "   'sodium',\n",
       "   'exenatide',\n",
       "   'imatinib',\n",
       "   'aripiprazole',\n",
       "   'mirabegron',\n",
       "   'tiotropium',\n",
       "   'tadalafil',\n",
       "   'entecavir',\n",
       "   'bevacizumab',\n",
       "   'foretinib',\n",
       "   'rosuvastatin',\n",
       "   'everolimus',\n",
       "   'panitumumab',\n",
       "   'roflumilast',\n",
       "   'dutasteride',\n",
       "   'tetrasodium',\n",
       "   'desvenlafaxine',\n",
       "   'enfuvirtide',\n",
       "   'aclidinium',\n",
       "   'pemetrexed',\n",
       "   'degarelix',\n",
       "   'azilsartan',\n",
       "   'lapatinib',\n",
       "   'pitavastatin',\n",
       "   'azelnidipine',\n",
       "   'disodium',\n",
       "   'potassium',\n",
       "   'etaracizumab'],\n",
       "  'reaction': ['diphtheria']},\n",
       " {'pmid': 21225012,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 17-Hydroxyprogesterone caproate; Abacavir sulfate/lamivudine, Aclidinium bromide, Adalimumab, Adefovir, Alemtuzumab, Alkaline phosphatase, Amlodipine, Apilimod mesylate, Aripiprazole, Axitinib, Azacitidine; Belotecan hydrochloride, Berberine iodide, Bevacizumab, Bortezomib, Bosentan, Bryostatin 1; Calcipotriol/hydrocortisone, Carglumic acid, Certolizumab pegol, Cetuximab, Cinacalcet hydrochloride, Cixutumumab, Coumarin, Custirsen sodium; Darbepoetin alfa, Darifenacin hydrobromide, Darunavir, Dasatinib, Denibulin hydrochloride, Denosumab, Diacetylmorphine, Dulanermin, Duloxetine hydrochloride; Ecogramostim, Enfuvirtide, Entecavir, Enzastaurin hydrochloride, Eplerenone, Escitalopram oxalate, Esomeprazole sodium, Etravirine, Everolimus, Ezetimibe; Fenofibrate/pravastatin sodium, Ferric carboxymaltose, Flavangenol, Fondaparinux sodium; Glutamine, GSK-1024850A; Hepatitis B hyperimmunoglobulin, Hib-MenC, HIV-LIPO-5; Immunoglobulin intravenous (human), Indacaterol maleate, Indibulin, Indium 111 (Â¹Â¹Â¹In) ibritumomab tiuxetan, Influenza A (H1N1) 2009 Monovalent vaccine, Inhalable human insulin, Insulin glulisine; Lapatinib ditosylate, Leucovorin/UFT; Maraviroc, Mecasermin, MMR-V, Morphine hydrochloride, Morphine sulfate/naltrexone hydrochloride, Mycophenolic acid sodium salt; Naproxen/esomeprazole magnesium, Natalizumab; Oncolytic HSV; Paliperidone, PAN-811, Paroxetine, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimecrolimus, Posaconazole, Pregabalin; Raltegravir potassium, Ranelic acid distrontium salt, Rasburicase, Rilpivirine hydrochloride; Sertindole, Sivelestat sodium hydrate, Sorafenib, Sumatriptan succinate/naproxen sodium, Sunitinib malate; Tafluprost, Telithromycin, Temsirolimus, Tenofovir disoproxil fumavate, Tenofovir disoproxil fumarate/emtricitabine, Teriparatide, Ticagrelor, Tigecycline, Tipranavir, Tirapazamine, Trimetrexate; Ulipristal acetate; Valganciclovir hydrochloride, Vicriviroc, Vorinostat; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pimecrolimus',\n",
       "   'denosumab',\n",
       "   'paroxetine',\n",
       "   'esomeprazole',\n",
       "   'vorinostat',\n",
       "   'indacaterol',\n",
       "   'maraviroc',\n",
       "   'magnesium',\n",
       "   'posaconazole',\n",
       "   'duloxetine',\n",
       "   'certolizumab',\n",
       "   'tipranavir',\n",
       "   'teriparatide',\n",
       "   'paliperidone',\n",
       "   'pegfilgrastim',\n",
       "   'sunitinib',\n",
       "   'adalimumab',\n",
       "   'amlodipine',\n",
       "   'abacavir',\n",
       "   'temsirolimus',\n",
       "   'immunoglobulin',\n",
       "   'alemtuzumab',\n",
       "   'bortezomib',\n",
       "   'sumatriptan',\n",
       "   'dasatinib',\n",
       "   'raltegravir',\n",
       "   'fondaparinux',\n",
       "   'sodium',\n",
       "   'valganciclovir',\n",
       "   'telithromycin',\n",
       "   'cetuximab',\n",
       "   'cinacalcet',\n",
       "   'tigecycline',\n",
       "   'natalizumab',\n",
       "   'aripiprazole',\n",
       "   'indium',\n",
       "   'entecavir',\n",
       "   'bevacizumab',\n",
       "   'azacitidine',\n",
       "   'axitinib',\n",
       "   'darunavir',\n",
       "   'everolimus',\n",
       "   'eplerenone',\n",
       "   'bosentan',\n",
       "   'enfuvirtide',\n",
       "   'aclidinium',\n",
       "   'pemetrexed',\n",
       "   'lapatinib',\n",
       "   'darbepoetin',\n",
       "   'disodium',\n",
       "   'potassium'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'influenza']},\n",
       " {'pmid': 21225019,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abatacept, Adalimumab, AdCD40L, Adefovir, Aleglitazar, Aliskiren fumarate, AM-103, Aminolevulinic acid methyl ester, Amlodipine, Anakinra, Aprepitant, Aripiprazole, Atazanavir sulfate, Axitinib; Belimumab, Bevacizumab, Bimatoprost, Bortezomib, Bupropion/naltrexone; Calcipotriol/betamethasone dipropionate, Certolizumab pegol, Ciclesonide, CYT-997; Darbepoetin alfa, Darunavir, Dasatinib, Desvenlafaxine succinate, Dexmethylphenidate hydrochloride cogramostim; Eltrombopag olamine, Emtricitabine, Escitalopram oxalate, Eslicarbazepine acetate, Eszopiclone, Etravirine, Everolimus-eluting coronary stent, Exenatide, Ezetimibe; Fenretinide, Filibuvir, Fludarabine; Golimumab; Hepatitis B hyperimmunoglobulin, HEV-239, HP-802-247, HPV-16/18 AS04, HPV-6/11/16/18, Human albumin, Human gammaglobulin; Imatinib mesylate, Inotuzumab ozogamicin, Invaplex 50 vaccine; Lapatinib ditosylate, Lenalidomide, Liposomal doxorubicin, Lopinavir, Lumiliximab, LY-686017; Maraviroc, Mecasermin rinfabate; Narlaprevir; Ocrelizumab, Oral insulin, Oritavancin, Oxycodone hydrochloride/naloxone; Paclitaxel-eluting stent, Palonosetron hydrochloride, PAN-811, Paroxetine, Pazopanib hydrochloride, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Pitavastatin calcium, Posaconazole, Pregabalin, Prucalopride succinate; Raltegravir potassium, Ranibizumab, RHAMM R3 peptide, Rosuvastatin calcium; Salclobuzic acid sodium salt, SCY-635, Selenate sodium, Semapimod hydrochloride, Silodosin, Siltuximab, Silybin, Sirolimus-eluting stent, SIR-Spheres, Sunitinib malate; Tapentadol hydrochloride, Tenofovir disoproxil fumarate, Tocilizumab, Tositumomab/iodine (I131) tositumomab, Trabectedin, TransVaxâ„¢ hepatitis C vaccine; Ustekinumab; V-260, Valspodar, Varenicline tartrate, VCL-IPT1, Vildagliptin, VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, VRC-HIVDNA016-00-VP; Yttrium 90 (90Y) ibritumomab tiuxetan, Yttrium Y90 Epratuzumab; Zibotentan, Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['eszopiclone',\n",
       "   'tocilizumab',\n",
       "   'paroxetine',\n",
       "   'fludarabine',\n",
       "   'bimatoprost',\n",
       "   'atazanavir',\n",
       "   'lopinavir',\n",
       "   'maraviroc',\n",
       "   'posaconazole',\n",
       "   'aliskiren',\n",
       "   'certolizumab',\n",
       "   'sunitinib',\n",
       "   'golimumab',\n",
       "   'trabectedin',\n",
       "   'adalimumab',\n",
       "   'calcium',\n",
       "   'amlodipine',\n",
       "   'eltrombopag',\n",
       "   'peptide',\n",
       "   'aprepitant',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'ozogamicin',\n",
       "   'raltegravir',\n",
       "   'pazopanib',\n",
       "   'sodium',\n",
       "   'ustekinumab',\n",
       "   'exenatide',\n",
       "   'abatacept',\n",
       "   'imatinib',\n",
       "   'anakinra',\n",
       "   'aripiprazole',\n",
       "   'ciclesonide',\n",
       "   'belimumab',\n",
       "   'emtricitabine',\n",
       "   'ocrelizumab',\n",
       "   'doxorubicin',\n",
       "   'siltuximab',\n",
       "   'bevacizumab',\n",
       "   'varenicline',\n",
       "   'rosuvastatin',\n",
       "   'axitinib',\n",
       "   'darunavir',\n",
       "   'ranibizumab',\n",
       "   'desvenlafaxine',\n",
       "   'inotuzumab',\n",
       "   'lumiliximab',\n",
       "   'pemetrexed',\n",
       "   'prucalopride',\n",
       "   'lapatinib',\n",
       "   'pitavastatin',\n",
       "   'darbepoetin',\n",
       "   'palonosetron',\n",
       "   'disodium',\n",
       "   'pertuzumab',\n",
       "   'potassium'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'hepatitis', 'hepatitis c']},\n",
       " {'pmid': 24445293,\n",
       "  'sentence': \"Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, RÃ¸der MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study\",\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['prostate cancer', 'prostate cancer']},\n",
       " {'pmid': 27090254,\n",
       "  'sentence': 'Pooled analysis of (R)-[11C]-verapamil PET data from two European centresM Bauer, M Feldmann, R Karch, W Wadsak, M Zeitlinger, MJ Koepp, M-C Asselin, E Pataraia, O LangerA13 In-vitro and in-vivo characterization of [18F]FE@SNAP and derivatives for the visualization of the melanin concentrating hormone receptor 1M Zeilinger, C Philippe, M Dumanic, F Pichler, J Pilz, M Hacker, W Wadsak, M MitterhauserA14 Reducing time in quality control leads to higher specific radioactivity of short-lived radiotracersL Nics, B Steiner, M Hacker, M Mitterhauser, W WadsakA15 In vitro 11C-erlotinib binding experiments in cancer cell lines with epidermal growth factor receptor mutationsA Traxl, Thomas Wanek, Kushtrim Kryeziu, Severin Mairinger, Johann Stanek, Walter Berger, Claudia Kuntner, Oliver LangerA16 7-[11C]methyl-6-bromopurine, a PET tracer to measure brain Mrp1 function: radiosynthesis and first PET evaluation in miceS Mairinger, T Wanek, A Traxl, M Krohn, J Stanek, T Filip, M Sauberer, C Kuntner, J Pahnke, O LangerA17 18F labeled azidoglucose derivatives as \"click\" agents for pretargeted PET imagingD Svatunek, C Denk, M Wilkovitsch, T Wanek, T Filip, C Kuntner-Hannes, J FrÃ¶hlich, H MikulaA18 Bioorthogonal tools for PET imaging: development of radiolabeled 1,2,4,5-TetrazinesC Denk, D Svatunek, T Wanek, S Mairinger, J Stanek, T Filip, J FrÃ¶hlich, H Mikula, C Kuntner-HannesA19 Preclinical evaluation of [18F]FE@SUPPY- a new PET-tracer for oncologyT Balber, J Singer, J Fazekas, C Rami-Mark, N BerroterÃ¡n-Infante, E Jensen-Jarolim, W Wadsak, M Hacker, H Viernstein, M MitterhauserA20 Investigation of Small [18F]-Fluoroalkylazides for Rapid Radiolabeling and In Vivo Click ChemistryC Denk, D Svatunek, B Sohr, H Mikula, J FrÃ¶hlich, T Wanek, C Kuntner-Hannes, T FilipA21 Microfluidic 68Ga-radiolabeling of PSMA-HBED-CC using a flow-through reactorS Pfaff, C Philippe, M Mitterhauser, M Hartenbach, M Hacker, W WadsakA22 Influence of 24-nor-ursodeoxycholic acid on hepatic disposition of [18F]ciprofloxacin measured with positron emission tomographyT Wanek, E Halilbasic, M Visentin, S Mairinger, B Stieger, C Kuntner, M Trauner, O LangerA23 Automated 18F-flumazenil production using chemically resistant disposable cassettesP Lam, M Aistleitner, R Eichinger, C ArtnerA24 Similarities and differences in the synthesis and quality control of 177Lu-DOTA-TATE, 177Lu -HA-DOTA-TATE and 177Lu-DOTA-PSMA (PSMA-617)H Eidherr, C Vraka, A Haug, M Mitterhauser, L Nics, M Hartenbach, M Hacker, W WadsakA25 68Ga- and 177Lu-labelling of PSMA-617H Kvaternik, R MÃ¼ller, D Hausberger, C Zink, RM AignerA26 Radiolabelling of liposomes with 67Ga and biodistribution studies after administration by an aerosol inhalation systemU CossÃ­o, M Asensio, A Montes, S Akhtar, Y te Welscher, R van Nostrum, V GÃ³mez-Vallejo, J LlopA27 Fully automated quantification of DaTscan SPECT: Integration of age and gender differencesF VandeVyver, T Barclay, N Lippens, M TrochA28 Lesion-to-background ratio in co-registered 18F-FET PET/MR imaging - is it a valuable tool to differentiate between low grade and high grade brain tumor?L Hehenwarter, B Egger, J Holzmannhofer, M Rodrigues-Radischat, C PirichA29 [11C]-methionine PET in gliomas - a retrospective data analysis of 166 patientsN PÃ¶tsch, I Rausch, D Wilhelm, M Weber, J Furtner, G Karanikas, A WÃ¶hrer, M Mitterhauser, M Hacker, T Traub-WeidingerA30 18F-Fluorocholine versus 18F-Fluorodeoxyglucose for PET/CT imaging in patients with relapsed or progressive multiple myeloma: a pilot studyT Cassou-Mounat, S Balogova, V Nataf, M Calzada, V Huchet, K Kerrou, J-Y Devaux, M Mohty, L Garderet, J-N TalbotA31 Prognostic benefit of additional SPECT/CT in sentinel lymph node mapping of breast cancer patientsS Stanzel, G Pregartner, T Schwarz, V Bjelic-Radisic, B Liegl-Atzwanger, R AignerA32 Evaluation of diagnostic value of TOF-18F-FDG PET/CT in patients with suspected pancreatic cancerS Stanzel, F Quehenberger, RM AignerA33 New quantification method for diagnosis of primary hyperpatahyroidism lesions and differential diagnosis vs thyropid nodular disease in dynamic scintigraphyA KoljeviÄ‡ MarkoviÄ‡, Milica JankoviÄ‡, V Miler JerkoviÄ‡, M PaskaÅ¡, G PupiÄ‡, R DÅ¾odiÄ‡, D PopoviÄ‡A34 A rare case of diffuse pancreatic involvement in patient with merkel cell carcinoma detected by 18F-FDGMC Fornito, D FamiliariA35 TSH-stimulated 18F-FDG PET/CT in the diagnosis of recurrent/metastatic radioiodine-negative differentiated thyroid carcinomas in patients with various thyroglobuline levelsP Koranda, H PolzerovÃ¡, I MetelkovÃ¡, L HenzlovÃ¡, R FormÃ¡nek, E BuriÃ¡nkovÃ¡, M KamÃ­nekA36 Breast Dose from lactation following I131 treatmentWH Thomson, C LewisA37 A new concept for performing SeHCAT studies with the gamma cameraWH Thomson, J O\\'Brien, G James, A NotghiA38 Whole body F-18-FDG-PET and tuberculosis: sensitivity compared to x-ray-CTH Huber, I StelzmÃ¼ller, R Wunn, M Mandl, F Fellner, B Lamprecht, M GabrielA39 Emerging role 18F-FDG PET-CT in the diagnosis and follow-up of the infection in heartware ventricular assist system (HVAD)MC Fornito, G LeonardiA40 Validation of Poisson resampling softwareWH Thomson, J O\\'Brien, G JamesA41 Protection of PET nuclear medicine personnel: problems in satisfying dose limit requirementsJ HudzietzovÃ¡, J Sabol, M FÃ¼lÃ¶p.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciprofloxacin'],\n",
       "  'reaction': ['growth',\n",
       "   'investigation',\n",
       "   'breast cancer',\n",
       "   'tuberculosis',\n",
       "   'infection']},\n",
       " {'pmid': 31165401,\n",
       "  'sentence': 'Probiotic supplementation significantly decreased weight (SMD -\\u20090.30; 95% CI, -\\u20090.53, -\\u20090.07; P\\u2009=\\u20090.01), body mass index (BMI) (SMD -\\u20090.29; 95% CI, -\\u20090.54, -\\u20090.03; P\\u2009=\\u20090.02), fasting plasma glucose (FPG) (SMD -\\u20090.26; 95% CI, -\\u20090.45, -\\u20090.07; P\\u2009<\\u20090.001), insulin (SMD -\\u20090.52; 95% CI, -\\u20090.81, -\\u20090.24; P\\u2009<\\u20090.001), homeostatic model assessment for insulin resistance (HOMA-IR) (SMD -\\u20090.53; 95% CI, -\\u20090.79, -\\u20090.26; P\\u2009<\\u20090.001), triglycerides (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), VLDL-cholesterol (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), C-reactive protein (CRP) (SMD -\\u20091.26; 95% CI, -\\u20092.14, -\\u20090.37; P\\u2009<\\u20090.001), malondialdehyde (MDA) (SMD -\\u20090.90; 95% CI, -\\u20091.16, -\\u20090.63; P\\u2009<\\u20090.001), hirsutism (SMD -\\u20090.58; 95% CI, -\\u20091.01, -\\u20090.16; P\\u2009<\\u20090.001), and total testosterone levels (SMD -\\u20090.58; 95% CI, -\\u20090.82, -\\u20090.34; P\\u2009<\\u20090.001), and also increased the quantitative insulin sensitivity check index (QUICKI) (SMD 0.41; 95% CI, 0.11, 0.70; P\\u2009<\\u20090.01), nitric oxide (NO) (SMD 0.33; 95% CI 0.08, 0.59; P\\u2009=\\u20090.01), total antioxidant capacity (TAC) (SMD 0.64; 95% CI, 0.38, 0.90; P\\u2009<\\u20090.001), glutathione (GSH) (SMD 0.26; 95% CI, 0.01, 0.52; P\\u2009=\\u20090.04), and sex hormone binding globulin (SHBG) levels (SMD 0.46; 95% CI, 0.08, 0.85; P\\u2009=\\u20090.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'globulin'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'fasting',\n",
       "   'insulin resistance',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'hirsutism']}]"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sent_counter.many_punctuations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': 1327785,\n",
       "  'sentence': \"The following compounds were evaluated for their inhibitory activity against clinical strains of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in both primary rabbit kidney (PRK) and HeLa cell cultures: (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA), 9-(2-phosphonylmethoxyethyl)adenine (PMEA), (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), (RS)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine (HPMPDAP), 5-(5-bromothien-2-yl)-2'-deoxyuridine (BTDU), 5-(5-chlorothien-2-yl)-2'-deoxyuridine (CTDU), 9-(2-deoxy-2-hydroxymethyl-beta-D-erythro-oxetanosyl)guanine (OXT-G), pentosan polysulfate, heparin, dextran sulfate (MW 10,000), acyclovir, 9-(2-hydroxyethoxymethyl)guanine (ACV), (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), 1-beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)-uracil (BVaraU), vidarabine (9-beta-D-arabinofuranosyladenine) (ara-A) and phosphonoformate (PFA).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin', 'acyclovir'],\n",
       "  'reaction': ['herpes simplex']},\n",
       " {'pmid': 1357680,\n",
       "  'sentence': 'The responses of cardiovascular functional parameters produced by these drugs included: (1) isoproterenol decreased the duration of a whole BP cycle (Wd), duration of the diastolic wave (Dd), peak amplitude of the systolic wave (SYa), amplitude of the diastolic notch (DNa), amplitude of the diastolic wave (DWa), pulse pressure (dp) and mean arterial pressure (mp) but increased the heart rate (HR) accompanied by prolonged R-R (RR) or P-P interval (PP) (2) propranolol decreased SYa, DNa, dp, mp, HR, the amplitude of the P wave (Pa) and amplitude of the S wave (Sa) but increased the duration of the QRS wave, P-R interval, duration of the R wave (Rd) and duration of the P wave (Pd); (3) adrenaline decreased HR (accompanied by prolonged RR and PP), Rd, Pa and amplitude of the T wave (Ta) but increased Pd, Wd, Dd, DNA, the time interval between aortic valve opening and closure (Dw), dp, mp, amplitude of the Q wave and amplitude of the R wave (Ra); (4) noradrenaline decreased HR (accompanied by prolonged RR and PP) and Pa but increased Wd, Pd, SYa, DNa, Dw, dp, mp, Ra and Ta; (5) phenylephrine decreased HR (accompanied by prolonged RR and PP) and Pa but increased Wd, Dd, DNa, mp and Ra; (6) phentolamine decreased SYa, DNa, DWa, Dw, dp and mp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['pulse pressure',\n",
       "   'mean arterial pressure',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 1448813,\n",
       "  'sentence': \"The 17-epimers of the anabolic steroids bolasterone (I), 4-chlorodehydromethyltestosterone (II), fluoxymesterone (III), furazabol (IV), metandienone (V), mestanolone (VI), methyltestosterone (VII), methandriol (VIII), oxandrolone (IX), oxymesterone (X), oxymetholone (XI), stanozolol (XII), and the human metabolites 7 alpha,17 alpha-dimethyl-5 beta-androstane-3 alpha,17 beta-diol (XIII) (metabolite of I), 6 beta-hydroxymetandienone (XIV) (metabolite of V), 17 alpha-methyl-5 beta-androst-1-ene-3 alpha,17 beta-diol (XV) (metabolite of V), 3'-hydroxystanozolol (XVI) (metabolite of XII), as well as the reference substances 17 beta-hydroxy-17 alpha-methyl-5 beta-androstan-3-one (XVII), 17 beta-hydroxy-17 alpha-methyl-5 beta-androst-1-en-3-one (XVIII) (also a metabolite of V), the four isomers 17 alpha-methyl-5 alpha-androstane-3 alpha,17 beta-diol (XIX) (also a metabolite of VI, VII, and XI), 17 alpha-methyl-5 alpha-androstane-3 beta,17 beta-diol (XX), 17 alpha-methyl-5 beta-androstane-3 alpha,17 beta-diol (XXI) (also a metabolite of V, VII, and VIII), 17 alpha-methyl-5 beta-androstane-3 beta,17 beta-diol (XXII), and 17 beta-hydroxy-7 alpha,17 alpha-dimethyl-5 beta-androstan-3-one (XXIII) were synthesized via a 17 beta-sulfate that spontaneously hydrolyzed in water to several dehydration products, and to the 17 alpha-hydroxy-17 beta-methyl epimer.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['stanozolol', 'oxandrolone', 'oxymetholone'],\n",
       "  'reaction': ['dehydration']},\n",
       " {'pmid': 2095724,\n",
       "  'sentence': \"The diagnoses were: a) coronary heart disease in 92 (20.1%) cases (InCor) and in 8 (8.2%) cases (CSSA); b) valvular heart disease in 46 (10.1%) cases (InCor) and in 9 (9.2%) cases (CSSA); c) mitral valve prolapse in 31 (6.8%) cases (InCor) and in 7 (7.1%) cases (CSSA); d) congenital heart disease in 10 (2.2%) cases (InCor) and in 1 (1%) case (CSSA); e) systemic arterial hypertension in 161 (35.2%) cases (InCor) and in 55 (56.1%) cases (CSSA); f) Chagas' infection or Chagas' heart disease in 44 (9.6%) cases (InCor) and in 8 (8.2%) cases (CSSA); g) cardiac rhythm disorders in 38 (8.3%) cases (InCor) and in 8 (8.2% cases (CSSA); h) other diseases in 33 (7.2%) cases (InCor) and in 1 (1%) (CSSA); i) diseases of the aorta in 2 (0.4%) cases (InCor) and in 1 (1%) (CSSA).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['mitral valve prolapse',\n",
       "   'prolapse',\n",
       "   'hypertension',\n",
       "   'infection']},\n",
       " {'pmid': 2932325,\n",
       "  'sentence': 'Of the large number investigated, the following fed ad lib in diets supplemented in a basal ration at the weight percentages indicated, proved to be hepatotrophic: anticonvulsants - mephenytoin (0.15), methsuximide (0.15), phensuximide (0.15) and primidone (0.10); benzodiazepines - clobazam (0.10), flurazepam hydrochloride (0.12), halazepam (0.070), oxazepam (0.030) and temazepam (0.10); anti-inflammatory agents - benoxaprofen (0.040), ibuprofen (0.10 and 0.20), naproxen (0.040) and sulindac (0.075); sedatives and hypnotics - ethinamate (0.75), glutethimide (0.075), methaqualone (0.030 and 0.10) and methprylon (0.30) and the analgesic and antipyretic, aminopyrine (0.15); antifungal - griseofulvin (0.50); anti-androgen - cyproterone acetate (0.020 and 0.050); uricosuric - sulfinpyrazone (0.050 and 0.20); skeletal muscle relaxant - chlorzoxazone (0.20); hydrocholeretic - florantyrone (0.30); anti-hypertensive - prazosin hydrochloride (0.010) and the thyroid inhibitor, methimazole (0.025).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal',\n",
       "   'sulindac',\n",
       "   'temazepam',\n",
       "   'oxazepam',\n",
       "   'flurazepam',\n",
       "   'prazosin',\n",
       "   'benoxaprofen',\n",
       "   'ibuprofen'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 6159029,\n",
       "  'sentence': '1 The vascular relaxant effects of histamine, adenosine, isoprenaline nitroglycerine, papaverine and 3-isobutyl-l-methylxanthine (IBMX) were assessed individually, in strips of rabbit renal artery moderately contracted with noradrenaline (NA) in the absence or presence of phosphodiesterase inhibitors (papaverine and IBMX) or verapamil, a Ca(2+) antagonist.2 The vasodilator effect of histamine was potentiated by papaverine (6.1 x 10(-7) M) and IBMX (4.4 x 10(-5) M) but inhibited dose-dependently by verapamil (5.1 and 51.0 x 10(-7) M).3 Adenosine-induced vascular relaxations were greatly increased in the presence of papaverine (6.1 x 10(-7) M) but significantly reduced in the presence of IBMX (4.4 x 10(-5) M) or verapamil (5.1 and 51.0 x 10(-7) M).4 The vasodilatation produced by isoprenaline was increased in the presence of IBMX (4.4 x 10(-5) M) or papaverine (6.1 x 10(-7) M), but inhibited by verapamil (5.1 and 51.0 x 10(-7) M).5 The vascular relaxant effects of nitroglycerine and papaverine were inhibited in the presence of IBMX (4.4 x 10(-5) M) or verapamil (5.1 and 51.0 x 10(-7) M).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['papaverine', 'verapamil'],\n",
       "  'reaction': ['vasodilatation']},\n",
       " {'pmid': 6840792,\n",
       "  'sentence': 'All ten compounds, fenofibrate (isopropyl-[4-(p-chlorobenzoyl)2-phenoxy-2-methyl] propionate; LS 2265 (taurine derivative of fenofibrate); bezafibrate (2-(4-(2-[4-chlorobenzamido)ethyl] phenoxy)-methyl propionic acid; gemfibrozil (5-2[2,5-dimethylphenoxy]2-2-dimethylpentanoic acid); methyl clofenapate (methyl-2-[4-(p-chlorophenyl)phenoxy]-2-methyl propionate); DG 5685 (5-[4-phenoxybenzyl]trans-2-(3-pyridyl)1,3-dioxane); DH 6463 (5-[4-phenoxybenzyl] trans-2-(3-pyrimidinyl)-1,3-dioxane); tiadenol(bis[hydroxyethylthio]-7, 10-decane); ciprofibrate (2,-[4-(2,2-dichlorocyclopropyl)-phenoxy]2-methyl propionic acid) and RMI-14,514 ( [5-tetradecycloxy]-2-furancarboxylic acid), produced a marked but variable increase in the activities of peroxisomal enzymes catalase, carnitine acetyltransferase, heat-labile enoyl-CoA hydratase and the fatty acid beta-oxidation system and in the amount of polypeptide PPA-80 as demonstrated by SDS-polyacrylamide gel electrophoresis.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciprofibrate',\n",
       "   'fenofibrate',\n",
       "   'polypeptide',\n",
       "   'bezafibrate'],\n",
       "  'reaction': ['carnitine']},\n",
       " {'pmid': 7718371,\n",
       "  'sentence': 'Dobutamine consistently increased mean splanchnic blood flow (control 0.6 (SD 0.2) vs 0.7 (0.2) litre min-1 m-2 (P < 0.05); normal cardiac output and dobutamine 0.7 (0.2) vs 1.1 (0.4) litre min-1 m-2 (P < 0.01); low cardiac output and dobutamine 0.4 (0.1) vs 0.7 (0.1) litre min-1 m-2 (P < 0.05)) and oxygen delivery (control 102 (29) vs 111 (28) ml min-1 m-2 (ns); normal cardiac output and dobutamine 106 (27) vs 156 (47) ml min-1 m-2 (P < 0.01); low cardiac output and dobutamine 75 (21) vs 110 (26) ml min-1 m-2 (P < 0.05)) but had no effect on splanchnic oxygen consumption (control 44 (10) vs 49 (10) ml min-1 m-2 (ns); normal cardiac output and dobutamine 45 (12) vs 51 (17) ml min-1 m-2 (ns); low cardiac output and dobutamine 37 (9) vs 40 (9) ml min-1 m-2 (ns)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output',\n",
       "   'cardiac output',\n",
       "   'delivery',\n",
       "   'cardiac output',\n",
       "   'cardiac output',\n",
       "   'oxygen consumption',\n",
       "   'oxygen consumption',\n",
       "   'cardiac output',\n",
       "   'cardiac output']},\n",
       " {'pmid': 8773730,\n",
       "  'sentence': 'At the end of the experimental period, the results obtained were as follows (mean +/- SEM): serum triacylglycerol (mM): CD + CLO 0.21 +/- 0.04 vs. CD 0.58 +/- 0.05 (p < 0.05); free fatty acids (microM): CD + CLO 257 +/- 20 vs. CD 288 +/- 22 (p = NS); total cholesterol (mM): CD + CLO 1.13 +/- 0.09 vs. CD 1.82 +/- 0.06 (p < 0.05); high-density lipoprotein cholesterol (mM): CD + CLO 0.58 +/- 0.08 vs. CD 1.07 +/- 0.04 (p < 0.05); plasma glucose (mM): CD + CLO 6.30 +/- 0.29 vs. CD 6.28 +/- 0.10 (p = NS); liver triacylglycerol (mumol/liver): CD + CLO 104.1 +/- 11.4 vs. CD 136.8 +/- 4.3 (p < 0.05); glycogen (mumol/g wet weight): CD + CLO 298.3 +/- 21.0 vs. CD 297.0 +/- 19.0 (p = NS); glucose-6-phosphate dehydrogenase (U/liver): CD + CLO 37.9 +/- 2.2 vs. CD 58.8 +/- 5.0 (p < 0.05); triacylglycerol secretion (nmol/min/100 g body weight): CD + CLO 101.0 +/- 2.0 vs. CD 166.0 +/- 9.7 (p < 0.01); removal of fat emulsion (K2% min-1): CD + CLO 15.0 x 10(-2) +/- 0.8 x 10(-2) vs. CD 8.2 x 10(-2) +/- 0.2 x 10(-2) (p < 0.01); intravenous glucose tolerance (kg 10(-2): CD + CLO 2.68 +/- 0.37 vs. CD 2.70 +/- 0.14 (p = NS); immunoreactive insulin (microU/ml/ min): with the area under the curve between 0 and 30 min CD + CLO 544 +/- 60 vs. CD 1,050 +/- 38 (p < 0.05), with the area under the curve between 0 and 60 min CD + CLO 1,188 +/- 150 vs. CD 2,160 +/- 137 (p < 0.05), and pancreas insulin content (microU/mg pancreas): CD + CLO 1.85 +/- 0.29 vs. CD 2.04 +/- 0.12 (p = NS).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight', 'glucose tolerance']},\n",
       " {'pmid': 8789588,\n",
       "  'sentence': 'Cardiac output decreased [from 4.1 (SEM 0.3) to 2.2 (SEM 0.3) 1.min-1] and heart rate [HR, from 64 (SEM 3) to 100 (SEM 7) beats.min-1], mean arterial pressure (MAP, from 77 (SEM 4) to 89 (SEM 2) mmHg [10.3 (SEM 0.53 to 11.9 (SEM 0.27) kPa]) and total peripheral resistance (TPR, from 19 (SEM 2) to 34 (SEM 4) mmHg.min.1-1 [2.5 (SEM 0.27) to 4.5 (SEM 0.53) kPa.min.1-1]) increased; but with the appearance of presyncopal symptoms, HR, MAP and TPR were reduced to 65 (SEM 8) beats.min-1, 46 (SEM 4) mmHg [6.1 (SEM 0.53) kPa] and 18 (SEM 3) mmHg.min.1-1 [2.4 (SEM 0.4) kPa.min-1.1-1], respectively (P < 0.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'mean arterial pressure']},\n",
       " {'pmid': 8861668,\n",
       "  'sentence': 'Haematocrit, haemoglobin, plasma protein (Prot) and electrolyte (Na+, K+) concentration, osmolality (osm), plasma concentrations of renin (Ren), aldosterone (Ald) and atrial natriuretic peptide (ANP) were determined at rest in a sitting position (T(-30)), and then after 30 min in an upright posture (R(0)), while running a marathon at 10 km (R(10)), 30 km (R(30)) and 42.2 km (R end), and after the marathon at 30 min (T(30)), 60 min (T(60)), 120 min (T(120)) and 24 h (TD(+1)), 48 h (TD(+2)) and 72 h (TD(+3)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['haematocrit',\n",
       "   'haematocrit',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin',\n",
       "   'renin']},\n",
       " {'pmid': 9037439,\n",
       "  'sentence': 'Metabolic studies of pioglitazone (CAS 105355-27-9, AD-4833), a new agent, in rats and dogs using liquid chromatography/tandem mass spectrometry and 1H-nuclear magnetic resonance led to characterization of the following metabolites; the parent compound, (+/-)-5-(p-hydroxybenzyl)-2-4-thiazolidinedione (M-I), (+/-)-5-[p-[2-(5-ethyl-2-pyridyl)-2-hydroxyethoxy]benzyl] -2,4-thiazolidinedione (M-II), (+/-)- 5-[p-[2-(5-acetyl-2-pyridyl)ethoxy]benzyl]2,4-thiazolidinedione (M-III), (+/-)-5-[p-[2-[5-(1-hydroxyethyl)-2- pyridyl]ethoxy]benzyl]-2,4-thiazolidinedione (M-IV), (+/-)-5-[p-[2-(5- carboxymethyl-2-pyridyl)ethoxy]- benzyl]-2,4-thiazolidinedione (M-V), and (+/-)-5-[p-[2-(5-carboxy-2- pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (M-VI).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pioglitazone'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 10967928,\n",
       "  'sentence': 'Cardiac diagnoses included patent ductus arteriosus (PDA) (N = 21, 28.7%), ventricular septal defect (VSD) (N = 9, 12.3%), transposition of great arteries (TGA) (N = 10, 13.7%), tetralogy of Fallot (TOF) (N = 7, 9.6%), double-outlet right ventricle (DORV) (N = 4, 5.5%), truncus arteriosus communis (TAC) (N = 4, 5.5%), hypoplastic left heart syndrome (HLHS) (N = 4, 5.5%), coarctation of aorta (CoAo) (N = 6, 8.2%), total anomalous pulmonary venous return (TAPVR) (N = 2, 2.7%), aortic stenosis (AoVS) (N = 3, 4.1%), interrupted aortic arch (IAA) (N = 1, 1.4%), pulmonary atresia (PA) (N = 1, 1.4%) and common atrioventricular canal (CAVC) (N = 1, 1.4%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'cardiac'],\n",
       "  'reaction': ['patent ductus arteriosus',\n",
       "   'ventricular septal defect',\n",
       "   'ventricular septal defect',\n",
       "   'aortic stenosis',\n",
       "   'stenosis']},\n",
       " {'pmid': 11101600,\n",
       "  'sentence': 'The algorithm for a new identification system was designed on the basis of colony color and morphology on CHROMagar Orientation medium in conjunction with simple biochemical tests such as indole (IND), lysine decarboxylase (LDC), and ornithine decarboxylase (ODC) utilization tests with gram-negative bacilli isolated from urine samples as well as pus, stool, and other clinical specimens by the following colony characteristics, biochemical reactions, and serological results: pinkish to red, IND positive (IND(+)), Escherichia coli; metallic blue, IND(+), LDC(+), and ODC negative (ODC(-)), Klebsiella oxytoca; IND(+), LDC(-), and ODC(+), Citrobacter diversus; IND(+) or IND(-), LDC(-), and ODC(-), Citrobacter freundii; IND(-), LDC(+), and ODC(+), Enterobacter aerogenes; IND(-), LDC(-), and ODC(+), Enterobacter cloacae; IND(-), LDC(+), and ODC(-), Klebsiella pneumoniae; diffuse brown and IND(+), Morganella morganii; IND(-), Proteus mirabilis; aqua blue, Serratia marcescens; bluish green and IND(+), Proteus vulgaris; transparent yellow-green, serology positive, Pseudomonas aeruginosa; clear and serology positive, Salmonella sp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['serology positive', 'serology positive']},\n",
       " {'pmid': 11226128,\n",
       "  'sentence': 'One minute intracarotid infusions of the agonists 5-HT (0.1 - 10 microg min(-1)), sumatriptan (0.3 - 10 microg min(-1); 5-HT(1B/1D)), 5-methoxytryptamine (1 - 100 microg min(-1); 5-HT(1), 5-HT(2), 5-HT(4), 5-ht(6) and 5-HT(7)) or DOI (0.31 - 10 microg min(-1); 5-HT(2)), but not 5-carboxamidotryptamine (0.01 - 0.3 microg min(-1); 5-HT(1), 5-ht(5A) and 5-HT(7)), 1-(m-chlorophenyl)-biguanide (mCPBG; 1 - 1000 microg min(-1); 5-HT(3)) or cisapride (1 - 1000 microg min(-1); 5-HT(4)), resulted in dose-dependent decreases in internal carotid blood flow, without changing blood pressure or heart rate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cisapride', 'sumatriptan'],\n",
       "  'reaction': ['blood pressure', 'heart rate', 'heart rate']},\n",
       " {'pmid': 11256860,\n",
       "  'sentence': 'Blood levels of PCP were associated negatively with (a) total lymphocyte counts (p = .0002), CD4/CD8 ratios (p = .0015), and absolute counts of CD3+ (p < .0001), CD4+ (p < .0001), CD16+ (p < .0001), CD25+ (p = .0003), DR+ (p < .0001), CD8+/56+ (p = .020), and CD19+ cells (p = .092); (b) plasma levels of interleukin-2 (IL-2) (p < .0001), soluble IL-2R (p < .0001), IL-6 (p < .0001), IL-10 (p = .0039), interferon-gamma (IFN-gamma) (p < .0001), tumor necrosis factor-alpha (TNF-alpha) (p < .0001), transforming-growth factor-beta2 (p = .023), soluble IL-1 receptor antagonist (sIL-1 RA) (p < .0001), soluble intercellular adhesion molecule-1 (p = .0003); and (c) immunoglobulin (Ig) M-anti-Fab type autoantibodies (p = .0353).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['necrosis', 'adhesion']},\n",
       " {'pmid': 11421686,\n",
       "  'sentence': 'The distance between the central-metal ions of ruthenium(II) and chromium(III) complexes in [Ru(phen)(3)](2)[Cr(CN)(6)]Cl.2(CH(3))(2)CO.14H(2)O (7.170 A) is shorter than that in [Ru(bpy)(3)](2)[Cr(CN)(6)]Cl.8H(2)O (9.173 A) by about 2 A, while the rate of energy transfer from the (3)MLCT state of [Ru(N-N)(3)](2+) to the (2)E(g) state of [Cr(CN)(6)](3-) in the former salt (9.5 x 10(5) s(-1)) is far slower than that in the latter one (6.0 x 10(6) s(-1)) at 77 K. These results indicate that the energy-transfer rate strongly depends, not upon the distance between central metal ions, rather, upon the mutual relative orientation between the donor and the acceptor complexes in double-complex salts.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 11669724,\n",
       "  'sentence': 'Crystal growth of metal tellurides and tellurometalates employing solvothermal reactions at temperatures below 200 degrees C have resulted in four new indium tellurium phases, [Fe(en)(3)](In(2)Te(6)) (I), [Zn(en)(3)](In(2)Te(6)) (II), and alpha- and beta-[Mo(3)(en)(3)(&mgr;(2)-Te(2))(3)(&mgr;(3)-Te)(&mgr;(3)-O)]In(2)Te(6) (III-alpha and III-beta).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['indium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 11670120,\n",
       "  'sentence': 'Oligomerization of a mixture of monomeric iron(III) 2-hydroxy-5,10,15,20-tetraphenylporphyrin, (2-OH-TPP)Fe(III)Cl, manganese(III) 2-hydroxy-5,10,15,20-tetraphenylporphyrin, (2-OH-TPP)Mn(III)Cl, and gallium(III) 2-hydroxy-5,10,15,20-tetraphenylporphyrin, (2-OH-TPP)Ga(III)Cl, complexes affords the series of heterometallic cyclic trimeric species of the general formula {[(2-O-TPP)Ga(III)](n)()[(2-O-TPP)Fe(III)](3)(-)(n)()}, {[(2-O-TPP)Ga(III)](n)()[(2-O-TPP)Mn(III)](3)(-)(n)()}, and {[(2-O-TPP)Fe(III)](n)()[(2-O-TPP)Mn(III)](3)(-)(n)()} (n = 0-3).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gallium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 11670241,\n",
       "  'sentence': 'Dehydration of [Co(H(2)O)(6)](X)(2) with 2,2-dimethoxypropane or HC(OMe)(3) and subsequent treatment with Me(3)TAC results in the formation of the methoxo cube fragment clusters [{(Me(3)TAC)Co}(3)(OMe)(4)](X)(2) (X = B(C(6)F(5))(4) (2a) and B(m-C(6)H(3)(CF(3))(2))(4) (2b)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac'],\n",
       "  'reaction': ['dehydration']},\n",
       " {'pmid': 11896427,\n",
       "  'sentence': 'To test this approach, 55 patients with relapsed/refractory or high-risk NHL or relapsed/refractory HD were enrolled in the following protocol: stem cell mobilization: cyclophosphamide (4.5 g/m(2)) + etoposide (2.0 g/m(2)) followed by GM-CSF or G-CSF; high-dose therapy: gemcitabine (1.0 g/m(2)) on day -5, BCNU (300 mg/m(2)) + gemcitabine (1.0 g/m(2)) on day -2, melphalan (140 mg/m(2)) on day -1, blood stem cell infusion on day 0; post-transplant immunotherapy (B cell NHL): rituxan (375 mg/m(2)) weekly for 4 weeks + GM-CSF (250 microg thrice weekly) (weeks 4-8); post-transplant involved-field radiotherapy (HD): 30-40 Gy to pre-transplant areas of disease (weeks 4-8); post-transplant consolidation chemotherapy (all patients): dexamethasone (40 mg daily)/cyclophosphamide (300 mg/m(2)/day)/etoposide (30 mg/m(2)/day)/cisplatin (15 mg/m(2)/day) by continuous intravenous infusion for 4 days + gemcitabine (1.0 g/m(2), day 3) (months 3 + 9) alternating with dexamethasone/paclitaxel (135 mg/m(2))/cisplatin (75 mg/m(2)) (months 6 + 12).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gemcitabine'],\n",
       "  'reaction': ['infusion', 'radiotherapy', 'chemotherapy', 'infusion']},\n",
       " {'pmid': 11942853,\n",
       "  'sentence': 'The hybrid density functional method B3LYP was used to study the mechanism of the hydrocarbon (methane, ethane, methyl fluoride, and ethylene) oxidation reaction catalyzed by the complexes cis-(H(2)O)(NH(2))Fe(mu-O)(2)(eta(2)-HCOO)(2)Fe(NH(2))(H(2)O), I, and cis-(HCOO)(Imd)Fe(mu-O)(2)(eta(2)-HCOO)(2)Fe(Imd)(HCOO) (Imd = Imidazole), I_m, the \"small\" and \"medium\" model of compound Q of the methane monooxygenase (MMO).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 11996197,\n",
       "  'sentence': 'The more recent trials indicate that: (1) diuretics and beta-blockers appear to be as effective in reducing overall morbidity/ mortality as other agents (Swedish Trial in Old Patients with Hypertension [STOP-2], United Kingdom Prospective Diabetes Study [UKPDS], Intervention as a Goal in Hypertension Treatment [INSIGHT], Nordic diltiazem [NORDIL]); (2) the use of an a-blocker results in more cardiovascular events, especially congestive heart failure, when compared with a diuretic (Antihypertensive Therapy and Lipid Lowering Heart Attack Trial [ALLHAT]); (3)the use of an angiotensin-converting enzyme (ACE) inhibitor results in fewer myocardial infarctions and episodes of heart failure than calcium channel blockers in the elderly and in diabetic patients (Fosinopril vs. Amlodipine Cardiovascular Events Randomized Trial [FACET], Appropriate Blood Pressure Control in Diabetes [ABCD], STOP-2) - other data (Captopril Prevention Project [CAPPP]) suggest that the use of an ACE inhibitor is preferred in diabetic patients; (4) overall cardiovascular events are similar with calcium channel blockers compared with a diuretic - however, there are fewer strokes with non-dihydropyridine calcium channel blockers (NORDIL) and a trend towards an increase in heart failure and myocardial infarctions with either a dihydropyridine or non-dihydropyridine calcium channel blockers compared with a diuretic (INSIGHT, NORDIL); (5) angiotensin receptor blockers (ARBs) will decrease proteinuria and slow progression of renal disease in type 2 diabetic patients when compared with regimens that do not include an ARB or an ACE inhibitor (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan [RENAAL], Irbesartan Type II Diabetic Nephropathy Trial [IDNT], Irbesartan Type II Diabetes with Microalbuminuria [IRMA Il]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['fosinopril',\n",
       "   'diltiazem',\n",
       "   'amlodipine',\n",
       "   'captopril',\n",
       "   'irbesartan',\n",
       "   'calcium',\n",
       "   'losartan'],\n",
       "  'reaction': ['hypertension',\n",
       "   'hypertension',\n",
       "   'elderly',\n",
       "   'blood pressure',\n",
       "   'proteinuria',\n",
       "   'diabetic nephropathy',\n",
       "   'nephropathy',\n",
       "   'microalbuminuria']},\n",
       " {'pmid': 12168815,\n",
       "  'sentence': 'With this model, growth was not inhibited by addition of vinblastine (1 microg/ml) to the culture medium, but in combination with tropane alkaloids, inhibition was observed with IC50 values categorized as: low (ranging from 0.17-0.62 microM) for 1 [3alpha-phenylacetoxy-6beta-(3,4,5-trimethaxycinnamoyloxy)-tropane], 3 [3alpha-(3,4,5-trimethoxybenzoyloxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)tropane], 4 [3alpha-(3,4,5-trimethoxybenzoyloxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)-7beta-hydroxytropane], 5 [3alpha,6beta-di-(3,4,5-trimethoxycinnamoyloxy)tropane], 6 [3alpha,6beta-di-(3,4,5-trimethoxycinnamoyloxy)-7beta-hydroxytropane] and 9 [6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane]; medium (2.0-3.7 microM) for 2 [3alpha-(3-hydroxyphenylacetoxy)-6beta-(3,4,5-trimethoxycinnamoyloxy)tropane] and 10 [7beta-acetoxy-6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane]; or high (9.8 microM) for 11 [6beta-benzoyloxy-3alpha-(3,4,5-trimethoxycinnamoyloxy)tropane-7beta-ol].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vinblastine', 'medium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 12377033,\n",
       "  'sentence': \"Initially, ammonia solutions of the metals were combined with the salen(t-Bu)H(2) ligands, and in the reaction of strontium with salen(t-Bu)H(2), the unusual tetrametallic cluster [(OC(6)H(2)(t-Bu)(2)CHN(CH(2))(2)NH(2))Sr(mu(3)-salean(t-Bu)H(2))Sr(mu(3)-OH)](2) (7) was produced (salean(t-Bu)H(4) = N,N'-bis(3,5-di-tert-butyl-2-hydroxybenzyl)ethylenediamine).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['strontium'],\n",
       "  'reaction': ['ammonia']},\n",
       " {'pmid': 12462273,\n",
       "  'sentence': 'The experimental period was 36 d. Treatments included: 1) a pelleted basal diet fed at 0.163 Mcal ME x (kg BW(0.75)) x 1 x d(-1) (LE); 2) the basal diet fed at 0.215 Mcal ME x (kg BW(0.75)) (-1) x d(-1) (HE); 3) the basal diet fed at 0.163 Mcal ME x (kg BW(0.75))(-1) x d(-1) with ruminal infusion of starch hydrolysate (SH) (RSH); 4) the basal diet fed at 0.163 Mcal ME x (kg BW(0.75))(-1) x d(-1) with abomasal infusion of SH (ASH); and 5) the basal diet fed at 0.163 Mcal ME x (kg BW(0.75))(-1) x d(-1) with abomasal infusion of glucose (AG).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['infusion', 'infusion', 'infusion']},\n",
       " {'pmid': 12517986,\n",
       "  'sentence': 'By contrast, water intake was inhibited by intracranial injection of eel atrial natriuretic peptide (eANP, 5x10(-13)-5x10(-10) mol), serotonin (5-HT, 5x10(-12)-5x10(-8) mol), ghrelin (5x10(-12)-5x10(-10) mol), gamma-amino butyric acid (GABA, 5x10(-11)-5x10(-8) mol), prolactin (PRL, 5x10(-10)-5x10(-9) mol), arginine vasotocin (AVT, 5x10(-12) mol), vasoactive intestinal peptide (VIP, 5x10(-11) mol), noradrenaline (5x10(-9) mol l(-1)) and phenylephrine (alpha-adrenoceptor agonist, 5x10(-11)-5x10(-9) mol).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 14715685,\n",
       "  'sentence': \"The molecular weight of the serum protein fractions had been extrapolated, so van't Hoff's law and nonlinear regression analysis of the curves permitted expression of the diagram as an equation: product Pi(s,Ott,2 degrees C,cmH2O)=x(alb)(0.338C(tot)+0.00339C(tot)(2))+x(alpha1)(0.518C(tot)+0.0107C(tot)(2))+x(alpha2)(0.203C(tot)+0.00155C(tot)(2))+x(beta)(0.187C(tot)+0.000577C(tot)(2))+x(gamma)(0.161C(tot)+0.000223C(tot)(2)), where Pi(s,Ott,2 degrees C,cmH2O) is Pi of serum at 2 degrees C (in cmH2O) computed from the 1956 diagram, C(tot) is the concentration (g/l) of total protein in serum, and x(alb), x(alpha1), x(alpha2), x(beta), and x(gamma) are the fractions of albumin, alpha1-, alpha2-, beta-, and gamma-globulin, respectively.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gamma-globulin'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 15041577,\n",
       "  'sentence': 'Compared with baseline (SF: 34.9 +/- 3.7 [AC], 34.1 +/- 3.7 [C] [not significant]; stroke volume index [SVI] 36 +/- 6 mL/m(2)[AC], 35 +/- 4 mL/m(2)[C] [not significant]; cardiac index [CI] 3.6 +/- 0.6 L/min/m(2)[AC], 3.2 +/- 0.5 L/min/m(2)[C] [not significant]), we found a significant decrease in SF and SVI in both groups at T1 (SF: 26.2 +/- 3.6 [AC] versus 28.6 +/- 3.6 [C] [P < 0.05]; SVI: 26 +/- 4 mL/m(2) [AC] versus 30 +/- 46 mL/m(2) [C] [P < 0.05]) and T2 (SF: 24.1 +/- 3.2 [AC] versus 28.2 +/- 2.5 [C] [P < 0.01], SVI: 26 +/- 6 mL/m(2) [AC] versus 31 +/- 5 mL/m(2) [C] [P < 0.01]), which was significantly greater in the AC group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'ac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 15107815,\n",
       "  'sentence': 'Median age: 9 years (0.5-20); diagnosis: ALL (9), AML (4), CML (1), HD (3), HLH (1), NHL (3), NBL (2); B-thal (1), FA (1), FEL (1), Krabbe (1), WAS (1), SAA (1); median follow-up: 11 months; conditioning: total body irradiation (TBI)-ablative (14), chemotherapy-ablative (6) and reduced intensity chemotherapy (9); GVHD prophylaxis: MMF/FK506 (18), cyclosporin A (CsA)+steroids+/-MMF (7) or CsA+methotrexate (MTX) (4); median total nucleated cells (TNC): 3.8 x 10(7)/kg (1.1-11); median CD34+: 2.3 x 10(5)/kg (0.2-9.9); and HLA match: 2 (6/6), 5 (5/6), 22 (4/6).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['chemotherapy', 'prophylaxis']},\n",
       " {'pmid': 15186998,\n",
       "  'sentence': 'Thereby, we estimate 1) ACTH SEC (microg.l(-1).day(-1)) of 0.27 +/- 0.04 basal and 0.87 +/- 0.07 pulsatile (means +/- SE); 2) cortisol SEC (micromol.l(-1).day(-1)) of 0.10 +/- 0.01 basal and 3.5 +/- 0.20 pulsatile; 3) free cortisol half-lives (min) of 1.8 +/- 0.20 (diffusion/advection) and 4.1 +/- 0.30 (elimination) and a half-life of total cortisol of 49 +/- 2.4 and of ACTH of 20 +/- 1.3; 4) ACTH potency (EC(50), ng/l) of 26 +/- 2.4, efficacy (nmol.l(-1).min(-1)) 10 +/- 1.8, and sensitivity (slope units) 0.65 +/- 0.09; 5) night/day augmentation of ACTH and cortisol SEC-burst mass by 2.1- and 1.7-fold (median); 6) abbreviation of the modal time to maximal ACTH and cortisol SEC rates by 4.4- and 4.3-fold, respectively, after a change point clock time of 0205 (median); 7) in vivo percentage distribution of cortisol as 6% free, 14% albumin bound, and 80% CBG bound with an absolute free cortisol CON (nmol/l) 11.5 +/- 0.54; and 8) significant (mean CV) stochastic variability in feedforward efficacy (140%), potency (38%), and sensitivity (56%) within the succession of paired ACTH/cortisol pulses of any given subject.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'mass',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol']},\n",
       " {'pmid': 15651865,\n",
       "  'sentence': 'The temperature dependence of the magnetic susceptibility was fitted to the spin Hamiltonian H = J(ab)S(a)S(b) + J(bc)S(b)S(c) + J(cd)S(c)S(d) + J(ad)S(a)S(d) + J(ac)S(a)S(c) + J(bd)S(b)S(d) with the exchange integrals J(ab) = J(bc) = J(cd) = J(ad) = -65(3) cm(-1) and J(ac) = J(bd) = +1(3) cm(-1).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 15757505,\n",
       "  'sentence': '2 The increase in mean arterial pressure evoked by 2.3 nmol of PYY was not blocked by intravenous pretreatment with: (i) the nicotinic ganglionic receptor antagonist pentolinium (PENT, 10 mg kg(-1)) alone, or in combination with the muscarinic receptor antagonist methylatropine (MeATR, 1 mg kg(-1)); (ii) the alpha(1)-adrenoceptor antagonist prazosin (PRAZ, 0.2 mg kg(-1)); (iii) the V(1)-vasopressin receptor antagonist [d(CH(2))(5)Tyr(Me)]AVP (AVPX, 20 microg kg(-1)); (iv) the combination of AVPX, PENT and MeATR; (v) the combination of PRAZ, AVPX, PENT, MeATR, and the alpha(2)-adrenoceptor antagonist yohimbine (0.3 mg kg(-1)); or (vi) the angiotensin II type 1 receptor antagonist ZD 7155 (1 mg kg(-1)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['prazosin'],\n",
       "  'reaction': ['mean arterial pressure']},\n",
       " {'pmid': 16477689,\n",
       "  'sentence': 'The high resolution offered by magic-angle spinning (MAS), when compared to the static condition in solid-state NMR of powders, has been used to full advantage in a (14)N MAS NMR study of some ammonium salts: CH(3)NH(3)Cl, (NH(4))(2)(COO)(2) x H(2)O, (CH(3))(3)(C(6)H(5)CH(2))NCl, (CH(3))(3)(C(6)H(5))NI, [(n-C(4)H(9))(4)N](2)Mo(2)O(7), (NH(4))(2)HPO(4), and NH(4)H(2)PO(4).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ammonium'],\n",
       "  'reaction': ['condition']},\n",
       " {'pmid': 16757145,\n",
       "  'sentence': \"Synergistic effect of polyoxometalates, K(6)[P(2)W(18)O(62)].14H(2)O (P(2)W(18)), K(4)[SiMo(12)O(40)].3H(2)O (SiMo(12)), K(7)[PTi(2)W(10)O(40)].6H(2)O (PTi(2)W(10)), and K(9)H(5)[alpha-Ge(2)Ti(6)W(18)O(77)].16H(2)O (Ge(2)Ti(6)W(18)), in combination with a beta-lactam oxacillin against methicillin-resistant and vancomycin-resistant Staphylococcus aureus (characterized by possessing the penicillin-binding protein 2' (PBP2') as a cell-wall synthesis enzyme) with a high initial inoculum of 1 x 10(8) cfu/ml (for in vivo test) was investigated with a help of the growth curve and the reverse transcription polymerase chain reaction (RT-PCR) analyses.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxacillin'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 16776635,\n",
       "  'sentence': 'Indirect reference intervals for most of the biochemical analytes were comparable, with small differences in lower [alkaline phosphatase (ALP) (male), alanine aminotransferase (ALT), creatine kinase, iron (male), total iron-binding capacity, folic acid, calcium (female), lactate dehydrogenase (LDH), lipoprotein (a) [Lp(a)], thyroid-stimulating hormone (TSH), total triiodothyronine (T(3)), direct bilirubin, apolipoprotein A-I (apoA-I), glucose, homocysteine, total cholesterol, ferritin, total protein, ceruloplasmin, sodium, blood urea nitrogen (BUN) and uric acid (female)] and/or upper limits [albumin, ALP (male), amylase, apoA-I, creatine kinase-MB (CK-MB), total iron-binding capacity, phosphorus, glucose, total cholesterol, gamma-glutamyltransferase (gamma-GT), magnesium, total protein, high-density lipoprotein cholesterol (HDL-C), total T(3), ALP (male), ALT, aspartate aminotransferase (AST) (male), direct bilirubin (male), creatine kinase, iron, folic acid (female), Lp(a), uric acid and triglycerides], to the reference intervals determined for healthy subjects in our laboratory.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'magnesium', 'cholesterol', 'sodium'],\n",
       "  'reaction': ['alanine aminotransferase',\n",
       "   'ceruloplasmin',\n",
       "   'blood urea',\n",
       "   'blood urea',\n",
       "   'amylase',\n",
       "   'amylase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'aspartate aminotransferase']},\n",
       " {'pmid': 16788687,\n",
       "  'sentence': 'Factors associated with cardiac events were (adjusted hazard ratios) tobacco (3.53; P<0.001), obesity (2.92; P<0.001), diabetes (2.63; P<0.001), multiple rejections (2.19; P=0.008), prior CVE (2.0; P=0.004), dialysis >1 year (1.91; P=0.007), and overweight status (1.68; P=0.04); with cerebrovascular events: diabetes and peritoneal dialysis (11.95; P<0.001), age >45 (6.77; P<0.001), diabetes (4.87; P<0.001), prior CVE (3.73; P<0.001), creatinine >141 micromol/l (3.16; P=0.001), peritoneal dialysis (3.06; P=0.027), and obesity (0.32; P=0.046); with peripheral-vascular events: diabetes (8.48; P<0.001), tobacco and cytomegalovirus (3.88; P<0.001), age >45 (2.31; P=0.019), and prior CVE (2.25; P=0.016); with mortality: tobacco and deceased-donor (3.52; P<0.001), age >45 (1.81; P=0.002), diabetes (1.76; P=0.002), pulse pressure (1.64; P=0.029), prior CVE (1.52; P=0.04), and dialysis >1 year (1.47; P=0.04).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['obesity',\n",
       "   'dialysis',\n",
       "   'overweight',\n",
       "   'peritoneal dialysis',\n",
       "   'dialysis',\n",
       "   'peritoneal dialysis',\n",
       "   'dialysis',\n",
       "   'obesity',\n",
       "   'pulse pressure',\n",
       "   'dialysis']},\n",
       " {'pmid': 17316791,\n",
       "  'sentence': 'The results showed that (1) intraventricular injection (icv) of anti-arginine vasopressin (AVP) serum completely reversed pain threshold increase induced by l-glutamate sodium (Glu) injection into the PVN, and local administration (icv) of anti-leucine-enkephalin (L-Ek) serum or anti-beta-endorphin (beta-Ep) serum partly attenuated pain threshold increase induced by Glu injection into the PVN, but pre-treatment of anti-oxytocin (OXT), dynorphinA(1-13) (DynA(1-13)), cholecystokinin-like peptide (CCK), neurotensin (NT), corticotrophin-releasing hormone (CRH), adrenocorticotrophin (ACTH), somatostatin (SST), prolactin-releasing hormone (PRH), angiotensinII (AngII), vasoactive intestinal polypeptide (VIP), melanotropin-releasing hormone (MRH), thyrotropin-releasing hormone (TRH), substance P (SP) or growth hormone-releasing hormone (GHRH) serum (icv) did not influence the analgesic effect of PVN administration with Glu; (2) PVN stimulation with Glu elevated the concentrations of AVP, OXT, CCK, NT, CRH, SST, PRH and DynA(1-13) in PVN perfusion liquid, and could not change the concentrations of L-Ek, beta-Ep, AngII, ACTH, VIP, MRH, TRH, SP and GHRH in PVN perfusion liquid; (3) Pain stimulation increased the concentrations of AVP, L-Ek, beta-Ep, DynA(1-13), CRH and ACTH in PVN perfusion liquid, and did not alter the concentrations of OXT, CCK, NT, SST, PRH, AngII, VIP, MRH, TRH, SP and GHRH in PVN perfusion liquid.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium',\n",
       "   'vasopressin',\n",
       "   'polypeptide',\n",
       "   'somatostatin',\n",
       "   'peptide'],\n",
       "  'reaction': ['injection',\n",
       "   'pain',\n",
       "   'injection',\n",
       "   'pain',\n",
       "   'injection',\n",
       "   'growth',\n",
       "   'pain']},\n",
       " {'pmid': 17340669,\n",
       "  'sentence': 'In vitro cytotoxic assays (IC(50)) in the human bladder cancer cell line 5637 and in the murine leukemia L1210 cell line revealed that [Pt(S,S-dach)(phen)](ClO(4))(2) (0.091 and 0.13 microM, respectively) and [Pt(R,R-dach)(phen)](ClO(4))(2) (0.54 and 1.50 microM, respectively) were more cytotoxic than cisplatin (0.31 and 0.50 microM, respectively) and considerably more cytotoxic than their methylated counterparts, [Pt(Me(2)-R,R-dach)(phen)](ClO(4))(2) and [Pt(Me(2)-S,S-dach)(phen)](ClO(4))(2) (both>23 microM).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['bladder cancer']},\n",
       " {'pmid': 17354463,\n",
       "  'sentence': 'Confidence intervals (p<0.05) for PCV (28.6-31.6%), RBC (0.40-0.44 T/L), MCV (686-732 fL), hemoglobin (6.41-7.20 g/dL), MCH (151-164 pg), MCHC (22.6-24.0%), WBC (18.7-22.3 G/L), neutrophils (58.4-63.4%), lymphocytes (23.9-29.8%), monocytes (2.1-3.8%), eosinophils (4.6-7.0%), basophils (2.9-4.1%), bleeding time (289-393s), coagulation time (452-696s), prothrombin time (76-128s), urinary density (1.0061-1.0089 g/mL), urinary pH (6,38-6.96)., fibrinogen (0.59-0.99 g/dL), total protein (4.19-4.49 g/dL), albumin (1.49-1.67 g/dL), alpha-1 globulin (0.20-0.24 g/dL), alpha-2 globulin (0.48-0.54 g/dL), beta globulin (0.68-0.77 g/dL), gamma globulin (1.28-1.42 g/dL), albumin/globulin ratio (0.50-0.58), creatinine (4.09-5.56 mg/L).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['globulin'],\n",
       "  'reaction': ['bleeding time',\n",
       "   'coagulation time',\n",
       "   'prothrombin time',\n",
       "   'beta globulin']},\n",
       " {'pmid': 17467332,\n",
       "  'sentence': 'The investigation of the new structures of Ag(I), Cu(II) and Au(III) complexes, [Ag(2)(Nor)(2)](NO(3))(2), [Cu(Nor)(2)(H(2)O)(2)]SO(4).5H(2)O and [Au(Nor)(2) (H(2)O)(2)]Cl(3) (where, Nor=norfloxacin) was done during the reaction of silver(I), copper(II) and gold(III) ions with norfloxacin drug ligand.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['norfloxacin'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 17482801,\n",
       "  'sentence': 'Different physicochemical properties of Langmuir films (monolayers) composed of 10 mixed systems of a bile acid, deoxycholic acid (DC) with various plant sterols, such as stigmasterol (Stig), beta-sitosterol (Sito) and campesterol (Camp) and a stanol, cholestanol (Chsta) in addition to an animal sterol, cholesterol (Ch) [these sterols and Chsta are abbreviated as St] and DC with 1:1 St mixtures; (Ch+Chsta), (Ch+Stig), (Stig+Chsta), (Ch+Sito) and (Ch+Camp) on the substrate of 5M aqueous NaCl solution (pH 1.2) at 25 degrees C, were investigated in terms of mean surface area per molecule (A(m)), the partial molecular area (PMA), surface excess Gibbs energy (DeltaG((ex))), interaction parameter (I(p)) as well as activity coefficients (f(1) and f(2)) in 2-D phase of each binary (or ternary) component system and elasticity (Cs(-1)) of formed films; these were analyzed on the basis of the respective surface pressure (pi) versus A(m) isotherms as a function of mole fraction of Sts (X(st)) in the DC/St(s) mixtures at discrete surface pressures.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'beta-sitosterol'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 17640936,\n",
       "  'sentence': 'Compared with control, both Man and Los significantly (P < 0.05) attenuated the improvement in mean arterial blood pressure (MAP), cardiac index and mesenteric blood flow (SMBF) in response to intravenous hypertonic NaCl: MAP, rapid response +45 mmHg versus +38 mmHg (Man) and +35 mmHg (Los); after 180 min, +32 mmHg versus +21 mmHg (Man) and +19 mmHg (Los); cardiac index after 180 min, +1.9 l min(-1) (m(2))(-1) versus +0.9 l min(-1) (m(2))(-1) (Man) and +0.9 l min(-1) (m(2))(-1) (Los); SMBF rapid response, +981 ml min(-1) versus +719 ml min(-1) (Man) and +744 ml min(-1) (Los); after 180 min, +602 ml min(-1) versus +372 ml min(-1) (Man) and +314 ml min(-1) (Los).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['blood pressure', 'cardiac index', 'cardiac index']},\n",
       " {'pmid': 17878600,\n",
       "  'sentence': 'To clarify this link, pulmonary ventilation parameters such as oxygen uptake (V(O(2))) and carbon dioxide output (V(CO(2))), as well as the HRV with spectral analysis (high- and low-frequency components of HRV, i.e., CCV(HF) and CCV(LF), reflecting cardiac parasympathetic and sympathetic activities, respectively), were measured in 66 healthy women aged 19-20 years after an overnight fast of 12 h. Significant correlations were found between the CCV(HF) of HRV and both the end-tidal carbon dioxide concentration (FET(CO(2))) and gas exchange ratio (V(CO(2))/V(O(2))) in the subjects (partial correlation coefficients r = 0.354 and 0.320, respectively), whereas there was no significant connection between the FET(CO(2)) and the V(CO(2))/V(O(2)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['carbon dioxide', 'carbon dioxide']},\n",
       " {'pmid': 17957564,\n",
       "  'sentence': 'The results showed that: (i) in physiological conditions, [Ca(2+)](i) was approximately 10% increased in the platelets of the mature subjects, and approximately 33% enhanced at the older group (vs. young), sustaining that biological ageing is associated with accumulation of free [Ca(2+)](i) within the platelets cytoplasm; (ii) in type 2 diabetes, [Ca(2+)](i) was approximately 16% and approximately 27% higher in the platelets of mature and older patients, respectively (vs. age-matched normals), demonstrating that ageing of diabetics is accompanied by alterations in calcium balance (vs. physiological ageing); (iii) thrombin (1U/ml) induced approximately 39% increase of [Ca(2+)](i) in platelets of matures and approximately 29% at older normals, and approximately 34% increase at the mature diabetics, approximately 84% at the older diabetics (vs. no thrombin condition), indicating that under thrombin stimulation simultaneous insults of diabetes and advanced age produced a higher thrombin-evoked mobilization of Ca(2+) from intracellular stores; (iv) the components of the diabetic milieu had various effects on platelet free [Ca(2+)](i): high enhancement ( approximately 73%) in 25.5 mM glucose (vs. 11 mM glucose), a minor increase ( approximately 15%) in 100 mM H(2)O(2), and a decrease (by approximately 56% and approximately 132%) in 1.7 mM AGE- poly-L-lysine (vs. poly-L-lysine) and 2.26 mM AGE- albumin (vs. albumin), respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['condition']},\n",
       " {'pmid': 18155914,\n",
       "  'sentence': 'Carbon-11 labeled cyclofenil derivatives, [(11)C]methyl-2-{4-[bis(4-hydroxyphenyl)methylene]cyclohexyl}acetate ([(11)C]16a), [(11)C]methyl-4-[bis(4-hydroxyphenyl)methylene]cyclohexanecarboxylate ([(11)C]16b), [(11)C]methyl-2-{3-[bis(4-hydroxyphenyl)methylene]cyclohexyl}acetate ([(11)C]18a), and [(11)C]methyl-3-[bis(4-hydroxyphenyl)methylene]cyclohexanecarboxylate ([(11)C]18b), have been synthesized as new potential PET agents for imaging breast cancer estrogen receptors.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cyclofenil'],\n",
       "  'reaction': ['breast cancer']},\n",
       " {'pmid': 18227124,\n",
       "  'sentence': \"TNF-alpha significantly increased HTSMC-neutrophil adhesions, and this effect was associated with increased expression of VCAM-1 on the HTSMCs and was blocked by the selective inhibitors of Src [4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1)], epidermal growth factor receptor [EGFR; 4-(3'-chloroanilino)-6,7-dimethoxy-quinazoline, (AG1478)], phosphatidylinositol 3-kinase (PI3K) [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride(LY294002) and wortmannin],calcium[1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester; BAPTA-AM], phosphatidylinositol-phospholipase C (PLC) [1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122)], protein kinase C (PKC) [12-(2-cyanoethyl)-6,7,12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (GÃ¶6976), rottlerin, and 3-1-[3-(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl) maleimide (bisindolylmaleimide IX) (Ro 31-8220)], CaM (calmidazolium chloride), CaM kinase II [(8R(*),9S(*),11S(*))-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-14-n-propoxy-2,3,9, 10-tetrahydro-8,11-epoxy, 1H,8H, 11H-2,7b,11a-triazadibenzo[a,g]cycloocta[cde]trinden-1-one (KT5926) and 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine (KN62)], p300 (curcumin), and HDAC (trichostatin A) or transfection with short interfering RNAs for Src, Akt, PKCalpha, PKCmu, and HDAC4.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 18414750,\n",
       "  'sentence': 'The first phosphane complexes of germanium(iv) fluoride, trans-[GeF(4)(PR(3))(2)] (R = Me or Ph) and cis-[GeF(4)(diphosphane)] (diphosphane = R(2)P(CH(2))(2)PR(2), R = Me, Et, Ph or Cy; o-C(6)H(4)(PR(2))(2), R = Me or Ph) have been prepared from [GeF(4)(MeCN)(2)] and the ligands in dry CH(2)Cl(2) and characterised by microanalysis, IR, Raman, (1)H, (19)F{(1)H} and (31)P{(1)H} NMR spectroscopy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['germanium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 18436666,\n",
       "  'sentence': 'Hepatic samples were tested for levels (parts per million; ppm) of aluminum (Al), antimony (Sb), arsenic (As), barium (Ba), boron (B), cadmium (Cd), calcium (Ca), chromium (Cr), cobalt (Co), copper (Cu), iron (Fe), lead (Pb), magnesium (Mg), manganese (Mn), mercury (Hg), molybdenum (Mo), nickel (Ni), phosphorus (P), potassium (K), selenium (Se), sodium (Na), sulfur (S), thalium (Tl), and zinc (Zn).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium',\n",
       "   'sodium',\n",
       "   'barium',\n",
       "   'chromium',\n",
       "   'selenium',\n",
       "   'magnesium',\n",
       "   'potassium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 18436686,\n",
       "  'sentence': 'Mean +/- SE metal concentrations (mg/kg wet weight) in liver were determined for vanadium (V) (0.12 +/- 0.01), chromium (Cr) (0.50 +/- 0.02), manganese (Mn) (2.68 +/- 0.11), iron (Fe) (1,019 +/- 103), nickel (Ni) (0.40 +/- 0.04), cobalt (Co) (0.08 +/- 0.02), copper (Cu) (6.43 +/- 0.40), mercury (Hg) (0.30 +/- 0.09), selenium (Se) (1.45 +/- 0.64), zinc (Zn) (59.2 +/- 4.70), molybdenum (Mo) (0.93 +/- 0.07), cadmium (Cd) (1.44 +/- 0.14), barium (Ba) (0.20 +/- 0.03), and lead (Pb) (0.17 +/- 0.03).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['selenium', 'barium', 'chromium', 'vanadium'],\n",
       "  'reaction': ['weight', 'weight', 'manganese']},\n",
       " {'pmid': 18966261,\n",
       "  'sentence': 'The complexation of urea (ur) with manganese(II), nickel(II) and zinc(II) ions has been studied by titration calorimetry in N,N-dimethylformamide (DMF) containing 0.4M (C(2)H(5))(4) NBF(4) as a constant ionic medium at 25 degrees C. The calorimetric data were well explained in terms of the formation of [Mn(ur)](2+), [Mn(ur)(2)](2+) and [Mn(ur)(4)](2+) for manganese(II), [Ni(ur)](2+) for nickel(II) and [Zn(ur)](2+) and [Zn(ur)(2)](2+) for zinc(II), and their formation constants, reaction enthalpies and entropies were determined.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['manganese', 'manganese']},\n",
       " {'pmid': 18969326,\n",
       "  'sentence': 'The thermodynamic dissociation constant pK(a)(T) was estimated by non-linear regression of {pK(a), I} data at 25 and 37 degrees C: for ambroxol p K (a ,1)(T )=8.05 (6) and 8.25 (4), logbeta (21)(T )=11.67 (6) and 11.83 (8), for antazoline p K (a ,1)(T )=7.79 (2) and 7.83 (6), p K (a ,2)(T )=9.74 (3) and 9.55 (2), for naphazoline pK (a ,1)(T )=10.81 (1) and 10.63 (1), for oxymethazoline pK (a ,1)(T )=10.62 (2) and 10.77 (7), pK(a,2)(T)=12.03(3) and 11.82 (4) and for ranitidine p K (a ,1)(T )=1.89 (1) and 1.77 (1).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['naphazoline', 'antazoline', 'ranitidine'],\n",
       "  'reaction': ['dissociation']},\n",
       " {'pmid': 19101674,\n",
       "  'sentence': 'It has been observed that, at 25.0+/-0.1 degrees C, [Co(NH(3))(6)](ClO(4))(3), [Co(en)(3)](ClO(4))(3), [Co(bpy)(3)](ClO(4))(3), and [Co(phen)(3)](ClO(4))(3) in the regions of 1.25-5.00 mM aqueous solutions cause a significant surface tension reduction (STR) of water by the surfactants, sodium dodecylsulfate (SDS) and sodium dodecylbenzenesulfonate (SBS), suggesting the formation of the 1:1 and 1:2 association complexes, {[complex](3+)(S(-))}(2+) and {[complex](3+)(S(-))(2)}(+) where [complex](3+)=[Co(NH(3))(6)](3+), [Co(en)(3)](3+), [Co(bpy)(3)](3+), or [Co(phen)(3)](3+), S(-)=DS(-) or BS(-).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['tension']},\n",
       " {'pmid': 19295068,\n",
       "  'sentence': 'The water quality parameters namely transparency (12.12-110 cm), colour (transparent-very turbid), turbidity (1-178 TNU), electrical conductivity (145.60-884 microS cm(-1)), total dissolved solids (260-500 mgl(-1)), pH (7.60-9.33), dissolved oxygen (4.86-14.59 mgl(-1)), free carbon dioxide (0-16.5 mgl(-1)), total alkalinity (70-290 mgl(-1)), total hardness (42-140 mgl(-1)), chloride (15.62-80.94 mgl(-1)), nitrate (0.008-0.025 mgl(-1)), nitrite (0.002-0.022 mgl(-1)), sulphate (3.50-45 mgl(-1)), phosphate (0.004-0.050 mgl(-1)), silicate (2.80-13.80 mgl(-1)), biochemical oxygen demand (0.60-5.67 mgl(-1)), chemical oxygen demand (2.40-26.80 mgl(-1)), ammonia (nil-0.56 mgl(-1)), sodium (14.30-54.40 mgl(-1)) and potassium (2.10 mgl(-1)-6.30 mgl(-1)) reflects on the pristine nature of the river in National Chambal sanctuary.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium', 'sodium'],\n",
       "  'reaction': ['carbon dioxide', 'ammonia']},\n",
       " {'pmid': 19474191,\n",
       "  'sentence': 'After intraperitoneal injection of 0.5 ng/g body wt 1,25(OH)(2)D(3), peak calcemic responses were observed at 24 h in all three genotypes in association with 1) a greater increase in serum Ca(2+) in C(-)P(-) mice than in the other genotypes on a Ca(2+)-replete diet that was attenuated by a Ca(2+)-deficient diet and pamidronate, 2) increased urinary Ca(2+)-to-creatinine ratios (UCa/Cr) in the C(+)P(-) and C(+)P(+) mice but a lowered ratio in the C(-)P(-) mice on a Ca(2+)-replete diet, and 3) no increase in calcitonin (CT) secretion in the C(+)P(+) and C(+)P(-) mice and a small increase in the C(-)P(-) mice.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pamidronate'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 19609518,\n",
       "  'sentence': 'They included the following: age 20-40 (1), sex (2), family history (3), Gulf returned (1), external occupation (1), primary (1), recurrent (5), symptoms (2), RBC (1), PC (1), COD (1), COM (2), UA (2), crystal aggregation (2), urinary infection (1), pH below 6 (1), bilateralism (2), kidney/U/B/U (1), passer (2), multiple organs (2), multiple number (2), incomplete removal (5), serum calcium (3), serum phosphorus (1), serum magnesium (1), serum creatinine (1), serum uric acid (4), urine volume (1), urine specific gravity (1), urine calcium (1), urine phosphorus (1), urine uric acid (5), urine magnesium (2), urine oxalate (8), urine citrate (8), calcium magnesium ratio (2), creatinine clearance (1), tubular reabsorption of phosphate (4), urine calcium oxalate ratio (2), urine oxalate citrate ratio (5), urine oxalate uric acid ratio (2), urine calcium uric acid ratio (2), stone COM/COD (2) and stone UA/cystine (2).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium', 'calcium'],\n",
       "  'reaction': ['infection',\n",
       "   'urine calcium',\n",
       "   'urine phosphorus',\n",
       "   'urine phosphorus',\n",
       "   'urine uric acid',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine calcium',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine calcium']},\n",
       " {'pmid': 19683453,\n",
       "  'sentence': 'Carbon-11 labeled celecoxib derivatives, [(11)C]methyl 2-(4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)acetate ([(11)C]6e), [(11)C]methyl 2-methyl-2-(4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)propanoate ([(11)C]6f), [(11)C]methyl 2-(4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)acetate ([(11)C]6g), and [(11)C]methyl 2-methyl-2-(4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)propanoate ([(11)C]6h), were prepared by O-[(11)C]methylation of their corresponding precursors using [(11)C]CH(3)OTf under basic condition and isolated by a simplified solid-phase extraction (SPE) method in 50-60% radiochemical yields based on [(11)C]CO(2) and decay corrected to end of bombardment (EOB).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['celecoxib'],\n",
       "  'reaction': ['condition']},\n",
       " {'pmid': 19690072,\n",
       "  'sentence': 'In the in vitro experiment, the enzymatically dispersed rat Leydig cells were prepared and challenged with forskolin (an adenylyl cyclase activator, 10(-4) M), 8-Br-cAMP (a membrane-permeable analog of cAMP, 10(-4) M), hCG (0.05 IU), the precursors of the biosynthesis testosterone, including 25-OH-C (10(-5) M), pregnenolone (10(-7) M), progesterone (10(-7) M), 17-OH-progesterone (10(-7) M), and androstendione (10(-7)-10(-5) M), nifedipine (L-type Ca(2+) channel blocker, 10(-6)-10(-4) M), nimodipine (L-type Ca(2+) channel blocker, 10(-5) M), tetrandrine (L-type Ca(2+) channel blocker, 10(-5) M), and NAADP (calcium-signaling messenger causing release of calcium from intracellular stores, 10(-6)-10(-4) M).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nifedipine', 'pregnenolone', 'calcium', 'nimodipine'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 19856969,\n",
       "  'sentence': 'Both Li(2)(BH(4))(NH(2)) and Li(4)(BH(4))(NH(2))(3) exhibit a lithium fast-ion conductivity of 2 x 10(-4) S/cm at RT, and the activation energy for conduction in Li(4)(BH(4))(NH(2))(3) is evaluated to be 0.26 eV, less than half those in Li(2)(BH(4))(NH(2)) and Li(BH(4)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 19900977,\n",
       "  'sentence': 'There were significant differences between SS/SLE and SLE-only patients in the following manifestations (p < 0.05): (1) sex ratio (F/M) (41/0 versus 184/30), age (42.8 +/- 41.0 years versus 31.8 +/- 31.0 years), disease duration (113.8 +/- 84.0 months versus 44.9 +/- 18.0 months); (2) clinical features, xerostomia (85.4% versus 6.1%), xerophthalmia (75.6% versus 2.3%), renal tubular acidosis (21.9% versus 0%), interstitial lung disease (12.2% versus 2.8%), facial rash (9.8% versus 46.3%), nephrotic syndrome (7.3% versus 31.3%), central nervous system involvement (4.9% versus 19.6%); (3) laboratory findings, ESR (64.6+/-75.0mm/h versus 46.5+/-34.0mm/h), C4 (14.8 +/- 12.2 g/dl versus 12.0 +/- 10.9 g/dl), IgG elevation (56.4% versus 29.9%) and IgA elevation (38.5% versus 20.4%), RF, anti-SSA and anti-SSB positive rates (70.8% versus 20.3%, 82.9% versus 43.4% and 39.0% versus 7.9%); (4) SLEDAI score (8.0 +/- 8.0 versus 10.2 +/- 10.0), glucocorticoid treatment (methylprednisolone bolus/1-2 mg kg(-1) day(-1) prednisone/<1 mg kg(-1) day(-1) prednisone) (8/26/7 versus 91/102/21), and importantly, rate of death and/or severe irreversible organ failure (2.4% versus 14.9%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['methylprednisolone'],\n",
       "  'reaction': ['xerophthalmia',\n",
       "   'renal tubular acidosis',\n",
       "   'acidosis',\n",
       "   'interstitial lung disease',\n",
       "   'rash',\n",
       "   'nephrotic syndrome',\n",
       "   'death',\n",
       "   'organ failure']},\n",
       " {'pmid': 20030371,\n",
       "  'sentence': 'The single-crystal X-ray crystallographic analysis on crystals of L(1) with tetrabutylammonium salts of nitrate (1), acetate (2), fluoride (3), and chloride (4) obtained in moist dioxane medium showed encapsulation of two NO(3)(-), [(AcO)(2)(H(2)O)(4)](2-), [F(2)(H(2)O)(6)](2-), and [Cl(2)(H(2)O)(4)](2-) respectively as the anionic guests inside the staggered dimeric capsular assembly of L(1).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 20048421,\n",
       "  'sentence': 'Erlotinib [systematic name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine], a small-molecule epidermal growth factor receptor inhibitor, useful for the treatment of non-small-cell lung cancer, has been crystallized as erlotinib monohydrate, C(22)H(23)N(3)O(4).H(2)O, (I), the erlotinib hemioxalate salt [systematic name: 4-amino-N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-1-ium hemioxalate], C(22)H(24)N(3)O(4)(+).0.5C(2)O(4)(2-), (II), and the cocrystal erlotinib fumaric acid hemisolvate dihydrate, C(22)H(23)N(3)O(4).0.5C(4)H(4)O(4).2H(2)O, (III).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['erlotinib'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 20095647,\n",
       "  'sentence': 'The reactions of manganese(II) acetate or perchlorate, sodium azide, and the inner-salt-type dicarboxylate ligand 1,3-bis(4-carboxylato-1-pyridinium)propane (L) under different conditions yielded four different Mn(II) coordination polymers with mixed azide and carboxylate bridges: {[Mn(L)(N(3))]ClO(4).0.5H(2)O}(n) (1), {[Mn(2)(L)(2)(N(3))(2)][Mn(N(3))(4)(H(2)O)(2)].2H(2)O}(n) (2), {[Mn(2)(L)(2)(N(3))(2)(H(2)O)(2)]Br(N(3)).2H(2)O}(n) (3), and [Mn(4) (L)(2)(N(3))(8)](n) (4).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 20199047,\n",
       "  'sentence': 'According to their E(T)(30) or E(T)(33) values, the hydroxyl ILs can be further classified into the following three groups: (Iota) acetate-based hydroxyl ILs [HOEMIm][AC] exhibit polarity scale (E(T)(30) = 51.2 kcal/mol) similar to short chain alcohol and fall in the range of the nonhydroxyl ILs; (II) Hydroxyl ILs containing anions [NO(3)], [DCA], and [Cl] exhibit comparable polarity (E(T)(30) = 55.5-56.9 kcal/mol), moderately higher than those of their nonhydroxyl ILs; (III) Hydroxyl ILs containing anions [PF(6)], [NTf(2)], and [ClO(4)] possess unusual \"hyperpolarity\" (E(T)(30) = 60.3-61.7 kcal/mol) close to protic ILs and water.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['fall']},\n",
       " {'pmid': 20572656,\n",
       "  'sentence': 'We find four different (meta-)stable species, namely (3)D(2h)-UO(2)(eta(2)-O(2)(*))(2) at lowest energy, (3)C(2v)-UO(4)(*)(eta(2)-O(2)(*)) and (1)D(3)-U(eta(2)-O(2))(3) at medium energies, and (1)O(h)-UO(6) at highest energy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['energy', 'energy']},\n",
       " {'pmid': 20604535,\n",
       "  'sentence': 'Salient features of the mechanism include: (1) the near thermoneutrality of the O(2)-alkene exchange reaction, consistent with experimentally observed reversible exchange between O(2) and alkenes at well-defined Pd centers, (2) end-on activation of triplet O(2) at an apical site of the trigonal Pd(0) center, resulting in formation of a Pd(I)(Î·(1)-superoxide) species, (3) rearrangement of the Pd(I)(Î·(1)-superoxide) species into a pseudo-octahedral (en)Pd(Î·(2)-O(2))(Î·(2)-C(2)H(4)) species with concomitant crossing from the triplet to singlet energy surfaces, and (4) release of alkene from an axial face of (en)Pd(II)(Î·(2)-peroxo) with a geometry in which the alkene leaves with an end-on trajectory (involving an interaction of the Pd d(z(2)) and alkene Ï€* orbitals).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 20936202,\n",
       "  'sentence': \"The reaction of molybdate with vanadium(V) in the presence of sulfite anions is explored showing how, via cation control, stepwise assembly through the {Mo(11)V(7)} cluster yields a {M(25)} cluster-based compound, [Mo(VI)(11)V(V)(5)V(IV)(2)O(52)(Î¼(9)-SO(3))(Mo(VI)(6)V(V)O(22))](10-) (1a), which was first discovered using cryospray mass spectrometry, whereas switching the cation away from ammonium allows the direct formation of the spherical 'Keplerate' {Mo(72)V(30)} cluster.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vanadium', 'ammonium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 21036717,\n",
       "  'sentence': 'In this study, binary combinations of four platinum compounds cisplatin (Cs), oxaliplatin (Ox), YH12 [trans-PtCl(2)(ammino) {imidazo-(1,2-Î±)pyridine}] and TH1 [{trans-PtCl(NH(3))(2)}(2) {trans-Pt(3-hydroxypyridine)(2)(H(2)N(CH(2)) 6NH(2))(2)}Cl(4)] and two plant-based mitotic inhibitors paclitaxel (Tx) and colchicine (Co) have been used against ovarian cancer cell lines A2780 and A2780(cisR) using five different sequences of addition: 0/0 h, 4/0 h, 0/4 h, 24/0 h and 0/24 h. The strongest synergistic effect was observed when the plant compound (Tx or Co) was added first followed by platinum four hours later with combination index at 50% effect level (fa= 0.5) ranging from 0.03 to 0.36 and 0.10 to 0.72 in A2780 and A2780(cisR) cells respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['paclitaxel', 'oxaliplatin', 'cisplatin'],\n",
       "  'reaction': ['ovarian cancer']},\n",
       " {'pmid': 21139332,\n",
       "  'sentence': 'However, we did not observe RPL3-mediated transport of several organic solutes such as [(14)C]androstenedione, [(3)H]dexamethasone, [(3)H]dehydroepiandrosterone sulfate, [(3)H]L-tryptophan, [(14)C]L-ascorbic acid, [(14)C]Î±-ketoglutarate, [(14)C]glutarate, [(3)H]methotrexate, [(3)H]bumetanide, [(3)H]probenecid, [(14)C]salicylic acid, [(14)C]theophylline and [(3)H]valproate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['methotrexate', 'bumetanide'],\n",
       "  'reaction': ['dehydroepiandrosterone']},\n",
       " {'pmid': 21461642,\n",
       "  'sentence': 'It was found that plasma creatol (CTL) was positively correlated (p\\u2009<\\u20090.01) with plasma malondialdehyde (MDA) (r\\u2009=\\u20090.775), nitric oxide (NO) (r\\u2009=\\u20090.768), methyguanididne (MG) (r\\u2009=\\u20090.995), CK (r\\u2009=\\u20090.768), urine glucose (r\\u2009=\\u20090.778), urine protein (r\\u2009=\\u20090.767), renal failure index (RFI) (r\\u2009=\\u20090.814) and urine sodium (r\\u2009=\\u20090.799) and negatively correlated (p\\u2009<\\u20090.01) with total antioxidant capacity (TAC) (r\\u2009=\\u2009-0.795), superoxide dismutase (SOD) (r\\u2009=\\u2009-0.815), glutathione peroxidase (GSH-Px) (r\\u2009=\\u2009-0.675), Vitamin C (r\\u2009=\\u2009-0.830), urine creatinine (r\\u2009=\\u2009-0.800), urine/plasma creatinine ratio (r\\u2009=\\u2009-0.827) and urine/plasma urea ratio (r\\u2009=\\u2009-0.807).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium', 'tac'],\n",
       "  'reaction': ['renal failure', 'urine sodium']},\n",
       " {'pmid': 21497577,\n",
       "  'sentence': 'Replacement of the dichlorido ligands in trans-[PtCl(2)(py)(2)] and trans-[PtCl(2)(NH(3))(py)] by valproato ligands (VPA(-1H)) to yield trans-[Pt(VPA(-1H))(2)(py)(2)] and trans-[Pt(VPA(-1H))(2)(NH(3))(py)] respectively, significantly enhanced cytotoxicity against A2780 (parental) and A2780 cisR (cisplatin resistant) ovarian cancer cells.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['ovarian cancer']},\n",
       " {'pmid': 21510702,\n",
       "  'sentence': 'Using (18)O-labeled cholesterol hydroperoxide (Ch(18)O(18)OH), we observed the formation of (18)O-labeled O(2) ((1)Î”(g)) [(18)O(2) ((1)Î”(g))] by the chemical trapping of (18)O(2) ((1)Î”(g)) with 9,10-diphenylanthracene (DPA) and detected the corresponding (18)O-labeled DPA endoperoxide (DPA(18)O(18)O) and the (18)O-labeled products of the Russell mechanism using high-performance liquid chromatography coupled to tandem mass spectrometry.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 21520919,\n",
       "  'sentence': 'Treatment of tris(acetylacetonate)manganese(III) [Mn(acac)(3)] with KTp* and tetra(ethyl)ammonium cyanide affords [NEt(4)][(Tp*)Mn(II)(Îº(2)-acac)(CN)] (1), as the first monocyanomanganate(II) complex; attempted oxidation of 1 with iodine affords {(Tp*)Mn(II)(Îº(2)-acac(3-CN))}(n) (2) as a one-dimensional chain and bimetallic {[NEt(4)][(Tp*)Mn(II)(Îº(2)-acac(3-CN))](2)(Î¼-CN) (3) as the major and minor products, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ammonium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 21619170,\n",
       "  'sentence': 'The extraction and dissociation constants of the ion-pair complexes, defined by K(ex) = [MP(ClO(4))(4)](org)[MP(4+)](aq)(-)(1)[ClO(4)(-)](aq)(-)(4), K(dis,1) = [MP(ClO(4))(3)(+)](org)[ClO(4)(-)](org)[MP(ClO(4))(4)](org)(-)(1), and K(dis,2) = [MP(ClO(4))(2)(2+)](org)[ClO(4)(-)](org)[MP(ClO(4))(3)(+)](org)(-)(1), were determined by taking into account the partition constant of sodium perchlorate (K(D) = 1.82 Â± 0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['dissociation']},\n",
       " {'pmid': 21706098,\n",
       "  'sentence': 'The compounds of the compositions [Zn(HL1)Cl(3)]Â·H(2)O (1), [Zn(3)(HL2)(2)Cl(8)] (2), (H(2)L3)[CuCl(4)] (4) and (H(2)L3)[ZnCl(4)] (5) have been prepared in dependence on the acidity of the medium used by the reactions of L1 with ZnCl(2)Â·1.5H(2)O or CuCl(2)Â·2H(2)O.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 21811737,\n",
       "  'sentence': \"Binuclear half-metallocene chromium complexes {Cp*[3-(CH==NR)-2-O-C(10)H(5)]CrCl}(2) [Cp* = C(5)Me(5); R = (i)Pr (1), Ph (2), 2,6-(i)Pr(2)C(6)H(3) (3)] based on 1,1'-binaphthyl ligands, as well as their mononuclear analogues Cp*[3-(CH==NR)-2'-R'-2-O-C(20)H(11)]CrCl [R = (i)Pr, R' = (n)BuO (4), R = Ph, R' = (n)BuO (5), R = 2,6-(i)Pr(2)C(6)H(3), R' = (n)BuO (6), R = (i)Pr, R' = H (7)], were synthesized and characterized by mass spectrometry, elemental analysis, magnetic measurement, and UV-vis spectroscopy.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 21864810,\n",
       "  'sentence': \"To investigate the structure-activity relationship of vanadium complexes in inhibiting protein tyrosine phosphatase1B (PTP1B), eight mixed-ligand oxovanadium(IV) complexes, [V(IV)O(SalAla)(NN)] (H(2)SalAla for salicylidene alanine, NN for N,N'-donor heterocyclic base, namely, 2,2'-bipyridine (bpy, 1), 1,10-phenanthroline (phen, 2), dipyrido[3,2-d:2',3'-f]quinoxaline (dpq, 3), dipyrido[3,2-a:2',3'-c]phenazine (dppz, 4)), [V(IV)O(SalLys)(dpq)] (5), [V(IV)O(SalLys)(dppz)] (6), [V(IV)O(SalAsp)(dppz)], (7) and [V(IV)O(SalTrp)(dppz)] (8)), of which 3-8 are new, have been prepared and characterized by elemental analysis, infrared, UV-visible, electrospray ionization mass spectrometry and conductivity.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vanadium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 21879081,\n",
       "  'sentence': 'The synthesis, magnetic characterization and X-ray crystal structures are reported for five new manganese compounds, [Mn(III)(teaH(2))(sal)]Â·(1/2)H(2)O (1), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(4)]Â·6MeOH (2), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(2)](n)Â·7MeOH (3), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(2)](n)Â·2MeOHÂ·Et(2)O (4) and [K(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(H(2)O)(2)](n)Â·5MeOH (5).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sal'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 21915428,\n",
       "  'sentence': 'The reactions of manganese(II) acetate or perchlorate, sodium azide or sodium cyanate, and the zwitterionic dicarboxylate ligand 1,4-bis(4-carboxylatopyridinium-1-methylene)benzene (L) under different conditions yielded three different Mn(II) coordination polymers with mixed carboxylate and azide (or cyanate) bridges: {[Mn (L(1))(0.5)(N(3))(OAc)]Â·3H(2)O}(n) (1), {[Mn(4)(L(1))(N(3))(8)(H(2)O)(4)(CH(3)OH)(2)]Â·[L(1)]}(n) (2), and {[Mn(3)(L(1))(NCO)(6)(H(2)O)(4)]Â·[L(1)]Â·[H(2)O](2)}(n) (3).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 21945914,\n",
       "  'sentence': \"The compounds 4-({[2-(4-nitrophenyl)-1H-benzimidazol-1-yl]acetyl}amino) benzoic acid (3a), N-ethyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3c), N-benzyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3d), N-(4-hydroxyphenyl)-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3f), 2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3h), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N'-phenylacetohydrazide (3k), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-(4-nitrophenyl) acetamide (3n) and 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3q) were found better to paralyze worms whereas N-ethyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3c), N-(4-nitrophenyl)-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3e), 4-({[2-(4-chlorophenyl)-1H-benzimidazol-1-yl] acetyl}amino) benzoic acid (3j), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-ethyl acetamide (31) and 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3q) were better to cause death of worms compared to the anthelmintic drug albendazole.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['albendazole'],\n",
       "  'reaction': ['death']},\n",
       " {'pmid': 22178778,\n",
       "  'sentence': 'The final model consisted of seven independent predictors of ORFs: [lowest quartile (Q(1)) vs highest quartile (Q(4))] physical activity score (Q(1) vs Q(4): â‰¤12.61 vs â‰¥15.38); relative risk estimate [RR], 2.87; (95% confidence interval [CI]: 1.88-4.38); ageâ‰¥60 years vs age<60 years (RR=2.43; 95% CI: 1.49-3.95); hand grip strength (Q(1) vs Q(4): â‰¤13.88 vs â‰¥17.28 kg) (RR=1.88; 95% CI: 1.15-3.05); BMD total hip (Q(1) vs Q(4): â‰¤0.784 vs 0.973 g/cm(2)) (RR=1.86; 95% CI: 1.26-2.75); dietary calcium intake (Q(1) vs Q(4): â‰¤391 vs â‰¥648 mg/day) (RR=1.66; 95% CI: 1.08-2.53); serum 25(OH)D (Q(1) vs Q(4): â‰¤17.9 vs â‰¥45.1 nmol/L) (RR=1.63; 95% CI: 1.06-2.51); and past year history of falls (RR=1.61; 95% CI: 1.06-2.48).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['grip strength', 'grip strength']},\n",
       " {'pmid': 22318905,\n",
       "  'sentence': 'A combination of nuclear quadrupole resonance spectroscopy (NQR) and mass spectrometry (MS) has been used to observe trends in electronic structure in three titanocenes: bis(cyclopentadienyl) titanium dichloride (Î·(5)-C(5)H(5))(2)TiCl(2), bis(pentamethylcyclopentadienyl) titanium dichloride (Î·(5)-C(5)(CH(3))(5))(2)TiCl(2) and dimethylsilylene-bridged ansa bis(cyclopentadienyl) titanium dichloride Si(CH(3))(2)(Î·(5)-C(5)H(5))(2)TiCl(2).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['titanium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 22358916,\n",
       "  'sentence': 'Using this strategy in the 500 L reactor, we predict that dissolved oxygen and CO(2) levels can be maintained in the range to support maximum productivity (40% DO, 76 mm Hg pCO(2)) for a culture at 10(7) cells/mL, and with a minimum sparge rate of 0.006 vessel volumes per minute.A = volumetric agitated gas-liquid interfacial area at the top of the liquid, 1/mB = cell broth bleeding rate from the vessel, L/minCER = carbon dioxide evolution rate in the bioreactor, mol/min[CO(2)] = dissolved CO(2) concentration in liquid, M[CO(2)](*) = CO(2) concentration in equilibrium with sparger gas, M[CO(2)](**) = CO(2) concentration in equilibrium with headspace gas, MCO(2)(1) = dissolved carbon dioxide molecule in water[C(T)] = total carbonic species concentration in bioreactor medium, M[C(T)](F) = total carbonic species concentration in feed medium, MD = bioreactor diameter, mD(I) = impeller diameter, mD(b) = the initial delivered bubble diameter, mF = fresh medium feeding rate, L/minH(L) = liquid height in the vessel, mk(A) = carbon dioxide transfer coefficient at liquid surface, m/mink (infA)           (supO) = oxygen transfer coefficient at liquid surface, m/min.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['carbon dioxide', 'carbon dioxide', 'carbon dioxide']},\n",
       " {'pmid': 22841193,\n",
       "  'sentence': 'Selected genes up-regulated before transplantation were: TNFRSF9 (tumor necrosis factor [TNF] receptor superfamily, member 9); IL2RB (interleukin-2 receptor beta); BCL2L2 (BCL2-like 2); NOX5 (NADPH) oxidase, EF-hand calcium binding domain 5); PEX5 (peroxisomal biogenesis factor 5); PPARG (peroxisome proliferator-activated receptor gamma); NIBP (IKK2 binding protein); NKIRAS2 (NFKappaBeta inhibitor interacting Ras-like 2); IL4 (interleukin-4); IL-4R (interleukin 4 receptor); ADH1A (alcohol dehydrogenase 1A, class 1); ALDH1L1 (aldehyde dehydrogenase 1 family, member L1); MPO (myeloperoxidase); NPPA (natriuretic peptide precursor A); BCL2A1 (BCL2-related protein A1); GADD45A (growth arrest and DNA-damage-inducible alpha); TEGT (Bax inhibitor 1); PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide); IFNGR2 (interferon gamma receptor 2); JAK2 (Janus Kinase 2); FAS (Fas, TNF receptor superfamily, member 6); TANK (TRAF family member-associated NFKB activator); TTRAP (TRAF and TNF receptor-associated protein); and ANXA5 (annexin A5).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'polypeptide', 'calcium'],\n",
       "  'reaction': ['necrosis', 'growth', 'interferon gamma']},\n",
       " {'pmid': 22905670,\n",
       "  'sentence': 'Meta-analysis carried out on data obtained in 1,141 obese patients, showed the LCD to be associated with significant decreases in body weight (-7.04 kg [95% CI -7.20/-6.88]), body mass index (-2.09 kg m(-2) [95% CI -2.15/-2.04]), abdominal circumference (-5.74 cm [95% CI -6.07/-5.41]), systolic blood pressure (-4.81 mm Hg [95% CI -5.33/-4.29]), diastolic blood pressure (-3.10 mm Hg [95% CI -3.45/-2.74]), plasma triglycerides (-29.71 mg dL(-1) [95% CI -31.99/-27.44]), fasting plasma glucose (-1.05 mg dL(-1) [95% CI -1.67/-0.44]), glycated haemoglobin (-0.21% [95% CI -0.24/-0.18]), plasma insulin (-2.24 micro IU mL(-1) [95% CI -2.65/-1.82]) and plasma C-reactive protein, as well as an increase in high-density lipoprotein cholesterol (1.73 mg dL(-1) [95%CI 1.44/2.01]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'blood pressure',\n",
       "   'blood pressure',\n",
       "   'fasting',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein']},\n",
       " {'pmid': 23132754,\n",
       "  'sentence': 'The ranges of the measured concentrations (Î¼g/g dry weight) in the tissues of H. fossilis were as follows: arsenic concentration was (0.2-0.4), (0.82-0.90), (3.29-3.99), (2.20-2.80), and (2.41-2.90), that of lead was (1.79-2.20), (4.95-6.55), (10.36-13.38), (5.74-9.70), and (18.20-18.79), that of cadmium was (0.3-0.4), (2.87-4.27), (1.03-1.63), (1.55-4.59), and (2.25-5.50), that of chromium was (1.40-1.70), (3.52-3.72), (2.28-5.29), (2.77-3.79), and (4.25-8.65), that of zinc was (24.47-28.82), (16.82-18.80), (20.22-22.20), (22.86-26.68), and (60.82-67.80), and that of copper was (7.80-8.50), (6.22-6.81), (38.21-44.25), (17.07-21.03), and (43.24-47.30) in the muscle, gill, stomach, intestine, and liver, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 23221245,\n",
       "  'sentence': 'Oxidation of (II) with ammonium hexanitratocerate(IV), (NH(4))(2)[Ce(NO(3))(6)], gave the oxide-bridged dimanganese(IV) complex di-Î¼-oxido-bis(bis{3-[bis(pyridin-2-ylmethyl)amino]propionato}manganese(IV)) bis[triaquatetranitratocerate(IV)], [Mn(2)O(2)(C(15)H(16)N(3)O(2))(2)][Ce(NO(3))(4)(H(2)O)(3)](2), (III).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ammonium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 23495004,\n",
       "  'sentence': 'Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed-dose combinations (FDCs), the most recent example being Stribild(TM); (ii) for hepatitis C virus (HCV), the pleiade of direct-acting antivirals (DAAs) that should be formulated in the most appropriate combinations so as to obtain a cure of the infection; (iii)-(v) new strategies (i.e., AIC316, AIC246, and FV-100) for the treatment of herpesvirus infections: herpes simplex virus (HSV), cytomegalovirus (CMV), and varicella-zoster virus (VZV), respectively; (vi) the role of a new tenofovir prodrug, tenofovir alafenamide (TAF) (GS-7340) for the treatment of HIV infections; (vii) the potential use of poxvirus inhibitors (CMX001 and ST-246); (viii) the usefulness of new influenza virus inhibitors (peramivir and laninamivir octanoate); (ix) the position of the hepatitis B virus (HBV) inhibitors [lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF)]; and (x) the potential of new compounds such as FGI-103, FGI-104, FGI-106, dUY11, and LJ-001 for the treatment of filoviruses (i.e., Ebola).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir', 'telbivudine', 'lamivudine'],\n",
       "  'reaction': ['immunodeficiency',\n",
       "   'hepatitis',\n",
       "   'hepatitis c',\n",
       "   'infection',\n",
       "   'herpes simplex',\n",
       "   'influenza',\n",
       "   'hepatitis',\n",
       "   'hepatitis b']},\n",
       " {'pmid': 23554700,\n",
       "  'sentence': 'Our results showed that the over-weight group had higher blood pressure [(130.15Â±19.01) mmHg vs (123.66Â±18.70) mmHg] and higher levels of blood sugar [(7.09Â±2.89) mmol/L vs (6.21Â±2.59) mmol/L], triglyceride [(1.93Â±1.19) mmol/L vs (1.44Â±0.85) mmol/L], total cholesterol [(4.26Â±1.06) mmol/L vs (4.09Â±0.99) mmol/L], low-density lipoprotein cholesterol (LDL-C) [(2.56Â±0.75) mmol/L vs (2.39Â±0.72) mmol/L], and apoB [(0.83Â±0.27) mg/L vs (0.78Â±0.23) mg/L], and a higher apoB/apoA1 ratio (0.83Â±0.27 vs 0.75Â±0.25) and lower levels high-density lipoprotein cholesterol [(1.10Â±0.26) mmol/L vs (1.21Â±0.31) mmol/L] and apoA1 [(1.04Â±0.20) mg/L vs (1.08Â±0.22) mg/L] than those of the normal weight group (all P < 0.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood pressure', 'weight', 'weight']},\n",
       " {'pmid': 24114923,\n",
       "  'sentence': 'The two iodido complexes, (S(Os),S(C))-[Os(Î·(6)-p-cym)(ImpyMe)I]PF6 (complex 2, (S)-ImpyMe: N-(2-pyridylmethylene)-(S)-1-phenylethylamine) and (R(Os),R(C))-[Os(Î·(6)-p-cym)(ImpyMe)I]PF6 (complex 4, (R)-ImpyMe: N-(2-pyridylmethylene)-(R)-1-phenylethylamine), showed higher anticancer activity (lower IC50 values) towards A2780 human ovarian cancer cells than cisplatin and were more active than the two chlorido derivatives, (S(Os),S(C))-[Os(Î·(6)-p-cym)(ImpyMe)Cl]PF6, 1, and (R(Os),R(C))-[Os(Î·(6)-p-cym)(ImpyMe)Cl]PF6, 3.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['ovarian cancer']},\n",
       " {'pmid': 24613419,\n",
       "  'sentence': 'Microcirculatory responses to acetylcholine [Ach, an endothelium-dependent vasodilator; 10(-8)M - *123.3Â±7.5% (C), 119.5Â±1.3% (EC), *98.1Â±3.2% (F) and 133.6Â±17.2% (EF); 10(-6)M - *133.0Â±4.1% (C), 135.6Â±4.3% (EC), *103.4Â±4.3% (F) and 134.1Â±5.9% (EF); 10(-4)M - *167.2Â±5.0% (C), 162.8Â±5.4% (EC), *123.8Â±6.3% (F) and 140.8Â±5.0% (EF)] and to sodium nitroprusside [SNP, an endothelium-independent vasodilator; 10(-8)M - 118.8Â±6.8% (C), 114.0Â±5.0% (EC), 100.2Â±2.9% (F), 104.9Â±4.4% (EF); 10(-6)M - 140.6Â±11.7% (C), 141.7Â±5.5% (EC), 125.0Â±4.7% (F), 138.3Â±2.8% (EF); 10(-4)M - 150.4Â±10.9% (C), 147.9Â±6.5% (EC), 139.2Â±7.3% (F), 155.9Â±4.7% (EF)] and macromolecular permeability increase induced by 30 min ischemia/reperfusion (I/R) procedure [14.4Â±3.5 (C), 30.0Â±1.9 (EC), *112.0Â±8.8 (F) and *22.4Â±0.9 leaks/cm(2) (EF)] have shown that endothelium-dependent vasodilatation was significantly reduced and I/R induced macromolecular permeability augmented in sedentary fructose (F) subgroup and both improved after AET.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['vasodilatation']},\n",
       " {'pmid': 24835147,\n",
       "  'sentence': 'The chiral triplesalen ligand H6chand(RR) has been used to synthesize the chiral heptanuclear complexes [{(chand(RR))Mn(III)3}2{Fe(II)(CN)6}](ClO4)2 ((RR)[Mn(III)6Fe(II)](ClO4)2) and [{(chand(RR))Fe(III)3}2{Fe(II)(CN)6}](ClO4)2 ((RR)[Fe(III)6Fe(II)](ClO4)2), which have been characterized by single-crystal X-ray diffraction, mass spectrometry, elemental analysis, FT-IR, MÃ¶ssbauer, and UV-vis spectroscopies, electrochemistry, as well as DC and AC magnetic susceptibility measurements.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 24967880,\n",
       "  'sentence': 'Reaction of manganese(ii) chloride and potassium dicyanoargentate(i) with (X)(pyridin-2-ylmethylene)isonicotinohydrazide ligands (HL(1) X = Ph, HL(2) X = Me, HL(3) X = H) produced the coordination polymer 2D-[Mn(Î¼-L(1))(Cl)(Î¼-NCAgCN)Mn0.5(CH3OH)]n (), 1D-{[Mn(L(2))(Cl)(Î¼-NCAgCN)Mn0.5(CH3OH)]CH3OH}n () and [Mn(L(3))(Cl)(Î¼-NCAgCN)Mn0.5(CH3OH)]n () in good yields.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 25036223,\n",
       "  'sentence': 'Compared to HFSC and HFSCEX groups, HF and HFEX ones presented increased visceral fat [(meanÂ±SEM) (HF)4.9Â±1.5 g and (HFEX)4.7Â±0.9 g vs. (HFSC)*3.0Â±0.7 g and (HFSCEX)*1.9Â±0.4 g/100 g BW]; impaired endothelial-dependent vasodilatation [Ach 10(-8) M (HF)87.9Â±2.7%; (HFSC)*116.7Â±5.9%; (HFEX)*109.1Â±4.6%; (HFSCEX)*105Â±2.8%; Ach10(-6) M (HF)95.3Â±3.1%; (HFSC)*126Â±6.2%; (HFEX)*122.5Â±2.8%; (HFSCEX)*118.1Â±4.3% and Ach10(-4) M (HF)109.5Â±4.8%; (HFSC)*149.6Â±6.6%; (HFEX)*143.5Â±5.4% and (HFSCEX)*139.4Â±5.2%], macromolecular permeability increase after ischemia/reperfusion [(HF)40.5Â±4.2; (HFSC)*19.0Â±1.6; (HFEX)*18.6Â±2.1 and (HFSCEX)* 21.5Â±3.7 leaks/cm2), decreased eNOS expression, increased leptin and glycaemic levels.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['leptin'],\n",
       "  'reaction': ['vasodilatation']},\n",
       " {'pmid': 25396269,\n",
       "  'sentence': 'Serum 25(OH)D and SNPs (n = 960) related to genes with relevance for skin pigmentation (tyrosinase [TYR], TYR-related protein 1 [TYRP1], dopachrome tautomerase [DCT], oculocutaneous albinism II [OCA2], two pore segment channel 2 [TPCN2], solute carrier family 24 A4 [SLC24A4], solute carrier family 45 A2 [SLC45A2], agouti signalling peptide [ASIP], cyclic AMP-dependent transcription factor [ATF1], microphthalmia-associated transcription factor [MITF], proopiomelanocortin [POMC], cAMP-dependent protein kinase catalytic subunit beta [PRKACB], cAMP-dependent protein kinase catalytic subunit gamma [PRKACG], cAMP-dependent protein kinase type I-alpha regulatory subunit [PRKAR1A], cAMP-dependent protein kinase type II-alpha regulatory subunit [PRKAR2A], cAMP-dependent protein kinase type II-beta regulatory subunit [PRKAR2B], tubulin beta-3 chain/melanocortin receptor 1 [TUBB3/MC1R], Cadherin-1 [CDH1], catenin beta 1 [CTNNB1], Endothelin 1 [EDN1], endothelin 3 [EDN3], endothelin receptor type B [EDNRB], fibroblast growth factor 2 [FGF2], KIT, KIT ligand [KITLG], nerve growth factor [NGF], interferon regulatory factor 4 [IRF4], exocyst complex component 2 [EXOC2], and tumor protein 53 [TP53]) were analyzed in a cohort of participants of the Ludwigshafen Risk and Cardiovascular Health Study (n = 2970).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['growth', 'growth']},\n",
       " {'pmid': 25678369,\n",
       "  'sentence': 'The results indicated that: 1) glucose flows easily from cell-to-cell through gap junctions; 2) high glucose solution (25 mM) disrupted chemical communication between cardiac cells and abolished the intercellular diffusion of glucose; 3) the effect of high glucose solution on the cell-to-cell diffusion of glucose was drastically reduced by Bis-1 (10(-9)M) which is a PKC inhibitor; 4) intracellular dialysis of Ang II (100 nM) or increment of intracellular calcium concentration (10(-8)M) also inhibited the intercellular diffusion of glucose; 5) high glucose enhances oxidative stress in heart cells; 6) calculation of gap junction permeability (Pj) (cm/s) indicated a value of 0.74Â±0.08Ã—10(-4) cm/s (5 animals) for the controls and 0.4Â±0.001Ã—10(-5) cm/s; n=35 (5 animals) (P<0.05) for cells incubated with high glucose solution for 24h; 7) measurements of Pj for cell pairs treated with high glucose plus Bis-1 (10(-9)M) revealed no significant change of Pj (P>0.05); 8) increase of intracellular Ca(2+) concentration (10(-8)M) drastically decreased Pj (Pj=0.3Â±0.003Ã—10(-5) cm/s).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'calcium'],\n",
       "  'reaction': ['dialysis', 'stress']},\n",
       " {'pmid': 25891669,\n",
       "  'sentence': \"Women with HIV infection demonstrated (mean (SD), HIV-positive vs healthy) a reduced cardiac index (2.8 (0.64) ml.min(-1) .m(-2) vs. 3.1 (0.7) ml.min(-1) .m(-2) , p = 0.029), reduced septal s' tissue Doppler velocity (8.5 (1.5) cm.s(-1) vs. 9.3 (1.7) cm.s(-1) , p = 0.042), increased left ventricular end-diastolic area (7.6 (2.1) cm2 vs. 6.3 (1.7) cm2 , p = 0.004), and reduced right ventricular s' and e' velocity (s' velocity 14.7 (3.1) cm.s(-1) vs. 7.0 (2.9) cm.s(-1) p = 0.001, e' velocity 16.3 (4.1) cm.s(-1) vs. 18.7 (3.4) cm.s(-1) , p = 0.013).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hiv infection', 'infection', 'cardiac index']},\n",
       " {'pmid': 26123164,\n",
       "  'sentence': 'The elements lithium (Li), boron (B), natrum (Na), magnesium (Mg), aluminium (AI), silicium (Si), kalium (K), calcium (Ca), vanadium (V), chromium (Cr), manganese (Mn), ferrum (Fe), cobalt (Co.), nickel (Ni), copper (Cu), zinc (Zn), arsenic (As), selenium (Se), molybdenum (Mo), cadmium (Cd), stannum (Sn), stibium (Sb), barium (Ba), hydrargyrum (Hg), thallium (Tl) and plumbum (Pb) in the pectoral muscles were determined using inductively coupled plasma mass spectrometry (ICP-MS).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['silicium',\n",
       "   'kalium',\n",
       "   'magnesium',\n",
       "   'vanadium',\n",
       "   'aluminium',\n",
       "   'thallium',\n",
       "   'calcium',\n",
       "   'chromium',\n",
       "   'selenium',\n",
       "   'lithium',\n",
       "   'barium'],\n",
       "  'reaction': ['manganese', 'mass']},\n",
       " {'pmid': 27640333,\n",
       "  'sentence': 'The results indicated that compared with optimal vitamin C supplementation, vitamin C deficiency (2.9\\xa0mg/kg diet) (1) increased reactive oxygen species, malondialdehyde and protein carbonyl (PC) contents (P\\xa0<\\xa00.05), decreased the copper/zinc superoxide dismutase, manganese superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activities and mRNA levels (P\\xa0<\\xa00.05), and glutathione and vitamin C contents (P\\xa0<\\xa00.05), down-regulated NF-E2-related factor 2 mRNA level (P\\xa0<\\xa00.05), and up-regulated Kelch-like ECH-associating protein (Keap) 1a (rather than Keap1b) mRNA level (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency induced oxidative injury in fish gill; (2) up-regulated caspase-3, -7, -8, -9, Fas ligand, B-cell lymphoma protein 2 associated X protein, apoptotic protease activating factor-1 mRNA levels (P\\xa0<\\xa00.05), and down-regulated inhibitor of apoptosis protein and B-cell lymphoma-2 (rather than myeloid cell leukemia-1) mRNA level (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency aggravated cell apoptosis in fish gill; (3) up-regulated pore-forming TJs Claudin-12, 15a, -15b, and related signaling molecules myosin light chain kinase, p38 mitogen-activated protein kinase (rather than c-Jun N-terminal kinases) mRNA levels (P\\xa0<\\xa00.05), and down-regulated barrier-forming TJs Occludin, zonula occludens (ZO) 1, ZO-2, Claudin-c, -3c, -7a, -7b mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency disrupted tight junctional complexes in fish gill; (4) decreased lysozyme and acid phosphatase (ACP) activities, and complement 3 (C3), C4 and IgM contents (P\\xa0<\\xa00.05), down-regulated the mRNA levels of antimicrobial peptides liver expressed antimicrobial peptide (LEAP) 2A, LEAP-2B, Hepcidin, Î²-defensin mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency decrease fish gill immune function; (5) down-regulated the mRNA levels of anti-inflammatory cytokines-related factors interleukin 10 (IL-10), IL-11, transforming growth factor (TGF) Î²1, TGF-Î²2, inhibitor of ÎºBa and eIF4E-binding protein 1 (4E-BP1) (rather than 4E-BP2) (P\\xa0<\\xa00.05), and up-regulated pro-inflammatory cytokines-related factors interferon Î³2, IL-1Î², IL-6, IL-8, IL-12 P35, IL-12 P40, nuclear factor ÎºB (NF-ÎºB) p65 (rather than NF-ÎºB p52), IÎºB kinases (IKK) (only IKKÎ± and IKKÎ³), target of rapamycin and ribosomal protein S6 kinase 1 mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency aggravated fish gill inflammation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['vitamin c deficiency',\n",
       "   'manganese',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'injury',\n",
       "   'b-cell lymphoma',\n",
       "   'lymphoma',\n",
       "   'apoptosis',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'apoptosis',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'growth',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'inflammation']},\n",
       " {'pmid': 28335545,\n",
       "  'sentence': 'The overall reference values of serum trace elements were 131.5 (55.8-265.0 Î¼g/dL for iron (Fe), 195.5 (107.0-362.4) Î¼g/dL for copper (Cu), 74.0 (51.8-111.3) Î¼g/dL for zinc (Zn), 22.3 (14.0-62.0) Î¼g/dL for rubidium (Rb), 72.2 (39.9-111.6) Î¼g/L for selenium (Se), 45.9 (23.8-104.3) Î¼g/L for strontium (Sr), 1.8 (1.2-3.6) Î¼g/L for molybdenum (Mo), 2.4 (1.2-8.4) Î¼g/L for manganese (Mn), 1.9 (0.6-9.0) ng/L for lead (Pb), 1.1 (0.3-5.6) ng/L for arsenic (As), 835.6 (219.8-4287.7) ng/L for chromium (Cr), 337.9 (57.0-1130.0) ng/L for cobalt (Co), 193.2 (23.6-2323.1) ng/L for vanadium (V), and 133.7 (72.1-595.1) ng/L for cadmium (Cd).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vanadium',\n",
       "   'rubidium',\n",
       "   'strontium',\n",
       "   'chromium',\n",
       "   'selenium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 28514699,\n",
       "  'sentence': 'An inductive coupled plasma-mass spectrometry (ICP-MS) method was developed and validated for simultaneous analysis of 26 inorganic elements, including sodium (Na), magnesium (Mg), aluminuim (Al), potassium (K), calcium (Ca), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), arsenic (As), selenium (Se), molybdenum (Mo), silver (Ag), cadmium (Cd), antimony (Sb), barium (Ba), lanthanum (La), cerium (Ce), thallium (Tl), lead (Pb), thorium (Th), and uranium (U) in illicit cocaine samples.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine',\n",
       "   'vanadium',\n",
       "   'chromium',\n",
       "   'calcium',\n",
       "   'thallium',\n",
       "   'barium',\n",
       "   'selenium',\n",
       "   'sodium',\n",
       "   'potassium',\n",
       "   'magnesium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 29140729,\n",
       "  'sentence': 'Abbreviations Inducible nitric oxide synthase (INOS), neutrophil cytosolic factor 1 (p47phox), adrenomedullin (ADM), atrial natriuretic peptide (ANP), osteopontin (OPN/SPP1), angiotensin converting enzyme (ACE), monocyte chemotactic protein 1 (MCP-1), cytochrome b-245 beta polypeptide (gp91phox), intercellular adhesion molecule 1 (ICAM-1), transforming growth factor beta 1 (TGF-Î²1), connective tissue growth factor (CTGF), endothelin-1 (ET-1), cytochrome B-245, alpha polypeptide (p22phox), endothelin receptor type B (ETB/EDNRB), brain natriuretic peptide (BNP), endothelin receptor type A (ETA/EDNRA), matrix metallopeptidase 13 (MMP13), type I collagen (Col1a1), matrix metallopeptidase 2 (MMP2), TIMP metallopeptidase inhibitor 1 (TIMP1), Type III collagen (Col3a1), interleukin 1 beta (IL-1Î²), beta myocin heavy chain (Î²-MHC), endothelin converting enzyme 1 (ECE1) matrix metallopeptidase 14 (MMP14), angiotensinogen (AGT), angiotensin II receptor Type 1 (AT1R), cytochrome C oxidase I (COX1), fms-like tyrosine kinase 1 (FLT1), TIMP metallopeptidase inhibitor 2 (TIMP2), phospholamban (PLN), vascular cell adhesion molecule 1 (VCAM1), extracellular matrix (ECM).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'polypeptide'],\n",
       "  'reaction': ['angiotensin converting enzyme',\n",
       "   'adhesion',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'brain natriuretic peptide',\n",
       "   'brain natriuretic peptide',\n",
       "   'adhesion']},\n",
       " {'pmid': 29199166,\n",
       "  'sentence': 'For the medication groups for which sufficient data were obtained (Figure 1), a systematic literature review in English was conducted using the keywords \"gastroesophageal reflux\" [MeSH Terms] and \"anti-inflammatory agents, non-steroidal\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"acetylsalicylic acid\" [MeSH Terms], \"gastroesophageal reflux\" [All Fields] and \"estrogenic agents\" [All Fields], \"gastroesophageal reflux\" [All Fields] and \"progesterones\" [All Fields], \"gastroesophageal reflux\" [All Fields] and \"hormone replacement therapy\" [All Fields], \"gastroesophageal reflux\" [MeSH Terms] and \"diphosphonates\" [MeSH Terms] OR \"diphosphonates\" [All Fields], \"calcium channel blockers\" [MeSH Terms] and \"gastroesophageal reflux\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"nitrates\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"antidepressive agents\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"benzodiazepines\" [MeSH Terms] and \"hypnotic drugs\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"cholinergic antagonists\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"theophylline\" [MeSH Terms], and \"gastroesophageal reflux [MeSH Terms] AND \"anti-asthmatic agents\" [MeSH Terms].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hormone replacement therapy']},\n",
       " {'pmid': 29292200,\n",
       "  'sentence': 'Results indicated that the optimal Met-Met supplementation: (1) increased fish growth performance, intestinal lysozyme (LZ) and acid phosphatase (ACP) activities, complement (C3 and C4) and immunoglobulin M (IgM) contents, up-regulated hepcidin, liver expressed antimicrobial peptide 2A (LEAP-2A), LEAP-2B, Î²-defensin-1 and Mucin2 mRNA levels; (2) down-regulated tumour necrosis factor Î± (TNF-Î±), interferon Î³2 (IFN-Î³2), interleukin 1Î² (IL-1Î²), IL-8 [only in the distal intestine (DI)], IL-12p35, IL-12p40 and IL-15 (not IL-17D) mRNA levels partially related to the down-regulation of IÎºB kinase Î² (IKKÎ²) and IKKÎ³ (rather than IKKÎ±), nuclear factor kappa B (NF-ÎºB) p65 and c-Rel (rather than NF-ÎºB p52) mRNA levels and the up-regulation of inhibitor of ÎºBÎ± (IÎºBÎ±) mRNA levels; (3) up-regulated IL-4/13A, IL-4/13B, IL-6, IL-10, IL-11 and transforming growth factor (TGF)-Î²1 (not TGF-Î²2) mRNA levels partially associated with the target of rapamycin (TOR) signalling pathway [TOR/ribosomal protein S6 kinases 1 (S6K1), eIF4E-binding proteins (4E-BP)] in three intestinal segments of juvenile grass carp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'immunoglobulin'],\n",
       "  'reaction': ['growth', 'tumour necrosis', 'necrosis', 'growth']},\n",
       " {'pmid': 29631831,\n",
       "  'sentence': 'Based on medication class, the highest and lowest cost medications were antiallergy agents (Zaditor [ketotifen], Vasocon [naphazoline]), antibiotic ophthalmic solutions (Vigamox [moxifloxacin], generic ciprofloxacin), oral antibiotics (Cipro [ciprofloxacin], generic cephalexin), antibiotic ophthalmic ointments (generic erythromycin, Tobrex [tobramycin]), antiviral treatment (Valtrex [oral valacyclovir], Viroptic [topical trifluridine]), blepharitis treatment (Zithromax [oral azithromycin], generic oral tetracycline), beta-adrenergic inhibitors (Timoptic [topical timolol], generic topical timolol), topical prostaglandin analogues (Xalatan [latanoprost], generic travoprost), oral carbonic anhydrase inhibitors (methazolamide, acetazolamide), topical carbonic anhydrase solutions (Trusopt preservative-free [dorzolamide], Azopt [brinzolamide]), topical alpha-adrenergic agonists (Alphagan [brimonidine], generic brimonidine), topical muscarinic agonists (Isopto carpine [pilocarpine], Diocarpine [pilocarpine]), topical combination glaucoma agents (Cosopt [dorzolamide-timolol], generic dorzolamide-timolol), topical lubricants (Lacri-lube, Isopto tears), topical nonsteroidal anti-inflammatory drugs (Acuvail [ketorolac], Ilevro [nepafenac]), and steroids (Durezol [difluprednate], Pred mild [prednisolone]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tobramycin',\n",
       "   'valacyclovir',\n",
       "   'ketorolac',\n",
       "   'tetracycline',\n",
       "   'ketotifen',\n",
       "   'brinzolamide',\n",
       "   'ciprofloxacin',\n",
       "   'methazolamide',\n",
       "   'latanoprost',\n",
       "   'azithromycin',\n",
       "   'moxifloxacin',\n",
       "   'acetazolamide',\n",
       "   'travoprost',\n",
       "   'trifluridine',\n",
       "   'pred',\n",
       "   'prednisolone',\n",
       "   'dorzolamide',\n",
       "   'naphazoline',\n",
       "   'timolol',\n",
       "   'erythromycin',\n",
       "   'nepafenac'],\n",
       "  'reaction': ['blepharitis', 'glaucoma']},\n",
       " {'pmid': 29886470,\n",
       "  'sentence': 'Results: There was no statistical significance in sex, age, height, body mass, initial diagnosis and re-diagnosis interval between the 2 groups (P>0.05); the total efficiency after ORS III and ORS I \\u2028treatment were 79.59% and 62.96%, respectively, with no statistical significance (Ï‡2=2.483, P>0.05); the HUTT negative conversion rate after ORS III and ORS I treatment were 51.02% and 48.16%, respectively, with no statistical significance (Ï‡2=0.058, P>0.05); before treatment, the serum sodium [(140.20Â±2.26) mmol/L vs (138.39Â±2.72) mmol/L; t=2.856, P<0.05] in the ORS III group was higher than that in the ORS I group, the serum phosphorus [(1.46Â±0.19) mmol/L \\u2028vs (1.65Â±0.29) mmol/L; t=3.146, P<0.05] in the ORS III group was lower than that in the ORS I \\u2028group; after treatment, the serum sodium [(140.31Â±2.01) mmol/L vs (138.88Â±2.08) mmol/L; \\u2028t=2.692, P<0.05] and serum calcium [(2.31Â±0.09) mmol/L vs (2.24Â±0.11) mmol/L; t=2.696, P<0.05] in the ORS III group were higher than those in the ORS I group, the serum phosphorus [(1.45Â±0.16) mmol/L vs (1.61Â±0.25) mmol/L; t=3.128, P<0.05] in the ORS III group was lower than that in the ORS I group; after ORS III treatment, there was no statistical significance in serum electrolytes between HUTT positive group and HUTT negative group (P>0.05); after ORS I treatment, the serum calcium [(2.29Â±0.10) mmol/L vs (2.19Â±0.10) mmol/L; t=2.501, P<0.05] and serum phosphorus [(1.71Â±0.24) mmol/L vs (1.50Â±0.21) mmol/L; t=2.392, P<0.05] in HUTT positive group were higher than those in HUTT negative group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'sodium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 30339843,\n",
       "  'sentence': \"The results were analysed by the Duncan's multiple-range test (P\\u202f<\\u202f0.05), indicating that compared with the control group (27\\u202fÎ¼g/kg diet), dietary DON levels up to 318\\u202fÎ¼g/kg diet: (1) decreased lysozyme (LZ) and acid phosphatase (ACP) activities, as well as complement 3 (C3), C4 and immunoglobulin M (IgM) content in the proximal intestine (PI), middle intestine (MI) and distal intestine (DI) of juvenile grass carp (P\\u202f<\\u202f0.05); (2) down-regulated the mRNA levels of anti-microbial substance: liver expressed antimicrobial peptide (LEAP) -2A, LEAP-2B, hepcidin, Î²-defensin-1 and mucin2 in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05); (3) up-regulated the mRNA levels of pro-inflammatory cytokines [interleukin 1Î² (IL-1Î²), tumour necrosis factor Î± (TNF-Î±), interferon Î³2 (INF-Î³2), IL-6 (only in PI), IL-8, IL-12p35, IL-12p40, IL-15 and IL-17D] in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05), which might be partly related to nuclear factor kappa B (NF-ÎºB) signalling [IÎºB kinase Î² (IKKÎ²) and IKKÎ³/inhibitor of ÎºBÎ± (IÎºBÎ±)/NF-ÎºB (p65 and c-Rel)]; and (4) down-regulated the mRNA levels of anti-inflammatory cytokines [IL-10, IL-11, IL-4/13A (not IL-4/13B), transforming growth factor Î²1 (TGF-Î²1) (not TGF-Î²2)] in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05), which might be partly related to target of rapamycin (TOR) signalling [TOR/ribosomal protein S6 kinases 1 (S6K1) and eIF4E-binding proteins (4E-BP)].\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'immunoglobulin'],\n",
       "  'reaction': ['tumour necrosis', 'necrosis', 'growth']},\n",
       " {'pmid': 30898618,\n",
       "  'sentence': 'After 8 weeks of feeding, the growth performance [weight gain (WG), specific growth rate (SGR) and feed conversion ratio (FCR)], haematological values [the red blood cell (RBC) count, haemoglobin (Hb) concentration, haematocrit (Ht) level and erythrocyte indices: mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC)], various immune parameters [white blood cell (WBC) count, oxidative radical production (nitroblue tetrazolium (NBT) assay), phagocytic activity (PA) and phagocytic index (PI), total protein (TP) and immunoglobulin M (IgM) levels, serum bactericidal (BA), lysozyme (LYZ) and myeloperoxidase (MPO) activities] and antioxidant capacity [tissue malondialdehyde (MDA) levels and superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) activities] were analysed.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin',\n",
       "   'haematocrit',\n",
       "   'haematocrit',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin',\n",
       "   'haemoglobin']},\n",
       " {'pmid': 31165401,\n",
       "  'sentence': 'Probiotic supplementation significantly decreased weight (SMD -\\u20090.30; 95% CI, -\\u20090.53, -\\u20090.07; P\\u2009=\\u20090.01), body mass index (BMI) (SMD -\\u20090.29; 95% CI, -\\u20090.54, -\\u20090.03; P\\u2009=\\u20090.02), fasting plasma glucose (FPG) (SMD -\\u20090.26; 95% CI, -\\u20090.45, -\\u20090.07; P\\u2009<\\u20090.001), insulin (SMD -\\u20090.52; 95% CI, -\\u20090.81, -\\u20090.24; P\\u2009<\\u20090.001), homeostatic model assessment for insulin resistance (HOMA-IR) (SMD -\\u20090.53; 95% CI, -\\u20090.79, -\\u20090.26; P\\u2009<\\u20090.001), triglycerides (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), VLDL-cholesterol (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), C-reactive protein (CRP) (SMD -\\u20091.26; 95% CI, -\\u20092.14, -\\u20090.37; P\\u2009<\\u20090.001), malondialdehyde (MDA) (SMD -\\u20090.90; 95% CI, -\\u20091.16, -\\u20090.63; P\\u2009<\\u20090.001), hirsutism (SMD -\\u20090.58; 95% CI, -\\u20091.01, -\\u20090.16; P\\u2009<\\u20090.001), and total testosterone levels (SMD -\\u20090.58; 95% CI, -\\u20090.82, -\\u20090.34; P\\u2009<\\u20090.001), and also increased the quantitative insulin sensitivity check index (QUICKI) (SMD 0.41; 95% CI, 0.11, 0.70; P\\u2009<\\u20090.01), nitric oxide (NO) (SMD 0.33; 95% CI 0.08, 0.59; P\\u2009=\\u20090.01), total antioxidant capacity (TAC) (SMD 0.64; 95% CI, 0.38, 0.90; P\\u2009<\\u20090.001), glutathione (GSH) (SMD 0.26; 95% CI, 0.01, 0.52; P\\u2009=\\u20090.04), and sex hormone binding globulin (SHBG) levels (SMD 0.46; 95% CI, 0.08, 0.85; P\\u2009=\\u20090.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'globulin'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'fasting',\n",
       "   'insulin resistance',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'hirsutism']},\n",
       " {'pmid': 31720354,\n",
       "  'sentence': 'Here, we describe the method development and validation for simultaneous determination of 25 trace elements (lithium [Li], beryllium [Be], magnesium [Mg], aluminium [Al], vanadium [V], chromium [Cr], manganese [Mn], iron [Fe], cobalt [Co], nickel [Ni], copper [Cu], zinc [Zn], gallium [Ga], arsenic [As], selenium [Se], rubidium [Rb], strontium [Sr], silver [Ag], cadmium [Cd], caesium [Cs], barium [Ba], mercury [Hg], thallium [Tl], lead [Pb], uranium [U]) using only 20\\u202fÎ¼L of human serum.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['aluminium',\n",
       "   'magnesium',\n",
       "   'selenium',\n",
       "   'gallium',\n",
       "   'vanadium',\n",
       "   'strontium',\n",
       "   'rubidium',\n",
       "   'barium',\n",
       "   'chromium',\n",
       "   'lithium',\n",
       "   'thallium'],\n",
       "  'reaction': ['manganese']}]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sent_counter.many_brackets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': 5033,\n",
       "  'sentence': '[Dopamine and shock.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['shock']},\n",
       " {'pmid': 5974,\n",
       "  'sentence': 'injection of timolol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['timolol'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 7135,\n",
       "  'sentence': 'A controlled double-blind investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 12378,\n",
       "  'sentence': 'Calcium oxalate crystalluria.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['crystalluria']},\n",
       " {'pmid': 12927,\n",
       "  'sentence': 'Fosfomycin in pneumococcal meningitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fosfomycin'],\n",
       "  'reaction': ['meningitis']},\n",
       " {'pmid': 15481,\n",
       "  'sentence': 'Cardiac output remained unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 23526,\n",
       "  'sentence': 'Ionised calcium during haemodialysis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['haemodialysis']},\n",
       " {'pmid': 24193,\n",
       "  'sentence': 'Prazosin in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['prazosin'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 24324,\n",
       "  'sentence': 'Minoxidil in severe hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['minoxidil'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 29438,\n",
       "  'sentence': 'Glaucoma treatment with timolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['timolol'],\n",
       "  'reaction': ['glaucoma']},\n",
       " {'pmid': 29796,\n",
       "  'sentence': 'Metronidazole treatment in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metronidazole'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 33971,\n",
       "  'sentence': 'Prolonged delirium with propanolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propanolol'],\n",
       "  'reaction': ['delirium']},\n",
       " {'pmid': 42587,\n",
       "  'sentence': 'Diazepam therapy in eclampsia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diazepam'],\n",
       "  'reaction': ['eclampsia']},\n",
       " {'pmid': 43112,\n",
       "  'sentence': 'Lorazepam in status epilepticus.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lorazepam'],\n",
       "  'reaction': ['status epilepticus']},\n",
       " {'pmid': 60028,\n",
       "  'sentence': 'Metronidazole and acne.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metronidazole'],\n",
       "  'reaction': ['acne']},\n",
       " {'pmid': 60635,\n",
       "  'sentence': 'Dopamine and schizophrenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['schizophrenia']},\n",
       " {'pmid': 65280,\n",
       "  'sentence': 'Pulmonary toxicity of bleomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 73797,\n",
       "  'sentence': 'Cimetidine in duodenal ulcer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['duodenal ulcer', 'ulcer']},\n",
       " {'pmid': 74226,\n",
       "  'sentence': 'Bleomycin hypersensitivity pneumonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['hypersensitivity',\n",
       "   'hypersensitivity pneumonitis',\n",
       "   'pneumonitis']},\n",
       " {'pmid': 79086,\n",
       "  'sentence': 'Dopamine and schizophrenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['schizophrenia']},\n",
       " {'pmid': 79558,\n",
       "  'sentence': 'IgE-mediated cardiac hypersensitivity reactions.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 86721,\n",
       "  'sentence': 'Cimetidine and gastric cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['gastric cancer']},\n",
       " {'pmid': 90758,\n",
       "  'sentence': 'Dapsone and severe hypoalbuminaemia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['hypoalbuminaemia']},\n",
       " {'pmid': 95728,\n",
       "  'sentence': 'Minoxidil in resistant hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['minoxidil'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 111462,\n",
       "  'sentence': 'Neurotoxicity of sodium cyanate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 121951,\n",
       "  'sentence': 'Sodium valproate and thrombocytopenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['thrombocytopenia']},\n",
       " {'pmid': 122639,\n",
       "  'sentence': 'Miconazole in coccidioidomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['miconazole'],\n",
       "  'reaction': ['coccidioidomycosis']},\n",
       " {'pmid': 122644,\n",
       "  'sentence': 'Miconazole in oral candidiasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['miconazole'],\n",
       "  'reaction': ['oral candidiasis']},\n",
       " {'pmid': 124132,\n",
       "  'sentence': 'Cardiac tamponade in myxedema.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 127936,\n",
       "  'sentence': 'Cardiac tumour in infant.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['infant']},\n",
       " {'pmid': 131644,\n",
       "  'sentence': 'Levodopa in Huntingtons chorea.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['chorea']},\n",
       " {'pmid': 133774,\n",
       "  'sentence': 'Endocrine effects of vasectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['vasectomy']},\n",
       " {'pmid': 135933,\n",
       "  'sentence': 'Overdose of lioresal.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lioresal'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 138189,\n",
       "  'sentence': '[Cardiac syncope].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['syncope']},\n",
       " {'pmid': 145453,\n",
       "  'sentence': 'Practolol and deafness.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['practolol'],\n",
       "  'reaction': ['deafness']},\n",
       " {'pmid': 150818,\n",
       "  'sentence': 'Phenytoin hypersensitivity reaction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 150826,\n",
       "  'sentence': 'Sclerosing peritonitis and propranolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['peritonitis']},\n",
       " {'pmid': 177387,\n",
       "  'sentence': 'Endocrine changes in sepsis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['sepsis']},\n",
       " {'pmid': 184219,\n",
       "  'sentence': 'after peptide injection.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 188174,\n",
       "  'sentence': '[Clostridium perfringens infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 215819,\n",
       "  'sentence': 'Sodium retention aTH administration.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['sodium retention']},\n",
       " {'pmid': 218542,\n",
       "  'sentence': 'Clostridium perfringens corneal ulcer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['ulcer']},\n",
       " {'pmid': 222526,\n",
       "  'sentence': 'Clostridium perfringens septic arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['arthritis']},\n",
       " {'pmid': 226363,\n",
       "  'sentence': 'sodium fluoride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 241601,\n",
       "  'sentence': 'Alclofenac in ankylosing spondylitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['alclofenac'],\n",
       "  'reaction': ['ankylosing spondylitis', 'spondylitis']},\n",
       " {'pmid': 273467,\n",
       "  'sentence': 'Echocardiography in adriamycin cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['adriamycin'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 279324,\n",
       "  'sentence': 'Metformin associated lactic acidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metformin'],\n",
       "  'reaction': ['lactic acidosis', 'acidosis']},\n",
       " {'pmid': 282230,\n",
       "  'sentence': 'Methotrexate encephalopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['encephalopathy']},\n",
       " {'pmid': 300701,\n",
       "  'sentence': 'Complications of cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 311191,\n",
       "  'sentence': 'Corynebacterium endophthalmitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['endophthalmitis']},\n",
       " {'pmid': 313404,\n",
       "  'sentence': 'Hyper immunoglobulin M immunodeficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['immunodeficiency']},\n",
       " {'pmid': 320671,\n",
       "  'sentence': 'Ibuprofen in osteoarthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ibuprofen'],\n",
       "  'reaction': ['osteoarthritis']},\n",
       " {'pmid': 321117,\n",
       "  'sentence': 'Thirty-six received concomitant chemotherapy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['chemotherapy']},\n",
       " {'pmid': 322009,\n",
       "  'sentence': 'A double-blind clinical investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 322923,\n",
       "  'sentence': 'Once-a-day pindolol in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['pindolol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 329154,\n",
       "  'sentence': 'Autopsy revealed cardiac infarction.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['autopsy', 'infarction']},\n",
       " {'pmid': 334211,\n",
       "  'sentence': 'Atenolol once-daily in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atenolol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 339249,\n",
       "  'sentence': 'Adriamycin extravasation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['adriamycin'],\n",
       "  'reaction': ['extravasation']},\n",
       " {'pmid': 339869,\n",
       "  'sentence': 'Physostigmine in mania.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['physostigmine'],\n",
       "  'reaction': ['mania']},\n",
       " {'pmid': 343006,\n",
       "  'sentence': 'Prazosin in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['prazosin'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 345433,\n",
       "  'sentence': 'Peritoneal dialysis and heparin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['peritoneal dialysis', 'dialysis']},\n",
       " {'pmid': 352211,\n",
       "  'sentence': 'Prehospital brady-asystolic cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 356435,\n",
       "  'sentence': 'Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 358764,\n",
       "  'sentence': 'Verapamil and pulmonary hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['pulmonary hypertension', 'hypertension']},\n",
       " {'pmid': 362830,\n",
       "  'sentence': 'A double-blind clinical investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 367480,\n",
       "  'sentence': 'Cyproheptadine in anorexia nervosa.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyproheptadine'],\n",
       "  'reaction': ['anorexia nervosa']},\n",
       " {'pmid': 368769,\n",
       "  'sentence': 'Haemodialysis without heparin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['haemodialysis']},\n",
       " {'pmid': 369449,\n",
       "  'sentence': 'Bupivacaine in spinal anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bupivacaine'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 382902,\n",
       "  'sentence': 'Penicillin hypersensitivity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['penicillin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 396081,\n",
       "  'sentence': 'Hydrochlorothiazide lowered cardiac output.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['hydrochlorothiazide', 'cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 403743,\n",
       "  'sentence': 'Choreoathetosis during phenytoin treatment.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['choreoathetosis']},\n",
       " {'pmid': 406865,\n",
       "  'sentence': 'Cardiac depression in bacteremia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 420641,\n",
       "  'sentence': 'Clindamycin in chronic toxoplasmosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clindamycin'],\n",
       "  'reaction': ['toxoplasmosis']},\n",
       " {'pmid': 426584,\n",
       "  'sentence': 'Fatal benign phenytoin lymphadenopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['lymphadenopathy']},\n",
       " {'pmid': 428828,\n",
       "  'sentence': 'Gynaecomastia associated with cimetidine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['gynaecomastia']},\n",
       " {'pmid': 435372,\n",
       "  'sentence': 'Triamcinolone in corticosteroid-resistant asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['triamcinolone'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 436047,\n",
       "  'sentence': 'Idiopathic calcium nephrolithiasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['nephrolithiasis']},\n",
       " {'pmid': 436048,\n",
       "  'sentence': 'Idiopathic calcium nephrolithiasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['nephrolithiasis']},\n",
       " {'pmid': 437404,\n",
       "  'sentence': 'Erythromycin ethylsuccinate-induced cholestasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['erythromycin'],\n",
       "  'reaction': ['cholestasis']},\n",
       " {'pmid': 443197,\n",
       "  'sentence': 'Heparin monitoring and thrombosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['thrombosis']},\n",
       " {'pmid': 447012,\n",
       "  'sentence': 'Cimetidine hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 448919,\n",
       "  'sentence': 'Lithium carbonate-induced hypothyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['hypothyroidism']},\n",
       " {'pmid': 449161,\n",
       "  'sentence': 'Acute nontraumatic cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 453873,\n",
       "  'sentence': 'Allergic hypersensitivity to neomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['neomycin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 462719,\n",
       "  'sentence': 'Bovine nasal granuloma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['granuloma']},\n",
       " {'pmid': 464524,\n",
       "  'sentence': 'Nasal hemangioma of pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 464631,\n",
       "  'sentence': 'Photosensitivity reaction to dibucaine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dibucaine'],\n",
       "  'reaction': ['photosensitivity reaction']},\n",
       " {'pmid': 469006,\n",
       "  'sentence': 'Adjusted calcium conflict resolved?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['adjusted calcium']},\n",
       " {'pmid': 471869,\n",
       "  'sentence': 'Cardiac disease in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 475168,\n",
       "  'sentence': 'Low-pressure cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 476356,\n",
       "  'sentence': 'High-dose propranolol in schizophrenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['schizophrenia']},\n",
       " {'pmid': 477381,\n",
       "  'sentence': 'Propranolol and alopecia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['alopecia']},\n",
       " {'pmid': 480622,\n",
       "  'sentence': 'Sulindac in ankylosing spondylitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sulindac'],\n",
       "  'reaction': ['ankylosing spondylitis', 'spondylitis']},\n",
       " {'pmid': 483112,\n",
       "  'sentence': 'Concomitant disease was frequent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['concomitant disease']},\n",
       " {'pmid': 485648,\n",
       "  'sentence': 'Endocrine studies of azoospermia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['azoospermia']},\n",
       " {'pmid': 508127,\n",
       "  'sentence': 'Amitriptyline in migraine prophylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amitriptyline'],\n",
       "  'reaction': ['migraine', 'prophylaxis']},\n",
       " {'pmid': 518198,\n",
       "  'sentence': 'Endocrine studies of azoospermia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['azoospermia']},\n",
       " {'pmid': 518830,\n",
       "  'sentence': 'Hypertrichosis due to minoxidil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['minoxidil'],\n",
       "  'reaction': ['hypertrichosis']},\n",
       " {'pmid': 521239,\n",
       "  'sentence': 'Imipramine in depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 525269,\n",
       "  'sentence': 'and by oxytocin infusion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxytocin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 537955,\n",
       "  'sentence': 'Lithium neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 563932,\n",
       "  'sentence': 'Clindamycin in infective endocarditis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clindamycin'],\n",
       "  'reaction': ['endocarditis']},\n",
       " {'pmid': 567202,\n",
       "  'sentence': 'Cardiac dysautonomia in leprosy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['leprosy']},\n",
       " {'pmid': 571544,\n",
       "  'sentence': 'Rat dopamine hypersensitivity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 571992,\n",
       "  'sentence': 'Diazepam and dialysis encephalopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diazepam'],\n",
       "  'reaction': ['dialysis', 'encephalopathy']},\n",
       " {'pmid': 577524,\n",
       "  'sentence': 'Hyperthyroidism after propranolol withdrawal.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['hyperthyroidism']},\n",
       " {'pmid': 577688,\n",
       "  'sentence': 'Fatal poisoning with verapamil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 578553,\n",
       "  'sentence': 'Doxycycline in abdominal surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxycycline'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 580672,\n",
       "  'sentence': 'Lithium neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 591941,\n",
       "  'sentence': 'Mood change and magnesium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['mood']},\n",
       " {'pmid': 596079,\n",
       "  'sentence': 'Gentamycin in cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac', 'gentamycin'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 596951,\n",
       "  'sentence': 'Cardiac abnormality in polymyositis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['polymyositis']},\n",
       " {'pmid': 601557,\n",
       "  'sentence': 'Erythromycin and anaerobic infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['erythromycin'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 615706,\n",
       "  'sentence': 'Methotrexate treatment in dermatomyositis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['dermatomyositis']},\n",
       " {'pmid': 615843,\n",
       "  'sentence': 'Idiopathic cholesterol pneumonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['pneumonitis']},\n",
       " {'pmid': 626666,\n",
       "  'sentence': 'Assessment of cardiac biopsy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['biopsy']},\n",
       " {'pmid': 626694,\n",
       "  'sentence': 'injection of pentazocine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pentazocine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 628214,\n",
       "  'sentence': 'Intraoral basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 630214,\n",
       "  'sentence': 'Fluorouracil cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 630550,\n",
       "  'sentence': 'Reserpine and breast cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['reserpine'],\n",
       "  'reaction': ['breast cancer']},\n",
       " {'pmid': 637061,\n",
       "  'sentence': 'Oxacillin hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['oxacillin'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 646289,\n",
       "  'sentence': 'Neomycin ototoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['neomycin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 646708,\n",
       "  'sentence': 'Nasal and paranasal sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 647693,\n",
       "  'sentence': 'Tamoxifen retinopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['retinopathy']},\n",
       " {'pmid': 660357,\n",
       "  'sentence': 'Diphenylhydantoin interstitial nephritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diphenylhydantoin'],\n",
       "  'reaction': ['nephritis']},\n",
       " {'pmid': 665523,\n",
       "  'sentence': 'Cardiac manifestations in polymyositis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['polymyositis']},\n",
       " {'pmid': 667366,\n",
       "  'sentence': 'Oxymetholone treatment in myelofibrosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['oxymetholone'],\n",
       "  'reaction': ['myelofibrosis']},\n",
       " {'pmid': 668146,\n",
       "  'sentence': 'Cholesterol balance during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 672825,\n",
       "  'sentence': 'Identification of cardiac output.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 677030,\n",
       "  'sentence': 'Cardiac sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 686319,\n",
       "  'sentence': 'Physostigmine in open-heart surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['physostigmine'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 686548,\n",
       "  'sentence': 'Interstitial pneumonia from mitomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitomycin'],\n",
       "  'reaction': ['pneumonia']},\n",
       " {'pmid': 690088,\n",
       "  'sentence': 'Lithium and hypothyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['hypothyroidism']},\n",
       " {'pmid': 691145,\n",
       "  'sentence': 'Doxorubicin cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 699674,\n",
       "  'sentence': 'Streptomycin pharmacokinetics in malnutrition.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['streptomycin'],\n",
       "  'reaction': ['malnutrition']},\n",
       " {'pmid': 708024,\n",
       "  'sentence': 'Single-dose doxycycline for cholera.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxycycline'],\n",
       "  'reaction': ['cholera']},\n",
       " {'pmid': 709954,\n",
       "  'sentence': 'Oxacillin induced neutropenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['oxacillin'],\n",
       "  'reaction': ['neutropenia']},\n",
       " {'pmid': 712530,\n",
       "  'sentence': 'Nasal glioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['glioma']},\n",
       " {'pmid': 724584,\n",
       "  'sentence': 'Hypocalcaemic cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 733136,\n",
       "  'sentence': 'Diphenylhydantoin teratogenicity in man.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diphenylhydantoin'],\n",
       "  'reaction': ['teratogenicity']},\n",
       " {'pmid': 734377,\n",
       "  'sentence': 'Cardiac involvement in polymyositis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['polymyositis']},\n",
       " {'pmid': 742823,\n",
       "  'sentence': 'Concomitant groin hernia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['hernia']},\n",
       " {'pmid': 751087,\n",
       "  'sentence': 'Peri-partum cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 760422,\n",
       "  'sentence': 'Amantadine and influenza A.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amantadine'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 761834,\n",
       "  'sentence': 'Hepatitis from dantrolene sodium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 776487,\n",
       "  'sentence': 'Atenolol in essential hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atenolol'],\n",
       "  'reaction': ['essential hypertension', 'hypertension']},\n",
       " {'pmid': 779692,\n",
       "  'sentence': 'Basal heart rate increased.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['heart rate', 'heart rate']},\n",
       " {'pmid': 779820,\n",
       "  'sentence': 'Pemphigus controlled by dapsone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['pemphigus']},\n",
       " {'pmid': 788118,\n",
       "  'sentence': 'Dapsone in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 790411,\n",
       "  'sentence': 'Lithium in tardive dyskinesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['tardive dyskinesia', 'dyskinesia']},\n",
       " {'pmid': 799987,\n",
       "  'sentence': 'Imipramine and rheumatoid factor.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['rheumatoid factor', 'rheumatoid factor']},\n",
       " {'pmid': 802927,\n",
       "  'sentence': 'High cardiac output hypertensions.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 807227,\n",
       "  'sentence': 'Postoperative magnesium deficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['magnesium deficiency']},\n",
       " {'pmid': 812582,\n",
       "  'sentence': 'Phenformin and lactic acidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenformin'],\n",
       "  'reaction': ['lactic acidosis', 'acidosis']},\n",
       " {'pmid': 818720,\n",
       "  'sentence': 'Sotalol in angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sotalol'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 820199,\n",
       "  'sentence': 'Corynebacterium diphtheriae endocarditis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['endocarditis']},\n",
       " {'pmid': 820396,\n",
       "  'sentence': 'Lithium carbonate prophylaxis failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 823921,\n",
       "  'sentence': '[Cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 830818,\n",
       "  'sentence': 'Nasal glioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['glioma']},\n",
       " {'pmid': 835151,\n",
       "  'sentence': 'Reserpine and cerebral vasospasm.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['reserpine'],\n",
       "  'reaction': ['vasospasm']},\n",
       " {'pmid': 835373,\n",
       "  'sentence': 'infusion of sodium DL-3-hydroxybutyrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 843097,\n",
       "  'sentence': 'Giant basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 843156,\n",
       "  'sentence': 'Doxorubicin hydrochloride-associated renal failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['renal failure']},\n",
       " {'pmid': 850435,\n",
       "  'sentence': 'and low cardiac output.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 850603,\n",
       "  'sentence': 'Erythromycin prophylaxis for pertussis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['erythromycin'],\n",
       "  'reaction': ['prophylaxis', 'pertussis']},\n",
       " {'pmid': 850712,\n",
       "  'sentence': 'Metastatic basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 857459,\n",
       "  'sentence': 'Cardiac output increased.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 860164,\n",
       "  'sentence': 'Levodopa in parkinsonism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['parkinsonism']},\n",
       " {'pmid': 864317,\n",
       "  'sentence': 'The nasal chondroma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['chondroma']},\n",
       " {'pmid': 866567,\n",
       "  'sentence': 'Practolol peritonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['practolol'],\n",
       "  'reaction': ['peritonitis']},\n",
       " {'pmid': 870275,\n",
       "  'sentence': 'Practolol peritonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['practolol'],\n",
       "  'reaction': ['peritonitis']},\n",
       " {'pmid': 880140,\n",
       "  'sentence': 'Cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 907335,\n",
       "  'sentence': 'Methicillin hemorrhagic cystitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methicillin'],\n",
       "  'reaction': ['cystitis']},\n",
       " {'pmid': 909485,\n",
       "  'sentence': 'Traumatic basal subarachnoid haemorrhage.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['subarachnoid haemorrhage', 'haemorrhage']},\n",
       " {'pmid': 909500,\n",
       "  'sentence': 'Agranulocytosis due to dapsone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['agranulocytosis']},\n",
       " {'pmid': 909662,\n",
       "  'sentence': 'Intrapartum fetal cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 911570,\n",
       "  'sentence': 'Recurrent migraine after propranolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['migraine']},\n",
       " {'pmid': 918510,\n",
       "  'sentence': 'Inspiratory nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 918518,\n",
       "  'sentence': 'Pathogenesis of nasal polyps.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal polyps']},\n",
       " {'pmid': 918705,\n",
       "  'sentence': 'Methoxyflurane hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methoxyflurane'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 921385,\n",
       "  'sentence': '[Cardiac neurosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['neurosis']},\n",
       " {'pmid': 931425,\n",
       "  'sentence': 'Cardiac biopsy in childhood.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['biopsy']},\n",
       " {'pmid': 937354,\n",
       "  'sentence': 'Methyldopa Hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methyldopa'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 938024,\n",
       "  'sentence': 'Ototoxicity of amikacin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amikacin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 939342,\n",
       "  'sentence': 'Hypersensitivity to prilocaine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['prilocaine'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 946271,\n",
       "  'sentence': 'Phenformin and lactic acidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenformin'],\n",
       "  'reaction': ['lactic acidosis', 'acidosis']},\n",
       " {'pmid': 952821,\n",
       "  'sentence': 'Acute endocrine exophthalmos.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['exophthalmos']},\n",
       " {'pmid': 958625,\n",
       "  'sentence': 'Acquired basal encephalocele.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['encephalocele']},\n",
       " {'pmid': 971456,\n",
       "  'sentence': 'Toxicity following methoxyflurane anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methoxyflurane'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 978335,\n",
       "  'sentence': 'Reversible oxacillin hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['oxacillin'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 980244,\n",
       "  'sentence': 'Unilateral endocrine exophthalmos.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['exophthalmos']},\n",
       " {'pmid': 989621,\n",
       "  'sentence': '[Endocrine ophthalmopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['endocrine ophthalmopathy']},\n",
       " {'pmid': 990154,\n",
       "  'sentence': 'Labetalol in resistant hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['labetalol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 1000625,\n",
       "  'sentence': 'Cardiac output was unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 1001288,\n",
       "  'sentence': 'Methoxyflurane nephropathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methoxyflurane'],\n",
       "  'reaction': ['nephropathy']},\n",
       " {'pmid': 1008262,\n",
       "  'sentence': 'Brain dopamine and ejaculation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['ejaculation']},\n",
       " {'pmid': 1009357,\n",
       "  'sentence': 'Metronidazole and anaerobic sepsis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metronidazole'],\n",
       "  'reaction': ['sepsis']},\n",
       " {'pmid': 1031656,\n",
       "  'sentence': 'Cardiac arrest in otorhinolaryngology.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1036572,\n",
       "  'sentence': 'Hyperkalemia with cardiac arrhythmia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['arrhythmia']},\n",
       " {'pmid': 1053373,\n",
       "  'sentence': 'Ototoxicity of tobramycin sulfate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tobramycin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 1054405,\n",
       "  'sentence': 'Colitis after clindamycin therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clindamycin'],\n",
       "  'reaction': ['colitis']},\n",
       " {'pmid': 1065313,\n",
       "  'sentence': 'Lithium neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 1067034,\n",
       "  'sentence': 'Gallium scanning in sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['gallium'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 1087569,\n",
       "  'sentence': 'Practolol and ocular toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['practolol'],\n",
       "  'reaction': ['ocular toxicity']},\n",
       " {'pmid': 1087570,\n",
       "  'sentence': 'Intracameral injection of gentamicin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['gentamicin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1092824,\n",
       "  'sentence': 'Minoxidil in refractory hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['minoxidil'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 1098458,\n",
       "  'sentence': 'Cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 1101590,\n",
       "  'sentence': '[Lithium prophylaxis].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 1107769,\n",
       "  'sentence': 'Alprenolol in angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['alprenolol'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 1124249,\n",
       "  'sentence': 'Management of nasal injury.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal injury', 'injury']},\n",
       " {'pmid': 1126102,\n",
       "  'sentence': 'Fatal overdose from Bendectin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bendectin'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 1127597,\n",
       "  'sentence': 'Dehydration of tetracycline.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tetracycline'],\n",
       "  'reaction': ['dehydration']},\n",
       " {'pmid': 1127784,\n",
       "  'sentence': 'Clostridium sordelli infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 1131682,\n",
       "  'sentence': 'Cardiac output was unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 1135748,\n",
       "  'sentence': 'Cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 1136851,\n",
       "  'sentence': 'Diazepam in cardioversion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diazepam'],\n",
       "  'reaction': ['cardioversion']},\n",
       " {'pmid': 1139429,\n",
       "  'sentence': 'Paradoxical nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 1145012,\n",
       "  'sentence': 'Phenylbutazone and hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenylbutazone'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1146615,\n",
       "  'sentence': 'infusion of calcium gluconate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 1146799,\n",
       "  'sentence': 'Barium peritonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['peritonitis']},\n",
       " {'pmid': 1155490,\n",
       "  'sentence': 'Tobramycin in renal impairment.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tobramycin'],\n",
       "  'reaction': ['renal impairment']},\n",
       " {'pmid': 1160758,\n",
       "  'sentence': 'Metastatic basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 1164123,\n",
       "  'sentence': 'Immunoglobulin A nephropathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['nephropathy']},\n",
       " {'pmid': 1167050,\n",
       "  'sentence': 'Photosensitivity reaction to vinblastine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vinblastine'],\n",
       "  'reaction': ['photosensitivity reaction']},\n",
       " {'pmid': 1170716,\n",
       "  'sentence': 'Reserpine decreases piribedil stereotypy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['reserpine'],\n",
       "  'reaction': ['stereotypy']},\n",
       " {'pmid': 1171416,\n",
       "  'sentence': 'Acute overdose with levodopa.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 1173118,\n",
       "  'sentence': 'Penicillin treatment of neurosyphilis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['penicillin'],\n",
       "  'reaction': ['neurosyphilis']},\n",
       " {'pmid': 1173185,\n",
       "  'sentence': 'Anicteric carbenicillin hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['carbenicillin'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1183262,\n",
       "  'sentence': 'One cardiac arrest recovered.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1185010,\n",
       "  'sentence': 'Miconazole in coccidioidomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['miconazole'],\n",
       "  'reaction': ['coccidioidomycosis']},\n",
       " {'pmid': 1185070,\n",
       "  'sentence': 'Nasal glioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['glioma']},\n",
       " {'pmid': 1188330,\n",
       "  'sentence': 'Metastasizing basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 1190148,\n",
       "  'sentence': 'Sodium fluoroacetate poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 1190819,\n",
       "  'sentence': 'Perinatal cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1193118,\n",
       "  'sentence': 'Cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 1194331,\n",
       "  'sentence': 'Induced ischemic cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1194764,\n",
       "  'sentence': 'Granulomas in nasal polyps.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal polyps']},\n",
       " {'pmid': 1217858,\n",
       "  'sentence': 'Levodopa and psoriasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['psoriasis']},\n",
       " {'pmid': 1241600,\n",
       "  'sentence': 'the complete growth medium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 1242170,\n",
       "  'sentence': 'Phencyclidine poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phencyclidine'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 1242320,\n",
       "  'sentence': 'Injection of heparin i.v.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1244825,\n",
       "  'sentence': 'Nasal sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 1249904,\n",
       "  'sentence': 'Haemodialysis in imipramine poisoning?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['haemodialysis', 'poisoning']},\n",
       " {'pmid': 1253632,\n",
       "  'sentence': 'Fosfomycin in Osteomyelitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fosfomycin'],\n",
       "  'reaction': ['osteomyelitis']},\n",
       " {'pmid': 1259264,\n",
       "  'sentence': 'Possible hepatotoxicity of Doxidan.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxidan'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 1266540,\n",
       "  'sentence': 'Vasopressin tachyphylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vasopressin'],\n",
       "  'reaction': ['tachyphylaxis']},\n",
       " {'pmid': 1266577,\n",
       "  'sentence': 'Clonus depression by propranolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['clonus', 'depression']},\n",
       " {'pmid': 1267495,\n",
       "  'sentence': 'L-dopa in hepatic coma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['l-dopa'],\n",
       "  'reaction': ['coma']},\n",
       " {'pmid': 1268838,\n",
       "  'sentence': 'infusion of 5-fluorouracil.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 1272160,\n",
       "  'sentence': 'Lithium carbonate and hypothyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['hypothyroidism']},\n",
       " {'pmid': 1289197,\n",
       "  'sentence': '[Cimetidine hepatitis].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1294592,\n",
       "  'sentence': '[Chronic Corynebacterium endophthalmitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['endophthalmitis']},\n",
       " {'pmid': 1295429,\n",
       "  'sentence': 'Hepatotoxicity of amiodarone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 1299208,\n",
       "  'sentence': 'Mechanisms of cardiac growth.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 1302724,\n",
       "  'sentence': '[Cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 1319709,\n",
       "  'sentence': 'Angioedema associated with lisinopril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lisinopril'],\n",
       "  'reaction': ['angioedema']},\n",
       " {'pmid': 1320694,\n",
       "  'sentence': 'injection of oxytocin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxytocin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1322108,\n",
       "  'sentence': 'Zidovudine and cytomegalovirus retinitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['zidovudine'],\n",
       "  'reaction': ['retinitis']},\n",
       " {'pmid': 1332350,\n",
       "  'sentence': 'Doxycycline and hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxycycline'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 1338308,\n",
       "  'sentence': 'Sodium transport in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 1338526,\n",
       "  'sentence': 'Angioedema complicating lisinopril therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lisinopril'],\n",
       "  'reaction': ['angioedema']},\n",
       " {'pmid': 1357774,\n",
       "  'sentence': '[Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 1374882,\n",
       "  'sentence': 'Propafenone associated agranulocytosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propafenone'],\n",
       "  'reaction': ['agranulocytosis']},\n",
       " {'pmid': 1375048,\n",
       "  'sentence': 'Chromium in the elderly.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['elderly']},\n",
       " {'pmid': 1390007,\n",
       "  'sentence': 'Magnesium and blood pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 1390008,\n",
       "  'sentence': 'Magnesium and blood pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 1390350,\n",
       "  'sentence': 'Carboplatin and retroperitoneal fibrosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['carboplatin'],\n",
       "  'reaction': ['retroperitoneal fibrosis', 'fibrosis']},\n",
       " {'pmid': 1395734,\n",
       "  'sentence': 'Amiodarone pneumonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pneumonitis']},\n",
       " {'pmid': 1400469,\n",
       "  'sentence': 'Magnesium and fluoride stoichiometry.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 1407096,\n",
       "  'sentence': '[Ibuprofen meningitis].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ibuprofen'],\n",
       "  'reaction': ['meningitis']},\n",
       " {'pmid': 1416572,\n",
       "  'sentence': 'Octreotide treatment of acromegaly.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['octreotide'],\n",
       "  'reaction': ['acromegaly']},\n",
       " {'pmid': 1421431,\n",
       "  'sentence': 'Late doxorubicin cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 1424038,\n",
       "  'sentence': 'Mechanical cardiac valve thrombosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['thrombosis']},\n",
       " {'pmid': 1432516,\n",
       "  'sentence': 'Levodopa and childhood amblyopia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['amblyopia']},\n",
       " {'pmid': 1435840,\n",
       "  'sentence': 'Tamoxifen and endometrial cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['endometrial cancer']},\n",
       " {'pmid': 1440881,\n",
       "  'sentence': 'Aluminium phosphide poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['aluminium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 1443457,\n",
       "  'sentence': 'Hypersensitivity to trimethoprim.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['trimethoprim'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 1451718,\n",
       "  'sentence': 'Phenytoin metabolism during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1458647,\n",
       "  'sentence': 'Perianal basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 1466225,\n",
       "  'sentence': 'Cardiac herniation after pneumonectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pneumonectomy']},\n",
       " {'pmid': 1473841,\n",
       "  'sentence': 'Immunoglobulin profile in schizophrenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['schizophrenia']},\n",
       " {'pmid': 1476502,\n",
       "  'sentence': 'Hypertension and cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypertension', 'cardiac failure']},\n",
       " {'pmid': 1479267,\n",
       "  'sentence': 'Benign nasal schwannoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['schwannoma']},\n",
       " {'pmid': 1484020,\n",
       "  'sentence': 'Enalapril in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enalapril'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 1484653,\n",
       "  'sentence': 'Endocrine disorders in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1502480,\n",
       "  'sentence': 'Cimetidine on-demand in dyspepsia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['dyspepsia']},\n",
       " {'pmid': 1503623,\n",
       "  'sentence': 'Cyclosporin for palmoplantar pustulosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['palmoplantar pustulosis']},\n",
       " {'pmid': 1519714,\n",
       "  'sentence': 'Phenytoin reduces suxamethonium-induced myalgia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['myalgia']},\n",
       " {'pmid': 1519893,\n",
       "  'sentence': 'Surgery for cardiac arrhythmias.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 1527158,\n",
       "  'sentence': 'Pneumothorax complicating cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pneumothorax', 'surgery']},\n",
       " {'pmid': 1530120,\n",
       "  'sentence': 'Primary nasal chondrosarcoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['chondrosarcoma']},\n",
       " {'pmid': 1535722,\n",
       "  'sentence': 'Lidocaine inhibited only cough.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['cough', 'cough']},\n",
       " {'pmid': 1538042,\n",
       "  'sentence': 'Pentoxifylline in cerebrovascular dementia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['pentoxifylline'],\n",
       "  'reaction': ['dementia']},\n",
       " {'pmid': 1540058,\n",
       "  'sentence': 'Familial cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 1542147,\n",
       "  'sentence': 'Ibuprofen overdose in adults.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ibuprofen'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 1547765,\n",
       "  'sentence': 'Nifedipine for epilepsy?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['epilepsy']},\n",
       " {'pmid': 1548455,\n",
       "  'sentence': 'Adenosine thallium stress test.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 1551787,\n",
       "  'sentence': 'Fluoxetine prophylaxis of migraine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluoxetine'],\n",
       "  'reaction': ['prophylaxis', 'migraine']},\n",
       " {'pmid': 1557510,\n",
       "  'sentence': 'injection with flumazenil.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['flumazenil'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1579662,\n",
       "  'sentence': 'injection of gadolinium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gadolinium'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1580169,\n",
       "  'sentence': 'Buserelin in premenstrual syndrome.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['buserelin'],\n",
       "  'reaction': ['premenstrual syndrome']},\n",
       " {'pmid': 1581749,\n",
       "  'sentence': 'Fluoxetine improves emotional incontinence.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluoxetine'],\n",
       "  'reaction': ['incontinence']},\n",
       " {'pmid': 1583082,\n",
       "  'sentence': 'Metformin and blood pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metformin'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 1586257,\n",
       "  'sentence': 'Bezafibrate induced rhabdomyolysis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bezafibrate'],\n",
       "  'reaction': ['rhabdomyolysis']},\n",
       " {'pmid': 1586887,\n",
       "  'sentence': 'Low-dose tamoxifen retinopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['retinopathy']},\n",
       " {'pmid': 1588605,\n",
       "  'sentence': 'Cardiac arrest occurred once.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1588868,\n",
       "  'sentence': 'Hepatitis due to nitrofurantoin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nitrofurantoin'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1589877,\n",
       "  'sentence': 'The carcinogenicity of ciclosporin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ciclosporin'],\n",
       "  'reaction': ['carcinogenicity']},\n",
       " {'pmid': 1594260,\n",
       "  'sentence': 'Lidocaine test in neuralgia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['neuralgia']},\n",
       " {'pmid': 1595783,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 1606530,\n",
       "  'sentence': 'Basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 1608015,\n",
       "  'sentence': 'Intermittent heparin flushing protocols.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['flushing']},\n",
       " {'pmid': 1611197,\n",
       "  'sentence': 'Cyclosporin for inflammatory pseudotumour.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['inflammatory pseudotumour']},\n",
       " {'pmid': 1627212,\n",
       "  'sentence': 'Zidovudine pharmacokinetics during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['zidovudine'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1638776,\n",
       "  'sentence': 'Concomitant glomerulonephritis, i.e.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['glomerulonephritis']},\n",
       " {'pmid': 1638915,\n",
       "  'sentence': 'Psychotherapy for cocaine dependence.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['psychotherapy', 'dependence']},\n",
       " {'pmid': 1642354,\n",
       "  'sentence': 'Phlebotomy versus sodium nitroprusside/isoflurane.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['phlebotomy']},\n",
       " {'pmid': 1642428,\n",
       "  'sentence': '[Cholesterol granuloma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['granuloma']},\n",
       " {'pmid': 1644089,\n",
       "  'sentence': 'Chagas cardiomyopathy and captopril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['captopril'],\n",
       "  'reaction': ['cardiomyopathy']},\n",
       " {'pmid': 1659918,\n",
       "  'sentence': 'Lithium in tricyclic-resistant depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 1664146,\n",
       "  'sentence': 'Immunoglobulin production during infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 1669288,\n",
       "  'sentence': 'Calcium imbalance in hypoparathyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypoparathyroidism']},\n",
       " {'pmid': 1683024,\n",
       "  'sentence': 'Levodopa increases life expectancy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['life expectancy']},\n",
       " {'pmid': 1683813,\n",
       "  'sentence': 'infusion of levodopa.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 1702587,\n",
       "  'sentence': 'Flagellate dermatitis after bleomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['flagellate dermatitis', 'dermatitis', 'dermatitis']},\n",
       " {'pmid': 1703751,\n",
       "  'sentence': 'Mebendazole poisoning in infancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mebendazole'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 1704473,\n",
       "  'sentence': 'Oxygen-exacerbated bleomycin pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 1715461,\n",
       "  'sentence': 'Cardiac output was normal.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 1728499,\n",
       "  'sentence': 'Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 1728501,\n",
       "  'sentence': 'Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 1728700,\n",
       "  'sentence': 'Cardiac fibroma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['fibroma']},\n",
       " {'pmid': 1728915,\n",
       "  'sentence': 'Carbamazepine-induced cardiac dysfunction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac dysfunction']},\n",
       " {'pmid': 1739393,\n",
       "  'sentence': 'Endocrine emergencies in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1747800,\n",
       "  'sentence': 'Cardiac disease in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1750314,\n",
       "  'sentence': 'Trabeculectomy with 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['trabeculectomy']},\n",
       " {'pmid': 1752473,\n",
       "  'sentence': 'Diclofenac hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diclofenac'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1752905,\n",
       "  'sentence': 'Epilepsy and cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['epilepsy', 'surgery']},\n",
       " {'pmid': 1754859,\n",
       "  'sentence': 'Ranitidine for non-ulcer dyspepsia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['dyspepsia']},\n",
       " {'pmid': 1760907,\n",
       "  'sentence': 'Barium meal or endoscopy?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['barium meal', 'endoscopy']},\n",
       " {'pmid': 1764870,\n",
       "  'sentence': 'Omeprazole drug interaction studies.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['omeprazole'],\n",
       "  'reaction': ['drug interaction']},\n",
       " {'pmid': 1772232,\n",
       "  'sentence': 'Acquired nostril stenosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nostril'],\n",
       "  'reaction': ['stenosis']},\n",
       " {'pmid': 1777597,\n",
       "  'sentence': 'Cardiac growth factors.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 1784154,\n",
       "  'sentence': 'Nasal myiasis in leprosy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['leprosy']},\n",
       " {'pmid': 1797416,\n",
       "  'sentence': 'infusion ranitidine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 1803972,\n",
       "  'sentence': 'Primary cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 1811582,\n",
       "  'sentence': 'Cardiac function in hypothermia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypothermia']},\n",
       " {'pmid': 1811584,\n",
       "  'sentence': 'Cardiac electrophysiology during hypothermia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypothermia']},\n",
       " {'pmid': 1811872,\n",
       "  'sentence': 'Cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 1821820,\n",
       "  'sentence': 'Lithium neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 1835910,\n",
       "  'sentence': 'Sodium-induced cardiac hypertrophy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy']},\n",
       " {'pmid': 1841578,\n",
       "  'sentence': 'Trabeculectomy with mitomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitomycin'],\n",
       "  'reaction': ['trabeculectomy']},\n",
       " {'pmid': 1849844,\n",
       "  'sentence': 'Endocrine pancreatic carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['pancreatic carcinoma']},\n",
       " {'pmid': 1854308,\n",
       "  'sentence': 'Post menopausal osteoporosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['menopausal'],\n",
       "  'reaction': ['osteoporosis']},\n",
       " {'pmid': 1854886,\n",
       "  'sentence': 'Cyclosporin for hypereosinophilic syndrome.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['hypereosinophilic syndrome']},\n",
       " {'pmid': 1860230,\n",
       "  'sentence': 'Cardiac epinephrine synthesis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['epinephrine']},\n",
       " {'pmid': 1866953,\n",
       "  'sentence': 'Rehabilitating elderly cardiac patients.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['elderly']},\n",
       " {'pmid': 1872757,\n",
       "  'sentence': 'Diclofenac hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diclofenac'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 1884341,\n",
       "  'sentence': 'Fluoxetine in panic disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluoxetine'],\n",
       "  'reaction': ['panic disorder']},\n",
       " {'pmid': 1885917,\n",
       "  'sentence': 'Corynebacterium minutissimum infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 1886137,\n",
       "  'sentence': 'cardiac troponin I.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['troponin', 'troponin', 'troponin i', 'troponin i']},\n",
       " {'pmid': 1888442,\n",
       "  'sentence': 'Acute cyclosporin overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 1888603,\n",
       "  'sentence': 'Calcium for resuscitation?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['resuscitation']},\n",
       " {'pmid': 1897064,\n",
       "  'sentence': 'Potassium and blood pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 1897247,\n",
       "  'sentence': 'injection of idarubicin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['idarubicin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1897692,\n",
       "  'sentence': 'Cyclosporin for steroid-dependent asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 1899292,\n",
       "  'sentence': '[Severe endocrine ophthalmopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['endocrine ophthalmopathy']},\n",
       " {'pmid': 1900318,\n",
       "  'sentence': 'Extramedullary nasal plasmacytoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['plasmacytoma']},\n",
       " {'pmid': 1914275,\n",
       "  'sentence': 'Familial recurring cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 1919307,\n",
       "  'sentence': 'Familial cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 1921657,\n",
       "  'sentence': 'Metastatic basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 1924004,\n",
       "  'sentence': 'Clostridium septicum infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 1924663,\n",
       "  'sentence': 'Desipramine treatment of alcoholism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['desipramine'],\n",
       "  'reaction': ['alcoholism']},\n",
       " {'pmid': 1927636,\n",
       "  'sentence': 'Cocaine induced hypertensive encephalopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['hypertensive encephalopathy', 'encephalopathy']},\n",
       " {'pmid': 1931112,\n",
       "  'sentence': '[Cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 1933678,\n",
       "  'sentence': 'A cardiac arrest policy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 1934445,\n",
       "  'sentence': 'Mechanical cardiac valve thrombosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['thrombosis']},\n",
       " {'pmid': 1935922,\n",
       "  'sentence': 'Endocrine complications of sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 1937644,\n",
       "  'sentence': 'Ciprofloxacin in typhoid fever.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ciprofloxacin'],\n",
       "  'reaction': ['typhoid fever']},\n",
       " {'pmid': 1938238,\n",
       "  'sentence': 'Vanadium transfer during haemodialysis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vanadium'],\n",
       "  'reaction': ['haemodialysis']},\n",
       " {'pmid': 1938862,\n",
       "  'sentence': 'Cardiac mesothelioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['mesothelioma']},\n",
       " {'pmid': 1942134,\n",
       "  'sentence': 'injection of carboplatin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['carboplatin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 1945253,\n",
       "  'sentence': 'Cardiac disease in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 1949970,\n",
       "  'sentence': 'Mania associated with clonazepam.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clonazepam'],\n",
       "  'reaction': ['mania']},\n",
       " {'pmid': 1950478,\n",
       "  'sentence': 'Experimental germanium myopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['germanium'],\n",
       "  'reaction': ['myopathy']},\n",
       " {'pmid': 1958166,\n",
       "  'sentence': 'Ranitidine and depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 1960984,\n",
       "  'sentence': 'Diltiazem and metoclopramide overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diltiazem'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 1969172,\n",
       "  'sentence': 'Bromazepam in generalized anxiety.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bromazepam'],\n",
       "  'reaction': ['anxiety']},\n",
       " {'pmid': 1969198,\n",
       "  'sentence': 'Itraconazole in onychomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['itraconazole'],\n",
       "  'reaction': ['onychomycosis']},\n",
       " {'pmid': 1971206,\n",
       "  'sentence': 'Cardiac hypertrophy in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy', 'hypertension']},\n",
       " {'pmid': 1976203,\n",
       "  'sentence': 'Somatostatin and epilepsy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['epilepsy']},\n",
       " {'pmid': 1985766,\n",
       "  'sentence': 'Intrapericardial infusion of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 1996731,\n",
       "  'sentence': 'Nasal lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 2000020,\n",
       "  'sentence': 'Origin of nasal polyps.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal polyps']},\n",
       " {'pmid': 2005708,\n",
       "  'sentence': 'Desmopressin in nocturnal enuresis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['desmopressin'],\n",
       "  'reaction': ['enuresis']},\n",
       " {'pmid': 2011932,\n",
       "  'sentence': 'Primary cardiac lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 2016404,\n",
       "  'sentence': 'Cocaine and infant behavior.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['infant']},\n",
       " {'pmid': 2019113,\n",
       "  'sentence': 'Corynebacterium striatus keratitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['keratitis']},\n",
       " {'pmid': 2021107,\n",
       "  'sentence': 'Clomipramine for obsessive-compulsive disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clomipramine'],\n",
       "  'reaction': ['obsessive-compulsive disorder']},\n",
       " {'pmid': 2028920,\n",
       "  'sentence': 'Primary cardiac lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 2035797,\n",
       "  'sentence': 'Flumazenil in intensive care.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['flumazenil'],\n",
       "  'reaction': ['intensive care']},\n",
       " {'pmid': 2039349,\n",
       "  'sentence': 'Adamantinoid basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 2062631,\n",
       "  'sentence': 'Purulent nasal discharge.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['discharge']},\n",
       " {'pmid': 2068826,\n",
       "  'sentence': 'Agranulocytosis associated with enalapril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enalapril'],\n",
       "  'reaction': ['agranulocytosis']},\n",
       " {'pmid': 2070626,\n",
       "  'sentence': 'Neoplastic cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 2073086,\n",
       "  'sentence': 'Anti-thymocyte globulin induced thrombocytopenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['globulin'],\n",
       "  'reaction': ['thrombocytopenia']},\n",
       " {'pmid': 2076316,\n",
       "  'sentence': '[Nasal angiomyolipoma].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['angiomyolipoma']},\n",
       " {'pmid': 2081273,\n",
       "  'sentence': 'Acyclovir and postherpetic neuralgia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['acyclovir'],\n",
       "  'reaction': ['neuralgia']},\n",
       " {'pmid': 2082239,\n",
       "  'sentence': 'Dopamine and myopia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['myopia']},\n",
       " {'pmid': 2092235,\n",
       "  'sentence': '[Acute propafenone poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propafenone'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2093922,\n",
       "  'sentence': 'Thrombolysis vs heparin].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['thrombolysis']},\n",
       " {'pmid': 2094696,\n",
       "  'sentence': 'Irish Cardiac Surgery Register.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2095260,\n",
       "  'sentence': 'ticarcillin as antibacterial prophylaxis.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ticarcillin'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 2103558,\n",
       "  'sentence': '[Thallium poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2110701,\n",
       "  'sentence': 'An endocrine neoplasm?',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['endocrine neoplasm', 'neoplasm']},\n",
       " {'pmid': 2113110,\n",
       "  'sentence': 'infusion of cisplatin].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2118134,\n",
       "  'sentence': 'Valproate sodium in epilepsy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['epilepsy']},\n",
       " {'pmid': 2118301,\n",
       "  'sentence': 'Cardiac index increased.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 2118650,\n",
       "  'sentence': 'Immunoglobulin heavy-chain-associated amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['amyloidosis']},\n",
       " {'pmid': 2126128,\n",
       "  'sentence': 'Nasal schwannoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['schwannoma']},\n",
       " {'pmid': 2131119,\n",
       "  'sentence': 'Tamoxifen retinopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['retinopathy']},\n",
       " {'pmid': 2136149,\n",
       "  'sentence': 'Calcium antagonists and vasospasm.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['vasospasm']},\n",
       " {'pmid': 2139490,\n",
       "  'sentence': 'Anosmia after doxycycline use.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxycycline'],\n",
       "  'reaction': ['anosmia']},\n",
       " {'pmid': 2141158,\n",
       "  'sentence': '[Renal cholesterol embolism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['embolism']},\n",
       " {'pmid': 2141664,\n",
       "  'sentence': 'Phenytoin hypersensitivity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 2142126,\n",
       "  'sentence': 'Hypertension-induced cardiac hypertrophy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy']},\n",
       " {'pmid': 2145869,\n",
       "  'sentence': 'Calcium and blood pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 2148195,\n",
       "  'sentence': 'Doxazosin in renal impairment.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxazosin'],\n",
       "  'reaction': ['renal impairment']},\n",
       " {'pmid': 2153087,\n",
       "  'sentence': 'Histopathology of cocaine hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 2155626,\n",
       "  'sentence': 'the undisturbed cardiac output.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 2157151,\n",
       "  'sentence': 'Polyneuropathy in lithium intoxication.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['polyneuropathy']},\n",
       " {'pmid': 2168126,\n",
       "  'sentence': 'Itraconazole treatment of coccidioidomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['itraconazole'],\n",
       "  'reaction': ['coccidioidomycosis']},\n",
       " {'pmid': 2170140,\n",
       "  'sentence': '5-Fluorouracil cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 2170477,\n",
       "  'sentence': 'Itraconazole treatment of phaeohyphomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['itraconazole'],\n",
       "  'reaction': ['phaeohyphomycosis']},\n",
       " {'pmid': 2178851,\n",
       "  'sentence': 'Desipramine relieves postherpetic neuralgia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['desipramine'],\n",
       "  'reaction': ['neuralgia']},\n",
       " {'pmid': 2186663,\n",
       "  'sentence': 'Suxamethonium and hyperkalaemia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['suxamethonium'],\n",
       "  'reaction': ['hyperkalaemia']},\n",
       " {'pmid': 2189127,\n",
       "  'sentence': 'Open-chest cardiac massage.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac massage', 'massage']},\n",
       " {'pmid': 2189338,\n",
       "  'sentence': '[Cardiac tumor mass.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 2198332,\n",
       "  'sentence': 'Cocaine use during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2207219,\n",
       "  'sentence': 'Clomipramine in obsessive-compulsive disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clomipramine'],\n",
       "  'reaction': ['obsessive-compulsive disorder']},\n",
       " {'pmid': 2213551,\n",
       "  'sentence': 'cocaine injection.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2222297,\n",
       "  'sentence': 'Cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 2222870,\n",
       "  'sentence': 'Poisoning by thallium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2224776,\n",
       "  'sentence': 'Nasal lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 2227733,\n",
       "  'sentence': 'Cocaine and fetal death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['death']},\n",
       " {'pmid': 2230066,\n",
       "  'sentence': 'Lithium and weight gain.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 2231837,\n",
       "  'sentence': 'Suicide by captopril overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['captopril'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 2237271,\n",
       "  'sentence': 'injection of furosemide.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['furosemide'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2238630,\n",
       "  'sentence': 'Magnesium deficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['magnesium deficiency']},\n",
       " {'pmid': 2244597,\n",
       "  'sentence': 'Concomitant neurocysticercosis and brucellosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['brucellosis']},\n",
       " {'pmid': 2244851,\n",
       "  'sentence': 'High density lipoprotein cholesterol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['high density lipoprotein', 'high density lipoprotein']},\n",
       " {'pmid': 2246201,\n",
       "  'sentence': 'Stress thallium myocardial scintigraphy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 2246803,\n",
       "  'sentence': ': cardiac output.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 2249217,\n",
       "  'sentence': 'Cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 2251470,\n",
       "  'sentence': 'Assessment of nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 2254902,\n",
       "  'sentence': 'Diclofenac induced immune thrombocytopenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diclofenac'],\n",
       "  'reaction': ['thrombocytopenia']},\n",
       " {'pmid': 2258539,\n",
       "  'sentence': '[5-Fluorouracil and trabeculectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['trabeculectomy']},\n",
       " {'pmid': 2258609,\n",
       "  'sentence': 'Cardiac myosin-induced myocarditis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['myocarditis']},\n",
       " {'pmid': 2259711,\n",
       "  'sentence': 'Prognosis of cardiac phobia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['phobia']},\n",
       " {'pmid': 2262922,\n",
       "  'sentence': '[Acute verapamil poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2268465,\n",
       "  'sentence': '[Nasal sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 2273139,\n",
       "  'sentence': 'injection of oxytocin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxytocin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2277172,\n",
       "  'sentence': '[Metrorrhagia and tamoxifen.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['metrorrhagia']},\n",
       " {'pmid': 2292563,\n",
       "  'sentence': 'Aluminium phosphide poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['aluminium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2293951,\n",
       "  'sentence': 'Nasal glioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['glioma']},\n",
       " {'pmid': 2294930,\n",
       "  'sentence': 'Dorsal nasal cyst formation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal cyst', 'cyst']},\n",
       " {'pmid': 2295446,\n",
       "  'sentence': '5-Fluorouracil neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 2296565,\n",
       "  'sentence': 'Open cardiac resuscitation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['resuscitation']},\n",
       " {'pmid': 2298719,\n",
       "  'sentence': 'Acyclovir pharmacokinetics in plasmapheresis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['acyclovir'],\n",
       "  'reaction': ['plasmapheresis']},\n",
       " {'pmid': 2300517,\n",
       "  'sentence': 'Oral ciprofloxacin for osteomyelitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ciprofloxacin'],\n",
       "  'reaction': ['osteomyelitis']},\n",
       " {'pmid': 2302280,\n",
       "  'sentence': 'Enalapril induced angioedema.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enalapril'],\n",
       "  'reaction': ['angioedema']},\n",
       " {'pmid': 2307831,\n",
       "  'sentence': 'Diclofenac associated hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diclofenac'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 2311746,\n",
       "  'sentence': 'Ofloxacin in miliary tuberculosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ofloxacin'],\n",
       "  'reaction': ['tuberculosis']},\n",
       " {'pmid': 2312827,\n",
       "  'sentence': 'Basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 2314596,\n",
       "  'sentence': 'Nifedipine for intractable hiccups.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['hiccups']},\n",
       " {'pmid': 2314838,\n",
       "  'sentence': 'Orbitofrontal cholesterol granuloma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['granuloma']},\n",
       " {'pmid': 2315392,\n",
       "  'sentence': 'Nasal surgery complications.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2330975,\n",
       "  'sentence': 'Analysis with furosemide infusion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['furosemide'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2331249,\n",
       "  'sentence': 'Elevated blood cholesterol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood cholesterol', 'blood cholesterol']},\n",
       " {'pmid': 2341585,\n",
       "  'sentence': 'Fluoxetine in panic disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluoxetine'],\n",
       "  'reaction': ['panic disorder']},\n",
       " {'pmid': 2351430,\n",
       "  'sentence': 'Rat brain natriuretic peptide.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['brain natriuretic peptide', 'brain natriuretic peptide']},\n",
       " {'pmid': 2355460,\n",
       "  'sentence': 'Cardiac sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 2356854,\n",
       "  'sentence': 'Adriamycin cardiotoxicity in vivo.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['adriamycin'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 2357445,\n",
       "  'sentence': 'Reoperation: cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2357765,\n",
       "  'sentence': 'infusion of cisplatin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2358294,\n",
       "  'sentence': 'Octreotide treatment of acromegaly.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['octreotide'],\n",
       "  'reaction': ['acromegaly']},\n",
       " {'pmid': 2372756,\n",
       "  'sentence': 'Social phobia and clonazepam.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clonazepam'],\n",
       "  'reaction': ['phobia']},\n",
       " {'pmid': 2375555,\n",
       "  'sentence': 'Labetalol hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['labetalol'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 2375961,\n",
       "  'sentence': 'Cimetidine induced pancytopenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['pancytopenia']},\n",
       " {'pmid': 2383375,\n",
       "  'sentence': 'Dopamine and nonmodulating hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2390386,\n",
       "  'sentence': 'Aluminium leaching and fluoride.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['aluminium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 2394155,\n",
       "  'sentence': 'Nasal and laryngeal sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 2398433,\n",
       "  'sentence': 'UTAH Cardiac Transplant Program.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['transplant']},\n",
       " {'pmid': 2404480,\n",
       "  'sentence': 'Doxycycline prophylaxis for shigellosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxycycline'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 2404483,\n",
       "  'sentence': 'Methotrexate in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 2407363,\n",
       "  'sentence': 'Immunosuppression following cardiac transplantation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['immunosuppression']},\n",
       " {'pmid': 2409845,\n",
       "  'sentence': 'Cardiac index changed variably.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 2410477,\n",
       "  'sentence': 'Calcium antagonists and asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 2413700,\n",
       "  'sentence': 'Gingival hyperplasia by nifedipine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['hyperplasia']},\n",
       " {'pmid': 2427067,\n",
       "  'sentence': 'injection of potassium chloride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2429088,\n",
       "  'sentence': 'Cardiac output was depressed.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 2438671,\n",
       "  'sentence': 'Cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 2441201,\n",
       "  'sentence': 'Cardiac index remained unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 2447513,\n",
       "  'sentence': 'Calcium and primary hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2447675,\n",
       "  'sentence': 'No cardiac tamponade occurred.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 2454097,\n",
       "  'sentence': 'Cardiac output was depressed.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 2463568,\n",
       "  'sentence': 'and cardiac failure.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 2466447,\n",
       "  'sentence': 'Hyperamylasemia after cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2475012,\n",
       "  'sentence': 'Fluoxetine treatment of depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fluoxetine'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 2485022,\n",
       "  'sentence': 'Cardiac index increased significantly.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 2486138,\n",
       "  'sentence': 'Accidental poisoning with dapsone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['accidental poisoning', 'poisoning']},\n",
       " {'pmid': 2486407,\n",
       "  'sentence': 'Cardiac neurosis and psychopathology.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['neurosis']},\n",
       " {'pmid': 2492600,\n",
       "  'sentence': 'School-based blood cholesterol screening.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood cholesterol', 'blood cholesterol']},\n",
       " {'pmid': 2503604,\n",
       "  'sentence': 'Transdermal delivery of levonorgestrel.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levonorgestrel'],\n",
       "  'reaction': ['delivery']},\n",
       " {'pmid': 2505971,\n",
       "  'sentence': 'Transdermal delivery of levonorgestrel.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levonorgestrel'],\n",
       "  'reaction': ['delivery']},\n",
       " {'pmid': 2512569,\n",
       "  'sentence': 'Transdermal delivery of levonorgestrel.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['levonorgestrel'],\n",
       "  'reaction': ['delivery']},\n",
       " {'pmid': 2521438,\n",
       "  'sentence': 'Methotrexate pneumonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['pneumonitis']},\n",
       " {'pmid': 2522723,\n",
       "  'sentence': 'Celiprolol in systemic hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['celiprolol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2533571,\n",
       "  'sentence': 'Transdermal peptide delivery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['delivery']},\n",
       " {'pmid': 2533597,\n",
       "  'sentence': 'Prednisolone purpura.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['prednisolone'],\n",
       "  'reaction': ['purpura']},\n",
       " {'pmid': 2535329,\n",
       "  'sentence': 'Selenium in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['selenium'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 2538002,\n",
       "  'sentence': 'Depression associated with enalapril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enalapril'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 2540374,\n",
       "  'sentence': 'Calcium metabolism and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2543924,\n",
       "  'sentence': 'Itraconazole in human histoplasmosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['itraconazole'],\n",
       "  'reaction': ['histoplasmosis']},\n",
       " {'pmid': 2544058,\n",
       "  'sentence': '[Low-molecular weight heparin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 2563965,\n",
       "  'sentence': 'Somatostatin in portal hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['portal hypertension', 'hypertension']},\n",
       " {'pmid': 2565629,\n",
       "  'sentence': 'injection of the tripeptide.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tripeptide'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2565755,\n",
       "  'sentence': 'injection of propranolol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2565947,\n",
       "  'sentence': 'injection of proglumide.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['proglumide'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2566009,\n",
       "  'sentence': 'Cyclosporin in juvenile dermatomyositis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['dermatomyositis']},\n",
       " {'pmid': 2571289,\n",
       "  'sentence': 'Nifedipine and systemic hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2576271,\n",
       "  'sentence': 'injection of neostigmine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['neostigmine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2582632,\n",
       "  'sentence': 'Nasal congestion during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal congestion', 'pregnancy']},\n",
       " {'pmid': 2590533,\n",
       "  'sentence': 'Trends in cardiac metastasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['metastasis']},\n",
       " {'pmid': 2595796,\n",
       "  'sentence': 'Peripartum cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 2604571,\n",
       "  'sentence': 'Cardiac index remained unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 2605865,\n",
       "  'sentence': 'Sodium retention from mouthwashes.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['sodium retention']},\n",
       " {'pmid': 2607295,\n",
       "  'sentence': 'Hypersensitivity to sodium hypochlorite.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 2607521,\n",
       "  'sentence': 'Felodipine in elderly hypertensives.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['felodipine'],\n",
       "  'reaction': ['elderly']},\n",
       " {'pmid': 2608211,\n",
       "  'sentence': 'Endoscopic nasal surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2608968,\n",
       "  'sentence': '[Acute lithium poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 2615533,\n",
       "  'sentence': 'Hypersensitivity reaction to epirubicin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['epirubicin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 2619152,\n",
       "  'sentence': 'Ocular toxicity of tamoxifen.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['ocular toxicity']},\n",
       " {'pmid': 2620478,\n",
       "  'sentence': 'Leukoencephalopathy after cisplatin therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['leukoencephalopathy']},\n",
       " {'pmid': 2624552,\n",
       "  'sentence': '[Amiodarone neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 2631559,\n",
       "  'sentence': 'Nasal meningioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['meningioma']},\n",
       " {'pmid': 2637592,\n",
       "  'sentence': 'All received cardiac surgery.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2643001,\n",
       "  'sentence': 'Endocrine aspects of obesity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['obesity']},\n",
       " {'pmid': 2644603,\n",
       "  'sentence': 'Acyclovir therapy during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['acyclovir'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2644915,\n",
       "  'sentence': 'Pulmonary toxicity of nitrofurantoin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nitrofurantoin'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 2649761,\n",
       "  'sentence': 'Cardiac disease in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2650468,\n",
       "  'sentence': 'Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 2653029,\n",
       "  'sentence': 'Calcium antagonists in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2654578,\n",
       "  'sentence': 'Agranulocytosis after ranitidine administration.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['agranulocytosis']},\n",
       " {'pmid': 2655462,\n",
       "  'sentence': 'Otospongiosis and sodium fluoride.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 2658744,\n",
       "  'sentence': 'Cocaine dependence.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 2660783,\n",
       "  'sentence': 'Ketotifen in asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketotifen'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 2661083,\n",
       "  'sentence': 'Cardiac arrhythmias during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2664653,\n",
       "  'sentence': 'Nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 2664654,\n",
       "  'sentence': 'Rhinitis and nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['rhinitis', 'nasal obstruction', 'obstruction']},\n",
       " {'pmid': 2664658,\n",
       "  'sentence': 'Nasal obstruction in children.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 2666458,\n",
       "  'sentence': 'Penile basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 2667275,\n",
       "  'sentence': 'Thrombocytopenia and heparin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['thrombocytopenia']},\n",
       " {'pmid': 2667871,\n",
       "  'sentence': 'Endocrine aspects of menopause.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['menopause']},\n",
       " {'pmid': 2669668,\n",
       "  'sentence': 'Seizure propensity with imipenem.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipenem'],\n",
       "  'reaction': ['seizure']},\n",
       " {'pmid': 2672701,\n",
       "  'sentence': '[Endocrine arterial hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2672702,\n",
       "  'sentence': '[Endocrine arterial hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2674920,\n",
       "  'sentence': 'Nonexercise cardiac stress testing.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 2677196,\n",
       "  'sentence': 'Calcium and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2693580,\n",
       "  'sentence': 'Lithium use during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2693844,\n",
       "  'sentence': 'Calcium and cell death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['cell death', 'death']},\n",
       " {'pmid': 2695220,\n",
       "  'sentence': 'Cardiac magnetic resonance imaging.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['magnetic resonance imaging']},\n",
       " {'pmid': 2703865,\n",
       "  'sentence': 'Recognizing cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 2705904,\n",
       "  'sentence': 'Levodopa improved dystonia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['levodopa'],\n",
       "  'reaction': ['dystonia']},\n",
       " {'pmid': 2722406,\n",
       "  'sentence': 'Depression and magnesium deficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['depression', 'magnesium deficiency']},\n",
       " {'pmid': 2735952,\n",
       "  'sentence': 'Cocaine produces hepatotoxicity.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 2735960,\n",
       "  'sentence': 'Methotrexate in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 2736497,\n",
       "  'sentence': 'Primary cardiac lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 2742225,\n",
       "  'sentence': 'Barium enema or colonoscopy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['colonoscopy']},\n",
       " {'pmid': 2742365,\n",
       "  'sentence': 'Parkinsonism and amiodarone therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['parkinsonism']},\n",
       " {'pmid': 2743898,\n",
       "  'sentence': 'Submucosal hypopharyngeal lipoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['submucosal'],\n",
       "  'reaction': ['lipoma']},\n",
       " {'pmid': 2748175,\n",
       "  'sentence': 'Post-rhinoplastic nasal obstruction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 2753064,\n",
       "  'sentence': 'infusion of nitrendipine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nitrendipine'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2755942,\n",
       "  'sentence': 'secretin infusion, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['secretin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2775959,\n",
       "  'sentence': 'Hyponatraemia and clomipramine therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clomipramine'],\n",
       "  'reaction': ['hyponatraemia']},\n",
       " {'pmid': 2776354,\n",
       "  'sentence': 'Corticosteroid-binding globulin in depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['globulin'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 2779969,\n",
       "  'sentence': 'Intravitreal injection of piperacillin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['piperacillin'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2780466,\n",
       "  'sentence': 'Pizotifen in deafferentation pain.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['pizotifen'],\n",
       "  'reaction': ['pain']},\n",
       " {'pmid': 2782986,\n",
       "  'sentence': '[Amiodarone keratopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['keratopathy']},\n",
       " {'pmid': 2799446,\n",
       "  'sentence': 'Cocaine and scleroderma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['scleroderma']},\n",
       " {'pmid': 2801834,\n",
       "  'sentence': 'Hypersensitivity to magnesium sulfate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 2802889,\n",
       "  'sentence': 'Heparin therapy during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 2807502,\n",
       "  'sentence': 'Diazepam induced delirium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diazepam'],\n",
       "  'reaction': ['delirium']},\n",
       " {'pmid': 2831524,\n",
       "  'sentence': 'Stress/catecholamine-induced cardiac necrosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['necrosis']},\n",
       " {'pmid': 2832836,\n",
       "  'sentence': 'Ganciclovir hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ganciclovir'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 2856052,\n",
       "  'sentence': 'Calcium antagonists and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2858193,\n",
       "  'sentence': 'Reversible ipecac myopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ipecac'],\n",
       "  'reaction': ['myopathy']},\n",
       " {'pmid': 2866093,\n",
       "  'sentence': 'Anaesthesia and cardiac electrophysiology.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 2866166,\n",
       "  'sentence': 'Bucindolol in essential hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bucindolol'],\n",
       "  'reaction': ['essential hypertension', 'hypertension']},\n",
       " {'pmid': 2866587,\n",
       "  'sentence': 'Pediatric endocrine surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 2871770,\n",
       "  'sentence': 'Vecuronium induced neuromuscular blockade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vecuronium'],\n",
       "  'reaction': ['neuromuscular blockade']},\n",
       " {'pmid': 2872366,\n",
       "  'sentence': 'injection of cetrimonium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cetrimonium'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 2875728,\n",
       "  'sentence': 'Verapamil in angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 2880457,\n",
       "  'sentence': 'Remoxipride in schizophrenia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['remoxipride'],\n",
       "  'reaction': ['schizophrenia']},\n",
       " {'pmid': 2880524,\n",
       "  'sentence': 'Vecuronium and phaeochromocytoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vecuronium'],\n",
       "  'reaction': ['phaeochromocytoma']},\n",
       " {'pmid': 2883805,\n",
       "  'sentence': 'Somatostatin in multiple sclerosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['multiple sclerosis']},\n",
       " {'pmid': 2894357,\n",
       "  'sentence': 'Nitrendipine in severe hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nitrendipine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2903653,\n",
       "  'sentence': 'Celiprolol in angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['celiprolol'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 2903654,\n",
       "  'sentence': 'Celiprolol in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['celiprolol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2910220,\n",
       "  'sentence': 'Clomipramine in obsessive-compulsive disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clomipramine'],\n",
       "  'reaction': ['obsessive-compulsive disorder']},\n",
       " {'pmid': 2912520,\n",
       "  'sentence': 'Low-dose continuous infusion 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 2923798,\n",
       "  'sentence': 'Long-term cyclosporin for psoriasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['psoriasis']},\n",
       " {'pmid': 2927404,\n",
       "  'sentence': 'Choreoathetosis induced by cyproheptadine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyproheptadine'],\n",
       "  'reaction': ['choreoathetosis']},\n",
       " {'pmid': 2930359,\n",
       "  'sentence': 'Cardiac contusion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac contusion', 'contusion']},\n",
       " {'pmid': 2934281,\n",
       "  'sentence': 'Pityriasis rosea and ketotifen.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketotifen'],\n",
       "  'reaction': ['pityriasis', 'pityriasis rosea']},\n",
       " {'pmid': 2936673,\n",
       "  'sentence': 'Encephalopathy associated with sulindac.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sulindac'],\n",
       "  'reaction': ['encephalopathy']},\n",
       " {'pmid': 2942388,\n",
       "  'sentence': 'Sodium and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2943144,\n",
       "  'sentence': 'Endocrinology of cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 2947159,\n",
       "  'sentence': '[Cardiotoxicity of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 2947461,\n",
       "  'sentence': 'Ipratropium bromide in asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ipratropium'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 2960467,\n",
       "  'sentence': 'pregnenolone to progesterone).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pregnenolone'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 2962704,\n",
       "  'sentence': 'Catecholamine induced cardiac hypertrophy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy']},\n",
       " {'pmid': 2962941,\n",
       "  'sentence': 'Cardiac hypertrophy in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy', 'hypertension']},\n",
       " {'pmid': 2968038,\n",
       "  'sentence': 'Cardiac involvement in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 2969678,\n",
       "  'sentence': 'Cough caused by cilazapril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cilazapril'],\n",
       "  'reaction': ['cough', 'cough']},\n",
       " {'pmid': 2969831,\n",
       "  'sentence': 'Rat cardiac hypertrophy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy']},\n",
       " {'pmid': 2988340,\n",
       "  'sentence': 'Tympanoplasty with calcium phosphate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['tympanoplasty']},\n",
       " {'pmid': 2994986,\n",
       "  'sentence': 'Enalapril in essential hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enalapril'],\n",
       "  'reaction': ['essential hypertension', 'hypertension']},\n",
       " {'pmid': 3018852,\n",
       "  'sentence': 'gadolinium DTPA/kg body weight.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gadolinium'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 3027837,\n",
       "  'sentence': 'Itraconazole in pityriasis versicolor.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['itraconazole'],\n",
       "  'reaction': ['pityriasis']},\n",
       " {'pmid': 3041563,\n",
       "  'sentence': 'Acyclovir crystalluria.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['acyclovir'],\n",
       "  'reaction': ['crystalluria']},\n",
       " {'pmid': 3043654,\n",
       "  'sentence': 'Environmental exposure to thallium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['environmental exposure']},\n",
       " {'pmid': 3047717,\n",
       "  'sentence': 'Estramustine inhibits monocyte phagocytosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['estramustine'],\n",
       "  'reaction': ['phagocytosis']},\n",
       " {'pmid': 3049402,\n",
       "  'sentence': 'Amiodarone in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3049689,\n",
       "  'sentence': 'Amoxicillin and diaper dermatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amoxicillin'],\n",
       "  'reaction': ['dermatitis', 'dermatitis']},\n",
       " {'pmid': 3055917,\n",
       "  'sentence': 'Sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 3057291,\n",
       "  'sentence': 'Infant orthotopic cardiac transplantation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['infant']},\n",
       " {'pmid': 3057327,\n",
       "  'sentence': 'Vancomycin ototoxicity and nephrotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vancomycin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 3062056,\n",
       "  'sentence': 'Calcium and colon cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['colon cancer']},\n",
       " {'pmid': 3063224,\n",
       "  'sentence': '[Chronic cardiac actinomycosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['actinomycosis']},\n",
       " {'pmid': 3063347,\n",
       "  'sentence': 'Noninvasive cardiac monitoring.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac monitoring']},\n",
       " {'pmid': 3063348,\n",
       "  'sentence': 'Invasive cardiac monitoring.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac monitoring']},\n",
       " {'pmid': 3064919,\n",
       "  'sentence': 'Nimodipine in migraine prophylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nimodipine'],\n",
       "  'reaction': ['migraine', 'prophylaxis']},\n",
       " {'pmid': 3067566,\n",
       "  'sentence': 'Asthma and nifedipine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 3076047,\n",
       "  'sentence': 'Calcium and osteoporosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['osteoporosis']},\n",
       " {'pmid': 3079193,\n",
       "  'sentence': 'Ultrasound cardiac output units.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3089051,\n",
       "  'sentence': 'Propofol and alfentanil infusion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['alfentanil'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3092371,\n",
       "  'sentence': 'Hypokalaemia after suxamethonium administration.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['suxamethonium'],\n",
       "  'reaction': ['hypokalaemia']},\n",
       " {'pmid': 3101625,\n",
       "  'sentence': 'Hypothyroxinemia in cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 3105999,\n",
       "  'sentence': 'concomitant folate deficiency).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['folate deficiency']},\n",
       " {'pmid': 3113026,\n",
       "  'sentence': 'Endocrine investigation and therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3120270,\n",
       "  'sentence': 'Selegiline in narcolepsy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['selegiline'],\n",
       "  'reaction': ['narcolepsy']},\n",
       " {'pmid': 3120929,\n",
       "  'sentence': 'Cardiac output during labour.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3142756,\n",
       "  'sentence': 'NG induces heparin resistance.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['heparin resistance']},\n",
       " {'pmid': 3152461,\n",
       "  'sentence': 'Cardiac abnormalities in neurofibromatosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['neurofibromatosis']},\n",
       " {'pmid': 3152743,\n",
       "  'sentence': 'Magnesium deficiency induced hyperlipaemia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['magnesium deficiency']},\n",
       " {'pmid': 3155993,\n",
       "  'sentence': 'Hypersensitivity reactions to amsacrine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amsacrine'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 3164275,\n",
       "  'sentence': 'Cardiac output is unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3168075,\n",
       "  'sentence': 'Epirubicin in rectal cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['epirubicin'],\n",
       "  'reaction': ['rectal cancer']},\n",
       " {'pmid': 3171379,\n",
       "  'sentence': 'Nasal granuloma gravidarum.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['granuloma']},\n",
       " {'pmid': 3172679,\n",
       "  'sentence': 'Cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 3176833,\n",
       "  'sentence': 'dopamine infusion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3190999,\n",
       "  'sentence': 'Quinapril and blood lipids.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['quinapril'],\n",
       "  'reaction': ['lipids']},\n",
       " {'pmid': 3208083,\n",
       "  'sentence': 'cocaine injection.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 3213390,\n",
       "  'sentence': 'Cardiac arrest during anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest', 'anaesthesia']},\n",
       " {'pmid': 3213837,\n",
       "  'sentence': 'Cardiac output remained unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3214388,\n",
       "  'sentence': 'Intravenous clonazepam in eclampsia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clonazepam'],\n",
       "  'reaction': ['eclampsia']},\n",
       " {'pmid': 3252037,\n",
       "  'sentence': 'infusion of propranolol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3260314,\n",
       "  'sentence': 'Autotransfusion after cardiac operation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac operation']},\n",
       " {'pmid': 3273933,\n",
       "  'sentence': 'Ultrasound cardiac output units.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3277802,\n",
       "  'sentence': 'Nifedipine and angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 3278828,\n",
       "  'sentence': 'Saddle nasal deformity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['deformity']},\n",
       " {'pmid': 3282816,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 3286141,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 3287969,\n",
       "  'sentence': 'Overview of cephalosporin prophylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cephalosporin'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 3290148,\n",
       "  'sentence': 'sodium nitroprusside infusion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3295012,\n",
       "  'sentence': 'Phenytoin hypersensitivity syndrome.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 3297378,\n",
       "  'sentence': 'Cardiac output decreased.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3298044,\n",
       "  'sentence': 'Cyclosporin A-induced hyperreninemic hypoaldosteronism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['hypoaldosteronism']},\n",
       " {'pmid': 3300968,\n",
       "  'sentence': 'Cardiotoxicity of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 3301983,\n",
       "  'sentence': 'Magnesium and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3303793,\n",
       "  'sentence': 'Ciamexon-treatment in endocrine ophthalmopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['endocrine ophthalmopathy']},\n",
       " {'pmid': 3304050,\n",
       "  'sentence': 'Methotrexate in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 3306179,\n",
       "  'sentence': 'Magnesium and pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3312372,\n",
       "  'sentence': 'Monosodium L-glutamate-induced asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['monosodium'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 3312526,\n",
       "  'sentence': 'Calcium antagonists in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3315414,\n",
       "  'sentence': 'Calcium and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3319758,\n",
       "  'sentence': '[Cardiotoxicity of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 3320865,\n",
       "  'sentence': 'Implications in nasal surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 3322818,\n",
       "  'sentence': 'Calcium homeostasis and osteoporosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['osteoporosis']},\n",
       " {'pmid': 3323168,\n",
       "  'sentence': 'Roxithromycin in nongonococcal urethritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['roxithromycin'],\n",
       "  'reaction': ['urethritis']},\n",
       " {'pmid': 3336381,\n",
       "  'sentence': 'Out-of-hospital cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 3341717,\n",
       "  'sentence': 'Rhinoplasty: nasal anatomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['rhinoplasty']},\n",
       " {'pmid': 3343636,\n",
       "  'sentence': 'Goniotomy with sodium hyaluronate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['goniotomy']},\n",
       " {'pmid': 3345239,\n",
       "  'sentence': 'Amitriptyline for post-traumatic agitation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amitriptyline'],\n",
       "  'reaction': ['agitation']},\n",
       " {'pmid': 3345766,\n",
       "  'sentence': 'Amiodarone during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3349001,\n",
       "  'sentence': 'Magnesium supplementation in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3354512,\n",
       "  'sentence': 'Corynebacterium xerosis septic arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['xerosis', 'arthritis']},\n",
       " {'pmid': 3356008,\n",
       "  'sentence': 'and intraarterial cisplatin infusion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3361221,\n",
       "  'sentence': 'A double-blind cross-over investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3366077,\n",
       "  'sentence': '[Gallopamil poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['gallopamil'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3377152,\n",
       "  'sentence': 'Adriamycin cardiomyopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['adriamycin'],\n",
       "  'reaction': ['cardiomyopathy']},\n",
       " {'pmid': 3383935,\n",
       "  'sentence': 'Milk of calcium hydronephrosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hydronephrosis']},\n",
       " {'pmid': 3391443,\n",
       "  'sentence': 'injection of verapamil.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 3394500,\n",
       "  'sentence': 'Nasal meningioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['meningioma']},\n",
       " {'pmid': 3397227,\n",
       "  'sentence': 'Anhedonic ejaculation with desipramine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['desipramine'],\n",
       "  'reaction': ['ejaculation']},\n",
       " {'pmid': 3399465,\n",
       "  'sentence': 'Stepwise detoxification from cocaine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['detoxification']},\n",
       " {'pmid': 3400632,\n",
       "  'sentence': 'Thrombocytosis elevates serum potassium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['thrombocytosis']},\n",
       " {'pmid': 3400846,\n",
       "  'sentence': 'Isoflurane for conscious sedation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['isoflurane'],\n",
       "  'reaction': ['sedation']},\n",
       " {'pmid': 3402642,\n",
       "  'sentence': 'Titanium balanitis with phimosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['titanium'],\n",
       "  'reaction': ['phimosis']},\n",
       " {'pmid': 3404567,\n",
       "  'sentence': 'Aluminium phosphide poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['aluminium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3407674,\n",
       "  'sentence': 'Acyclovir in Pregnancy Registry.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['acyclovir'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3416517,\n",
       "  'sentence': 'Nifedipine overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 3435325,\n",
       "  'sentence': 'Nifedipine hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 3442196,\n",
       "  'sentence': 'Cardiac contusion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac contusion', 'contusion']},\n",
       " {'pmid': 3465327,\n",
       "  'sentence': 'Reproductive toxicity of ofloxacin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ofloxacin'],\n",
       "  'reaction': ['reproductive toxicity']},\n",
       " {'pmid': 3468287,\n",
       "  'sentence': 'Hydralazine and breast cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['hydralazine'],\n",
       "  'reaction': ['breast cancer']},\n",
       " {'pmid': 3473872,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 3490834,\n",
       "  'sentence': 'Cephalosporin therapy for salmonellosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cephalosporin'],\n",
       "  'reaction': ['salmonellosis']},\n",
       " {'pmid': 3492341,\n",
       "  'sentence': 'Age and cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 3499141,\n",
       "  'sentence': 'Dependence on calcium concentration.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 3502034,\n",
       "  'sentence': 'Trimethoprim associated aseptic meningitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['trimethoprim'],\n",
       "  'reaction': ['meningitis']},\n",
       " {'pmid': 3503797,\n",
       "  'sentence': '[Cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 3510595,\n",
       "  'sentence': 'Sodium and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3523396,\n",
       "  'sentence': 'Imipramine reduces experimental pain.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['pain']},\n",
       " {'pmid': 3526234,\n",
       "  'sentence': 'Basal joint arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['arthritis']},\n",
       " {'pmid': 3527029,\n",
       "  'sentence': 'A double-blind investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3530300,\n",
       "  'sentence': 'Verapamil in arrhythmia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['arrhythmia']},\n",
       " {'pmid': 3532871,\n",
       "  'sentence': 'Cardiac output measurements.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3535862,\n",
       "  'sentence': 'Renin and vasopressin responses.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vasopressin'],\n",
       "  'reaction': ['renin']},\n",
       " {'pmid': 3539080,\n",
       "  'sentence': 'Nasal obstruction in infancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 3544909,\n",
       "  'sentence': 'Magnesium deficiency in alcoholism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['magnesium deficiency', 'alcoholism']},\n",
       " {'pmid': 3544935,\n",
       "  'sentence': 'Ketotifen and methacholine-induced bronchospasm.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketotifen'],\n",
       "  'reaction': ['bronchospasm']},\n",
       " {'pmid': 3547010,\n",
       "  'sentence': 'Cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 3552464,\n",
       "  'sentence': 'Nifedipine in asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 3554491,\n",
       "  'sentence': 'Cisapride in non-ulcer dyspepsia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisapride'],\n",
       "  'reaction': ['dyspepsia']},\n",
       " {'pmid': 3556704,\n",
       "  'sentence': 'Metastatic basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 3560004,\n",
       "  'sentence': 'Cardiac regulation and depression.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 3560089,\n",
       "  'sentence': 'Phenytoin in rheumatoid arthritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['rheumatoid arthritis', 'arthritis']},\n",
       " {'pmid': 3566473,\n",
       "  'sentence': 'Cardiac tuberculosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['tuberculosis']},\n",
       " {'pmid': 3573808,\n",
       "  'sentence': 'injection of fluorouracil.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['fluorouracil'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 3575317,\n",
       "  'sentence': 'Acute lithium neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 3575401,\n",
       "  'sentence': 'Biopharmaceutical investigation of fenoprofen.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fenoprofen'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3578966,\n",
       "  'sentence': 'Verapamil reverses calcium cardiotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium', 'verapamil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 3582722,\n",
       "  'sentence': 'Amoxycillin in bronchitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amoxycillin'],\n",
       "  'reaction': ['bronchitis']},\n",
       " {'pmid': 3583423,\n",
       "  'sentence': 'Ototoxicity of cisplatin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 3596172,\n",
       "  'sentence': 'Cyclosporin A-induced cholestasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclosporin'],\n",
       "  'reaction': ['cholestasis']},\n",
       " {'pmid': 3598027,\n",
       "  'sentence': 'Hypersensitivity reaction to desipramine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['desipramine'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 3605432,\n",
       "  'sentence': 'Lorazepam for psychogenic catatonia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lorazepam'],\n",
       "  'reaction': ['catatonia']},\n",
       " {'pmid': 3608599,\n",
       "  'sentence': 'Complications of cardiac resuscitation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['resuscitation']},\n",
       " {'pmid': 3618993,\n",
       "  'sentence': 'Memory of cardiac anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 3625616,\n",
       "  'sentence': 'Potassium homeostasis in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3630884,\n",
       "  'sentence': 'Basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 3632445,\n",
       "  'sentence': 'Experimental doxorubicin myopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['myopathy']},\n",
       " {'pmid': 3633592,\n",
       "  'sentence': 'Advanced cardiac life support.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['life support']},\n",
       " {'pmid': 3644283,\n",
       "  'sentence': 'Noninvasive cardiac monitoring.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac monitoring']},\n",
       " {'pmid': 3657258,\n",
       "  'sentence': 'Cardiac index increased postoperatively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 3663443,\n",
       "  'sentence': 'Malignant hyperpyrexia and isoflurane.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['isoflurane'],\n",
       "  'reaction': ['hyperpyrexia']},\n",
       " {'pmid': 3663962,\n",
       "  'sentence': '[Cardiotoxicity of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 3668482,\n",
       "  'sentence': 'Fatal verapamil poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3668848,\n",
       "  'sentence': 'cocaine injection.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 3671215,\n",
       "  'sentence': 'Preventing sudden cardiac death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden cardiac death', 'cardiac death', 'death']},\n",
       " {'pmid': 3673867,\n",
       "  'sentence': 'Cocaine and sudden death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['sudden death', 'death']},\n",
       " {'pmid': 3674355,\n",
       "  'sentence': 'Suxamethonium in myasthenia gravis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['suxamethonium'],\n",
       "  'reaction': ['myasthenia gravis']},\n",
       " {'pmid': 3675245,\n",
       "  'sentence': 'Basal forebrain infarction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['infarction']},\n",
       " {'pmid': 3679605,\n",
       "  'sentence': 'Cardiac tamponade following varicella.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade', 'varicella']},\n",
       " {'pmid': 3686147,\n",
       "  'sentence': 'Pneumomediastinum after cocaine smoking.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['pneumomediastinum']},\n",
       " {'pmid': 3692093,\n",
       "  'sentence': 'Hepatotoxicity of mebendazole.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mebendazole'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 3699120,\n",
       "  'sentence': 'Calcium metabolism in sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 3700831,\n",
       "  'sentence': 'Metastatic basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 3706351,\n",
       "  'sentence': 'Thiazide treatment of hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thiazide'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3707803,\n",
       "  'sentence': 'lignocaine on adrenaline-induced vasoconstriction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lignocaine'],\n",
       "  'reaction': ['vasoconstriction']},\n",
       " {'pmid': 3714094,\n",
       "  'sentence': '[Clofibrate hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clofibrate'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 3717435,\n",
       "  'sentence': 'Depression associated with ranitidine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['depression']},\n",
       " {'pmid': 3723994,\n",
       "  'sentence': 'infusion of sodium thiosulfate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3729526,\n",
       "  'sentence': 'Cardiac manifestations in brucellosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['brucellosis']},\n",
       " {'pmid': 3732098,\n",
       "  'sentence': 'Diuretics in cardiac oedema.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['oedema']},\n",
       " {'pmid': 3734283,\n",
       "  'sentence': 'Psychosomatic nasal disorder.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal disorder']},\n",
       " {'pmid': 3738414,\n",
       "  'sentence': 'Calcium and cystic fibrosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['cystic fibrosis', 'fibrosis']},\n",
       " {'pmid': 3739633,\n",
       "  'sentence': 'Fetal cardiac arrhythmia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['arrhythmia']},\n",
       " {'pmid': 3740030,\n",
       "  'sentence': 'Ranitidine and leukocytosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['leukocytosis']},\n",
       " {'pmid': 3740090,\n",
       "  'sentence': 'Nifedipine overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 3741146,\n",
       "  'sentence': 'Acute fatal selenium poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['selenium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3744788,\n",
       "  'sentence': 'Seizures after pentazocine overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['pentazocine'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 3752656,\n",
       "  'sentence': 'Massive diltiazem overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diltiazem'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 3752763,\n",
       "  'sentence': 'Calcium and cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium', 'cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 3755294,\n",
       "  'sentence': 'Furosemide produces chronic hypercalciuria.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['furosemide'],\n",
       "  'reaction': ['hypercalciuria']},\n",
       " {'pmid': 3755330,\n",
       "  'sentence': 'Primary intranasal Fusarium infection.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['intranasal'],\n",
       "  'reaction': ['fusarium infection', 'infection']},\n",
       " {'pmid': 3757816,\n",
       "  'sentence': '[Atenolol poisoning].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atenolol'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3758172,\n",
       "  'sentence': 'injection of imipramine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 3766923,\n",
       "  'sentence': 'Nasal glioma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['glioma']},\n",
       " {'pmid': 3768768,\n",
       "  'sentence': 'Anaphylactoid reaction to atracurium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atracurium'],\n",
       "  'reaction': ['anaphylactoid reaction']},\n",
       " {'pmid': 3769489,\n",
       "  'sentence': 'Diagnosis of cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 3778598,\n",
       "  'sentence': 'Intraosseous infusion of phenytoin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 3791133,\n",
       "  'sentence': 'Fatal overdose with amantadine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amantadine'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 3798634,\n",
       "  'sentence': 'Corynebacterium group D2 pyelonephritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['pyelonephritis']},\n",
       " {'pmid': 3800529,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 3800549,\n",
       "  'sentence': '[Cocaine poisoning].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3804354,\n",
       "  'sentence': 'Poisoning associated with potassium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3805669,\n",
       "  'sentence': 'Cimetidine hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 3805799,\n",
       "  'sentence': 'Dapsone dependent nodular panniculitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['panniculitis']},\n",
       " {'pmid': 3818550,\n",
       "  'sentence': 'Imipramine and tinnitus.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['imipramine'],\n",
       "  'reaction': ['tinnitus']},\n",
       " {'pmid': 3821172,\n",
       "  'sentence': 'Magnesium intake during pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 3822964,\n",
       "  'sentence': 'Corynebacterium endocarditis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['endocarditis']},\n",
       " {'pmid': 3829739,\n",
       "  'sentence': 'Cardiac dysrhythmia following pneumonectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pneumonectomy']},\n",
       " {'pmid': 3830693,\n",
       "  'sentence': '[Lithium poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3835092,\n",
       "  'sentence': '[Cardiac sudden death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sudden death', 'death']},\n",
       " {'pmid': 3836112,\n",
       "  'sentence': 'Experimental endocarditis and fosfomycin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fosfomycin'],\n",
       "  'reaction': ['endocarditis']},\n",
       " {'pmid': 3840216,\n",
       "  'sentence': '[Endocrine ophthalmopathy].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['endocrine ophthalmopathy']},\n",
       " {'pmid': 3843427,\n",
       "  'sentence': 'Barium poisoning is rare.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3857219,\n",
       "  'sentence': 'Epirubicin in colorectal cancer.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['epirubicin'],\n",
       "  'reaction': ['colorectal cancer']},\n",
       " {'pmid': 3870534,\n",
       "  'sentence': 'Tamoxifen caused hypercalcaemia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['hypercalcaemia']},\n",
       " {'pmid': 3879963,\n",
       "  'sentence': 'T-lymphocyte-subsets in endocrine exophthalmos.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['exophthalmos']},\n",
       " {'pmid': 3885980,\n",
       "  'sentence': 'Hypersensitivity to cardiac antigens.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 3888030,\n",
       "  'sentence': 'Otospongiosis and sodium fluoride.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 3888837,\n",
       "  'sentence': 'Vasopressin versus renin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vasopressin'],\n",
       "  'reaction': ['renin']},\n",
       " {'pmid': 3890392,\n",
       "  'sentence': 'changes in cardiac output.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3893304,\n",
       "  'sentence': '[Immunogenic cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 3899166,\n",
       "  'sentence': 'Atracurium and intraocular pressure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atracurium'],\n",
       "  'reaction': ['intraocular pressure']},\n",
       " {'pmid': 3901231,\n",
       "  'sentence': 'Peptide hormones in saliva.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['saliva']},\n",
       " {'pmid': 3909754,\n",
       "  'sentence': 'A double-blind investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3912182,\n",
       "  'sentence': 'Felodipine in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['felodipine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 3918215,\n",
       "  'sentence': 'Mitomycin C extravasation ulcers.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitomycin'],\n",
       "  'reaction': ['extravasation']},\n",
       " {'pmid': 3919673,\n",
       "  'sentence': '[Acute amiodarone poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3922063,\n",
       "  'sentence': 'Sodium valproate poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 3923977,\n",
       "  'sentence': '[Antenatal cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 3930473,\n",
       "  'sentence': 'Treatment-emergent incontinence with lithium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['incontinence']},\n",
       " {'pmid': 3938205,\n",
       "  'sentence': 'Tamoxifen and oligospermia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['oligospermia']},\n",
       " {'pmid': 3938225,\n",
       "  'sentence': '[Cardiotoxicity of 5-fluorouracil.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['cardiotoxicity']},\n",
       " {'pmid': 3943237,\n",
       "  'sentence': 'Erythromycin hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['erythromycin'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 3946978,\n",
       "  'sentence': 'Amiodarone hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 3953311,\n",
       "  'sentence': 'Cardiac amyloidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac amyloidosis', 'amyloidosis']},\n",
       " {'pmid': 3954426,\n",
       "  'sentence': 'Immunoglobulin for neonatal agranulocytosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['agranulocytosis']},\n",
       " {'pmid': 3956107,\n",
       "  'sentence': 'Cardiac output was unaffected.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3956523,\n",
       "  'sentence': 'Felodipine in ventricular dysfunction.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['felodipine'],\n",
       "  'reaction': ['ventricular dysfunction']},\n",
       " {'pmid': 3958957,\n",
       "  'sentence': 'Sodium hyaluronate vitrectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['vitrectomy']},\n",
       " {'pmid': 3959594,\n",
       "  'sentence': 'Vitamin B6 and magnesium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['vitamin b6']},\n",
       " {'pmid': 3959692,\n",
       "  'sentence': '[Cisplatin ototoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['ototoxicity']},\n",
       " {'pmid': 3962737,\n",
       "  'sentence': 'Hepatotoxicity of amiodarone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 3962815,\n",
       "  'sentence': 'Nifedipine in exercise-induced asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 3964456,\n",
       "  'sentence': 'Anaphylactic reaction to lidocaine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['anaphylactic reaction']},\n",
       " {'pmid': 3970338,\n",
       "  'sentence': 'Delayed cardiac tamponade.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac tamponade']},\n",
       " {'pmid': 3974116,\n",
       "  'sentence': 'Thermodilution cardiac output measurement.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 3979230,\n",
       "  'sentence': 'Cocaine colitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['colitis']},\n",
       " {'pmid': 3979751,\n",
       "  'sentence': 'Diltiazem and granulomatous hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diltiazem'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 3984945,\n",
       "  'sentence': 'Polypoid nasal pseudolymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['pseudolymphoma']},\n",
       " {'pmid': 3985727,\n",
       "  'sentence': 'Propranolol for portal hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['portal hypertension', 'hypertension']},\n",
       " {'pmid': 3986895,\n",
       "  'sentence': 'A double-blind investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 3994563,\n",
       "  'sentence': 'Phenytoin disposition in obesity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['obesity']},\n",
       " {'pmid': 3996152,\n",
       "  'sentence': 'Barium peritonitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['peritonitis']},\n",
       " {'pmid': 4000241,\n",
       "  'sentence': 'Calcium absorption and achlorhydria.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['achlorhydria']},\n",
       " {'pmid': 4003734,\n",
       "  'sentence': 'Isoflurane in paediatric anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['isoflurane'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 4005088,\n",
       "  'sentence': 'Recurring cardiac myxoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac myxoma']},\n",
       " {'pmid': 4006538,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 4010598,\n",
       "  'sentence': 'Cimetidine and ulcer surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['ulcer', 'surgery']},\n",
       " {'pmid': 4014301,\n",
       "  'sentence': 'Insulin-induced cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 4019123,\n",
       "  'sentence': 'Mitoxantrone in malignant lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitoxantrone'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 4022059,\n",
       "  'sentence': 'Cocaine use in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 4022515,\n",
       "  'sentence': 'Intravenous immunoglobulin in pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 4025157,\n",
       "  'sentence': 'Pathophysiology of cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 4026494,\n",
       "  'sentence': 'Cardiac disability.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['disability']},\n",
       " {'pmid': 4028761,\n",
       "  'sentence': 'Occult metoprolol overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metoprolol'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 4036534,\n",
       "  'sentence': 'Enflurane hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['enflurane'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 4037466,\n",
       "  'sentence': 'Neurotoxicity of meperidine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['meperidine'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 4038874,\n",
       "  'sentence': 'Cisplatin potentiation of radiotherapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cisplatin'],\n",
       "  'reaction': ['radiotherapy']},\n",
       " {'pmid': 4042715,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 4063896,\n",
       "  'sentence': 'Chylopericardium following cardiac surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 4064482,\n",
       "  'sentence': 'The competitive barium meal.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['barium'],\n",
       "  'reaction': ['barium meal']},\n",
       " {'pmid': 4067057,\n",
       "  'sentence': 'Subungual basal cell carcinoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['basal cell carcinoma']},\n",
       " {'pmid': 4072446,\n",
       "  'sentence': '[Cardiac anxiety syndrome.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['anxiety']},\n",
       " {'pmid': 4075214,\n",
       "  'sentence': 'Anaesthesia and amiodarone.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 4075217,\n",
       "  'sentence': 'Hypertension after epidural meperidine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['meperidine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 4080127,\n",
       "  'sentence': 'Basal arterial occlusive disease.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['arterial occlusive disease']},\n",
       " {'pmid': 4080331,\n",
       "  'sentence': 'Intraocular injection of lidocaine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 4198108,\n",
       "  'sentence': 'Endocrine studies in anencephaly.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['anencephaly']},\n",
       " {'pmid': 4266975,\n",
       "  'sentence': 'Lithium and pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 4279126,\n",
       "  'sentence': 'Vasculitis with alclofenac therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['alclofenac'],\n",
       "  'reaction': ['vasculitis']},\n",
       " {'pmid': 4329003,\n",
       "  'sentence': 'Effects of sodium fluoride.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 4549486,\n",
       "  'sentence': 'Perpartum cardiac failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac failure']},\n",
       " {'pmid': 4642792,\n",
       "  'sentence': 'Procaine in malignant hyperpyrexia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['procaine'],\n",
       "  'reaction': ['hyperpyrexia']},\n",
       " {'pmid': 4699591,\n",
       "  'sentence': 'Lithium and pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 4699592,\n",
       "  'sentence': 'Lithium and pregnancy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 4723794,\n",
       "  'sentence': 'injection of propranolol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 4731336,\n",
       "  'sentence': 'Amitriptyline in migraine prophylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amitriptyline'],\n",
       "  'reaction': ['migraine', 'prophylaxis']},\n",
       " {'pmid': 4750443,\n",
       "  'sentence': 'infusion of exogenous vasopressin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vasopressin'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 4907812,\n",
       "  'sentence': 'Hypotension caused by L-dopa.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['l-dopa'],\n",
       "  'reaction': ['hypotension']},\n",
       " {'pmid': 5058735,\n",
       "  'sentence': 'Pathogenesis of cardiac oedema.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['oedema']},\n",
       " {'pmid': 5257120,\n",
       "  'sentence': 'Minimization of polypeptide energy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['polypeptide'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 5263023,\n",
       "  'sentence': 'Minimization of polypeptide energy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['polypeptide'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 5411600,\n",
       "  'sentence': 'Azotaemia aggravated by tetracycline.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tetracycline'],\n",
       "  'reaction': ['azotaemia']},\n",
       " {'pmid': 5429106,\n",
       "  'sentence': 'Miosis during L-dopa therapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['l-dopa'],\n",
       "  'reaction': ['miosis']},\n",
       " {'pmid': 5475845,\n",
       "  'sentence': 'taken after cardiac arrest.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 5702295,\n",
       "  'sentence': 'Calcium metabolism in acromegaly.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['acromegaly']},\n",
       " {'pmid': 5901156,\n",
       "  'sentence': 'Cardiac myoglobin in myoglobinuria.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['myoglobinuria']},\n",
       " {'pmid': 6087525,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 6099918,\n",
       "  'sentence': 'Ketoconazole and fungal sinusitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketoconazole'],\n",
       "  'reaction': ['sinusitis']},\n",
       " {'pmid': 6102487,\n",
       "  'sentence': 'Ketotifen in adult asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketotifen'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 6118208,\n",
       "  'sentence': 'Lorazepam in intensive care.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lorazepam'],\n",
       "  'reaction': ['intensive care']},\n",
       " {'pmid': 6118964,\n",
       "  'sentence': 'Inhaled prazosin in asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['prazosin'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 6124264,\n",
       "  'sentence': 'Labetalol in essential hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['labetalol'],\n",
       "  'reaction': ['essential hypertension', 'hypertension']},\n",
       " {'pmid': 6124942,\n",
       "  'sentence': '[Bromazepam in anxiety.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bromazepam'],\n",
       "  'reaction': ['anxiety']},\n",
       " {'pmid': 6125537,\n",
       "  'sentence': 'injection of flunitrazepam.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['flunitrazepam'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 6128928,\n",
       "  'sentence': 'Concomitant psychotherapy is advisable.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['psychotherapy']},\n",
       " {'pmid': 6131366,\n",
       "  'sentence': 'Somatostatin mydriasis in mice.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['mydriasis']},\n",
       " {'pmid': 6131649,\n",
       "  'sentence': 'Somatostatin treatment of psoriasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['psoriasis']},\n",
       " {'pmid': 6135591,\n",
       "  'sentence': 'Diazepam in tardive dyskinesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['diazepam'],\n",
       "  'reaction': ['tardive dyskinesia', 'dyskinesia']},\n",
       " {'pmid': 6135840,\n",
       "  'sentence': 'Query cardiac pain.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pain']},\n",
       " {'pmid': 6137174,\n",
       "  'sentence': 'Aids to cardiac auscultation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['auscultation']},\n",
       " {'pmid': 6137950,\n",
       "  'sentence': 'Regression of cardiac hypertrophy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy', 'hypertrophy']},\n",
       " {'pmid': 6144307,\n",
       "  'sentence': 'Sodium and potassium dependence.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium', 'sodium'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 6148892,\n",
       "  'sentence': 'Dopamine receptors and hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 6149801,\n",
       "  'sentence': 'Vecuronium in renal failure.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vecuronium'],\n",
       "  'reaction': ['renal failure']},\n",
       " {'pmid': 6150774,\n",
       "  'sentence': 'Hepatotoxicity of sodium valproate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 6151395,\n",
       "  'sentence': 'Calcium dependence.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 6156569,\n",
       "  'sentence': 'Cholesterol granuloma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['granuloma']},\n",
       " {'pmid': 6160325,\n",
       "  'sentence': 'Labetalol in essential hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['labetalol'],\n",
       "  'reaction': ['essential hypertension', 'hypertension']},\n",
       " {'pmid': 6162398,\n",
       "  'sentence': 'Bleomycin therapy and anaesthesia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 6163843,\n",
       "  'sentence': 'Experimental potassium depletion myopathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['myopathy']},\n",
       " {'pmid': 6195855,\n",
       "  'sentence': 'Cardiac output was unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 6197849,\n",
       "  'sentence': 'Cyclofenil in childhood scleroderma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cyclofenil'],\n",
       "  'reaction': ['scleroderma']},\n",
       " {'pmid': 6198058,\n",
       "  'sentence': 'Adriamycin versus quadruple chemotherapy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['adriamycin'],\n",
       "  'reaction': ['chemotherapy']},\n",
       " {'pmid': 6201520,\n",
       "  'sentence': 'Methotrexate hepatotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['hepatotoxicity']},\n",
       " {'pmid': 6212200,\n",
       "  'sentence': 'Exfoliative dermatitis from captopril.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['captopril'],\n",
       "  'reaction': ['dermatitis', 'dermatitis']},\n",
       " {'pmid': 6215793,\n",
       "  'sentence': 'Piperacillin in paediatric surgery.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['piperacillin'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 6217226,\n",
       "  'sentence': 'Downbeat nystagmus with phenytoin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['nystagmus']},\n",
       " {'pmid': 6222099,\n",
       "  'sentence': 'Dopamine and mania.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['mania']},\n",
       " {'pmid': 6222125,\n",
       "  'sentence': 'A controlled double-blind investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 6224126,\n",
       "  'sentence': 'Endocrine aspects of acne.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['acne']},\n",
       " {'pmid': 6229774,\n",
       "  'sentence': '[Immunoglobulin A glomerulonephritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['glomerulonephritis']},\n",
       " {'pmid': 6231152,\n",
       "  'sentence': 'Cardiac function in hyperthyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hyperthyroidism']},\n",
       " {'pmid': 6233126,\n",
       "  'sentence': 'Hypersensitivity reaction to doxorubicin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 6236237,\n",
       "  'sentence': 'Experimental ampicillin glomerulonephropathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ampicillin'],\n",
       "  'reaction': ['glomerulonephropathy']},\n",
       " {'pmid': 6240359,\n",
       "  'sentence': 'Hydralazine and lupus nephritis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['hydralazine'],\n",
       "  'reaction': ['lupus nephritis', 'nephritis']},\n",
       " {'pmid': 6255614,\n",
       "  'sentence': 'Tamoxifen and hypercalcaemia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['hypercalcaemia']},\n",
       " {'pmid': 6264066,\n",
       "  'sentence': 'injection of sodium orthovanadate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 6275248,\n",
       "  'sentence': 'Possible ranitidine hepatitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['hepatitis']},\n",
       " {'pmid': 6277011,\n",
       "  'sentence': '[Corynebacterium endocarditis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['corynebacterium'],\n",
       "  'reaction': ['endocarditis']},\n",
       " {'pmid': 6278797,\n",
       "  'sentence': '[Calcium lithiasis II.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['lithiasis']},\n",
       " {'pmid': 6298137,\n",
       "  'sentence': 'Clostridium perfringens meningitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['meningitis']},\n",
       " {'pmid': 6301046,\n",
       "  'sentence': '[Cardiac sarcoidosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sarcoidosis']},\n",
       " {'pmid': 6310967,\n",
       "  'sentence': 'A tetracycline labelling investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tetracycline'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 6310979,\n",
       "  'sentence': 'Amiodarone pulmonary toxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['pulmonary toxicity']},\n",
       " {'pmid': 6315039,\n",
       "  'sentence': 'penbutolol in angina pectoris.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['penbutolol'],\n",
       "  'reaction': ['angina pectoris']},\n",
       " {'pmid': 6316783,\n",
       "  'sentence': 'Acute cocaine poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 6322733,\n",
       "  'sentence': 'Tympanoplasty with calcium phosphate.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['tympanoplasty']},\n",
       " {'pmid': 6326789,\n",
       "  'sentence': 'Myasthenia gravis and atracurium.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['atracurium'],\n",
       "  'reaction': ['myasthenia gravis']},\n",
       " {'pmid': 6329862,\n",
       "  'sentence': 'Ranitidine in reflux oesophagitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ranitidine'],\n",
       "  'reaction': ['oesophagitis']},\n",
       " {'pmid': 6335004,\n",
       "  'sentence': 'Nifedipine and cardiopulmonary bypass.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['cardiopulmonary bypass']},\n",
       " {'pmid': 6339686,\n",
       "  'sentence': 'Phenytoin and postoperative epilepsy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['phenytoin'],\n",
       "  'reaction': ['epilepsy']},\n",
       " {'pmid': 6340638,\n",
       "  'sentence': 'Cardiac papilloma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['papilloma']},\n",
       " {'pmid': 6340940,\n",
       "  'sentence': 'Endocrine hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 6348587,\n",
       "  'sentence': 'Nadolol in essential tremor.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nadolol'],\n",
       "  'reaction': ['essential tremor', 'tremor']},\n",
       " {'pmid': 6350411,\n",
       "  'sentence': 'Nifedipine in bronchial asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 6352269,\n",
       "  'sentence': 'Calcium and cell death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['cell death', 'death']},\n",
       " {'pmid': 6352306,\n",
       "  'sentence': 'Nasal reactivity in rhinitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['rhinitis']},\n",
       " {'pmid': 6353622,\n",
       "  'sentence': 'Magnesium and sudden death.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['sudden death', 'death']},\n",
       " {'pmid': 6355533,\n",
       "  'sentence': 'Verapamil prophylaxis of migraine.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['prophylaxis', 'migraine']},\n",
       " {'pmid': 6357298,\n",
       "  'sentence': 'a medium mutagenic effect.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['mutagenic effect']},\n",
       " {'pmid': 6358076,\n",
       "  'sentence': 'Renal and endocrine hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 6359563,\n",
       "  'sentence': 'Ketotifen and nocturnal asthma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ketotifen'],\n",
       "  'reaction': ['asthma']},\n",
       " {'pmid': 6364798,\n",
       "  'sentence': 'Cimetidine disposition in obesity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['obesity']},\n",
       " {'pmid': 6369520,\n",
       "  'sentence': 'Tinidazole prophylaxis in appendicectomies.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['tinidazole'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 6369936,\n",
       "  'sentence': 'Clostridium difficile colitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clostridium'],\n",
       "  'reaction': ['clostridium difficile colitis', 'colitis']},\n",
       " {'pmid': 6375276,\n",
       "  'sentence': 'Thiazide prophylaxis of urolithiasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thiazide'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 6375965,\n",
       "  'sentence': 'Cimetidine for stress-ulcer prophylaxis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['prophylaxis']},\n",
       " {'pmid': 6376759,\n",
       "  'sentence': 'Metronidazole in periodontitis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metronidazole'],\n",
       "  'reaction': ['periodontitis']},\n",
       " {'pmid': 6380541,\n",
       "  'sentence': 'Calcium and osteoporosis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['osteoporosis']},\n",
       " {'pmid': 6385206,\n",
       "  'sentence': 'A double-blind cross-over investigation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 6385318,\n",
       "  'sentence': 'Cardiac output remained unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 6385444,\n",
       "  'sentence': 'Prophylactic trimethoprim for prostatectomy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['trimethoprim'],\n",
       "  'reaction': ['prostatectomy']},\n",
       " {'pmid': 6387197,\n",
       "  'sentence': 'Migraine prevention with timolol.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['timolol'],\n",
       "  'reaction': ['migraine']},\n",
       " {'pmid': 6396069,\n",
       "  'sentence': 'Hemodynamics of cardiac massage.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac massage', 'massage']},\n",
       " {'pmid': 6396073,\n",
       "  'sentence': 'Pediatric cardiac arrest.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest']},\n",
       " {'pmid': 6397858,\n",
       "  'sentence': 'Peptide inhibitors of renin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['renin']},\n",
       " {'pmid': 6401597,\n",
       "  'sentence': 'Mitomycin C extravasation injuries.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitomycin'],\n",
       "  'reaction': ['extravasation']},\n",
       " {'pmid': 6402103,\n",
       "  'sentence': 'Cardiac surgery in Wessex.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 6406547,\n",
       "  'sentence': 'Immunoglobulin A nephropathy.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['nephropathy']},\n",
       " {'pmid': 6407402,\n",
       "  'sentence': 'Benoxaprofen improves psoriasis.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['benoxaprofen'],\n",
       "  'reaction': ['psoriasis']},\n",
       " {'pmid': 6407653,\n",
       "  'sentence': 'Erythromycin estolate and jaundice.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['erythromycin'],\n",
       "  'reaction': ['jaundice']},\n",
       " {'pmid': 6416719,\n",
       "  'sentence': 'Peptide inhibitors of renin.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['renin']},\n",
       " {'pmid': 6423822,\n",
       "  'sentence': 'Lithium and symptomatic hyperparathyroidism.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['lithium'],\n",
       "  'reaction': ['hyperparathyroidism']},\n",
       " {'pmid': 6445814,\n",
       "  'sentence': 'Clindamycin for tetracycline-resistant acne.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['clindamycin'],\n",
       "  'reaction': ['acne']},\n",
       " {'pmid': 6450569,\n",
       "  'sentence': 'Dapsone hypersensitivity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dapsone'],\n",
       "  'reaction': ['hypersensitivity']},\n",
       " {'pmid': 6462352,\n",
       "  'sentence': 'nasal obstruction and It.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['nasal obstruction', 'obstruction']},\n",
       " {'pmid': 6467631,\n",
       "  'sentence': 'infusion of phenytoin sodium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['phenytoin', 'sodium'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 6476501,\n",
       "  'sentence': 'injection of lidocaine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 6477312,\n",
       "  'sentence': 'Ischaemic cardiac pain.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['pain']},\n",
       " {'pmid': 6478466,\n",
       "  'sentence': 'Verapamil in ventricular tachycardia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['verapamil'],\n",
       "  'reaction': ['ventricular tachycardia', 'tachycardia']},\n",
       " {'pmid': 6479059,\n",
       "  'sentence': '[Chronic thallium poisoning.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['thallium'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 6479848,\n",
       "  'sentence': 'Enhancement by calcium deficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['calcium deficiency']},\n",
       " {'pmid': 6484580,\n",
       "  'sentence': 'Mitoxantrone in malignant lymphoma.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['mitoxantrone'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 6488753,\n",
       "  'sentence': 'Sodium restriction in hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 6489162,\n",
       "  'sentence': 'Once-daily propranolol for hypertension.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 6489391,\n",
       "  'sentence': 'Cimetidine neurotoxicity.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['neurotoxicity']},\n",
       " {'pmid': 6489413,\n",
       "  'sentence': 'Fenofibrate therapy of hypertriglyceridaemia.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['fenofibrate'],\n",
       "  'reaction': ['hypertriglyceridaemia']},\n",
       " {'pmid': 6499696,\n",
       "  'sentence': 'Magnesium deficiency.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['magnesium deficiency']},\n",
       " {'pmid': 6503226,\n",
       "  'sentence': 'Fatal metoprolol overdose.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['metoprolol'],\n",
       "  'reaction': ['overdose']},\n",
       " {'pmid': 6507377,\n",
       "  'sentence': 'Protracted vinblastine infusion.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['vinblastine'],\n",
       "  'reaction': ['infusion']},\n",
       " {'pmid': 6508972,\n",
       "  'sentence': 'Clinical anaesthesia with isoflurane.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['isoflurane'],\n",
       "  'reaction': ['anaesthesia']},\n",
       " {'pmid': 6516495,\n",
       "  'sentence': '[Dihydrotachysterol poisoning].',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['dihydrotachysterol'],\n",
       "  'reaction': ['poisoning']},\n",
       " {'pmid': 6524456,\n",
       "  'sentence': 'Amiodarone in atrial fibrillation.',\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['amiodarone'],\n",
       "  'reaction': ['atrial fibrillation']},\n",
       " ...]"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sent_counter.short_sents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'pmid': 19118,\n",
       "  'sentence': \"In DS-rats, pindolol (10-50 mug/kg) produced a dose-dependent fall in blood pressure and elevation of resting heart rate.2 The hypotensive response and tachycardia produced by oral pindolol (50 mug/kg) in DS-rats were prevented by propranolol (5 mg/kg), suggesting that pindolol's effects are mediated by beta-adrenoceptor stimulation.3 After mecamylamine (10 mg/kg), oral pindolol (50 mug/kg) produced a further fall in blood pressure in DS-rats, suggesting that its hypotensive effects are probably mediated in the peripheral vasculature.4 Pretreatment with oral pindolol (10 or 50 mug/kg) resulted in a reduction of neuronally-induced tachycardia in pithed DS-rats; neuronally-evoked pressor effects were also antagonized by pindolol (50 mug/kg, orally).5 Whereas pindolol, 50 mug/kg orally or intraperitoneally, produced a marked and progressive hypotensive response of rapid onset (20 min) in DS-rats the same dose intravenously produced a smaller response of delayed onset (80 minutes).6 In anaesthetized DS-rats, an equivalent degree of cardiac beta-adrenoceptor blockade was produced by pretreatment with pindolol, 50 mug/kg orally (2 h previously) or intravenously (1 h previously).7 After administration of pindolol, 2 mg/kg intravenously, to conscious DS-rats, the tachycardia produced by intravenous isoprenaline, 3 mug/kg, was almost abolished for the first 60 min of the study, whereas a hypotensive response to pindolol was delayed in onset (100 minutes).8 The hypotensive response and tachycardia produced by oral pindolol 50 mug/kg, in DS-rats were prevented by inhibition of metabolic enzyme activity by pretreatment with Proadifen (SKF 525-A), 80 mg/kg.9 The results suggest that pindolol's effects on blood pressure and heart rate in the conscious DS-rat are mediated by a metabolite(s) acting by stimulation of peripheral beta-adrenoceptors.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol', 'cardiac', 'pindolol'],\n",
       "  'reaction': ['fall',\n",
       "   'blood pressure',\n",
       "   'tachycardia',\n",
       "   'fall',\n",
       "   'blood pressure',\n",
       "   'tachycardia',\n",
       "   'tachycardia',\n",
       "   'tachycardia',\n",
       "   'enzyme activity',\n",
       "   'blood pressure',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 233401,\n",
       "  'sentence': \"(1) cAMP content of the tissue of the fundus mucosa and of the forestomach decreased before the significant increase of gastric H+ output and ulcer development; (2) the gastric H+ outputs depended on the breakdown of ATP in the fundus mucosa; (3) the gastric H+ secretion was inhibited in a dose-dependent way by theophylline, epinephrine and cimetidine; (4) the inhibition of gastric H+ secretion by epinephrine , theophylline or epinephrine plus theophylline associated with a significant increase in the mucosal cAMP of the gastric fundus (5) the significant increase in gastric H+ secretion due to histamine associated with a significant decrease in fundic mucosal cAMP; (6) the gastric H+ secretion could be inhibited dose-dependently by ADP, AMP, cyclic 2', 3'-AMP and cAMP; (7) the inhibition of gastric H+ secretion by cimetidine developed without and with histamine application in pylorus-ligated rats; (8) the histamine on gastric H+ secretion could not be stimulated further with theophylline (9) no significant correlation was found between the mucosal cAMP level and the gastric H+ secretion and/or between the decrease of mucosal cAMP content and gastric H+ secretion.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['ulcer', 'epinephrine', 'epinephrine', 'epinephrine']},\n",
       " {'pmid': 393369,\n",
       "  'sentence': \"A comparison of two rapid and inexpensive in vivo mammalian assays and the Ames Salmonella assay is presented for 61 agents; Acetylsalicylic acid; Acriflavine; Actinomycin D; 2(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2); Aflatoxin B1; 2-aminofluorene; Aminopterin; Aroclor 1254; Ascorbic acid; Azathioprine; Benzo(a)pyrene; 5-Bromo-2'-deoxyuridine; Busulphan, Butylated hydroxytoluene; Cadmium chloride; Caffeine; Calcium cyclamate; Chloral hydrate; Chloromycetin succinate; Codeine phosphate, Colchicine; Cycloheximide; Cyclophosphamide; DDT; 2,4-Diaminoanisole; Dibutylnitrosamine; 9, 10 Dimethyl-1,2-benzanthracene; 1,1-Dimethylhydrazine; Dimethylnitrosamine; Epinephrine; Ethyl methane sulphonate (EMS); 2-formylamino-4-(5-nitro-2-furyl)thiazole (FANFT); 2-(2-formylhydrazino)-4-(5-nitro-2-furyl)thiazole (FNT); Glucose, Griseofulvin; Hycanthone methane sulphonate; Hydroxyurea; 5-Iodo-2'-deoxyuridine; Lead acetate; Mechlorethamine; 3-Methylcholanthrene; Methyl mercury acetate; Methyl methane sulfonate (MMS); N-methyl-N-nitro-N'-nitrosoguanidine; Mitomycin C; Monosodium glutamate; 1-Naphthalamine; 2-Naphthalamine; Nitrofurazone; 4-Nitro-O-phenylene diamine; 4-Nitro-quinoline-1-oxide (4-NQO); Phenobarbitone; Procarbazine; Quinacrine dihydrochloride; Radiation (gamma-rays); Sodium chloride; Triethylene thiophosphoramide; Trimethyl phosphate; Tris(2-methyl-1-arizidinyl) phosphine oxide; Urethan; Vinblastine.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['monosodium',\n",
       "   'vinblastine',\n",
       "   'quinacrine',\n",
       "   'mitomycin',\n",
       "   'actinomycin',\n",
       "   'sodium',\n",
       "   'calcium'],\n",
       "  'reaction': ['epinephrine']},\n",
       " {'pmid': 507308,\n",
       "  'sentence': \"We conclude that (1) the activated clotting time (ACT) is an accurate method of monitoring anti-coagulation during peripheral vascular surgery and can easily be performed by a technician in the operating room or at the bedside; (2) an initial heparinizing dose of 120 to 130 units/kg is adequate in 95 per cent of the patients; (3) the ACT should be maintained at greater than twice the control values (180 to 200 seconds), which required supplementation within 2 hours in 21 per cent; (4) the response to heparin is twofold: an initial sensitivity or resistance followed by an independent and variable rate of consumption; (5) the patient's heparin dose-response curve should be used to calculate the amount of supplemental heparin needed to maintain the ACT at a safe level; (6) protamine should be given if the ACT at the conclusion of the operation is greater than 150 seconds (50 per cent of our patients); and (7) a final ACT 15 to 30 minutes postoperatively should be obtained to ensure adequate reversal or to detect heparin rebound or depletion of clotting factors.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 519108,\n",
       "  'sentence': '1 Synthetic analogues of oxytocin and of lysine-vasopressin with an hydroxyl group in either the L ro D configuration replacing the primary amino group have been tested for biological activity.2 [1-(L-2-Hydroxy-3-mercaptopropanoic acid)] oxytocin ([L-Hmp(1)]oxytocin) was 1.5 to 2 times more potent than oxytocin on the rat uterus in situ, the rat mammary strip and the rat mammary gland in situ and 3 times more potent on the rat isolated uterus.3 The pressor activity of [1-(L-2-hydroxy-3-mercaptopropanoic acid)-8-lysine]vasopressin ([L-Hmp(1), Lys(8)] vasopressin) was 2.2 and the antidiuretic activity 2.1 times that of lysine-vasopressin.4 The [D-Hmp(1)] analogues of oxytocin and vasopressin were much less potent than the [L-Hmp(1)] analogues.5 The responses to oxytocin and its hydroxy analogues in vivo were qualitatively indistinguishable but the pressor and antidiuretic responses to the hydroxy analogues of lysine-vasopressin were prolonged compared with those to the parent hormone.6 The hydroxy analogues of oxytocin and lysine-vasopressin were not inactivated by pregnancy plasma oxytocinase.7 The results are discussed in relation to the importance of the primary amino group for the biological activity and metabolism of the neurohypophysial hormones.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxytocin', 'vasopressin'],\n",
       "  'reaction': ['pregnancy']},\n",
       " {'pmid': 571302,\n",
       "  'sentence': '1 The content of adrenaline (Ad), noradrenaline (NA) and dopamine was measured in human, guinea-pig, cat, rabbit and rat blood platelets by a highly sensitive and specific radioenzymatic method.2 In all platelet specimens analyzed, the content of the three catecholamines (CA) was several thousand times lower than that of 5-hydroxytryptamine (5-HT).3 In basal conditions, the NA concentration in platelets and plasma always exceeded that of Ad and dopamine.4 In rat and rabbit platelets, Ad, NA and dopamine were present only in the free (unconjugated) form.5 Platelets of rats with storage pool deficiency (Fawn-hooded) contained much less 5-HT and CA than normal rat platelets.6 Following restraint stress, platelets of Fawn-hooded rats, in contrast to normal rat platelets, did not accumulate CA in spite of a dramatic rise in plasma CA.7 Reserpine, a monoamine depletor, released CA as well as 5-HT from rabbit platelets in vivo.8 Subcellular fractionation experiments with rabbit platelets indicate that both CA and 5-HT are most concentrated in the fraction consisting of pure 5-HT organelles.9 Both in humans and rabbits the concentration gradient between platelets and plasma was much lower for CA than for 5-HT, indicating that a high affinity transport mechanism operates in vivo for 5-HT but not for CA.10 In conclusion, the present data show that both human and animal platelets contain Ad, NA and dopamine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal', 'dopamine', 'reserpine'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 596073,\n",
       "  'sentence': 'Pulmonary mean and systemic mean pressure during haemorrhage and retransfusion do not change in parallel; 2. there is a rapid rise in pulmonary arterial [PA] and pulmonary capillary [PC] pressure during retransfusion; 3. cardiac output and its pulmonary fraction decrease during shock and cardiac output failed to normalise on retransfusion of the lost blood; 4. pulmonary vascular resistance, pulmonary total resistance increase significantly at the end of the shock period and after retransfusion; 5. shunt volume, alveolo-arterial O2 difference, the difference in arterio-alveolar co2 tension and dead space ventilation increase; while 6. o2 consumption and CO2 production decrease; 7. arterial blood gas values alone do not indicate those serious metabolic; circulatory and respiratory changes which develop in the lung during shock; 8. effective pulmonary compliance and the plasma oncotic pressure decrease, indicating interstitial oedema; 9. the primary mechanism responsible for the disorder during shock is not entirely clear but beside a number of other factors, the importance of the hypoperfusion of the bronchial circulation is stressed; 10. the conclusions permit a certain insight into the pathogenesis and therapeutic possibilities of the adult respiratory distress syndrome.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['haemorrhage',\n",
       "   'cardiac output',\n",
       "   'shock',\n",
       "   'cardiac output',\n",
       "   'shock',\n",
       "   'tension',\n",
       "   'shock',\n",
       "   'oedema',\n",
       "   'shock',\n",
       "   'hypoperfusion',\n",
       "   'respiratory distress']},\n",
       " {'pmid': 799565,\n",
       "  'sentence': 'The pilot phase of the British multicentre randomized controlled trial of treatment for mild hypertension has shown: (1) that unselected subjects, aged 35-64 years, with mild hypertension are willing to enter and remain in a long-term trial even though asymptomatic; (2) that the differences of mean systolic and mean diastolic pressure achieved between treated and control subjects is sufficient to produce the expected difference in terminating events with the 18000 patients calculated as needed for the full-scale trial; (3) that side effects with the two selected active primary regimens (bendrofluazide and propranolol) are common but mild (no serious side effects or toxic reactions have been reported); (4) that the work load imposed by the trial, though considerable during screening and the initiation of patients into the trial, can largely be taken by specially trained nursing staff, and when screening is completed the trial does not impose a heavy burden of follow-up examinations; (5) that there are no adverse psychological effects caused by alerting asymptomatic people to their raised pressure and enrolling them into a prolonged programme of clinical attendance; (6) that the total costs of carrying out a full-scale trial--estimated at about lb.2m ($U.S.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['hypertension', 'hypertension']},\n",
       " {'pmid': 1093055,\n",
       "  'sentence': \"In chronic uremia, the clinical disorders o calcium and phosphorus metabolism are influenced by the following factors: (1) intestinal absorption of calcium and phosphate, resulting in a negative calcium and phosphate balance at normal dietary intakes; (2) renal handling of calcium and phosphate: the fractional transport of calcium (the isoosmotic reabsorption taking place in the proximal tubule) is not affected by GFR modifications, whereas the Tm-limited reabsorption is severely impaired; the external phosphate balance is kept, even in the presence of a reduced nephron population, by means of a proportional reduction in TmPO4 values; (3) physiochemical state and turnover of body calcium and phosphate: in uremic patients, the distribution spaces, turnover rate of calcium, and accretion rate of bones are increased in comparison with the controls; the calcium infusion test in patients with renal osteomalacia is followed by a regular increase in plasma [PO4], whereas a significant decrease is observed in patients with renal osteitis fibrosa, due to the extreme 'avidity' of bones for calcium phosphate; the role of hyperphosphatemia is critical in keeping the plasma [Ca] lower than the expected values for a given metabolic set; moreover, an increased cell uptake of phosphate could counteract to some extent the reduced renal clearance of phosphate; (4) structural and biochemical modifications of bone tissue: uremic osteodystrophy consists mainly of two components: (a) osteomalacia, with osteoid excess, disappearance of the calcification front, and diffuse pathologic mineralization, and (b) osteitis fibrosa, with severe resorption of normally mineralized bone, slight osteoid excess, and almost normal calcification front; (5) hormonal factors: chronic stimulation of parathyroid glands may result in suppressible or even autonomous hyperparathyroidism.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['infusion',\n",
       "   'osteomalacia',\n",
       "   'osteitis',\n",
       "   'osteomalacia',\n",
       "   'osteitis',\n",
       "   'hyperparathyroidism']},\n",
       " {'pmid': 1101920,\n",
       "  'sentence': \"In 57 patients with non-Hodgkin's lymphoma, a clinical, radiographic, scintigraphic and pathological correlative study showed the following results: (1) the inferior venacavagram, lymphangiogram and gallium-67 scan have a low sensitivity in detecting lymphoma: their accuracy is high when the findings are interpreted as abnormal (93%, 83% and 80% respectively), but low when they are interpreted as normal (47%, 67% and 58% respectively); (2) the clinical evaluation of spleen and liver is unreliable; (3) the incidence of lymphocytic lymphoma in the para-aortic-iliac nodes is high; (4) a pattern of involvement by contiguity and a predilection for the spleen were observed in lymphocytic lymphoma; (5) in lymphocytic lymphoma there is no liver involve without concomitant splenic involvement; (6) no definite pattern of spread could be seen in histiocytic lymphoma; (7) surgical staging changed the classification of the lymphoma in 56% of cases, 46% being reclassified to a more advanced stage; (8) surgical staging significantly improves the assessment of the stage of disease and therefore permits accurate treatment planning.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['lymphoma',\n",
       "   'lymphoma',\n",
       "   'lymphocytic lymphoma',\n",
       "   'lymphoma',\n",
       "   'lymphocytic lymphoma',\n",
       "   'lymphoma',\n",
       "   'lymphocytic lymphoma',\n",
       "   'lymphoma',\n",
       "   'lymphoma',\n",
       "   'lymphoma']},\n",
       " {'pmid': 1149042,\n",
       "  'sentence': 'The DNA appearing in the supernatant does not seem to be due to dead or dying cells since: (a) the same amount of DNA was found in the medium whether the incubation lasted 2 hr or as long as 16 hr; (b) cell death rate had no effect on the amount of extracellular DNA; (c) when the lymphocytes were centrifuged and placed in a new medium several times in a row, a similar amount of extracellular DNA was isolated from each of the successive supernatants, whereas if, after centrifugation, the lymphocytes were put back in their original medium, no increase in the amount of extracellular DNA was observed, suggesting an active regulatory mechanism independent of a mechanical effect; (d) it took more than 1 hr for extracellular DNA to reach its maximum concentration, a fact that also argues against a mechanical effect; (e) the specific activity of the released DNA was different from that of the cellular DNA, depending on the time of labeling; and (f) the cells that had excreted DNA kept their functional integrity, as shown by their fully maintained capacity to increase DNA synthesis after stimulation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['cell death', 'death']},\n",
       " {'pmid': 1254709,\n",
       "  'sentence': 'The Y.e.rh+ differed from the Y.e.rh- and Y. pseudotuberculosis in their ability to ferment raffinose and lactose, utilize citrate and in their inability to grow on Hektoen enteric agar at 22 or 37 C, on Salmonella-Shigella agar at 37 C, and scant on xylose-lysine-deoxycholate agar at 37 C. An extensive temperature-dependent profile of characteristics was established for the Y.e.rh+: motility, acetoin production, citrate utilization, growth on Salmonella-Shigella agar, and ampicillin resistance occurred at 22 C but not 37 C; fermentation of melibiose, raffinose, and cellobiose occurred within 24 h at 22 C, but not before 5 days at 37 C; fermentation of rhamnose and production of beta-galactosidase occurred within 24 h at 22 C, but not before 48 h at 37 C; greater resistance to ampicillin, chloramphenicol, streptomycin, kanamycin, carbenicillin, and gentamicin was observed at 22 than 37 C; and good growth on xylose-lysine-deoxycholate agar occurred at 22 but not 37 C. For optimal recovery of Y.e.rh+ from mixed culture, e.g., stools, two MacConkey plates should be inoculated and incubated, one at 37 C, and one at 22 C. Lactose-negative colonies appearing after 48 h on the 22 C MacConkey agar but not the 37 C MacConkey agar should be considered possible Y.e.rh+.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['kanamycin',\n",
       "   'gentamicin',\n",
       "   'carbenicillin',\n",
       "   'streptomycin',\n",
       "   'ampicillin'],\n",
       "  'reaction': ['growth', 'growth']},\n",
       " {'pmid': 1286136,\n",
       "  'sentence': 'Among their findings, the panel concluded that (1) existing data provide considerable support for a causal relationship between low HDL and CHD; however, with respect to TG data are mixed and the evidence on a causal relationship is incomplete; (2) initial TG and/or HDL levels modify benefit achieved by lowering low density lipoprotein cholesterol (LDL-C); however, evidence from clinical trials is insufficient to draw conclusions about specific benefits of TG and/or HDL altering therapy; (3) HDL-C measurement should be added to total cholesterol measurement when evaluating CHD risk in healthy individuals provided accuracy of measurement, appropriate counseling, and followup can be assured; (4) there is general agreement with the Adult Treatment Panel (ATP) guidelines that LDL-C is essential in cardiovascular risk assessment, as well as that persons with elevations of LDL-C greater than 150 mg/dl refractory to nondrug therapies may require drug treatment; (5) there is a strong consensus that hygienic approaches (diet, exercise, smoking cessation, weight loss) should be employed to lower TG and/or raise HDL; there is no consensus for the use of drug treatment in patients with borderline hypertriglyceridemia and low HDL-C levels in the presence of a desirable LDL-C level.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['low density lipoprotein',\n",
       "   'low density lipoprotein',\n",
       "   'weight',\n",
       "   'weight']},\n",
       " {'pmid': 1293287,\n",
       "  'sentence': 'In fifteen tests in eight dogs (in one dog responses of both left and right kidneys were determined), at a constant aortic pressure (AoP) of 92.0 +/- 3.2 mmHg, and carotid sinus pressure (CSP) of 95.0 +/- 2.0 mmHg, stimulation of left atrial receptors with balloon inflation resulted in significant increases in renal blood flow (RBF) by 8.3 +/- 0.9 from 255.0 +/- 14.6 ml min-1 (100 g kidney weight)-1 (n = 9), in glomerular filtration rate (GFR) by 4.1 +/- 0.6 from 21.2 +/- 1.9 ml min-1 (100 g)-1, in filtration fraction (FF) by 0.04 +/- 0.003 from 0.20 +/- 0.01, in urine flow rate (V) by 0.08 +/- 0.02 from 0.33 +/- 0.05 ml min-1 (100 g)-1, in sodium excretion (UNaV) by 4.4 +/- 0.9 from 27.7 +/- 4.2 mumol min-1 (100 g)-1, in osmolar excretion (UosmV) by 62.0 +/- 5.6 from 303.0 +/- 28.3 mu osmol min-1 (100 g)-1, and in a decrease in free water clearance (CH2O) by 0.13 +/- 0.03 from -0.63 +/- 0.04 ml min-1 (100 g)-1.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate',\n",
       "   'urine flow']},\n",
       " {'pmid': 1357680,\n",
       "  'sentence': 'The responses of cardiovascular functional parameters produced by these drugs included: (1) isoproterenol decreased the duration of a whole BP cycle (Wd), duration of the diastolic wave (Dd), peak amplitude of the systolic wave (SYa), amplitude of the diastolic notch (DNa), amplitude of the diastolic wave (DWa), pulse pressure (dp) and mean arterial pressure (mp) but increased the heart rate (HR) accompanied by prolonged R-R (RR) or P-P interval (PP) (2) propranolol decreased SYa, DNa, dp, mp, HR, the amplitude of the P wave (Pa) and amplitude of the S wave (Sa) but increased the duration of the QRS wave, P-R interval, duration of the R wave (Rd) and duration of the P wave (Pd); (3) adrenaline decreased HR (accompanied by prolonged RR and PP), Rd, Pa and amplitude of the T wave (Ta) but increased Pd, Wd, Dd, DNA, the time interval between aortic valve opening and closure (Dw), dp, mp, amplitude of the Q wave and amplitude of the R wave (Ra); (4) noradrenaline decreased HR (accompanied by prolonged RR and PP) and Pa but increased Wd, Pd, SYa, DNa, Dw, dp, mp, Ra and Ta; (5) phenylephrine decreased HR (accompanied by prolonged RR and PP) and Pa but increased Wd, Dd, DNa, mp and Ra; (6) phentolamine decreased SYa, DNa, DWa, Dw, dp and mp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['pulse pressure',\n",
       "   'mean arterial pressure',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 1371512,\n",
       "  'sentence': 'Under the conditions employed, the following observations were made: (1) in the presence of AFP, fatty acids (oleic and arachidonic acid) are bound to cells by a two-component pathway; one is a saturable process, evidenced when the fatty acid to AFP (FA/AFP) molar ratio was fixed at 1 and the concentration of the fatty acid and the protein varied from 0.1 to 3.2 microM, and the second is a nonsaturable function of FA/AFP molar ratio and was linearly related to the unbound fatty acid concentration in the medium over the entire range studied; (2) in the absence of AFP, the nonsaturable process appears to be the only component of fatty acid binding; 3) at all tested concentrations of free (unbound) fatty acid in the medium, net fatty acid binding by either resting or activated T cells was considerably greater in the presence than in the absence of AFP; (4) in the presence of AFP, fatty acid binding was much higher in activated T cells than in resting T cells, whereas in the absence of AFP, nonsignificant differences were observed between activated and resting T cells; and (5) the time course of fatty acid and AFP binding at 4 degrees C revealed that, at equilibrium, the number of fatty acid molecules bound to the cell was much greater than that of AFP suggesting an accelerated dissociation of the fatty acid upon interaction of the AFP-fatty acid complex with putative cell receptors.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['dissociation']},\n",
       " {'pmid': 1377308,\n",
       "  'sentence': 'After 3 months of treatment, we found (a) significant decreases in systolic (147 +/- 18 vs. 166 +/- 16 mm Hg, p less than 0.001) and diastolic blood pressure (90 +/- 8 vs. 107 +/- 8 mm Hg, p less than 0.0007), triglycerides (107 +/- 47 vs. 120 +/- 49 mg/dl, p less than 0.0007), and cholesterol (236 +/- 4 vs. 257 +/- 44 mg/dl, p less than 0.00075) in blood, and in K excretion (50 +/- 19 vs. 46 +/- 19 mEq/g of creatinine, p less than 0.0007) and excreted fraction of K (49 +/- 6% vs. 8 +/- 5%, p less than 0.0012) in urine; (b) significant increases in HDL cholesterol (65 +/- 13 vs. 58 +/- 13 mg/dl, p less than 0.001) in blood, and in Na (115 +/- 73 vs. 109 +/- 69 mEq/g of creatinine, p less than 0.0007) in urine; and (c) no significant change in the remaining biochemical parameters, or in heart rate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood pressure', 'heart rate', 'heart rate']},\n",
       " {'pmid': 1379559,\n",
       "  'sentence': 'Specifically, we report that: (1) Sperm membrane potential changes, Ca(i) elevation, and acrosomal exocytosis have similar K+ dose dependencies, consistent with a characteristic requirement of a large depolarization for activation of the sperm VDCC; (2) High affinity binding sites (Kd approximately 0.35 +/- 0.03 and 0.45 +/- 0.06 nM; Bmax = 16.0 +/- 1.4 and 5.8 +/- 0.8 fmole/mg protein) for the VDCC antagonist, PN200-110, respectively, are present in membrane preparations from sperm of the ram and bull; (3) PN200-110 and the other VDCC antagonists nitrendipine, nisoldipine, verapamil, diltiazem, Ni2+, or Co2+ inhibit (IC50 = 0.1, 0.4, 0.6, 0.8, 1.0, 60, and 110 microM, respectively) the acrosomal exocytosis produced by combined elevation of pH0 and membrane depolarization; (4) Exocytosis induced by the ZP3 agonist of the mammalian egg also is inhibited by VDCC antagonists with similar dose dependencies; (5) Depolarizing treatments that presumably activate the sperm VDCC bypass the blockade of ZP3-induced exocytosis imposed by pertussis toxin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['verapamil', 'nitrendipine', 'nisoldipine', 'diltiazem'],\n",
       "  'reaction': ['pertussis']},\n",
       " {'pmid': 1394228,\n",
       "  'sentence': 'The studies established the following observations: (a) in contrast to previous results in a bulky tumor model in hamsters, intact antibodies are more therapeutic than MAb fragments for both NP-4 and Mu-9; (b) tumor nodule size, even on the microscopic level, affects therapeutic outcome; antibodies were more effective when administered 7 days postimplantation (mean nodule diameter, 150 microns) compared with treatment 14 days postimplantation (mean nodule diameter, 750 microns); (c) administration of radioiodinated Mu-9 was exquisitely effective on single avascular tumor cells that had seeded in lung; irrelevant antibody was minimally radiotoxic; (d) as in the bulky disease model, the anti-colon-specific antigen p antibody delivers a higher rad dose than the anti-CEA antibody and is significantly more therapeutic in the micrometastasis model; (e) a higher affinity anti-CEA antibody (MN-14) recognizing the same epitope on CEA as NP-4 was equally therapeutic; (f) the use of MAb directed against the lung endothelium was not as therapeutic as a tumor-associated antibody; and (g) all tumor-associated antibodies were more efficacious than administration of the maximal tolerated dose of 5-fluorouracil and leucovorin in this human tumor-xenograft model.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['5-fluorouracil'],\n",
       "  'reaction': ['nodule', 'nodule', 'nodule']},\n",
       " {'pmid': 1448813,\n",
       "  'sentence': \"The 17-epimers of the anabolic steroids bolasterone (I), 4-chlorodehydromethyltestosterone (II), fluoxymesterone (III), furazabol (IV), metandienone (V), mestanolone (VI), methyltestosterone (VII), methandriol (VIII), oxandrolone (IX), oxymesterone (X), oxymetholone (XI), stanozolol (XII), and the human metabolites 7 alpha,17 alpha-dimethyl-5 beta-androstane-3 alpha,17 beta-diol (XIII) (metabolite of I), 6 beta-hydroxymetandienone (XIV) (metabolite of V), 17 alpha-methyl-5 beta-androst-1-ene-3 alpha,17 beta-diol (XV) (metabolite of V), 3'-hydroxystanozolol (XVI) (metabolite of XII), as well as the reference substances 17 beta-hydroxy-17 alpha-methyl-5 beta-androstan-3-one (XVII), 17 beta-hydroxy-17 alpha-methyl-5 beta-androst-1-en-3-one (XVIII) (also a metabolite of V), the four isomers 17 alpha-methyl-5 alpha-androstane-3 alpha,17 beta-diol (XIX) (also a metabolite of VI, VII, and XI), 17 alpha-methyl-5 alpha-androstane-3 beta,17 beta-diol (XX), 17 alpha-methyl-5 beta-androstane-3 alpha,17 beta-diol (XXI) (also a metabolite of V, VII, and VIII), 17 alpha-methyl-5 beta-androstane-3 beta,17 beta-diol (XXII), and 17 beta-hydroxy-7 alpha,17 alpha-dimethyl-5 beta-androstan-3-one (XXIII) were synthesized via a 17 beta-sulfate that spontaneously hydrolyzed in water to several dehydration products, and to the 17 alpha-hydroxy-17 beta-methyl epimer.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['stanozolol', 'oxandrolone', 'oxymetholone'],\n",
       "  'reaction': ['dehydration']},\n",
       " {'pmid': 1451600,\n",
       "  'sentence': 'Using this method it was possible to obtain direct evidence for the following cell type- and stimulus-specific differences in signal transduction pathways: 1) n-formyl-methionyl-leucyl-phenylalanine (FMLP)/cytochalasin B-induced oxidative burst is several-fold higher in granulocytes than in monocytes although the calcium fluxes have similar amplitudes in the two cell types; 2) stimulus-induced calcium fluxes in granulocytes are mainly due to release from intracellular stores, whereas monocytes mobilize calcium mainly by influx from the medium; 3) the FMLP/cytochalasin B-induced calcium flux in monocytes is less sensitive to the G-protein inhibitor pertussis toxin than the flux in granulocytes; 4) in contrast to FMLP/cytochalasin B, the protein kinase C activator phorbol myristate acetate (PMA) induces an oxidative burst that is not preceded by a cytoplasmic calcium flux; 5) the PMA-induced oxidative burst can be triggered in monocytes and granulocytes that are depleted of intracellular calcium ions, whereas that induced by FMLP/cytochalasin B can not; 6) the G-protein inhibitor pertussis toxin blocks an early event in the signal transduction pathway of FMLP/cytochalasin B, as shown by inhibition of both calcium fluxes and oxidative burst; and 7) 100 nM of the protein kinase inhibitor staurosporine blocks the FMLP/cytochalasin B-induced respiratory burst by interfering with a step downstream to cytoplasmic calcium fluxes, whereas only 10-20 nM is necessary to block PMA-induced oxidative burst.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium', 'calcium'],\n",
       "  'reaction': ['pertussis', 'pertussis']},\n",
       " {'pmid': 1577864,\n",
       "  'sentence': 'Double staining with a battery of labeled antibodies against membrane-associated proteins, myofibrillar proteins, and stress fiber proteins reveals the following: (a) dissociated, cultured cardiac myocytes reconstitute intercalated discs consisting of adherens junctions (AJs) and desmosomes at sites of cell-cell contact and sub-sarcolemmal adhesion plaques (SAPs) at sites of cell-substrate contact; (b) each AJ or SAP associates proximally with a striated myofibril, and conversely every striated myofibril is capped at either end by an AJ or a SAP; (C) the invariant association between a given myofibril and its SAP is especially prominent at the earliest stages of myofibrillogenesis; nascent myofibrils are capped by oppositely oriented SAPs; (d) the insertion of nascent myofibrils into AJs or into SAPs invariably involves vinculin, alpha-actin, and sarcomeric alpha-actinin (s-alpha-actinin); (e) AJs are positive for A-CAM but negative for talin and integrin; SAPs lack A-CAM but are positive for talin and integrin; (f) in cardiac cells all alpha-actinin-containing structures invariably are positive for the sarcomeric isoform, alpha-actin and related sarcomeric proteins; they lack non-s-alpha-actinin, gamma-actin, and caldesmon; (g) in fibroblasts all alpha-actinin-containing structures are positive for the non-sarcomeric isoform, gamma-actin, and related non-sarcomeric proteins, including caldesmon; and (h) myocytes differ from all other types of adherent cultured cells in that they do not assemble authentic stress fibers; instead they assemble stress fiber-like structures of linearly aligned I-Z-I-like complexes consisting exclusively of sarcomeric proteins.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['stress', 'adhesion', 'stress', 'stress']},\n",
       " {'pmid': 1702144,\n",
       "  'sentence': \"One hundred ninety-three patients with stage II, III, or IV follicular large-cell, diffuse large-cell, diffuse mixed, immunoblastic, or diffuse small noncleaved-cell (non-Burkitt's) lymphoma were randomized to receive either cyclophosphamide 650 mg/m2 intravenously (IV), doxorubicin 25 mg/m2 IV, etoposide 120 mg/m2 IV on day 1, mechlorethamine 6 mg/m2 IV, vincristine 1.4 mg/m2 (no cap at 2 mg total dose) IV on day 8, prednisone 60 mg/m2 orally daily days 1 through 14, procarbazine 100 mg/m2 orally daily days 8 through 14, and methotrexate 500 mg/m2 IV on day 15 with leucovorin 50 mg/m2 orally every 6 hours for four doses beginning 24 hours after methotrexate with cycles repeated every 28 days (ProMACE-MOPP) or same day-1 treatment as ProMACE-MOPP plus cytarabine 300 mg/m2 IV, bleomycin 5 U/m2 IV, vincristine 1.4 mg/m2 (no cap at 2 mg total dose) IV, and methotrexate 120 mg/m2 IV on day 8, leucovorin 25 mg/m2 orally every 6 hours for four doses beginning 24 hours after methotrexate, and prednisone 60 mg/m2 orally daily days 1 through 14 with cycles repeated every 21 days (ProMACE-CytaBOM).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['doxorubicin', 'methotrexate', 'bleomycin', 'cytarabine'],\n",
       "  'reaction': ['lymphoma']},\n",
       " {'pmid': 1756423,\n",
       "  'sentence': 'When inhibitors of respiratory processes were placed in the outer saline during the middle hour, production changed significantly, as follows: (a) sodium iodoacetate at 10(-3) M stopped production (87.2 +/- 10.3 and 100% reductions, successive hours; n = 6), at 10(-4) M it reduced production (60.0 +/- 10.3 and 63.4 +/- 9.3% reduction, successive hours; n = 12); (b) sodium fluoride, 10(-3) M, almost stopped production (93.2 +/- 12.1 and 89.5 +/- 9.3% reductions, successive hours; n = 6); (c) sodium cyanide at high concentration (10(-3) M) reduced production slowly (35.5 +/- 12.3 and 73.1 +/- 22.4%; successive hours; n = 6); (d) sodium azide, 10(-3) M, also reduced production (67.6 +/- 14.2 and 59.7 +/- 14.0%, successive hours; n = 6); total lactate lost rose 1.8 +/- 0.5 fold; (e) dinitrophenol produced strong reabsorptions; at 10(-3) M, production fell 115.4 +/- 15.9 and 113.1 +/- 47.3%, successive hours (n = 4), and at 2 x 10(-4) M it fell 143.8 +/- 33.8 and 153.4 +/- 26.7%, successive hours (n = 6); total lactate lost rose 2- to 3-fold.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['fluoride']},\n",
       " {'pmid': 1832521,\n",
       "  'sentence': 'The response of plasma atrial natriuretic peptide to three changes in posture that alter atrial stretch was examined in the late phase of pregnancy: (1) after 20 minutes in lateral recumbency, remaining upright for 2 hours decreased median plasma atrial natriuretic peptide values from 37.8 (25th percentile, 22.9 and 75th percentile; 64.2) to 21.8 (10.1 and 28.4) pg/ml in pregnant women (p less than 0.05) and from 39.2 (27.8 and 51.2) to 24.0 (18.9 and 35.4) pg/ml (p less than 0.001) in age-matched nonpregnant women; (2) prolongation of lateral recumbency from 20 to 80 minutes increased median plasma atrial natriuretic peptide levels from 31.9 (25.6 and 37.3) to 47.8 (33.0 and 74.6) pg/ml in pregnant women (p less than 0.001) and from 36.5 (22 and 58.6) to 54.0 (36.3 and 111.7) pg/ml in nonpregnant women (p less than 0.01); (3) adoption of supine posture during the late phase of normal pregnancy did not alter median plasma atrial natriuretic peptide values significantly [30.4 (26.7 and 42.5) pg/ml during lateral recumbency compared with 34.2 (25.4 and 43.5) pg/ml while supine].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['pregnancy', 'pregnancy']},\n",
       " {'pmid': 1837999,\n",
       "  'sentence': 'Among the urinary parameters we considered, cyclic GMP (cGMP) increased after ANP infusion in all subjects (N: PL = 129.1 +/- 56.3 pmol/mL, ANP = 199.2 +/- 85.4 pmol/mL; EH: PL = 106.55 +/- 56.2 pmol/mL, ANP = 220.03 +/- 92.7 pmol/mL, p less than 0.05); diuresis showed a prompt and significant increase in EH (N: PL = 837 +/- 368 mL, ANP = 1066 +/- 340 mL; EH: PL = 713 +/- 286 mL, ANP = 1043 +/- 280 mL, p less than 0.005), and so did natriuresis (N: PL = 23 +/- 14.3 mEq/L, ANP = 33 +/- 14.6 mEq/L; EH: PL = 25.6 +/- 8.9 mEq/L, ANP = 41.9 +/- 13.8 mEq/L, p less than 0.01); urinary potassium excretion was significantly reduced in EH (N: PL = 18.7 +/- 12.9 mEq/L, ANP = 14.2 +/- 6.9 mEq/L; EH: PL = 16.5 +/- 7.9 mEq/L, ANP = 10.7 +/- 4.8 mEq/L, p less than 0.005), while no changes were noted in glomerular filtration rate (GFR), estimated as creatinine clearance, urinary magnesium, albumin and aldosterone excretion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium', 'potassium'],\n",
       "  'reaction': ['infusion',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate']},\n",
       " {'pmid': 1843108,\n",
       "  'sentence': 'This paper discusses several new developments over the last year, particularly advances in our understanding of 1) the antitumor efficacy and ultimate clinical role of several novel analogues that appear to have improved therapeutic indices in certain malignancies such as idarubicin in acute myelogenous leukemia, epirubicin in breast cancer, and vinorelbine in breast and non-small cell lung cancers; 2) the nature, risks, detection, and prevention of serious nonhematologic toxicities such as the role of the carbon monoxide diffusion capacity test in the early detection of pulmonary toxicity from bleomycin, and youth as a risk factor for anthracycline cardiomyopathy; 3) the optimal scheduling and administration of these agents including chronic low-dose oral, infusional, and intraperitoneal administration schedules for the epipodophyllotoxins and infusional schedules for the vinca alkaloids; 4) differences in the pharmacology and recommendations for the use of the epipodophyllotoxin etoposide in patients with excretory organ dysfunction; and 5) the clinical feasibility of reversing multidrug resistance by using calcium channel blockers, the potential utility of other classes of agents to modulate multidrug resistance in the clinic, and new insights on resistance to bleomycin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['epirubicin', 'calcium', 'bleomycin', 'idarubicin'],\n",
       "  'reaction': ['breast cancer', 'pulmonary toxicity', 'cardiomyopathy']},\n",
       " {'pmid': 1918624,\n",
       "  'sentence': 'The major findings are: (1) Sideband inhibitory areas were observed in spatial profiles of rate changes of PVCN choppers whereas they were absent in those of AN fibers; (2) spatial profiles of rate changes and mean discharge rates of PVCN choppers were sharper than those of high spontaneous-rate (HSR) AN fibers and were comparable to those of low and medium SR (LMSR) AN fibers for 1 kHz at 50 and 70 dB SPL re: 20 microPa; (3) to 5 kHz, 30 dB SPL, PVCN choppers were strongly driven comparable to HSR AN fibers whereas LMSR AN fibers were weakly driven (implying higher thresholds); (4) PVCN choppers exhibited higher maximum discharge rates (300-600 spikes/s) than either LMSR AN fibers (200-250 spikes/s) or HSR AN fibers (150-250 spikes/s); (5) mean-to-sigma ratios of PVCN choppers, particularly at 70 dB SPL, were much higher than those of LMSR or HSR AN fibers; (6) rate-change profiles of LMSR AN fibers were distinct from those of HSR AN fibers, more conspicuously for 1 kHz than for 5 kHz; (7) the neural response profiles to 5 kHz were sharper than those to 1 kHz; and (8) 45% of PVCN choppers in the present study exhibited SR greater than 20 spikes/s whereas only 11%-12% of AVCN choppers in previous studies of anesthetized cats exhibited the same SR, which may represent an effect of anesthesia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['discharge', 'discharge']},\n",
       " {'pmid': 1930879,\n",
       "  'sentence': 'After about 5 months, a regeneration of autonomic nerves was clearly shown: first, by a complete recovery of neuronal uptake, indicated by: a) potentiation by cocaine of epinephrine (EPI) dose-response curves (T = 1.47 +/- 0.25, controls (C) = 1.50 +/- 0.14 log units); b) reversion to normal levels of pD2 values for norepinephrine (NE) and EPI (T = 6.6 +/- 0.1; 7.0 +/- 0.1, and C = 6.4 +/- 0.1; 6.9 +/- 0.1, respectively); second, a partial restoration of nerve terminals, and corresponding pools of NE, which was seen through histofluorescence and was indicated by a percent increase of: a) NE content, 47% (T = 3.8 +/- 0.8, C = 8.5 +/- 0.7 micrograms/g); b) dopamine-beta-hydroxylase (DBH) activity, 37% (T = 136 +/- 80, C = 364 +/- 15 nmol(hr.g); c) release of NE by 57 mM-potassium, 23% (T = 33.0 +/- 12.0, C = 147 +/- 14 ng/g.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['epinephrine']},\n",
       " {'pmid': 2095724,\n",
       "  'sentence': \"The diagnoses were: a) coronary heart disease in 92 (20.1%) cases (InCor) and in 8 (8.2%) cases (CSSA); b) valvular heart disease in 46 (10.1%) cases (InCor) and in 9 (9.2%) cases (CSSA); c) mitral valve prolapse in 31 (6.8%) cases (InCor) and in 7 (7.1%) cases (CSSA); d) congenital heart disease in 10 (2.2%) cases (InCor) and in 1 (1%) case (CSSA); e) systemic arterial hypertension in 161 (35.2%) cases (InCor) and in 55 (56.1%) cases (CSSA); f) Chagas' infection or Chagas' heart disease in 44 (9.6%) cases (InCor) and in 8 (8.2%) cases (CSSA); g) cardiac rhythm disorders in 38 (8.3%) cases (InCor) and in 8 (8.2% cases (CSSA); h) other diseases in 33 (7.2%) cases (InCor) and in 1 (1%) (CSSA); i) diseases of the aorta in 2 (0.4%) cases (InCor) and in 1 (1%) (CSSA).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['mitral valve prolapse',\n",
       "   'prolapse',\n",
       "   'hypertension',\n",
       "   'infection']},\n",
       " {'pmid': 2145777,\n",
       "  'sentence': 'To evaluate the role of vasopressin in the renal changes during combined acute hypoxemia and acute hypercapnic acidosis, eight conscious female mongrel dogs prepared with controlled sodium intake at 80 meq/24 h for 4 days were studied in one of the following six protocols: acute hypoxemia (80 min, arterial PO2 34 +/- 1 mmHg) followed by combined acute hypoxemia and hypercapnic acidosis (40 min, arterial PO2 35 +/- 1 mmHg, arterial PCO2 58 +/- 1 mmHg, pH = 7.20 +/- 0.01) during 1) intrarenal vehicle at 0.5 ml/min (N = 8); or 2) intrarenal infusion of vasopressin V1-receptor antagonist [d(CH2)5Tyr(Me)]AVP at 5 ng.kg-1.min-1 (N = 5); and with normal gas exchange during 3) intrarenal vasopressin at 0.05 mU.kg-1.min-1 (N = 8); 4) simultaneous infusion of intrarenal vasopressin and [d(CH2)5Tyr(Me)]AVP, 5 ng.kg-1.min-1 (N = 4); 5) intrarenal [d(CH2)5Tyr(Me)]AVP, 5 ng.kg-1.min-1 (N =4); and 6) intrarenal vehicle at 0.5 ml/min (N = 7).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vasopressin', 'sodium'],\n",
       "  'reaction': ['acidosis',\n",
       "   'po2',\n",
       "   'acidosis',\n",
       "   'po2',\n",
       "   'pco2',\n",
       "   'infusion',\n",
       "   'infusion']},\n",
       " {'pmid': 2210017,\n",
       "  'sentence': 'We investigated the changes in blood glucose, plasma non-esterified fatty acids (NEFA), bicarbonate and glucagon after stopping insulin infusion between 08.00 h. and 14.00 h. Insulin infusion cessation resulted in: 1) a similar increase in blood glucose in both groups after 2 hours of interruption (group 1: 9.45 +/- 1.28 mmol/L versus basal levels of 6.94 +/- 0.96 mmol/L, p less than 0.05; group 2: 8.11 +/- 2.87 mmol/L versus 5.75 +/- 2.17 mmol/L, p less than 0.02) and a greater increase in blood glucose in group 1 than group 2 after 4 hours (p less than 0.05) and after 6 hours (p less than 0.05); 2) a progressive increase in NEFA in group 1 throughout the study period (08.00 h.: 0.51 +/- 0.28 mmol/L; 14.00 h: 1.44 +/- 0.45 mmol/L, p less than 0.05) that was significant after 4 and 6 hours of CSII interruption; there were no changes in NEFA in group 2; 3) plasma level of IA correlated inversely with final glycemia (r = -0.67, p less than 0.01) and final NEFA (r = -0.56, p = 0.02).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['blood glucose',\n",
       "   'blood glucose',\n",
       "   'infusion',\n",
       "   'infusion',\n",
       "   'blood glucose',\n",
       "   'blood glucose',\n",
       "   'blood glucose',\n",
       "   'blood glucose']},\n",
       " {'pmid': 2244556,\n",
       "  'sentence': 'Analysis, by intention-to-treat, of the 3-month end points, revealed the following: recurrent ischemia occurred in 7 patients (22%) after aspirin, in 6 patients (25%) after heparin and warfarin, and in 16 patients (43%) after aspirin combined with heparin and then warfarin; coronary revascularization occurred in 12 patients (38%) after aspirin, in 12 patients (50%) after heparin and warfarin, and in 22 patients (60%) after aspirin combined with heparin and then warfarin; myocardial infarction occurred in 1 patient (3%) after aspirin, in 3 patients (13%) after heparin and warfarin, and in no patient after aspirin combined with heparin and then warfarin; no deaths occurred after aspirin or after aspirin combined with heparin and then warfarin, but 1 patient (4%) died after warfarin alone; major bleeding occurred in 3 patients (9%) after aspirin, in 2 patients (8%) after heparin and warfarin, and in 3 patients (8%) after aspirin combined with heparin and then warfarin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['heparin'],\n",
       "  'reaction': ['myocardial infarction', 'infarction']},\n",
       " {'pmid': 2251997,\n",
       "  'sentence': 'Pericardiocentesis produced the following changes: group I--significant (p less than 0.03) decreases in intrapericardial pressure (7 +/- 2 mm Hg), right atrial pressure (3 +/- 2 mm Hg), pulmonary arterial wedge pressure (2 +/- 2 mm Hg), and the inspiratory decrease in arterial systolic pressure (3 +/- 4 mm Hg) but no significant change in cardiac output; group II--significant (p less than 0.02) decreases in intrapericardial pressure (11 +/- 5 mm Hg), right atrial pressure (6 +/- 4 mm Hg), pulmonary arterial wedge pressure (4 +/- 5 mm Hg), and inspiratory decrease in arterial systolic pressure (8 +/- 7 mm Hg), and increase in cardiac output (1.1 +/- 1.2 liters/min); group III--significant (p less than 0.001) decreases in intrapericardial pressure (16 +/- 7 mm Hg), right atrial pressure (9 +/- 4 mm Hg), pulmonary arterial wedge pressure (8 +/- 5 mm Hg), inspiratory decrease in arterial systolic pressure (17 +/- 11 mm Hg), and increase in cardiac output (2.8 +/- 1.5 liters/min).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['right atrial pressure',\n",
       "   'cardiac output',\n",
       "   'right atrial pressure',\n",
       "   'cardiac output',\n",
       "   'right atrial pressure',\n",
       "   'cardiac output']},\n",
       " {'pmid': 2284718,\n",
       "  'sentence': \"Using the method of multi-dimensional statistical analysis in the evaluation of relations between the coronary score and risk factors in 120 men with ischaemic heart disease type stable angine, and in 30 men in a control group the authors revealed: age is a significant negative discriminator of the presence and indicator of the severity of atherosclerotic narrowing of the coronary arteries, cholesterol is a statistically significant positive independent discriminator of the presence and indicator of the severity of atherosclerotic narrowing of the coronary arteries, HDL-cholesterol is a significant negative independent indicator of the severity of the atherosclerotic narrowing of the coronary arteries, triacylglycerols are a positive indicator of the severity of the atherosclerotic narrowing of the coronary arteries only at the borderline of statistical significance, Broca's index of relative body weight is a positive discriminator of atherosclerotic narrowing of the coronary arteries only at the borderline of significance, there is a statistically significant positive additive relationship of quantitative risk factors with the atherosclerotic narrowing of coronary arteries, physical activity is a significant positive discriminator of the presence of atherosclerotic narrowing of the coronary arteries, the oral glucose tolerance test is a positive discriminator of the presence of the atherosclerotic narrowing of the coronary arteries.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight', 'glucose tolerance']},\n",
       " {'pmid': 2303254,\n",
       "  'sentence': 'The results indicate that (1) 69% of the amino acids in the catalytic domain, but only 23% of the amino acids in the activation peptide, are identical in humans and the six species; (2) the catalytic domain evolves at a slower rate, but the extent and pattern of conservation of amino acids in the activation peptide suggest that the peptide functions as more than a cleavage spacer that separates the heavy and light chains in the catalytically inactive zymogen; (3) 37% of the amino acids in the activation peptide and 34% of the amino acids in the catalytic domain are factor IX-specific; i.e., they are either identical or changed in a highly conservative fashion in factor IX, but not in other related coagulation proteases; (4) these conserved factor IX-specific amino acids fall into three clusters, which are candidates for involvement in the protein interactions specific to factor IX; (5) there is a human-specific deletion after lysine 142 and a rodent-specific insertion after alanine 161; (6) in guinea pig, the insertion is associated with a seven-amino-acid repeat that corresponds to a perfect repeat of a 21-bp sequence; (7) humans have lost a potential N-glycosylation site that is conserved in the other species; (8) in each species, a few nonconservative changes occur in amino acids that are otherwise completely conserved, suggesting that compensatory mutations may have occurred; and (9) when compared to that of mouse, the amino acid identity with guinea pig factor IX is no greater than that found for the non-rodent species, a result compatible with the postulated increased rate of evolution in rodents.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['fall']},\n",
       " {'pmid': 2323699,\n",
       "  'sentence': 'Aging appeared to result in a generalized widening of the stromal layer from 19.3 +/- 2.4 microns (10-20 years; n = 4) to 60.0 +/- 11.5 microns (80-90 years; n = 3) in ciliary processes and from 53.0 +/- 6.8 microns to 107.6 +/- 15.2 microns in the ground plate between ciliary valleys and ciliary muscle, a density increase of collagenous fibers from 39.3 +/- 4.9 to 83.5 +/- 14.6 fibers/microns 2 and a concomitant decrease in mean fiber diameter from 62.8 +/- 3.4 nm to 55.7 +/- 1.5 nm, a decline of stromal cell density from 31.4 +/- 1.8 to 9.6 +/- 1.0 cells/0.014 mm2, a progressive thickening of the inner and outer limiting membranes from 0.8 +/- 0.4 micron to 8.1 +/- 1.5 microns and 2.1 +/- 0.6 microns to 4.5 +/- 0.5 microns respectively as well as the endothelial basement membrane from 0.13 +/- 0.004 micron to 0.25 +/- 0.03 micron, a gradual widening of the perivascular space between capillaries and overlying pigment epithelium from 6.2 +/- 1.5 microns to 11.3 +/- 2.9 microns, an increase in number of fenestrations in the capillary endothelium from 39.0 +/- 8.5 to 69.0 +/- 7.0 pores/100 microns, and finally a continuous augmentation of degenerative elements including lipids, lipofuscin granules, and lysosomes from 1.5 +/- 0.06% to 7.2 +/- 0.6% within the non-pigmented epithelium (NPE) over the 71-year period studied.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['lipids']},\n",
       " {'pmid': 2335181,\n",
       "  'sentence': 'Results after 1 year of treatment in 30 type 1 diabetics (HCP-negative; age at onset of diabetes 16.5 +/- 1.7 years; duration of diabetes 18.5 +/- 1.6 years, on multiple insulin injections before catheter-pen application): 1. better quality of life (reduction of frequency of needle pricks, more flexibility, inconspicuous application of insulin in public); 2. daily insulin--increased number of \"injections\" (4.2 +/- 0.1 vs 5.8 +/- 0.1, p less than 0.01), reduction of units per kg BW (0.70 +/- 0.02 vs 0.60 +/- 0.01, p less than 0.01), reduction of intermediate-acting insulin (14.1 +/- 1.3 vs 9.2 +/- 1.2 U/d, p less than 0.05); 3. no change of HbA1 (10.8 +/- 0.8 vs 10.2 +/- 0.2%, normal range 7.7 to 8.4%), mean blood glucose (MBG) in stress situation (8.4 +/- 0.4 vs 7.7 +/- 0.3 mmol/l), serum cholesterol and body weight, both within normal range; 4. improvement (p less than 0.05) of serum triglycerides, serum HDL-cholesterol, ratio of apolipoprotein A1/B; 5. rare skin reactions at the needle site.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['quality of life',\n",
       "   'blood glucose',\n",
       "   'blood glucose',\n",
       "   'stress',\n",
       "   'weight',\n",
       "   'weight']},\n",
       " {'pmid': 2351840,\n",
       "  'sentence': 'These experiments indicate that to provide optimal cell growth and MAb production: (i) the concentration of glutamine in the nutritive medium should be maintained at 8 mM, otherwise it falls on some days to 0 with a significant amount of cell death; at 25 mM, glucose concentration is not a limiting factor, whatever the culture conditions; (ii) with a semi-continuous mode of cultivation, a perfusion rate of 40%/day appears optimal; without cell recycling, a rate of 20% does not provide enough nutrients and/or does not remove enough metabolites, whereas a rate of 60% washes over the cells; with cell recycling, rates of 60 (moderately) or 100% (considerably) increase cellular metabolism without concurrent augmentation of MAb secretion; (iii) the recycling of the cells increases the mean cell densities and the rate of production of the MAb, as well as the rate of consumption of nutrients and of production of metabolites; recycling of 33-66% is optimal, since the total recycling progressively raises the number of dead cells and debris; (iv) there are maximal values for cell densities (ca.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth', 'cell death', 'death']},\n",
       " {'pmid': 2355360,\n",
       "  'sentence': \"Several important developments were reported at the 1989 Annual Meeting of the American Society of Anesthesiologists: (1) a computerized machine called HealthQuiz asks patients health questions, and in less than 10 minutes provides a printout of answers, a summary of symptoms, and a list of suggested laboratory tests; (2) a simple device provides continuous measurements of a critically ill patient's oxygen and carbon dioxide levels; (3) near-infrared reflectance is a new technique that may provide the first accurate real-time measurement of critical oxygen levels in the brain; (4) pulse oximeters may provide false readings in patients who smoke cigarettes; (5) a new test may accurately predict the survival chances of a child in a coma; (6) the fastest growing subspecialty in anesthesiology is chronic pain management clinics; (7) alpha-2 adrenergic agonists improve pain relief without the unwanted side effects of narcotics; (8) clonidine appears to suppress the dangerous shivering that often occurs in postanesthesia patients; (9) flumazenil was successfully tested as an agent to reverse the drowsiness caused by midazolam; and (10) ephedrine minimizes nausea and vomiting in patients undergoing ambulatory surgery.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['flumazenil'],\n",
       "  'reaction': ['carbon dioxide',\n",
       "   'coma',\n",
       "   'pain',\n",
       "   'pain management',\n",
       "   'pain',\n",
       "   'nausea',\n",
       "   'vomiting',\n",
       "   'surgery']},\n",
       " {'pmid': 2372720,\n",
       "  'sentence': 'The results show that: 1) the ratio of fat in the non-consumed food (7.5% in wet weight) exceeds that of the proposed intake (6.6%); 2) the consumed food (1,900 KCal/d) represents 80% of the initial total calorie allowance and includes 37.5% lipid calories (71% of initial lipid allowance); 3) the distribution of the consumed fatty acids (FA) is identical to that of the fatty acids of the initial intake and not in conformity with the recommendations of the FAO/WHO Board: 53% saturated FA, 34% mononunsaturated FA, 13% polyunsaturated FA and P/S ratio: 0.23; 4) mono and polyunsaturated FA are eliminated in the non-consumed food, more particularly in unclean plates where the distribution is very near the recommended one: 48% monounsaturated FA, 21% polyunsaturated FA, 31% saturated FA and P/S ratio: 0.8; 5) in spite of these data, the consumption of essential FA remains satisfactory: 7 g of linoleic acid, and 1.5 g of linolenic acid; 6) the consumption of cholesterol (215 mg/d), corresponding to 3/4 of the initial allowance, is satisfactory.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 2415320,\n",
       "  'sentence': 'Twelve other cases in CP and 9 reference cases showed some abnormal sleep EEG patterns as follows: (i) in CP cases absence of EEG patterns characteristic of wakefulness, NREM sleep and REM sleep without spindles (n = 3); porencephaly with microcephaly (n = 1) and cytomegalovirus infection (n = 2), no characteristic EEG patterns of stages 1-4 without spindles (n = 2); cardiac arrest (n = 1) and agenesis of corpus callosum with lissencephaly (n = 1), absence of REM sleep (n = 1); kernicterus, spindles with an extremely low incidence (n = 5); perinatal anoxia (n = 2), kernicterus (n = 1), Lesch-Nyhan syndrome (n = 1) and cerebral palsy due to unknown etiologies (n = 1), and extreme spindles (n = 1); cerebral palsy due to unknown etiologies, (ii) in reference cases no spindles (n = 2), spindles with an extremely low incidence (n = 6), and extreme spindles (n = 1).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['microcephaly',\n",
       "   'cytomegalovirus infection',\n",
       "   'infection',\n",
       "   'cardiac arrest',\n",
       "   'anoxia',\n",
       "   'cerebral palsy',\n",
       "   'cerebral palsy']},\n",
       " {'pmid': 2525957,\n",
       "  'sentence': \"In 1989 the following indications for surgical treatment of acute myocardial infarction are: (1) acute evolving myocardial infarction less than 6 h from onset, in patients in whom percutaneous transluminal coronary angioplasty (PTCA) or streptokinase (SK), depending on the coronary anatomy, has been unsuccessful; if single vessel disease, coronary artery bypass grafting (CABG) is unlikely; if multiple vessel disease, CABG is preferable to SK/PTCA unless a very major 'culprit' lesion can be identified with certainty; (2) postinfarction angina hours to days after a transmural myocardial infarction unyielding to maximal medical therapy and in patients with a coronary artery obstruction not amenable to PTCA; (3) occlusion of a coronary artery during cardiac catheterization that cannot be fixed by PTCA and/or SK; (4) occlusion of a coronary artery during PTCA causing hemodynamic obstruction and a threatened myocardium subtended by the obstructed coronary artery; (5) balloon-dependent patients in cardiogenic shock without mechanical defects who have adequate residual left ventricular function as determined by regional wall motion studies; (6) ventricular septal defect secondary to myocardial infarction unless there is terminal organ damage; (7) mitral valve replacement with coronary bypass for acute papillary muscle rupture; (8) semi-emergency cardiac transplantation, either with or without a mechanical bridge to transplant in young individuals (less than 50 years) who have suffered massive destruction of left ventricular myocardium by an acute coronary occlusion with or without recurring ventricular tachyarrhythmias.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['acute myocardial infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'coronary angioplasty',\n",
       "   'angioplasty',\n",
       "   'coronary artery bypass',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'obstruction',\n",
       "   'obstruction',\n",
       "   'cardiogenic shock',\n",
       "   'shock',\n",
       "   'ventricular septal defect',\n",
       "   'ventricular septal defect',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'mitral valve replacement',\n",
       "   'muscle rupture',\n",
       "   'transplant']},\n",
       " {'pmid': 2555878,\n",
       "  'sentence': 'The studies on the mechanism of action indicate that the ACTH-induced reversal of hemorrhagic shock (a) is an extra-hormonal, adrenal-independent effect, because it is not affected by adrenalectomy and is shared by many ACTH-fragments practically devoid of corticotropic activity; (b) is antagonized by morphine in a surmontable way; (c) needs the functional integrity of the sympathetic nervous system (it is prevented by guanethidine, reserpine, and clonidine) and the availability of peripheral alpha-adrenoceptors (it is antagonized by dibenamine, prazosin and yohimbine, but not by practolol); (d) requires the integrity of afferent vagal fibers (it is almost completely abolished by vagotomy); (e) involves central cholinergic networks (it is antagonized by atropine sulphate, but not by atropine methyl bromide; and it is prevented by the intracerebroventricular injection of hemicholinium-3); (f) is associated with a massive increase in the volume of circulating blood, likely due to a mobilization from peripheral pooling sites (it is largely prevented by splenectomy or by suprahepatic veins ligature, and is associated with a restoration of the venous blood flow in peripheral vascular beds and with a normalization of venous PO2); (g) is associated with a restoration of heart and spleen adrenoceptors, whose number is significantly decreased during hemorrhagic shock.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['reserpine', 'practolol', 'prazosin'],\n",
       "  'reaction': ['shock',\n",
       "   'adrenalectomy',\n",
       "   'injection',\n",
       "   'splenectomy',\n",
       "   'po2',\n",
       "   'shock']},\n",
       " {'pmid': 2620314,\n",
       "  'sentence': 'In a nominally calcium free solution, strontium (1.35-10.8 mmol.litre-1): (1) caused a time, rate and concentration dependent shift of the plateau to more positive potentials, prolonged the action potential and decreased the maximum diastolic potential; (2) increased the time to peak and amplitude of the twitch and caused a tonic force which relaxed only on repolarisation; (3) was rapidly overcome in its effects by calcium (1.35-2.7 mmol.litre-1); (4) was antagonised by manganese (1 mmol.litre-1) and cadmium (0.1-0.2 mmol.litre-1); (5) was potentiated by noradrenaline (0.1 mumol.litre-1); (6) could induce action potentials in 27 mmol.litre-1 [K]o; (7) induced a tail following the action potential when the pacemaker potential had been blocked by caesium; (8) could induce a tail in 8 mmol.litre-1 [K]o which sustained force development and was reduced by calcium antagonists; (9) if applied to a quiescent fibre, induced a prolongation of the first resumed action potential and tonic force but a small twitch, and these effects were antagonised by calcium and manganese; and (10) induced a strong twitch after a period of quiescence in low [Na]o.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['strontium', 'calcium'],\n",
       "  'reaction': ['manganese', 'manganese']},\n",
       " {'pmid': 2646460,\n",
       "  'sentence': 'General morbidity data are as follows: cerebrovascular event, 0.6%; paraplegia, 1 case; cardiac event, 15.1% (age, previous episode of congestive heart failure, and/or electrocardiogram [ECG] evidence of a previous myocardial infarction); myocardial infarction, 5.2% (advancing age, angina, and/or prolonged aortic cross-clamp time); congestive heart failure, 8.9% (previous history of congestive heart failure, ECG evidence of ischemia, and/or chronic obstructive lung disease); arrhythmia requiring treatment, 10.5% (preoperative ventricular premature beats and/or respiratory failure requiring ventilation for more than 48 hours); new arrhythmia, 8.4% (angina and/or chronic obstructive lung disease); respiratory failure, 8.4% (chronic obstructive lung disease, large volume of blood transfused, and/or occurrence of postoperative bleeding, cerebrovascular accident, congestive heart failure, or myocardial infarction); renal damage with rise in creatinine or blood urea nitrogen, 5.4% and/or renal failure requiring dialysis, 0.6% (elevated preoperative creatinine, suprarenal aortic cross-clamping, and/or renal vein ligation); diarrhea without evidence of ischemia colitis, 7.1% and ischemic colitis, 0.6% (pelvic flow interrupted); prolonged ileus, 11.0% (aortoiliac occlusive disease, deterioration of renal function, prolonged ventilation, and/or preoperative history of angina); superficial wound infection, 1.5% and deep infection, 0.5% (femoral anastomosis and/or female sex); coagulopathy, 1.1% (large volume of blood transfused).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['paraplegia',\n",
       "   'electrocardiogram',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'arrhythmia',\n",
       "   'respiratory failure',\n",
       "   'arrhythmia',\n",
       "   'respiratory failure',\n",
       "   'cerebrovascular accident',\n",
       "   'accident',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'blood urea',\n",
       "   'blood urea',\n",
       "   'renal failure',\n",
       "   'dialysis',\n",
       "   'colitis',\n",
       "   'colitis',\n",
       "   'ileus',\n",
       "   'wound',\n",
       "   'wound infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'coagulopathy']},\n",
       " {'pmid': 2655939,\n",
       "  'sentence': 'Several potential culprits have been tried: (1) \"energy failure\", or depletion of high-energy phosphates, occurs very quickly after ischemia, but energy metabolites recover even in tissues where functional return does not occur; (2) \"tissue lactacidosis\" enhances ischemic cell necrosis, but this factor is not the indispensable cause of neuronal necrosis because acidosis is minimal or nonexistent under conditions of hypoglycemia and seizures; (3) \"impairment of the microcirculation\" may be a contributing factor, but such microcirculatory impairment cannot be the initiating event as it is known that irreversible neuronal injury precedes the development of microcirculatory abnormalities; (4) the effects of \"excitatory neurotransmitters\", especially glutamate, may explain the \"delayed neuronal death\" or the protracted necrosis of neurons in the CA1 sector of the hippocampus; (5) ionic pump alterations: studies of experimental myocardial ischemia tend to support a contributory role of Ca2+ in the aggravation of cell necrosis; however, lack of an experimental model in which steady-state conditions can be maintained has left unresolved the potential participation of calcium ions in ischemic cell necrosis; (6) the same statement, concerning the lack of an experimental model, can be made about the role of free-radical species; oxygen free radicals and superoxides are abundant in the reperfusion stage of ischemic injury, but it is unclear how significant their contribution might be as initiators of ischemic necrosis; and (7) the \"ischemic penumbra\" is a zone or portion of brain tissue that is sufficiently hypoperfused as to be functionless, but where the cells are likely to recover once normal perfusion is reestablished.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['energy',\n",
       "   'energy',\n",
       "   'necrosis',\n",
       "   'necrosis',\n",
       "   'acidosis',\n",
       "   'injury',\n",
       "   'death',\n",
       "   'necrosis',\n",
       "   'necrosis',\n",
       "   'necrosis',\n",
       "   'injury',\n",
       "   'necrosis']},\n",
       " {'pmid': 2731169,\n",
       "  'sentence': 'Results indicated that: (a) these cells were inhibited from proliferating for extended periods (up to 30 days) when placed in charcoal-dextran-stripped sera; they remained, however, viable because they proliferated when sex hormones were added to this medium; (b) the inhibitory effect of sera was reversed by the addition of 5 alpha-dihydrotestosterone at 3 x 10(-10) M, 17 beta-estradiol at 3 x 10(-8) M and higher concentrations, and progesterone at 3 x 10(-10) M and higher concentrations; (c) while the dose response to androgens was biphasic (i.e., 5 alpha-dihydrotestosterone at concentrations higher than 3 x 10(-10) M resulted in progressively lower cell yields), estrogens and progestagens exhibited a monophasic pattern; (d) these cells were exceedingly sensitive to the nutritional environment in which they grew; (e) while these cells have androgen receptors (68 fmol/mg protein; Kd = 2 x 10(-9) M), estrogen and progestagen receptors could not be detected by biochemical and immunocytochemical techniques; (f) tumors grew at the site of inoculation in castrated nude mice carrying 17 beta-estradiol and progesterone pellets and in intact male nude mice implanted with placebo pellets, while tumors did not grow in castrated nude mice implanted with a 5 alpha-dihydrotestosterone pellet.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['progesterone', 'androgens', 'progesterone']},\n",
       " {'pmid': 2759974,\n",
       "  'sentence': 'The objective of this study was to develop an empirical model relating human running performance to some characteristics of metabolic energy-yielding processes using A, the capacity of anaerobic metabolism (J/kg); MAP, the maximal aerobic power (W/kg); and E, the reduction in peak aerobic power with the natural logarithm of race duration T, when T greater than TMAP = 420 s. Accordingly, the model developed describes the average power output PT (W/kg) sustained over any T as PT = [S/T(1 - e-T/k2)] + 1/T integral of T O [BMR + B(1 - e-t/k1)]dt where S = A and B = MAP - BMR (basal metabolic rate) when T less than TMAP; and S = A + [Af ln(T/TMAP)] and B = (MAP - BMR) + [E ln(T/TMAP)] when T greater than TMAP; k1 = 30 s and k2 = 20 s are time constants describing the kinetics of aerobic and anaerobic metabolism, respectively, at the beginning of exercise; f is a constant describing the reduction in the amount of energy provided from anaerobic metabolism with increasing T; and t is the time from the onset of the race.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 2896422,\n",
       "  'sentence': 'With this model, effects of thoracic epidural anaesthesia (TEA) on mean arterial pressure (MAP), cardiac output (CO), systemic vascular resistance (SVR), stroke volume (SV), heart rate (HR), central venous pressure (CVP), left ventricular end-diastolic pressure (LVEDP) and maximal increase of pressure in the left ventricle (max dp/dt) were studied in six groups of animals: 1) In conscious animals (n = 10) MAP, CO, SV and HR decreased significantly by 12%, 25%, 10% and 16%, respectively, while SVR increased significantly by 20% during TEA; 2) In chloralose-anaesthetized animals (n = 7) the reduction in CO during TEA was less pronounced and there were no significant changes in SV or SVR; 3) In conscious animals (n = 6) LVEDP, CVP and max dp/dt decreased significantly during TEA; 4) Hexamethonium, when administered to pharmacologically vagotomized conscious animals during TEA (n = 8), induced a significant decrease in SVR (23%) but no change in HR; 5) Changes in haemodynamics after cardiac adrenoceptor blockade with metoprolol, in conscious animals (n = 12), did not differ significantly from those seen during TEA, except for an unchanged SV after metoprolol; 6) 50 microliters of bupivacaine (5 mg/ml) when given i.v.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['metoprolol', 'bupivacaine', 'cardiac'],\n",
       "  'reaction': ['anaesthesia',\n",
       "   'mean arterial pressure',\n",
       "   'cardiac output',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'central venous pressure',\n",
       "   'venous pressure']},\n",
       " {'pmid': 2936762,\n",
       "  'sentence': 'In 10 subjects alpha hANP given as an initial bolus of 50 micrograms followed by a 45-min maintenance infusion at 6.25 micrograms/min increased plasma alpha hANP from 58 +/- 12 to 625 +/- 87 (mean +/- SEM) pg/ml; caused an acute fall in diastolic BP (-12%, P less than 0.001) and a hemoconcentration (hematocrit +7%, P less than 0.01) not fully explained by a negative body fluid balance; increased GFR (+15%, P less than 0.05) despite unchanged or decreased ERPF (filtration fraction +37%, P less than 0.001); augmented (P less than 0.05- less than 0.001) urinary chloride (+317%), sodium (+224%), calcium (+158%), magnesium (+110%), phosphate excretion (+88%), and free water clearance (from -0.76 to +2.23 ml/min, P less than 0.001) with only little change in potassium excretion; and increased plasma norepinephrine (P less than 0.001) while plasma and urinary epinephrine and dopamine, and plasma ADH, angiotensin II, and aldosterone levels were unchanged.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium', 'dopamine', 'sodium', 'calcium', 'magnesium'],\n",
       "  'reaction': ['infusion', 'fall', 'epinephrine']},\n",
       " {'pmid': 2961516,\n",
       "  'sentence': 'Thus, in 1987, the following indications for surgical treatment of acute myocardial infarction are: 1) acute evolving myocardial infarction less than six hours from onset, in patients in whom PTCA or streptokinase, depending on the coronary anatomy, has been unsuccessful; in single vessel disease, CABG is unlikely; in multiple-vessel disease, CABG is preferable to SK/PTCA therapy unless a very major \"culprit\" lesion can be identified with certainty; 2) post-infarction angina hours to days after a transmural myocardial infarction unyielding to maximal medical therapy and in patients with a coronary artery obstruction not amenable to PTCA; 3) occlusion of a coronary artery during cardiac catheterization that cannot be fixed by PTCA and/or streptokinase; 4) occlusion of a coronary artery during PTCA causing hemodynamic obstruction and threatened myocardium subtended by the obstructed coronary artery; 5) balloon-dependent patients in cardiogenic shock without mechanical defects who have adequate residual left ventricular function as determined by regional wall motion studies; 6) ventricular septal defect secondary to myocardial infarction unless there is terminal organ damage; 7) mitral valve replacement with or without coronary bypass for acute papillary muscle rupture; 8) semi-emergent cardiac transplantation, either with or without a mechanical bridge to transplant in young individuals (less than 50 years) who have suffered massive destruction of left ventricular myocardium by an acute coronary occlusion with or without recurring ventricular tachyarrhythmias.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['acute myocardial infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'obstruction',\n",
       "   'obstruction',\n",
       "   'cardiogenic shock',\n",
       "   'shock',\n",
       "   'ventricular septal defect',\n",
       "   'ventricular septal defect',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'mitral valve replacement',\n",
       "   'muscle rupture',\n",
       "   'transplant']},\n",
       " {'pmid': 2989044,\n",
       "  'sentence': 'By pulse-labeling cells with [35S]methionine, separating polypeptides by 2D-PAGE, and semiquantitatively comparing the rates of synthesis of 778 individual polypeptides by fluorography, the following results were obtained: a detailed program of protein synthesis accompanies the preaggregative (0-7 hr) and aggregative (7-10.5 hr) periods of development; this includes significant decreases in the rate of synthesis of 93 polypeptides synthesized during vegetative growth and significant increases in the rate of synthesis of 74 polypeptides either undetectable or synthesized at relatively low rates during vegetative growth; 35 polypeptides are transiently synthesized at different times during the preaggregative and aggregative periods; two peaks of activity are clearly defined for both increases and decreases; these peaks correlate temporally with the first and second rate-limiting components of the preaggregative period; the majority of changes (74%) which occur during the first rate-limiting component will occur in the absence of close cell-cell associations, but the majority (66%) which normally occur during the second rate-limiting component do not occur in the absence of close cell-cell associations; a high concentration of cAMP in the medium of continuous suspension cultures does not stimulate most of the changes which are dependent upon close cell-cell associations; even though cAMP stimulates progress through the second rate-limiting component in suspension cultures first allowed to associate for 4.5 hr (\"competent\" cells) prior to disaggregation it still does not stimulate most of the changes which are dependent upon close cell-cell associations; and synthesis of only 3 out of 778 polypeptides appears to be stimulated by addition of exogenous cAMP, and only in resuspended cultures of \"competent\" cells.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth', 'growth']},\n",
       " {'pmid': 2995414,\n",
       "  'sentence': 'We find that (a) epidermal growth factor (EGF) stimulates ornithine decarboxylase (ODC) activity and the rate of cell division without stimulating cAMP; (b) alone, pituitary extract (PEX) does not stimulate ODC activity, cAMP levels, or cell division; (c) when PEX is added to medium containing EGF there is a further increase in both ODC activity and the rate of cell division, again with no increase in cAMP levels; (d) in contrast, alone, L-epinephrine (EPI) stimulates an increase in both ODC and cAMP but does not stimulate cell division; (e) when EPI is added to medium containing both EGF and PEX a further increase in the rate of cell division is noted; (f) the specific inhibitor of ODC, alpha-(difluoromethyl)-ornithine (DMFO), also inhibits NHBE cell proliferation; and (g) the beta-adrenergic receptor antagonist propranolol inhibits the mitogenic action and ODC induction by EPI observed under condition e. We conclude that an increase in ODC activity is necessary but not sufficient for an increase in proliferation of NHBE cells.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol', 'medium'],\n",
       "  'reaction': ['growth', 'condition']},\n",
       " {'pmid': 3079407,\n",
       "  'sentence': \"Notable conclusions from each of the discussed sections suggest that: (a) oral contraceptives do not increase a woman's risk for breast cancer; (b) the vast majority of women with resected premalignant breast lesions do well for prolonged periods after diagnosis regardless of therapy; (c) satisfactory cosmetic results can occur with either lumpectomy, axillary nodal dissection, and radiotherapy or with mastectomy and breast reconstruction; (d) the primary tumor thymidine labeling index can give prognostic information; (e) immunohistochemical methods can accurately measure tumor estrogen receptors; (f) there are multiple hormonal therapies of similar efficacy; (g) two new single agent chemotherapy drugs deserving further investigation are idarubicin and lonidamine; (h) none of several combination chemotherapy regimens is clearly superior to any of the other 'standard' regimens; (i) there is a lack of consensus among the conclusions of recent adjuvant breast cancer consensus conferences held in the United States and London; (j) inflammatory breast cancer patients treated with initial combination chemotherapy consistently appear to have improved relapse-free and overall survivals when compared to historical controls; and (k) the prognosis in locally recurrent breast cancer patients is better in those previously treated with lumpectomy and irradiation when compared to those previously treated with mastectomy.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['idarubicin'],\n",
       "  'reaction': ['breast cancer',\n",
       "   'radiotherapy',\n",
       "   'mastectomy',\n",
       "   'breast reconstruction',\n",
       "   'chemotherapy',\n",
       "   'investigation',\n",
       "   'chemotherapy',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'chemotherapy',\n",
       "   'breast cancer',\n",
       "   'mastectomy']},\n",
       " {'pmid': 3144026,\n",
       "  'sentence': 'The results of the investigation were that 1. in all patients, as well as in patients with aplastic anemia, no correlation was there between the degree of the indium chloride accumulation and peripheral blood counts, 2. in patients with aplastic anemia and pure red cell aplasia (PRCA) a tendency to reduction in uptake of indium chloride in bone marrow, 3. in patients with these two good correlation between the degree of indium chloride accumulation and histology of the erythroid bone marrow, but in patients with chronic myelocytic leukemia (CML) and atypical leukemia no correlation between the two, so it seemed unlikely that indium chloride should reflect the effective production of erythrocytes, 4. four patients with leukemia were studied with indium chloride bone marrow imaging two times to evaluate their responses to chemotherapy, and peripheral expansion was no change or reduced in two patients with acute myelocytic leukemia (AML) and one patient with acute lymphocytic leukemia (ALL) who obtained complete remission, but on the other hand, it enlarged in one patient with acute myelocytic leukemia who obtained partial remission, and 5. in two patients with chronic myelocytic leukemia it enlarged up to the ankle joints, which was considerably specific.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['indium'],\n",
       "  'reaction': ['investigation', 'aplasia', 'histology', 'chemotherapy']},\n",
       " {'pmid': 3156871,\n",
       "  'sentence': 'A group of 23 seriously ill men with various disorders, ill for a week or longer, was age-matched to a control group of 25 men, and the following changes were found: 1) basal serum cortisol concentrations were elevated in the ill group (P less than 0.001), 2) basal serum DHA and DHAS concentrations tended to be lower in the ill group (P less than 0.1); 3) basal serum DHA to cortisol and DHAS to cortisol ratios were decreased in the ill group by 80.3% and 77.2%, respectively (P less than 0.001); 4) ACTH-stimulated serum cortisol concentrations increased by the same absolute amount in both groups, whereas the increase in stimulated DHA concentrations in the ill group was 57.2% less (P less than 0.05), indicating a defect in ACTH-stimulated DHA reserve in serious illness; 5) basal daily unconjugated DHA excretion was lower in the ill group (P less than 0.05); (6) basal daily cortisol excretion was higher in the ill group (P less than 0.05); and 7) the basal daily urinary unconjugated DHA to cortisol ratio was 85.4% lower in the ill group (P less than 0.001).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol']},\n",
       " {'pmid': 3215008,\n",
       "  'sentence': 'Studies on binding and endocytosis of labelled PIIINP in cultures of purified populations of liver cells can be summarized as follows: 1) Uptake and degradation were observed mainly in LEC; 2) PIIINP associated with Kupffer and parenchymal cells, but degradation was very low; 3) Serum was not required for binding of PIIINP to LEC; 4) Binding was specific, that is, other ligands, such as collagen type III, hyaluronan, chondroitin sulfate, formaldehyde-treated albumin, and mannose, that are recognized by distinct receptors on LEC, did not compete with PIIINP for binding; 5) BPIIINP, TC-BPIIINP, and rat PIIINP (RPIIINP) were recognized with the same specificity by LEC; 6) BPIIINP bound to LEC with high affinity (dissociation constant = 1 nM), and about 4.2 x 10(5), 3.2 x 10(5), and 1.6 x 10(5) molecules of BPIIINP, TC-PIIINP, and R-PIIINP, respectively were bound per cell; 7) PIIINP could not be degraded by conditioned medium from cultured Kupffer cells; 8) Leupeptin, which is a strong inhibitor of lysosomal collagenolysis, only weakly inhibited degradation of PIIINP; 9) Binding and endocytosis of PIIINP was not Ca++-dependent; 10) Agents that inhibit the endocytic machinery inhibited uptake and degradation of PIIINP.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['dissociation']},\n",
       " {'pmid': 3349075,\n",
       "  'sentence': 'Several lines of evidence strongly suggest that the 150 kDa protein from duck red cell membranes is an integral component of the (Na + K + Cl)-cotransport system in these cells: (1) Photolabelling of this protein by [3H]BSTBA is blocked when 10 microM unlabelled bumetanide is included in the initial incubation medium with [3H]BSTBA; (2) Photoincorporation of [3H]BSTBA into the 150 kDa protein is markedly increased when the initial incubation medium is hypertonic or contains norepinephrine, conditions which similarly stimulate both (Na + K + Cl) cotransport and saturable [3H]bumetanide binding in duck red cells; (3) The photolabelling of this protein shows a saturable dependence on [3H]BSTBA concentration, with a K1/2 (0.06 microM) similar to that for the reversible, saturable binding of [3H]BSTBA and [3H]bumetanide to duck red cells; and (4) [3H]BSTBA photoincorporation into the 150 kDa protein, like saturable [3H]bumetanide binding to intact cells, requires the simultaneous presence of Na+, K+, and Cl- in the medium containing the radiolabelled diuretic.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bumetanide', 'medium'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 3378033,\n",
       "  'sentence': 'Comparative kinetic, melting, and equilibrium binding studies of actinomycin D (ACTD) with d(ATATACGTATAT), four d(TGCA)-containing dodecamers, and poly(dG-dC).poly(dG-dC) revealed that (1) the affinity of ACTD for the dC-dG sequence is much less than for the dG-dC sequence; (2) ACTD forms 1:1 and 2:1 drug-duplex complexes with d(TATATGCATATA) and d(TATGCATGCATA), respectively, and their SDS driven dissociations exhibit single-exponential characteristics with rates (approximately 5 X 10(-4)s-1 at 20 degrees C) slightly slower than that of poly(dG-dC).poly(dG-dC); (3) although the melting temperature of d(CATGCATGCATG) is 8-9 deg higher than that of d(TATGCATGCATA), the rates of ACTD dissociation from these two oligomers are not greatly different and binding constants of (1-5) X 10(7) M-1 have been estimated for both; (4) a 3:1 stoichiometry is exhibited by ACTD binding to duplex d(TGCATGCATGCA) and the complex dissociates with two characteristic times, the fast component (1/k = approximately 100 s) comprising 2/3 of the contribution and the slow process (approximately 2000 s) contributing the other 1/3; and (5) the slow dissociation kinetics of an oligomer appears to be correlated to the higher percentage of slow association kinetics detectable by non-stop-flow techniques.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['actinomycin'],\n",
       "  'reaction': ['dissociation', 'dissociation']},\n",
       " {'pmid': 3478929,\n",
       "  'sentence': 'From the present investigation it can be summarized that breaking strength of an incisional wound, measured with the sutures in situ, decreased markedly early after the operation in all tissues investigated if the sutures were inserted 1.5 mm from the incision; that the decrease was also found if new sutures, placed between and substituting the old, were inserted before measuring breaking strength, indicating that the decrease in strength occurs all along the wound; that breaking strength did not decrease if the sutures were inserted 3 mm from the incision; that breaking strength decreased markedly in the wounds sutured under stretching, even if the sutures were inserted 4 mm from the incision; that collagen content and solubility, and the histological appearance of the submucosal collagen layer, were only insignificantly changed in the early period after the operation; that the decrease in breaking strength was eliminated in animals made neutropenic by anti-neutrophil serum; that the decrease in breaking strength was reduced, but not eliminated, by oxygen free radical scavengers; that the decrease in breaking strength was eliminated by a group-specific serine proteinase inhibitor and was reduced, but not eliminated, by proposed collagenase inhibitors; that the serine proteinase inhibitor and the oxygen free radical scavengers did not reduce the increase in myeoloperoxidase activity in the anastomotic segment and did not, at histological examination, reduce the accumulation of neutrophils there, and that the serine proteinase inhibitor did not impair the subsequent gain in breaking strength, measured after removal of the sutures, during the fibroplasia period.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['submucosal'],\n",
       "  'reaction': ['investigation', 'wound', 'wound']},\n",
       " {'pmid': 3499193,\n",
       "  'sentence': 'The results demonstrate that 1) increased release of granulocyte-macrophage colony stimulating factor (GM-CSF) in vitro from pokeweed mitogen stimulated mouse spleen cells and from human mononuclear blood cells occurred at lowered O2 tension, and that human mononuclear blood leukocytes were more sensitive to the LF-induced suppression of GM-CSF release when cells were cultured at 5%, compared to 20%, O2 tension; 2) LF administered intravenously (IV) to mice pretreated with sublethal intraperitoneal dosages of Cytoxan decreased the cycling status of marrow and spleen granulocyte-macrophage (CFU-GM), erythroid (BFU-E-2 and BFU-E-1) and multipotential (CFU-GEMM) progenitor cells and the absolute numbers of these progenitors; these effects were most noticeable if care was taken to deplete endotoxin from the LF samples prior to testing LF in vivo and if the control medium was endotoxin free; 3) endotoxin-depleted LF decreased the cycling status of marrow and spleen CFU-GM, BFU-E, and CFU-GEMM and the numbers of these progenitors in the marrows of mice previously untreated with Cytoxan; these effects were most apparent when assessment of progenitor cells and their cycling rates were evaluated in vitro at lowered (5%) O2 tension; 4) purified natural human CSF-1 increased the absolute numbers of marrow CFU-GM and the cycling status of marrow CFU-GM and CFU-GEMM in mice pretreated with LF; and 5) purified recombinant murine IL-3 stimulated proliferation of day 8 and day 12 CFU-S (colony forming unit-spleen) in mice not previously treated with Cytoxan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cytoxan', 'medium'],\n",
       "  'reaction': ['tension', 'tension', 'tension']},\n",
       " {'pmid': 3551968,\n",
       "  'sentence': 'Peak effects were observed at 2 h. At peak effects, cardiac index increased from 2.53 to 3.07 l/min/m2 (+20%, p less than 0.01), stroke volume index from 35 to 41 ml/beat/m2 (+18%, p less than 0.05), stroke work index from 35 to 44 g X m/beat/m2 (+26%, p less than 0.05), epinephrine from 0.05 to 0.15 ng/ml (+200%, p less than 0.05), urine volume from 50 to 81 ml/h (+61%, p less than 0.05), pulmonary capillary wedge pressure decreased from 23 to 18 mmHg (-24%, p less than 0.001), mean pulmonary arterial pressure from 33 to 27 mmHg (-19%, p less than 0.001), right atrial pressure from 10 to 7 mmHg (-27%, p less than 0.001), systemic vascular resistance from 1735 to 1546 dyne X s X cm-5 (-11%, p less than 0.1), pulmonary vascular resistance from 204 to 168 dyne X s X cm-5 (-25%, p less than 0.05), arterio-venous oxygen difference from 6.09 to 5.36 ml/dl (-12%, p less than 0.05), norepinephrine from 0.45 to 0.34 ng/ml (-24%, p less than 0.1), renin activity 1.80 to 1.26 ng/ml/h (-30%, p less than 0.05), respectively, whereas there were no significant changes in blood gases, heart rate, blood pressure, double product, aldosterone, urine Na+, K+ or lactate/pyruvate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index',\n",
       "   'epinephrine',\n",
       "   'pulmonary arterial pressure',\n",
       "   'right atrial pressure',\n",
       "   'renin',\n",
       "   'blood gases',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'blood pressure']},\n",
       " {'pmid': 3793667,\n",
       "  'sentence': \"Hemodynamic parameters, including cardiac output (CO), mean aortic pressure (MAP), heart rate (HR), LV pressures and their first derivatives (dP/dt), and the LV regional dimension, were measured and compared before and every 30 min after burns were produced (up to 360 min) in four groups: group A (n = 7), dogs with sham burns; group B (n = 5), dogs with nonresuscitated full-thickness burns involving 50% of the total body surface area; group C (n = 6), dogs with burns resuscitated with lactated Ringer's solution at 4 ml X kg X % burn/24 h; and group D (n = 6), dogs with burns resuscitated with 1.5% dextran in lactated Ringer's solution at 2 ml X kg X % burn/24 h. From these measurements, we obtained the LV end-diastolic segment length (EDL) as an index of preload and three indices of cardiac contractility, i.e., peak dP/dt, the percentage of shortening (% delta L), and mean Vcf.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'body surface area',\n",
       "   'body surface area']},\n",
       " {'pmid': 3819218,\n",
       "  'sentence': 'Lung resistance was 1.5 +/- 0.3 cm H2O/L/sec in group A, 1.8 +/- 0.3 in group B, and 5.9 +/- 1.3 in group C. Trapping volume (functional residual capacity by plethysmography and by helium rebreathing technique) was 0 +/- 0.1 L in group A, 0.05 +/- 0.1 in group B, and 0.51 +/- 0.17 in group C. Upstream resistance at peak flow did not differ between any two groups, but upstream resistance near residual volume was 1.8 +/- 0.3 cm H2O/L/sec in A, 6.2 +/- 1.0 in B, and 28 +/- 6 in C. In BAL, total cells were 25 +/- 5 X 10(4)/ml in A, 35 +/- 8 in B, and 31 +/- 6 in C. Macrophages in BAL were 16 +/- 2 in A, 27 +/- 9 in B, and 24 +/- 4 in C. Neutrophils were 0.5 +/- 0.2 in A, 3.4 +/- 2.5 in B, 2.8 +/- 1.5 in C. Eosinophils were 0.1 +/- 0.1 in A, 0.5 +/- 0.2 in B, and 0.9 +/- 0.3 in C (p less than 0.05 group C versus group A).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['helium'],\n",
       "  'reaction': ['functional residual capacity',\n",
       "   'plethysmography',\n",
       "   'macrophages']},\n",
       " {'pmid': 3872972,\n",
       "  'sentence': 'Evolution of a case of chronic lymphocytic leukemia (CLL) into blast crisis was found to be characterized by three unusual features (1) the phenotype of the emerging blast cells was that of pre-plasmacytoid cells as shown by plasma cell morphology and an immunological phenotype corresponding partially with CLL- or intermediate B-cells, partially with plasma cells (terminal transferase-, common acute lymphocytic leukemia antigen-, Ia+, surface immunoglobulin heavy chains-, surface kappa light chains+, intracytoplasmic immunoglobulin A+ and G+, BA-1+, polyclonal gammaglobulin production); (2) cytogenetic analysis of spontaneous metaphases revealed that in addition to the typical CLL abnormality, trisomy 12, in all of the cells, an additional translocation between chromosomes 14 and 17 was present in 40% with a presumptive breakpoint on chromosome 14 (q12-3) never described before (commonly q32) and (3) the progression of the disease was associated with a striking increase in the expression by the transformed cells of specific binding sites for estradiol (E2) due to an actual increase in total cellular receptor proteins and not to a change in receptor affinity for E2.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['blast cells', 'plasma cells']},\n",
       " {'pmid': 3905588,\n",
       "  'sentence': 'The major epidemiological associations are: the high degree of geographic correlation between the incidence rate of BL and the intensity of P. falciparum transmission, both at a global level and within individual countries; the close correlation between the age incidence of BL and the age of acquiring maximum levels of antimalarial immunoglobulin; the relative protection from BL by residence in urban areas, where levels of malaria transmission are lower, compared with rural areas; the decline in BL incidence in areas where death rates due to malaria have declined and, within such areas, a differential decline in BL incidence in people making better use of health facilities; the older age of onset in patients who have migrated from low-intensity to high-intensity malaria areas as compared with patients born in the high-intensity areas - the higher absolute age-specific incidence rate in those above age ten in this immigrant group being consistent with the hypothesis that intense malaria infection and consequent host defence response serve as the major triggering event in the pathogenesis of the lymphoma; the inverse geographic correlation between the average age of onset of BL and the intensity of falciparum malaria infection.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['malaria',\n",
       "   'death',\n",
       "   'malaria',\n",
       "   'malaria',\n",
       "   'malaria',\n",
       "   'infection',\n",
       "   'lymphoma',\n",
       "   'malaria',\n",
       "   'infection']},\n",
       " {'pmid': 3905780,\n",
       "  'sentence': 'Upon sequencing the peptides by the automated Edman method, the following sequence was obtained: A D T N A P L C L C D E P G I L G R N Q L V T P E V K E K I E K A V E A V A E E S G V S G R G F S L F S H H P V F R E C G K Y E C R T V R P E H T R C Y N F P P F V H F T S E C P V S T R D C E P V F G Y T V A G E F R V I V Q A P R A G F R Q C V W Q H K C R Y G S N N C G F S G R C T Q Q R S V V R L V T Y N L E K D G F L C E S F R T C C G C P C R N Y Carcinoscorpius coagulogen consists of a single polypeptide chain with a total of 175 amino acid residues and a calculated molecular weight of 19,675.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['polypeptide'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 3936489,\n",
       "  'sentence': 'Stimulation of the cells by PDGF for 10 min at 37 degrees C induced the following changes in lipids: in cells prelabelled with [32P]Pi, a 28% decrease in [32P]phosphatidylinositol 4,5-bisphosphate, a 41% decrease in [32P]phosphatidylinositol 4-phosphate and a 1.7-fold increase in the 32P-labelling of phosphatidic acid; in cells prelabelled with [3H8]arachidonic acid, a 17.9-fold increase in [3H]phosphatidic acid, a 20% decrease in [3H]phosphatidylinositol (PtdIns), an 8.6-fold increase in [3H]arachidonic acid released into the medium, a 57-fold increase in [3H]prostaglandin E2 in the medium, and a 5.3-fold increase in [3H]monoacylglycerol released into the medium (the last was identified as the 2-acyl derivative); in cells prelabelled with [2-3H]glycerol, a 1.7-fold increase in [3H]diacylglycerol, a 6.7-fold increase in [3H]phosphatidic acid, a 1.6-fold increase in [3H]lysophosphatidylcholine (lysoPtdCho), a 9% decrease in [3H]PtdIns, and a 1.6-fold increase in [3H]monoacylglycerol released into the medium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['lipids']},\n",
       " {'pmid': 3981794,\n",
       "  'sentence': 'Results indicate: 1) the incidence of VT in 310 AMI patients was 16.1% (50 patients); 2) the higher incidence of ventricular fibrillation and mortalities were observed in VT group compared with non-VT group; 3) the incidence of VT was higher in inferior infarction group (21.0%) than anterior group (13.1%); 4) more frequent VT were seen in patients with more severe heart failure; 5) two peaks of VT occurrence, on the first day and in the 4th week after the onset of AMI, were recognized especially in anterior infarction group; 6) supraventricular arrhythmias were more frequent than ventricular premature beats during one minute preceding VT; 7) the successful termination of VT was achieved in 63.9% of episodes by thump-version, 61.5% by lidocaine, 66.7% by disopyramide and 100% by mexiletine; 8) prophylactic effect on VT by class Ia antiarrhythmic agents seemed stronger than others; 9) IABP was effective to prevent VT in some cases; 10) poor prognosis was determined by frequent and later onset of VT, and combination of severe heart failure.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lidocaine'],\n",
       "  'reaction': ['ventricular fibrillation', 'infarction', 'infarction']},\n",
       " {'pmid': 4042121,\n",
       "  'sentence': 'The results show that: 1) pyruvate (1 to 10 mmol X litre-1) decreases and then increases contractile force in Tyrode solution or in the presence of a low concentration of strophanthidin without modifying the action potential magnitude or configuration; 2) during the decreasing (but not the increasing) phase of strophanthidin (2 to 5 X 10(-7) mol X litre-1) inotropy, pyruvate increases contractile force; 3) beta-hydroxybutyrate has effects similar to those of pyruvate; 4) glucose increases contractile force and more so during the descending phase of strophanthidin inotropy; 5) the positive inotropic effect of pyruvate during declining strophanthidin inotropy is not prevented by glucose-lack and/or by iodoacetate but is markedly reduced in a hypoxic solution; 6) in contrast, glucose under similar conditions has the usual effects in hypoxia but not in the presence of iodoacetate; 7) the combination of hypoxia and glucose-lack leads to a decline in contractile force and to contracture: strophanthidin increases both contractile and resting force whereas O2 and/or glucose relax the contracture; 8) pyruvate has a positive inotropic effect also in the presence of high (greater than 10 mmol X litre-1) calcium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hypoxia', 'hypoxia']},\n",
       " {'pmid': 4813892,\n",
       "  'sentence': 'Analysis of protein degradation during the life cycle of Blastocladiella emersonii showed that (i) protein degradation is especially high during two phases of differentiation (sporulation, 12%/h and germination, 5%/h) in contrast with a much smaller degradation rate in the other phases (growth and zoospores, less than 1%/hr); (ii) protein degradation during germination in growth medium, as well as most of the germination process, is quantitatively unaffected by cycloheximide; (iii) a caseinolytic protease (pH optimum 5.5, apparent molecular weight 55,000 to 60,000) is present in extracts of zoospores and germinating cells; (iv) this protease activity is very low (perhaps absent) in extracts of late growth phase cells, but reappears during induced sporulation; (v) a different class of caseinolytic protease activity (pH optima 7 and 10; apparent molecular weight 25,000 to 30,000) is found in cellular extracts of late growth phase and early phases of sporulation; (vi) the latter class of enzyme activity is released into the medium during later phases of sporulation and is replaced in the cells by the former class.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth',\n",
       "   'growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth',\n",
       "   'enzyme activity']},\n",
       " {'pmid': 5270206,\n",
       "  'sentence': \"As there was evidence to suggest that this second series of pneumonic cases was less suitable for cultural examination than the first series, some of the other factors that might have improved the recovery rate were investigated.Some improvement was probably achieved by inoculating the liquid medium with three or four different dilutions of pneumonic tissue, each dilution always being in duplicate, and by incubating the inoculated tubes for over 3 weeks before discarding them.A second advantage could have derived from the fact that all batches of liquid medium were tested for their ability to support the growth of M. suipneumoniae before being used to culture field material.THE EFFECT OF VARYING ONE CONSTITUENT AT A TIME WAS OBSERVED IN CONTROLLED EXPERIMENTS: different batches of pig sera had a marked, variable effect on the growth of both M. suipneumoniae and Mycoplasma hyorhinis; medium made with purchased Hartley's broth was found to be superior to medium incorporating broth made in this laboratory, more so for the growth of M. suipneumoniae than M. hyorhinis; the incorporation of yeast extract made in this laboratory gave a marginal advantage for the growth of M. hyorhinis; and both mycoplasmas grew equally well in medium containing or lacking thallium acetate.Some batches of medium were, by chance, markedly selective for the growth of M. suipneumoniae compared with M. hyorhinis.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['thallium', 'medium'],\n",
       "  'reaction': ['growth', 'growth', 'growth', 'growth', 'growth']},\n",
       " {'pmid': 6159029,\n",
       "  'sentence': '1 The vascular relaxant effects of histamine, adenosine, isoprenaline nitroglycerine, papaverine and 3-isobutyl-l-methylxanthine (IBMX) were assessed individually, in strips of rabbit renal artery moderately contracted with noradrenaline (NA) in the absence or presence of phosphodiesterase inhibitors (papaverine and IBMX) or verapamil, a Ca(2+) antagonist.2 The vasodilator effect of histamine was potentiated by papaverine (6.1 x 10(-7) M) and IBMX (4.4 x 10(-5) M) but inhibited dose-dependently by verapamil (5.1 and 51.0 x 10(-7) M).3 Adenosine-induced vascular relaxations were greatly increased in the presence of papaverine (6.1 x 10(-7) M) but significantly reduced in the presence of IBMX (4.4 x 10(-5) M) or verapamil (5.1 and 51.0 x 10(-7) M).4 The vasodilatation produced by isoprenaline was increased in the presence of IBMX (4.4 x 10(-5) M) or papaverine (6.1 x 10(-7) M), but inhibited by verapamil (5.1 and 51.0 x 10(-7) M).5 The vascular relaxant effects of nitroglycerine and papaverine were inhibited in the presence of IBMX (4.4 x 10(-5) M) or verapamil (5.1 and 51.0 x 10(-7) M).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['papaverine', 'verapamil'],\n",
       "  'reaction': ['vasodilatation']},\n",
       " {'pmid': 6209475,\n",
       "  'sentence': 'Caffeine was found to: (a) increase the contractile force quickly and then slowly in a dose-dependent manner, causing contracture only at high concentrations; (b) shift to more positive values and shorten the plateau, slow the final phase III repolarization, and cause a slow return of potential to the resting value during diastole at high concentrations; (c) increase the magnitude but retard the relaxation of the twitch; (d) cause these effects independently of alpha- or beta-adrenergic mechanisms; (e) shift the plateau to more negative values in the absence of calcium; (f) shift the plateau of the slow response action potentials to more positive values and increase the contractile force without prolonging the late phase III in high K; (g) induce less pronounced effects in the presence of local anesthetics or tetrodotoxin; (h) still increase force in the presence of manganese, verapamil, and ryanodine; (i) induce more pronounced effects in the presence of strophantidin; and (j) retard the fall in contractile force on exposure to zero calcium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'verapamil'],\n",
       "  'reaction': ['manganese', 'fall']},\n",
       " {'pmid': 6235735,\n",
       "  'sentence': 'Cardiac index increased 38% over baseline (from 1.9 +/- 0.4 to 2.6 +/- 0.4 liters/min/m2, p less than 0.01), arteriovenous oxygen difference decreased by 30% (from 8.0 +/- 1.4 to 5.6 +/- 1.2 vol%, p less than 0.01), heart rate increased by 8% (from 85 +/- 16 to 92 +/- 16 beats/min, p less than 0.05), stroke volume index increased by 22% (from 23 +/- 5 to 28 +/- 4 ml/beat/m2, p less than 0.05), left ventricular stroke work increased by 24% (from 18 +/- 5 to 22 +/- 5 g-m/m2, p less than 0.01), mean arterial pressure decreased by 10% (from 79 +/- 6 to 71 +/- 9 mm Hg, p less than 0.01), mean right atrial pressure decreased by 40% (from 10 +/- 5 to 6 +/- 4 mm Hg, p less than 0.01), and mean pulmonary artery wedge pressure decreased by 36% (from 22 +/- 5 to 14 +/- 6 mm Hg, p less than 0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac index',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'mean arterial pressure',\n",
       "   'right atrial pressure']},\n",
       " {'pmid': 6292441,\n",
       "  'sentence': 'We describe here a process subsequent to sequestration involving internalization and degradation of bound nerve growth factor and showing that bound nerve growth factor is not degraded under the following conditions: (1) low temperature, ie 4 degrees C; (2) when a large excess of unlabeled nerve growth factor is added concomitantly with the labeled nerve growth factor and the temperature is raised from 4 degrees C to 37 degrees C; (3) when metabolic inhibitors sodium fluoride and dinitrophenol are added concomitantly with the labeled nerve growth factor and the temperature is raised from 4 degrees to 37 degrees C. On the other hand, conditions that allow bound nerve growth factor to be degraded are the following: (1) incubation of the sensory nerve cells at low temperature (ie, 4 degrees C) only in the presence of labeled nerve growth factor, then raising the temperature to 37 degrees C; (2) when sodium fluoride and dinitrophenol are added when the temperature is raised to 37 degrees C; (3) when excess unlabeled nerve growth factor is added when the temperature is raised to 37 degrees C. These studies are consistent with the idea that nerve growth factor has to bind to the cells in order to be degraded; however, binding is not sufficient for degradation to occur.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['growth',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'fluoride',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'fluoride',\n",
       "   'growth',\n",
       "   'growth']},\n",
       " {'pmid': 6470325,\n",
       "  'sentence': 'Compared with group A, patients in group B had greater anterior ST elevation (1.2 versus 0.7 mV, p less than 0.025); higher serum peak creatine kinase (2,475 versus 1,147 IU/liter, p less than 0.005); higher Killip scores (2.1 versus 1.3, p less than 0.001); more in-hospital complications (60 versus 17%, p less than 0.05); lower mean left ventricular ejection fraction (34 versus 55%, p less than 0.001); more frequent regional left ventricular dysfunction in anterolateral (91 versus 44%, p less than 0.05), posterolateral (36 versus 0%, p less than 0.05) and inferior (100 versus 6%, p less than 0.005) regions; greater wall motion abnormality scores (10.0 versus 5.5, p less than 0.005); higher frequency of concomitant left circumflex or right coronary artery disease, or both (80 versus 28%, p less than 0.01); more frequent postinfarction angina (100 versus 39%, p less than 0.001) and lower New York Heart Association functional classification scores (1.7 versus 2.4, p less than 0.05) at 6 month follow-up.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['ejection fraction',\n",
       "   'ejection fraction',\n",
       "   'left ventricular dysfunction',\n",
       "   'ventricular dysfunction',\n",
       "   'coronary artery disease']},\n",
       " {'pmid': 6492174,\n",
       "  'sentence': 'The following results were obtained: (1) Caffeine (9 mM) quickly abolished the arrhythmias induced by strophanthidin (10(-6)M) in Purkinje fibers by inducing quiescence at a depolarized level; (2) A lower concentration of caffeine (3 mM) hastened the appearance of the arrhythmias by favoring the onset of spontaneous activity at a depolarized level but abolished the oscillatory potential at lower strophanthidin concentrations (2-5 X 10(-7)M); (3) Caffeine (9-10 mM) abolished the oscillatory potentials and after-contractions induced by cardiotonic steroids in ventricular muscle fibers; (4) Caffeine prevented the induction of oscillatory potentials and of arrhythmias by cardiotonic steroids; (5) In the presence of cardiotonic steroids and norepinephrine, the oscillatory potentials can induce fast discharge in myocardial fibers which is eliminated by caffeine; (6) High calcium and norepinephrine (singly or together) induce oscillatory potentials and after-contractions which are abolished by caffeine; (7) The elimination of the oscillatory potentials by caffeine in myocardial fibers is associated with the development of contracture.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['discharge']},\n",
       " {'pmid': 6522878,\n",
       "  'sentence': 'In the patients over 65 years old, compared to those under the age of 65, we observed that: the previous condition of the cardiac valves was more commonly unknown (39% compared to 21%), rheumatic valvular disease was rare (12% of cases), the diagnosis was not delayed, the reason for hospital admission was usually a complication (30% compared to 7%), the two cardinal signs (pyrexia and a cardiac murmur) were always present, as in the younger age group, the urinary tract was the only commoner site of primary infection, the blood cultures were as frequently positive in both groups (79% compared to 85%), in cases with negative blood cultures, antibiotics had not always been given beforehand, but this was commoner than in the younger age group, the causal organisms and usual biological changes were unremarkable, echocardiography, often more difficult because of the high incidence of valvular thickening, remained a valuable tool for diagnosis and management, cardiac failure was more common (55% compared to 37%) as were neurological complications (24% compared to 10%) and renal failure, mortality was greater (39% compared to 25%) and higher in both groups in patients with aortic valve disease and infection with staph-aureus.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['condition',\n",
       "   'pyrexia',\n",
       "   'cardiac murmur',\n",
       "   'infection',\n",
       "   'cardiac failure',\n",
       "   'renal failure',\n",
       "   'aortic valve disease',\n",
       "   'infection']},\n",
       " {'pmid': 6588243,\n",
       "  'sentence': 'The following conclusions and speculations can be tentatively drawn from the changes in lipoprotein composition and metabolism: (1) The presence of apo B-48 in serum VLDL and the high serum apo A-IV concentrations indicate a greater than normal contribution of alimentary remnant particles to the hypertriglyceridemia of uremic patients, (2) The presence of apo E and C in triglyceride-enriched serum LDL, together with the triglyceride enrichment of all lipoproteins, probably stems from a deficiency of lipoprotein lipase (LPL) and hepatic lipase (HL) activity, (3) The decreased ratio of serum apo C-II/C-III in VLDL is at least in part responsible for the depressed activity of LPL, (4) The accumulation of lipoprotein particles with distorted apoprotein and lipid patterns (particularly beta-VLDL with enrichment in cholesterol) could be associated with an increased atherogenesis because a recent study has demonstrated a strong association between raised serum IDL and VLDL concentrations and the degree of coronary atherosclerosis, (5) The increased apo E content of VLDL and HDL in uremic patients could particularly point to a disturbed cholesterol metabolism because such lipoproteins could interact with LDL at apo B, E receptors, (6) The decrease in serum HDL-cholesterol has been shown to be strongly associated with atheromatous vascular disease, and this could also hold for uremic patients; however, it is probable that low serum HDL-cholesterol together with a diminished capacity to form cholesterol-rich, apo E containing HDL represents a decrease in the antiatherogenic defense of the organism rather than an increased atherogenic potential [21].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['lipase', 'lipase', 'lipase', 'lipase']},\n",
       " {'pmid': 6602637,\n",
       "  'sentence': 'In the process of evaluating roles for purified preparations of lactoferrin, transferrin and acidic isoferritins in the regulation of myelopoiesis, it was found that: (1) values reported for lactoferrin in the serum and plasma of normal donors are in most cases an over-estimation, (2) lactoferrin suppresses the production/release of granulocyte-macrophage colony stimulatory factors (GM-CSF) from monocytes in the absence of T-lymphocytes and also suppresses the production/release of acidic isoferritin-inhibitory activity from monocytes, (3) lactoferrin, transferrin and acidic isoferritins act on their specific target cells which express Ia-like antigens, (4) lactoferrin and transferrin act in vivo to suppress rebound myelopoiesis in mice recovering from sublethal dosages of Cytoxan, with preliminary observations suggesting that lactoferrin has a greater apparent effect on the bone marrow and transferrin has a greater apparent effect on the spleen, (5) active lactoferrin derives from Fc receptor positive subpopulations of PMN from patients with CML as well as from normal donors, but the percentage of Fc receptor containing PMN is lower in CML, as is the amount of active lactoferrin found in their PMN, and (6) lactoferrin, transferrin and acidic isoferritins suppress the colony formation of U937 clonogenic cells, with lactoferrin and transferrin decreasing the release of growth factors from U937 cells which are needed to stimulate U937 colony formation, and lactoferrin and acidic isoferritins suppress the colony formation of WEHI-3 cells, with lactoferrin decreasing the release of growth factors from WEHI-3 cells which are needed to stimulate WEHI-3 colony formation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cytoxan'],\n",
       "  'reaction': ['transferrin',\n",
       "   'transferrin',\n",
       "   'transferrin',\n",
       "   'transferrin',\n",
       "   'transferrin',\n",
       "   'transferrin',\n",
       "   'growth',\n",
       "   'growth']},\n",
       " {'pmid': 6609962,\n",
       "  'sentence': 'We found that: a) thoracic duct lymphocytes (TDL) were similar in their proportion of T cells (83% +/- 6 OKT3+), OKT4+ subset (65% +/- 8), and OKT8+ subset (22% +/- 6) to peripheral blood lymphocytes (PBL): b) fewer natural killer-like cells were present in TDL (5% +/- 4 Leu-7+; 2% +/- 2 Leu-11+: 8% +/- 2 OKM -1+) than in PBL (20% +/- 10 Leu-7+: 11% +/- 6 Leu-11+; 18% +/- 5 OKM -1) (p less than 0.01); c) TDL differed from synovial fluid lymphocytes ( SFL ) and synovial membrane lymphocytes ( SML ) in that TDL lacked a high percentage of activated lymphocytes (T cells bearing Ia antigen, OKT10 , and transferrin receptor): d) immature T cells (expressing either OKT6 antigen or reactive with peanut agglutinin) were not found in TDL even late in the course of TDD: and e) in vitro functional studies demonstrated that TDL were similar to PBL in their ability to synthesize immunoglobulin after mitogen stimulation and to generate cytotoxic T lymphocytes capable of lysing autologous EBV-transformed B cells.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['transferrin']},\n",
       " {'pmid': 6662128,\n",
       "  'sentence': '(1) delays the decay velocity of myocardial ATP by a factor of 7-8 in comparison with pure ischaemia; (2) leads to a good myocardial recovery with regard to metabolic, morphological, and functional criteria after an ischaemic stress of 300 min at 23 +/- 1 degrees C--especially after the addition of quinine; (3) is considerably reduced in its protective efficacy by adding 50 mumol l-1 Ca2+; (4) causes a calcium paradox if it is infused for 30 min at 35 degrees C; this does not happen if it is infused for 60 min at 25 degrees C or for 120 min at 15 degrees C; on adding 50 mumol l-1 Ca2+ to the solution the risk of a calcium paradox is significantly reduced, even after infusion for 35 min at 35 degrees C; (5) effects an evident delay of recovery, if a continuous ischaemic stress of 300 min at 23 degrees +/- 1 degree C is reduced to 3 X 100 min of ischaemia at 17 +/- 1 degrees C by intermittent cardioplegic reperfusion; (6) considerably improves the myocardial recovery even after intermittent cardioplegia if 50 mumol l-1 Ca2+ are added or Mg2+ is reduced from 9 to 4 mmol l-12.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'paradox'],\n",
       "  'reaction': ['ischaemia', 'stress', 'infusion', 'stress', 'ischaemia']},\n",
       " {'pmid': 6684130,\n",
       "  'sentence': 'Results of feeding low (2.2 kg), medium (3.8 kg), or high (6.9 kg) concentrate dry matter daily per cow were: concentrate as a percent of total dry matter consumed, 12.2, 20.2, and 37.1%; dry matter intake from forage, 15.6, 14.5, and 11.6 kg/day; dry matter intake as percent of body weight, 3.25, 3.32, and 3.33; crude fiber as percent of dry matter consumed, 25.2, 23.6, and 20.5; crude protein as percent of dry matter consumed, 15.7, 15.4, and 15.1; total digestible nutrients consumed per day, 10.8, 11.4, and 12.2 kg; milk produced as milk/day, 18.7, 19.9, and 21.3 kg; fat-corrected milk/day, 18.6, 20.0, and 20.7 kg; fat-corrected milk as percent of body weight, 3.44, 3.68, and 3.78; and fat-corrected milk as gram per weight kg .75, 166, 178, and 183; fat content of milk, 4.00, 4.11, and 3.92%; protein content of milk, 3.49, 3.58, and 3.61%; gross efficiency of milk production, .591, .579, and .595 kg total digestible nutrients/kg fat-corrected milk; and net efficiency, .304, .308, and .332 kg total digestible nutrients/kg fat-corrected milk.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight', 'weight', 'weight']},\n",
       " {'pmid': 6686521,\n",
       "  'sentence': 'To examine the relationship between the sleep rhythm and the gonadal feedback system in the guinea pig, the effects of estrous cycle, gonadal steroids and brain deafferentiations on the sleep rhythm were studied and the following results were obtained; 1) the guinea pigs did not show an apparent circadian rhythmicity in the sleep-wakefulness cycle but showed an ultradian rhythm, whereas, the activity rhythm was circadian, 2) the rhythm in paradoxical sleep(PS) showed changes associated with the estrous cycle which were characterized by a decrease and rebound-like increase in PS amounts on the day of proestrus, 3) the horizontal deafferentation above the medial preoptic area at the level of the anterior commissure (MPO roof cut) did not disrupt the estrous cycle dependent changes in the PS rhythm, but the prechiasmatic deafferentiation of the medial basal hypothalamus (PCD) and the large complete deafferentation of the medial basal hypothalamus (CDL) disrupted them, 4) ovariectomy (OVX) did not result in any changes in sleep and activity rhythms, 5) an administration of estradiol benzoate (E2) to OVX guinea pig caused a decrease in the amount of PS and an administration of progesterone (P) 48h after E2 caused a more pronounced decrease and rebound-like increase in the amount of PS, 6) the MPO roof cut did not affect the steroidal modification of the PS rhythm and the PCD disrupted it, while the CDL-animal also showed a E2-induced PS decrease.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 6695728,\n",
       "  'sentence': 'The study revealed that (1) caffeine induces an oscillatory potential (Vos) superimposed on early diastolic depolarization in driven fibers; (2) Vos magnitude increases (within limits) with the concentration of caffeine (0.5 to 3 mM) and as a function of time of exposure; (3) if the drive is interrupted, Vos may attain the threshold and initiate spontaneous repetitive activity; (4) caffeine increases the rate of discharge in spontaneously active fibers, also through a Vos; (5) Vos shows the same characteristics as under other conditions of calcium overload; that is, it disappears after a long pause, increases after a shorter pause, can be suppressed by overdrive and can initiate spontaneous discharge at normal or depolarized levels; (7) Vos is dependent on cellular calcium as it appears at lower caffeine concentrations in fibers that are loaded with calcium by increasing extracellular calcium concentration [Ca]o, by decreasing extracellular sodium concentration [Na]o or by administering strophanthidin; (8) caffeine-induced Vos is made to peak sooner and to initiate fast spontaneous rhythms by norepinephrine; (9) Vos is reduced by low [Ca]o but not by propranolol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'propranolol', 'sodium'],\n",
       "  'reaction': ['discharge', 'discharge']},\n",
       " {'pmid': 6761139,\n",
       "  'sentence': 'Several criteria have been met to prove that prostanoids mediate erythropoiesis: 1) several E-type prostaglandins (PGE2, 15-methyl prostaglandin E2, 16,16-dimethyl E2, 6-keto-E1 and PGE1) produced a significant increase in radioiron incorporation in red cells of exhypoxic polycythemic mice; 2) prostaglandin E2 increased kidney production of erythropoietin in the isolated perfused dog kidney; 3) arachidonic acid, a precursor for all bisenoic prostaglandins, increased kidney production of erythropoietin in the isolated perfused dog kidney which was blocked by pretreatment with the cyclo-oxygenase inhibitor drug indomethacin; 4) hypoxemic perfusion of the isolated perfused dog kidney increased kidney production of erythropoietin and produced an elevation in prostacyclin in the perfusates; 5) albuterol, a beta-2 adrenergic agonist, produced a significant increase in perfusate levels of erythropoietin and PGE in the isolated perfused dog kidney; 6) renal ischemia increased Ep and PGE levels in renal venous plasma which was blocked by pretreatment with indomethacin; 7) prostaglandin E2 and arachidonic acid produced a significant increase in erythroid colonies (CFU-E) in vitro in normal mouse bone marrow; 8) E-type prostaglandins (15-methyl E2) increased in vivo erythroid colony (CFU-E) formation in bone marrows of post-hypoxic polycythemic mice; and 9) injections of 15-methyl E2 daily for six weeks in normal and hypoxic mice produced a significant elevation in the total circulating red cell mass.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['albuterol'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 6774229,\n",
       "  'sentence': 'In the present report we have provided experimental evidence that; (i) hypoxia of cardiac cells resulted in the production of adenosine (and its degradative products) which can be responsible for the hypoxic dilation observed by several workers; (ii) the release of metabolites such as potassium and inorganic phosphate was unchanged due to a 30-minute hypoxia of cardiac cells; (iii) the release of prostaglandin E but not F was enhanced due to hypoxia of cardiac cells which may be due to the storage pools in the cells; (iv) prostaglandin E1, E2 and F2 alpha inhibited the uptake of adenosine at pharmacological concentrations but not at physiological concentrations; (v) prostaglandin synthetase inhibitors (aspirin and indomethacin) nonspecifically inhibited the uptake of adenosine in the cardiac cells; (vi) lowering of pH resulted in inhibition in the uptake of adenosine and its incorporation into adenine nucleotides in cardiac cells; (vii) lowering the pH of the perfusion medium resulted in the increased release of perfusate adenosine (and its degradative products) with a simultaneous increase in coronary blood flow; (ix) specific adenosine receptor sites were found in cardiac muscle, coronary arteries, and carotid arteries of the dog and rabbit aorta, which satisfy the basic characteristic of receptor binding; and (x) these receptor binding sites were different from the adenosine uptake protein and were competitively blocked by theophylline or aminophylline.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium', 'cardiac', 'potassium'],\n",
       "  'reaction': ['hypoxia', 'hypoxia', 'hypoxia']},\n",
       " {'pmid': 6821310,\n",
       "  'sentence': 'Relative to sham operated rats, endocrine effects of the ovarian grafts were as follows: 1) Animals with ovarian grafts showed an advancement of puberty, 2) rats with bilateral grafts showed more 5 day estrous cycles and higher FSH levels, 3) hemi-ovariectomy of animals with bilateral grafts produced a greater increase in both LH and FSH 6-8 hr post-surgery in contrast to controls which only showed an increase in serum FSH levels, 4) weights of the bilateral grafts were comparable to intact ovaries, but the unilateral grafts were small and comparable to their original size at the time of transplantation (the intact ovary showing compensatory hypertrophy), 5) both control and bilateral ovarian graft groups showed ovarian compensatory hypertrophy, 6) removal of the small unilateral ovarian graft had no detectable endocrine effect on the remaining intact ovary which had already undergone compensatory hypertrophy, 7) removal of the intact ovary of rats with a unilateral graft produced a remarkable increase in the weight of the remaining small autograft such that these animals had the largest remaining gonad as well as higher uterine weights than controls.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'weight',\n",
       "   'weight']},\n",
       " {'pmid': 6839060,\n",
       "  'sentence': 'This contraction was also abolished after storage at 4 degrees C for 7 days or incubation in Na-deficient or Ca-free medium.3 After treatment with G-I (3 x 10(-5) M), which did not alter the tension of the preparation, transmural stimulation (10-50 Hz, 0.5 ms, supramaximal voltage, for 3 s) induced a slower contraction (second contraction) following the first rapid contraction caused by stimulation.4 The second contraction was inhibited or abolished by reserpine (2 mg/kg on 2 days), phentolamine (2 x 10(-7) M and 10(-6) M) and TTX (2 x 10(-8) M), but was not affected by atropine (10(-6) M) and mecamylamine (3 x 10(-5) M).5 G-I (3 x 10(-5) M) shifted the dose-response curves for noradrenaline (NA), acetylcholine and high-K contractions to the left in a parallel manner and slightly increased the maximal response to these agonists.6 G-I (3 x 10(-4) M) caused a release of endogenous NA from the vas deferens which was approximately 120 times that of control preparations.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['reserpine'],\n",
       "  'reaction': ['tension']},\n",
       " {'pmid': 6871235,\n",
       "  'sentence': 'The main characteristics of the plasma lipoprotein spectrum, as determined by sequential and density gradient preparative ultracentrifugation, analytical ultracentrifugation and gel filtration chromatography, were (1) a low concentration of very-low-density components (d less than 1.006 g/ml, about 20 mg/100 ml); (2) a continuity between the low (1.006-1.063 g/ml) and high (1.063-1.21 g/ml) density components, the former (about 150 mg/100 ml) exhibiting a considerable heterogeneity upon polyacrylamide gel electrophoresis while the latter were largely predominating (570 mg/100 ml); (3) the presence, at a density of 1.087 g/ml, of a band migrating electrophoretically like human low-density lipoproteins, a finding consistent with the results of apolipoprotein electrophoresis, which showed the presence of a high-molecular-weight counterpart to apolipoprotein B, in both the low- and high-density ranges defined above; (4) the presence, throughout the entire density spectrum, of an apolipoprotein with molecular weight and mobility in polyacrylamide/urea gels similar to human apolipoprotein A-I, and (5) the presence of very-high-density lipoproteins (d 1.178-1.259 g/ml) responsible for the transport of approximately 15% of plasma cholesterol and 20% of phospholipids.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['apolipoprotein b', 'weight', 'weight', 'mobility']},\n",
       " {'pmid': 6987108,\n",
       "  'sentence': 'Are thus reviewed: (1) the research on the influence of racial or genetic factors in pemphigus vulgaris; (2) the striking differences between the immunological criteria of the two; (3) the clinical polymorphism of pemphigus: besides pemphigus superficialis, non-bullous forms, usually milder, of various types: herpetiformis, circinate ... are now being described; (4) the importance in all cases of eosinophilic spongiosis; (5) the clinical monomorphism of classical bullous pemphigus; on the contrary, the differences, both from clinical and prognostic points of view, in localized bullous pemphigoid (from the benign mucocutaneous form to the severe scarring disease) and in bullous pemphigoid of children; (3) the cases of genuine pemphigus induced by drugs (D-penicillamine, rifampicine) and the problem of the pemphigus-like antibodies; (7) bullous pemphigoid, UV light and practolol; (8) the outstanding association of two major immune diseases, pemphigus vulgaris, myasthenia and thymoma; (9) the mixed bullous dermatoses: pemphigus vulgaris and dermatosis herpetiformis (to separate from herpetiform pemphigus), bullous pemphigoid and dermatosis herpetiformis (bringing up the unsolved problem of mixed or intermediate forms of the two diseases), bullous pemphigoid and pemphigus vulgaris, exceptionally seen, and (10) some news on therapy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['practolol'],\n",
       "  'reaction': ['pemphigus',\n",
       "   'pemphigus',\n",
       "   'pemphigus',\n",
       "   'pemphigus',\n",
       "   'pemphigoid',\n",
       "   'pemphigoid',\n",
       "   'pemphigus',\n",
       "   'pemphigoid',\n",
       "   'pemphigus',\n",
       "   'thymoma',\n",
       "   'pemphigus',\n",
       "   'dermatosis',\n",
       "   'pemphigus',\n",
       "   'pemphigoid',\n",
       "   'dermatosis',\n",
       "   'pemphigoid',\n",
       "   'pemphigus']},\n",
       " {'pmid': 7195292,\n",
       "  'sentence': 'Incubation of the ileum with clondine (1.0 mum) for 0.5 h at 37 degrees C did not increase responsiveness to phentolamine.2 The increase in responsiveness to phentolamine was directly related to the clonidine concentration in the incubation fluid over the range 0.01 to 1.0 mum.3 The magnitude of the contracture to phentolamine of ilea incubated with clonidine (1.0 mum) (withdrawal contracture) was directly related to the challenge dose of phentolamine over the range 0.3 to 1.0 mum.4 Yohimbine (1.0 mum) or piperoxane (1.0 mum) elicited a response comparable to that elicited by phentolamine but propranolol (1.0 mum) was inactive.5 Addition of phentolamine (1.0 mum) to clonidine (1.0 mum) in the incubation fluid abolished the increased response of the preparation to subsequent challenge with phentolamine.6 Addition of hyoscine (0.5 mum) immediately after challenge with phentolamine restored the tension of the withdrawal contracture to its resting level.7 Tetrodotoxin (3.0 mum) given before challenge, prevented phentolamine from eliciting a withdrawal contracture.8 Ileal segments incubated with clonidine (1.0 mum) were unresponsive to challenge with naloxone (100 nm); and segments incubated with normorphine (1.0 mum) were unresponsive to phentolamine (1.0 mum), although responsive to naloxone.9 Normorphine (1.0 mum) restored to resting level the tension of the clonidine withdrawal contracture; and clonidine (0.1 mum) restored to resting level the tension of the contracture to naloxone in ileal segments incubated with normorphine.10 These experiments indicate that incubation with clonidine induces, in the final cholinergic motor neurones of the myenteric plexus of the isolated ileum, a dependence the withdrawal from which is expressed as a contracture in response to alpha-adrenoceptor antagonists.11 Although opiate receptors are not involved in clonidine dependence nor alpha-adrenoceptors in opiate dependence, the findings that normorphine suppresses the clonidine withdrawal-contracture and that clonidine suppresses the contracture of opiate-dependent ileum to naloxone, suggest that the withdrawal effect studied in both clonidine and normorphine dependence in this preparation is mediated by release of acetylcholine from the final motor neurone.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol'],\n",
       "  'reaction': ['tension',\n",
       "   'tension',\n",
       "   'tension',\n",
       "   'dependence',\n",
       "   'dependence',\n",
       "   'dependence',\n",
       "   'dependence']},\n",
       " {'pmid': 7270912,\n",
       "  'sentence': 'This investigation demonstrated that: (1) Data from untouched animals cannot serve as proper controls because treatment with SAL altered the level of the MI, but only during the diurnal, not the nocturnal, phase of the circadian cycle; (2) the presence of the EAC depressed the level of the MI, but this inhibition was only detected during the diurnal period; (3) treatment with 500 mg/kg HU injected at 0500 caused more perturbation in this rhythm than did treatment with 500 mg/kg HU at 1700; (4) when 500 mg/kg HU was given at 2000 and 0100 and 0500, the perturbation of the rhythm was greater than when 500 mg/kg HU was given at 0900 and 1400 and 1700; (5) when 3000 mg/kg HU was given at 1700 and compared to 500 mg/kg HU at 1700, little difference in the overall circadian profiles of these rhythms was observed, indicating that the circadian control mechanisms operating on the MI exerted a greater influence than did a dosage change from 500 to 3000 mg/kg HU; and (6) a comparison of the practice of plotting experimental and control data as \"hours after treatment\" versus using a \"time of day\" plot for the same data demonstrated that the \"hours after treatment\" plot is very misleading because it fails to account for the significant circadian oscillation in this in vivo system.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sal'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 7449120,\n",
       "  'sentence': 'Serum was separated after blood was allowed to stand, for 0, 2, 4, 6, 8, 24, or 48 h at 4, 23, or 30 degrees C. Results obtained for bilirubin, albumin, zinc sulfate turbidity, thymol turbidity, cholinesterase (EC 3.1.1.8), alkaline phosphatase (EC 3.1.3.1), leucine aminopeptidase (EC 3.4.11.1), amylase (EC 3.2.1.2), total cholesterol, triglycerides, beta-lipoprotein, serum urea nitrogen, creatinine, uric acid, and gamma-glutamyltransferase (EC 2.3.2.2) were not influenced by storage at 4, 24, or 30 degrees C for as long as 48 h. Negligible differences were seen for potassium in sera in contact with cells as long as 24 h at 23 degrees C and for inorganic phosphorus after 48 h at 4 degrees C. However, at 4 degrees C we noted an increase at 8 h, a slight decrease at 30 degrees C. Statistically significant changes were seen for total protein and calcium after 48 h at 30 degrees C; for aspartate aminotransferase (EC 2.6.1.1), and alanine aminotransferase (EC 2.6.1.2), between 8 and 24 h at 23 degrees C and as soon as 6 h at 30 degrees C; for lactate dehydrogenase (EC 1.1.1.27) after 8 h at 30 degrees C and between 8 and 24 h at 23 degrees C; for glucose at 24, 4, or 2 h of storage at 4, 23, or 30 degrees C, respectively; for inorganic phosphorus after 48 h at 23 degrees C or 8 h at 30 degrees C; for potassium after 4 h at 4 degrees C or 24 h at 30 degrees C; and for sodium after 48 h at 4 degrees C or 6 h at 23 or 30 degrees C.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'sodium', 'cholesterol', 'potassium'],\n",
       "  'reaction': ['amylase',\n",
       "   'amylase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'alanine aminotransferase']},\n",
       " {'pmid': 7612816,\n",
       "  'sentence': 'The salient results are as follows: 1) an odd-even effect is observed for the SCC versus carbon position, k, whose amplitude increases with temperature; 2) calculation of SCC, from nonequivalent deuterons on the sn-2 chain of lipids, SCC2, leads to negative values, indicating the tendency for the C1-C2 bond to be oriented parallel to the bilayer surface; this bond becomes more parallel to the surface as the temperature increases or when cholesterol is added; 3) calculation on the sn-2 chain length can be performed from C1 to Cn, where n is the number of carbon atoms in the chain, and leads to 10.4, 12.2, and 13.8 A for DLPC, DMPC, and DPPC close to the transition temperature, TC, of each of the systems and to 9.4, 10.9, and 12.6 for T-TC = 30-40 degrees C, respectively; 4) separation of intra- and intermolecular motions allows quantitation of the number of gauche defects per chain, which is equal to 1.9, 2.7, and 3.5 for DLPC, DMPC, and DPPC near TC and to 2.7, 3.5, and 4.4 at T-TC = 30-40 degrees C, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['lipids']},\n",
       " {'pmid': 7718371,\n",
       "  'sentence': 'Dobutamine consistently increased mean splanchnic blood flow (control 0.6 (SD 0.2) vs 0.7 (0.2) litre min-1 m-2 (P < 0.05); normal cardiac output and dobutamine 0.7 (0.2) vs 1.1 (0.4) litre min-1 m-2 (P < 0.01); low cardiac output and dobutamine 0.4 (0.1) vs 0.7 (0.1) litre min-1 m-2 (P < 0.05)) and oxygen delivery (control 102 (29) vs 111 (28) ml min-1 m-2 (ns); normal cardiac output and dobutamine 106 (27) vs 156 (47) ml min-1 m-2 (P < 0.01); low cardiac output and dobutamine 75 (21) vs 110 (26) ml min-1 m-2 (P < 0.05)) but had no effect on splanchnic oxygen consumption (control 44 (10) vs 49 (10) ml min-1 m-2 (ns); normal cardiac output and dobutamine 45 (12) vs 51 (17) ml min-1 m-2 (ns); low cardiac output and dobutamine 37 (9) vs 40 (9) ml min-1 m-2 (ns)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output',\n",
       "   'cardiac output',\n",
       "   'delivery',\n",
       "   'cardiac output',\n",
       "   'cardiac output',\n",
       "   'oxygen consumption',\n",
       "   'oxygen consumption',\n",
       "   'cardiac output',\n",
       "   'cardiac output']},\n",
       " {'pmid': 7726130,\n",
       "  'sentence': 'The recommendations are as follows: (1) Total serum cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) are presently the recommended screening tests for dyslipidemia in the general population; (2) The National Cholesterol Education Program (NCEP) recommends measuring TC and HDL-C in adults with a single sample at 5-year intervals beginning at age 20; (3) The NCEP recommends measuring TC in children with at least one parent having TC > or = 6.24 mmol/L (> or = 240 mg/dL); (4) The NCEP recommends a lipoprotein analysis consisting of a 12-hour fasting TC, HDL-C, triglyceride, and estimated low density lipoprotein-cholesterol (LDL-C) in adults with the following results: (a) TC > or = 6.24 mmol/L (> or = 240 mg/dL); (b) borderline TC of 5.20-6.23 mmol/L (200-239 mg/dL) and HDL-C < 0.91 mmol/L (< 35 mg/dL) or two or more risk factors; (c) desirable TC of < 5.20 mmol/L (< 200 mg/dL), but HDL-C < 0.91 mmol/L (< 35 mg/dL); (5) The NCEP recommends a lipoprotein analysis in children with documented CHD in a parent or grandparent, or in children that have a TC of > or = 5.20 mmol/L (> or = 200 mg/dL); (6) Two or three separate lipoprotein analyses should be done to confirm the LDL-C result before therapeutic intervention.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['fasting']},\n",
       " {'pmid': 7754672,\n",
       "  'sentence': 'Analyses of the synthesis and processing of recombinant full-length glycoprotein D of equine herpesvirus type 1 (EHV-1; gD392) or recombinant truncated gD (gD352) expressed in baculovirus-infected Sf9 cells revealed the following: (1) gD polypeptides encoded by both recombinant baculoviruses react with gD-specific antibodies including peptide-specific antiserum that neutralizes EHV-1 in a plaque reduction assay, (2) both the full-length recombinant gD392 and the truncated gD352 are expressed predominantly as gD species that contain high mannose-type oligosaccharides (55 kDa and 52 kDa, respectively), (3) both the full-length recombinant gD392 and the truncated gD352 are also expressed in lesser amounts as gD species that contain complex-type oligosaccharides (58 kDa and 55 kDa, respectively) as well as the unglycosylated forms of gD (43 kDa and 37 kDa, respectively), (4) flow cytometric analyses of cells expressing gD392 revealed that gD first appears on the cell surface at 24 h post infection; by 60 h, 95% of the cells express high levels of cell surface gD, (5) cells expressing gD352, in contrast to cells expressing gD392, secrete gD into the extracellular medium.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['infection']},\n",
       " {'pmid': 7767867,\n",
       "  'sentence': 'Inferior vena cava occlusion was performed for 60 s, and the maximum changes in R-R were measured in 44 rats: (i) in control conditions, during phenylephrine (alpha 1-adrenergic agonist), and during a combined infusion of phenylephrine and isoproterenol the R-R shortened significantly (-16.8 +/- 1.4, -24.1 +/- 2.2, and -4.9 +/- 1.2 ms, respectively); (ii) isoproterenol and phentolamine and prazosin (nonselective and selective alpha-adrenergic antagonists) prolonged the R-R paradoxically (+89.2 +/- 9.5, +58.9 +/- 4.1, and +64.4 +/- 10.2 ms, respectively); (iii) atropine and right vagotomy did not affect the phentolamine-induced R-R prolongation (+66.0 +/- 2.4 and +73.8 +/- 13.7 ms, respectively), but it was blocked by left vagotomy (-9.6 +/- 1.1 ms); (iv) propranolol inhibited the prazosin-induced R-R prolongation (-14.3 +/- 2.8 ms,); (v) epinephrine (alpha- and beta-adrenergic agonist) shortened the R-R interval (-9.5 +/- 2.2 ms), but following prazosin, epinephrine induced R-R prolongation (+13.7 +/- 6.0 ms,); (vi) norepinephrine induced R-R prolongation (+21.0 +/- 6.7 ms).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['propranolol', 'prazosin'],\n",
       "  'reaction': ['infusion', 'epinephrine', 'epinephrine']},\n",
       " {'pmid': 7939948,\n",
       "  'sentence': 'Results of the study showed that (1) a single dose of 300 mg mebendazole (locally produced) resulted in cure rates of 50%, 0% and 0% and egg reduction rates of 87.3%, -15.3%, and 28.3%, for ascariasis, hookworm infection and Trichuris respectively; (2) a single dose of 300 mg mebendazole (original) resulted in cure rates of 100.0%, 9.1%, and 43.3%, and egg reduction rates of 100.0%, 72.0%, and 77.9%, for Ascaris, hookworm, and Trichuris respectively; (3) a single dose 500 mg mebendazole (original) resulted in cure rates of 100.0%, 30.2%, and 70.3%, and egg reduction rates of 100.0%, 70.4% and 89.9%, for Ascaris, hookworm, and Trichuris respectively and (4) a single dose of 400 mg albendazole (original) resulted in cure rates of 100.0%, 84.3%, and 67.4%, and egg reduction rates of 100.0%, 96.0% and 87.0%, for Ascaris, hookworm, and Trichuris respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['albendazole', 'mebendazole'],\n",
       "  'reaction': ['ascariasis', 'hookworm infection', 'infection']},\n",
       " {'pmid': 8132608,\n",
       "  'sentence': 'mild methanolysis, periodate-Smith degradation, and hydrazinolysis-nitrous acid deamination), enzymatic (endo-beta-galactosidase, peptide:N-glycanase, and Newcastle disease virus sialidase) digestion, and instrumental analyses (one- and two-dimensional proton nuclear magnetic resonance spectroscopy and fast atom bombardment mass spectrometry) which revealed novel and unique features: (a) the presence of highly branched poly-N-acetylactosamino pentaantennary structures; (b) the presence of a beta-galactosylated Lewis X antigenic epitope, Gal beta 1-->4 Gal beta 1-->4 (Fuc alpha 1-->3) GlcNAc beta 1-->; (c) the presence of a beta-galactosylated sialyl Lewis X structure, Gal beta 1-->4 (Neu5Ac alpha 2-->3) Gal beta 1-->4(Fuc alpha 1-->3) GlcNAc beta 1-->; (d) the presence of Gal beta 1-->4 Gal beta 1--> and Gal beta 1--> 4Gal beta 1-->4Gal beta 1--> as the major and minor groupings, respectively; and (e) the presence of the branched Gal residues, -->4GlcNAc beta 1-->3(Gal beta 1-->4) Gal beta 1-->.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 8145710,\n",
       "  'sentence': 'Other updated or new sections include a) a listing of vaccines and other immunobiologics available in the United States by type and recommended routes, advice on the proper storage and handling of immunobiologics, a section on the recommended routes for administration of vaccines, and discussion of the use of jet injectors; b) revisions in the guidelines for spacing administration of immune globulin preparations and live virus vaccines, a discussion of vaccine interactions and recommendations for the simultaneous administration of multiple vaccines, a section on the interchangeability of vaccines from different manufacturers, and a discussion of hypersensitivity to vaccine components; c) a discussion of vaccination during pregnancy, a section on breast-feeding and vaccination, recommendations for the vaccination of premature infants, and updated schedules for immunizing infants and children (including recommendations for the use of Haemophilus influenzae type b conjugate vaccines); d) sections on the immunization of hemophiliacs and immunocompromised persons; e) discussion of the Standards for Pediatric Immunization Practices (including a new table of contraindications and precautions to vaccination), information on the National Vaccine Injury Compensation Program, the Vaccine Adverse Events Reporting System, and Vaccine Information Pamphlets; and f) guidelines for vaccinating persons without documentation of immunization, a section on vaccinations received outside the United States, and a section on reporting of vaccine-preventable diseases.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['globulin'],\n",
       "  'reaction': ['hypersensitivity', 'pregnancy', 'injury']},\n",
       " {'pmid': 8218069,\n",
       "  'sentence': 'In this study, 223 cases of esophageal atresia (Type IIIb: 85.7%; Type II: 5.8%; Type IIIc: 4.0%; Type IIIa: 2.2%; Type IV: 2.2%) from 6 pediatric surgery centers of Austria, were retrospectively examined for the following parameters and their influence on the prognosis: Birth weight (2494.7 +/- 702.0 g), gestation week (range 27-42 weeks; mean 37.3 +/- 3.1 weeks), sex (male: n = 128; female: n = 95), long-gap atresia (> or = 2 cm: n = 33), Tracheomalacia (n = 16), associated malformations (n = 122; cardiac 27.4%, renal 17.9%, skeletal 17.0%, anal: 10.3%, intestinal 9.9%, mediastinal 7.6%, chromosomal 2.2%), preoperative aspiration (n = 92), pneumonia (n = 96), anastomotic insufficiency (n = 45), empyema (n = 5), mediastinitis (n = 8), sepsis (n = 32), other medical complications (n = 122, in 80 infants), other surgical complications (n = 57).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'tracheomalacia',\n",
       "   'aspiration',\n",
       "   'pneumonia',\n",
       "   'empyema',\n",
       "   'mediastinitis',\n",
       "   'sepsis']},\n",
       " {'pmid': 8328691,\n",
       "  'sentence': 'A substantial number (n) of the operations (30 or more) and associated operative deaths included left ventricular (LV) aneurysmectomy or plication (LVA-P) with coronary artery bypass (CAB) grafts with, or, without other cardiac procedures (OCP; n = 261; d = 11.1%), cardiac reoperations (n = 65; d = 4.6%), CAB grafts plus mitral or aortic valve replacement (n = 59; d = 1.7%), combined mitral and aortic valve replacement (MAVR) with, or without tricuspid valve (TV) replacement and CAB grafts (n = 52; d = 7.7%), CAB grafting for an end-stage coronary artery disease (CAD; n = 40; d = none), emergency CAB grafts for an acute myocardial infarction (MI) with cardiogenic shock (n = 37; d = 24.3%), complex internal thoracic artery (ITA) grafting (n = 30; d = none), and miscellaneous (n = 43; d = 2.3%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery bypass',\n",
       "   'aortic valve replacement',\n",
       "   'aortic valve replacement',\n",
       "   'coronary artery disease',\n",
       "   'acute myocardial infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'cardiogenic shock',\n",
       "   'shock']},\n",
       " {'pmid': 8597455,\n",
       "  'sentence': 'Dietary DHEA leads to: (1) decrease in body weight gain; (2) relative increases in liver weight; (3) liver color change; (4) induction of hepatic peroxisomal enzymes; (5) proliferation of hepatic peroxisomes with increased cross-sectional area; (6) decreased hepatic mitochondrial cross-sectional area; (7) elevated levels of hepatic cytosolic malic enzyme; (8) slight decreases, significant decreases, or significant increases in serum triglyceride levels, depending on mouse strain; (9) increases in total serum cholesterol levels; (10) significant decreases in the hepatic rates of fatty acid synthesis; (11) significant increases in the hepatic rates of cholesterol synthesis; (12) decreases in both protein content and specific activity of hepatic mitochondrial carbamoyl phosphate synthetase-I without concomitant changes in serum urea nitrogen; (13) induction of glutathione S-transferase activity in liver; (14) decrease in hepatic endogenous protein phosphorylation; (15) increase in hepatic AMPase and GTPase activities; (16) formation of 5-androstene-3 beta,17 beta-diol as a major metabolite of DHEA by subcellular fractions of liver, which is reflected in serum and tissue levels; and (17) reduction in serum prolactin levels.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'concomitant'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight']},\n",
       " {'pmid': 8612501,\n",
       "  'sentence': 'A12 dopaminergic neurons in the arcuate nucleus expressed significantly higher levels of tyrosine hydroxylase mRNA in apo-sus rats, suggesting that the reduced stress-induced PRL release could be due to an increased inhibitory control by dopaminergic neurons; 2) in apo-sus rats, stress resulted in a sustained elevation of ACTH and free corticosterone levels, whereas the total corticosterone levels were not different between the two rat lines; 3) under basal morning conditions, apo-sus rats had significantly higher plasma ACTH, but, in contrast, lower free corticosterone than apo-unsus rats; total plasma corticosterone levels were not different; 4) the basal evening ACTH level was elevated in apo-sus rats; after removal of the adrenals in the morning, this increased ACTH level in apo-sus rats persisted into the afternoon 6 h postadrenalectomy; and 5) hippocampal mineralocorticoid (MR), but not glucocorticoid (GR), receptor capacity for the ligand comparable between the groups; the MR of apo-sus rats displayed an increased retention of [3H]corticosterone in all hippocampal cell fields measured 24 h adrenalectomy; MR and GR mRNA in hippocampus as well as GR mRNA in the paraventricular nucleus were not significantly different in the two rat lines.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['stress', 'adrenalectomy']},\n",
       " {'pmid': 8707393,\n",
       "  'sentence': 'Compared with untreated SHR or WKY, we found the following: (1) Systolic arterial pressure was normalized (P < .025) and LVH completely reversed (P < .025) in SHR, with no significant reduction in systolic arterial pressure or left ventricular mass in WKY; (2) morphometrically determined myocardial fibrosis in SHR was significantly reversed (P < .025) and associated with improved diastolic stiffness (P < .05), which was measured in the isolated heart by calculation of the stiffness constant of the myocardium; no significant changes occurred in WKY; (3) reversal of myocardial fibrosis was accompanied by an increase (P < .025) in myocardial matrix metalloproteinase 1 activity determined by degradation of [14C]collagen with myocardial tissue extracts after trypsin activation of myocardial promatrix metalloproteinase 1; matrix metalloproteinase 1 activity remained unchanged in WKY treated with lisinopril; and (4) systolic dysfunction, measured by a significantly (P < .025) diminished slope of the systolic stress-strain relation under isovolumic conditions of the left ventricle, was found in 110-week-old SHR, and it could be prevented by lisinopril treatment.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lisinopril'],\n",
       "  'reaction': ['mass',\n",
       "   'myocardial fibrosis',\n",
       "   'fibrosis',\n",
       "   'myocardial fibrosis',\n",
       "   'fibrosis',\n",
       "   'systolic dysfunction']},\n",
       " {'pmid': 8725178,\n",
       "  'sentence': 'This clone expresses alpha 1 type (I) procollagen mRNA and secretes type I procollagen C-peptide at both temperatures, although the levels were slightly elevated at 40 degrees C. The cell line expresses alkaline phosphatase activity at 34 degrees C, and the basal level of this enzyme increases 2- to 6-fold at 40 degrees C. Alkaline phosphatase activity is induced 4- to 8-fold by 1 alpha,25-dihydroxyvitamin D3 (vitamin D3) at both temperatures, but transforming growth factor-beta 1 (TGF-beta 1) suppresses enzyme expression > 90% at 40 degrees C. Vitamin D3 also induces a 10-fold increase in osteocalcin secretion when the clone is maintained at 34 degrees C, and this induction is enhanced > 8-fold at 40 degrees C. Parathyroid hormone and forskolin stimulate a 4- to 6-fold increase in the production of intracellular cyclic AMP (cAMP) by the cells at 34 degrees C, and this stimulation is enhanced 2- to 4-fold at 40 degrees C. In contrast, prostaglandin E2 stimulates a 7- to 8-fold increase in cAMP only when the cells are maintained at 34 degrees C. This cell line secretes TGF-beta 1 and interleukin-6 (IL-6) at 34 degrees C, but only the basal secretion of IL-6 increases 70% at 40 degrees C. Finally, alizarin red-S histochemical staining demonstrates that these cells produce mineralized nodules at both temperatures.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 8745215,\n",
       "  'sentence': 'We have observed that: (a) At 2 Hz stimulation, the ventricular -Ca2+-i-dependent fluorescence decay is biexponential and continues to decay throughout the interstimulus interval; (b) at 4 Hz and 6 Hz, the [Ca2+]i decay is monoexponential; (c) end-diastolic [Ca2+]i is elevated at higher stimulation frequencies; (d) net [Ca2+]i flux per cycle is reduced at higher stimulation frequencies and is therefore correlated inversely with stimulation frequency and end-diastolic [Ca2+]i; (e) \"heart rate * [Ca2+]i flux product\" which is a measure of the work done in cycling calcium, is directly proportional to stimulation frequency; (f) the hysteresis between peak ventricular isovolumic pressure and peak fluorescence is decreased at higher stimulation frequencies; (g) no correlation was detected between the PCr/ATP ratio and stimulation frequency; (h) despite a 60% decrease in the myocardial PCr/ATP ratio after beta-GPA feeding, rat heart is able to maintain the end-diastolic [Ca2+]i-dependent fluorescence, and therefore the [Ca2+]i staircase relationship, similar to that of normal rat heart.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['heart rate', 'heart rate']},\n",
       " {'pmid': 8773730,\n",
       "  'sentence': 'At the end of the experimental period, the results obtained were as follows (mean +/- SEM): serum triacylglycerol (mM): CD + CLO 0.21 +/- 0.04 vs. CD 0.58 +/- 0.05 (p < 0.05); free fatty acids (microM): CD + CLO 257 +/- 20 vs. CD 288 +/- 22 (p = NS); total cholesterol (mM): CD + CLO 1.13 +/- 0.09 vs. CD 1.82 +/- 0.06 (p < 0.05); high-density lipoprotein cholesterol (mM): CD + CLO 0.58 +/- 0.08 vs. CD 1.07 +/- 0.04 (p < 0.05); plasma glucose (mM): CD + CLO 6.30 +/- 0.29 vs. CD 6.28 +/- 0.10 (p = NS); liver triacylglycerol (mumol/liver): CD + CLO 104.1 +/- 11.4 vs. CD 136.8 +/- 4.3 (p < 0.05); glycogen (mumol/g wet weight): CD + CLO 298.3 +/- 21.0 vs. CD 297.0 +/- 19.0 (p = NS); glucose-6-phosphate dehydrogenase (U/liver): CD + CLO 37.9 +/- 2.2 vs. CD 58.8 +/- 5.0 (p < 0.05); triacylglycerol secretion (nmol/min/100 g body weight): CD + CLO 101.0 +/- 2.0 vs. CD 166.0 +/- 9.7 (p < 0.01); removal of fat emulsion (K2% min-1): CD + CLO 15.0 x 10(-2) +/- 0.8 x 10(-2) vs. CD 8.2 x 10(-2) +/- 0.2 x 10(-2) (p < 0.01); intravenous glucose tolerance (kg 10(-2): CD + CLO 2.68 +/- 0.37 vs. CD 2.70 +/- 0.14 (p = NS); immunoreactive insulin (microU/ml/ min): with the area under the curve between 0 and 30 min CD + CLO 544 +/- 60 vs. CD 1,050 +/- 38 (p < 0.05), with the area under the curve between 0 and 60 min CD + CLO 1,188 +/- 150 vs. CD 2,160 +/- 137 (p < 0.05), and pancreas insulin content (microU/mg pancreas): CD + CLO 1.85 +/- 0.29 vs. CD 2.04 +/- 0.12 (p = NS).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight', 'glucose tolerance']},\n",
       " {'pmid': 8788237,\n",
       "  'sentence': 'The present analysis, based on studies of sedentary and exercise trained humans, proposes the following: that (1) the ANS profile in exercise consists in enhanced dopaminergic (DA) relative to noradrenergic (NA) activity and increased vagal tone; (2) DA is the principal catecholamine neuromodulator/neurotransmitter of the brain, directly involved in motor control in the striatum and is key to the mechanism underlying increased and maintained efficiency of exercise trained humans; (3) DA is a major participant in many aspects of motor function which include the regulation of cardiovascular and renal function (heart rate, blood pressure, and other), muscle tone, visual processing, calcium homeostasis, protein synthesis and conceivably the optimal utilization of food intake; (4) the peripheral actions of DA reflect and are functionally interrelated to the observed global activation of brain DA systems in exercising animals, and probably man; (5) that a different enzyme profile evolves in exercise training which may potentiate DA synthesis and preserve the structural and functional integrity of central DA neurons; (6) that a shift to enhanced DA vs. NA activity occurs in exercise trained Whites which resembles the norm for sedentary Africans and confers distinct physiological advantages; (7) there is unequivocal evidence for the physiological efficiency of a DA dominated ANS profile which can be correlated to the low incidence of DA related diseases in aging Africans; (8) data suggests that the superiority of top-class African athletes in distance running and their endurance capacity are related to an inherent neurophysiological advantage, to efficient DA and protein synthesis, a decreased rate of DA decline during aging and to improved calcium homeostasis, inter alia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['heart rate', 'heart rate', 'blood pressure']},\n",
       " {'pmid': 8791009,\n",
       "  'sentence': 'The following data were obtained: (1) one class of binding site was identified by Scatchard analysis of [125I]VIP binding to cell membranes with a Kd of 0.41 nM and a Bmax of 1.62 pmol/mg protein; (2) the constant Ki for the inhibition of [125I]VIP binding by VIP and related peptides was: VIP (0.9 nM) = pituitary adenylate cyclase-activating peptide (PACAP)-27 (1.3 nM) < PACAP-38 (6.8 nM) < helodermin (46.0 nM) < human growth hormone-releasing factor (GRF) (0.6 microM) < peptide histidine methionineamide (2.0 microM) < secretin (> 10 microM); (3) cross-linking experiments using [125I]VIP identified a single M(r) 67000 recombinant receptor; (4) VIP stimulated cAMP production in Clone 15 cells with an EC50 of 0.20 nM; (5) some previously described VIP receptor antagonists including [4-Cl-D-Phe6, Leu17]VIP, [Ac-Tyr1,D-Phe2]GRF-(1-29) amide and VIP-(10-28) inhibited [125I]VIP binding with a Ki of 0.7, 1.6 and 2.5 microM, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['secretin', 'histidine', 'peptide'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 8857488,\n",
       "  'sentence': 'Conclusions from this review, based primarily on study of 39 cardiac allografts in place for >2 months, but also on a study of 37 grafts in place for </=2 months, might include the following: (1) allograft vascular disease affects all layers of the epicardial coronary arteries and usually the intramural coronary arteries in the outer one-half of the left ventricular wall; (2) the resulting intimal lesion is relatively uniform, consisting mainly of cellular and acellular fibrous tissue; it is diffuse, affecting all segments of the major and minor epicardial coronary arteries; (3) the degree of resulting luminal narrowing is similar in most 5-mm coronary segments, making coronary angiography hazardous in reliably predicting accurately the degree of luminal narrowing; (4) the extensive adventitial fibrosis and the extensive fibrous tissue infiltration of the subepicardial tissues probably inhibit dilation and remodeling of the epicardial coronary arteries and indeed may constrict them; (5) luminal narrowing of the epicardial coronary arteries after transplantation may be the consequence of both intraluminal lesions and exterior compression from the surrounding fibrous tissue; (6) intraluminal and intralesion thrombus is commonly observed as are multiluminal channels in coronary plaques, suggesting that organization of thrombi plays some role in the progression of post-transplant epicardial coronary disease; (7) the coronary lesions developing after cardiac transplantation are morphologically quite different in composition than those occurring in natural (nontransplantation) atherosclerosis; and (8) inflammatory cellular infiltrates are often extensive in the subepicardial tissues and the infiltrates in this area may be extensive even when interstitial myocardial inflammatory infiltrates are minimal or absent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['fibrosis', 'tissue infiltration']},\n",
       " {'pmid': 8968213,\n",
       "  'sentence': 'The events that lead to these autoimmune diseases are not clear but the following sequential steps are critical: (a) the breaking of tolerance, a process in which cytokines, molecular mimicry, or superantigens may play a role in rendering previously anergic T cells to recognize neural autoantigens; (b) antigen recognition by the T-cell receptor complex and processing of the antigen via the major histocompatibility complex class I or II; (c) costimulatory factors especially B7 and B7-binding proteins (CD28, CTLA-4) and intercellular adhesion molecule (ICAM)-1 and its leukocyte function-associated (LFA)-1 ligand; (d) traffic of the activated T cells across the blood-brain or blood-nerve barrier via a series of adhesion molecules that include selectins, leukocyte integrins (LFA-1, Mac-1, very late activating antigen [VLA]-4) and their counterreceptors (ICAM-1, vascular cell adhesion molecule [VCAM]) on the endothelial cells; and (e) tissue injury when the activated T cells, macrophages, or specific autoantibodies find their antigenic targets on glial cells, myelin, axon, calcium channels, or muscle.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['adhesion',\n",
       "   'adhesion',\n",
       "   'adhesion',\n",
       "   'tissue injury',\n",
       "   'injury',\n",
       "   'macrophages']},\n",
       " {'pmid': 8978323,\n",
       "  'sentence': 'The major new findings in this study are that in healthy humans (1) renal cortical blood flow decreases (basal versus handgrip, 4.4 +/- 0.1 versus 3.5 +/- 0.1 mL.min-1.g-1; P = .008) and renal cortical vascular resistance increases (basal versus handgrip, 17 +/- 1 versus 26 +/- 2 U; P = .01) in response to static handgrip exercise; (2) central command and/or the mechanoreflex contributes importantly to the early decrease in renal blood flow (basal versus handgrip, 4.2 +/- 0.2 versus 3.5 +/- 0.3 mL.min-1.g-1; P = .04) and to the increase in renal cortical vascular resistance (basal versus handgrip, 20 +/- 1 versus 25 +/- 2 U; P = .04); (3) the muscle metaboreflex contributes to further decreases in renal blood flow (basal versus posthandgrip circulatory arrest, 4.3 +/- 0.1 versus 3.5 +/- 0.2 mL.min-1.g-1; P = .002) and increases in renal cortical vascular resistance (basal versus handgrip, 18 +/- 1 versus 25 +/- 3 U; P = .002); and (4) exogenous adenosine activates the muscle metaboreflex producing reflex renal vasoconstriction and decreased renal blood flow, which may implicate endogenous adenosine generated during ischemic exercise as a potential activator of the muscle metaboreflex during ischemic handgrip exercise.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['vasoconstriction']},\n",
       " {'pmid': 9045028,\n",
       "  'sentence': 'The results showed: a) a higher prevalence of hypertension, nearly always diastolic, and of ECG abnormalities in the group of pilots of turboprop aircraft compared to jet plane pilots and to controls (p < 0.005 and p < 0.01 respectively); b) a higher prevalence of orthostatic hypotension in the two groups of pilots than in the controls (p < 0.05); c) a higher prevalence of hypertension with audiometric deficit compared to hypertension without audiometric deficit both in the more heavily and in the less heavily exposed to noise (p < 0.05), and a higher prevalence of hypertension with audiometric deficit in subjects exposed to higher levels of noise compared to hypertension with deficit but in subjects with lower levels of exposure (p < 0.05); d) a higher prevalence of abnormalities of basal, maximum effort and recovery ECG in pilots exposed to higher noise intensity (p < 0.05); e) improved hypertensive response to ergometric test in pilots with basal hypertension; f) subjects with a maximal load up to 120 W belonged prevalently to the group exposed to more intense noise (p < 0.001), while those with maximal load up to 210 W (p < 0.001) belonged to the group exposed to less intense noise.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['hypertension',\n",
       "   'orthostatic hypotension',\n",
       "   'hypotension',\n",
       "   'hypertension',\n",
       "   'hypertension',\n",
       "   'hypertension',\n",
       "   'hypertension',\n",
       "   'hypertension']},\n",
       " {'pmid': 9141254,\n",
       "  'sentence': 'Mean values of the variables obtained before and after phototherapy in the study group and in the controls were, respectively: urine osmolality (osm/kg H2O): 0.147 +/- 0.009, 0.174 +/- 0.011, and 0.153 +/- 0.018; endogenous creatinine clearance (mL/min per 1.73 m2): 45.7 +/- 2.15, 46.0 +/- 1.6 and 46.7 +/- 3.9; fractional excretion of sodium (%): 1.27 +/- 0.30, 0.79 +/- 0.19 and 1.24 +/- 0.07; tubular phosphorus reabsorption (%): 85.8 +/- 3.3, 87.8 +/- 2.8 and 86.6 +/- 1.7; urinary N-acetyl-beta-D glucosaminidase/creatinine (IU/mg): 0.617 +/- 0.226, 0.574 +/- 0.214 and 0.619 +/- 0.210; fractional excretion of alkaline phosphatase (%): 0.422 +/- 0.103, 1.001 +/- 0.374 and 0.596 +/- 0.201; fractional excretion of lactic dehydrogenase (LDH; %): 0.102 +/- 0.019, 0.121 +/- 0.023 and 0.119 +/- 0.041; fractional excretion of AST (%): 0.433 +/- 0.127, 0.530 +/- 0.113 and 0.502 +/- 0.074; fractional excretion of alanine aminotransferase (ALT; %) 0.856 +/- 0.413, 1.619 +/- 1.076 and 1.066 +/- 0.366.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['alanine aminotransferase']},\n",
       " {'pmid': 9160162,\n",
       "  'sentence': 'The major findings of this study are: (i) The amount of Ca exchanged through CaNa/Ca is clearly dependent on temperature (Q10 approximately 1.6) in the range studied (17-37 degrees C); (ii) the addition of 1 microM nifedipine does not modify the temperature dependence of CaNa/Ca; (iii) the sarcolemmal bound fraction contributing to CaNa/Ca is not changed by temperature; (iv) the increase in CaNa/Ca with temperature is explained by an increment in the contribution of SR-Ca to CaNa/Ca; (v) a fraction of SR which does not exchange via CaNa/Ca at low temperatures can be released and mobilized by caffeine-this caffeine sensitive fraction is reduced as temperature is increased and is no longer measurable as a separate entity at 37 degrees C; (vi) if we consider (iv) and (v) together, SR content would be temperature dependent with a Q10 of approximately 1.5; (vii) a La displaceable pool, which represents over 66% of the total exchangeable Ca, increases in the range of 22-33 degrees C with a Q10 of 1.25 which is consistent with a pool distribution of 70% SL-bound and 30% SR-derived [Post J.A., Langer G.A.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nifedipine'],\n",
       "  'reaction': ['dependence']},\n",
       " {'pmid': 9436415,\n",
       "  'sentence': 'There are several potential clinical applications of 3D such as the measurement and serial follow-up of left ventricular volumes; in valvular heart disease (the abnormalities can be delineated more precisely and in greater detail than conventional imaging, including a detailed definition of mitral apparatus in mitral stenosis), in mitral valve prolapse both leaflets can be seen from the left atrial view and in endocarditis it can aid in deciding when and how to intervene; in complex congenital heart disease, such as reconstruction of double outlet right ventricle, left-sided obstructive and regurgitant lesions and subaortic obstructive cases, in atrial and ventricular septal defects, displaying size, geometry and relationships to other structures; another expression of cardiac disorders are blood flow disturbances (visualisation of flows in 3D could allow a better qualitative and quantitative assessment of their size and severity; the pictures so far generated allow a good perception of the size and shape of mitral, aortic and tricuspid regurgitation jets, by examining them from a new perspective, it also has the potential to display the flow convergence zone and quantify the regurgitant volume).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['stenosis',\n",
       "   'mitral valve prolapse',\n",
       "   'prolapse',\n",
       "   'endocarditis',\n",
       "   'regurgitation']},\n",
       " {'pmid': 9605758,\n",
       "  'sentence': 'For the delayed effect, all treatments produced the same maximum effect at 96 h, although treatments for < or = 12 h showed higher IC50s than longer treatments, whereas treatments for > or = 24 h showed indistinguishable IC50s; (c) treatment for as brief as 3 h was sufficient to induce apoptosis, which occurred with a lag time of about 24 h, although longer treatments produced a greater extent of apoptosis; (d) The intracellular and extracellular concentrations reached an equilibrium at approximately 5 h, which rules out slow and/or insufficient uptake as the cause of the lower effects at shorter treatment times (i.e., < 24 h); (e) upon removal of drug-containing medium, the amount of drug retained intracellularly was about 10% of the applied dose and was reduced to approximately 0.5% after three successive washes, separated by 3-h equilibration periods; and (f) the delayed effect of the 3-h treatment was largely due to the drug retained intracellularly, whereas the delayed effect of the 24 h treatment was independent of the drug retained intracellularly.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['apoptosis', 'apoptosis']},\n",
       " {'pmid': 9620459,\n",
       "  'sentence': 'The principles underlying these surgical techniques include (1) expeditious establishment of total cardiopulmonary bypass with moderate hypothermia and meticulous attention to myocardial protection; (2) transinfarct approach to ventricular septal defect with the site of ventriculotomy determined by the location of the transmural infarction; (3) thorough trimming of the left ventricular margins of the infarct back to viable muscle to prevent delayed rupture of the closure; (4) conservative trimming of the right ventricular muscle as required for complete visualization of the margins of the defect; (5) inspection of the left ventricular papillary muscles and concomitant replacement of the mitral valve only if there is frank papillary muscular rupture; (6) closure of the septal defect without tension, which in most instances will require the use of prosthetic material; (7) closure of the infarctectomy without tension with generous use of prosthetic material as indicated, and epicardial placement of the patch to the free wall to avoid strain on the friable endocardial tissue; and (8) buttressing of the suture lines with pledgets or strips of Teflon felt or similar material to prevent sutures from cutting through friable muscle.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['cardiopulmonary bypass',\n",
       "   'hypothermia',\n",
       "   'ventricular septal defect',\n",
       "   'ventricular septal defect',\n",
       "   'infarction',\n",
       "   'tension',\n",
       "   'tension']},\n",
       " {'pmid': 9666272,\n",
       "  'sentence': \"Cocaine's in vitro effects on (a) permeability, (b) immune cell migration, (c) adhesion molecules, and (d) cytokine expression were investigated in a blood-brain barrier model constructed with brain microvascular endothelial cells and fetal astrocytes with the following results: (a) cocaine and tumor necrosis factor-alpha (TNF-alpha) increased the model's permeability to inulin similarly in a dose-responsive fashion; (b) cocaine (10(-4) to 10(-8_ M) enhanced monocyte migration across the barrier with the maximum increase, approximately 100%, by 10(-5) M cocaine; (c) cocaine treatment also increased the expression of endothelial adhesion molecules, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecules-1 (VCAM-1) and platelet/endothelial cell adhesion molecule-1 (PECAM-1); (d) although the cocaine in vitro effects on cytokine production by mononuclear cells have been difficult to assess due to a heterogeneity in the degree of responsiveness between individuals, the data suggest that mononuclear cells from cocaine addicts are sensitized to in vitro cocaine challenge with hypersecretion of inflammatory cytokines.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['adhesion',\n",
       "   'necrosis',\n",
       "   'adhesion',\n",
       "   'adhesion',\n",
       "   'adhesion',\n",
       "   'adhesion']},\n",
       " {'pmid': 9821173,\n",
       "  'sentence': 'In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 \"resectable\" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better \"clinical benefit response\" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gemcitabine', '5-fluorouracil', 'endocrine'],\n",
       "  'reaction': ['pain',\n",
       "   'performance status',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth',\n",
       "   'adenocarcinoma']},\n",
       " {'pmid': 9873236,\n",
       "  'sentence': \"The following issues are raised: (1) industry-funded research studies which result in negative findings sometimes do not get published; (2) placebo washout procedures may bias results in some studies; (3) there are serious questions about the integrity of the double-blind procedure; (4) the 'true' antidepressant drug effect in adults appears to be relatively small; (5) there is minimal evidence of antidepressant efficacy in children; (6) side effects are fairly common even with the newer antidepressants; (7) combining medications raises the risk for more serious complications; (8) all antidepressants can cause withdrawal symptoms; (9) genetic influences on unipolar depression appear to be weaker than environmental influences; (10) biochemical theories of depression are as yet unproven; (11) biological markers specific for depression have been elusive; (12) dosage and plasma levels of antidepressants have been minimally related to treatment outcome; (13) preliminary evidence suggests that patients who improve with cognitive-behavioral psychotherapy show similar biological changes as those who respond to medication, and (14) the evidence suggests that psychological interventions are at least as effective as pharmacotherapy in treating depression, even if severe, especially when patient-rated measures are used and long-term follow-up is considered.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['depression',\n",
       "   'depression',\n",
       "   'depression',\n",
       "   'psychotherapy',\n",
       "   'depression']},\n",
       " {'pmid': 9972672,\n",
       "  'sentence': 'The results indicate that: a) in SHAM animals, basal plasma ACTH levels were significantly higher in females than in males, and this sexual dimorphism was overridden by ADX, regardless of the time post-surgery; b) although basal anterior pituitary (AP) ACTH content was similar in SHAM animals of both sexes, 3- and 6-week ADX induced higher AP ACTH in males than in females; c) at 3- and 6-weeks, ADX rats of hoth sexes had an AVP:CRH ratio (r), in the median eminence (ME) and medial basal hypothalamus (MBH), increased several fold over the respective SHAM-value and, although no sexual dimorphism was found at week 3 post-ADX, by 6-weeks post ADX, these ratios were significantly higher in both brain tissues of females than in those of males; and d) the in vitro ME CRH and AVP output in response to high potassium concentrations (hK+; 28 and 56 mmol/I), was concentration-related, regardless of sex and surgery, and was characterized by enhanced secretion of neuropeptides by MEs from ADX in comparison to SHAM rats of both sexes, and a sexual dimorphism was found in this parameter, consisting in general, in greater neuropeptide output from tissues of female than of male animals.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal', 'potassium'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 10222208,\n",
       "  'sentence': 'This strategy is illustrated by several findings, each of which involves an unexpected structural prediction: (i) a number of previously undetected proteins with the HSP70-actin fold are identified, including a highly conserved and nearly ubiquitous family of metal-dependent proteases (typified by bacterial O-sialoglycoprotease) that represent an adaptation of this fold to a new type of enzymatic activity; (ii) we show that, contrary to the previous conclusions, ATP-dependent and NAD-dependent DNA ligases are confidently predicted to possess the same fold; (iii) the C-terminal domain of 3-phosphoglycerate dehydrogenase, which binds serine and is involved in allosteric regulation of the enzyme activity, is shown to typify a new superfamily of ligand-binding, regulatory domains found primarily in enzymes and regulators of amino acid and purine metabolism; (iv) the immunoglobulin-like DNA-binding domain previously identified in the structures of transcription factors NFkappaB and NFAT is shown to be a member of a distinct superfamily of intracellular and extracellular domains with the immunoglobulin fold; and (v) the Rag-2 subunit of the V-D-J recombinase is shown to contain a kelch-type beta-propeller domain which rules out its evolutionary relationship with bacterial transposases.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['enzyme activity']},\n",
       " {'pmid': 10374089,\n",
       "  'sentence': 'Results showed that: (i) diethylenetriamine (DETA)/NO (1 x 10(-6), 1 x 10(-5), 1 x 10(-4) M), an NO donor, caused a dose-dependent increase in progesterone synthesis (355 +/- 43, 443 +/- 46, 647 +/- 55 ng/g ovary respectively, P < 0.01) with a concomitant decrease in ovarian oestradiol secretion (408.1 +/- 50.7, 272.9 +/- 28.2, 132.6 +/- 34.6 pg/g ovary respectively, P < 0.01); (ii) neither progesterone nor oestradiol concentrations in the culture medium were altered by DETA without NO; (iii) NG-nitro-l-arginine methyl ester (1 x 10(-4) M), an inhibitor of NO synthesis, did not significantly affect progesterone and oestradiol secretion by rat ovaries; (iv) PGF2 alpha(1 x 10(-6) M) caused a fall in progesterone and oestradiol synthesis; (v) co-incubation with DETA/NO, significantly reversed the PGF2 alpha-induced decrease in progesterone concentrations from 184 +/- 29 to 388 +/- 60 ng/g (P < 0.01), but not that of oestradiol.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium', 'concomitant'],\n",
       "  'reaction': ['progesterone',\n",
       "   'oestradiol',\n",
       "   'progesterone',\n",
       "   'oestradiol',\n",
       "   'progesterone',\n",
       "   'oestradiol',\n",
       "   'fall',\n",
       "   'progesterone',\n",
       "   'oestradiol',\n",
       "   'progesterone',\n",
       "   'oestradiol']},\n",
       " {'pmid': 10548440,\n",
       "  'sentence': 'Eight clusters were suggested: Entrepreneurs (n = 19) were frequently involved in delinquent activity and were highly entrenched in the street lifestyle; Drifters (n = 35) had infrequent social contact, displayed lower than average family dysfunction, and were not highly entrenched in the street lifestyle; Partiers (n = 40) were distinguished by their recreational motivation for alcohol and drug use and their below average entrenchment in the street lifestyle; Retreatists (n = 32) were distinguished by their high coping motivation for substance use; Fringers (n = 48) were involved marginally in the street lifestyle and showed lower than average family dysfunction; Transcenders (n = 21), despite above average physical and sexual abuse, reported below average mental health or substance use problems; Vulnerables (n = 12) were characterized by high family dysfunction (including physical and sexual abuse), elevated mental health outcomes, and use of alcohol and other drugs motivated by coping and escapism; Sex Workers (n = 4) were highly entrenched in the street lifestyle and reported frequent commercial sexual work, above average sexual abuse, and extensive use of crack cocaine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['substance use',\n",
       "   'sexual abuse',\n",
       "   'substance use',\n",
       "   'sexual abuse',\n",
       "   'sexual abuse']},\n",
       " {'pmid': 10909980,\n",
       "  'sentence': 'With the aim of investigating glucose-mediated glucose disposal (glucose effectiveness [GE]) in 15 (3 female and 12 male subjects) insulin-resistant normoglycemic relatives of patients with type 2 diabetes (DM2), and 15 age-, sex-, and BMI-matched control subjects without a family history of DM2, we performed 2 studies: 1) a 5-h euglycemic near-normoinsulinemic pancreatic clamp with somatostatin (360 microg/h), insulin (0.25 mU x kg(-1) x min(-1)), glucagon (0.5 ng x kg(-1) x min(-1)), growth hormone (6 ng x kg(-1) x min(-1)), and tritiated glucose infusion and indirect calorimetry; and 2) on a separate day, an identical 5-h clamp but at hyperglycemia (approximately 12 mmol/l) over the last 2 h. Fasting plasma insulin (PI) concentrations were elevated in the relatives compared with control subjects (49 +/- 6 vs. 32 +/- 5 pmol/l, P < 0.04), whereas plasma glucose (PG) was not (5.6 +/- 0.1 vs. 5.5 +/-0.1 mmol/l).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['growth', 'infusion', 'fasting']},\n",
       " {'pmid': 10967928,\n",
       "  'sentence': 'Cardiac diagnoses included patent ductus arteriosus (PDA) (N = 21, 28.7%), ventricular septal defect (VSD) (N = 9, 12.3%), transposition of great arteries (TGA) (N = 10, 13.7%), tetralogy of Fallot (TOF) (N = 7, 9.6%), double-outlet right ventricle (DORV) (N = 4, 5.5%), truncus arteriosus communis (TAC) (N = 4, 5.5%), hypoplastic left heart syndrome (HLHS) (N = 4, 5.5%), coarctation of aorta (CoAo) (N = 6, 8.2%), total anomalous pulmonary venous return (TAPVR) (N = 2, 2.7%), aortic stenosis (AoVS) (N = 3, 4.1%), interrupted aortic arch (IAA) (N = 1, 1.4%), pulmonary atresia (PA) (N = 1, 1.4%) and common atrioventricular canal (CAVC) (N = 1, 1.4%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'cardiac'],\n",
       "  'reaction': ['patent ductus arteriosus',\n",
       "   'ventricular septal defect',\n",
       "   'ventricular septal defect',\n",
       "   'aortic stenosis',\n",
       "   'stenosis']},\n",
       " {'pmid': 11101600,\n",
       "  'sentence': 'The algorithm for a new identification system was designed on the basis of colony color and morphology on CHROMagar Orientation medium in conjunction with simple biochemical tests such as indole (IND), lysine decarboxylase (LDC), and ornithine decarboxylase (ODC) utilization tests with gram-negative bacilli isolated from urine samples as well as pus, stool, and other clinical specimens by the following colony characteristics, biochemical reactions, and serological results: pinkish to red, IND positive (IND(+)), Escherichia coli; metallic blue, IND(+), LDC(+), and ODC negative (ODC(-)), Klebsiella oxytoca; IND(+), LDC(-), and ODC(+), Citrobacter diversus; IND(+) or IND(-), LDC(-), and ODC(-), Citrobacter freundii; IND(-), LDC(+), and ODC(+), Enterobacter aerogenes; IND(-), LDC(-), and ODC(+), Enterobacter cloacae; IND(-), LDC(+), and ODC(-), Klebsiella pneumoniae; diffuse brown and IND(+), Morganella morganii; IND(-), Proteus mirabilis; aqua blue, Serratia marcescens; bluish green and IND(+), Proteus vulgaris; transparent yellow-green, serology positive, Pseudomonas aeruginosa; clear and serology positive, Salmonella sp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['serology positive', 'serology positive']},\n",
       " {'pmid': 11239510,\n",
       "  'sentence': 'The following are important experimentally-based reasons for recommending the incorporation of target therapeutic concentration monitoring of mycophenolic acid: (1) the MPA dose-interval area-under-the-concentration-time curve, and less precisely, MPA predose concentrations predict the risk for development of acute rejection; (2) the strong correlation between mycophenolic acid plasma concentrations and expression of important cell surface activation antigens, whole blood pharmacodynamic assays of lymphocyte proliferation and median graft rejection scores in a heart transplant animal model; (3) the greater than 10-fold interindividual variation of MPA area under the concentration time curve values in heart and renal transplant patients receiving a fixed dose of the parent drug; (4) drug-drug interactions involving other immunosuppressives are such that when switching from one to another (eg, from cyclosporine to tacrolimus or vice-versa) substantial changes in MPA concentrations can occur in patients receiving a fixed dose of the parent drug; (5) significant effects of liver and kidney diseases on the steady-state total and free mycophenolic acid area under the concentration time curve values; (6) the need to closely monitor mycophenolic acid when a major change in immunosuppression is planned such as steroid withdrawal.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tacrolimus'],\n",
       "  'reaction': ['heart transplant',\n",
       "   'transplant',\n",
       "   'renal transplant',\n",
       "   'transplant',\n",
       "   'immunosuppression']},\n",
       " {'pmid': 11246343,\n",
       "  'sentence': 'Some well characterized and common topographic phenotypes of H. pylori gastritis and atrophic gastritis can be delineated as follows: Predominance or restriction of the H. pylori-related inflammation in antrum, in association with a nonatrophic corpus mucosa--of which phenotype is the most common--and with an increased risk of peptic ulcer disease, duodenal ulcer in particular (\"duodenal ulcer phenotype\" of gastritis); the presence of atrophic gastritis in corpus of the stomach (\"corpus predominant gastritis\"), which indicates a low risk of peptic ulcer and a reduction in the capacity of the patient to secrete acid; the occurrence of advanced atrophic gastritis and intestinal metaplasia multifocally in the stomach (advanced \"multifocal atrophic gastritis\"), which are features of a gastritis type and which also indicate a low acid secretion capacity and an increased risk of gastric neoplasias (\"gastric cancer phenotype of gastritis\"), suggesting a need for a careful exclusion of concomitant presence of small focal neoplastic or dysplastic lesions; and the presence of normal and healthy gastric mucosa, which indicates an extremely low risk of both peptic ulcer disease or gastric cancer and, therefore, is a finding of high clinical relevance.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['gastritis',\n",
       "   'gastritis',\n",
       "   'inflammation',\n",
       "   'peptic ulcer',\n",
       "   'ulcer',\n",
       "   'duodenal ulcer',\n",
       "   'ulcer',\n",
       "   'duodenal ulcer',\n",
       "   'ulcer',\n",
       "   'gastritis',\n",
       "   'gastritis',\n",
       "   'gastritis',\n",
       "   'peptic ulcer',\n",
       "   'ulcer',\n",
       "   'gastritis',\n",
       "   'intestinal metaplasia',\n",
       "   'metaplasia',\n",
       "   'gastritis',\n",
       "   'gastritis',\n",
       "   'gastric cancer',\n",
       "   'gastritis',\n",
       "   'peptic ulcer',\n",
       "   'ulcer',\n",
       "   'gastric cancer']},\n",
       " {'pmid': 11320539,\n",
       "  'sentence': 'This order influences magnetic resonance (MR) in vivo-in particular 1H-spectra-by a series of effects that have very distinct physical sources and biomedical applications: (a) bulk fat (extramyocellular lipids, EMCL) along fasciae forms macroscopic plates, changing the susceptibility within these structures compared to the spherical droplets that contain intra-myocellular lipids (IMCL); this effect leads to a separation of the signals from EMCL and IMCL; (b) dipolar coupling effects due to anisotropic motional averaging have been shown for 1H-resonances of creatine, taurine, and lactate; (c) aromatic protons of carnosine show orientation-dependent effects that can be explained by dipolar coupling, chemical shift anisotropy or by relaxation anisotropy; (d) limited rotational freedom and/or compartmentation may explain differences of 1H-MR-visibility of the creatine/phosphocreatine resonances; (e) lactate 1H-MR resonances are reported to reveal information on tissue compartmentation; (f) transverse relaxation of water and metabolites show multiple components, indicative of intra-, extracellular and/or macromolecular-bound pools, and in addition dipolar or J-coupling lead to a modulation of the signal decay, hindering straightforward interpretation; (g) diffusion weighted 31P-MRS has shown restricted diffusion of phosphocreatine; (h) magnetization transfer (MT) indicates that there is a motionally restricted proton pool in spin-exchange with free creatine; reduced availability or restricted motion of creatine is particularly important for an estimation of ADP from 31P-MR spectra, and in addition MT effects may alter the signal intensity of creatine 1H-resonances following water-suppression pulses; (i) transcytolemmal water-exchange can be studied in 1H-MRS by contrast-agents applied to the extracellular space; (k) transport of glucose across the cell membrane has been studied in diabetes patients using a combination of 13C- and 31P-MRS; and l residual quadrupolar interaction in 23Na MR spectra from human skeletal muscle suggest that sodium ions are bound to ordered muscular structures.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['lipids', 'lipids']},\n",
       " {'pmid': 11391068,\n",
       "  'sentence': 'The presentations were (1) Tribute to Professor Rajendar K. Chawla, by Craig J. McClain; (2) Dysregulated TNF signaling in alcoholic liver disease, by Craig J. McClain, S. Joshi-Barve, D. Hill, J Schmidt, I. Deaciuc, and S. Barve; (3) The role of mitochondria in ethanol-mediated sensitization of the liver, by Anna Colell, Carmen Garcia-Ruiz, Neil Kaplowitz, and Jose C. Fernandez-Checa; (4) A peroxisome proliferator (bezafibrate) can prevent superoxide anion release into hepatic sinusoid after acute ethanol administration, by Hirokazu Yokoyama, Yukishige Okamura, Yuji Nakamura, and Hiromasa Ishii; (5) S-adenosylmethionine affects tumor necrosis factor-alpha gene expression in macrophages, by Rajendar K. Chawla, S. Barve, S. Joshi-Barve, W. Watson, W. Nelson, and C. McClain; (6) Iron, retinoic acid and hepatic macrophage TNFalpha gene expression in ALD, by Hidekazu Tsukamoto, Min Lin, Mitsuru Ohata, and Kenta Motomura; and (7) Role of Kupffer cells and gut-derived endotoxin in alcoholic liver injury, by N. Enomoto, K. Ikejima, T. Kitamura, H. Oide, Y. Takei, M. Hirose, B. U. Bradford, C. A. Rivera, H. Kono, S. Peter, S. Yamashina, A. Konno, M. Ishikawa, H. Shimizu, N. Sato, and R. Thurman.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bezafibrate'],\n",
       "  'reaction': ['alcoholic liver disease',\n",
       "   'necrosis',\n",
       "   'macrophages',\n",
       "   'liver injury',\n",
       "   'injury']},\n",
       " {'pmid': 11421686,\n",
       "  'sentence': 'The distance between the central-metal ions of ruthenium(II) and chromium(III) complexes in [Ru(phen)(3)](2)[Cr(CN)(6)]Cl.2(CH(3))(2)CO.14H(2)O (7.170 A) is shorter than that in [Ru(bpy)(3)](2)[Cr(CN)(6)]Cl.8H(2)O (9.173 A) by about 2 A, while the rate of energy transfer from the (3)MLCT state of [Ru(N-N)(3)](2+) to the (2)E(g) state of [Cr(CN)(6)](3-) in the former salt (9.5 x 10(5) s(-1)) is far slower than that in the latter one (6.0 x 10(6) s(-1)) at 77 K. These results indicate that the energy-transfer rate strongly depends, not upon the distance between central metal ions, rather, upon the mutual relative orientation between the donor and the acceptor complexes in double-complex salts.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 11432770,\n",
       "  'sentence': 'The data showed the following effects of oral feeding of BEC: (1) feeding for 30 d did not affect the blood pressure and heart rate (determined telemetrically) of adult SHR and WKY; (2) feeding for 90 d did not affect the development of hypertension in 1-month-old prehypertensive SHR; (3) feeding for 4 d dose-dependently (0.2--3.2 ml/kg per d) attenuated cardiac hypertrophy in experimentally-induced (coarctation of the abdominal aorta) cardiac hypertrophic SD; (4) feeding to 1-month-old prehypertensive SHR for 11 months did not affect the age-related development of hypertension in this animal; (5) there was significant attenuation of the age-related development of hypertension (determined by tail-cuff plethysmography) in the WKY (P = 0.011) when the animals drank an average of 7.5 ml BEC/kg body weight per d, measured during the last 2 months of the 11-month treatment period; (6) there was chronic, as in the previous treatment, attenuation of the age-related development of cardiac hypertrophy and arteriosclerosis (quantified morphometrically) in the SHR when the animals drank an average of 2.4 ml BEC/kg per d, measured during the last 2 months of the 11-month treatment period.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'hypertension',\n",
       "   'cardiac hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'hypertension',\n",
       "   'hypertension',\n",
       "   'plethysmography',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'cardiac hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'arteriosclerosis']},\n",
       " {'pmid': 11462757,\n",
       "  'sentence': 'This model is consistent with all of the present knowledge about ADHD including (a) the increased frequency of ADHD in the relatives of ADHD probands, (b) the presence of a wide spectrum of comorbid behaviors (depression, anxiety, learning, conduct, oppositional-defiant, conduct and substance abuse disorders) in ADHD probands and their relatives on both parental sides, (c) the close relationship to Tourette syndrome (TS), (d) the failure to find the genes for TS using linkage analysis, (e) the brain imaging studies showing hypometabolism of the frontal lobes, (f) the relationship between dopamine D2 receptor density and regional blood flow, (g) the correlation between tics and dopamine D2 receptor density in TS, (h) the motor hyperactivity of dopamine transporter and dopamine D3 receptor gene knockout mice, (i) the LeMoal and Shaywitz dopamine deficiency animal models of ADHD, (j) the NE models of ADHD, (k) the failure to explain ADHD on the basis of any single neurotransmitter defect, (l) the response of ADHD to dopamine and alpha 2-adrenergic agonists, (m) the small percentage of the variance of specific behaviors accounted for by each gene, and numerous other aspects of ADHD.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['depression', 'anxiety', 'substance abuse', 'hypometabolism']},\n",
       " {'pmid': 11471880,\n",
       "  'sentence': 'The study identified the following new interferants: acid phosphatase in serum by ibuprofen and theophylline; non-prostatic acid phosphatase in serum by cefoxitin and doxycycline; creatine kinase MB in serum by doxycycline; total bilirubin in serum (Jendrassik-Grof method) by rifampicin and intralipid; total bilirubin in serum (DPD method) by intralipid; creatinine in serum (Jaffe method) by cefoxitin; fructosamine in serum by levodopa and methyldopa; uric acid in serum by levodopa, methyldopa and tetracycline; carbamazepine in serum by doxycycline, levodopa, methyldopa and metronidazole; digitoxin in serum by rifampicin; phenytoin in serum by doxycycline, ibuprofen, metronidazole and theophylline; theophylline in serum by acetaminophen, cefoxitin, doxycycline, levodopa, phenylbutazone and rifampicin; tobramycin in serum by cefoxitin, doxycycline, levodopa, rifampicin and phenylbutazone; valproic acid in serum by phenylbutazone; C3 in serum by intralipid; C4 in serum by doxycycline; rheumatoid factor in serum by ibuprofen and metronidazole; pancreatic amylase and total amylase in urine by acetylcysteine, ascorbic acid, cefoxitin, gentamicin, levodopa, methyldopa and ofloxacin; magnesium in urine by acetylcysteine, gentamicin and methyldopa; beta2-microglobulin in urine by ascorbic acid; total protein in urine by ascorbic acid, Ca-dobesilate and phenylbutazone.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tobramycin',\n",
       "   'methyldopa',\n",
       "   'phenylbutazone',\n",
       "   'ofloxacin',\n",
       "   'ibuprofen',\n",
       "   'doxycycline',\n",
       "   'phenytoin',\n",
       "   'tetracycline',\n",
       "   'gentamicin',\n",
       "   'magnesium',\n",
       "   'levodopa',\n",
       "   'metronidazole'],\n",
       "  'reaction': ['rheumatoid factor',\n",
       "   'rheumatoid factor',\n",
       "   'amylase',\n",
       "   'amylase',\n",
       "   'amylase',\n",
       "   'amylase']},\n",
       " {'pmid': 11768247,\n",
       "  'sentence': 'Selected important clinical learning points include the following: (1) glucose absorption mediated by SGLT1 is controlled by mRNA abundance, as well as by posttranscriptional processes including protein trafficking; (2) inducers of cytochrome P-450 decrease glucose and fructose absorption and increase glucose consumption in the intestine; (3) the regulated release of nutrients from the stomach into the upper intestine ensures that the modest intestinal transport reserve capacity is not exceeded; (4) hepatocyte growth factor and short-chain fatty acids may enhance intestinal adaptation and prevent the atrophy seen when total parenteral nutrition is infused; (5) inhibitors of pancreatic lipase and phospholipase H2 may be useful clinically to reduce absorption as part of a treatment program for obesity and hyperlipidemia; (6) several membrane-bound and cytosolic proteins have been identified in the enterocyte as well as in the hepatocyte and may be the target for the future therapeutic manipulation of bile acid metabolism and control of hyperlipidemia; (7) suspect bile acid malabsorption in the patient with otherwise unexplained chronic diarrhea; (8) a proportion of lipid absorption is protein-mediated, and this opens the way to targeting these proteins and thereby therapeutically modifying lipid absorption; (9) a high protein diet may be useful to increase the intestinal absorption of drugs transported by the H+/dipeptide cotransporter; (10) a metal transporter DCT1 has been identified, and this may open the way to a better understanding of disorders of, for example, iron and zinc metabolism; (11) the nutrient transporters such as SGLT1 are responsible for a portion of the intestinal absorption of water; (12) the influence of nitric oxide on intestinal water absorption and secretion depends on its concentration; (13) a trial of bile acid-sequestering agent may prove useful in the treatment of the patient who experiences diarrhea while taking an enteral diet; (14) a proteolytic extract from pineapple stems may prove to be useful to treat diarrhea, although the mechanism of this effect remains to be established; and (15) the antisecretory effect of the new peptide, sorbin, needs to be tested in a clinical situation on patients with diarrhea.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['growth',\n",
       "   'atrophy',\n",
       "   'parenteral nutrition',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'obesity',\n",
       "   'bile acid malabsorption',\n",
       "   'malabsorption']},\n",
       " {'pmid': 11775122,\n",
       "  'sentence': 'Furthermore, all antihypertensive drug classes can be divided into R drugs that block the renin factor, or V drugs that reduce body sodium volume; 5) these findings document our conception of two biochemically and physiologically different final factors that sustain all BP in which the sodium-volume factor continuously sustains cardiac output and flow while plasma renin-angiotensin sets total peripheral resistance (TPR), which, within the Poiseuille Equation (BP = cardiac output [CO] x TPR) describes our [Na+-volume x renin-angiotensin vasoconstriction] model that supports all normotension or hypertension; 6) in this light, we designed a visit-by-visit method for treating untreated hypertensives using the ambient plasma renin level and BP responses to guide primary drug therapy against either the V or R factor; and 7) for also correcting nonresponders receiving multiple drugs where renin testing correctly guides addition or subtraction of drugs depending on whether the test indicates unresponsiveness due to a reactive sodium-volume excess, or to lack of effectiveness of an R drug in a V patient or of a V drug in an R patient, or from large reactive increases in renin that override the R drug, calling for strengthening the R and/or removing V drugs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium', 'cardiac'],\n",
       "  'reaction': ['renin',\n",
       "   'cardiac output',\n",
       "   'cardiac output',\n",
       "   'vasoconstriction',\n",
       "   'hypertension',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'renin']},\n",
       " {'pmid': 11807119,\n",
       "  'sentence': 'Schemes are presented that propose a series of metabolic changes that result in a seamless transition through the following states: (1) the import of K(+), Cl(-) and water from the apoplast to the vacuole, the K(+) being admitted to the cytoplasm via a Ca(2+)-activated K(+)-H(+) symport and the water via a Ca(2+)-activated aquaporin; (2) the continued import of K(+) and water from the apoplast to the vacuole with the concomitant export of protons and the synthesis of malate from glucose in the cytoplasm for importation into the vacuole; (3) when the tension on the water column is optimal, respiration and photosynthesis is maximal resulting in biosynthetic reactions and growth; (4) when tension on the water column increases, K(+), Cl(-) and water are exported from the vacuole to the apoplast; (5) the continued export of K(+) and water from the vacuole to the apoplast with malate for export being synthesized in the cytoplasm; the export of K(+) resulting in the acidification of the vacuole; and (6) a further increase in tension results in the deactivation of the plasmalemma H(+)/ATPase by a further increase in cytoplasmic Ca(2+) which also indirectly activates the alternative oxidase.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['tension', 'growth', 'tension', 'tension']},\n",
       " {'pmid': 11819266,\n",
       "  'sentence': 'AIM:To study the short-term effect of Danshen (Salvia miltiorrhiza) on acetic acid induced chronic gastric ulcer in rats and its long-term effect in preventing recurrence.METHODS:Rats with acetic acid-induced gastric ulcer were treated with Danshen and cimetidine for 30 days.Traditional gastric mucosal auto-radiography and (3)H-TdR incorporation into gastric mucosa in vitro were employed to study the effects of Danshen in rat acetic acid-induced chronic gastric ulcer, including ulcer index (UI), ulcer inhibitory rate (IR) and label rate (LR).RESULTS:On the day 5, 30 and 126 of ulcer-making, the UI in the Danshen group was obviously lower than that in the cimetidine group and the control group (42.3 Â± 3.9, 3.6 Â± 1.2, 4.4 Â± 2.3; 49.1 Â± 3.6, 5.9 Â± 1.4, 9.2 Â± 1.3; 61.0 Â± 3.8, 8.9 Â± 2.5, 12.4 Â± 2.4, respectively, P < 0.01), the IR (%) in the Danshen group was obviously higher than that in the cimetidine group (31, 59, 64.8; 19, 33, 26, respectively), and the LR in the Danshen group was obviously higher than that in the cimetidine group and the control group (10.0 Â± 0.5,16.2 Â± 0.8, 15.0 Â± 0.6; 9.0 Â± 0.5, 13.9 Â± 0.6, 10.8 Â± 0.7; 6.5 Â± 0.7, 10.1 Â± 0.5, 8.0 Â± 0.7, respectively, P < 0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cimetidine'],\n",
       "  'reaction': ['gastric ulcer',\n",
       "   'ulcer',\n",
       "   'gastric ulcer',\n",
       "   'ulcer',\n",
       "   'gastric ulcer',\n",
       "   'ulcer',\n",
       "   'ulcer',\n",
       "   'ulcer']},\n",
       " {'pmid': 11819531,\n",
       "  'sentence': 'After incubating for 1h under 1g tension, varied concentrations of CCK-8 and secretin were added respectively in the tissue chamber and the contractile response was measured isometrically on ink-writing recorders.RESULTS:CCK-8 could increase (1) all regional circular and longitudinal muscular tension at rest (fundus LM 19.7% Â± 2.1%, P < 0.01; fundus CM 16.7% Â± 2.2%, P < 0.01; gastric body LM 16.8% Â± 2.3%, P < 0.01; body CM 12.7% Â± 2.6%, P <0.01; antrum LM 12.3% Â± 1.3%, P < 0.01; antrum CM 16.7% Â± 4.5%, P < 0.01; pylous CM 12.7% Â± 5.0%, P < 0.05);(2)contractile frequencies of body LM, both LM and CM of antrum and pylorus CM (5.1/min Â± 0.2/min to 5.6/min Â± 0.2/min, 5.9/min Â± 0.2/min to 6.6/min Â± 0.1/min, 5.4/min Â± 0.3/min to 6.3/min Â± 0.4/min, 1.3/min Â± 0.2/min to 2.3/min Â± 0.3/min, respectively, P < 0.05); the mean contractile amplitude of antral circular muscle (58.6% Â± 18.4%, P < 0.05) and (3)the motility index of pylorus CM (145.0% Â± 23.8%, P < 0.01), but decrease the mean contractile amplitude of gastric body and antral LM (-10.3% Â± 3.3%, -10.5% Â± 4.6%, respectively, P < 0.05 =.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['secretin'],\n",
       "  'reaction': ['tension', 'tension']},\n",
       " {'pmid': 11819637,\n",
       "  'sentence': 'AIM:To study relationship of injury induced by nitric oxide, oxidation, peroxidation,lipoperoxidation with chronic cholecystitis.METHODS:The values of plasma nitric oxide (P-NO), plasma vitamin C (P-VC), plasma vitamin E (P-VE), plasma beta-carotene (P-beta-CAR), plasma lipoperoxides (P-LPO), erythrocyte superoxide dismutase (E-SOD), erythrocyte catalase (E-CAT), erythrocyte glutathione peroxidase (E-GSH-Px) activities and erythrocyte lipoperoxides (E-LPO) level in 77 patients with chronic cholecystitis and 80 healthy control subjects were determined, differences of the above average values between the patient group and the control group and differences of the average values between preoperative and postoperative patients were analyzed and compared, linear regression and correlation of the disease course with the above determination values as well as the stepwise regression and correlation of the course with the values were analyzed.RESULTS:Compared with the control group, the average values of P-NO, P-LPO, E-LPO were significantly increased (P<0.01), and of P-VC, P-VE, P-beta-CAR, E-SOD, E-CAT and E-GSH-Px decreased (P <0.01) in the patient group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['beta-carotene'],\n",
       "  'reaction': ['injury', 'cholecystitis']},\n",
       " {'pmid': 11835089,\n",
       "  'sentence': 'After enalaprilat administration, there was significant differences between Groups 1 and 2, as follows: systolic blood pressure was 138 plus minus 16 versus 127 plus minus 14 mmHg (p = 0.05), left ventricular end-diastolic pressure was 15 plus minus 6 versus 7 plus minus 4 mmHg (p = 0.04), systemic vascular resistance was 1341 plus minus 290 versus 965 plus minus 271 dyne/sec/cm(minus sign5) (p = 0.05), pulmonary vascular resistance was 174 plus minus 39 versus 156 plus minus 15 dyne/sec/cm(minus sign5) (p = 0.05), end-diastolic volume was 87 plus minus 34 versus 107 plus minus 17 ml (p = 0.03), cardiac index was 3.0 versus 4.5 L min(minus sign1) m(minus sign2) (p = 0.01), left ventricle end-systolic wall stress was 31 plus minus 10 versus 22 plus minus 9 k dyne cm(minus sign5) (p = 0.01), ejection fraction was 69 plus minus 12 versus 81 plus minus 8% (p = 0.01), and wall motion index was 1.14 plus minus 0.1 versus 1.02 plus minus 0.1 (p = 0.001).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['enalaprilat', 'cardiac'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'cardiac index',\n",
       "   'stress',\n",
       "   'ejection fraction',\n",
       "   'ejection fraction']},\n",
       " {'pmid': 11843442,\n",
       "  'sentence': \"Ames' contentions that naturally occurring carcinogens are far more widespread than man-made ones, that pesticides prevent cancer by providing fruits and vegetables at lower costs to the poor, and that animal data on high risks with high doses cannot predict low risks from low doses in humans do not address key issues: 1) fruits and vegetables contain mixtures of carcinogens and anti-carcinogens, and selection effects from human exposures to these mixtures go back more than a million years; 2) exposures from bioconcentrations of biopersistent organochlorines in the food chain create particular risks for meat-eaters, who have higher cancer risks than vegetarians; 3) even low doses from ingestion of produce containing pesticide residues can cause tissue injury, which could itself promote cancer; 4) epidemiologic data show rises in cancer incidences in older people in many countries, major differences in cancer risks between countries, and converging trends in risks for populations migrating to certain countries; 5) studies of pesticide-exposed workers consistently show increased rates of cancers and birth defects and cancers in their offspring; 6) epidemiologic studies based on large databases tend to underestimate risks from environmental causes because of exposure misclassification; 7) exposures to many organochlorines may have pervasive effects on endocrine function; 8) crop yields can be increased with less use of pesticides.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['tissue injury', 'injury']},\n",
       " {'pmid': 11882576,\n",
       "  'sentence': 'We found that (1) compared with C57 mice, eNOS-/- mice that underwent sham surgery had significantly increased systolic blood pressure (P<0.05) and increased LV mass both initially and at 1 to 3 months, although cardiac function and histological findings did not differ between strains; (2) the development of HF and myocardial remodeling were similar after MI in both strains; and (3) ACEi improved cardiac function and remodeling in C57 mice, as evidenced by increased LV ejection fraction (LVEF) and LV shortening fraction (LVSF) and decreased diastolic LV dimension, mass, myocyte cross-sectional area, and interstitial collagen fraction, but these benefits were absent or diminished in eNOS-/- mice (for C57 versus eNOS-/-: increase in LVEF after ACEi, 14.2 +/- 2% versus -4.9 +/- 2.5%, respectively [P<0.001]; increase in LVSF, 8.6 +/- 2.1% versus -7.2 +/- 2.8%, respectively [P<0.01]; and decrease in LV mass, -16.6 +/- 15 versus 73 +/- 23 mm(3), respectively [P<0.01]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['surgery',\n",
       "   'blood pressure',\n",
       "   'mass',\n",
       "   'ejection fraction',\n",
       "   'ejection fraction',\n",
       "   'mass',\n",
       "   'mass']},\n",
       " {'pmid': 11896427,\n",
       "  'sentence': 'To test this approach, 55 patients with relapsed/refractory or high-risk NHL or relapsed/refractory HD were enrolled in the following protocol: stem cell mobilization: cyclophosphamide (4.5 g/m(2)) + etoposide (2.0 g/m(2)) followed by GM-CSF or G-CSF; high-dose therapy: gemcitabine (1.0 g/m(2)) on day -5, BCNU (300 mg/m(2)) + gemcitabine (1.0 g/m(2)) on day -2, melphalan (140 mg/m(2)) on day -1, blood stem cell infusion on day 0; post-transplant immunotherapy (B cell NHL): rituxan (375 mg/m(2)) weekly for 4 weeks + GM-CSF (250 microg thrice weekly) (weeks 4-8); post-transplant involved-field radiotherapy (HD): 30-40 Gy to pre-transplant areas of disease (weeks 4-8); post-transplant consolidation chemotherapy (all patients): dexamethasone (40 mg daily)/cyclophosphamide (300 mg/m(2)/day)/etoposide (30 mg/m(2)/day)/cisplatin (15 mg/m(2)/day) by continuous intravenous infusion for 4 days + gemcitabine (1.0 g/m(2), day 3) (months 3 + 9) alternating with dexamethasone/paclitaxel (135 mg/m(2))/cisplatin (75 mg/m(2)) (months 6 + 12).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gemcitabine'],\n",
       "  'reaction': ['infusion', 'radiotherapy', 'chemotherapy', 'infusion']},\n",
       " {'pmid': 11982721,\n",
       "  'sentence': 'The key points are: (i) approved therapeutic agents for chronic hepatitis B (CHB) are IFN, lamivudine and thymosin (in a few countries only); (ii) indications for IFN therapy are viremia in compensated CHB patients with moderately raised ALT; (iii) lamivudine has broader therapeutic indications: it is effective in subgroups of CHB patients with compensated or decompensated liver diseases, but generally works better if patients have raised ALT; (iv) lamivudine has a potent suppressive action on HBV replication, including HBeAg-negative variants, but cannot eliminate cccDNA; this is the reason for the relapse of disease after discontinuing treatment, unless HBeAg seroconversion is obtained; (v) successful use of lamivudine aims at HBeAg seroconversion or profound suppression of HBV-DNA to serum levels of less than 100 000 viral copies/mL, in order to prevent emergence of drug-resistant YMDD mutants (which commences from 6 months onward); (vi) YMDD mutants may cause a flare of hepatitis, resulting in deterioration of liver histology and, occasionally, liver failure; (vii) combination therapy of lamivudine with IFN (standard or pegylated) or other nucleoside analogs should be the next advance.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lamivudine'],\n",
       "  'reaction': ['chronic hepatitis',\n",
       "   'chronic hepatitis b',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'hepatitis',\n",
       "   'histology']},\n",
       " {'pmid': 11994582,\n",
       "  'sentence': 'The planned three-stage forehead flap technique of nasal repair with an intermediate operation (1) transfers subtle, conforming forehead skin of ideal thinness for cover, with little risk of necrosis; (2) uses primary and delayed primary grafts and permits modification of initial cartilage grafts to correct failures of design, malposition, or scar contraction before flap division; (3) creates an ideal, rigid subsurface framework of hard and soft tissue that is reflected through overlying skin and blends well into adjacent recipient tissues; (4) expands the application of lining techniques to include the use of skin grafts for lining at the first stage, or as a \"salvage procedure\" during the second stage, and also permits the aesthetic use of folded forehead flaps for lining; (5) ensures maximal blood supply and vascular safety to all nasal layers; (6) provides the surgeon with options to salvage reconstructive catastrophes; (7) improves the aesthetic result while decreasing the number and difficulty of revision operations and overall time for repair; and (8) emphasizes the interdependence of anatomy (cover, lining, and support) and provides insight into the nature of wound injury and repair in nasal reconstruction.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['necrosis', 'scar', 'wound', 'injury']},\n",
       " {'pmid': 11996197,\n",
       "  'sentence': 'The more recent trials indicate that: (1) diuretics and beta-blockers appear to be as effective in reducing overall morbidity/ mortality as other agents (Swedish Trial in Old Patients with Hypertension [STOP-2], United Kingdom Prospective Diabetes Study [UKPDS], Intervention as a Goal in Hypertension Treatment [INSIGHT], Nordic diltiazem [NORDIL]); (2) the use of an a-blocker results in more cardiovascular events, especially congestive heart failure, when compared with a diuretic (Antihypertensive Therapy and Lipid Lowering Heart Attack Trial [ALLHAT]); (3)the use of an angiotensin-converting enzyme (ACE) inhibitor results in fewer myocardial infarctions and episodes of heart failure than calcium channel blockers in the elderly and in diabetic patients (Fosinopril vs. Amlodipine Cardiovascular Events Randomized Trial [FACET], Appropriate Blood Pressure Control in Diabetes [ABCD], STOP-2) - other data (Captopril Prevention Project [CAPPP]) suggest that the use of an ACE inhibitor is preferred in diabetic patients; (4) overall cardiovascular events are similar with calcium channel blockers compared with a diuretic - however, there are fewer strokes with non-dihydropyridine calcium channel blockers (NORDIL) and a trend towards an increase in heart failure and myocardial infarctions with either a dihydropyridine or non-dihydropyridine calcium channel blockers compared with a diuretic (INSIGHT, NORDIL); (5) angiotensin receptor blockers (ARBs) will decrease proteinuria and slow progression of renal disease in type 2 diabetic patients when compared with regimens that do not include an ARB or an ACE inhibitor (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan [RENAAL], Irbesartan Type II Diabetic Nephropathy Trial [IDNT], Irbesartan Type II Diabetes with Microalbuminuria [IRMA Il]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['fosinopril',\n",
       "   'diltiazem',\n",
       "   'amlodipine',\n",
       "   'captopril',\n",
       "   'irbesartan',\n",
       "   'calcium',\n",
       "   'losartan'],\n",
       "  'reaction': ['hypertension',\n",
       "   'hypertension',\n",
       "   'elderly',\n",
       "   'blood pressure',\n",
       "   'proteinuria',\n",
       "   'diabetic nephropathy',\n",
       "   'nephropathy',\n",
       "   'microalbuminuria']},\n",
       " {'pmid': 12018412,\n",
       "  'sentence': 'Antibiotic regimens (intramammary antibiotic, penicillin-based parenteral treatment) and intramuscular oxytocin were tested for effectiveness against experimental infection by Streptococcus uberis with the following results from 54 animals: a) no treatment led to deterioration of infected quarters, requiring intervention within 48 h for cow health; b) aggressive intramammary antibiotic at every milking achieved 70% clinical cure in 3 d and 100% cure within 6 d; overall bacteriological cure was 80%; c) parenteral treatment alone used about 14 times as much antibiotic with 18% clinical cure in 3 d and 91% within 6 d; overall bacteriological cure was 80%; d) combination of aggressive intramammary and parenteral treatments achieved 61% clinical cure in 3 d and 100% within 6 d; overall bacteriological cure was 72%; e) intramammary antibiotic at labeled rates (1x for 3 d) achieved 27% clinical cure in 3 d but 91% within 6 d of treatment; overall bacteriological cure was 64%; f) use of oxytocin alone for 3 d failed to achieve clinical improvement with an increase in the severity of mastitis; g) combining oxytocin with labeled use of intramammary antibiotic (1x for 3 d) was unsuccessful: 0% clinical cures in 3 d, 10% in 6 d; significantly poorer than intramammary antibiotic alone.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxytocin'],\n",
       "  'reaction': ['infection', 'mastitis']},\n",
       " {'pmid': 12025913,\n",
       "  'sentence': 'The results showed that plasma levels of CRP are significantly higher in patients with UA than those in patients with SA and control subjects (5.1 +/- 1.4 mg/L vs 1.7 +/- 0.4 mg/L and 1.3 +/- 0.2 mg/L, p<0.01, respectively) with no difference between the latter two groups (p>0.05); the total incidence of clinical events during in-hospital follow-up was higher in the group A (p<0.01); the scores of coronary stenosis are significantly higher in patients with SA than those in patients with UA (4.9 +/- 2.1 vs 3.4 +/- 1.4, p<0.05); there is no correlation between plasma levels of CRP and serum total cholesterol (TC) as well as high-density lipoprotein cholesterol (HDL-C) in both groups (p>0.05 respectively); there was no correlation between plasma levels of CRP and severity of coronary stenosis was found in patients with UA (p>0.05) but a significant positive association in patients with SA (p<0.001); and the patients with persistent, severe, treatment-unresponsive UA had significantly higher CRP levels as well as incidence of clinical events than patients with treatment-responsive UA (7.4 +/- 1.8 mg/L vs 2.6 +/- 1.3 mg/L, p<0.01; 0 vs 22.2%, p<0.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['stenosis', 'stenosis']},\n",
       " {'pmid': 12087878,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abiciximab, acetylcholine chloride, acetylcysteine, alefacept, alemtuzumab, alicaforsen, alteplase, aminopterin, amoxicillin sodium, amphotericin B, anastrozole, argatroban monohydrate, arsenic trioxide, aspirin, atazanavir, atorvastatin, augmerosen, azathioprine; Benzylpenicillin, BMS-284756, botulinum toxin type A, botulinum toxin type B, BQ-123, budesonide, BXT-51072; Calcium folinate, carbamazepine, carboplatin, carmustine, ceftriaxone sodium, cefuroxime axetil, chorionic gonadotropin (human), cimetidine, ciprofloxacin hydrochloride, cisplatin, citalopram hydrobromide, cladribine, clarithromycin, clavulanic acid, clofarabine, clopidogrel hydrogensulfate, clotrimazole, CNI-1493, colesevelam hydrochloride, cyclophosphamide, cytarabine; Dalteparin sodium, daptomycin, darbepoetin alfa, debrisoquine sulfate, dexrazoxane, diaziquone, didanosine, docetaxel, donezepil, doxorubicin hydrochloride liposome injection, DX-9065a; Eberconazole, ecogramostim, eletriptan, enoxaparin sodium, epoetin, epoprostenol sodium, erlizumab, ertapenem sodium, ezetimibe; Fampridine, fenofibrate, filgrastim, fluconazole, fludarabine phosphate, fluorouracil, 5-fluorouracil/epinephrine, fondaparinux sodium, formoterol fumarate; Gabapentin, gemcitabine, gemfibrozil, glatiramer; Heparin sodium, homoharringtonine; Ibuprofen, iloprost, imatinib mesilate, imiquimod, interferon alpha-2b, interferon alpha-2c, interferon-beta; KW-6002; Lamotrigine, lanoteplase, metoprolol tartrate, mitoxantrone hydrochloride; Naproxen sodium, naratriptan, Natalizumab, nelfinavir mesilate, nevirapine, nifedipine, NSC-683864; Oral heparin; Paclitaxel, peginterferon alfa-2b, phenytoin, pimecrolimus, piperacillin, pleconaril, pramipexole hydrochloride, prednisone, pregabalin, progesterone; Rasburicase, ravuconazole, reteplase, ribavirin, rituximab, rizatriptan, rosiglitazone maleate, rotigotine; Semaxanib, sildenafil citrate, simvastatin, stavudine, sumatriptan; Tacrolimus, tamoxifen citrate, tanomastat, tazobactam, telithromycin, tenecteplase, tolafentrine, tolterodine tartrate, triamcinolone acetonide, trimetazidine, troxacitabine; Valproic acid, vancomycin hydrochloride, vincristine, voriconazole, Warfarin sodium; Ximelagatran, Zidovudine, zolmitriptan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['daptomycin',\n",
       "   'natalizumab',\n",
       "   'zolmitriptan',\n",
       "   'clofarabine',\n",
       "   'nelfinavir',\n",
       "   'amoxicillin',\n",
       "   'eletriptan',\n",
       "   'cytarabine',\n",
       "   'rituximab',\n",
       "   'mitoxantrone',\n",
       "   'alteplase',\n",
       "   'fluorouracil',\n",
       "   'gemcitabine',\n",
       "   'carboplatin',\n",
       "   'cimetidine',\n",
       "   'telithromycin',\n",
       "   'ertapenem',\n",
       "   'tenecteplase',\n",
       "   'cladribine',\n",
       "   'imiquimod',\n",
       "   'triamcinolone',\n",
       "   'zidovudine',\n",
       "   'epoetin',\n",
       "   'anastrozole',\n",
       "   'stavudine',\n",
       "   'argatroban',\n",
       "   'fludarabine',\n",
       "   'benzylpenicillin',\n",
       "   'paclitaxel',\n",
       "   'darbepoetin',\n",
       "   'pimecrolimus',\n",
       "   'piperacillin',\n",
       "   'docetaxel',\n",
       "   'clopidogrel',\n",
       "   'simvastatin',\n",
       "   'voriconazole',\n",
       "   'nifedipine',\n",
       "   'enoxaparin',\n",
       "   'tacrolimus',\n",
       "   'imatinib',\n",
       "   'sumatriptan',\n",
       "   'sodium',\n",
       "   'tazobactam',\n",
       "   'ibuprofen',\n",
       "   'phenytoin',\n",
       "   'cisplatin',\n",
       "   'heparin',\n",
       "   'fluconazole',\n",
       "   'glatiramer',\n",
       "   'ciprofloxacin',\n",
       "   'vancomycin',\n",
       "   'clarithromycin',\n",
       "   'fenofibrate',\n",
       "   'tamoxifen',\n",
       "   'atorvastatin',\n",
       "   'calcium',\n",
       "   'carmustine',\n",
       "   'rizatriptan',\n",
       "   'acetonide',\n",
       "   'rosiglitazone',\n",
       "   'metoprolol',\n",
       "   'alefacept',\n",
       "   'dalteparin',\n",
       "   'naratriptan',\n",
       "   'doxorubicin',\n",
       "   'sildenafil',\n",
       "   'alemtuzumab',\n",
       "   'formoterol',\n",
       "   'atazanavir',\n",
       "   'fondaparinux',\n",
       "   'budesonide',\n",
       "   'filgrastim'],\n",
       "  'reaction': ['injection', 'progesterone']},\n",
       " {'pmid': 12088915,\n",
       "  'sentence': 'Agents widely used in clinical practice include: (a) uptake and storage of radiolabelled cholesterol analogues via the low density lipoprotein (LDL) receptor and cholesterol ester storage pool in the adrenal cortex ((131)I-6-beta-iodomethyl-norcholesterol, (75)Se-selenomethyl-norcholesterol); (b) catecholamine type I, presynaptic, uptake mechanism and intracellular granule uptake and storage mechanism in the adrenal medulla and extra-adrenal paraganglia ((131)I-, (123)I- and (124)I-meta-iodo-benzyl-guanidine (MIBG), (18)F-metafluoro-benzyl-guanidine); (c) cell surface receptor binding of peptides/neurotransmitters/modulators such as for the family of five subtypes of somatostatin receptors ((123)I-tyr-octreotide, (111)In-DTPA-octreotide, (111)In-DOTA-octreotide and many others); (d) although not specific for the adrenal gland, increased glycolysis by tumours, particularly the most malignant varieties, (18)F-2-fluoro-d-deoxyglucose can thus be expected to depict certain malignant lesions such as malignant pheochromocytomas (particularly the minority which are not detected by MIBG) and adrenal incidentalomas (particularly when they occur in patients with known extra-adrenal malignancies).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'somatostatin'],\n",
       "  'reaction': ['low density lipoprotein', 'low density lipoprotein']},\n",
       " {'pmid': 12092009,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, acarbose, alefacept, alteplase, amisulpride, amoxicillin trihydrate, apomorphine hydrochloride, aprepitant, argatroban monohydrate, aspirin, atenolol; Betamethasone dipropionate, betamethasone valerate, bicalutamide, bleomycin sulfate; Calcium carbonate, candesartan cilexetil, celecoxib, cetirizine hydrochloride, cisplatin, clarithromycin, clavulanate potassium, clomethiazole edisilate, clopidogrel hydrogensulfate, cyclophosphamide, chorionic gonadotropin (human); Dalteparin sodium, desloratadine, dexamethasone, doxorubicin, DPC-083; Efalizumab, efavirenz, enoxaparin sodium, eprosartan mesilate, etanercept, etoposide, ezetimibe; Faropenem daloxate, fenofibrate, fluocinolone acetonide, flutamide, fluvastatin sodium, follitropin beta, fondaparinux sodium; Gabapentin, glibenclamide, goserelin, granisetron hydrochloride; Haloperidol, hydrochlorothiazide; Imiquimod, interferon beta-1a, irbesartan, iseganan hydrochloride; L-758298, lamivudine, lanoteplase, leflunomide, leuprorelin acetate, loratadine, losartan potassium; Melagatran, metformin hydrochloride, methotrexate, metronidazole, micafungin sodium, mitoxantrone hydrochloride; Nelfinavir mesilate, neutral insulin injection, nizatidine; Olopatadine hydrochloride, omeprazole, ondansetron hydrochloride; Pamidronate sodium, paracetamol, paroxetine hydrochloride, perindopril, pimecrolimus, pioglitazone hydrochloride, piroxicam, pleconaril, pralmorelin, pravastatin sodium, prednisolone, prednisone, propofol; Raloxifene hydrochloride, ranpirnase, remifentanil hydrochloride, risedronate sodium, risperidone, rofecoxib, ropinirole hydrochloride, rosuvastatin calcium; Sevoflurane, sildenafil citrate, simvastatin, somatropin; Tacrolimus, tamoxifen citrate, telmisartan, temozolomide, thiopental sodium, tinzaparin sodium, tirofiban hydrochloride, treosulfan, triamcinolone acetonide; Urokinase; Valsartan, vardenafil, vincristine; Warfarin sodium; Ximelagatran; Zidovudine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['prednisolone',\n",
       "   'candesartan',\n",
       "   'ondansetron',\n",
       "   'aprepitant',\n",
       "   'nizatidine',\n",
       "   'imiquimod',\n",
       "   'zidovudine',\n",
       "   'rofecoxib',\n",
       "   'simvastatin',\n",
       "   'haloperidol',\n",
       "   'sodium',\n",
       "   'treosulfan',\n",
       "   'bicalutamide',\n",
       "   'fenofibrate',\n",
       "   'methotrexate',\n",
       "   'efavirenz',\n",
       "   'tirofiban',\n",
       "   'piroxicam',\n",
       "   'loratadine',\n",
       "   'celecoxib',\n",
       "   'atenolol',\n",
       "   'dalteparin',\n",
       "   'sildenafil',\n",
       "   'granisetron',\n",
       "   'micafungin',\n",
       "   'losartan',\n",
       "   'fluvastatin',\n",
       "   'lamivudine',\n",
       "   'risedronate',\n",
       "   'nelfinavir',\n",
       "   'alteplase',\n",
       "   'efalizumab',\n",
       "   'olopatadine',\n",
       "   'metronidazole',\n",
       "   'triamcinolone',\n",
       "   'leuprorelin',\n",
       "   'paroxetine',\n",
       "   'clopidogrel',\n",
       "   'bleomycin',\n",
       "   'sevoflurane',\n",
       "   'acetonide',\n",
       "   'alefacept',\n",
       "   'valsartan',\n",
       "   'amoxicillin',\n",
       "   'abacavir',\n",
       "   'rosuvastatin',\n",
       "   'argatroban',\n",
       "   'pimecrolimus',\n",
       "   'enoxaparin',\n",
       "   'eprosartan',\n",
       "   'tacrolimus',\n",
       "   'cisplatin',\n",
       "   'potassium',\n",
       "   'clarithromycin',\n",
       "   'tamoxifen',\n",
       "   'fluocinolone',\n",
       "   'vardenafil',\n",
       "   'goserelin',\n",
       "   'tinzaparin',\n",
       "   'omeprazole',\n",
       "   'fondaparinux',\n",
       "   'etanercept',\n",
       "   'raloxifene',\n",
       "   'desloratadine',\n",
       "   'pamidronate',\n",
       "   'telmisartan',\n",
       "   'metformin',\n",
       "   'mitoxantrone',\n",
       "   'perindopril',\n",
       "   'pioglitazone',\n",
       "   'hydrochlorothiazide',\n",
       "   'pravastatin',\n",
       "   'flutamide',\n",
       "   'risperidone',\n",
       "   'calcium',\n",
       "   'doxorubicin',\n",
       "   'amisulpride',\n",
       "   'remifentanil',\n",
       "   'irbesartan'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 12211284,\n",
       "  'sentence': \"Although many of the recommendations in the 2002 guidelines are the same as those in 1996, they include some key changes: * Recommendation of universal prenatal screening for vaginal and rectal GBS colonization of all pregnant women at 35-37 weeks' gestation, based on recent documentation in a large retrospective cohort study of a strong protective effect of this culture-based screening strategy relative to the risk-based strategy * Updated prophylaxis regimens for women with penicillin allergy * Detailed instruction on prenatal specimen collection and expanded methods of GBS culture processing, including instructions on antimicrobial susceptibility testing * Recommendation against routine intrapartum antibiotic prophylaxis for GBS-colonized women undergoing planned cesarean deliveries who have not begun labor or had rupture of membranes * A suggested algorithm for management of patients with threatened preterm delivery * An updated algorithm for management of newborns exposed to intrapartum antibiotic prophylaxis Although universal screening for GBS colonization is anticipated to result in further reductions in the burden of GBS disease, the need to monitor for potential adverse consequences of intrapartum antibiotic use, such as emergence of bacterial antimicrobial resistance or increased incidence or severity of non-GBS neonatal pathogens, continues, and intrapartum antibiotics are still viewed as an interim strategy until GBS vaccines achieve licensure.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['penicillin'],\n",
       "  'reaction': ['prophylaxis', 'prophylaxis', 'delivery', 'prophylaxis']},\n",
       " {'pmid': 12370077,\n",
       "  'sentence': 'This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125/R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP-14637, NMS03); for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril); for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947); for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and D-cyclohexenylguanine); for the treatment of VZV infections, bicyclic furopyrimidine analogues; for the treatment of CMV infections, fomivirsen; for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); for the treatment of HBV infections, adefovir dipivoxil; for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tipranavir',\n",
       "   'emtricitabine',\n",
       "   'zanamivir',\n",
       "   'oseltamivir',\n",
       "   'atazanavir'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 12550067,\n",
       "  'sentence': 'Serum chromium level appeared to be higher in the general population in our country compared to western countries (36.5-59.5 nmol/L as compared to 2.3-40.3 nmol/L) However, the local diabetics were found to have a lower serum chromium level than the healthy controls (32.3 nmol/L against 44.7 nmol/L; p < 0.0001) and a mean increase of 3.5 nmol/L was noted after 12 weeks of chromium supplementation that was, expectedly, not seen in the placebo phase (p < 0.0001).Significant improvement in glycaemic control was noted in the chromium-treated group (DeltaFasting serum glucose = 0.44 mmol/L, p < 0.001; DeltaPost-prandial serum glucose = 1.97 mmol/L, p < 0.001; Deltaglycated hemoglobin = 0.01; p = 0.04, in comparison to placebo) This was accompanied by a significant greater fall in fasting serum insulin in the chromium-treated group, p < 0.05.The change in lipid parameters (total serum cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides) did not show significant difference between the chromium and placebo groups.Clinically significant hematological, renal or hepatic toxicity were excluded by routine hemogram, serum urea, creatinine, alanine amino transferase (ALT) and alkaline phosphatase estimations.In conclusion, chromium supplementation seems to improve glycaemic control in type 2 diabetic patients, which appears to be due to an increase in insulin action rather than stimulation of insulin secretion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'chromium'],\n",
       "  'reaction': ['fall',\n",
       "   'fasting',\n",
       "   'high density lipoprotein',\n",
       "   'high density lipoprotein',\n",
       "   'low density lipoprotein',\n",
       "   'low density lipoprotein']},\n",
       " {'pmid': 12598934,\n",
       "  'sentence': 'The results are as follows: (1) after H/R injury, cardiomyocytes contracted, tending to get round in shape and its pseudopods decreased, while marked morphological changes were not observed in ADO group; (2) LDH leakage maintained at a lower level in ADO group than that in the control group during H/R (both P<0.01); (3) ADO significantly reduced the concentration of calcium in cells and prevented calcium overload during H/R (both P<0.01); (4) ADO markedly reduced the content of MDA during H/R (both P<0.01); (5) ADO inhibited the production of TNF-alpha during H/R (both P<0.01); and (6) ADO down-regulated NF-kappaB binding activity of cardiomyocytes during H/R (both P<0.01) The results suggest that (1) exogenous ADO attenuates H/R injury of cultured cardiomyocytes; (2) exogenous ADO inhibits the production of TNF-alpha after H/R injury; (3) exogenous ADO prevents the activation of NF-kappaB, which may be the molecular mechanism of down-regulation of TNF-alpha expression.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['injury', 'injury', 'injury']},\n",
       " {'pmid': 12616707,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, adalimumab, adefovir dipivoxil, AdGVVEGF121.10, anastrozole, anecortave acetate, aripiprazole, asulacrine isethionate, atazanavir, ATL-962, 16-Aza-epothilone B; Bevacizumab, bicalutamide, blonanserin, BMS-188667, bosentan; Celecoxib, celmoleukin, cetuximab, cilomilast, cinacalcet hydrochloride, CNTF(Ax15), colesevelam hydrochloride; Daclizumab, delavirdine mesilate, desogestrel, desoxyepothilone B, dexmethylphenidate hydrochloride, duloxetine hydrochloride; Ecogramostim, emtricitabine, epalrestat, escitalopram oxalate, examorelin, exendin-4, ezetimibe; Fidarestat, frovatriptan; HIV-1 Immunogen; Iloperidone, insulin detemir, insulin lispro, irinotecan hydrochloride; Keratinocyte growth factor; Lasofoxifene tartrate, levetiracetam, levormeloxifene, levosimendan, lumiracoxib, LY-307161 SR; Memantine hydrochloride, MEN-10755, metformin hydrochloride, metreleptin, motexafin gadolinium; Naratriptan hydrochloride, natalizumab, nesiritide, nicotine, NN-2211, NN-414; Olanzapine, omalizumab; Pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegvisomant, pimecrolimus, pirfenidone, pramlintide acetate prasterone, pregabalin; Quetiapine fumarate; Rabeprazole sodium, raloxifene hydrochloride, raltitrexed, rDNA insulin, rFGF-2, risedronate sodium, rofecoxib, roflumilast, rosiglitazone maleate; SN-22995; Tacrolimus, tadalafil, tegaserod maleate, tiotropium bromide, tomoxetine hydrochloride, trastuzumab, trimegestone; Voglibose, Voriconazole; Ziprasidone hydrochloride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['memantine',\n",
       "   'tadalafil',\n",
       "   'bicalutamide',\n",
       "   'rofecoxib',\n",
       "   'irinotecan',\n",
       "   'rabeprazole',\n",
       "   'delavirdine',\n",
       "   'sodium',\n",
       "   'raltitrexed',\n",
       "   'levetiracetam',\n",
       "   'quetiapine',\n",
       "   'naratriptan',\n",
       "   'tegaserod',\n",
       "   'iloperidone',\n",
       "   'bosentan',\n",
       "   'duloxetine',\n",
       "   'atazanavir',\n",
       "   'emtricitabine',\n",
       "   'desogestrel',\n",
       "   'tacrolimus',\n",
       "   'trastuzumab',\n",
       "   'frovatriptan',\n",
       "   'adalimumab',\n",
       "   'celecoxib',\n",
       "   'aripiprazole',\n",
       "   'voriconazole',\n",
       "   'raloxifene',\n",
       "   'omalizumab',\n",
       "   'natalizumab',\n",
       "   'risedronate',\n",
       "   'daclizumab',\n",
       "   'abacavir',\n",
       "   'tiotropium',\n",
       "   'cinacalcet',\n",
       "   'metformin',\n",
       "   'pimecrolimus',\n",
       "   'anastrozole',\n",
       "   'rosiglitazone',\n",
       "   'cetuximab',\n",
       "   'bevacizumab',\n",
       "   'roflumilast',\n",
       "   'gadolinium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 12642392,\n",
       "  'sentence': '(2) Our results indicate that: (1) cadmium is taken up by the neurons in a dose and serum dependent way; (2) cadmium, at concentrations from 1 micro M or 10 micro M (depending on the absence or the presence of serum) up to 100 micro M, decreases the metabolic capacity, which was evaluated by the XTT (tetrazolium salt) test; (3) cadmium induces apoptosis and LDH (lactate dehydrogenase) release in a dose dependent way; (4) in a serum-free medium, the cadmium-induced apoptosis is accompanied by caspase-3 activation; (5) both the caspase-3 activation and the cadmium-induced apoptosis are reversed by N-acethyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO), a selective caspase-3 inhibitor, indicating that the caspase-3 pathway is involved in cadmium-induced apoptosis in cortical neurons; and (6) the cadmium concentrations which produce caspase-3 activation do not modify the intracellular ATP levels; however, higher cadmium concentrations lead to both intracellular ATP depletion and ATP release, but do not increase the caspase-3 activity, indicating that cadmium also produces cellular death by necrosis.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['apoptosis',\n",
       "   'apoptosis',\n",
       "   'apoptosis',\n",
       "   'apoptosis',\n",
       "   'death',\n",
       "   'necrosis']},\n",
       " {'pmid': 12846561,\n",
       "  'sentence': 'The obtained data revealed (i) the extent of light-induced formation of about one Q(A)(-*)per 230 chlorophylls (Chl) remains virtually invariant to dehydration down to the lowest values of relative humidity (6-8% RH); (ii) a decrease of the RH to 30% leads to severe blockage of the electron transfer from Q(A)(-*) to Q(B) and the progressive replacement of water oxidation by photooxidation of high potential (HP) cytochrome (Cyt) b559 in untreated PS II samples or accessory Chl and carotenoid (Car) molecules in samples with preoxidized Cyt b559; (iii) photooxidation of Cyt b559 is followed by its photoreduction, concomitant with photooxidation of Chl and Car; (iv) in dry samples with preoxidized Cyt b559, not more than a half of total Cyt b559 can be photochemically reduced, independent of the extent of Cyt b559 in the HP form; (v) at low RH values, Cyt b559 photoreduction in samples with preoxidized heme groups and photoaccumulation of Q(A)(-*) take place with biphasic kinetics with similar rate constants for both processes; (vi) Cyt b559 photoreduction in dry samples is DCMU insensitive, while the dark rereduction of photooxidized Cyt b559 is inhibited by DCMU; (vii) fast and slow kinetic phases of Cyt b559 photoreduction dramatically differ in their dependencies on the intensity of CW illumination and are associated with electron donation to Cyt b559 from Q(A)(-*) and pheophytin(-*), respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['dehydration']},\n",
       " {'pmid': 12877764,\n",
       "  'sentence': 'In contrast, nandrolone decanoate treatment of suspended animals reduced unweighting-induced atrophy in the muscle and maintained: (1) the relative amplitude of twitch tension to the maximal Ca(2+) activated in saponin-treated fibers (control: 3.6 +/- 0.4%, unloaded: 6.9 +/- 1.1% and unloaded-treated: 4.6 +/- 0.2%), (2) the time to peak tension (control: 130 +/- 18 ms, unloaded: 85 +/- 12 ms and unloaded-treated: 110 +/- 11 ms), (3) the time constant of relaxation (control: 320 +/- 12 ms, unloaded: 120 +/- 13 ms and unloaded-treated: 349 +/- 20 ms), (4) the relative amplitude of K(+) contracture tension to the maximal Ca(2+) activated in saponin-treated fibers (control: 82.9 +/- 3.1%, unloaded: 65.1 +/- 2.8%, and unloaded-treated: 91.7 +/- 1.9%), (5) the potential at 50% of the activation curve (control: -40.4 +/- 1.2 mV, unloaded: -35.5 +/- 1.6 mV, and unloaded-treated: -48.4 +/- 1.2 mV), and (6) the potential at 50% of the inactivation curve (control: 42.2 +/- 1.9 mV, unloaded: -34.5 +/- 1.1 mV, and unloaded-treated: -37.9 +/- 1.1 mV).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nandrolone'],\n",
       "  'reaction': ['atrophy', 'tension', 'tension', 'tension']},\n",
       " {'pmid': 14453773,\n",
       "  'sentence': 'This paper reports on laboratory studies made in guinea-pigs on puncture wounds infected with fixed rabies virus and treated one hour later with various substances, the purpose being to review the experience of previous workers and to explore new approaches to the problem of local treatment of wounds inflicted by rabid animals.AMONG THE MEASURES AFFORDING GREATER OR LESSER PROTECTION WERE: nitric acid cauterization; direct application of benzalkonium chloride to the wound or its infiltration, as well as that of methylbenzethonium chloride, proximal to the wound; repeated swabbing and flushing with 20% soap solution or benzalkonium chloride; local inoculation of procaine anaesthetics; infiltration of the leg wound, or inoculation of the opposite leg, with antirabies gamma-globulin; and infiltration of the wound with interferon prepared in guinea-pig tissue cultures.Protection was not afforded by flushing with 20% soap solution alone; topical application of aqueous or tincture preparations of iodine or thiomersal; inoculation of phenoxybenzamine, physostigmine or diphenhydramine hydrochloride; or infiltration of the wound with interferon prepared on monkey kidney tissue cultures.The authors conclude that, at the present time, very vigorous cleansing of the wound with 20% soap solution or 2% benzalkonium chloride, local infiltration of the wound with antirabies serum and-to minimize pain-the use of procaine in saline are indicated in the local treatment of wounds for the prevention of rabies.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['benzalkonium',\n",
       "   'physostigmine',\n",
       "   'gamma-globulin',\n",
       "   'procaine'],\n",
       "  'reaction': ['rabies',\n",
       "   'wound',\n",
       "   'wound',\n",
       "   'flushing',\n",
       "   'wound',\n",
       "   'wound',\n",
       "   'flushing',\n",
       "   'wound',\n",
       "   'wound',\n",
       "   'wound',\n",
       "   'rabies']},\n",
       " {'pmid': 14518092,\n",
       "  'sentence': \"The following differences were found between the respective groups: 1. the ultrasonographic examination of carotid arteries demonstrated sclerotic plates or carotid stenosis in 21.3% of patients with florid Cushing's syndrome and 41.4% in patients with corticolism having been cured-up against 11.7% in the relevant control group; 2. the examination of skin microcirculation by the laser-doppler method revealed a lower velocity of perfusion increase during examination of postocclusion hyperemia in patients with florid Cushing's syndrome and hypercortisolism having been cured-up against a control group (CUSH., P < 0.04; previous cured-up, P < 0.02) as well as thermally-induced hyperemia (CUSH., P < 0.03; formerly cured-up, P < 0.04); 3. the laboratory examination of patients with florid Cushing's syndrome revealed higher values of LDL-cholesterol (P < 0.05) and total cholesterol (P < 0.001), malonyldialdehyde as an indicator of increased formation of oxygen radicals (P < 0.05) and oromucoid, the protein of acute phase, signaling a chronic inflammation (P < 0.05); 4. in patients who previously suffered from hypercortisolism increased levels of fibrinogen (P < 0.03) and the cytoadhesive molecule ICAM-1 (P < 0.05) were accompanied by decreased levels of the growth factor of vascular endothelia (VEGF) (P < 0.05) against patients with florid Cushing's syndrome.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['stenosis', 'inflammation', 'growth']},\n",
       " {'pmid': 14571286,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abetimus sodium, adefovir dipivoxil, AGI-1067, alefacept, alemtuzumab, ALVAC-p53, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, Anti-CTLA-4 Mab, AOD-9604, apafant, aprinocarsen sodium, arsenic trioxide; Balaglitazone, BIM-23190, bimatoprost, bortezomib, bosentan, BR-1; Canertinib dihydrochloride, CDP-850, cevimeline hydrochloride, cinacalcet hydrochloride, clenoliximab, clevudine, CN-787; D-003, darusentan, deferasirox, desloratadine dexanabinol, duloxetine hydrochloride; E-5564, edaravone, efaproxiral sodium, elvucitabine emfilermin, EN-101, enfuvirtide, entecavir, epithalon, eplerenone, erlotinib hydrochloride, escitalopram oxalate, esomeprazole magnesium, eszopiclone, etilefrine pivalate hydrochloride etoricoxib, everolimus, exenatide; Fidarestat, fondaparinux sodium; Ganstigmine hydrochloride; Homoharringtonine, HuMax-IL-15, hyperimmune IVIG; Imatinib mesylate, IMC-1C11, Inhaled insulin, irofulven, iseganan hydrochloride, ISIS-14803, ISIS-5132, ivabradine hydrochloride; Keratinocyte growth factor; Lafutidine, lanthanum carbonate, LAS-34475, levocetirizine, liraglutide, LY-307161 SR; Magnesium sulfate, maribavir, melatonin, mycobacterium cell wall complex; NN-414, NO-aspirin, nociceptin, nolomirole hydrochloride; Olmesartan medoxomil oral insulin, ospemifene; PDX, perillyl alcohol, pimecrolimus, pitavastatin calcium, pramlintide acetate, prasterone, pregabalin, PRO-542, PV-701, pyrazoloacridine; R-744, ranelic acid distrontium salt, rasburicase, rDNA insulin, resiniferatoxin, reslizumab, ridogrel, riplizumab ropivacaine, rosuvastatin calcium, roxifiban acetate, ruboxistaurin mesilate hydrate; Satraplatin, Sch-58500, semaxanib, sitaxsentan sodium, SMP-114, SU-6668; Teriparatide, tetrathiomolybdate, tipifarnib, tolvaptan, travoprost, treprostinil sodium; Valdecoxib, valganciclovir hydrochloride, vardenafil hydrochloride hydrate, vatalanib succinate; Ximelagatran; Z-335, ziprasidone hydrochloride, zoledronic acid monohydrate, ZYC-00101.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bimatoprost',\n",
       "   'erlotinib',\n",
       "   'eszopiclone',\n",
       "   'vardenafil',\n",
       "   'eplerenone',\n",
       "   'sodium',\n",
       "   'valganciclovir',\n",
       "   'olmesartan',\n",
       "   'treprostinil',\n",
       "   'calcium',\n",
       "   'exenatide',\n",
       "   'desloratadine',\n",
       "   'bosentan',\n",
       "   'duloxetine',\n",
       "   'bortezomib',\n",
       "   'enfuvirtide',\n",
       "   'pitavastatin',\n",
       "   'magnesium',\n",
       "   'reslizumab',\n",
       "   'alefacept',\n",
       "   'alemtuzumab',\n",
       "   'ropivacaine',\n",
       "   'entecavir',\n",
       "   'lafutidine',\n",
       "   'tolvaptan',\n",
       "   'liraglutide',\n",
       "   'esomeprazole',\n",
       "   'rosuvastatin',\n",
       "   'imatinib',\n",
       "   'everolimus',\n",
       "   'teriparatide',\n",
       "   'travoprost',\n",
       "   'fondaparinux',\n",
       "   'valdecoxib',\n",
       "   'cinacalcet',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 14656957,\n",
       "  'sentence': 'The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120-139 mm Hg or diastolic BP 80-89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['thiazide', 'calcium'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'hypertension',\n",
       "   'blood pressure',\n",
       "   'hypertension',\n",
       "   'chronic kidney disease',\n",
       "   'hypertension']},\n",
       " {'pmid': 14695491,\n",
       "  'sentence': '(1) In response to the application of Agm (0.1-1.0 micromol/L) into the superfusate for 2 min, the spontaneous discharge rates (SDR) of 38/47 (80.9%) neurons were decreased significantly in a dose-dependent manner, while that of 9/47 (19.1%) neurons showed no change in discharge rate; (2) pretreatment with L-glutamate (L-Glu, 0.2 mmol/L) led to a marked increase in SDR of 9/12 (75%) neurons in an epileptiform pattern and that of 2/12 (25%) neurons were not affected, then after Agm (1.0 micromol/L) was applied into the superfusate for 2 min, the epileptiform discharges were suppressed significantly; (3) in 7 neurons, perfusion of the selective L-type calcium channel agonist, Bay K-8644 (0.1 micromol/L), induced an increase in the SDR of 6/7 (85.7%) neurons, while that of 1/7 (14.3%) neuron showed no change, and the discharges were also decreased by application of Agm (1.0 micromol/L) into the superfusate; and (4) application of NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME, 50 micromol/L) into the superfusate 5 min later also significantly increased the SDR in all 13 (100%) neurons; then Agm (1.0 micromol/L) applied into the superfusate inhibited the discharges of 11/13 (84.6%) neurons, while those of 2/13 (15.4%) neurons were not affected.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['discharge', 'discharge']},\n",
       " {'pmid': 14715685,\n",
       "  'sentence': \"The molecular weight of the serum protein fractions had been extrapolated, so van't Hoff's law and nonlinear regression analysis of the curves permitted expression of the diagram as an equation: product Pi(s,Ott,2 degrees C,cmH2O)=x(alb)(0.338C(tot)+0.00339C(tot)(2))+x(alpha1)(0.518C(tot)+0.0107C(tot)(2))+x(alpha2)(0.203C(tot)+0.00155C(tot)(2))+x(beta)(0.187C(tot)+0.000577C(tot)(2))+x(gamma)(0.161C(tot)+0.000223C(tot)(2)), where Pi(s,Ott,2 degrees C,cmH2O) is Pi of serum at 2 degrees C (in cmH2O) computed from the 1956 diagram, C(tot) is the concentration (g/l) of total protein in serum, and x(alb), x(alpha1), x(alpha2), x(beta), and x(gamma) are the fractions of albumin, alpha1-, alpha2-, beta-, and gamma-globulin, respectively.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gamma-globulin'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 14753393,\n",
       "  'sentence': 'By experiments of acute carbon-monoxide intoxication, acute nitrogen hypoxia and histotoxic hypoxia using sodium cyanide in cats, and by hemodynamic studies using plastic branch models, the following was elucidated; (1) severe tissue hypoxia, regardless of the underlying cause, and subsequent slight ischemia of the brain due to mild hypotension induce selective involvement of the cerebral white matter and pallidum, these two conditions being necessary and sufficient and this encephalopathy should be separately categorized as \"hypoxic-ischemic encephalopathy\" in hypoxic brain injuries, (2) the background of the selective involvement of these structures is an enormous development of the cerebrum in the brain, which induces thick white matter resulting in proper and long medullary artery, and especially small diameter ratio of the pallidal perforators to the middle cerebral artery, (3) the long course of the medullary artery produces the blood pressure drop in the deep white matter according to Hagen-Poiseuille\\'s low, and according to that the smaller the diameter ratio, the larger the branching-loss coefficient (energy-loss co-efficient), smaller diameter ratio of the pallidal perforator, as compared with that of the putaminal perforator, induces more severe loss of the local blood flow selectively to the pallidum.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['hypoxia',\n",
       "   'hypoxia',\n",
       "   'hypoxia',\n",
       "   'hypotension',\n",
       "   'encephalopathy',\n",
       "   'encephalopathy',\n",
       "   'blood pressure']},\n",
       " {'pmid': 14988742,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaforsen sodium, almotriptan, alpharadin, anakinra, anatumomab mafenatox, ANG-453, anti-CTLA-4 Mab, AP-12009, aprepitant, aripiprazole, arsenic trioxide, astemizole, atlizumab, atomoxetine hydrochloride; Bevacizumab, BG-9928, BMS-188667, botulinum toxin type B, BufferGel; Caffeine, CDP-870, cetuximab, cilomilast, ciluprevir, clofarabine, continuous erythropoiesis receptor activator, CP-461; Darbepoetin alfa, deferasirox, desloratadine, desoxyepothilone B, diflomotecan, dolasetron, drotrecogin alfa (activated), duloxetine hydrochloride; ED-71, efalizumab, efaproxiral sodium, EKB-569, eletriptan, EMD-72000, enfuvirtide, erlotinib hydrochloride, escitalopram oxalate, etoricoxib; Fampridine, ferumoxytol, fondaparinux sodium; Gadofosveset sodium, gastrazole, gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride glutamine; hLM609, HSPPC-96, human insulin; IDD-1, imatinib mesylate, indisulam, inhaled insulin, ixabepilone; Keratinocyte growth factor; Lapatinib, laquinimod, LDP-02, LE-SN38, levetiracetam, levosimendan, licofelone, liposomal doxorubicin, liposomal NDDP, lopinavir, lumiracoxib, LY-156735; Morphine hydrochloride, morphine-6-glucuronide, motexafin gadolinium, MS-27-275, MVA-5T4, MVA-Muc1-IL-2; Nemifitide ditriflutate, neridronic acid nitronaproxen, NSC-683864, NSC-703940, NVP-LAF-237; Oblimersen sodium, ocinaplon, oncomyc-NG, OPC-28326, ortataxel, ospemifene; Palonosetron hydrochloride, PEG-filgrastim peginterferon alfa-2(a), peginterferon alfa-2b, pegsunercept, pemetrexed disodium, pregabalin, prilocaine, pyridoxamine; RDP-58, recombinant glucagon-like peptide-1 (7-36) amide, recombinant human ApoA-I milano/phospholipid complex; SB-715992, soblidotin, sodium dichloroacetate, St. John's Wort extract; TAS-102, terfenadine, TG-1024, TG-5001, 4'-Thio-ara-C, tipranavir, topixantrone hydrochloride, trabectedin, transdermal selegiline, trimethoprim, troxacitabine, TT-232; Vatalanib succinate, vinflunine; Ximelagatran; Ziprasidone hydrochloride, Zoledronic acid monohydrate.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['erlotinib',\n",
       "   'clofarabine',\n",
       "   'sodium',\n",
       "   'trimethoprim',\n",
       "   'levetiracetam',\n",
       "   'efalizumab',\n",
       "   'lapatinib',\n",
       "   'gemtuzumab',\n",
       "   'selegiline',\n",
       "   'desloratadine',\n",
       "   'doxorubicin',\n",
       "   'duloxetine',\n",
       "   'enfuvirtide',\n",
       "   'palonosetron',\n",
       "   'anakinra',\n",
       "   'alemtuzumab',\n",
       "   'aripiprazole',\n",
       "   'ozogamicin',\n",
       "   'eletriptan',\n",
       "   'dolasetron',\n",
       "   'imatinib',\n",
       "   'prilocaine',\n",
       "   'aprepitant',\n",
       "   'tipranavir',\n",
       "   'darbepoetin',\n",
       "   'lopinavir',\n",
       "   'fondaparinux',\n",
       "   'cetuximab',\n",
       "   'atomoxetine',\n",
       "   'bevacizumab',\n",
       "   'pemetrexed',\n",
       "   'almotriptan',\n",
       "   'trabectedin',\n",
       "   'gefitinib',\n",
       "   'disodium',\n",
       "   'gadolinium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 15041577,\n",
       "  'sentence': 'Compared with baseline (SF: 34.9 +/- 3.7 [AC], 34.1 +/- 3.7 [C] [not significant]; stroke volume index [SVI] 36 +/- 6 mL/m(2)[AC], 35 +/- 4 mL/m(2)[C] [not significant]; cardiac index [CI] 3.6 +/- 0.6 L/min/m(2)[AC], 3.2 +/- 0.5 L/min/m(2)[C] [not significant]), we found a significant decrease in SF and SVI in both groups at T1 (SF: 26.2 +/- 3.6 [AC] versus 28.6 +/- 3.6 [C] [P < 0.05]; SVI: 26 +/- 4 mL/m(2) [AC] versus 30 +/- 46 mL/m(2) [C] [P < 0.05]) and T2 (SF: 24.1 +/- 3.2 [AC] versus 28.2 +/- 2.5 [C] [P < 0.01], SVI: 26 +/- 6 mL/m(2) [AC] versus 31 +/- 5 mL/m(2) [C] [P < 0.01]), which was significantly greater in the AC group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'ac'],\n",
       "  'reaction': ['cardiac index']},\n",
       " {'pmid': 15050428,\n",
       "  'sentence': 'At the time of the terminal acute experiment, acute saline volume expansion (VE, 5% body wt/30 min) significantly increased renal interstitial hydrostatic pressure (RIHP), urinary sodium excretion (U(Na)V) and urine flow rate (V) in all groups, but the increases (Delta) were significantly attenuated in both CP (1.7 +/- 0.2mmHg, 12.0 +/- 1.5 microEq.min(-1).g kidney wt(-1) and 76.2 +/- 10.9 microl.min(-1).g kidney wt(-1) for DeltaRIHP, DeltaU(Na)V and DeltaV respectively) and DP (1.3 +/- 0.1 mmHg, 6.8 +/- 1.8 microEq.min(-1).g kidney wt(-1) and 32.3 +/- 9.3 microl.min(-1).g kidney wt(-1) for DeltaRIHP, DeltaU(Na)V and DeltaV respectively) group of rats as compared to NP (4.0 +/- 0.6 mmHg, 21.6 +/- 1.4 microEq.min(-1).g kidney wt(-1)and 136.8 +/- 10.5 microl.min(-1).g kidney wt(-1) for DeltaRIHP, DeltaU(Na)V and DeltaV respectively) group of rats.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['urine flow']},\n",
       " {'pmid': 15069595,\n",
       "  'sentence': 'From their discussions, the panel concluded that: (1) osteoporosis is a disease that requires continuing medical attention to ensure optimal therapeutic benefits; (2) when given in appropriate doses, calcium and vitamin D have been shown to be pharmacologically active (particularly in patients with dietary deficiencies), safe, and effective for the prevention and treatment of osteoporotic fractures; (3) calcium and vitamin D are an essential, but not sufficient, component of an integrated management strategy for the prevention and treatment of osteoporosis in patients with dietary insufficiencies, although maximal benefit in terms of fracture prevention requires the addition of antiresorptive therapy; (4) calcium and vitamin D are a cost-effective medication in the prevention and treatment of osteoporosis; (5) it is apparent that awareness of the efficacy of calcium and vitamin D in osteoporosis is still low and further work needs to be done to increase awareness among physicians, patients, and women at risk; and (6) in order that calcium and vitamin D continues to be manufactured to Good Manufacturing Practice standards and physicians and other health care professionals continue to provide guidance for the optimal use of these agents, they should continue to be classified as medicinal products.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['osteoporosis',\n",
       "   'vitamin d',\n",
       "   'vitamin d',\n",
       "   'osteoporosis',\n",
       "   'fracture',\n",
       "   'vitamin d',\n",
       "   'osteoporosis',\n",
       "   'vitamin d',\n",
       "   'osteoporosis',\n",
       "   'vitamin d']},\n",
       " {'pmid': 15071612,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, l-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, Bi-20, binodenoson, biphasic insulin aspart, bivatuzumab, 186Re-bivatuzumab, BMS-181176, bosentan, botulinum toxin type B, BQ-123, bryostatin 1; Carboxy- amidotriazole, caspofungin acetate, CB-1954, CC-4047, CDP-860, cerivastatin sodium, clevidipine, CTL-102; 3,4-DAP, darbepoetin alfa, decitabine, desloratadine, DHA-paclitaxel, duloxetine hydrochloride; Efalizumab, EGF vaccine, eletriptan, eniluracil, ENMD-0997, eplerenone, eplivanserin, erlosamide, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, eszopiclone, everolimus, exatecan mesilate, exenatide, ezetimibe; Fondaparinux sodium, FR-901228, FTY-720; Gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride; Hexyl insulin M2, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, iodine (I131) tositumomab, ISV-205, ivabradine hydrochloride, ixabepilone; Levetiracetam, levocetirizine, linezolid, liposomal NDDP, lonafarnib, lopinavir, LY-156735; Mafosfamide cyclohexylamine salt, magnesium sulfate, maxacalcitol, meclinertant, melagatran, melatonin, MENT, mepolizumab, micafungin sodium, midostaurin, motexafin gadolinium; Nesiritide, NS-1209, NSC-601316, NSC-683864; Osanetant; Palonosetron hydrochloride, parecoxib sodium, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, pemetrexed disodium, perillyl alcohol, picoplatin, pimecrolimus, pixantrone maleate, plevitrexed, polyglutamate paclitaxel, posurdex, pramlintide acetate, prasterone, pregabalin; Rasburicase, rimonabant hydrochloride, rostaporfin, rosuvastatin calcium; SDZ-SID-791, sibrotuzumab, sorafenib, SU-11248; Tadalafil, targinine, tegaserod maleate, telithromycin, TheraCIM, tigecycline, tiotropium bromide, tipifarnib, tirapazamine, treprostinil sodium; Valdecoxib, Valganciclovir hydrochloride, Vardenafil hydrochloride hydrate; Ximelagatran; Zofenopril calcium, Zoledronic acid monohydrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tadalafil',\n",
       "   'eszopiclone',\n",
       "   'cerivastatin',\n",
       "   'eplerenone',\n",
       "   'vardenafil',\n",
       "   'sodium',\n",
       "   'micafungin',\n",
       "   'levetiracetam',\n",
       "   'efalizumab',\n",
       "   'valganciclovir',\n",
       "   'gemtuzumab',\n",
       "   'treprostinil',\n",
       "   'exenatide',\n",
       "   'calcium',\n",
       "   'desloratadine',\n",
       "   'ertapenem',\n",
       "   'tegaserod',\n",
       "   'bosentan',\n",
       "   'duloxetine',\n",
       "   'mepolizumab',\n",
       "   'magnesium',\n",
       "   'parecoxib',\n",
       "   'palonosetron',\n",
       "   'alemtuzumab',\n",
       "   'aripiprazole',\n",
       "   'ozogamicin',\n",
       "   'caspofungin',\n",
       "   'eletriptan',\n",
       "   'esomeprazole',\n",
       "   'rosuvastatin',\n",
       "   'imatinib',\n",
       "   'everolimus',\n",
       "   'aprepitant',\n",
       "   'paclitaxel',\n",
       "   'darbepoetin',\n",
       "   'tiotropium',\n",
       "   'lopinavir',\n",
       "   'fondaparinux',\n",
       "   'valdecoxib',\n",
       "   'tigecycline',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'pemetrexed',\n",
       "   'telithromycin',\n",
       "   'linezolid',\n",
       "   'gefitinib',\n",
       "   'disodium',\n",
       "   'gadolinium'],\n",
       "  'reaction': ['protein c']},\n",
       " {'pmid': 15110154,\n",
       "  'sentence': 'Applying fluorescent confocal microscopy and tight-seal recording of transmembrane ion currents to freshly isolated vascular myocytes we have demonstrated that: (1) Ca(2+) sparks originate from clustered opening of ryanodine receptors (RyRs) and build up a cell-wide increase in [Ca(2+)](i) upon myocyte excitation; (2) spontaneous Ca(2+) sparks occurred at the highest rate at certain preferred locations, frequent discharge sites (FDS), which are associated with a prominent portion of the sarcoplasmic reticulum (SR) located close to the cell membrane; (3) Ca(2+)-dependent K(+) and Cl(-) channels sense the local changes in [Ca(2+)](i) during a calcium spark and thereby couple changes in [Ca(2+)](i) within a microdomain to changes in the membrane potential, thus affecting excitability of the cell; (4) an intercommunication between RyRs and inositol trisphosphate receptors (IP(3)Rs) is one of the important determinants of intracellular calcium dynamics that, in turn, can modulate the cell membrane potential through differential targeting of calcium dependent membrane ion channels.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['discharge']},\n",
       " {'pmid': 15115441,\n",
       "  'sentence': \"The main recommendations for the use of ciclosporin in the management of psoriasis are: (i) intermittent short courses (average of 12 weeks duration) of ciclosporin are preferable; (ii) ciclosporin should be given in the dose range 2.5-5.0 mg kg(-1) day(-1) (doses greater than 5.0 mg kg(-1) day(-1) should only be given in exceptional circumstances); (iii) treatment regimens should be tailored to the needs of each patient; (iv) selection of patients should take into account psychosocial disability, as well as clinical extent of disease and failure of previous treatment; (v) each patient's renal function (as measured by serum creatinine) should be thoroughly assessed before and during treatment; (vi) each patient's blood pressure should be carefully monitored before and during treatment; (vii) adherence to treatment guidelines substantially reduces the risk of adverse events; (viii) long-term continuous ciclosporin therapy may be appropriate in a subgroup of patients; however, duration of treatment should be kept below 2 years whenever possible; and (ix) when long-term continuous ciclosporin therapy is necessary, annual evaluation of glomerular filtration rate may be useful to accurately monitor renal function.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciclosporin'],\n",
       "  'reaction': ['psoriasis',\n",
       "   'disability',\n",
       "   'blood pressure',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate']},\n",
       " {'pmid': 15117561,\n",
       "  'sentence': 'This study included the following experiments: (1) effects of dextrose solution (250 mL of water containing 75 g of dextrose) or honey solution (250 mL of water containing 75 g of natural honey) on plasma glucose level (PGL), plasma insulin, and plasma C-peptide (eight subjects); (2) effects of dextrose, honey, or artificial honey (250 mL of water containing 35 g of dextrose and 40 g of fructose) on cholesterol and triglycerides (TG) (nine subjects); (3) effects of honey solution, administered for 15 days, on PGL, blood lipids, C-reactive protein (CRP), and homocysteine (eight subjects); (4) effects of honey or artificial honey on cholesterol and TG in six patients with hypercholesterolemia and five patients with hypertriglyceridemia; (5) effects of honey for 15 days on blood lipid and CRP in five patients with elevated cholesterol and CRP; (6) effects of 70 g of dextrose or 90 g of honey on PGL in seven patients with type 2 diabetes mellitus; and (7) effects of 30 g of sucrose or 30 g of honey on PGL, plasma insulin, and plasma C-peptide in five diabetic patients.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['lipids',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'diabetes mellitus']},\n",
       " {'pmid': 15186998,\n",
       "  'sentence': 'Thereby, we estimate 1) ACTH SEC (microg.l(-1).day(-1)) of 0.27 +/- 0.04 basal and 0.87 +/- 0.07 pulsatile (means +/- SE); 2) cortisol SEC (micromol.l(-1).day(-1)) of 0.10 +/- 0.01 basal and 3.5 +/- 0.20 pulsatile; 3) free cortisol half-lives (min) of 1.8 +/- 0.20 (diffusion/advection) and 4.1 +/- 0.30 (elimination) and a half-life of total cortisol of 49 +/- 2.4 and of ACTH of 20 +/- 1.3; 4) ACTH potency (EC(50), ng/l) of 26 +/- 2.4, efficacy (nmol.l(-1).min(-1)) 10 +/- 1.8, and sensitivity (slope units) 0.65 +/- 0.09; 5) night/day augmentation of ACTH and cortisol SEC-burst mass by 2.1- and 1.7-fold (median); 6) abbreviation of the modal time to maximal ACTH and cortisol SEC rates by 4.4- and 4.3-fold, respectively, after a change point clock time of 0205 (median); 7) in vivo percentage distribution of cortisol as 6% free, 14% albumin bound, and 80% CBG bound with an absolute free cortisol CON (nmol/l) 11.5 +/- 0.54; and 8) significant (mean CV) stochastic variability in feedforward efficacy (140%), potency (38%), and sensitivity (56%) within the succession of paired ACTH/cortisol pulses of any given subject.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'mass',\n",
       "   'cortisol',\n",
       "   'cortisol',\n",
       "   'cortisol']},\n",
       " {'pmid': 15216418,\n",
       "  'sentence': 'These puzzling observations have now been explored in greater detail, with the following major findings: a) the large inward TRK currents are not carried by influx of either K(+) or H(+), but rather by an efflux of chloride ions; b) with normal expression levels for Trk1p and Trk2p in potassium-replete cells, the inward TRK currents are contributed approximately half by Trk1p and half by Trk2p; but c) strain background strongly influences the absolute magnitude of these currents, which are nearly twice as large in W303-derived spheroplasts as in S288c-derived cells (same cell-size and identical recording conditions); d) incorporation of mutations that increase cell size (deletion of the Golgi calcium pump, Pmr1p) or that upregulate the TRK2 promoter, can further substantially increase the TRK currents; e) removal of intracellular chloride (e.g., replacement by sulfate or gluconate) reveals small inward currents that are K(+)-dependent and can be enhanced by K(+) starvation; and f) finally, the latter currents display two saturating kinetic components, with preliminary estimates of K(0.5) at 46 micro M [K(+)](out) and 6.8 m M [K(+)](out), and saturating fluxes of approximately 5 m M/min and approximately 10 m M/min (referred to intracellular water).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['starvation']},\n",
       " {'pmid': 15277794,\n",
       "  'sentence': 'Appropriate results were obtained by the following principles: (1) A modified approach that considers three subunits consisting of the dorsum, tip, and ala was used; (2) a forehead flap is the best option for an entire subunit or a full-thickness defect repair; (3) the forehead flap design should be paramedian, oblique, and opposite to the major defect to avoid the hairline and allow better caudal advancement; (4) ear or costal cartilages are good options for structural support (the septum is a nasal growth center that should not be touched); (5) infundibular undermining of vestibular mucosa, turnover flaps, and skin grafts are good options for internal lining; (6) reconstruction is a three-stage procedure (an intermediate operation is added to thin the flap and perform secondary revisions for lining and support); (7) reconstruction should be completed before the child is school aged, to achieve good aesthetic results immediately and avoid psychosocial repercussions; and (8) the reconstructed nose, with skin, lining, and support, will grow with the child (no final surgery should be planned at the age of 18, other than revisions of late complications).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['growth', 'surgery']},\n",
       " {'pmid': 15319808,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 166Ho-DOTMP 5A8; A-179578, abetimus sodium, adefovir dipivoxil, AGI-1067, AIDSVAX gp120 B/B, AK-602, alefacept alemtuzumab, aliskiren fumarate, ALVAC vCP1433, ALVAC vCP1452, anecortave acetate, arzoxifene hydrochloride, atazanavir sulfate, atlizumab, avasimibe; Binodenoson, BMS-488043; Choriogonadotropin alfa, ciclesonide, COL-1621, CVT-3146, CVT-E002, Cypher; Daptomycin, darbepoetin alfa, darunavir, D-D4FC, deferasirox, desloratadine, desmoteplase, duloxetine hydrochloride, DX-9065a; E-5564, efalizumab, emfilermin, emivirine, emtricitabine, enfuvirtide, estradiol acetate, ezetimibe; Frovatriptan; Gallium maltolate, gefitinib; HIV-1 Immunogen, human insulin; Iguratimod, IL-4/IL-13 Trap, imatinib mesylate, inhaled insulin, insulin glargine, irofulven, ISS-1018, ivabradine hydrochloride; Lutropin alfa; Melatonin; Nesiritide; O6-Benzylguanine, omapatrilat, oritavancin, ospemifene; Parecoxib sodium, peginterferon alfa-2a, pexelizumab, pimecrolimus, pirfenidone, pramlintide acetate, prasterone sulfate PT-141; Rasburicase, razaxaban hydrochloride, recombinant malaria vaccine, rhBMP-2/ACS, roflumilast, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; SCH-D, sitaxsentan sodium, solifenacin succinate; Targinine hydrochloride, taxus, TER-199, tramadol hydrochloride/acetaminophen; Valdecoxib, valganciclovir hydrochloride, vatalanib succinate, VEG Trap(R1R2); Ximelagatran; Yttrium Y90 Epratuzumab.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['aliskiren',\n",
       "   'gefitinib',\n",
       "   'desloratadine',\n",
       "   'duloxetine',\n",
       "   'ciclesonide',\n",
       "   'roflumilast',\n",
       "   'sodium',\n",
       "   'gallium',\n",
       "   'darbepoetin',\n",
       "   'enfuvirtide',\n",
       "   'alemtuzumab',\n",
       "   'parecoxib',\n",
       "   'darunavir',\n",
       "   'efalizumab',\n",
       "   'alefacept',\n",
       "   'frovatriptan',\n",
       "   'pimecrolimus',\n",
       "   'daptomycin',\n",
       "   'imatinib',\n",
       "   'atazanavir',\n",
       "   'valganciclovir',\n",
       "   'valdecoxib',\n",
       "   'emtricitabine',\n",
       "   'rosiglitazone'],\n",
       "  'reaction': ['malaria']},\n",
       " {'pmid': 15319815,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol; Valganciclovir hydrochloride, val-mCyd, vardenafil hydrochloride hydrate, vinflunine, voriconazole; Ximelagatran, XTL-002; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gefitinib',\n",
       "   'desloratadine',\n",
       "   'calcium',\n",
       "   'duloxetine',\n",
       "   'voriconazole',\n",
       "   'lopinavir',\n",
       "   'galiximab',\n",
       "   'azimilide',\n",
       "   'treprostinil',\n",
       "   'sodium',\n",
       "   'telithromycin',\n",
       "   'darbepoetin',\n",
       "   'enfuvirtide',\n",
       "   'tadalafil',\n",
       "   'travoprost',\n",
       "   'alemtuzumab',\n",
       "   'vardenafil',\n",
       "   'parecoxib',\n",
       "   'omalizumab',\n",
       "   'efalizumab',\n",
       "   'fosamprenavir',\n",
       "   'alefacept',\n",
       "   'natalizumab',\n",
       "   'adalimumab',\n",
       "   'tolvaptan',\n",
       "   'frovatriptan',\n",
       "   'bortezomib',\n",
       "   'ertapenem',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'valganciclovir',\n",
       "   'tipranavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'caspofungin',\n",
       "   'dutasteride',\n",
       "   'emtricitabine',\n",
       "   'everolimus',\n",
       "   'doxorubicin',\n",
       "   'rosuvastatin',\n",
       "   'nelfinavir'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 15339255,\n",
       "  'sentence': 'We conclude and propose that: (a) the control of the S-W system is highly complex and distributed, but is organized hierarchically in a well-defined rostro-caudal manner; the rostral-most or highest level (telencephalon), is the most functionally complex/adaptative and regulates the lower levels; the diencephalic/basal forebrain, or middle level, has a pivotal role in inducing switching between S and W and in coordinating the lowest (brainstem) and highest levels; (b) W can occur independently in both the forebrain and brainstem, but true NREMS- and REMS-generating mechanisms exist exclusively in the forebrain and brainstem, respectively; (c) forebrain and brainstem S-W processes can operate independently from each other and are preprogrammed at birth; this helps understanding normal and abnormal polygraphic/behavioral dissociations in humans and normal dissociations/splitting in aquatic mammals; (d) NREMS homeostasis is present in the IF, but only REMS pressure after deprivation persists in the decerebrate cat; (e) the thalamus engages in both NREMS and W; (f) insomnia in diencephalic cats is the result of an imbalance between antagonistic W- and S-promoting cellular groups in the ventral brain (normally modulated by the telencephalon); (g) the EEG waves, which are signature for each S-W state, appear to truly drive the concomitant behaviors, e.g.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['insomnia']},\n",
       " {'pmid': 15340100,\n",
       "  'sentence': 'Investigational antiobesity agents consist of 1) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (bupropion), selective serotonin 2c receptor agonists, antiseizure agents (topiramate, zonisamide), some dopamine antagonists, and cannabinoid-1 receptor antagonists (rimonabant); 2) leptin/insulin/central nervous system pathway agents, including leptin analogues, leptin transport and/or leptin receptor promoters, ciliary neurotrophic factor (Axokine), neuropeptide Y and agouti-related peptide antagonists, proopiomelanocortin and cocaine and amphetamine regulated transcript promoters, alpha-melanocyte-stimulating hormone analogues, melanocortin-4 receptor agonists, and agents that affect insulin metabolism/activity, which include protein-tyrosine phosphatase-1B inhibitors, peroxisome proliferator activated receptor-gamma receptor antagonists, short-acting bromocriptine (ergoset), somatostatin agonists (octreotide), and adiponectin; 3) gastrointestinal-neural pathway agents, including those that increase cholecystokinin activity, increase glucagon-like peptide-1 activity (extendin 4, liraglutide, dipeptidyl peptidase IV inhibitors), and increase protein YY3-36 activity and those that decrease ghrelin activity, as well as amylin analogues (pramlintide); 4) agents that may increase resting metabolic rate (\"selective\" beta-3 stimulators/agonist, uncoupling protein homologues, and thyroid receptor agonists); and 5) other more diverse agents, including melanin concentrating hormone antagonists, phytostanol analogues, functional oils, P57, amylase inhibitors, growth hormone fragments, synthetic analogues of dehydroepiandrosterone sulfate, antagonists of adipocyte 11B-hydroxysteroid dehydrogenase type 1 activity, corticotropin-releasing hormone agonists, inhibitors of fatty acid synthesis, carboxypeptidase inhibitors, indanones/indanols, aminosterols, and other gastrointestinal lipase inhibitors (ATL962).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['leptin',\n",
       "   'dopamine',\n",
       "   'octreotide',\n",
       "   'peptide',\n",
       "   'liraglutide',\n",
       "   'somatostatin',\n",
       "   'cocaine'],\n",
       "  'reaction': ['amylase',\n",
       "   'amylase',\n",
       "   'growth',\n",
       "   'dehydroepiandrosterone',\n",
       "   'lipase',\n",
       "   'lipase']},\n",
       " {'pmid': 15349141,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: ABI-007, Ad.Egr.TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['aliskiren',\n",
       "   'gefitinib',\n",
       "   'rasagiline',\n",
       "   'teriparatide',\n",
       "   'calcium',\n",
       "   'duloxetine',\n",
       "   'anakinra',\n",
       "   'ciclesonide',\n",
       "   'ramelteon',\n",
       "   'conivaptan',\n",
       "   'lopinavir',\n",
       "   'treprostinil',\n",
       "   'trabectedin',\n",
       "   'sodium',\n",
       "   'reslizumab',\n",
       "   'darbepoetin',\n",
       "   'travoprost',\n",
       "   'alemtuzumab',\n",
       "   'vardenafil',\n",
       "   'efalizumab',\n",
       "   'alefacept',\n",
       "   'eculizumab',\n",
       "   'palonosetron',\n",
       "   'aprepitant',\n",
       "   'tolvaptan',\n",
       "   'exenatide',\n",
       "   'bortezomib',\n",
       "   'gamma-globulin',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'eletriptan',\n",
       "   'clofarabine',\n",
       "   'atazanavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'bimatoprost',\n",
       "   'telbivudine',\n",
       "   'caspofungin',\n",
       "   'everolimus',\n",
       "   'rosuvastatin',\n",
       "   'erlotinib'],\n",
       "  'reaction': ['prostate cancer']},\n",
       " {'pmid': 15372629,\n",
       "  'sentence': 'Here, we show (1) nontoxic concentrations of TGF-beta1 up-regulates uPA expression in HRA and SKOV-3 human ovarian cancer cells, (2) TGF-beta1 activates Smads (phosphorylation of Smad2 and nuclear translocation of Smad3) and subsequently up-regulates PAI-1 expression in HRA cells, whereas TGF-beta1 neither activates Smads nor up-regulates PAI-1 in SKOV-3 cells, (3) pharmacological Src inhibitor PP2 or antisense (AS) c-Src oligodeoxynucleotide (ODN) treatment significantly induces TGF-beta1-dependent activation of Smads, leading to PAI-1 synthesis, compared with controls, in SKOV-3 cells, (4) combination of TGF-beta1 and PP2, which activates PAI-1 expression and reduces uPA expression in SKOV-3, results in decreased invasiveness, (5) pharmacological inhibitors for mitogen-activated protein kinase (MAPK) (PD98059) and phosphoinositide-3-kinase (PI3K) (LY294002 and wortmannin) or AS-PI3K ODN transfection do not affect TGF-beta1-induced Smad signaling and up-regulation of PAI-1 expression in SKOV-3 cells pretreated with PP2, and (6) the induction of PAI-1 protein was partially inhibited by an inhibitor of Sp1-DNA binding, mithramycin, implicating, at least in part, Sp1 in the regulation of this gene by TGF-beta1.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['mithramycin'],\n",
       "  'reaction': ['ovarian cancer']},\n",
       " {'pmid': 15448874,\n",
       "  'sentence': 'At 120 min, thalidomide (Thalid) and pentoxifylline (Ptx) inhibited (P < 0.05) the increase in perfusion pressure caused by the venom (control = 114.0 +/- 1.3; venom = 137.1 +/- 1.5; Thalid = 121.0 +/- 2.5; Ptx = 121.4 +/- 4.0 mmHg), renal vascular resistance (control = 4.5 +/- 0.2; venom = 7.3 +/- 0.6; Thalid = 4.5 +/- 0.9; Ptx = 4.8 +/- 0.6 mmHg/ml g-1 min-1), urinary flow (control = 0.23 +/- 0.001; venom = 0.44 +/- 0.01; Thalid = 0.22 +/- 0.007; Ptx = 0.21 +/- 0.009 ml g-1 min-1), glomerular filtration rate (control = 0.72 +/- 0.06; venom = 1.91 +/- 0.11; Thalid = 0.75 +/- 0.04; Ptx = 0.77 +/- 0.05 ml g-1 min-1) and the decrease in percent tubular sodium transport (control = 77.0 +/- 0.9; venom = 73.9 +/- 0.66; Thalid = 76.6 +/- 1.1; Ptx = 81.8 +/- 2.0%), percent tubular chloride transport (control = 77.1 +/- 1.2; venom = 71.4 +/- 1.1; Thalid = 77.6 +/- 1.7; Ptx = 76.8 +/- 1.2%), and percent tubular potassium transport (control = 72.7 +/- 1.1; venom = 63.0 +/- 1.1; Thalid = 72.6 +/- 1.0; Ptx = 74.8 +/- 1.0%), 30 min before and during the stimulation of macrophages with C.d.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pentoxifylline', 'sodium', 'potassium'],\n",
       "  'reaction': ['glomerular filtration rate',\n",
       "   'glomerular filtration rate',\n",
       "   'macrophages']},\n",
       " {'pmid': 15538546,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 101M, 166Ho-DOTMP, 3-AP; Abatacept, abetimus sodium, ACR-16, adefovir dipivoxil, alefacept, AMD-070, aminolevulinic acid hexyl ester, anatumomab mafenatox, anti-CTLA-4 MAb, antigastrin therapeutic vaccine, AP-12009, AP-23573, APC-8024, aripiprazole, ATL-962, atomoxetine hydrochloride; Bevacizumab, bimatoprost, bortezomib, bosentan, BR-1; Calcipotriol/betamethasone dipropionate, cinacalcet hydrochloride, clofazimine, colchicine, cold-adapted influenza vaccine trivalent, CRM197; Desloratadine, desoxyepothilone B, diethylhomospermine; Edodekin alfa, efalizumab, elcometrine, eletriptan, enfuvirtide, entecavir, EP-2101, eplerenone, erlotinib hydrochloride, etoricoxib, everolimus, exherin, ezetimibe; Febuxostat, fluorescein lisicol, fosamprenavir calcium, frovatriptan; Hemoglobin raffimer, HSPPC-96, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, IRX-2, istradefylline, IV gamma-globulin, ixabepilone; Kahalalide F; L-759274, levodopa/carbidopa/entacapone, licofelone, lonafarnib, lopinavir, lurtotecan, LY-156735; MAb G250, mecasermin, melatonin, midostaurin, muraglitazar; Nesiritide, nitronaproxen; O6-Benzylguanine, olmesartan medoxomil, olmesartan medoxomil/hydrochlorothiazide, omapatrilat, oral insulin; Parecoxib sodium, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, pemetrexed disodium, peptide YY3-36, PG-CPT, phenoxodiol, pimecrolimus, posaconazole; Rasagiline mesilate, rDNA insulin, RG228, rimonabant hydrochloride, rosuvastatin calcium, rotigotine hydrochloride; S-3304, safinamide mesilate, salcaprozic acid sodium salt, SDZ-SID-791, SGN-30, soblidotin, squalamine; Telmisartan/hydrochlorothiazide, testosterone gel, TF(c)-KLH conjugate vaccine, TH-9507, theraloc, tipifarnib, tocilizumab, travoprost; ValboroPro, valdecoxib, veglin, voriconazole; Ximelagatran.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rasagiline',\n",
       "   'desloratadine',\n",
       "   'abatacept',\n",
       "   'calcium',\n",
       "   'cinacalcet',\n",
       "   'voriconazole',\n",
       "   'lopinavir',\n",
       "   'pemetrexed',\n",
       "   'sodium',\n",
       "   'peptide',\n",
       "   'enfuvirtide',\n",
       "   'travoprost',\n",
       "   'atomoxetine',\n",
       "   'parecoxib',\n",
       "   'olmesartan',\n",
       "   'efalizumab',\n",
       "   'fosamprenavir',\n",
       "   'alefacept',\n",
       "   'aripiprazole',\n",
       "   'frovatriptan',\n",
       "   'bortezomib',\n",
       "   'gamma-globulin',\n",
       "   'tocilizumab',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'bevacizumab',\n",
       "   'eletriptan',\n",
       "   'entecavir',\n",
       "   'disodium',\n",
       "   'bosentan',\n",
       "   'bimatoprost',\n",
       "   'valdecoxib',\n",
       "   'eplerenone',\n",
       "   'everolimus',\n",
       "   'rosuvastatin',\n",
       "   'posaconazole',\n",
       "   'erlotinib'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 15636693,\n",
       "  'sentence': 'The results of BNLI studies have demonstrated that MOPP (mechlorethamine/vincristine/procarbazine/prednisone) chemotherapy is superior to MOP (mechlorethamine/vincristine/procarbazine) chemotherapy; that there are no significant differences between MOPP and B-MOPP (MOPP plus bleomycin); that there is no significant benefit from maintenance therapy with lomustine/vinblastine/bleomycin; that LOPP (chlorambucil/vincristine/procarbazine/prednisone) is as effective as MOPP and has less acute toxicity; that alternating therapy with LOPP and EVAP (etoposide/vinblastine/doxorubicin/prednisolone) is superior to EVAP alone or hybrid LOPP and EVA (etoposide/vinblastine/doxorubicin); that alternating therapy with ChlVPP (a substitute for MOPP) and prednisolone/doxorubicin/bleomycin/vincristine/etoposide regimens is superior to the latter regimen alone; that the Stanford V regimen (doxorubicin/vinblastine/mechlorethamine/vincristine/bleomycin/etoposide/prednisone) combined with disciplined radiation therapy is safe and effective; that hybrid therapy with ChlVPP and EVA and alternating therapy with ChlVPP and prednisolone/doxorubicin/bleomycin/vincristine/etoposide are as effective as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) alone; and that there is no additional benefit from total nodal irradiation or combined-modality therapy compared with MOPP; and that treatment with high-dose BEAM (carmustine/etoposide/cytarabine/melphalan) and autologous bone marrow transplantation is superior to mini-BEAM (lower-dose BEAM not requiring bone marrow rescue) for poor-risk relapsed and refractory disease.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bleomycin'],\n",
       "  'reaction': ['chemotherapy', 'chemotherapy']},\n",
       " {'pmid': 15735095,\n",
       "  'sentence': 'We used data from the Third National Health and Nutrition Examination Survey, 1988-1994, to investigate the relation between serum lycopene concentrations and sex, age, geographical location, race-ethnicity, education, alcohol, smoking, BMI, blood pressure, serum total cholesterol and triacylglycerol, and intakes of fat, tomatoes and tomato-based products in 3413 individuals aged 17-90 y. Multivariate adjusted mean lycopene concentrations were 48.3% lower in individuals > or =70 y old than in those 17 to <30 y old (P < 0.0001), 7.6% lower in women than in men (P = 0.0045), 15.1% lower in people living in the South than those in the West (P < 0.0001), 10.3 and 61.0% lower in the 1st quartile than in the 4th quartile for dietary fat intake (P = 0.0173) and serum cholesterol (P < 0.0001), respectively, 11.1% lower in tomato noneaters than those who ate tomatoes > or =31 times/mo (P = 0.0085), 13.5% lower in pizza noneaters than those who ate pizza > or =16 times/mo (P = 0.0016), and 20.6% lower in pasta noneaters than those who ate pasta (with tomato sauce) > or =16 times/mo (P < 0.0001).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood pressure']},\n",
       " {'pmid': 15834459,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs:[188Re]-HDD; A-179578, adalimumab, AK-602, albumin interferon alfa, alfimeprase, amelubant, anakinra, anti-CD2 MAb, APD-356, aripiprazole, atvogen; Bimatoprost, bimosiamose, BLP-25, brivaracetam; Caspofungin acetate, cilansetron, CMV vaccine (bivalent), conivaptan hydrochloride, Cypher; Darbepoetin alfa, darifenacin hydrobromide, D-D4FC, decitabine, dnaJP1, doranidazole, dronedarone hydrochloride; Efalizumab, efaproxiral sodium, emtricitabine, Endeavor, entecavir, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, etravirine, ezetimibe; Fampridine, fenretinide, ferumoxtran-10, forodesine hydrochloride; Gantacurium chloride, gemi-floxacin mesilate, Glyminox, GW-501516; HBV-ISS, hepavir B, human insulin, HuMax-CD20, hyaluronic acid, HyCAMP; Icatibant, IDEA-070, IGN-311, imatinib mesylate, insulin detemir, insulin glargine, insulin glulisine; Lapatinib, lasofoxifene tartrate, LB-80380, liarozole fumarate, liposome encapsulated doxorubicin, lumiracoxib, LY-570310; MC-1, melatonin, merimepodib, metanicotine, midostaurin; Natalizumab, nicotine conjugate vaccine, NYVAC-HIV C; Patupilone, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pelitinib, Peru-15, pexelizumab, PHP, pimecrolimus, prednisolone sodium metasulfobenzoate; Recombinant alfa1-antitrypsin (AAT), retigabine, rHA influenza vaccine, rifalazil, rofecoxib, rosiglitazone maleate/Metformin hydrochloride, rostaporfin, rosuvastatin calcium, rubitecan; Selenite sodium, semilente insulin, SMP-797, sorafenib; Talampanel, tenofovir disoproxil fumarate, TER-199, tiotropium bromide, torcetrapib, treprostinil sodium, TTA; ValboroPro, valdecoxib, val-mCyd, valtorcitabine dihydrochloride: XP-828L.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium',\n",
       "   'prednisolone',\n",
       "   'anakinra',\n",
       "   'conivaptan',\n",
       "   'treprostinil',\n",
       "   'sodium',\n",
       "   'darbepoetin',\n",
       "   'brivaracetam',\n",
       "   'retigabine',\n",
       "   'efalizumab',\n",
       "   'aripiprazole',\n",
       "   'natalizumab',\n",
       "   'adalimumab',\n",
       "   'dronedarone',\n",
       "   'pimecrolimus',\n",
       "   'imatinib',\n",
       "   'entecavir',\n",
       "   'icatibant',\n",
       "   'bimatoprost',\n",
       "   'tiotropium',\n",
       "   'valdecoxib',\n",
       "   'caspofungin',\n",
       "   'lapatinib',\n",
       "   'rofecoxib',\n",
       "   'emtricitabine',\n",
       "   'doxorubicin',\n",
       "   'rosuvastatin',\n",
       "   'erlotinib',\n",
       "   'rosiglitazone'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 15905157,\n",
       "  'sentence': 'By the completion of this experiment, students are expected to be able to: 1) describe the basics of maintenance of anesthesia in a live animal; 2) describe basic surgical technique; 3) observe the procedure for proper cannulation of blood vessels; 4) describe the proper method of controlling hemorrhage from a bleeding source; 5) describe the measurement and recording of four physiological parameters: mean arterial pressure from a pressure transducer, heart rate from an ECG, hindquarters resistance from Doppler measurement of femoral arterial blood flow, and cardiac contractility by calculating dP/dt from left ventricular pressure measured with a Millar transducer; 6) perform a premortem exam of the heart and lungs and appreciate the in situ cardiothoracic anatomy of the living animal; 7) assist in the induction of ventricular fibrillation and perform direct cardiac massage; 8) characterize the autonomic responses activated by the baroreceptor reflex; 9) describe the effects of the adrenergic agonists epinephrine, norepinephrine, and isoproterenol on cardiovascular parameters and construct a dose response curve for each agent; 10) describe the effects of the adrenergic antagonists propranolol and prazosin on cardiovascular parameters and explain how they affect cardiovascular responses to adrenergic agonists; 11) describe the difference between endothelium-dependent and endothelium-independent vasodilation using acetylcholine, nitroprusside, and atropine; 12) observe the pressor response of angiotensin II and describe why this response is not blocked by pretreatment with prazosin; and 13) participate in the collection and analysis of experimental data and the presentation of results.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['prazosin', 'propranolol', 'cardiac'],\n",
       "  'reaction': ['mean arterial pressure',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'ventricular fibrillation',\n",
       "   'cardiac massage',\n",
       "   'massage',\n",
       "   'epinephrine']},\n",
       " {'pmid': 15970957,\n",
       "  'sentence': 'Cathodal high-voltage pulsed current (CHVPC) at 120 pulses per second and 90% of visible motor threshold is known to curb edema formation after blunt trauma to the hind limbs of rats.Objective: To examine the effects of ibuprofen, continuous CHVPC, and simultaneous ibuprofen and CHVPC on acute edema formation after blunt trauma to the hind limbs of rats.Design: Randomized, parallel-group, repeated-measures design.Setting: Laboratory animal facility.Participants: A total of 21 3-month-old Zucker Lean rats (mass = 288 +/- 55 g) were studied.Intervention(s): We assessed the effects of ibuprofen, continuous CHVPC, and simultaneous ibuprofen and CHVPC on acute edema formation after blunt trauma to the hind limbs of rats.Main Outcome Measure(s): Limb volumes were measured immediately before and after trauma and every 30 minutes over the 4 hours of the experiment.Results: Volumes of treated limbs of all 3 experimental groups were smaller (P < .05) than those of untreated limbs, but no treatment was more effective than another.Conclusions: Ibuprofen, CHVPC, and simultaneous ibuprofen and CHVPC effectively curbed edema after blunt injury by roughly 50% relative to untreated but similarly injured control limbs of rats.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ibuprofen'],\n",
       "  'reaction': ['mass', 'injury']},\n",
       " {'pmid': 16010300,\n",
       "  'sentence': 'The clinical issues addressed and recommendations made were: population-based screening for H. pylori in asymptomatic children to prevent gastric cancer is not warranted; testing for H. pylori in children should be considered if there is a family history of gastric cancer; the goal of diagnostic interventions should be to determine the cause of presenting gastrointestinal symptoms and not the presence of H. pylori infection; recurrent abdominal pain of childhood is not an indication to test for H. pylori infection; H. pylori testing is not required in patients with newly diagnosed gastroesophageal reflux disease; H. pylori testing may be considered before the use of long-term proton pump inhibitor therapy; testing for H. pylori infection should be considered in children with refractory iron deficiency anemia when no other cause has been found; when investigation of pediatric patients with persistent or severe upper abdominal symptoms is indicated, upper endoscopy with biopsy is the investigation of choice; the 13C-urea breath test is currently the best noninvasive diagnostic test for H. pylori infection in children; there is currently insufficient evidence to recommend stool antigen tests as acceptable diagnostic tools for H. pylori infection; serological antibody tests are not recommended as diagnostic tools for H. pylori infection in children; first-line therapy for H. pylori infection in children is a twice-daily, triple-drug regimen comprised of a proton pump inhibitor plus two antibiotics (clarithromycin plus amoxicillin or metronidazole); the optimal treatment period for H. pylori infection in children is 14 days; and H. pylori culture and antibiotic sensitivity testing should be made available to monitor population antibiotic resistance and manage treatment failures.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['clarithromycin', 'amoxicillin', 'metronidazole'],\n",
       "  'reaction': ['gastric cancer',\n",
       "   'gastric cancer',\n",
       "   'infection',\n",
       "   'abdominal pain',\n",
       "   'pain',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'iron deficiency',\n",
       "   'investigation',\n",
       "   'endoscopy',\n",
       "   'biopsy',\n",
       "   'investigation',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection']},\n",
       " {'pmid': 16043938,\n",
       "  'sentence': 'Age > or = 72 years ([RR]: 2.24; 95% CI 1.56 - 3.24), male gender ([RR]: 1.4; 95%CI 1.02 - 1.76), clinical history of coronary artery disease ([RR]: 1.25; 95% CI 1.02 - 1.76), pulse pressure > or = 79 mmHg ([RR]: 1.33; 95% CI 1.03 - 1.87), heart rate > or = 81 bpm ([RR]: 1.32; 95% CI 1.10 - 1.96), atrial fibrillation ([RR]: 1.82; 95% CI 1.18 - 2.81), left ventricular hypertrophy ([RR]: 1.42; 95% CI 1.01 - 2.02), diabetes ([RR]: 1.35; 95% CI 1.02 - 1.78), vital capacity < or = 81% of the theoretical value ([RR]: 2.50; 95% CI 1.88 - 3.32), forced expiratory volume in 1 second < or = 72% of the theoretical value ([RR]: 2.02; 95% CI 1.55 - 2.72) and serum sodium level < or = 139 mmol/L ([RR]: 1.95; 95% CI 1.44 - 2.63) predicted CHF mortality.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'pulse pressure',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'atrial fibrillation',\n",
       "   'left ventricular hypertrophy',\n",
       "   'ventricular hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'vital capacity',\n",
       "   'forced expiratory volume',\n",
       "   'forced expiratory volume']},\n",
       " {'pmid': 16082422,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciclosporin',\n",
       "   'paclitaxel',\n",
       "   'desipramine',\n",
       "   'lapatinib',\n",
       "   'methylprednisolone',\n",
       "   'tiotropium',\n",
       "   'desloratadine',\n",
       "   'pitavastatin',\n",
       "   'filgrastim',\n",
       "   'fluvastatin',\n",
       "   'anakinra',\n",
       "   'etonogestrel',\n",
       "   'voriconazole',\n",
       "   'enfuvirtide',\n",
       "   'atazanavir',\n",
       "   'carmustine',\n",
       "   'paroxetine',\n",
       "   'sodium',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'atorvastatin',\n",
       "   'clopidogrel',\n",
       "   'olmesartan',\n",
       "   'gefitinib',\n",
       "   'icatibant',\n",
       "   'maraviroc',\n",
       "   'fluorouracil',\n",
       "   'docetaxel',\n",
       "   'estramustine',\n",
       "   'cisplatin',\n",
       "   'bevacizumab',\n",
       "   'travoprost',\n",
       "   'mitoxantrone',\n",
       "   'timolol',\n",
       "   'venlafaxine',\n",
       "   'ciclesonide',\n",
       "   'tacrolimus',\n",
       "   'bortezomib',\n",
       "   'busulfan',\n",
       "   'darbepoetin',\n",
       "   'lovastatin',\n",
       "   'famciclovir',\n",
       "   'zidovudine',\n",
       "   'lamivudine',\n",
       "   'calcium',\n",
       "   'prasugrel',\n",
       "   'sirolimus',\n",
       "   'dutasteride',\n",
       "   'aripiprazole',\n",
       "   'lopinavir',\n",
       "   'certolizumab',\n",
       "   'clofarabine',\n",
       "   'cytarabine',\n",
       "   'pravastatin',\n",
       "   'haloperidol',\n",
       "   'alemtuzumab',\n",
       "   'etanercept',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'nelfinavir',\n",
       "   'heparin',\n",
       "   'rosuvastatin',\n",
       "   'ipratropium',\n",
       "   'imatinib',\n",
       "   'efavirenz',\n",
       "   'infliximab',\n",
       "   'eletriptan',\n",
       "   'telithromycin',\n",
       "   'varenicline',\n",
       "   'budesonide',\n",
       "   'fluocinolone',\n",
       "   'atomoxetine',\n",
       "   'rasagiline',\n",
       "   'tegaserod',\n",
       "   'trabectedin',\n",
       "   'rituximab',\n",
       "   'exenatide',\n",
       "   'methotrexate',\n",
       "   'latanoprost',\n",
       "   'treprostinil',\n",
       "   'duloxetine',\n",
       "   'tigecycline',\n",
       "   'acetonide',\n",
       "   'emtricitabine',\n",
       "   'gemcitabine',\n",
       "   'stavudine',\n",
       "   'valdecoxib',\n",
       "   'mitomycin',\n",
       "   'lorazepam',\n",
       "   'tetrasodium',\n",
       "   'adalimumab',\n",
       "   'ritonavir',\n",
       "   'levonorgestrel',\n",
       "   'desvenlafaxine',\n",
       "   'indium',\n",
       "   'bimatoprost',\n",
       "   'fludarabine',\n",
       "   'tadalafil',\n",
       "   'doxorubicin',\n",
       "   'alefacept',\n",
       "   'capecitabine',\n",
       "   'fondaparinux',\n",
       "   'omalizumab',\n",
       "   'simvastatin',\n",
       "   'enoxaparin'],\n",
       "  'reaction': ['prostate cancer']},\n",
       " {'pmid': 16179960,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T 4; NBI-56418, NCX-4016, nesiritide, nicotine conjugate vaccine, NSC-330507; Oglufanide, omalizumab, oxipurinol; Palifermin, palonosetron hydrochloride, parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, PEGylated interferon alfacon-1, perospirone hydrochloride, pimecrolimus, pixantrone maleate, plerixafor hydrochloride, PowderJect lidocaine, pradefovir mesylate, prasterone, pregabalin, Prostvac VF, PT-141, PTC-124, pyridoxamine; QS-21, quercetin; R-126638, R-411, ralfinamide, rasagiline mesilate, rF-PSA, RG-2077, rhThrombin, rimonabant hydrochloride, rofecoxib, rosuvastatin calcium, rotigotine hydrochloride, rV-PSA; S-18886, S-303, seocalcitol, SGN-40, sitaxsentan sodium, SPP-301, St. John's Wort extract; Tadalafil, taxus, telithromycin, tenatoprazole, tenofovir disoproxil fumarate, testosterone MDTS, testosterone transdermal patch, tgAAC-09, TH-9507, thioacetazone, tipifarnib, TQ-1011, trabectedin, travoprost, trimethoprim; Valdecoxib, valganciclovir hydrochloride, valopicitabine, voriconazole; Xcellerated T cells.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['palifermin',\n",
       "   'exenatide',\n",
       "   'gamma-globulin',\n",
       "   'anidulafungin',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'magnesium',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'parecoxib',\n",
       "   'trimethoprim',\n",
       "   'emtricitabine',\n",
       "   'cetuximab',\n",
       "   'valdecoxib',\n",
       "   'travoprost',\n",
       "   'anakinra',\n",
       "   'linezolid',\n",
       "   'esomeprazole',\n",
       "   'bosentan',\n",
       "   'valganciclovir',\n",
       "   'adalimumab',\n",
       "   'plerixafor',\n",
       "   'voriconazole',\n",
       "   'rosuvastatin',\n",
       "   'enfuvirtide',\n",
       "   'rofecoxib',\n",
       "   'atazanavir',\n",
       "   'bimatoprost',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'eletriptan',\n",
       "   'telithromycin',\n",
       "   'palonosetron',\n",
       "   'aprepitant',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'alefacept',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'doxorubicin',\n",
       "   'eplerenone',\n",
       "   'lidocaine',\n",
       "   'atomoxetine',\n",
       "   'fondaparinux',\n",
       "   'dutasteride',\n",
       "   'gefitinib',\n",
       "   'eszopiclone',\n",
       "   'rasagiline',\n",
       "   'aripiprazole',\n",
       "   'icatibant',\n",
       "   'fosamprenavir',\n",
       "   'omalizumab',\n",
       "   'trabectedin',\n",
       "   'lopinavir'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 16196037,\n",
       "  'sentence': 'The topics covered in the parts that follow are: (1) a listing of the 18 most desirable properties of an IBC (e.g., easy injectability, high radiopacity, and a resorption rate that is neither too high nor too low); (2) descriptions of the four classes of IBCs (calcium phosphates, acrylic bone cements, calcium sulfates, and composites); (3) concerns that have been raised with regard to the use of IBCs (such as the potential for thermal necrosis of tissue at the peri-augmentation site, when an acrylic bone cement is used); (4) explicative summaries of the main findings of literature studies on the influence of nine factors (such as powder particle size, powder-to-liquid ratio, and the method used to mix the powder and the liquid) on the values of various properties of IBCs; (5) explicative summaries of the main findings of literature studies on five fundamental matters, such as the aging mechanism of the powder, the thermokinetics of a setting dough, and the influence of the type of IBC used on various ex vivo biomechanical performance measures of VP- and KP-augmented vertebral bodies; and (6) descriptions of topics in six areas for future research, such as the determination of an overall index of the fatigue performance of an IBC and the development of internationally recognized standardized testing protocols to employ when a synthetic cancellous bone void model is used in the rapid in vitro screening of IBCs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['necrosis', 'fatigue']},\n",
       " {'pmid': 16216550,\n",
       "  'sentence': 'Analysis showed that, compared with WT mice, Sptlc1(+/-) and Sptlc2(+/-) mice had: (1) decreased liver Sptlc1 and Sptlc2 mRNA by 44% and 57% (P<0.01 and P<0.0001, respectively); (2) decreased liver Sptlc1 mass by 50% and Sptlc2 mass by 70% (P<0.01 and P<0.01, respectively), moreover, Sptlc1 mass decreased by 70% in Sptlc2(+/-) mouse liver, while Sptlc2 mass decreased by 53% in Sptlc1(+/-) mouse liver (P<0.001 and P<0.01, respectively); (3) decreased liver SPT activity by 45% and 60% (P<0.01, respectively); (4) decreased liver ceramide (22% and 39%, P<0.05 and P<0.01, respectively) and sphingosine levels (22% and 31%, P<0.05 and P<0.01, respectively); (5) decreased plasma ceramide (45% and 39%, P<0.01, respectively), sphingosine-1-phosphate (31% and 32%, P<0.01, respectively) and sphingosine levels (22.5% and 25%, P<0.01, respectively); (6) dramatically decreased plasma lysosphingomyelin (17-fold and 16-fold, P<0.0001, respectively); and (7) no change of plasma sphingomyelin, triglyceride, total cholesterol, phospholipids, and liver sphingomyelin levels.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['mass', 'mass', 'mass', 'mass']},\n",
       " {'pmid': 16387060,\n",
       "  'sentence': 'Body surface potential mapping assessed mean cardiac electrical activation times displayed by isochronal maps in the right ventricle (RV; right ventricle mean activation time [mRV]), anterior septal area (anterior septal area mean activation time [mAS]), and left ventricle (left ventricle mean activation time [mLV]) of 28 patients (mean, 61.07 years; congestive heart failure class III-IV; ejection fraction, < or =40%; left bundle-branch block [LBBB] QRS, 180.17 milliseconds), before and after biventricular pacemaker implantation, comparing them, using reference values from a control group of healthy individuals with normal hearts (GNL), in (1) baseline native LBBB, where mRV and mAS values were similar (40.99 vs 43.62 milliseconds), with mLV delayed (80.99 milliseconds, P < .01) and dyssynchronous with RV/anterior septal area; (2) single-site RV pacing, where mRV was greater than in GNL (86.82 milliseconds, P < .001), with greater mAS/mLV difference (63.41 vs 102.7 milliseconds; P < .001); and (3) biventricular pacing (BIV-PM), where mLV and mRV were similar (71.99 vs 71.58 milliseconds), mRV was greater than in GNL and native LBBB (71.58 vs 35.1 and 40.99 milliseconds; P < .001), and mAS approached values in GNL and native LBBB (51.28 vs 50.14 and 43.62 milliseconds).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['ejection fraction', 'ejection fraction']},\n",
       " {'pmid': 16636723,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium, mycophenolate mofetil, mycophenolic acid sodium salt; Nitisinone; Omalizumab, omapatrilat, ONYX-015, oxaliplatin; Paclitaxel, paclitaxel nanoparticles, panitumumab, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pertuzumab, phosphatidylcholine-rich phospholipid mixture, pimecrolimus, pioglitazone hydrochloride, pramlintide acetate, prasterone; QR-333; Ranelic acid distrontium salt, ranolazine, rasagiline mesilate, RFB4(dsFv)-PE38, ribavirin, rifabutin, risperidone, rituximab, rofecoxib, rosiglitazone maleate, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; S-236, salmeterol xinafoate, sarizotan hydrochloride, sildenafil, sildenafil citrate, sunitinib malate; Tadalafil, tegaserod maleate, temozolomide, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipifarnib, trabectedin, treprostinil sodium; Vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, vinflunine, virosome influenza vaccine, voriconazole; Zidovudine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['carboplatin',\n",
       "   'ciclosporin',\n",
       "   'fluorouracil',\n",
       "   'paclitaxel',\n",
       "   'docetaxel',\n",
       "   'lapatinib',\n",
       "   'methotrexate',\n",
       "   'haloperidol',\n",
       "   'tiotropium',\n",
       "   'treprostinil',\n",
       "   'drospirenone',\n",
       "   'rosiglitazone',\n",
       "   'clarithromycin',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'trabectedin',\n",
       "   'cisplatin',\n",
       "   'desloratadine',\n",
       "   'magnesium',\n",
       "   'epoetin',\n",
       "   'etanercept',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'panitumumab',\n",
       "   'gadolinium',\n",
       "   'vardenafil',\n",
       "   'gemcitabine',\n",
       "   'cetuximab',\n",
       "   'abatacept',\n",
       "   'fluconazole',\n",
       "   'metformin',\n",
       "   'anakinra',\n",
       "   'pioglitazone',\n",
       "   'salmeterol',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'voriconazole',\n",
       "   'montelukast',\n",
       "   'rofecoxib',\n",
       "   'abacavir',\n",
       "   'lomustine',\n",
       "   'pertuzumab',\n",
       "   'axitinib',\n",
       "   'irinotecan',\n",
       "   'teriparatide',\n",
       "   'sildenafil',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'fludarabine',\n",
       "   'carmustine',\n",
       "   'zidovudine',\n",
       "   'lamivudine',\n",
       "   'amlodipine',\n",
       "   'enalapril',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'tadalafil',\n",
       "   'letrozole',\n",
       "   'alefacept',\n",
       "   'sunitinib',\n",
       "   'erlotinib',\n",
       "   'cinacalcet',\n",
       "   'omalizumab',\n",
       "   'gefitinib',\n",
       "   'rasagiline',\n",
       "   'tegaserod',\n",
       "   'aripiprazole',\n",
       "   'vandetanib',\n",
       "   'risperidone',\n",
       "   'rituximab',\n",
       "   'dicycloverine',\n",
       "   'oxaliplatin'],\n",
       "  'reaction': ['influenza', 'influenza', 'influenza', 'influenza']},\n",
       " {'pmid': 16662324,\n",
       "  'sentence': 'This shock protein seems to arise from the cell surface, not from the interior of leaky cells or from broken cells, because (a) the protein differs quantitatively and qualitatively from protein of cell homogenates as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; (b) peroxidase, phosphatase, and malate dehydrogenase activities, which are associated with the cell surface, are detected in the shock fluids; (c) the specific activities of enzymes in shock fluids are different than those of cell homogenates; (d) the amount of protein released is correlated with tissue mass, not number of cut surfaces and is not diminished by pre-washing the tissue.Some of the shock protein may arise from plasmodesmata; this suggestion is based on (a) the cell surface origin of the protein; (b) the presence in the shock fluid of NADPH-cytochrome c reductase activity, usually associated with the endoplasmic reticulum which traverses plasmodesmata; (c) on the release of smaller amounts of protein after plasmolysis with polyethylene glycol 4000, an osmoticum which may tend to preserve plasmodesmata.The amount of protein released by osmotic shock is correlated with the extent of inhibition of fusicoccin-enhanced H(+) excretion.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['shock', 'shock', 'shock', 'mass', 'shock', 'shock', 'shock']},\n",
       " {'pmid': 16680015,\n",
       "  'sentence': 'Application of constant voltage pulses to the caudal vagus ends (STIM: 5 V, 2 ms, 6 Hz for 15 min, 5 min after the beginning of reperfusion) increased survival rate (VGX + SAO + Sham STIM = 0% at 4 h of reperfusion; VGX + SAO + STIM = 90% at 4 h of reperfusion), reverted the marked hypotension, inhibited IkappaBalpha liver loss, blunted the augmented nuclear factor-kappaB activity, decreased hepatic tumor necrosis factor (TNF)-alpha mRNA (VGX + SAO + Sham STIM = 1.0 +/- 1.9 TNF-alpha/glyceraldehyde-3-phosphate dehydrogenase ratio; VGX + SAO + STIM = 0.3 +/- 0.2 TNF-alpha/glyceraldehyde-3-phosphate dehydrogenase ratio), reduced plasma TNF-alpha (VGX + SAO + Sham STIM = 118 +/- 19 pg/mL; VGX + SAO + STIM = 39 +/- 8 pg/mL), ameliorated leukopenia, and decreased leukocyte accumulation, as revealed by means of myeloperoxidase activity in the ileum (VGX + SAO + Sham STIM = 7.9 +/- 1 U/g tissue; VGX + SAO + STIM = 3.1 +/- 0.7 U/g tissue) and in the lung (VGX + SAO + Sham STIM = 8.0 +/- 1.0 U/g tissue; VGX + SAO + STIM = 3.2 +/- 0.6 U/g tissue).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['stim'],\n",
       "  'reaction': ['hypotension', 'necrosis', 'leukopenia']},\n",
       " {'pmid': 16733338,\n",
       "  'sentence': \"In this review of aging, IPD, parkinsonian syndromes, tremor, Alzheimer's disease (AD), motor neuron disease (MND), Huntington's chorea (HC) and inherited ataxia, the following observations are made: (1) olfactory senescence starts at about the age of 36 years in both sexes and accelerates with advancing years, involving pleasant odours preferentially; (2) olfactory dysfunction is near-universal, early and often severe in IPD and AD developing before any movement or cognitive disorder; (3) normal smell identification in IPD is rare and should prompt review of diagnosis unless the patient is female with tremor-dominant disease; (4) anosmia in suspected progressive supranuclear palsy and corticobasal degeneration is atypical and should likewise provoke diagnostic review; (5) subjects with hyposmia and one ApoE4 allele have an approximate 5-fold increased risk of later AD; (6) impaired sense of smell may be seen in some patients at 50% risk of parkinsonism, and possibly in patients with unexplained hyposmia; (7) smell testing in HC and MND where abnormality may be found is not likely to be of clinical value, and (8) biopsy of olfactory nasal neurons reveals non-specific changes in IPD and AD and at present will not aid diagnosis.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['tremor',\n",
       "   'chorea',\n",
       "   'ataxia',\n",
       "   'cognitive disorder',\n",
       "   'anosmia',\n",
       "   'progressive supranuclear palsy',\n",
       "   'hyposmia',\n",
       "   'parkinsonism',\n",
       "   'hyposmia',\n",
       "   'biopsy']},\n",
       " {'pmid': 16757145,\n",
       "  'sentence': \"Synergistic effect of polyoxometalates, K(6)[P(2)W(18)O(62)].14H(2)O (P(2)W(18)), K(4)[SiMo(12)O(40)].3H(2)O (SiMo(12)), K(7)[PTi(2)W(10)O(40)].6H(2)O (PTi(2)W(10)), and K(9)H(5)[alpha-Ge(2)Ti(6)W(18)O(77)].16H(2)O (Ge(2)Ti(6)W(18)), in combination with a beta-lactam oxacillin against methicillin-resistant and vancomycin-resistant Staphylococcus aureus (characterized by possessing the penicillin-binding protein 2' (PBP2') as a cell-wall synthesis enzyme) with a high initial inoculum of 1 x 10(8) cfu/ml (for in vivo test) was investigated with a help of the growth curve and the reverse transcription polymerase chain reaction (RT-PCR) analyses.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxacillin'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 16776635,\n",
       "  'sentence': 'Indirect reference intervals for most of the biochemical analytes were comparable, with small differences in lower [alkaline phosphatase (ALP) (male), alanine aminotransferase (ALT), creatine kinase, iron (male), total iron-binding capacity, folic acid, calcium (female), lactate dehydrogenase (LDH), lipoprotein (a) [Lp(a)], thyroid-stimulating hormone (TSH), total triiodothyronine (T(3)), direct bilirubin, apolipoprotein A-I (apoA-I), glucose, homocysteine, total cholesterol, ferritin, total protein, ceruloplasmin, sodium, blood urea nitrogen (BUN) and uric acid (female)] and/or upper limits [albumin, ALP (male), amylase, apoA-I, creatine kinase-MB (CK-MB), total iron-binding capacity, phosphorus, glucose, total cholesterol, gamma-glutamyltransferase (gamma-GT), magnesium, total protein, high-density lipoprotein cholesterol (HDL-C), total T(3), ALP (male), ALT, aspartate aminotransferase (AST) (male), direct bilirubin (male), creatine kinase, iron, folic acid (female), Lp(a), uric acid and triglycerides], to the reference intervals determined for healthy subjects in our laboratory.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'magnesium', 'cholesterol', 'sodium'],\n",
       "  'reaction': ['alanine aminotransferase',\n",
       "   'ceruloplasmin',\n",
       "   'blood urea',\n",
       "   'blood urea',\n",
       "   'amylase',\n",
       "   'amylase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'gamma-glutamyltransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'aspartate aminotransferase']},\n",
       " {'pmid': 16788687,\n",
       "  'sentence': 'Factors associated with cardiac events were (adjusted hazard ratios) tobacco (3.53; P<0.001), obesity (2.92; P<0.001), diabetes (2.63; P<0.001), multiple rejections (2.19; P=0.008), prior CVE (2.0; P=0.004), dialysis >1 year (1.91; P=0.007), and overweight status (1.68; P=0.04); with cerebrovascular events: diabetes and peritoneal dialysis (11.95; P<0.001), age >45 (6.77; P<0.001), diabetes (4.87; P<0.001), prior CVE (3.73; P<0.001), creatinine >141 micromol/l (3.16; P=0.001), peritoneal dialysis (3.06; P=0.027), and obesity (0.32; P=0.046); with peripheral-vascular events: diabetes (8.48; P<0.001), tobacco and cytomegalovirus (3.88; P<0.001), age >45 (2.31; P=0.019), and prior CVE (2.25; P=0.016); with mortality: tobacco and deceased-donor (3.52; P<0.001), age >45 (1.81; P=0.002), diabetes (1.76; P=0.002), pulse pressure (1.64; P=0.029), prior CVE (1.52; P=0.04), and dialysis >1 year (1.47; P=0.04).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['obesity',\n",
       "   'dialysis',\n",
       "   'overweight',\n",
       "   'peritoneal dialysis',\n",
       "   'dialysis',\n",
       "   'peritoneal dialysis',\n",
       "   'dialysis',\n",
       "   'obesity',\n",
       "   'pulse pressure',\n",
       "   'dialysis']},\n",
       " {'pmid': 16810345,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: ABT-510, adalimumab, alefacept, alemtuzumab, AMG-531, anakinra, armodafinil, asenapine maleate, atazanavir sulfate, atorvastatin; Bortezomib, bosentan; CEB-1555, cetuximab, ciclesonide, clodronate, CT-011; Darifenacin hydrobromide, desloratadine; E-7010, ecallantide, eculizumab, efalizumab, eltrombopag, erlotinib hydrochloride, eslicarbazepine acetate, eszopiclone, ezetimibe; Febuxostat, fosamprenavir calcium, fulvestrant; Gefitinib, genistein; Haemophilus influenzae B vaccine, human papillomavirus vaccine; Imatinib mesylate, insulin glargine; Lenalidomide, liposomal cisplatin; MAb G250, mapatumumab, midostaurin, MP4, mycophenolic acid sodium salt; Natalizumab, neridronic acid, NSC-330507; Oblimersen sodium, ofatumumab, omalizumab, oral insulin, oregovomab; Paliperidone, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pegylated arginine deiminase 20000, pemetrexed disodium, pimecrolimus, pitavastatin, pneumococcal 7-valent conjugate vaccine, prasterone, pregabalin, pumosetrag hydrochloride; Recombinant malaria vaccine, retigabine, rivaroxaban, Ro-26-9228, romidepsin, rosuvastatin calcium, rotavirus vaccine; SGN-30, sitaxsentan sodium, solifenacin succinate, sorafenib, sunitinib malate; Tadalafil, tegaserod maleate, temsirolimus, TER-199, tifacogin, tiludronic acid, tiotropium bromide; Vildagliptin, VNP-40101M, vorinostat; YM-150, yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zoledronic acid monohydrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['eltrombopag',\n",
       "   'tifacogin',\n",
       "   'tiotropium',\n",
       "   'clodronate',\n",
       "   'alemtuzumab',\n",
       "   'cisplatin',\n",
       "   'desloratadine',\n",
       "   'pitavastatin',\n",
       "   'natalizumab',\n",
       "   'pimecrolimus',\n",
       "   'pemetrexed',\n",
       "   'cetuximab',\n",
       "   'fulvestrant',\n",
       "   'anakinra',\n",
       "   'paliperidone',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'ofatumumab',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'rivaroxaban',\n",
       "   'atazanavir',\n",
       "   'vorinostat',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'temsirolimus',\n",
       "   'eculizumab',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'alefacept',\n",
       "   'efalizumab',\n",
       "   'atorvastatin',\n",
       "   'sunitinib',\n",
       "   'erlotinib',\n",
       "   'omalizumab',\n",
       "   'gefitinib',\n",
       "   'eszopiclone',\n",
       "   'tegaserod',\n",
       "   'fosamprenavir',\n",
       "   'retigabine'],\n",
       "  'reaction': ['malaria']},\n",
       " {'pmid': 16842350,\n",
       "  'sentence': 'A novel strain of Rhizopus oryzae WPG secretes a noninduced lipase (ROLw) in the culture medium; purified ROLw is a protein of 29 kDa, the 45 N-terminal amino acid residues were sequenced, this sequence is very homologous to Rhizopus delemar lipase (RDL), Rhizopus niveus lipase (RNL) and R. oryzae lipase (ROL29) sequences; the cloning and sequencing of the part of the gene encoding the mature ROLw, shows two nucleotides differences with RDL, RNL and ROL29 sequences corresponding to the change of the residues 134 and 200; ROLw does not present the interfacial activation phenomenon when using tripropionin or vinyl propionate as substrates; the lipase activity is maximal at pH 8 and at 37 degrees C, specific activities of 3500 or 900 U mg(-1) were measured at 37 degrees C and at pH 8, using olive oil emulsion or tributyrin as substrates, respectively; ROLw is unable to hydrolyse triacylglycerols in the presence of high concentration of bile salts; it is a serine enzyme as it is inhibited by tetrahydrolipstatin and was stable between pH 5 and pH 8.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'lipase']},\n",
       " {'pmid': 16845450,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 131-I-chlorotoxin; Ad5CMV-p53, adalimumab, albumin interferon alfa, alemtuzumab, aliskiren fumarate, aminolevulinic acid methyl ester, anakinra, AR-C126532, atomoxetine hydrochloride; Bevacizumab, bosentan, botulinum toxin type B, brimonidine tartrate/timolol maleate; Calcipotriol/betamethasone dipropionate, cangrelor tetrasodium, cetuximab, ciclesonide, cinacalcet hydrochloride, collagen-PVP, Cypher; Darbepoetin alfa, darusentan, dasatinib, denosumab, desloratadine, dexosome vaccine (lung cancer), dexrazoxane, dextromethorphan/quinidine sulfate, duloxetine hydrochloride; ED-71, eel calcitonin, efalizumab, entecavir, etoricoxib; Falciparum merozoite protein-1/AS02A, fenretinide, fondaparinux sodium; gamma-Hydroxybutyrate sodium, gefitinib, ghrelin (human); hLM609; Icatibant acetate, imatinib mesylate, ipsapirone, irofulven; LBH-589, LE-AON, levocetirizine, LY-450139; Malaria vaccine, mapatumumab, motexafin gadolinium, muraglitazar, mycophenolic acid sodium salt; nab-paclitaxel, nelarabine; O6-Benzylguanine, olmesartan medoxomil, orbofiban acetate; Panitumumab, peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, peptide YY3-36, pleconaril, prasterone, pregabalin; Ranolazine, rebimastat, recombinant malaria vaccine, rosuvastatin calcium; SQN-400; Taxus, tegaserod maleate, tenofovir disoproxil fumarate, teriparatide, troxacitabine; Valganciclovir hydrochloride, Val-Tyr sardine peptidase, VNP-40101M, vorinostat.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'denosumab',\n",
       "   'peptide',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'aliskiren',\n",
       "   'desloratadine',\n",
       "   'pemetrexed',\n",
       "   'bevacizumab',\n",
       "   'panitumumab',\n",
       "   'gadolinium',\n",
       "   'cetuximab',\n",
       "   'anakinra',\n",
       "   'tetrasodium',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'valganciclovir',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'teriparatide',\n",
       "   'vorinostat',\n",
       "   'imatinib',\n",
       "   'darbepoetin',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'efalizumab',\n",
       "   'atomoxetine',\n",
       "   'cinacalcet',\n",
       "   'olmesartan',\n",
       "   'fondaparinux',\n",
       "   'gefitinib',\n",
       "   'tegaserod',\n",
       "   'icatibant',\n",
       "   'dasatinib'],\n",
       "  'reaction': ['malaria', 'malaria']},\n",
       " {'pmid': 16889835,\n",
       "  'sentence': 'These points stressed the importance of: a well-defined, biologically plausible hypothesis as the foundation of in utero studies for assessing neurodevelopmental outcomes; understanding of the exposure to the environmental chemical(s) of interest, underlying mechanisms of toxicity, and anticipated outcomes; the use of a prospective, longitudinal cohort design that, when possible, runs for periods of 2-5 years, and possibly even longer, in an effort to assess functions at key developmental epochs; measuring potentially confounding variables at regular, fixed time intervals; including measures of specific cognitive and social-emotional domains along with non-cognitive competence in young children, as well as comprehensive measures of health; consistency of research design protocols across studies (i.e., tests, covariates, and analysis styles) in an effort to improve interstudy comparisons; emphasis on design features that minimize introduction of systematic error at all stages of investigation: participant selection, data collection and analysis, and interpretation of results; these would include (but not be limited to) reducing selection bias, using double-blind designs, and avoiding post hoc formulation of hypotheses; a priori data analysis strategies tied to hypotheses and the overall research design, particularly for methods used to characterize and address confounders in any neurodevelopmental study; actual quantitative measurements of exposure, even if indirect, rather than methods based on subject recall; careful examination of standard test batteries to ensure that the battery is tailored to the age group as well as what is known about the specific neurotoxic effects on the developing nervous system; establishment of a system for neurodevelopmental surveillance for tracking the outcomes from in utero exposure across early developmental time periods to determine whether central nervous system injuries may be lying silent until developmentally challenged; ongoing exploration of computerized measures that are culturally and linguistically sensitive, and span the age range from birth into the adolescent years; routine incorporation of narrative in manuscripts concerning the possibility of spurious (i.e., false positive and false negative) test results in all research reportage (this can be facilitated by detailed, transparent reporting of design, covariates, and analyses so that others can attempt to replicate the study); forthright, disciplined, and intellectually honest treatment of the extent to which results of any study are conclusive--that is, how generalizable the results of the study are in terms of the implications for the individual study participants, the community studied, and human health overall; confinement of reporting to the actual research questions, how they were tested, and what the study found, and avoiding, or at least keeping to a minimum, any opinions or speculation concerning public health implications; education of clinicians and policymakers to critically read scientific reports, and to interpret study findings and conclusions appropriately; and recognition by investigators of their ethical duty to report negative as well as positive findings, and the importance of neither minimizing nor exaggerating these findings.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['investigation']},\n",
       " {'pmid': 16927289,\n",
       "  'sentence': 'Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24-49] vs. 47 [24-67] or 44 [18-73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1-8.7] vs. 6.5 [<3.7-8.7] or 6.5 [<3.7-8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lamivudine'],\n",
       "  'reaction': ['hepatitis',\n",
       "   'hepatitis b',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'hepatitis']},\n",
       " {'pmid': 16997896,\n",
       "  'sentence': 'We observed several key differences in the cardiovascular responses to changes in the inspiratory P(ITP) excursion between health and CHF; namely, 1) removing approximately 70% of the normally produced inspiratory P(ITP) excursion during exercise (with 15 cmH(2)O inspiratory positive pressure ventilation) significantly reduced stroke volume (SV) in healthy animals by 5 +/- 2% (P < 0.05) but significantly increased SV and cardiac output (Q(TOT)) in animals with CHF by 5 +/- 1% (P < 0.05); 2) doubling the magnitude of the inspiratory P(ITP) excursion had no effect on SV or Q(TOT) in healthy animals but significantly reduced steady-state Q(TOT) and SV in animals with CHF by -4 +/- 3% and -10 +/- 3%, respectively; 3) removing the majority of the normally produced inspiratory P(ITP) excursion had no effect on blood flow distribution in healthy animals but increased hindlimb blood flow (9 +/- 3%, P < 0.05) out of proportion to the increases in Q(TOT); and 4) the only similarity between healthy and CHF animals was that increasing the inspiratory P(ITP) excursion significantly reduced steady-state locomotor limb blood flow by 5 +/- 2% and 6 +/- 3%, respectively (P < 0.05 for both).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output']},\n",
       " {'pmid': 17003851,\n",
       "  'sentence': 'The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'exenatide',\n",
       "   'tiotropium',\n",
       "   'anidulafungin',\n",
       "   'dabigatran',\n",
       "   'treprostinil',\n",
       "   'peptide',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'desloratadine',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'pemetrexed',\n",
       "   'emtricitabine',\n",
       "   'cetuximab',\n",
       "   'fulvestrant',\n",
       "   'anakinra',\n",
       "   'telbivudine',\n",
       "   'bosentan',\n",
       "   'ciclesonide',\n",
       "   'valganciclovir',\n",
       "   'voriconazole',\n",
       "   'tolvaptan',\n",
       "   'rosuvastatin',\n",
       "   'adalimumab',\n",
       "   'teriparatide',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'clindamycin',\n",
       "   'alefacept',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'erlotinib',\n",
       "   'eplerenone',\n",
       "   'prasugrel',\n",
       "   'atomoxetine',\n",
       "   'cinacalcet',\n",
       "   'fondaparinux',\n",
       "   'omalizumab',\n",
       "   'gefitinib',\n",
       "   'hydralazine',\n",
       "   'eszopiclone',\n",
       "   'aripiprazole',\n",
       "   'tegaserod',\n",
       "   'vandetanib',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['hepatitis', 'hepatitis c']},\n",
       " {'pmid': 17023528,\n",
       "  'sentence': 'The results were as follows: 1) treatment with estrogen increased phosphorylation and MgATPase activity and decreased NMM-II-B filamentation; 2) estrogen effects could be blocked by antisense nucleotides for the estrogen receptor-alpha and by ICI-182,780, tamoxifen, and the casein kinase-II (CK2) inhibitor, 5,6-dichloro-1-beta-(D)-ribofuranosylbenzimidazole and attenuated by AG1478 and PD98059 (inhibitors of epithelial growth factor receptor and ERK/MAPK) but not staurosporine [blocker of protein kinase C (PKC)]; 3) treatments with the PKC activator sn-1,2-dioctanoyl diglyceride induced biphasic effect on NMM-II-B MgATPase activity: an increase at 1 nm to 1 microM and a decrease in activity at more than 1 microM; 4) sn-1,2-dioctanoyl diglyceride also decreased NMM-II-B filamentation in a monophasic and saturable dose dependence (EC(50) 1-10 microM); 5) when coincubated directly with purified NMM-II-B filaments, both CK2 and PKC decreased filamentation and increased MgATPase activity; 6) assays done on disassembled NMM-II-B filaments showed MgATPase activity in filaments obtained from estrogen-treated cells but not estrogen-depleted cells; and 7) incubations in vitro with CK2, but not PKC, facilitated MgATPase activity, even in disassembled NMM-II-B filaments.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tamoxifen'],\n",
       "  'reaction': ['growth', 'dependence']},\n",
       " {'pmid': 17103447,\n",
       "  'sentence': 'Bone and cartilage and their disorders are addressed under the following headings: functions of bone; normal and abnormal bone remodeling; osteopetrosis and osteoporosis; epithelial-mesenchymal interaction, condensation and differentiation; osteoblasts, markers of bone formation, osteoclasts, components of bone, and pathology of bone; chondroblasts, markers of cartilage formation, secondary cartilage, components of cartilage, and pathology of cartilage; intramembranous and endochondral bone formation; RUNX genes and cleidocranial dysplasia (CCD); osterix; histone deacetylase 4 and Runx2; Ligand to receptor activator of NFkappaB (RANKL), RANK, osteoprotegerin, and osteoimmunology; WNT signaling, LRP5 mutations, and beta-catenin; the role of leptin in bone remodeling; collagens, collagenopathies, and osteogenesis imperfecta; FGFs/FGFRs, FGFR3 skeletal dysplasias, craniosynostosis, and other disorders; short limb chondrodysplasias; molecular control of the growth plate in endochondral bone formation and genetic disorders of IHH and PTHR1; ANKH, craniometaphyseal dysplasia, and chondrocalcinosis; transforming growth factor beta, Camurati-Engelmann disease (CED), and Marfan syndrome, types I and II; an ACVR1 mutation and fibrodysplasia ossificans progressiva; MSX1 and MSX2: biology, mutations, and associated disorders; G protein, activation of adenylyl cyclase, GNAS1 mutations, McCune-Albright syndrome, fibrous dysplasia, and Albright hereditary osteodystrophy; FLNA and associated disorders; and morphological development of teeth and their genetic mutations.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['leptin'],\n",
       "  'reaction': ['osteopetrosis',\n",
       "   'osteoporosis',\n",
       "   'bone formation',\n",
       "   'bone formation',\n",
       "   'dysplasia',\n",
       "   'osteogenesis imperfecta',\n",
       "   'craniosynostosis',\n",
       "   'growth',\n",
       "   'bone formation',\n",
       "   'dysplasia',\n",
       "   'chondrocalcinosis',\n",
       "   'growth',\n",
       "   'dysplasia']},\n",
       " {'pmid': 17235418,\n",
       "  'sentence': \"This issue focuses on the following selection of drugs: 5-Methyltetrahydrofolate, 9-aminocamptothecin; AdPEDF.11, AE-37, albumin interferon alfa, alicaforsen sodium, alvocidib hydrochloride, AMG-706, arginine butyrate, avanafil, axitinib, azimilide hydrochloride; BAY-579352, belagenpumatucel-L, beta-lapachone, BHT-3009, BIBW-2992, bremelanotide, BX-471; Casopitant mesylate, cediranib, certolizumab pegol, CH-1504, ChimeriVax-West Nile, clofazimine, CpG-7909, curcumin, Cypher; Dapoxetine hydrochloride, darusentan, diflomotecan, D-methionine, dnaJP1, D-serine, DTPw-HB Hib-MenAC, DTPw-HepB-Hib; E-7010, ecogramostim, edodekin alfa, EGFRvlll peptide vaccine, elcometrine, elcometrine/ethinylestradiol, elsilimomab, enrasentan, ertumaxomab, etalocib sodium, exisulind; Fenretinide, fesoterodine, fingolimod hydrochloride, fontolizumab; Gefitinib, gemtuzumab ozogamicin, ghrelin (human), GV-1001; HTU-PA, human papillomavirus vaccine; Indacaterol, indiplon, interleukin-21, intranasal insulin, irinotecan hydrochloride/floxuridine, ISIS-301012, ispinesib mesylate, ixabepilone; K562/GM-CSF; Lapatinib, L-BLP-25, linezolid, liposome encapsulated paclitaxel, LY-2124275; MC-1, MC-1/lisinopril, MDX-066, melanoma vaccine, MMR-V, multivalent (ACYW) meningitis vaccine; Nilotinib, nobori, nociceptin; Oblimersen sodium, orbofiban acetate, ospemifene; Paliperidone, panitumumab, PEG-filgrastim, PEGylated interferon alfacon-1, perflubutane, pertuzumab, phenserine tartrate, phVEGF-A165, pleconaril, prasugrel, prednisolone sodium metasulfobenzoate; R-411, recombinant malaria vaccine, rhGM-CSF, roflumilast, romidepsin, ruboxistaurin mesilate hydrate; Sirolimus-eluting stent, SR-4554, St. John's Wort extract; Talabostat, Taxus, TGN-255, tifacogin, tiotropium bromide, tolevamer sodium, trabectedin, tretinoin LF; Vatalanib succinate; Yellow fever vaccine, YM-155.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tifacogin',\n",
       "   'paclitaxel',\n",
       "   'lapatinib',\n",
       "   'indacaterol',\n",
       "   'tiotropium',\n",
       "   'peptide',\n",
       "   'nilotinib',\n",
       "   'dapoxetine',\n",
       "   'panitumumab',\n",
       "   'paliperidone',\n",
       "   'linezolid',\n",
       "   'intranasal',\n",
       "   'irinotecan',\n",
       "   'ozogamicin',\n",
       "   'pertuzumab',\n",
       "   'axitinib',\n",
       "   'roflumilast',\n",
       "   'prednisolone',\n",
       "   'sodium',\n",
       "   'azimilide',\n",
       "   'gemtuzumab',\n",
       "   'prasugrel',\n",
       "   'fingolimod',\n",
       "   'gefitinib',\n",
       "   'trabectedin',\n",
       "   'certolizumab',\n",
       "   'cediranib'],\n",
       "  'reaction': ['meningitis', 'malaria']},\n",
       " {'pmid': 17316791,\n",
       "  'sentence': 'The results showed that (1) intraventricular injection (icv) of anti-arginine vasopressin (AVP) serum completely reversed pain threshold increase induced by l-glutamate sodium (Glu) injection into the PVN, and local administration (icv) of anti-leucine-enkephalin (L-Ek) serum or anti-beta-endorphin (beta-Ep) serum partly attenuated pain threshold increase induced by Glu injection into the PVN, but pre-treatment of anti-oxytocin (OXT), dynorphinA(1-13) (DynA(1-13)), cholecystokinin-like peptide (CCK), neurotensin (NT), corticotrophin-releasing hormone (CRH), adrenocorticotrophin (ACTH), somatostatin (SST), prolactin-releasing hormone (PRH), angiotensinII (AngII), vasoactive intestinal polypeptide (VIP), melanotropin-releasing hormone (MRH), thyrotropin-releasing hormone (TRH), substance P (SP) or growth hormone-releasing hormone (GHRH) serum (icv) did not influence the analgesic effect of PVN administration with Glu; (2) PVN stimulation with Glu elevated the concentrations of AVP, OXT, CCK, NT, CRH, SST, PRH and DynA(1-13) in PVN perfusion liquid, and could not change the concentrations of L-Ek, beta-Ep, AngII, ACTH, VIP, MRH, TRH, SP and GHRH in PVN perfusion liquid; (3) Pain stimulation increased the concentrations of AVP, L-Ek, beta-Ep, DynA(1-13), CRH and ACTH in PVN perfusion liquid, and did not alter the concentrations of OXT, CCK, NT, SST, PRH, AngII, VIP, MRH, TRH, SP and GHRH in PVN perfusion liquid.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium',\n",
       "   'vasopressin',\n",
       "   'polypeptide',\n",
       "   'somatostatin',\n",
       "   'peptide'],\n",
       "  'reaction': ['injection',\n",
       "   'pain',\n",
       "   'injection',\n",
       "   'pain',\n",
       "   'injection',\n",
       "   'growth',\n",
       "   'pain']},\n",
       " {'pmid': 17335301,\n",
       "  'sentence': 'black triangle Sorafenib is an oral multikinase inhibitor that targets the mitogen-activated protein kinase signalling pathway and receptor tyrosine kinases involved in tumour proliferation and angiogenesis.black triangle In the large, phase III, randomised, double-blind, multicentre Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) of patients with advanced clear-cell renal cell cancer in whom previous systemic therapy had failed, median progression-free survival was doubled in patients receiving sorafenib compared with those receiving placebo (5.9 vs 2.8mo).black triangle Significantly more patients receiving sorafenib than those receiving placebo in the phase III trial experienced complete or partial responses or stable disease.black triangle Age, risk-assessment score, prior treatment, metastasis in lung or liver, or time from diagnosis did not affect the improved progression-free survival in sorafenib recipients.black triangle In a randomised, phase II discontinuation trial of patients with advanced renal cancer, in which only those showing stable disease with sorafenib were randomised to further sorafenib or placebo, more patients receiving sorafenib were free of progressive disease 12 weeks after randomisation than were those receiving placebo, and median progression-free survival was longer in sorafenib recipients.black triangle In clinical trials, most drug-related adverse events were mild to moderate in severity.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['double-blind'],\n",
       "  'reaction': ['renal cancer', 'metastasis', 'renal cancer']},\n",
       " {'pmid': 17344945,\n",
       "  'sentence': \"This issues focuses on the following selection of drugs: 4'-Thio-ara-C, 5-methyltetrahydrofolate; ABT-089, AD-237, AF-37702, alvocidib hydrochloride, apricitabine, armodafinil, atrasentan, AVE-5883, avian influenza vaccine, azimilide hydrochloride; Banoxantrone, BIBF-1120; CD34+ cells, certolizumab pegol, CHIR-258, cilansetron, CoFactor, CX-3543, cystemustine; D-003, dexloxiglumide, DMXB-anabaseine; Ecogramostim, elcometrine, elcometrine/ethinylestradiol, etravirine; Fenretinide, fingolimod hydrochloride, fospropofol disodium; Gaboxadol, gestodene, glutamine; Human insulin, hyaluronic acid; Incyclinide, indacaterol, ispronicline, istradefylline; Labradimil, lamifiban, lapatinib, L-arginine hydrochloride, liposomal cisplatin, liposome encapsulated paclitaxel, LY-517717; Manidipine hydrochloride/delapril hydrochloride, maraviroc, MBP(82-98), MD-0727, MDX-214, melanotan I, MMR vaccine; Nacystelyn, nalfurafine hydrochloride, nibentan, nilotinib, NK-105; OBI-1, oblimersen sodium, olmesartan medoxomil, olmesartan medoxomil/hydrochlorothiazide, oregovomab; Pexelizumab, PG-116800, PG-CPT, PHA-794428, prasugrel; RC-3095, rDNA insulin, RFB4(dsFv)-PE38, rhEndostatin, rhenium Re-186 etidronate, rhGM-CSF, roflumilast, romidepsin; Sarcosine, SGLU1, SGN-40, succinobucol; TAU, teduglutide, telatinib, tesofensine, tipifarnib, tirapazamine, TKA-731, tolvaptan, trabectedin; Vaccimel, vatalanib succinate, velafermin, vildagliptin, vinflunine; XP-19986; YM-155.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['etidronate',\n",
       "   'disodium',\n",
       "   'sodium',\n",
       "   'paclitaxel',\n",
       "   'azimilide',\n",
       "   'lapatinib',\n",
       "   'prasugrel',\n",
       "   'indacaterol',\n",
       "   'roflumilast',\n",
       "   'olmesartan',\n",
       "   'fingolimod',\n",
       "   'teduglutide',\n",
       "   'cisplatin',\n",
       "   'maraviroc',\n",
       "   'tolvaptan',\n",
       "   'trabectedin',\n",
       "   'nilotinib',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['avian influenza', 'influenza']},\n",
       " {'pmid': 17482801,\n",
       "  'sentence': 'Different physicochemical properties of Langmuir films (monolayers) composed of 10 mixed systems of a bile acid, deoxycholic acid (DC) with various plant sterols, such as stigmasterol (Stig), beta-sitosterol (Sito) and campesterol (Camp) and a stanol, cholestanol (Chsta) in addition to an animal sterol, cholesterol (Ch) [these sterols and Chsta are abbreviated as St] and DC with 1:1 St mixtures; (Ch+Chsta), (Ch+Stig), (Stig+Chsta), (Ch+Sito) and (Ch+Camp) on the substrate of 5M aqueous NaCl solution (pH 1.2) at 25 degrees C, were investigated in terms of mean surface area per molecule (A(m)), the partial molecular area (PMA), surface excess Gibbs energy (DeltaG((ex))), interaction parameter (I(p)) as well as activity coefficients (f(1) and f(2)) in 2-D phase of each binary (or ternary) component system and elasticity (Cs(-1)) of formed films; these were analyzed on the basis of the respective surface pressure (pi) versus A(m) isotherms as a function of mole fraction of Sts (X(st)) in the DC/St(s) mixtures at discrete surface pressures.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'beta-sitosterol'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 17612047,\n",
       "  'sentence': 'Supporting evidence includes the following: [1] expression of constitutive COX-2-catalyzed prostaglandin biosynthesis is induced by most cancer-causing agents including tobacco smoke and its components (polycylic aromatic amines, heterocyclic amines, nitrosamines), essential polyunsaturated fatty acids (unconjugated linoleic acid), mitogens, growth factors, proinflammatory cytokines, microbial agents, tumor promoters, and other epigenetic factors, [2] COX-2 expression is a characteristic feature of all premalignant neoplasms, [3] COX-2 expression is a characteristic feature of all malignant neoplasms, and expression intensifies with stage at detection and cancer progression and metastasis, [4] all essential features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, metastasis, and immunosuppression) are linked to COX-2-driven prostaglandin (PGE-2) biosynthesis, [5] animal studies show that COX-2 up-regulation (in the absence of genetic mutations) is sufficient to stimulate the transformation of normal cells to invasive cancer and metastatic disease, [6] non-selective COX-2 inhibitors, such as aspirin and ibuprofen, reduce the risk of human cancer and precancerous lesions, and [7] selective COX-2 inhibitors, such as celecoxib, reduce the risk of human cancer and precancerous lesions at all anatomic sites thus far investigated.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ibuprofen', 'celecoxib'],\n",
       "  'reaction': ['growth',\n",
       "   'metastasis',\n",
       "   'apoptosis',\n",
       "   'metastasis',\n",
       "   'immunosuppression']},\n",
       " {'pmid': 17640936,\n",
       "  'sentence': 'Compared with control, both Man and Los significantly (P < 0.05) attenuated the improvement in mean arterial blood pressure (MAP), cardiac index and mesenteric blood flow (SMBF) in response to intravenous hypertonic NaCl: MAP, rapid response +45 mmHg versus +38 mmHg (Man) and +35 mmHg (Los); after 180 min, +32 mmHg versus +21 mmHg (Man) and +19 mmHg (Los); cardiac index after 180 min, +1.9 l min(-1) (m(2))(-1) versus +0.9 l min(-1) (m(2))(-1) (Man) and +0.9 l min(-1) (m(2))(-1) (Los); SMBF rapid response, +981 ml min(-1) versus +719 ml min(-1) (Man) and +744 ml min(-1) (Los); after 180 min, +602 ml min(-1) versus +372 ml min(-1) (Man) and +314 ml min(-1) (Los).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['blood pressure', 'cardiac index', 'cardiac index']},\n",
       " {'pmid': 17826044,\n",
       "  'sentence': 'In summary, these statements are as follows: (1) Patients with diabetes have an increased risk for cardiovascular disease that contributes to decreased life expectancy; (2) prognosis after a cardiovascular event is poorer in patients with diabetes; (3) pathogenetic mechanisms include insulin resistance, endothelial dysfunction, dyslipidemia, chronic inflammation, procoagulability, and impaired fibrinolysis; (4) management of established cardiovascular risk factors, for example with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and antihypertensive therapy, reduces cardiovascular event rates in diabetes; (5) correction of hyperglycemia can reduce macrovascular event rates, but the coupling to hyperglycemia is less tight for macrovascular events than it is for reduction of microvascular complications; (6) patients with diabetes should be screened for additional cardiovascular risk factors and appropriate interventions should be initiated; (7) results of observational and interventional studies have indicated that some insulin sensitizers appear to reduce the incidence of cardiovascular events and improve survival; (8) thiazolidinediones have beneficial effects on metabolism that may improve cardiovascular risk, and a randomized clinical trial in patients with advanced atherosclerosis indicates that addition of pioglitazone to therapy for hyperglycemia may reduce the incidence of cardiovascular events such as myocardial infarction and stroke.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pioglitazone'],\n",
       "  'reaction': ['life expectancy',\n",
       "   'insulin resistance',\n",
       "   'endothelial dysfunction',\n",
       "   'inflammation',\n",
       "   'fibrinolysis',\n",
       "   'myocardial infarction',\n",
       "   'infarction']},\n",
       " {'pmid': 17957564,\n",
       "  'sentence': 'The results showed that: (i) in physiological conditions, [Ca(2+)](i) was approximately 10% increased in the platelets of the mature subjects, and approximately 33% enhanced at the older group (vs. young), sustaining that biological ageing is associated with accumulation of free [Ca(2+)](i) within the platelets cytoplasm; (ii) in type 2 diabetes, [Ca(2+)](i) was approximately 16% and approximately 27% higher in the platelets of mature and older patients, respectively (vs. age-matched normals), demonstrating that ageing of diabetics is accompanied by alterations in calcium balance (vs. physiological ageing); (iii) thrombin (1U/ml) induced approximately 39% increase of [Ca(2+)](i) in platelets of matures and approximately 29% at older normals, and approximately 34% increase at the mature diabetics, approximately 84% at the older diabetics (vs. no thrombin condition), indicating that under thrombin stimulation simultaneous insults of diabetes and advanced age produced a higher thrombin-evoked mobilization of Ca(2+) from intracellular stores; (iv) the components of the diabetic milieu had various effects on platelet free [Ca(2+)](i): high enhancement ( approximately 73%) in 25.5 mM glucose (vs. 11 mM glucose), a minor increase ( approximately 15%) in 100 mM H(2)O(2), and a decrease (by approximately 56% and approximately 132%) in 1.7 mM AGE- poly-L-lysine (vs. poly-L-lysine) and 2.26 mM AGE- albumin (vs. albumin), respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['condition']},\n",
       " {'pmid': 17982511,\n",
       "  'sentence': '12B75, 274150; Abacavir sulfate/lamivudine, Abatacept, Ad2/HIF-1alpha, Adalimumab, Adefovir, Adefovir dipivoxil, AGN-201904-Z, AIDSVAX, Albinterferon alfa-2b, Alemtuzumab, Aliskiren fumarate, Alvimopan hydrate, Amlodipine besylate/atorvastatin calcium, Amlodipine besylate/Olmesartan medoxomil, Ammonium tetrathiomolybdate, Amodiaquine, Apaziquone, Aprepitant, Arsenic trioxide, Artesunate/Amodiaquine, Ascorbic acid, Atazanavir sulfate, Atazanavir/ritonavir, Atomoxetine hydrochloride, Atrigel-Leuprolide, Axitinib; Bevacizumab, Binodenoson, Bortezomib, Bovine lactoferrin; Calcipotriol/betamethasone dipropionate, Carisbamate, Certolizumab pegol, Ciclesonide, Conivaptan hydrochloride, CP-690550, CP-751871, Cypher; Dapivirine, Darbepoetin alfa, Darunavir, Dasatinib, del-1 Genemedicine, Denosumab, Desloratadine, Dexlansoprazole, DiabeCell, Drospirenone/ethinylestradiol, DTaP-HepB-IPV, Duloxetine hydrochloride, Dutasteride; Eculizumab, Eldecalcitol, Eletriptan, Emtricitabine, Entecavir, Eritoran tetrasodium, Ertapenem sodium, Escitalopram oxalate, Eslicarbazepine acetate, Esomeprazole magnesium, Estradiol acetate, Eszopiclone, ETEC vaccine, Etoricoxib, Exenatide, Ezetimibe; Fluticasone furoate, Fosmidomycin, Fosmidomycin/clindamycin; Glutamine; Heat Shock Protein 10, Hepatitis B hyperimmunoglobulin, HIV vaccine, Hochuekki-to, Human Albumin, Human papillomavirus vaccine; Immune globulin subcutaneous [human], IMP-321, Interferon omega, ISIS-301012, Istaroxime; Japanese encephalitis virus vaccine; Latanoprost/timolol maleate, Lenalidomide, Linaclotide acetate, Lumiracoxib, LY-517717; Malaria vaccine, MAS-063D, Meningitis B vaccine, Mepolizumab, Methylnaltrexone bromide, Micafungin sodium, MK-0822A, Morphine glucuronide, Morphine hydrochloride, Mycophenolic acid sodium salt; Natalizumab, Nesiritide, Norelgestromin/ethinyl estradiol, NT-201; Oblimersen sodium, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Omalizumab, Otamixaban; Paclitaxel nanoparticles, Panitumumab, Panobinostat, Parathyroid hormone (human recombinant), Parecoxib sodium, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pegvisomant, PI-88, Pimecrolimus, Pneumococcal 7-valent conjugate vaccine, Pneumococcal 9-valent conjugate vaccine, Pneumococcal conjugate vaccine, Poloxamer-188, Prasugrel, Pregabalin, Prulifloxacin; R-109339, Ramipril/amlodipine, Ranolazine, Rasburicase, rHA influenza vaccine, Ro-50-3821, Rosuvastatin calcium, Rotavirus vaccine, Rotigotine, Ruboxistaurin mesilate hydrate; Satavaptan, SC-75416, Solifenacin succinate, Sorafenib, Sugammadex sodium, Sunitinib malate, Synthetic conjugated estrogens B; Tadalafil, Talnetant, Taxus, Tegaserod maleate, Telbivudine, Temsirolimus, Tenofovir disoproxil fumarate, Tetomilast, Tiotropium bromide, Tipifarnib, Tofimilast, Tremelimumab, Trimethoprim; Udenafil, Urocortin 2; Valdecoxib, Vernakalant hydrochloride; XP-828L.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['paclitaxel',\n",
       "   'entecavir',\n",
       "   'exenatide',\n",
       "   'ertapenem',\n",
       "   'denosumab',\n",
       "   'tiotropium',\n",
       "   'conivaptan',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'aliskiren',\n",
       "   'desloratadine',\n",
       "   'magnesium',\n",
       "   'darunavir',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'panitumumab',\n",
       "   'parecoxib',\n",
       "   'trimethoprim',\n",
       "   'pimecrolimus',\n",
       "   'emtricitabine',\n",
       "   'valdecoxib',\n",
       "   'abatacept',\n",
       "   'esomeprazole',\n",
       "   'telbivudine',\n",
       "   'tetrasodium',\n",
       "   'micafungin',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'abacavir',\n",
       "   'axitinib',\n",
       "   'atazanavir',\n",
       "   'globulin',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'temsirolimus',\n",
       "   'ammonium',\n",
       "   'eletriptan',\n",
       "   'linaclotide',\n",
       "   'dexlansoprazole',\n",
       "   'eculizumab',\n",
       "   'aprepitant',\n",
       "   'amlodipine',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'prasugrel',\n",
       "   'atomoxetine',\n",
       "   'olmesartan',\n",
       "   'dutasteride',\n",
       "   'eszopiclone',\n",
       "   'tegaserod',\n",
       "   'omalizumab',\n",
       "   'dasatinib',\n",
       "   'mepolizumab',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['shock',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'encephalitis',\n",
       "   'malaria',\n",
       "   'meningitis',\n",
       "   'influenza']},\n",
       " {'pmid': 18040531,\n",
       "  'sentence': '(-)-Epigallocatechin gallate, [188Re]-P2045, 12B75, 89-12; Abacavir sulfate/lamivudine, Abatacept, Abiraterone acetate, ABT-869, Adalimumab, Ad-rh Endostatin, AI-700, Alemtuzumab, Alvimopan hydrate, Amrubicin hydrochloride, AP-12009, Apomab 7.3, Arformoterol tartrate, Aripiprazole, AS-1404, Azacitidine, AZD-0530; Bevacizumab, BHT-3009, Biapenem, Bortezomib, Bosentan, Bremelanotide; CA9-SCAN, Calcitonin gene-related peptide, Canertinib dihydrochloride, Cannabidiol, Carboxyamidotriazole, Caspofungin acetate, Celgosivir, Certolizumab pegol, Cinacalcet hydrochloride, Clevudine, CP-751871, Curcumin, Cx-401, Cypher; Darunavir, Decitabine, Deforolimus, Dexamet, Dipyridamole/prednisolone, Drospirenone, Drospirenone/estradiol, DTPw-HepB-Hib, Duloxetine hydrochloride; Efalizumab, Emtricitabine, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone; Ferumoxtran-10, Ferumoxytol, Fondaparinux sodium, Fosaprepitant dimeglumine; gamma-Hydroxybutyrate sodium, Gefitinib, Genistein, Ghrelin (human), Gimatecan, GM-CSF PMED, Golimumab, gp100 PMED; Imatinib mesylate, Immunoglobulin intravenous (human), IV Gamma-globulin; LA-419, Laropiprant, L-BLP-25, Levodopa/carbidopa/entacapone, Lidocaine/prilocaine, Lopinavir/ritonavir, Lumiracoxib, LY-2076962; Mepolizumab, Methylnaltrexone bromide, Mitiglinide calcium hydrate, Mycophenolic acid sodium salt, Myristyl nicotinate; Natalizumab, Nesiritide, Niacin/lovastatin; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Ozarelix; Palonosetron hydrochloride, Parathyroid hormone (human recombinant), Pazopanib hydrochloride, Pegaptanib octasodium, Pegfilgrastim, Peginterferon alfa- 2a, Peginterferon alfa-2b, Pegvisomant, Pemetrexed disodium, Pexelizumab, Picoplatin, Pimecrolimus, Posaconazole, Pregabalin, PRO-1762, Progesterone caproate, Prulifloxacin; Ramelteon, Ranelic acid distrontium salt, Reparixin, Rosuvastatin calcium; Rotigotine; Satraplatin, Sertraline, Sipuleucel-T, SLIT-cisplatin, SNDX-275, Solifenacin succinate, Sunitinib malate; Tadalafil, Talnetant, Tanespimycin, Taxus, Tegaserod maleate, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate/emtricitabine, Teriparatide, tgAAC-94, Tiotropium bromide, Tocilizumab, Tolvaptan, Trimethoprim; Vardenafil hydrochloride hydrate, Vatalanib succinate, Vinflunine, Voriconazole, VX-680; XL-880; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ramelteon',\n",
       "   'azacitidine',\n",
       "   'gamma-globulin',\n",
       "   'tiotropium',\n",
       "   'drospirenone',\n",
       "   'peptide',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'darunavir',\n",
       "   'natalizumab',\n",
       "   'bevacizumab',\n",
       "   'pimecrolimus',\n",
       "   'vardenafil',\n",
       "   'trimethoprim',\n",
       "   'pemetrexed',\n",
       "   'emtricitabine',\n",
       "   'abatacept',\n",
       "   'immunoglobulin',\n",
       "   'golimumab',\n",
       "   'fosaprepitant',\n",
       "   'bosentan',\n",
       "   'ofatumumab',\n",
       "   'tolvaptan',\n",
       "   'voriconazole',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'abacavir',\n",
       "   'teriparatide',\n",
       "   'endostatin',\n",
       "   'imatinib',\n",
       "   'bortezomib',\n",
       "   'palonosetron',\n",
       "   'tadalafil',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'caspofungin',\n",
       "   'efalizumab',\n",
       "   'posaconazole',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'erlotinib',\n",
       "   'cinacalcet',\n",
       "   'olmesartan',\n",
       "   'fondaparinux',\n",
       "   'gefitinib',\n",
       "   'pazopanib',\n",
       "   'eszopiclone',\n",
       "   'aripiprazole',\n",
       "   'tegaserod',\n",
       "   'tocilizumab',\n",
       "   'mepolizumab',\n",
       "   'certolizumab'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 18080975,\n",
       "  'sentence': 'Results indicated that the TCM competences of BSN graduates from technological universities should include the following: (1) to understand the basic concepts of TCM, including Yin/Yang, the Five Evolutive Phases, holistic view, the Five Viscera and Six Bowels, Meridians, etiology, and concepts of therapy and health preservation; (2) to recognize the cold and hot nature of food; (3) to illustrate the common dietetic care for immune enhancement in the four seasons, and the foods that help postnatal and postoperative physical regeneration; (4) to illustrate the properties, indications, and administration of common Chinese medicines, including: Ginseng, Lycium, Astragalus, Angelica sinensis (danggui), Chrysanthemum, Pinellia, Zizyphi fructus; (5) to describe the properties, indications, adverse effects, and administration of Siwutang and Shenghuatang; (6) to describe basic principles of administering both Chinese medicine and Western medicine; (7) to describe the indications and cautions of the following techniques: acupuncture, scraping therapy, and cupping; (8) to implement acupressure as a measure for promoting comfort under the following conditions: pain, vomiting, insomnia, palpitations; and (9) to demonstrate an open mind and cautious attitude to respect consumers using TCM.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lycium'],\n",
       "  'reaction': ['acupuncture', 'pain', 'vomiting', 'insomnia', 'palpitations']},\n",
       " {'pmid': 18227124,\n",
       "  'sentence': \"TNF-alpha significantly increased HTSMC-neutrophil adhesions, and this effect was associated with increased expression of VCAM-1 on the HTSMCs and was blocked by the selective inhibitors of Src [4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP1)], epidermal growth factor receptor [EGFR; 4-(3'-chloroanilino)-6,7-dimethoxy-quinazoline, (AG1478)], phosphatidylinositol 3-kinase (PI3K) [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride(LY294002) and wortmannin],calcium[1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester; BAPTA-AM], phosphatidylinositol-phospholipase C (PLC) [1-[6-[[17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U73122)], protein kinase C (PKC) [12-(2-cyanoethyl)-6,7,12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (GÃ¶6976), rottlerin, and 3-1-[3-(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl) maleimide (bisindolylmaleimide IX) (Ro 31-8220)], CaM (calmidazolium chloride), CaM kinase II [(8R(*),9S(*),11S(*))-(-)-9-hydroxy-9-methoxycarbonyl-8-methyl-14-n-propoxy-2,3,9, 10-tetrahydro-8,11-epoxy, 1H,8H, 11H-2,7b,11a-triazadibenzo[a,g]cycloocta[cde]trinden-1-one (KT5926) and 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine (KN62)], p300 (curcumin), and HDAC (trichostatin A) or transfection with short interfering RNAs for Src, Akt, PKCalpha, PKCmu, and HDAC4.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 18326919,\n",
       "  'sentence': 'The studies discussed here include the following: i) a phase I study of a chemotherapy doublet gemcitabine plus capecitabine, combined with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma (abstract #141); ii) a phase II study of gemcitabine, bevacizumab, and erlotinib in locally advanced and metastatic adenocarcinoma of the pancreas (abstract #151); iii) final results of the multicenter phase II study on gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (abstract #198); iv) interim results from a phase II study of volociximab in combination with gemcitabine in patients with metastatic pancreatic cancer (abstract #142); v) a pilot study of combination chemotherapy with S-1 and irinotecan for advanced pancreatic cancer (abstract #155); vi) a multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer (abstract #212); vii) a phase I/II study of PHY906 plus capecitabine in patients with advanced pancreatic carcinoma (abstract #260); and viii) the final results of a phase II trial of Genexol-PM(R), a novel cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (abstract #269).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['irinotecan',\n",
       "   'gemcitabine',\n",
       "   'paclitaxel',\n",
       "   'erlotinib',\n",
       "   'capecitabine',\n",
       "   'bevacizumab'],\n",
       "  'reaction': ['chemotherapy',\n",
       "   'adenocarcinoma',\n",
       "   'adenocarcinoma',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'pancreatic carcinoma']},\n",
       " {'pmid': 18359490,\n",
       "  'sentence': 'The surface tensions were measured at atmospheric pressure, with use of a ring tensiometer, of a series of alcoholic solutions of closely related ionic liquids: 1-methyl-3-methylimidazolium methylsulfate, [MMIM][CH3SO4] in alcohol (methanol, or ethanol, or 1-butanol at 298.15 K), 1-butyl-3-methylimidazolium methylsulfate, [BMIM][CH3SO4] in alcohol (methanol, or ethanol, or 1-butanol at 298.15 K), 1-butyl-3-methylimidazolium octylsulfate, [BMIM][OcSO4] in alcohol (methanol, or 1-butanol at 298.15 K) and of 1-hexyloxymethyl-3-methylimidazolium tetrafluoroborate, [C6H(13)OCH2MIM][BF4], 1,3-dihexyloxymethylimidazolium tetrafluoroborate, [(C6H13OCH2)2IM][BF4] in alcohol (methanol, or 1-butanol, or 1-hexanol at 308.15 and 318.5 K) and hexyl(2-hydroxyethyl)dimethylammonium bromide, C6Br in 1-octanol at 298.15 K. The set of ammonium ionic liquids of different cations and anions (C2Br, C2BF4, C2PF6, C2N(CN)2, C3Br, C4Br and C6Br) was chosen to show the influence of small amount of the ammonium ionic liquid on the surface tension of water at 298.15 K. The influence of the cation, or anion alkyl chain length on the properties under study (densities and surface tension) was tested.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ammonium'],\n",
       "  'reaction': ['tension', 'tension']},\n",
       " {'pmid': 18475514,\n",
       "  'sentence': 'The results indicate that: (a) basal B but not ACTH plasma levels were significantly higher in female than in male mice; (b) LPS significantly increased both ACTH and B plasma levels over the baseline 2 h after injection, both hormone levels being higher in female than in male mice; (c) although plasma ACTH concentrations recovered the basal value at 72 h after LPS in animals of both sexes, plasma B levels returned to the baseline only at 120 h after treatment; (d) E plasma levels significantly increased 2 h after LPS and returned to the baseline at 72 h post-treatment, in both sexes; (e) at 2 h after LPS, testosterone plasma levels significantly decreased in male mice and increased in female mice, recovering the baseline level at 120 and 72 h after LPS, respectively; (f) AP ACTH content was similar in both sexes in basal condition and it was significantly diminished 72 h post-treatment without sex difference; whereas AP ACTH returned to basal content 120 h after LPS in males, it remained significantly decreased in females; (g) basal adrenal B content was higher in female than in male mice, and it significantly increased in both sexes 2 h post-LPS, maintaining this sex difference.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['injection', 'condition']},\n",
       " {'pmid': 18483169,\n",
       "  'sentence': 'During the exercise trial: 1) two, six, and four participants were orthostatically intolerant at T2, T3, and T4, respectively; 2) changes in heart rate variability were only observed at T2; 3) supine MAP (baseline = 81 +/- 6 mmHg) was lower (P < 0.05) by 14% at T3 and 8% at T4, whereas standing MAP (75 +/- 7 mmHg) was lower by 16% at T2, 37% at T3, and 15% at T4; 4) Pet(CO(2)) was reduced (P < 0.05) at all times while supine (-3-4 Torr) and standing (-4-5 Torr) during exercise trial; 5) standing MCAv was reduced (P < 0.05) by 23% at T3 and 30% at T4 during the exercise trial; 6) changes in MCAv with standing always correlated (P < 0.01) with changes in Pet(CO(2)) (r = 0.78-0.93), but only with changes in MAP at T1, T2, and T3 (P < 0.05; r = 0.62-0.84); and 7) only two individuals showed minor elevations in cardiac troponin I.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['heart rate',\n",
       "   'heart rate',\n",
       "   'heart rate variability',\n",
       "   'troponin',\n",
       "   'troponin',\n",
       "   'troponin i',\n",
       "   'troponin i']},\n",
       " {'pmid': 18533725,\n",
       "  'sentence': 'To this end, the following successive steps were carried out: (i) the NMR-based conformational analysis of CRK was put into practice, and, in the light of the results derived, the best energy CRK structure meeting the requirements of the input NMR data was identified; (ii) molecular docking of the CRK structure with the X-ray FKBP conformation was implemented, and energy refining the simulated structural complex was realized; (iii) the matrix of distances between amino acids of the ligand and receptor was computed to specify the FKBP stretch keeping in touch with CRK followed by analyzing the types of interactions stabilizing the over-molecular ensemble; (iv) 3D structure of this stretch in the unbound status referred to as the FKBP peptide was predicted, and its collation with the X-ray conformation of the identical FKBP site was performed; (v) the potential energy function and its constituents were studied for the structural complex generated by molecular docking of the CRK molecule with the FKBP peptide; and (vi) from all evidence, the virtual FKBP-derived peptide was submitted to be utilized as a prospective structural framework in the anti-HIV-1 drug design.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['energy', 'energy', 'energy']},\n",
       " {'pmid': 18582084,\n",
       "  'sentence': 'We found that (1) in two days, up to 80% of the Cd in the solution was absorbed by the plant, and the Cd could not be released back to the growth solution in the chase period; (2) approximately 1 mg of Cd was accumulated in the water hyacinth/g of dry weight in this condition; (3) invading Cd was bound rapidly as the low-molecular-weight (LMW) complex serving as the transient form for further sequestration; (4) the LMW complex in water hyacinth contained no phytochelatins and was different from the LMW complex in fission yeast; (5) the Cd absorbed in the plant was essentially stored in the high-molecular-weight (HMW) form after 1 week; (6) a small fraction of the absorbed Cd was found in the upper part of the plant (stem and leaves) in the form of complexes; (7) the HMW complex was composed of phytochelatins PC 3 and PC 4 primarily, with only a small amount of PC 2; (8) a rare PC-related peptide was found in the HMW complex that might be derived from PC 3.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['growth', 'weight', 'weight', 'condition']},\n",
       " {'pmid': 18592338,\n",
       "  'sentence': 'These assumptions are based on the following facts: 1) in estrogen-supplemented animals, progesterone has been shown to reactivate the growth of regressed tumour xenograft obtained from breast cancer cell lines, expressing both estrogen and progesterone receptor; 2) antiprogestin has been revealed to suppress the reactivation of the growth of tumour xenograft and to fully suppress the development of breast cancer in an animal model for BRCA1 gene mutation; 3) metabolites of progesterone have been recognised as potent regulators of cell proliferation, cell detachment and apoptosis; 4) progesterone has been shown to inhibit, in a dose-dependent manner, apoptosis in breast cancer cell lines and apoptosis induced by doxorubicin and 5-fluorouracyl (drugs used in breast cancer treatment); 5) an association between breast cancer and HRT was suspected upon the addition of progestin on a regular basis for the prevention of endometrial cancer; 6) in a randomised placebo-controlled trial on HRT an increased risk of breast cancer was shown for the combination of estrogen and progestin, but not for estrogen alone; 7) in epidemiological studies on POC the recognition of an increased breast cancer risk was most probably impeded due to previously unrecognised systematic selection bias; 8) in a large epidemiological study on the risk of early-onset breast cancer in association with COC an increased risk was detected for COC use up to 1975, but no increased, even a slightly decreased, risk was shown for users of low-dose COC, applied since 1976; 9) a considerably higher number of breast cancer cases have been reported from Germany on POC than on the widespread used COC [corrected] (111 versus 12); 10) the big resemblance among the breast cancers reported for POC and their similarity with breast malignancies diagnosed in pregnancy suggest the existence of a pattern rather than pure coincidence [corrected]',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['doxorubicin'],\n",
       "  'reaction': ['progesterone',\n",
       "   'growth',\n",
       "   'breast cancer',\n",
       "   'progesterone',\n",
       "   'growth',\n",
       "   'breast cancer',\n",
       "   'brca1 gene mutation',\n",
       "   'gene mutation',\n",
       "   'progesterone',\n",
       "   'apoptosis',\n",
       "   'progesterone',\n",
       "   'apoptosis',\n",
       "   'breast cancer',\n",
       "   'apoptosis',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'endometrial cancer',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'pregnancy']},\n",
       " {'pmid': 18597009,\n",
       "  'sentence': '(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC-1779; Belimumab, BIBW-2992, Binodenoson, Bortezomib, Bosutinib, Brivaracetam; Cediranib, Clevidipine, CNTO-328, CP-751871, Curcumin; Darapladib, Deforolimus, Denosumab, Desvenlafaxine succinate, Dipyridamole/prednisolone, Dronedarone hydrochloride, DTPw-HBV/Hib 2.5; Ecogramostim, Elacytarabine, Eltrombopag, Eprodisate sodium; Farnesylthiosalicylic acid, Febuxostat, Fenretinide, Ferumoxytol, FMP2.1/AS02A, Forodesine hydrochloride, FP-0011; HuLuc-63, Human Fibroblast Growth Factor 1; Idraparinux sodium, Indium 111 (111In) ibritumomab tiuxetan, Interleukin-21, Ipilimumab, ISS-1018, ITF-2357; Lapaquistat acetate, Laropiprant, Liposomal vincristine, LY-518674; Masitinib mesylate, MAXY-G34, MGCD-0103, Midostaurin, Mitumprotimut-T, MK-0343, MLN-1202, MM-093, Motexafin gadolinium; NB-001, NB-002, Niacin/laropiprant; Oblimersen sodium, Ocrelizumab, Omacetaxine mepesuccinate; Panobinostat, Patupilone, PBI-1402, Perifosine, PHA-739358, Plerixafor hydrochloride, Prasugrel; Regadenoson, RHAMM R3 peptide, Rilonacept, Rivaroxaban, Romiplostim; Safinamide mesilate, Salinosporamide A, Selenite sodium, Sotrastaurin; Thrombin alfa, Tipifarnib, TRO-19622; Vatalanib succinate, Vernakalant hydrochloride, VRC-WNVDNA017-00-VP; YM-155, Yttrium 90 (90Y) ibritumomab tiuxetan; Zosuquidar trihydrochloride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['eltrombopag',\n",
       "   'ipilimumab',\n",
       "   'romiplostim',\n",
       "   'dronedarone',\n",
       "   'denosumab',\n",
       "   'peptide',\n",
       "   'gadolinium',\n",
       "   'omacetaxine',\n",
       "   'plerixafor',\n",
       "   'desvenlafaxine',\n",
       "   'rivaroxaban',\n",
       "   'indium',\n",
       "   'zosuquidar',\n",
       "   'bortezomib',\n",
       "   'sodium',\n",
       "   'belimumab',\n",
       "   'bosutinib',\n",
       "   'brivaracetam',\n",
       "   'prasugrel',\n",
       "   'ocrelizumab',\n",
       "   'cediranib'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 18680693,\n",
       "  'sentence': 'The present review describes some of the adverse effects of antiretroviral drugs in which a genetic predisposition may be involved: efavirenz-induced neurological toxicity, generally associated with the 516G>T polymorphism of liver enzyme cytochrome P450 2B6 (CYP2B6); hypersensitivity reactions to nevirapine, associated with specific alleles of major histocompatibility complex, mainly the HLA-DRB1*0101 allele, which, in combination with a high CD4 lymphocyte count, has been associated with systemic reactions and hepatitis in Caucasians, and the HLA-Cw8 allele, which is associated with hypersensitivity reactions in persons from the Italian island of Sardinia and from Japan; nevirapine-induced hepatotoxicity associated with the C>T polymorphism in position 3435T of the ABCB1 (MDR-1) gene codifying for glycoprotein P (lower risk); hyperbilirubinemia in patients exposed to atazanavir or indinavir carrying the UGT1A1*28 polymorphism; peripheral neuropathy with nucleoside analogues associated with haplogroup T of the mitochondrial genome (higher risk) and with the HFE C282Y genotype of the hemochromatosis gene (lower risk); the mutation in codon 964 (R964C) of the POLG gene that codifies the mitochondrial polymerase DNA gamma described in a Thai patient with lactic acidosis; the ABCC2 gene haplotypes associated with tenofovir-induced proximal tubulopathy, and the risk of pancreatitis in persons with mutations in the CFTR and SPINK-1 genes.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['atazanavir', 'indinavir'],\n",
       "  'reaction': ['hypersensitivity',\n",
       "   'lymphocyte count',\n",
       "   'lymphocyte count',\n",
       "   'hepatitis',\n",
       "   'hypersensitivity',\n",
       "   'hepatotoxicity',\n",
       "   'lactic acidosis',\n",
       "   'acidosis',\n",
       "   'pancreatitis']},\n",
       " {'pmid': 18764719,\n",
       "  'sentence': 'Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['elvitegravir', 'cyclosporin'],\n",
       "  'reaction': ['papilloma',\n",
       "   'herpes simplex',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'influenza',\n",
       "   'hepatitis',\n",
       "   'hepatitis c',\n",
       "   'immunodeficiency']},\n",
       " {'pmid': 18806898,\n",
       "  'sentence': '(+)-Dapoxetine hydrochloride, (R)-Etodolac; Abatacept, ABT-510, Adalimumab, Agatolimod sodium, Alemtuzumab, Alvocidib hydrochloride, Aminolevulinic acid methyl ester, Aripiprazole, AS01B, AS02B, AS02V, Azacitidine; Becatecarin, Bevacizumab, Bevirimat, Bortezomib, Bremelanotide; CAIV-T, Canfosfamide hydrochloride, CHR-2797, Ciclesonide, Clevidipine; Darbepoetin alfa, Decitabine, Degarelix acetate, Dendritic cell-based vaccine, Denosumab, Desloratadine, DMXB-Anabaseine, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Eicosapentaenoic acid/docosahexaenoic acid, Eletriptan, Enzastaurin hydrochloride, Erlotinib hydrochloride, Escitalopram oxalate, Etoricoxib, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumarate, Fulvestrant; Gefitinib, GM-CSF DNA, GSK-690693; H5N1 avian flu vaccine, Hepatitis B hyperimmunoglobulin, Human Fibroblast Growth Factor 1, Hypericin-PVP; Icatibant acetate, Iclaprim, Immunoglobulin intravenous (human), Ipilimumab, ISS-1018; L19-IL-2, Lapuleucel-T, Laropiprant, Liposomal doxorubicin, LP-261, Lumiracoxib, LY-518674; MDV-3100, MGCD-0103, Mirabegron, MyoCell; NASHA/Dx, Niacin/laropiprant; O6-Benzylguanine, Ocrelizumab, Olmesartan medoxomil, Omalizumab; P-276-00, Paclitaxel nanoparticles, Paclitaxel nanoparticles, Padoporfin, Paliperidone, PAN-811, Pegaptanib octasodium, Pegfilgrastim, Pemetrexed disodium, PF-00299804, Pimecrolimus, Prasugrel, Pregabalin; Reolysin, Rimonabant, Rivaroxaban, Rosuvastatin calcium; Satraplatin, SCH-697243,Selenite sodium, Silodosin, Sorafenib, Sunitinib malate; Talarozole, Taxus, Temsirolimus, Tocilizumab, Tolevamer potassium sodium, Tremelimumab, TTP-889; Uracil; V-260, Valsartan/amlodipine besylate, Vardenafil hydrochloride hydrate, Varenicline tartrate, Varespladib, Vitespen, Voclosporin, VX-001; Xience V; Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['paclitaxel',\n",
       "   'ipilimumab',\n",
       "   'azacitidine',\n",
       "   'denosumab',\n",
       "   'uracil',\n",
       "   'duloxetine',\n",
       "   'alemtuzumab',\n",
       "   'desloratadine',\n",
       "   'everolimus',\n",
       "   'pimecrolimus',\n",
       "   'bevacizumab',\n",
       "   'vardenafil',\n",
       "   'pemetrexed',\n",
       "   'abatacept',\n",
       "   'immunoglobulin',\n",
       "   'fulvestrant',\n",
       "   'paliperidone',\n",
       "   'degarelix',\n",
       "   'ciclesonide',\n",
       "   'adalimumab',\n",
       "   'rosuvastatin',\n",
       "   'rivaroxaban',\n",
       "   'bortezomib',\n",
       "   'darbepoetin',\n",
       "   'temsirolimus',\n",
       "   'eletriptan',\n",
       "   'varenicline',\n",
       "   'potassium',\n",
       "   'calcium',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'doxorubicin',\n",
       "   'sunitinib',\n",
       "   'pegfilgrastim',\n",
       "   'erlotinib',\n",
       "   'prasugrel',\n",
       "   'mirabegron',\n",
       "   'olmesartan',\n",
       "   'dutasteride',\n",
       "   'gefitinib',\n",
       "   'ocrelizumab',\n",
       "   'omalizumab',\n",
       "   'aripiprazole',\n",
       "   'icatibant',\n",
       "   'tocilizumab'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'growth']},\n",
       " {'pmid': 18850047,\n",
       "  'sentence': '(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept, Aliskiren fumarate, Apixaban, Atazanavir sulfate, Atrasentan, Axitinib; BI-1744-CL, BIBF-1120, BIBW-2992, Bortezomib; Carboxyamidotriazole, Caspofungin acetate, CBP-501, Cediranib, Ceftobiprole, Certolizumab pegol, Cetuximab, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, CHP-NY-ESO-1, Cypher; Dalbavancin, Dalcetrapib, Daptomycin, Darapladib, Deferasirox, Deforolimus, Denosumab, DNA-HIV-C, Dovitinib, DR-5001, Dronedarone hydrochloride, DT388IL3; E75, EC-17/EC-90, Ecogramostim, Efungumab, Entecavir, EP HIV-1090, EP-2101, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Faropenem daloxate, Fluticasone furoate, Fondaparinux sodium, Fospropofol disodium, Fulvestrant; Golimumab, GSK-089, GW-590735; HO/03/03, hTERT572, hTERT572Y; Iloperidone; Immunoglobulin intravenous (human), Ispinesib mesylate, Istradefylline, Ixabepilone; JR-031, JX-594; KLH; Laropiprant, Lecozotan hydrochloride, Lenalidomide, Lestaurtinib, Linezolid; MGCD-0103, MK-0646, MVA-BN Measles; NI-0401, Niacin/laropiprant, NSC-719239, NYVAC-C; Ospemifene; Paliperidone palmitate, PAN-811, PCV7, Pegfilgrastim, Peginterferon alfa-2a, PEGirinotecan, Perifosine, Pertuzumab, PF-00299804, Picoplatin, Pimavanserin tartrate, Pitavastatin calcium, Pomalidomide, Prasterone, Pratosartan, Prucalopride, PSMA27/pDOM, Pyridoxal phosphate; QS-21, Quercetin; Rebimastat, Rimonabant, Rolofylline, Romidepsin, Rosuvastatin calcium, RTS,S/SBAS2; SCH-530348, SN-29244, Soblidotin, Sodium dichloroacetate, Solifenacin succinate, Sorafenib, Spheramine, SU-6668, Succinobucol; Taranabant, Taxus, Telaprevir, Telavancin hydrochloride, Telbivudine, Tenofovir disoproxil fumarate, Tigecycline, Tiotropium bromide, Tocilizumab, Triphendiol; UC-781, Udenafil, UNIL-025; V-5 Immunitor, Valsartan/amlodipine besylate, Varenicline tartrate, Velafermin, Vernakalant hydrochloride, Vinflunine, Vitespen, Vorinostat, VX-001; Xience V, XRP-0038; Yttrium Y90 Epratuzumab; Z-360, Ziconotide, Ziprasidone hydrochloride, Zotarolimus, Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'cetuximab',\n",
       "   'vorinostat',\n",
       "   'pegfilgrastim',\n",
       "   'atazanavir',\n",
       "   'certolizumab',\n",
       "   'disodium',\n",
       "   'linezolid',\n",
       "   'alefacept',\n",
       "   'apixaban',\n",
       "   'tigecycline',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'golimumab',\n",
       "   'cediranib',\n",
       "   'pitavastatin',\n",
       "   'sodium',\n",
       "   'denosumab',\n",
       "   'aliskiren',\n",
       "   'fondaparinux',\n",
       "   'bortezomib',\n",
       "   'rosuvastatin',\n",
       "   'dronedarone',\n",
       "   'telbivudine',\n",
       "   'prucalopride',\n",
       "   'tocilizumab',\n",
       "   'daptomycin',\n",
       "   'tiotropium',\n",
       "   'immunoglobulin',\n",
       "   'adalimumab',\n",
       "   'abatacept',\n",
       "   'iloperidone',\n",
       "   'caspofungin',\n",
       "   'paliperidone',\n",
       "   'varenicline',\n",
       "   'fulvestrant',\n",
       "   'calcium',\n",
       "   'pertuzumab',\n",
       "   'dovitinib'],\n",
       "  'reaction': ['measles']},\n",
       " {'pmid': 18985183,\n",
       "  'sentence': 'The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Perillyl alcohol, Perphenazine 4-aminobutyrate, PeviPRO/breast cancer, PF-03814735, PHA-739358, Pimecrolimus, Plitidepsin, Posaconazole, Prasterone, Prasugrel, Pregabalin, Prucalopride, PRX-08066; rAAV2-TNFR:Fc, Ranelic acid distrontium salt, Ranibizumab, rCD154-CLL, Retapamulin, RTS,S/SBAS2, rV-PSA-TRICOM/rF-PSA-TRICOM; SG-2000, Sinecatechins, Sirolimus-eluting stent, Sorafenib, SP-1640, Strontium malonate, Succinobucol, Sunitinib malate; Taxus, Teduglutide, Telavancin hydrochloride, Telbivudine, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ustekinumab; V-5 Immunitor, Voriconazole, Vorinostat; Xience V, XL-184, XL-647, XL-765; Y-39983, Zibotentan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir',\n",
       "   'cetuximab',\n",
       "   'vorinostat',\n",
       "   'irinotecan',\n",
       "   'bevacizumab',\n",
       "   'imatinib',\n",
       "   'anakinra',\n",
       "   'nilotinib',\n",
       "   'disodium',\n",
       "   'teduglutide',\n",
       "   'alefacept',\n",
       "   'dasatinib',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'paclitaxel',\n",
       "   'sunitinib',\n",
       "   'sodium',\n",
       "   'posaconazole',\n",
       "   'denosumab',\n",
       "   'aliskiren',\n",
       "   'darbepoetin',\n",
       "   'bortezomib',\n",
       "   'ciclesonide',\n",
       "   'bazedoxifene',\n",
       "   'telbivudine',\n",
       "   'prucalopride',\n",
       "   'tocilizumab',\n",
       "   'dexlansoprazole',\n",
       "   'brivanib',\n",
       "   'lumiliximab',\n",
       "   'strontium',\n",
       "   'emtricitabine',\n",
       "   'daptomycin',\n",
       "   'ozogamicin',\n",
       "   'aprepitant',\n",
       "   'gefitinib',\n",
       "   'ustekinumab',\n",
       "   'duloxetine',\n",
       "   'azacitidine',\n",
       "   'caspofungin',\n",
       "   'aripiprazole',\n",
       "   'prasugrel',\n",
       "   'voriconazole',\n",
       "   'fulvestrant',\n",
       "   'dutasteride',\n",
       "   'dovitinib',\n",
       "   'aclidinium',\n",
       "   'ranibizumab',\n",
       "   'pemetrexed',\n",
       "   'gemtuzumab',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['fibrin']},\n",
       " {'pmid': 18985959,\n",
       "  'sentence': 'The Food and Drug Administration (FDA) is amending its labeling regulation authorizing a health claim on the relationship between calcium and a reduced risk of osteoporosis to include vitamin D so that, in addition to the claim for calcium and osteoporosis, an additional claim can be made for calcium and vitamin D and osteoporosis; eliminate the requirement that the claim list sex, race, and age as specific risk factors for the development of osteoporosis; eliminate the requirement that the claim does not state or imply that the risk of osteoporosis is equally applicable to the general U.S. population, and that the claim identify the populations at particular risk for the development of osteoporosis; eliminate the requirement that the claim identify the mechanism by which calcium reduces the risk of osteoporosis and instead make it optional; eliminate the requirement that the claim include a statement that a total dietary intake greater than 200 percent of the recommended daily intake (2,000 milligrams (mg) of calcium) has no further benefit to bone health when the food contains 400 mg or more of calcium per reference amount customarily consumed or per total daily recommended supplement intake; and allow reference for the need of physical activity in either of the health claims to be optional rather then required.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['osteoporosis',\n",
       "   'vitamin d',\n",
       "   'osteoporosis',\n",
       "   'vitamin d',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis']},\n",
       " {'pmid': 19026018,\n",
       "  'sentence': 'In Part 1 of this review we discuss the impact of exercise on CVD, and we highlight the effects of exercise on (i) endothelial function by regulation of endothelial genes mediating oxidative metabolism, inflammation, apoptosis, cellular growth and proliferation, increased superoxide dismutase (SOD)-1, down-regulation of p67phox, changes in intracellular calcium level, increased vascular endothelial nitric oxide synthase (eNOS), expression and eNOS Ser-1177 phosphorylation; (ii) vascular smooth muscle function by either an increased affinity of the Ca2+ extrusion mechanism or an augmented Ca2+ buffering system by the superficial sarcoplasmic reticulum to increase Ca2+ sequestration, increase in K+ channel activity and/or expression, and increase in L-type Ca2+ current density; (iii) antioxidant systems by elevation of Mn-SOD, Cu/Zn-SOD and catalase, increases in glutathione peroxidase activity and activation of vascular nicotinamide adenine dinucleotide phosphate [(NAD(P)H] oxidase and p22phox expression; (iv) heat shock protein (HSP) expression by stimulating HSP70 expression in myocardium, skeletal muscle and even in human leucocytes, probably through heat shock transcription factor 1 activity; (v) inflammation by reducing serum inflammatory cytokines such as high-sensitivity C-reactive protein (hCRP), interleukin (IL)-6, IL-18 and tumour necrosis factor-alpha and by regulating Toll-like receptor 4 pathway.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['inflammation',\n",
       "   'apoptosis',\n",
       "   'growth',\n",
       "   'shock',\n",
       "   'shock',\n",
       "   'inflammation',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'tumour necrosis',\n",
       "   'necrosis']},\n",
       " {'pmid': 19069852,\n",
       "  'sentence': 'In the present investigation the minimum and maximum value of water temperature, Transparency, Turbidity, TSS, TDS, Electric Conductivity, water pH, dissolve oxygen, free Carbon dioxide, Alkalinity, Acidity, Hardness, BOD, COD, Sulphate, Phosphate, Nitrite, Sodium, Calcium, Potassium, Manganese and Iron were noted as 21.6 and 32.2 degrees C; 15 and 66 cm; 16 and 22 NTU; 74 and 125 mg L(-1); 255 and 305 mg L(-1); 159 and 275 microS cm(-1); 1.10 mg L(-1) 8.18 mg L(-1); 7.5 and 8.3; 1.1 and 8.3 mg L(-1); 27.5 and 35.5 mg L(-1); 350 and 610 mg L(-1); 32.4 and 171 mg L(-1); 310 and 529 mg L(-1); 13 and 31 mg L(-1); 290 and 365 mg L(-1); 42046 and 57.35 mg L(-1); 4.89 and 11.46 mg L(-1); 0.54 and 1.82 mg L(-1); 16.8 and 33.9 mg L(-1); 1.5 and 6.9 mg L(-1); 49 and 94 mg L(-1); 31 and 59 mg L(-1); 2.6 and 3.8 mg L(-1), respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium', 'calcium', 'sodium'],\n",
       "  'reaction': ['investigation', 'carbon dioxide', 'manganese']},\n",
       " {'pmid': 19088949,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: (+)-Dapoxetine hydrochloride, (S)-Tenatoprazole sodium salt monohydrate 19-28z, Acotiamide hydrochloride hydrate, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, Aliskiren fumarate, Asenapine maleate, Axitinib; Bavituximab, Becatecarin, beta-1,3/1,6-Glucan, Bevacizumab, Bremelanotide; Calcipotriol/betamethasone dipropionate, Casopitant mesylate, Catumaxomab, CDX-110, Cediranib, CMD-193, Cositecan; Darinaparsin, Denosumab, DP-b99, Duloxetine hydrochloride; E75, Ecogramostim, Elacytarabine, EMD-273063, EndoTAG-1, Enzastaurin hydrochloride, Eplerenone, Eribulin mesilate, Esomeprazole magnesium, Etravirine, Everolimus, Ezetimibe; Faropenem daloxate, Febuxostat, Fenretinide; Ghrelin (human); I-131 ch-TNT-1/B, I-131-3F8, Iclaprim, Iguratimod, Iloperidone, Imatinib mesylate, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, Ispinesib mesylate, Ixabepilone; Lapatinib ditosylate, Laquinimod sodium, Larotaxel dehydrate, Linezolid, LOR-2040; Mapatumumab, MKC-1, Motesanib diphosphate, Mycophenolic acid sodium salt; NK-012; Olanzapine pamoate, Oncolytic HSV, Ortataxel; Paclitaxel nanoparticles, Paclitaxel poliglumex, Paliperidone palmitate, Panitumumab, Patupilone, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, Picoplatin, Pimavanserin tartrate, Pimecrolimus, Plerixafor hydrochloride, PM-02734, Poly I:CLC, PR1, Prasugrel, Pregabalin, Progesterone caproate, Prucalopride, Pumosetrag hydrochloride; RAV-12, RB-006, RB-007, Recombinant human erythropoietin alfa, Rimonabant, Romidepsin; SAR-109659, Satraplatin, Sodium butyrate; Tadalafil, Talampanel, Tanespimycin, Tarenflurbil, Tariquidar, Taurine, Tecovirimat, Telatinib, Telavancin hydrochloride, Telcagepant, Terameprocol, Tesofensine, Tetrodotoxin, Tezampanel, Tipifarnib, TPI-287, Tremelimumab; Valspodar, Vatalanib succinate, VCL-CB01, vCP1452, Vorinostat; XL-228; Ziprasidone hydrochloride.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['esomeprazole',\n",
       "   'vorinostat',\n",
       "   'pegfilgrastim',\n",
       "   'bevacizumab',\n",
       "   'imatinib',\n",
       "   'aflibercept',\n",
       "   'indacaterol',\n",
       "   'linezolid',\n",
       "   'everolimus',\n",
       "   'axitinib',\n",
       "   'paclitaxel',\n",
       "   'cediranib',\n",
       "   'denosumab',\n",
       "   'sodium',\n",
       "   'aliskiren',\n",
       "   'prucalopride',\n",
       "   'ipilimumab',\n",
       "   'lapatinib',\n",
       "   'magnesium',\n",
       "   'duloxetine',\n",
       "   'iloperidone',\n",
       "   'paliperidone',\n",
       "   'prasugrel',\n",
       "   'tadalafil',\n",
       "   'eplerenone',\n",
       "   'panitumumab',\n",
       "   'plerixafor',\n",
       "   'pertuzumab',\n",
       "   'eribulin',\n",
       "   'pimecrolimus'],\n",
       "  'reaction': ['progesterone']},\n",
       " {'pmid': 19101237,\n",
       "  'sentence': 'Four hundred ten consecutive patients with compensated HF (New York Heart Association class II to IV) aged 53 to 86 years, with ejection fractions <35% and serum creatinine <2 mg/dl, were randomized into 8 groups: group A (n = 52): 1,000 ml/day of fluid intake, 120 mmol/day, and 250 mg furosemide twice daily; group B (n = 51): 1,000 ml/day of fluid intake, 120 mmol/day, and 125 mg furosemide twice daily; group C (n = 51): 1,000 ml/day fluid intake, 80 mmol/day, and 250 mg furosemide twice daily; group D (n = 51): 1,000 ml/day fluid intake, 80 mmol/day, and 125 mg furosemide twice daily; group E (n = 52): 2,000 ml/day fluid intake, 120 mmol/day, and 250 mg furosemide twice daily; group F (n = 50): 2,000 ml/day fluid intake, 120 mmol/day, and 125 mg furosemide twice daily; group G (n = 52): 2,000 ml/day fluid intake, 80 mmol/day, and 250 mg furosemide twice daily; and group H (n = 51): 2,000 ml/day fluid intake, 80 mmol/day, and 125 mg furosemide twice daily.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['furosemide'],\n",
       "  'reaction': ['fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake',\n",
       "   'fluid intake']},\n",
       " {'pmid': 19101674,\n",
       "  'sentence': 'It has been observed that, at 25.0+/-0.1 degrees C, [Co(NH(3))(6)](ClO(4))(3), [Co(en)(3)](ClO(4))(3), [Co(bpy)(3)](ClO(4))(3), and [Co(phen)(3)](ClO(4))(3) in the regions of 1.25-5.00 mM aqueous solutions cause a significant surface tension reduction (STR) of water by the surfactants, sodium dodecylsulfate (SDS) and sodium dodecylbenzenesulfonate (SBS), suggesting the formation of the 1:1 and 1:2 association complexes, {[complex](3+)(S(-))}(2+) and {[complex](3+)(S(-))(2)}(+) where [complex](3+)=[Co(NH(3))(6)](3+), [Co(en)(3)](3+), [Co(bpy)(3)](3+), or [Co(phen)(3)](3+), S(-)=DS(-) or BS(-).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['tension']},\n",
       " {'pmid': 19108583,\n",
       "  'sentence': 'To this end, the following problems were solved: (i) the NMR-based conformational analysis of the HIV-MN V3 loop was put into effect, and its low energy structure fitting the input experimental observations was determined; (ii) molecular docking of this V3 structure with the X-ray conformation of CycA was carried out, and the energy refining the simulated structural complex was performed; (iii) the matrix of inter-atomic distances for the amino acids of the molecules forming part of the built over-molecular ensemble was computed, the types of interactions responsible for its stabilization were analyzed, and the CycA stretch, which accounts for the binding to V3, was identified; (iv) the most probable 3D structure for this stretch in the unbound state was predicted, and its collation with the X-ray structure for the corresponding site of CycA was performed; (v) the potential energy function and its constituents were studied for the structural complex generated by molecular docking of the V3 loop with the CycA peptide offering the virtual molecule that imitates the CycA segment, making a key contribution to the interactions of the native protein with the HIV-1 principal neutralizing determinant; (vi) as a result of the studies above, the designed molecule was shown to be capable of the efficacious blockading the functionally crucial V3 sites; and (vii) based on the joint analysis of the evidence obtained previously and in the present study, the composition of the peptide cocktail presenting the promising anti-AIDS pharmacological substance was developed.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['energy', 'energy', 'energy']},\n",
       " {'pmid': 19142668,\n",
       "  'sentence': 'At the end of study, median urine volume was 3.27 [95% confidence interval (CI) 2.04-4.50] ml/kg per hour in the HA+FU infusion group and 1.33 (95% CI 0.79-1.88) ml/kg per hour in the FU infusion group (P = 0.01); the median daily sodium excretion was 58 (95% CI 30-366) mEq and 30 (95% CI 10-122) mEq (P = 0.08), respectively The changes in other variables included weight loss [HA+FU 5.2% (95% CI 3.1-8.8); FU 0.8% (95% CI -1.9 to 4.1); P = 0.006]; urine osmolality [HA+FU 315 (95% CI 220-426) mOsm/kg; FU 368 (95% CI 318-446) mOsm/kg; P = 0.13]; osmolal clearance [HA+FU 1600 (95% CI 916-4140) ml/day; FU 880 (95% CI 510-2105) ml/day; P = 0.01; free water clearance [HA+FU -190 (95% CI -960 to 280) ml/day; FU -162 (95% CI -446 to -70) ml/day; P = 0.18].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['infusion', 'infusion', 'weight', 'weight']},\n",
       " {'pmid': 19200547,\n",
       "  'sentence': 'The studies can be summarized as follows: (1) apolipoprotein B predicts ischemic cardiovascular events in both genders, and is better than LDL cholesterol in this respect; (2) linkage disequilibrium structure in APOB is more complex than expected from HapMap data, because a minimal set of tag single nucleotide polymorphisms capturing the entire variation in APOB cannot be identified, and thus most polymorphisms must be evaluated separately in association studies; (3) APOB mutations and polymorphisms are associated with a range of apolipoprotein B and LDL cholesterol levels, although the magnitude of effect sizes of common polymorphisms are modest; (4) both mutations and polymorphisms are associated with LDL metabolism in vivo; (5) association of APOB mutations and polymorphisms with lipid and disease phenotype cannot be predicted in silico using evolutionary conservation or existing prediction programs; and finally, (6) except for the E4154K polymorphism that possibly predicts a reduction in risk of ischemic cerebrovascular disease and ischemic stroke, common APOB polymorphisms with modest effect sizes on lipid levels do not predict risk of ischemic heart disease, myocardial infarction, ischemic cerebrovascular disease, or ischemic stroke in the general population.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['apolipoprotein b',\n",
       "   'apolipoprotein b',\n",
       "   'myocardial infarction',\n",
       "   'infarction']},\n",
       " {'pmid': 19295068,\n",
       "  'sentence': 'The water quality parameters namely transparency (12.12-110 cm), colour (transparent-very turbid), turbidity (1-178 TNU), electrical conductivity (145.60-884 microS cm(-1)), total dissolved solids (260-500 mgl(-1)), pH (7.60-9.33), dissolved oxygen (4.86-14.59 mgl(-1)), free carbon dioxide (0-16.5 mgl(-1)), total alkalinity (70-290 mgl(-1)), total hardness (42-140 mgl(-1)), chloride (15.62-80.94 mgl(-1)), nitrate (0.008-0.025 mgl(-1)), nitrite (0.002-0.022 mgl(-1)), sulphate (3.50-45 mgl(-1)), phosphate (0.004-0.050 mgl(-1)), silicate (2.80-13.80 mgl(-1)), biochemical oxygen demand (0.60-5.67 mgl(-1)), chemical oxygen demand (2.40-26.80 mgl(-1)), ammonia (nil-0.56 mgl(-1)), sodium (14.30-54.40 mgl(-1)) and potassium (2.10 mgl(-1)-6.30 mgl(-1)) reflects on the pristine nature of the river in National Chambal sanctuary.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium', 'sodium'],\n",
       "  'reaction': ['carbon dioxide', 'ammonia']},\n",
       " {'pmid': 19307624,\n",
       "  'sentence': 'The data provide evidence that 1) DMI (18%), BW (17%), and BF (5%) together explained 40% of the variation in plasma leptin concentrations (r(2) = 0.396); 2) unlike the acute postprandial increase in plasma insulin as a result of increased nutrient density (H 1.42 +/- 0.09, M 1.02 +/- 0.09, L 0.68 +/- 0.11 ng/mL), plasma leptin concentrations did not respond acutely with a distinct postprandial profile; 3) although plasma leptin concentrations increased with age, leptin at puberty did not differ among treatment groups (H 5.63 +/- 2.48, M 4.28 +/- 0.55, L 4.12 +/- 0.72 ng/mL) and there was no evidence of an abrupt transition in prepubertal plasma leptin concentrations; 4) plasma leptin concentrations may not be a critical trigger for puberty in rapidly growing heifers, but are apparently essential for puberty in heifers with normal or restricted growth rates; and 5) plasma concentrations of insulin (H 0.59 +/- 0.07, M 0.43 +/- 0.09, L 0.30 +/- 0.09 ng/mL), IGF-1 (H 151.08 +/- 16.47, L 82.51 +/- 17.47 ng/mL), and glucose (H 81.35 +/- 3.39, M 73.59 +/- 2.34, L 68.25 +/- 3.39 mg/dL) reflected nutrient density, whereas GH (H 1.82 +/- 0.23, L 5.87 +/- 0.45 ng/mL) and NEFA (H 209.54 +/- 50.83, L 234.93 +/- 48.97 microM) were inversely related to the plane of nutrition.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['leptin'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 19463965,\n",
       "  'sentence': \"The value of maximal inhibition was approximately 63% when measured at 25 degrees C, approximately 52% at 37 degrees C and approximately 45% at 42 degrees C. The lowest value of P(d) (corresponding to the basal permeability to water) was approximately 3 x 10(-3) cm s(-1) at 25 degrees C. For the RBCs from red-necked wallaby (M. rufogriseus) the values of P(d) (cm s(-1)) were 7 x 10(-3) at 25 degrees C, 8 x 10(-3) at 30 degrees C, 10 x 10(-3) at 37 degrees C, and 12 x 10(-3) at 42 degrees C. Higher values of P(d) (cm s(-1)) were found for the RBCs from Goodfellow's tree kangaroo (D. goodfellowi): 8.5 x 10(-3) at 25 degrees C, 10 x 10(-3) at 30 degrees C, 13 x 10(-3) at 37 degrees C, and 15 x 10(-3) at 42 degrees C. The mean values of the activation energy of water diffusion (E(a,d)) were approximately 25 kJ mol(-1) for RBCs from the agile wallaby and tree kangaroo, respectively, and approximately 23 kJ mol(-1) for RBCs from red-necked wallaby.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 19466522,\n",
       "  'sentence': 'Low-density lipoprotein cholesterol increase was +1.64% after 6 h with a decrease of -0.82% at 9 and 12 h. A significant sICAM-1, hsCRP, and sE-selectin variation was observed after 6 and 9 h, while a significant sVCAM-1 change occurred after 3, 6, and 9 h. Soluble ICAM-1 increase was +20.58% at 3 h, +34.10% at 6 h (P < 0.05 vs 0) +25.94% at 9 h (P < 0.01 vs 0), and +19.14% at 12 h; sVCAM-1 increase was +13.97% (P < 0.05 vs 0) at 3 h, +18.55% at 6 h (P < 0.01 vs 0), +12.02% at 9 h (P < 0.05 vs 0), and +8.70% at 12 h. High-sensitivity CRP increase was +36.36% at 3 h, +90.91% at 6 h (P < 0.01 vs 0), +63.64% at 9 h (P < 0.05 vs 0), and +36.36% at 12 h. Soluble E-selectin increase was +27.11% at 3 h, +51.90% at 6 h (P < 0.05 vs 0), +45.19% at 9 h (P < 0.01 vs 0), and +20.12% at 12 h. Interleukin-6 increase was +61.11% at 3 h (P < 0.05 vs 0), +83.33% at 6 h (P < 0.001 vs 0), +55.56% at 9 h (P < 0.01 vs 0), and +22.22% at 12 h. Tumor necrosis factor-alpha increase was +42.86% at 3 h (P < 0.05 vs 0), +71.43% at 6 h (P < 0.01 vs 0), (+50.00% at 9 h (P < 0.05 vs 0), and +28.57% at 12 h. We observed that the OFL induces a complex and massive systemic inflammatory response that includes IL-6, TNF-alpha, hsCRP, and cell adhesion molecules, even before Tg significantly rises.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['necrosis', 'adhesion']},\n",
       " {'pmid': 19609518,\n",
       "  'sentence': 'They included the following: age 20-40 (1), sex (2), family history (3), Gulf returned (1), external occupation (1), primary (1), recurrent (5), symptoms (2), RBC (1), PC (1), COD (1), COM (2), UA (2), crystal aggregation (2), urinary infection (1), pH below 6 (1), bilateralism (2), kidney/U/B/U (1), passer (2), multiple organs (2), multiple number (2), incomplete removal (5), serum calcium (3), serum phosphorus (1), serum magnesium (1), serum creatinine (1), serum uric acid (4), urine volume (1), urine specific gravity (1), urine calcium (1), urine phosphorus (1), urine uric acid (5), urine magnesium (2), urine oxalate (8), urine citrate (8), calcium magnesium ratio (2), creatinine clearance (1), tubular reabsorption of phosphate (4), urine calcium oxalate ratio (2), urine oxalate citrate ratio (5), urine oxalate uric acid ratio (2), urine calcium uric acid ratio (2), stone COM/COD (2) and stone UA/cystine (2).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium', 'calcium'],\n",
       "  'reaction': ['infection',\n",
       "   'urine calcium',\n",
       "   'urine phosphorus',\n",
       "   'urine phosphorus',\n",
       "   'urine uric acid',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine calcium',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine oxalate',\n",
       "   'urine calcium']},\n",
       " {'pmid': 19649342,\n",
       "  'sentence': '(+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate, Ambrisentan, Amlodipine, Aripiprazole, Atrasentan, Azacitidine, Azelnidipine; Belotecan hydrochloride, Bevacizumab, Bilastine, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin acetate, CG-100649, Cinacalcet hydrochloride, Clindamycin phosphate/ benzoyl peroxide; Dasatinib, Denosumab, Duloxetine hydrochloride, Dutasteride, Dutasteride/tamsulosin; Ecogramostim, Eculizumab, Eltrombopag olamine, EndoTAG-1, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe; FAHF-2, Fondaparinux sodium; Gefitinib, Golimumab; HEV-239, HSV-TK; Imatinib mesylate, Indium 111 ((111)In) ibritumomab tiuxetan, Influenza vaccine(surface antigen, inactivated, prepared in cell culture), Insulin glargine; Kisspeptin-54; Lidocaine/prilocaine, Lomitapide; Maraviroc, Mirodenafil hydrochloride, MK-8141, MVA-Ag85A; Nilotinib hydrochloride monohydrate; Olmesartan medoxomil; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pitavastatin calcium, Prasugrel; Recombinant human relaxin H2, RHAMM R3 peptide, Rivaroxaban, Rosuvastatin calcium, RRz2; Sagopilone, Salinosporamide A, SB-509, Serlopitant, Sirolimus-eluting stent, Sorafenib, Sunitinib malate; Tadalafil, Temsirolimus, Teriparatide, TG-4010, Tositumomab/iodine (I131) tositumomab; Velusetrag Hydrochloride; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['amlodipine',\n",
       "   'alemtuzumab',\n",
       "   'calcium',\n",
       "   'maraviroc',\n",
       "   'bortezomib',\n",
       "   'pitavastatin',\n",
       "   'azacitidine',\n",
       "   'denosumab',\n",
       "   'prasugrel',\n",
       "   'tadalafil',\n",
       "   'pemetrexed',\n",
       "   'aripiprazole',\n",
       "   'azelnidipine',\n",
       "   'imatinib',\n",
       "   'indium',\n",
       "   'abatacept',\n",
       "   'pegfilgrastim',\n",
       "   'dutasteride',\n",
       "   'cinacalcet',\n",
       "   'olmesartan',\n",
       "   'aliskiren',\n",
       "   'duloxetine',\n",
       "   'lomitapide',\n",
       "   'teriparatide',\n",
       "   'bevacizumab',\n",
       "   'temsirolimus',\n",
       "   'bilastine',\n",
       "   'erlotinib',\n",
       "   'exenatide',\n",
       "   'everolimus',\n",
       "   'gefitinib',\n",
       "   'sunitinib',\n",
       "   'clindamycin',\n",
       "   'nilotinib',\n",
       "   'dasatinib',\n",
       "   'sodium',\n",
       "   'disodium',\n",
       "   'golimumab',\n",
       "   'peptide',\n",
       "   'caspofungin',\n",
       "   'eltrombopag',\n",
       "   'rivaroxaban',\n",
       "   'rosuvastatin',\n",
       "   'fondaparinux',\n",
       "   'bosentan',\n",
       "   'ambrisentan',\n",
       "   'eculizumab',\n",
       "   'adalimumab'],\n",
       "  'reaction': ['influenza']},\n",
       " {'pmid': 19683453,\n",
       "  'sentence': 'Carbon-11 labeled celecoxib derivatives, [(11)C]methyl 2-(4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)acetate ([(11)C]6e), [(11)C]methyl 2-methyl-2-(4-(5-p-tolyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)propanoate ([(11)C]6f), [(11)C]methyl 2-(4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)acetate ([(11)C]6g), and [(11)C]methyl 2-methyl-2-(4-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenylsulfonamidooxy)propanoate ([(11)C]6h), were prepared by O-[(11)C]methylation of their corresponding precursors using [(11)C]CH(3)OTf under basic condition and isolated by a simplified solid-phase extraction (SPE) method in 50-60% radiochemical yields based on [(11)C]CO(2) and decay corrected to end of bombardment (EOB).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['celecoxib'],\n",
       "  'reaction': ['condition']},\n",
       " {'pmid': 19900977,\n",
       "  'sentence': 'There were significant differences between SS/SLE and SLE-only patients in the following manifestations (p < 0.05): (1) sex ratio (F/M) (41/0 versus 184/30), age (42.8 +/- 41.0 years versus 31.8 +/- 31.0 years), disease duration (113.8 +/- 84.0 months versus 44.9 +/- 18.0 months); (2) clinical features, xerostomia (85.4% versus 6.1%), xerophthalmia (75.6% versus 2.3%), renal tubular acidosis (21.9% versus 0%), interstitial lung disease (12.2% versus 2.8%), facial rash (9.8% versus 46.3%), nephrotic syndrome (7.3% versus 31.3%), central nervous system involvement (4.9% versus 19.6%); (3) laboratory findings, ESR (64.6+/-75.0mm/h versus 46.5+/-34.0mm/h), C4 (14.8 +/- 12.2 g/dl versus 12.0 +/- 10.9 g/dl), IgG elevation (56.4% versus 29.9%) and IgA elevation (38.5% versus 20.4%), RF, anti-SSA and anti-SSB positive rates (70.8% versus 20.3%, 82.9% versus 43.4% and 39.0% versus 7.9%); (4) SLEDAI score (8.0 +/- 8.0 versus 10.2 +/- 10.0), glucocorticoid treatment (methylprednisolone bolus/1-2 mg kg(-1) day(-1) prednisone/<1 mg kg(-1) day(-1) prednisone) (8/26/7 versus 91/102/21), and importantly, rate of death and/or severe irreversible organ failure (2.4% versus 14.9%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['methylprednisolone'],\n",
       "  'reaction': ['xerophthalmia',\n",
       "   'renal tubular acidosis',\n",
       "   'acidosis',\n",
       "   'interstitial lung disease',\n",
       "   'rash',\n",
       "   'nephrotic syndrome',\n",
       "   'death',\n",
       "   'organ failure']},\n",
       " {'pmid': 19992316,\n",
       "  'sentence': \"The analysis is of 55 cases admitted into St. Mark's Hospital from 1922 to 1940.The incidence was 3.35% of all cases of cancer of the rectum, anal canal and anus admitted during this period.Sex distribution-27 males and 28 females.The average age (61.7 years) is higher than that of columnar-cell carcinoma of the rectum (57.4 years).Histology.-The cases have been graded into three grades of malignancy-low grade, medium grade, and high grade.Low grade squamous carcinoma is twice as frequent in men as in women, and generally originates at the anal margin.Medium grade squamous carcinoma is equally distributed between men and women; it may arise at the anus or in the anal canal.High grade squamous carcinoma is much more common in the female sex and is almost entirely limited to the anal canal.Quadrant affected-about one-third of the anal margin growths and one-half of the anal canal growths were situated anteriorly.Differential diagnosis from simple papilloma, simple ulcer, chronic inflammation, tuberculous ulcer, tuberculide, primary chancre, amoebic ulcer, basal-cell carcinoma, columnar-cell carcinoma.Biopsy and grading essential before treatment is decided upon.The results of treatment in the three grades of malignancy are described.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['papilloma', 'ulcer', 'inflammation', 'ulcer', 'ulcer']},\n",
       " {'pmid': 20095647,\n",
       "  'sentence': 'The reactions of manganese(II) acetate or perchlorate, sodium azide, and the inner-salt-type dicarboxylate ligand 1,3-bis(4-carboxylato-1-pyridinium)propane (L) under different conditions yielded four different Mn(II) coordination polymers with mixed azide and carboxylate bridges: {[Mn(L)(N(3))]ClO(4).0.5H(2)O}(n) (1), {[Mn(2)(L)(2)(N(3))(2)][Mn(N(3))(4)(H(2)O)(2)].2H(2)O}(n) (2), {[Mn(2)(L)(2)(N(3))(2)(H(2)O)(2)]Br(N(3)).2H(2)O}(n) (3), and [Mn(4) (L)(2)(N(3))(8)](n) (4).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 20140276,\n",
       "  'sentence': '[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarotene, BIBW-2992, BMS-690514, Bortezomib, Bosentan, Briakinumab; Capecitabine, Certolizumab pegol, Cetuximab, Cholecalciferol, Choline fenofibrate, Chorionic gonadotropin (human), Cixutumumab, Clopidogrel, CP-690550 citrate; Dabigatran, Dacetuzumab, Daclizumab, Dapagliflozin, Darbepoetin alfa, Dasatinib, Denosumab; Efavirenz, Elisidepsin, Enoxaparin, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Everolimus, Exenatide; Fenobam, Figitumumab, Filibuvir, Fondaparinux sodium, Fresolimumab; Gefitinib, Golimumab, Golnerminogene pradenovec; Ifosfamide, Imatinib mesylate, Ipilimumab, Ivabradine hydrochloride, Ixabepilone; Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liposomal vincristine, Liraglutide; M-118, Masitinib mesylate, Metformin hydrochloride, Micafungin sodium, Moxifloxacin hydrochloride; Neratinib; Oblimersen sodium, Ofatumumab, Olmesartan medoxomil; Paclitaxel nanoparticles, Palifosfamide lysine, Panobacumab, Panobinostat, Patupilone, Peginterferon alfa-2a, Pegylated arginine deiminase 20000, Piclozotan hydrochloride hydrate, Pixantrone maleate, Prasterone, Prasugrel, Prednisone, Progesterone, Prucalopride, pVGI.1 (VEGF-2); Retigabine, rhFSH, Rituximab, Rivaroxaban, Rosuvastatin calcium; Salinosporamide A, Selumetinib, Sipuleucel-T, Somatropin, Sorafenib, SSR-244738, Sunitinib malate; Tamoxifen citrate, Teduglutide, Telavancin hydrochloride, Telmisartan, Telmisartan/amlodipine, Telmisartan/hydrochlorothiazide, Temsirolimus, Tenofovir disoproxil fumarate, Tipifarnib, Tolvaptan, Trastuzumab, Trastuzumab-MCC-DM1, Travoprost, Tremelimumab; Valsartan/amlodipine besylate, Valsartan/amlodipine besylate/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Vandetanib, Vorinostat.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['retigabine',\n",
       "   'amlodipine',\n",
       "   'capecitabine',\n",
       "   'tamoxifen',\n",
       "   'calcium',\n",
       "   'bortezomib',\n",
       "   'paclitaxel',\n",
       "   'dabigatran',\n",
       "   'prasugrel',\n",
       "   'denosumab',\n",
       "   'aflibercept',\n",
       "   'imatinib',\n",
       "   'trastuzumab',\n",
       "   'micafungin',\n",
       "   'liraglutide',\n",
       "   'metformin',\n",
       "   'olmesartan',\n",
       "   'aliskiren',\n",
       "   'lapatinib',\n",
       "   'aprepitant',\n",
       "   'travoprost',\n",
       "   'bevacizumab',\n",
       "   'temsirolimus',\n",
       "   'darbepoetin',\n",
       "   'teduglutide',\n",
       "   'ipilimumab',\n",
       "   'erlotinib',\n",
       "   'exenatide',\n",
       "   'everolimus',\n",
       "   'efavirenz',\n",
       "   'prucalopride',\n",
       "   'certolizumab',\n",
       "   'fenofibrate',\n",
       "   'gefitinib',\n",
       "   'rituximab',\n",
       "   'sunitinib',\n",
       "   'neratinib',\n",
       "   'dasatinib',\n",
       "   'vandetanib',\n",
       "   'sodium',\n",
       "   'golimumab',\n",
       "   'selumetinib',\n",
       "   'moxifloxacin',\n",
       "   'vorinostat',\n",
       "   'cetuximab',\n",
       "   'rivaroxaban',\n",
       "   'eribulin',\n",
       "   'rosuvastatin',\n",
       "   'fondaparinux',\n",
       "   'bosentan',\n",
       "   'telmisartan',\n",
       "   'ofatumumab',\n",
       "   'enoxaparin',\n",
       "   'daclizumab',\n",
       "   'adalimumab',\n",
       "   'clopidogrel',\n",
       "   'tolvaptan'],\n",
       "  'reaction': ['growth', 'progesterone']},\n",
       " {'pmid': 20143728,\n",
       "  'sentence': 'The range of various parameters of reservoir water (water temperature 15.92-31.87 degrees C, water depth 2.90-8.25 m, transparency 66.59-116.00 cm, electrical conductivity 108-246.30 microS cm(-1), turbidity 2.17-16.72 NTU, total dissolved solids 166.37-239.00 mg l(-1), pH 7 41-8.95, dissolved oxygen 6.78-11.59 mg I(-1), free carbon dioxide nil-6.32 mg l(-1), total alkalinity 64.25-146.25 mg l(-1), total hardness 34.00-75.25 mg l(-1), chlorides 13.13-22.36 mg l(-1), calcium 11.21-33.81 mg l(-1), sulphates 1.50-8.87 mg l(-1), nitrates 0.011-0.033 mg l(-1), nitrites 0.004-0.029 mg l(-1), phosphates 0.013-0.054 mg l(-1), silicates 0.65-8.42 mg l(-1), ammonia nil-0.84 mg l(-1), biochemical oxygen demand 0.93-4.68 mg l(-1), chemical oxygen demand 3.60-17.40 mg l(-1), magnesium 1.17-5.60 mg l(-1), sodium 16.75-34.30 mg l(-1) and potassium 1.97-4.86 mg l(-1)) exhibit monthly as well as seasonal fluctuations.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium', 'calcium', 'potassium', 'sodium'],\n",
       "  'reaction': ['carbon dioxide', 'ammonia']},\n",
       " {'pmid': 20183226,\n",
       "  'sentence': 'New isotope laboratories can achieve the goal of reporting the same isotopic composition within analytical uncertainty for the same material analysed decades apart by (1) writing their own acceptance testing procedures and putting them into their mass spectrometric or laser-based isotope-ratio equipment procurement contract, (2) requiring a manufacturer to demonstrate acceptable performance using all sample ports provided with the instrumentation, (3) for each medium to be analysed, prepare two local reference materials substantially different in isotopic composition to encompass the range in isotopic composition expected in the laboratory and calibrated them with isotopic reference materials available from the International Atomic Energy Agency (IAEA) or the US National Institute of Standards and Technology (NIST), (4) using the optimum storage containers (for water samples, sealing in glass ampoules that are sterilised after sealing is satisfactory), (5) interspersing among sample unknowns local laboratory isotopic reference materials daily (internationally distributed isotopic reference materials can be ordered at three-year intervals, and can be used for elemental analyser analyses and other analyses that consume less than 1 mg of material) - this process applies to H, C, N, O, and S isotope ratios, (6) calculating isotopic compositions of unknowns by normalising isotopic data to that of local reference materials, which have been calibrated to internationally distributed isotopic reference materials, (7) reporting results on scales normalised to internationally distributed isotopic reference materials (where they are available) and providing to sample submitters the isotopic compositions of internationally distributed isotopic reference materials of the same substance had they been analysed with unknowns, (8) providing an audit trail in the laboratory for analytical results - this trail commonly will be in electronic format and might include a laboratory information management system, (9) making at regular intervals a complete backup of laboratory analytical data (both of samples logged into the laboratory and of mass spectrometric analyses), being sure to store one copy of this backup offsite, and (10) participating in interlaboratory comparison exercises sponsored by the IAEA and other agencies at regular intervals.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['mass', 'energy', 'mass']},\n",
       " {'pmid': 20303034,\n",
       "  'sentence': 'These are (1) avoidance of unnecessary transfusions through the use of evidence-based transfusion guidelines, to reduce potentially fatal (infectious as well as noninfectious) transfusion complications; (2) reduction in the risk of transfusion-related acute lung injury in recipients of platelet transfusions through the use of single-donor platelets collected from male donors, or female donors without a history of pregnancy or who have been shown not to have white blood cell (WBC) antibodies; (3) prevention of hemolytic transfusion reactions through the augmentation of patient identification procedures by the addition of information technologies, as well as through the prevention of additional red blood cell alloantibody formation in patients who are likely to need multiple transfusions in the future; (4) avoidance of pooled blood products (such as pooled whole blood-derived platelets) to reduce the risk of transmission of emerging transfusion-transmitted infections (TTIs) and the residual risk from known TTIs (especially transfusion-associated sepsis [TAS]); (5) WBC reduction of cellular blood components administered in cardiac surgery to prevent the poorly understood increased mortality seen in cardiac surgery patients in association with the receipt of non-WBC-reduced (compared with WBC-reduced) transfusion; and (6) pathogen reduction of platelet and plasma components to prevent the transfusion transmission of most emerging, potentially fatal TTIs and the residual risk of known TTIs (especially TAS).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['transfusion',\n",
       "   'transfusion',\n",
       "   'acute lung injury',\n",
       "   'injury',\n",
       "   'pregnancy',\n",
       "   'transfusion',\n",
       "   'sepsis',\n",
       "   'surgery',\n",
       "   'surgery',\n",
       "   'transfusion',\n",
       "   'transfusion']},\n",
       " {'pmid': 20355292,\n",
       "  'sentence': 'The main findings include: (1) complexation with KNO(3) leads to an \"inverse anomeric effect\", with the beta-glucose complex more stable than the alpha-glucose by approximately 1.74 kcal mol(-1); (2) as temperature is increased to 600 K, the KNO(3) remains undissociated in the 1 : 1 complex, with the K(+) hooked to the equilibrium site, and the NO(3)(-) bound to it, undergoing large-amplitude bending/torsional motions; (3) for n > or = 3 water molecules added to the system, charge separation into K(+) and NO(3)(-) ions takes place; (4) for the sugar-water system with n = 11 water molecules all hydroxyl groups are hydrated with the glucose adopting a surface position, indicative of a surfactant property of the sugar; and (5) comparison of DL_POLY with MP2/TZP structure predictions indicates that the empirical force field predicts global and local minimum structures reasonably well, but errs in giving the energy rankings of the different minima.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['surfactant'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 20435455,\n",
       "  'sentence': 'Compared to the CO group, the following was observed: only the Î²I group showed a decrease in the mean number of visible hepatocyte nodules (P<.05); Î²I and GOH groups had reduced mean number of persistent preneoplastic lesions (pPNLs) (P<.05), but no differences regarding number of remodeling PNL (rPNLs) were observed; only the Î²I group exhibited smaller rPNL size and percentage of liver sections occupied by pPNLs (P<.05), whereas the GOH group displayed a smaller percentage of liver sections occupied by rPNLs (P<.05); a trend was observed in the Î²I group, which showed reduced cell proliferation of pPNLs (P<.10), and the GOH group had increased apoptosis in pPNLs and rPNLs (P<.05); only the Î²I group displayed reduced total plasma cholesterol concentrations (P<.05) and increased hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase mRNA levels (P<.05); only the GOH group had lower hepatic membrane RhoA protein levels (P<.05); both the Î²I- and GOH-treated groups had higher hepatic concentrations of Î²I and GOH, respectively (P<.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['apoptosis']},\n",
       " {'pmid': 20503305,\n",
       "  'sentence': 'The patients exhibited strikingly similar features according to their age: craniofacial, large fontanelle, hypertelorism, short and downslanting palpebral fissures, blue sclerae, short nose with hypoplastic columella, low-set and rotated ears, high palate, long philtrum, thin vermilion of the upper lip, small mouth, and micro-retrognathia in infancy; slender and asymmetric face with protruding jaw from adolescence; skeletal, congenital contractures of fingers, wrists, and hips, and talipes equinovarus with anomalous insertions of flexor muscles; progressive joint laxity with recurrent dislocations; slender and/or cylindrical fingers and progressive talipes valgus and cavum or planus, with diaphyseal narrowing of phalanges, metacarpals, and metatarsals; pectus deformities; scoliosis or kyphoscoliosis with decreased physiological curvatures of thoracic spines and tall vertebrae; cutaneous, progressive hyperextensibility, bruisability, and fragility with atrophic scars; fine palmar creases in childhood to acrogeria-like prominent wrinkles in adulthood, recurrent subcutaneous infections with fistula formation; cardiovascular, cardiac valve abnormalities, recurrent large subcutaneous hematomas from childhood; gastrointestinal, constipation, diverticula perforation; respiratory, (hemo)pneumothorax; and ophthalmological, strabismus, glaucoma, refractive errors.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['talipes',\n",
       "   'joint laxity',\n",
       "   'talipes',\n",
       "   'scoliosis',\n",
       "   'kyphoscoliosis',\n",
       "   'fistula',\n",
       "   'constipation',\n",
       "   'perforation',\n",
       "   'pneumothorax',\n",
       "   'strabismus',\n",
       "   'glaucoma']},\n",
       " {'pmid': 20504214,\n",
       "  'sentence': 'The results showed: (1) Pain stimulation increased norepinephrine (NE), but not epinephrine, dopamine (DA), 3,4-dihydroxyphenylacetic acid (DA metabolic product), homovanilic acid (DA metabolic product), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HT metabolic product), acetycholine (Ach), choline (Ach metabolic product), gamma-aminobutyric acid (GABA), and L-glutamate acid concentrations in the PVN perfusion liquid; (2) PVN stimulation with L-glutamate sodium, which excited local neurons only, did not influence the concentrations of the studied classical neurotransmitter and metabolic product in the PVN perfusion liquid; (3) Microinjection of NE, epinephrine, or L-glutamate sodium into the PVN elevated pain threshold, and local administration of GABA decreased pain threshold in a dose-dependent manner, but PVN administration of Ach, DA, or 5-HT did not change pain threshold; (4) Microinjection of phentolamine (alpha-receptor antagonist) or MK801 [NMDA-receptor antagonist] into the PVN reduced pain threshold, and local administration of bicuculline (GABA-receptor antagonist) raised pain threshold, but PVN administration of propranolol (beta-receptor antagonist), atropine (Muscarinic cholinergic receptor antagonist), 6-OH gallamine (Nicotinic cholinergic receptor antagonist), fluperidol (DA-receptor antagonist), or cyproheptadine (5-HT-receptor antagonist) did not alter pain threshold.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cyproheptadine', 'sodium', 'dopamine', 'propranolol'],\n",
       "  'reaction': ['pain',\n",
       "   'epinephrine',\n",
       "   'epinephrine',\n",
       "   'pain',\n",
       "   'pain',\n",
       "   'pain',\n",
       "   'pain',\n",
       "   'pain',\n",
       "   'pain']},\n",
       " {'pmid': 20587827,\n",
       "  'sentence': '- r=0.3877, p<0.0014; focal infection contamination - r=0.2599, p<0.0366; often use of coffee - r=0.2819, p<0.0229; ulitis up to veneer - r=0.2444, p<0.0498; appearance line of demarcation - with the mechanical factor - r=0.3479, p<0.0045; use of synthetic fluids, - r=0.3823, p<0.0017; recurrence caries - with gastro-intestinal pathologies r=0.2924, p<0.0181; of a focal infection contamination - r=0.2756, p<0.0263; by feeding priority by carbohydrates - r=0.2324, p<0.0625; decompensate caries - r=0.2583, p<0.0377; Exhibiting of a pathological microflora - among males - r=0.2772, p<0.0254; by smoking - r=0.3227, p<0.0087; gastro-intestinal pathologies - r=0.2365, p<0.0579; by endocrine diseases - r=0.2546, p<0.0407; by focal infection contamination - r=0.5416, p<0.0000; decompensate caries - r= 0.2530, p<0.0420; by an ulitis - r=0.4551, p<0.0001; by a hygienic index - r=0.4611; p<0.0001; periodontal index - r=0.4611, p<0.0001; PMA index - r=0.3529, p<0.0039.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['infection', 'infection', 'infection']},\n",
       " {'pmid': 20604535,\n",
       "  'sentence': 'Salient features of the mechanism include: (1) the near thermoneutrality of the O(2)-alkene exchange reaction, consistent with experimentally observed reversible exchange between O(2) and alkenes at well-defined Pd centers, (2) end-on activation of triplet O(2) at an apical site of the trigonal Pd(0) center, resulting in formation of a Pd(I)(Î·(1)-superoxide) species, (3) rearrangement of the Pd(I)(Î·(1)-superoxide) species into a pseudo-octahedral (en)Pd(Î·(2)-O(2))(Î·(2)-C(2)H(4)) species with concomitant crossing from the triplet to singlet energy surfaces, and (4) release of alkene from an axial face of (en)Pd(II)(Î·(2)-peroxo) with a geometry in which the alkene leaves with an end-on trajectory (involving an interaction of the Pd d(z(2)) and alkene Ï€* orbitals).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['concomitant'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 20664824,\n",
       "  'sentence': '[Â¹Â¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[Â¹â¸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin acetate, Cediranib, Cetuximab, ChimeriVax-Dengue, Choriogonadotropin alfa, Cinacalcet hydrochloride, Cizolirtine citrate, Clofarabine, Cocaine conjugate vaccine, CX-717; Darbepoetin alfa, Dasatinib, Decitabine, Denosumab, Desvenlafaxine succinate, Dexamethasone sodium phosphate, Dienogest, Diphencyprone, Doripenem, DTaP-HepB-IPV, Dutasteride; E-7010, Ecallantide, Ecstasy, Eicosapentaenoic acid/docosahexaenoic acid, Emtricitabine, Enfuvirtide, Erlotinib hydrochloride, Eszopiclone, Etonogestrel/ethinyl estradiol, Etoricoxib, Everolimus, Everolimus-eluting coronary stent EVT-201, Ezetimibe, Ezetimibe/simvastatin; Ferumoxytol, Fesoterodine fumavate, Figitumumab, Filgrastim, Fingolimod hydrochloride, Fluticasone furoate, Fluval P, Fluzone, Fondaparinux sodium, Fulvestrant, Fungichromin; Gamma-hydroxybutyrate sodium, Gefitinib, GHB-01L1, GLY-230, GSK-1349572; Hib-MenCY-TT, Hib-TT, HPV-6/11/16/18, Hydrocodone bitartrate; IC-51, Icatibant acetate, Imatinib mesylate, Immunoglobulin intravenous (human), Indetanib, Influenza A (H1N1) 2009 Monovalent Vaccine, Inhalable human insulin, Insulin glargine, Insulin glulisine, Interferon-beta, Ispinesib mesylate, Ixabepilone; Laromustine, Latanoprost/timolol maleate, L-Citrulline, Lenalidomide, Lexatumumab, Linezolid, Lopinavir/ritonavir, Lutropin alfa; Mapatumumab, MDX-066, MDX-1388, Mepolizumab, Methoxy polyethylene glycol-epoetin-beta, Metreleptin, Micafungin sodium, Mometasone furoate/oxymetazoline hydrochloride, Mx-dnG1, Mycophenolic acid sodium salt; Nabiximols, Natalizumab, Nemonoxacin, Norelgestromin/ethinyl estradiol; Oblimersen sodium, Ocriplasmin, Olmesartan medoxomil, Omacetaxine mepesuccinate; Paclitaxel-eluting stent, Pagoclone, Paliperidone, Panitumumab, Pazopanib hydrochloride, PCV7, Pegaptanib octasodium, Peginterferon alfa-2a, Peginterferon alfa-2b/ ribavirin, Pegvisomant, Pemetrexed disodium, Perifosine, Pimecrolimus, Pitavastatin calcium, Plerixafor hydrochloride, Plitidepsin, Posaconazole, Pregabalin, Progesterone capriate; Raltegravir potassium, Ramucirumab, Ranelic acid distrontium salt, Rasburicase, Recombinant Bet V1, Recombinant human insulin, rhFSH, Rolofylline, Romidepsin, Romiplostim, Rosuvastatin calcium; Sapacitabine, Sevelamer carbonate, Sinecatechins, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, SN-29244, Sorafenib, Sugammadex sodium, Sunitinib malate; Tadalafil, Tafenoquine, Talnetant, Tanezumab, Tapentadol hydrochloride, Tasocitinib citrate, Technosphere/Insulin, Telcagepant, Tenofovir disoproxil fumarate, Teriparatide, Ticagrelor, Tigecycline, Tiotropium bromide, Tipifarnib, Tocilizumab, TS-041; Ulipristal acetate, Urtoxazumab, Ustekinumab; Vandetanib, Varenicline tartrate, Vicriviroc, Voriconazole, Vorinostat, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP; Zoledronic acid monohydrate.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pimecrolimus',\n",
       "   'denosumab',\n",
       "   'eszopiclone',\n",
       "   'gefitinib',\n",
       "   'icatibant',\n",
       "   'tocilizumab',\n",
       "   'atazanavir',\n",
       "   'sevelamer',\n",
       "   'vorinostat',\n",
       "   'posaconazole',\n",
       "   'aliskiren',\n",
       "   'aflibercept',\n",
       "   'teriparatide',\n",
       "   'paliperidone',\n",
       "   'sunitinib',\n",
       "   'caspofungin',\n",
       "   'mepolizumab',\n",
       "   'cediranib',\n",
       "   'romiplostim',\n",
       "   'olmesartan',\n",
       "   'adalimumab',\n",
       "   'calcium',\n",
       "   'plerixafor',\n",
       "   'omacetaxine',\n",
       "   'immunoglobulin',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'raltegravir',\n",
       "   'pazopanib',\n",
       "   'clofarabine',\n",
       "   'fondaparinux',\n",
       "   'sodium',\n",
       "   'ustekinumab',\n",
       "   'cetuximab',\n",
       "   'cinacalcet',\n",
       "   'vandetanib',\n",
       "   'tigecycline',\n",
       "   'linezolid',\n",
       "   'imatinib',\n",
       "   'voriconazole',\n",
       "   'natalizumab',\n",
       "   'aripiprazole',\n",
       "   'emtricitabine',\n",
       "   'micafungin',\n",
       "   'tiotropium',\n",
       "   'tadalafil',\n",
       "   'fulvestrant',\n",
       "   'ramucirumab',\n",
       "   'fingolimod',\n",
       "   'bevacizumab',\n",
       "   'varenicline',\n",
       "   'rosuvastatin',\n",
       "   'panitumumab',\n",
       "   'everolimus',\n",
       "   'apixaban',\n",
       "   'dutasteride',\n",
       "   'bosentan',\n",
       "   'desvenlafaxine',\n",
       "   'enfuvirtide',\n",
       "   'filgrastim',\n",
       "   'sitagliptin',\n",
       "   'pemetrexed',\n",
       "   'atomoxetine',\n",
       "   'erlotinib',\n",
       "   'darbepoetin',\n",
       "   'pitavastatin',\n",
       "   'disodium',\n",
       "   'potassium',\n",
       "   'cocaine'],\n",
       "  'reaction': ['influenza', 'progesterone']},\n",
       " {'pmid': 20738705,\n",
       "  'sentence': 'The present review critically examines the evidence to support the proposed functions of 17,20beta-P in males, including listing of the evidence for the presence of 17,20beta-P in the blood plasma of male fishes and discussion of why, in many species, it appears to be absent (or present at low and, in some cases, unvarying concentrations); consideration of the evidence, obtained mainly from in vitro studies, for this steroid being predominantly produced by the testis, for its production being under the control of luteinizing hormone (gonadotrophin II) and, at least in salmonids, for two cell types (Leydig cells and sperm cells) being involved in its synthesis; discussion of the factors involved in the regulation of the switch from androgen to 17,20beta-P production that seems to occur in many species just at the time of spermiation; discussion of the effects of in vivo injection and application of 17,20beta-P (and closely related compounds) in males; a listing of previously published evidence that supports the proposed new function of 17,20beta-P as an initiator of meiosis; finally, discussion of the evidence for environmental endocrine disruption by progestins in fishes.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 20853781,\n",
       "  'sentence': \"To correctly diagnose occupational asbestos-related disease, a specialist in occupational health has to answer a set of questions: (A) is the asbestos-related disease diagnosed by a specialist in pulmonology with the help of a radiologist and cardiologist occupational or non-occupational; (B) is the occupational asbestos-related disease caused by more than one source of asbestos dust, and, if it is, to what has of each of these sources contributed to the development of the disease; (C) how many functional disorders and symptoms (pulmonary, cardiac, chest pain, reactive fear from death, reactive psychoneurotic disorder in which fear is not the main symptom) has occupational asbestos-related disease produced and to what degree; (D) have these disorders and symptoms permanently reduced patient's work ability, and, if they have, can we speak of work disability; (E) have these disorders permanently reduced vital activity, and, if they have, can we speak of vital disability; and (F) does the patient suffer mental pain because of reduced vital activity, and if he does, what sort of pain.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['chest pain',\n",
       "   'pain',\n",
       "   'fear',\n",
       "   'death',\n",
       "   'fear',\n",
       "   'disability',\n",
       "   'disability',\n",
       "   'pain',\n",
       "   'pain']},\n",
       " {'pmid': 20941334,\n",
       "  'sentence': \"After reviewing the literature about the microbial spectrum, the risk factors of post-operative infections, and the results of surgical interventions, the following recommendation can be made for the management of bite wounds:FRESH, OPEN WOUNDS: surgical debridement, if appropriate, then an antiseptic lavage with a fluid consisting of povidone iodine and ethanol (e.g., Betaseptic(Â®)), no antibiotics, primary wound closurenearly closed fresh wounds (e.g., cat bites): surgical debridement, if appropriate, dressing with an antiseptic-soaked compress for ~60 minutes with repeated soaking (e.g., Betaseptic(Â®)), no antibioticsolder wounds after ~4 hours: surgical debridement, if appropriate, dressing with an antiseptic-soaked compress or bandage for ~60 minutes with repeated soaking (e.g., Betaseptic(Â®)), at the same time intravenous or dose-adapted oral antibiotics (Amoxicillin and/or clavulanic acid)older wounds after ~24 hours: surgical debridement, then antiseptic lavage (Betaseptic(Â®)), in case of clinically apparent infection or inflammation surgical revision with opening of wound and treatment with antibiotics according to resistogram (empirical start with Amoxicillin and/or clavulanic acid).For each kind of bite wound, the patient's tetanus immunization status as well as the risk of exposure to rabies have to be assessed.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['amoxicillin'],\n",
       "  'reaction': ['bite',\n",
       "   'debridement',\n",
       "   'wound',\n",
       "   'debridement',\n",
       "   'debridement',\n",
       "   'debridement',\n",
       "   'infection',\n",
       "   'inflammation',\n",
       "   'wound',\n",
       "   'bite',\n",
       "   'wound',\n",
       "   'rabies']},\n",
       " {'pmid': 21069103,\n",
       "  'sentence': 'Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen placarbil, Aripiprazole, ARQ-621, Azelnidipine, Azilsartan medoxomil potassium; Bevacizumab, Biphasic insulin aspart, Bortezomib; Choriogonadotropin alfa, CTS-1027; Dapagliflozin, Dasatinib, Deforolimus, Degarelix acetate, Denufosol tetrasodium, Desvenlafaxine succinate, Dronedarone hydrochloride, Duloxetine hydrochloride, Dutasteride; Enfuvirtide, Entecavir, Etaracizumab, Everolimus, Exenatide, Ezetimibe; Ferric carboxymaltose, Fludarabine, Foretinib; Gefitinib, GFT-505, GSK-256066; HPV-6/11/16/18, HuM195/rGel, HyperAcute-Lung cancer vaccine; I5NP, Imatinib mesylate, Imexon, Insulin detemir, Insulin glargine, Ivabradine hydrochloride; L2G7, Lacosamide, Lapatinib ditosylate, Lenalidomide, Lidocaine/prilocaine, Liposomal vincristine, Liraglutide, Lixivaptan; Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Methoxy polyethylene glycol-epoetin-Î², Mirabegron, Morphine/oxycodone, MR Vaccine, MSC-1936369B, Mycophenolic acid sodium salt; Narlaprevir, N-Desmethylclozapine; Ocriplasmin, Olaparib, Olmesartan medoxomil, Olmesartan medoxomil/azelnidipine, ONO-5334, ONO-8539; Palifermin, Panitumumab, Pardoprunox hydrochloride, PCV7, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pexelizumab, PF-337210, Pitavastatin calcium; Raltegravir potassium, Recombinant interleukin-7, Regadenoson, Reniale, Roflumilast, Rosuvastatin calcium; Safinamide mesilate, SB-1518, SCH-527123, Selumetinib, Sipuleucel-T, Solifenacin succinate, Sorafenib, Sunitinib malate; Tadalafil, Talaporfin sodium, Tanespimycin, Technosphere/Insulin, Telaprevir, Telatinib, Telcagepant, Telmisartan/hydrochlorothiazide, Teriparatide, Testosterone transdermal gel, TH-302, Tiotropium bromide, Tocilizumab, Trabedersen, Tremelimumab; Valsartan/amlodipine besylate, Vernakalant hydrochloride, Visilizumab, Voreloxin, Vorinostat.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tocilizumab',\n",
       "   'gefitinib',\n",
       "   'fludarabine',\n",
       "   'vorinostat',\n",
       "   'duloxetine',\n",
       "   'liraglutide',\n",
       "   'teriparatide',\n",
       "   'sunitinib',\n",
       "   'selumetinib',\n",
       "   'olmesartan',\n",
       "   'calcium',\n",
       "   'amlodipine',\n",
       "   'alemtuzumab',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'palifermin',\n",
       "   'raltegravir',\n",
       "   'dronedarone',\n",
       "   'sodium',\n",
       "   'exenatide',\n",
       "   'imatinib',\n",
       "   'aripiprazole',\n",
       "   'mirabegron',\n",
       "   'tiotropium',\n",
       "   'tadalafil',\n",
       "   'entecavir',\n",
       "   'bevacizumab',\n",
       "   'foretinib',\n",
       "   'rosuvastatin',\n",
       "   'everolimus',\n",
       "   'panitumumab',\n",
       "   'roflumilast',\n",
       "   'dutasteride',\n",
       "   'tetrasodium',\n",
       "   'desvenlafaxine',\n",
       "   'enfuvirtide',\n",
       "   'aclidinium',\n",
       "   'pemetrexed',\n",
       "   'degarelix',\n",
       "   'azilsartan',\n",
       "   'lapatinib',\n",
       "   'pitavastatin',\n",
       "   'azelnidipine',\n",
       "   'disodium',\n",
       "   'potassium',\n",
       "   'etaracizumab'],\n",
       "  'reaction': ['diphtheria']},\n",
       " {'pmid': 21225012,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: 17-Hydroxyprogesterone caproate; Abacavir sulfate/lamivudine, Aclidinium bromide, Adalimumab, Adefovir, Alemtuzumab, Alkaline phosphatase, Amlodipine, Apilimod mesylate, Aripiprazole, Axitinib, Azacitidine; Belotecan hydrochloride, Berberine iodide, Bevacizumab, Bortezomib, Bosentan, Bryostatin 1; Calcipotriol/hydrocortisone, Carglumic acid, Certolizumab pegol, Cetuximab, Cinacalcet hydrochloride, Cixutumumab, Coumarin, Custirsen sodium; Darbepoetin alfa, Darifenacin hydrobromide, Darunavir, Dasatinib, Denibulin hydrochloride, Denosumab, Diacetylmorphine, Dulanermin, Duloxetine hydrochloride; Ecogramostim, Enfuvirtide, Entecavir, Enzastaurin hydrochloride, Eplerenone, Escitalopram oxalate, Esomeprazole sodium, Etravirine, Everolimus, Ezetimibe; Fenofibrate/pravastatin sodium, Ferric carboxymaltose, Flavangenol, Fondaparinux sodium; Glutamine, GSK-1024850A; Hepatitis B hyperimmunoglobulin, Hib-MenC, HIV-LIPO-5; Immunoglobulin intravenous (human), Indacaterol maleate, Indibulin, Indium 111 (Â¹Â¹Â¹In) ibritumomab tiuxetan, Influenza A (H1N1) 2009 Monovalent vaccine, Inhalable human insulin, Insulin glulisine; Lapatinib ditosylate, Leucovorin/UFT; Maraviroc, Mecasermin, MMR-V, Morphine hydrochloride, Morphine sulfate/naltrexone hydrochloride, Mycophenolic acid sodium salt; Naproxen/esomeprazole magnesium, Natalizumab; Oncolytic HSV; Paliperidone, PAN-811, Paroxetine, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b/ribavirin, Pegvisomant, Pemetrexed disodium, Pimecrolimus, Posaconazole, Pregabalin; Raltegravir potassium, Ranelic acid distrontium salt, Rasburicase, Rilpivirine hydrochloride; Sertindole, Sivelestat sodium hydrate, Sorafenib, Sumatriptan succinate/naproxen sodium, Sunitinib malate; Tafluprost, Telithromycin, Temsirolimus, Tenofovir disoproxil fumavate, Tenofovir disoproxil fumarate/emtricitabine, Teriparatide, Ticagrelor, Tigecycline, Tipranavir, Tirapazamine, Trimetrexate; Ulipristal acetate; Valganciclovir hydrochloride, Vicriviroc, Vorinostat; Yttrium 90 (90Y) ibritumomab tiuxetan.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pimecrolimus',\n",
       "   'denosumab',\n",
       "   'paroxetine',\n",
       "   'esomeprazole',\n",
       "   'vorinostat',\n",
       "   'indacaterol',\n",
       "   'maraviroc',\n",
       "   'magnesium',\n",
       "   'posaconazole',\n",
       "   'duloxetine',\n",
       "   'certolizumab',\n",
       "   'tipranavir',\n",
       "   'teriparatide',\n",
       "   'paliperidone',\n",
       "   'pegfilgrastim',\n",
       "   'sunitinib',\n",
       "   'adalimumab',\n",
       "   'amlodipine',\n",
       "   'abacavir',\n",
       "   'temsirolimus',\n",
       "   'immunoglobulin',\n",
       "   'alemtuzumab',\n",
       "   'bortezomib',\n",
       "   'sumatriptan',\n",
       "   'dasatinib',\n",
       "   'raltegravir',\n",
       "   'fondaparinux',\n",
       "   'sodium',\n",
       "   'valganciclovir',\n",
       "   'telithromycin',\n",
       "   'cetuximab',\n",
       "   'cinacalcet',\n",
       "   'tigecycline',\n",
       "   'natalizumab',\n",
       "   'aripiprazole',\n",
       "   'indium',\n",
       "   'entecavir',\n",
       "   'bevacizumab',\n",
       "   'azacitidine',\n",
       "   'axitinib',\n",
       "   'darunavir',\n",
       "   'everolimus',\n",
       "   'eplerenone',\n",
       "   'bosentan',\n",
       "   'enfuvirtide',\n",
       "   'aclidinium',\n",
       "   'pemetrexed',\n",
       "   'lapatinib',\n",
       "   'darbepoetin',\n",
       "   'disodium',\n",
       "   'potassium'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'influenza']},\n",
       " {'pmid': 21225019,\n",
       "  'sentence': 'This issue focuses on the following selection of drugs: Abatacept, Adalimumab, AdCD40L, Adefovir, Aleglitazar, Aliskiren fumarate, AM-103, Aminolevulinic acid methyl ester, Amlodipine, Anakinra, Aprepitant, Aripiprazole, Atazanavir sulfate, Axitinib; Belimumab, Bevacizumab, Bimatoprost, Bortezomib, Bupropion/naltrexone; Calcipotriol/betamethasone dipropionate, Certolizumab pegol, Ciclesonide, CYT-997; Darbepoetin alfa, Darunavir, Dasatinib, Desvenlafaxine succinate, Dexmethylphenidate hydrochloride cogramostim; Eltrombopag olamine, Emtricitabine, Escitalopram oxalate, Eslicarbazepine acetate, Eszopiclone, Etravirine, Everolimus-eluting coronary stent, Exenatide, Ezetimibe; Fenretinide, Filibuvir, Fludarabine; Golimumab; Hepatitis B hyperimmunoglobulin, HEV-239, HP-802-247, HPV-16/18 AS04, HPV-6/11/16/18, Human albumin, Human gammaglobulin; Imatinib mesylate, Inotuzumab ozogamicin, Invaplex 50 vaccine; Lapatinib ditosylate, Lenalidomide, Liposomal doxorubicin, Lopinavir, Lumiliximab, LY-686017; Maraviroc, Mecasermin rinfabate; Narlaprevir; Ocrelizumab, Oral insulin, Oritavancin, Oxycodone hydrochloride/naloxone; Paclitaxel-eluting stent, Palonosetron hydrochloride, PAN-811, Paroxetine, Pazopanib hydrochloride, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pertuzumab, Pitavastatin calcium, Posaconazole, Pregabalin, Prucalopride succinate; Raltegravir potassium, Ranibizumab, RHAMM R3 peptide, Rosuvastatin calcium; Salclobuzic acid sodium salt, SCY-635, Selenate sodium, Semapimod hydrochloride, Silodosin, Siltuximab, Silybin, Sirolimus-eluting stent, SIR-Spheres, Sunitinib malate; Tapentadol hydrochloride, Tenofovir disoproxil fumarate, Tocilizumab, Tositumomab/iodine (I131) tositumomab, Trabectedin, TransVaxâ„¢ hepatitis C vaccine; Ustekinumab; V-260, Valspodar, Varenicline tartrate, VCL-IPT1, Vildagliptin, VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, VRC-HIVDNA016-00-VP; Yttrium 90 (90Y) ibritumomab tiuxetan, Yttrium Y90 Epratuzumab; Zibotentan, Zotarolimus-eluting stent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['eszopiclone',\n",
       "   'tocilizumab',\n",
       "   'paroxetine',\n",
       "   'fludarabine',\n",
       "   'bimatoprost',\n",
       "   'atazanavir',\n",
       "   'lopinavir',\n",
       "   'maraviroc',\n",
       "   'posaconazole',\n",
       "   'aliskiren',\n",
       "   'certolizumab',\n",
       "   'sunitinib',\n",
       "   'golimumab',\n",
       "   'trabectedin',\n",
       "   'adalimumab',\n",
       "   'calcium',\n",
       "   'amlodipine',\n",
       "   'eltrombopag',\n",
       "   'peptide',\n",
       "   'aprepitant',\n",
       "   'bortezomib',\n",
       "   'dasatinib',\n",
       "   'ozogamicin',\n",
       "   'raltegravir',\n",
       "   'pazopanib',\n",
       "   'sodium',\n",
       "   'ustekinumab',\n",
       "   'exenatide',\n",
       "   'abatacept',\n",
       "   'imatinib',\n",
       "   'anakinra',\n",
       "   'aripiprazole',\n",
       "   'ciclesonide',\n",
       "   'belimumab',\n",
       "   'emtricitabine',\n",
       "   'ocrelizumab',\n",
       "   'doxorubicin',\n",
       "   'siltuximab',\n",
       "   'bevacizumab',\n",
       "   'varenicline',\n",
       "   'rosuvastatin',\n",
       "   'axitinib',\n",
       "   'darunavir',\n",
       "   'ranibizumab',\n",
       "   'desvenlafaxine',\n",
       "   'inotuzumab',\n",
       "   'lumiliximab',\n",
       "   'pemetrexed',\n",
       "   'prucalopride',\n",
       "   'lapatinib',\n",
       "   'pitavastatin',\n",
       "   'darbepoetin',\n",
       "   'palonosetron',\n",
       "   'disodium',\n",
       "   'pertuzumab',\n",
       "   'potassium'],\n",
       "  'reaction': ['hepatitis', 'hepatitis b', 'hepatitis', 'hepatitis c']},\n",
       " {'pmid': 21296068,\n",
       "  'sentence': \"): i), compounds C1 and C2 produced significant anti-allodynic activity during the acute phase of the Complete Freund's Adjuvant (CFA)-induced persistent pain model; ii) compound C1 produced significant anti-hypernociception activity in the carrageenan-induced pain model; iii) compound C2 presented a significant loss of activity after p-chlorophenylalanine methyl ester hydrochloride (PCPA) [5-HT synthesis inhibitor] treatment, suggesting that the mechanisms of action could be related to either the synthesis or release of serotonin; iv) compound C1 presented a significant loss of activity after ondansetron (5-HT(3) receptor antagonist) treatment suggesting activity upon 5-HT(3) serotonin receptors; v) compound C1 presented a significant loss of activity after efaroxan (mixed I(1) imidazoline/Î±(2)-adrenoceptor antagonist) treatment suggesting the participation of this compound upon imidazoline I(1) receptors; and vi) both compounds C1 and C2 did not appear to exert their activity via 5-HT(1A), 5-HT(2A), imidazoline I(2), Î±(2)-adrenoceptor, nitric oxide, GABA(A), acetylcholine muscarinic, and nicotinic receptors when evaluated in acetic acid-induced nociception.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ondansetron'],\n",
       "  'reaction': ['pain', 'pain']},\n",
       " {'pmid': 21438788,\n",
       "  'sentence': 'The most important revisions from the previous recommendations are: (1) it is recommended that treatment during pregnancy starts at the latest at gestational week 14-18; (2) ongoing efficient treatment at confirmed pregnancy may, with a few exceptions, be continued; (3) lopinavir/r and atazanavir/r are equally recommended protease inhibitors; (4) if maternal HIV RNA is >50 copies/ml close to delivery, a planned caesarean section, intravenous zidovudine, oral nevirapine for the mother and post-exposure prophylaxis for the infant with 3 antiretroviral drugs are recommended; (5) for delivery at <34 gestational weeks, intravenous zidovudine and oral nevirapine for the mother and at 48-72 h for the infant is recommended, in addition to other prophylaxis; (6) intravenous zidovudine is not recommended when HIV RNA is <50 copies/ml and a caesarean section is performed; (7) it is recommended that prophylaxis for the infant is started within 4 h; (8) prophylactic zidovudine for the infant may be administered twice daily instead of 4 times a day, as was the case previously; and (9) the number of sampling occasions for the infant has been decreased.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['zidovudine'],\n",
       "  'reaction': ['pregnancy',\n",
       "   'pregnancy',\n",
       "   'delivery',\n",
       "   'caesarean section',\n",
       "   'prophylaxis',\n",
       "   'infant',\n",
       "   'delivery',\n",
       "   'infant',\n",
       "   'prophylaxis',\n",
       "   'caesarean section',\n",
       "   'prophylaxis',\n",
       "   'infant',\n",
       "   'infant',\n",
       "   'infant']},\n",
       " {'pmid': 21619170,\n",
       "  'sentence': 'The extraction and dissociation constants of the ion-pair complexes, defined by K(ex) = [MP(ClO(4))(4)](org)[MP(4+)](aq)(-)(1)[ClO(4)(-)](aq)(-)(4), K(dis,1) = [MP(ClO(4))(3)(+)](org)[ClO(4)(-)](org)[MP(ClO(4))(4)](org)(-)(1), and K(dis,2) = [MP(ClO(4))(2)(2+)](org)[ClO(4)(-)](org)[MP(ClO(4))(3)(+)](org)(-)(1), were determined by taking into account the partition constant of sodium perchlorate (K(D) = 1.82 Â± 0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['dissociation']},\n",
       " {'pmid': 21683665,\n",
       "  'sentence': 'Since previous publication in 2005, the most significant changes that have been addressed in the 2010 International Liaison Committee on Resuscitation (ILCOR) recommendations are as follows: (i) use of 2 vital characteristics (heart rate and breathing) to initially evaluate progression to the following step in resuscitation; (ii) oximetry monitoring for the evaluation of oxygenation (assessment of color is unreliable); (iii) for babies born at term it is better to start resuscitation with air rather than 100% oxygen; (iv) administration of supplementary oxygen should be regulated by blending oxygen and air; (v) controversy about endotraqueal suctioning of depressed infants born through meconium-stained amniotic fluid; (vi) chest compression-ventilation ratio should remain at 3/1 for neonates unless the arrest is known to be of cardiac etiology, in which case a higher ratio should be considered; (vii) use of therapeutic hypothermia for infants born at term or near term evolving to moderate or severe hypoxic-ischemic encephalopathy, with protocol and follow-up coordinated through a regional perinatal system (post-resuscitation management); (viii) cord clamping delay for at least 1 minute in babies who do not require resuscitation (there is insufficient evidence to recommend a time for clamping in those who require resuscitation) and, (ix) it is appropriate to consider discontinuing resuscitation if there has been no detectable heart rate for 10 minutes, although many factors contribute to the decision to continue beyond 10 minutes.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['resuscitation',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'resuscitation',\n",
       "   'resuscitation',\n",
       "   'hypothermia',\n",
       "   'encephalopathy',\n",
       "   'resuscitation',\n",
       "   'resuscitation',\n",
       "   'resuscitation',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 21811737,\n",
       "  'sentence': \"Binuclear half-metallocene chromium complexes {Cp*[3-(CH==NR)-2-O-C(10)H(5)]CrCl}(2) [Cp* = C(5)Me(5); R = (i)Pr (1), Ph (2), 2,6-(i)Pr(2)C(6)H(3) (3)] based on 1,1'-binaphthyl ligands, as well as their mononuclear analogues Cp*[3-(CH==NR)-2'-R'-2-O-C(20)H(11)]CrCl [R = (i)Pr, R' = (n)BuO (4), R = Ph, R' = (n)BuO (5), R = 2,6-(i)Pr(2)C(6)H(3), R' = (n)BuO (6), R = (i)Pr, R' = H (7)], were synthesized and characterized by mass spectrometry, elemental analysis, magnetic measurement, and UV-vis spectroscopy.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 21878668,\n",
       "  'sentence': 'Significant associations with decreased death/re-MI were observed with hospital strategies to facilitate primary percutaneous coronary intervention for ST-elevation MI patients (38/428 [8.9%] versus 30/154 [19.5%], P<0.001) and after adjustment (odds ratio [OR], 0.47 [95% confidence interval (CI), 0.24 to 0.90], P<0.023), electronic discharge checklists (none: 233/1956 [11.9%], integrated; 43/251[17.1%], P=0.069, electronic; 6/124 [4.8%], P<0.001) and after adjustment (integrated versus none: OR, 1.66 [95% CI, 0.98 to 2.80], P=0.057 and electronic versus none: OR, 0.49 [95% CI, 0.35 to 0.68], P<0.001), and intensive cardiac care unit (ICCU) staff-to-patient ratios (neither: 200/1257 (15.9%), CCU: 135/1051 (12.8%), ICCU: 8/84 (9.5%), P=0.049 and after adjustment (CCU versus neither: OR, 0.74 [95% CI, 0.47 to 1.14], P=0.172 and ICCU versus neither: OR, 0.55; [95% CI, 0.38 to 0.81] P=0.003).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['percutaneous coronary intervention', 'discharge']},\n",
       " {'pmid': 21879081,\n",
       "  'sentence': 'The synthesis, magnetic characterization and X-ray crystal structures are reported for five new manganese compounds, [Mn(III)(teaH(2))(sal)]Â·(1/2)H(2)O (1), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(4)]Â·6MeOH (2), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(2)](n)Â·7MeOH (3), [Na(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(MeOH)(2)](n)Â·2MeOHÂ·Et(2)O (4) and [K(I)(2)Mn(II)(4)Mn(III)(4)(teaH)(6)(sal)(4)(N(3))(2)(H(2)O)(2)](n)Â·5MeOH (5).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sal'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 21915428,\n",
       "  'sentence': 'The reactions of manganese(II) acetate or perchlorate, sodium azide or sodium cyanate, and the zwitterionic dicarboxylate ligand 1,4-bis(4-carboxylatopyridinium-1-methylene)benzene (L) under different conditions yielded three different Mn(II) coordination polymers with mixed carboxylate and azide (or cyanate) bridges: {[Mn (L(1))(0.5)(N(3))(OAc)]Â·3H(2)O}(n) (1), {[Mn(4)(L(1))(N(3))(8)(H(2)O)(4)(CH(3)OH)(2)]Â·[L(1)]}(n) (2), and {[Mn(3)(L(1))(NCO)(6)(H(2)O)(4)]Â·[L(1)]Â·[H(2)O](2)}(n) (3).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['manganese']},\n",
       " {'pmid': 21945914,\n",
       "  'sentence': \"The compounds 4-({[2-(4-nitrophenyl)-1H-benzimidazol-1-yl]acetyl}amino) benzoic acid (3a), N-ethyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3c), N-benzyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3d), N-(4-hydroxyphenyl)-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3f), 2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3h), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N'-phenylacetohydrazide (3k), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-(4-nitrophenyl) acetamide (3n) and 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3q) were found better to paralyze worms whereas N-ethyl-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3c), N-(4-nitrophenyl)-2-[2-(4-nitrophenyl)-1H-benzimidazol-1-yl] acetamide (3e), 4-({[2-(4-chlorophenyl)-1H-benzimidazol-1-yl] acetyl}amino) benzoic acid (3j), 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-ethyl acetamide (31) and 2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N-phenyl acetamide (3q) were better to cause death of worms compared to the anthelmintic drug albendazole.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['albendazole'],\n",
       "  'reaction': ['death']},\n",
       " {'pmid': 22130699,\n",
       "  'sentence': 'In the following chapter, we thoroughly describe this experimental approach that has helped to improve the understanding of the pathophysiology of the acute coronary syndromes (Badimon et al., Arteriosclerosis 6:312-320, 1986; Badimon et al., J Lab Clin Med 110:706-718, 1987; Badimon et al., Blood 73:961-967, 1989; Mailhac et al., Circulation 90:988-996, 1994) and is a useful tool for the study and screening of new antithrombotic and platelet-inhibitory compounds (Badimon et al., Thromb Haemost 71:511-516, 1994; Vilahur et al., Circulation 110:1686-1693; Vilahur et al., Thromb Haemost 92:191-200, 2004; Vilahur et al., Cardiovasc Res 61:806-816; Vilahur et al., Thromb Haemost 98:662-669, 2007; Vilahur et al., Thromb Haemost 97:650-657, 2007; Zafar et al., J Thromb Haemost 5:1195-1200, 2007; Lev et al., J Am Coll Cardiol 43:966-971) and for the evaluation of the thrombogenicity associated to synthetic/prosthetic surfaces (Badimon et al., J Biomater Appl 5:27-48, 1990; Badimon et al., ASAIO Trans 33:621-625, 1987) and/or plasma components (cholesterol, glucose levels, etc.)',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['arteriosclerosis']},\n",
       " {'pmid': 22178778,\n",
       "  'sentence': 'The final model consisted of seven independent predictors of ORFs: [lowest quartile (Q(1)) vs highest quartile (Q(4))] physical activity score (Q(1) vs Q(4): â‰¤12.61 vs â‰¥15.38); relative risk estimate [RR], 2.87; (95% confidence interval [CI]: 1.88-4.38); ageâ‰¥60 years vs age<60 years (RR=2.43; 95% CI: 1.49-3.95); hand grip strength (Q(1) vs Q(4): â‰¤13.88 vs â‰¥17.28 kg) (RR=1.88; 95% CI: 1.15-3.05); BMD total hip (Q(1) vs Q(4): â‰¤0.784 vs 0.973 g/cm(2)) (RR=1.86; 95% CI: 1.26-2.75); dietary calcium intake (Q(1) vs Q(4): â‰¤391 vs â‰¥648 mg/day) (RR=1.66; 95% CI: 1.08-2.53); serum 25(OH)D (Q(1) vs Q(4): â‰¤17.9 vs â‰¥45.1 nmol/L) (RR=1.63; 95% CI: 1.06-2.51); and past year history of falls (RR=1.61; 95% CI: 1.06-2.48).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['grip strength', 'grip strength']},\n",
       " {'pmid': 22293774,\n",
       "  'sentence': 'The following 10 statements were deemed false: \"It\\'s okay for 12-year-old pitchers to throw curve balls; it\\'s the pitch count that matters\"; \"Resistance training (\\'weight lifting\\') should be avoided until physeal closure\"; \"Jogging during pregnancy is to be avoided\"; \"At an athletic event, if sideline coverage is offered by an emergency medical technician and athletic trainer, there is little additional benefit from having a physician present\"; \"Contact sport athletes who sustain a second concussion should be excluded from contact sports permanently\"; \"The utility of pre-season medical screening is derived from the history; as such, student-athletes should complete a questionnaire, with physical examination reserved for only those with a positive relevant history\"; \"Femoroacetabular impingement is a myth-the designation of anatomic variation as disease\"; \"An AC (acromioclavicular) separation in a contact athlete should not be treated surgically if the athlete won\\'t give up the sport; it will fail\"; \"Ankle taping induces weakness and atrophy of the dynamic stabilizers of the ankle\"; \"Only autografts should be used in ACL (anterior cruciate ligament) surgery, as allografts have an unnecessary high failure rate in clinical practice.\"',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['pregnancy', 'concussion', 'atrophy', 'surgery']},\n",
       " {'pmid': 22358916,\n",
       "  'sentence': 'Using this strategy in the 500 L reactor, we predict that dissolved oxygen and CO(2) levels can be maintained in the range to support maximum productivity (40% DO, 76 mm Hg pCO(2)) for a culture at 10(7) cells/mL, and with a minimum sparge rate of 0.006 vessel volumes per minute.A = volumetric agitated gas-liquid interfacial area at the top of the liquid, 1/mB = cell broth bleeding rate from the vessel, L/minCER = carbon dioxide evolution rate in the bioreactor, mol/min[CO(2)] = dissolved CO(2) concentration in liquid, M[CO(2)](*) = CO(2) concentration in equilibrium with sparger gas, M[CO(2)](**) = CO(2) concentration in equilibrium with headspace gas, MCO(2)(1) = dissolved carbon dioxide molecule in water[C(T)] = total carbonic species concentration in bioreactor medium, M[C(T)](F) = total carbonic species concentration in feed medium, MD = bioreactor diameter, mD(I) = impeller diameter, mD(b) = the initial delivered bubble diameter, mF = fresh medium feeding rate, L/minH(L) = liquid height in the vessel, mk(A) = carbon dioxide transfer coefficient at liquid surface, m/mink (infA)           (supO) = oxygen transfer coefficient at liquid surface, m/min.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['carbon dioxide', 'carbon dioxide', 'carbon dioxide']},\n",
       " {'pmid': 22399882,\n",
       "  'sentence': 'The experimental studies showed: (1) as many as fifteen spectral up-shifted and two spectral down-shifted sidebands were obtained simultaneously with spectral bandwidth broader than 1.8 octaves from near ultraviolet (360 nm) to near infrared (1.2 Î¼m); (2) the obtained sidebands were spatially separated well and had extremely high beam quality with M(2) factor better than 1.1; (3) the wavelengths of the generated multicolor sidebands could be conveniently tuned by changing the crossing angle or simply replacing with different media; (4) as short as 15-fs negatively chirped or nearly transform limited 20-fs multicolored femtosecond pulses were obtained when one of the two input beams was negatively chirped and the other was positively chirped; (5) the pulse energy of the sideband can reach a Î¼J level with power stability better than 1% RMS; (6) broadband two-dimensional (2-D) multicolored arrays with more than ten periodic columns and more than ten rows were generated in a sapphire plate; (7) the obtained sidebands could be simultaneously spectra broadened and power amplified in another bulk medium by using cross-phase modulation (XPM) in conjunction with four-wave optical parametric amplification (FOPA).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 22444893,\n",
       "  'sentence': 'The focus is on (i) plants such as Ananas comosus (pine apple), Momordica charantia (bitter gourd) and Azadirachta indica (neem) containing anthelmintic compounds and for their use for controlling internal parasites; (ii) plants containing polyphenols and their applications for protecting proteins from degradation in the rumen, increasing efficiency of microbial protein synthesis in rumen and decreasing methane emission; for using as antioxidants, antibacterial and antihelmintic agents; and for changing meat colour and for increasing n-3 fatty acids and conjugated linoleic acid in meat; (iii) saponin-rich plants such as quillaja, yucca and Sapindus saponaria for increasing the efficiency of rumen fermentation, decreasing methane emission and enhancing growth; for producing desired nutritional attributes such as lowering of cholesterol in monogastric animals; for increasing growth of fish (common carp and Nile tilapia) and for changing male to female ratio in tilapia; and for use as molluscicidal agents; (iv) Moringa oleifera leaves as a source of plant growth factor(s), antioxidants, beta-carotene, vitamin C, and various glucosinolates and their degraded products for possible use as antibacterial, antioxidant, anticarcinogenic and antipest agents; (v) Jatropha curcas toxic variety with high levels of various phytochemicals such as trypsin inhibitor, lectin, phytate and phorbol esters in seeds limiting the use of seed meal in fish and livestock diets; and the use of phorbol esters as bio-pesticidal agent; and (vi) lesser-known legumes such as Entada phaseoloides seeds containing high levels of trypsin inhibitor and saponins, Sesbania aculeate seeds rich in non-starch polysaccharides and Mucuna pruriens var.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol', 'beta-carotene'],\n",
       "  'reaction': ['growth', 'growth', 'growth']},\n",
       " {'pmid': 22461826,\n",
       "  'sentence': 'A Multidisciplinary National Panel of Experts in the management of Menopause and Postmenopausal Osteoporosis was created to determine the specific positioning of Bazedoxifene acetate (BZA), a third-generation selective estrogen receptor modulator (SERM), in the field of available therapeutic options in prevention and treatment of postmenopausal osteoporosis.There are various therapeutic options in prevention and treatment for postmenopausal osteoporosis, but nevertheless the problem of osteoporosis and osteoporosis-related fractures is not yet resolved today.In view of this unmet medical need, to have new treatments with efficacy and safety profile so good to therapeutically manage even larger groups of population is the conceptual basis to reduce the devastating impact of this disease on individual\\'s morbidity and mortality, and on public health expense.The Panel has, moreover, pointed up the need to increase the awareness about the issue \"osteopenia\" as a risk factor for fracture to consider in daily clinical practice and the opportunity to evaluate fracture risk using an adequate algorithm (for example, FRAXÂ®, deFRAÂ®), which integrates the result obtained by densitometry (Bone Mineral Density, BMD) (1, 2) and clinical risk factors, in order to consider threshold values for pharmacological intervention.As for prevention and treatment and different groups of age in women\\'s life, it is evident as in the group ranging in age 50 to 65 years the reference Specialist may be the Gynecologist, as the Woman\\'s doctor, even if other Specialists could be interested (Endocrinologist, Rheumatologist, Internist, General Practitioner, or other Specialist who is seeing a patient with osteopenia/osteoporosis).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bazedoxifene'],\n",
       "  'reaction': ['menopause',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis',\n",
       "   'osteoporosis',\n",
       "   'osteopenia',\n",
       "   'fracture',\n",
       "   'fracture']},\n",
       " {'pmid': 22504718,\n",
       "  'sentence': 'Anti-influenza Drugs</b>     â— Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities by Guanhua Du (Chinese Academy of Medical Sciences and Peking Union Medical College, China)     â— Mechanisms and consequences of phagocytosis of influenza virus-infected cells by Yoshinobu Nakanishi (Kanazawa University, Japan)     â— Nuclear export inhibitors; a possible target for novel anti-influenza viral drugs by Ken Watanabe (Nagasaki University, Japan)     â— Catalytic asymmetric synthesis of oseltamivir phosphate directing toward its stable worldwide supply by Motomu Kanai (The University of Tokyo, Japan)     â— Clinical effects of probiotic bifidobacterium in the prevention of influenza virus infections and allergic diseases by Jin-zhong Xiao (Morinaga Milk Industry Co., Ltd., Japan)     â— Production of anti-influenza PR8-scFv using a phage display by Normaiza Zamri (Tokai University, Japan)          <b>Session V. Anti-infection/Antiviral Drugs</b>     â— Emerging infectious diseases and anti-viral drugs: Urgent need to develop effective drugs which cause less resistant virus by Nobuyuki Kobayashi (Nagasaki University, Japan)     â— Design, synthesis and antiviral evaluation of novel heterocyclic compounds as HIV-1 NNRTIs by Xinyong Liu (Shandong University, China)     â— Antiviral drug screening from microbial products by Eisaku Tsujii (Astellas Pharma Inc., Japan)     â— Viral factors that determine the natural course of chronic hepatitis B viral infection by Hiroshi Yotsuyanagi (The University of Tokyo, Japan)     â— Effect of andrographolide derivatives having Î±-glucosidase inhibition, on HBsAg, HBeAg secretion in HepG2 2.2.15 cells by Hongmin Liu (Zhengzhou University, China)     â— Current and future antiviral therapy for influenza by Hideki Asanuma (Tokai University, Japan)     â— Establishment of an HIV-based pseudotyping system as a safe model for screening inhibitors on bird flu H5N1 entry by Ying Guo (Peking Union Medical Collegee Chinese Academy of Medical Sciences, China)     â— Strategy of discovery for novel antibiotics using silkworm infection model by Hiroshi Hamamoto (The University of Tokyo, Japan)     â— Potent neuraminidase inhibitors and anti-inflammatory substances from Chaenomeles speciosa by Li Zhang (Chinese Academy of Medical Sciences and Peking Union Medical College, China)     â— High-throughput screening assay for hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon by Hidenori Tani (Waseda University and National Institute of Advanced Industrial Science and Technology, Japan)          <b>Session VI.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oseltamivir', 'bifidobacterium'],\n",
       "  'reaction': ['influenza',\n",
       "   'phagocytosis',\n",
       "   'influenza',\n",
       "   'influenza',\n",
       "   'chronic hepatitis',\n",
       "   'chronic hepatitis b',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'viral infection',\n",
       "   'infection',\n",
       "   'influenza',\n",
       "   'infection',\n",
       "   'hepatitis',\n",
       "   'hepatitis c']},\n",
       " {'pmid': 22544019,\n",
       "  'sentence': 'Compared with placebo, significant treatment-related increases were observed for weight gain with olanzapine (mean Â± SD = 3.99 Â± 0.42 kg; 95% credible interval, 3.17-4.84 kg), clozapine (2.38 Â± 1.13 kg; 95% credible interval, 0.19-4.62 kg), risperidone (2.02 Â± 0.32 kg; 95% credible interval, 1.39-2.66 kg), quetiapine (1.74 Â± 0.38 kg; 95% credible interval, 0.99-2.5 kg), and aripiprazole (0.89 Â± 0.32 kg; 95% credible interval, 0.26-1.51 kg); glucose levels with risperidone (3.7 Â± 1.36 mg/dL; 95% credible interval, 1.08-6.42 mg/dL) and olanzapine (2.09 Â± 1.08 mg/dL; 95% credible interval, 0.13-4.32 mg/dL); cholesterol levels with quetiapine (10.77 Â± 2.14 mg/dL; 95% credible interval, 6.6-14.95 mg/dL) and olanzapine (4.46 Â± 1.65 mg/dL; 95% credible interval, 1.24-7.73 mg/dL); triglyceride levels with olanzapine (20.18 Â± 5.26 mg/dL; 95% credible interval, 9.85-30.53 mg/dL) and quetiapine (19.5 Â± 3.92 mg/dL; 95% credible interval, 11.84-27.17 mg/dL); hyperprolactinemia with risperidone (OR, 38.63; 95% credible interval, 8.62-125.6), olanzapine (OR, 15.6; 95% credible interval, 4.39-41.1), and ziprasidone (OR, 9.35; 95% credible interval, 1.24-37.03); and EPS with ziprasidone (OR, 20.56; 95% credible interval, 3.53-68.94), olanzapine (OR, 6.36; 95% credible interval, 2.43-13.84), aripiprazole (OR, 3.79; 95% credible interval, 2.17-6.17), and risperidone (OR, 3.71; 95% credible interval, 2.18-6.02).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['quetiapine',\n",
       "   'risperidone',\n",
       "   'aripiprazole',\n",
       "   'cholesterol'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 22740596,\n",
       "  'sentence': 'The Eighth Liquid Matter Conference contents  The Eighth Liquid Matter ConferenceChristoph Dellago, Gerhard Kahl and Christos N Likos  Comparing light-induced colloidal quasicrystals with different rotational symmetriesMichael Schmiedeberg and Holger Stark  Hydrogen bond network relaxation in aqueous polyelectrolyte solutions: the effect of temperatureS Sarti, D Truzzolillo and F Bordi  Equilibrium concentration profiles and sedimentation kinetics of colloidal gels under gravitational stressS Buzzaccaro, E Secchi, G Brambilla, R Piazza and L Cipelletti  The capillary interaction between two vertical cylindersHimantha Cooray, Pietro Cicuta and Dominic Vella  Hydrodynamic and viscoelastic effects in polymer diffusionJ Farago, H Meyer, J Baschnagel and A N Semenov  A density-functional theory study of microphase formation in binary Gaussian mixturesM Carta, D Pini, A Parola and L Reatto  Microcanonical determination of the interface tension of flat and curved interfaces from Monte Carlo simulationsA TrÃ¶ster and K Binder  Phase diagrams of particles with dissimilar patches: X-junctions and Y-junctionsJ M Tavares and P I C Teixeira  The unbearable heaviness of colloids: facts, surprises, and puzzles in sedimentationRoberto Piazza, Stefano Buzzaccaro and Eleonora Secchi  Exploring water and other liquids at negative pressureFrÃ©dÃ©ric Caupin, Arnaud Arvengas, Kristina Davitt, Mouna El Mekki Azouzi, Kirill I Shmulovich, Claire Ramboz, David A Sessoms and Abraham D Stroock  The configurational space of colloidal patchy polymers with heterogeneous sequencesIvan Coluzza and Christoph Dellago  Repeated sorption of water in SBA-15 investigated by means of in situ small-angle x-ray scatteringM Erko, D Wallacher, G H Findenegg and O Paris  Transition of the hydration state of a surfactant accompanying structural transitions of self-assembled aggregatesM Hishida and K Tanaka  The effects of topology on the structural, dynamic and mechanical properties of network-forming materialsMark Wilson  Surface tension of an electrolyte-air interface: a Monte Carlo studyAlexandre Diehl, Alexandre P dos Santos and Yan Levin  Water and other tetrahedral liquids: order, anomalies and solvationB Shadrack Jabes, Divya Nayar, Debdas Dhabal, Valeria Molinero and Charusita Chakravarty  Diffusion coefficient and shear viscosity of rigid water modelsSami Tazi, Alexandru BoÅ£an, Mathieu Salanne, Virginie Marry, Pierre Turq and Benjamin Rotenberg  Phase behaviour of colloidal assemblies on 2D corrugated substratesSamir El Shawish, Emmanuel Trizac and Jure Dobnikar  Structural properties of dendrimer-colloid mixturesDominic A Lenz, Ronald Blaak and Christos N Likos  Fluid-fluid demixing of off-critical colloid-polymer systems confined between parallel platesE A G Jamie, R P A Dullens and D G A L Aarts  Simulations of nematic homopolymer melts using particle-based models with interactions expressed through collective variablesKostas Ch Daoulas, Victor RÃ¼hle and Kurt Kremer  Smectic shellsTeresa Lopez-Leon, Alberto Fernandez-Nieves, Maurizio Nobili and Christophe Blanc  Intrinsic profiles and the structure of liquid surfacesP Tarazona, E ChacÃ³n and F Bresme  Competing ordered structures formed by particles with a regular tetrahedral patch decorationGÃ¼nther Doppelbauer, Eva G Noya, Emanuela Bianchi and Gerhard Kahl  Heterogeneous crystallization in colloids and complex plasmas: the role of binary mobilitiesH LÃ¶wen, E Allahyarov, A Ivlev and G E Morfill  Isotope effects in water as investigated by neutron diffraction and path integral molecular dynamicsAnita Zeidler, Philip S Salmon, Henry E Fischer, JÃ¶rg C Neuefeind, J Mike Simonson and Thomas E Markland  Confined cubic blue phases under shearO Henrich, K Stratford, D Marenduzzo, P V Coveney and M E Cates  Depletion-induced biaxial nematic states of boardlike particlesS Belli, M Dijkstra and R van Roij  Active Brownian motion tunable by lightIvo Buttinoni, Giovanni Volpe, Felix KÃ¼mmel, Giorgio Volpe and Clemens Bechinger  Structure and stability of charged clustersMark A Miller, David A Bonhommeau, Christopher J Heard, Yuyoung Shin, Riccardo Spezia and Marie-Pierre Gaigeot  Non-equilibrium relaxation and tumbling times of polymers in semidilute solutionChien-Cheng Huang, Gerhard Gompper and Roland G Winkler  Thermophoresis of colloids by mesoscale simulationsDaniel LÃ¼sebrink, Mingcheng Yang and Marisol Ripoll  Computing the local pressure in molecular dynamics simulationsThomas W Lion and Rosalind J Allen  Gradient-driven fluctuations in microgravityA Vailati, R Cerbino, S Mazzoni, M Giglio, C J Takacs and D S Cannell.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['surfactant'],\n",
       "  'reaction': ['tension', 'tension']},\n",
       " {'pmid': 22810216,\n",
       "  'sentence': 'This review finds evidence of many parallels between the two, including: (1) microtubule degeneration, specifically large, long-range axon degeneration with subsequent abortive axonal sprouting (short, thin axons); (2) dentritic overgrowth; (3) neuroinflammation; (4) microglial/astrocytic activation; (5) brain immune response activation; (6) elevated glial fibrillary acidic protein; (7) oxidative stress and lipid peroxidation; (8) decreased reduced glutathione levels and elevated oxidized glutathione; (9) mitochondrial dysfunction; (10) disruption in calcium homeostasis and signaling; (11) inhibition of glutamic acid decarboxylase (GAD) activity; (12) disruption of GABAergic and glutamatergic homeostasis; (13) inhibition of IGF-1 and methionine synthase activity; (14) impairment in methylation; (15) vascular endothelial cell dysfunction and pathological changes of the blood vessels; (16) decreased cerebral/cerebellar blood flow; (17) increased amyloid precursor protein; (18) loss of granule and Purkinje neurons in the cerebellum; (19) increased pro-inflammatory cytokine levels in the brain (TNF-Î±, IFN-Î³, IL-1Î², IL-8); and (20) aberrant nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 22841193,\n",
       "  'sentence': 'Selected genes up-regulated before transplantation were: TNFRSF9 (tumor necrosis factor [TNF] receptor superfamily, member 9); IL2RB (interleukin-2 receptor beta); BCL2L2 (BCL2-like 2); NOX5 (NADPH) oxidase, EF-hand calcium binding domain 5); PEX5 (peroxisomal biogenesis factor 5); PPARG (peroxisome proliferator-activated receptor gamma); NIBP (IKK2 binding protein); NKIRAS2 (NFKappaBeta inhibitor interacting Ras-like 2); IL4 (interleukin-4); IL-4R (interleukin 4 receptor); ADH1A (alcohol dehydrogenase 1A, class 1); ALDH1L1 (aldehyde dehydrogenase 1 family, member L1); MPO (myeloperoxidase); NPPA (natriuretic peptide precursor A); BCL2A1 (BCL2-related protein A1); GADD45A (growth arrest and DNA-damage-inducible alpha); TEGT (Bax inhibitor 1); PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide); IFNGR2 (interferon gamma receptor 2); JAK2 (Janus Kinase 2); FAS (Fas, TNF receptor superfamily, member 6); TANK (TRAF family member-associated NFKB activator); TTRAP (TRAF and TNF receptor-associated protein); and ANXA5 (annexin A5).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'polypeptide', 'calcium'],\n",
       "  'reaction': ['necrosis', 'growth', 'interferon gamma']},\n",
       " {'pmid': 23074387,\n",
       "  'sentence': 'A summary decision analytic model was then developed to encapsulate the data from each of these reports (available on the OHTAC and MAS website).The Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease series is made up of the following reports, which can be publicly accessed at the MAS website at: www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlSINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY WITH CONTRAST FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based Analysis64-Slice Computed Tomographic Angiography for the Diagnosis of Coronary Artery Disease: An Evidence-Based AnalysisCARDIAC MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisPease note that two related evidence-based analyses of non-invasive cardiac imaging technologies for the assessment of myocardial viability are also available on the MAS website:POSITRON EMISSION TOMOGRAPHY FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: An Evidence-Based AnalysisMAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: an Evidence-Based AnalysisThe Toronto Health Economics and Technology Assessment Collaborative has also produced an associated economic report entitled:The Relative Cost-effectiveness of Five Non-invasive Cardiac Imaging Technologies for Diagnosing Coronary Artery Disease in Ontario [Internet].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'magnetic resonance imaging',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease']},\n",
       " {'pmid': 23074389,\n",
       "  'sentence': 'A summary decision analytic model was then developed to encapsulate the data from each of these reports (available on the OHTAC and MAS website).The Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease series is made up of the following reports, which can be publicly accessed at the MAS website at: www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlSINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY WITH CONTRAST FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based Analysis64-Slice Computed Tomographic Angiography for the Diagnosis of Coronary Artery Disease: An Evidence-Based AnalysisCARDIAC MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisPease note that two related evidence-based analyses of non-invasive cardiac imaging technologies for the assessment of myocardial viability are also available on the MAS website:POSITRON EMISSION TOMOGRAPHY FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: An Evidence-Based AnalysisMAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: an Evidence-Based AnalysisThe Toronto Health Economics and Technology Assessment Collaborative has also produced an associated economic report entitled:The Relative Cost-effectiveness of Five Non-invasive Cardiac Imaging Technologies for Diagnosing Coronary Artery Disease in Ontario [Internet].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'magnetic resonance imaging',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease']},\n",
       " {'pmid': 23074411,\n",
       "  'sentence': 'A summary decision analytic model was then developed to encapsulate the data from each of these reports (available on the OHTAC and MAS website).The Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease series is made up of the following reports, which can be publicly accessed at the MAS website at: www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlSINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY WITH CONTRAST FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based Analysis64-Slice Computed Tomographic Angiography for the Diagnosis of Coronary Artery Disease: An Evidence-Based AnalysisCARDIAC MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisPease note that two related evidence-based analyses of non-invasive cardiac imaging technologies for the assessment of myocardial viability are also available on the MAS website:POSITRON EMISSION TOMOGRAPHY FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: An Evidence-Based AnalysisMAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: an Evidence-Based AnalysisThe Toronto Health Economics and Technology Assessment Collaborative has also produced an associated economic report entitled:The Relative Cost-effectiveness of Five Non-invasive Cardiac Imaging Technologies for Diagnosing Coronary Artery Disease in Ontario [Internet].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'magnetic resonance imaging',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease']},\n",
       " {'pmid': 23074412,\n",
       "  'sentence': 'A summary decision analytic model was then developed to encapsulate the data from each of these reports (available on the OHTAC and MAS website).The Non-Invasive Cardiac Imaging Technologies for the Diagnosis of Coronary Artery Disease series is made up of the following reports, which can be publicly accessed at the MAS website at: www.health.gov.on.ca/mas\">www.health.gov.on.ca/mas or at www.health.gov.on.ca/english/providers/program/mas/mas_about.htmlSINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisSTRESS ECHOCARDIOGRAPHY WITH CONTRAST FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based Analysis64-Slice Computed Tomographic Angiography for the Diagnosis of Coronary Artery Disease: An Evidence-Based AnalysisCARDIAC MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: An Evidence-Based AnalysisPease note that two related evidence-based analyses of non-invasive cardiac imaging technologies for the assessment of myocardial viability are also available on the MAS website:POSITRON EMISSION TOMOGRAPHY FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: An Evidence-Based AnalysisMAGNETIC RESONANCE IMAGING FOR THE ASSESSMENT OF MYOCARDIAL VIABILITY: an Evidence-Based AnalysisThe Toronto Health Economics and Technology Assessment Collaborative has also produced an associated economic report entitled:The Relative Cost-effectiveness of Five Non-invasive Cardiac Imaging Technologies for Diagnosing Coronary Artery Disease in Ontario [Internet].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease',\n",
       "   'magnetic resonance imaging',\n",
       "   'coronary artery disease',\n",
       "   'coronary artery disease']},\n",
       " {'pmid': 23221137,\n",
       "  'sentence': 'In severe sepsis and septic shock should be early goal-directed resuscitation of the septic patient during the first 6 hrs after recognition; -appropriate diagnostic studies to ascertain causative organisms before starting antibiotics; -early administration of broad-spectrum antibiotic therapy; -reassessment of antibiotic therapy with microbiology and clinical data to narrow coverage, when appropriate; -a usual 7-10 days of antibiotic therapy guided by clinical response; -source control with attention to the method that balances risks and benefits; -equivalence of crystalloid and colloid resuscitation; aggressive fluid challenge to restore mean circulating filling pressure; -vasopressor preference for norepinephrine and dopamine; -cautious use of vasopressin pending further studies; -avoiding low-dose dopamine administration for renal protection; consideration of dobutamine inotropic therapy in some clinical situations; -stress-dose steroid therapy for septic shock; use of recombinant activated protein C in patients with severe sepsis and high risk for death; -with resolution of tissue hypoperfusion and in the absence of coronary artery disease or acute hemorrhage, targeting a hemoglobin of 7-9 g/dL; -a low tidal volume and limitation of inspiratory plateau pressure strategy for acute lung injury and acute respiratory distress syndrome; -application of a minimal amount of positive end-expiratory pressure in acute lung injury/acute respiratory distress syndrome; -protocols for weaning and sedation, using either intermittent bolus sedation or continuous infusion sedation with daily interruptions/lightening; -avoidance of neuromuscular blockers, if at all possible; -maintenance of blood glucose <150 mg/dL after initial stabilization.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vasopressin', 'dopamine'],\n",
       "  'reaction': ['sepsis',\n",
       "   'septic shock',\n",
       "   'shock',\n",
       "   'resuscitation',\n",
       "   'antibiotic therapy',\n",
       "   'antibiotic therapy',\n",
       "   'antibiotic therapy',\n",
       "   'resuscitation',\n",
       "   'septic shock',\n",
       "   'shock',\n",
       "   'protein c',\n",
       "   'sepsis',\n",
       "   'death',\n",
       "   'hypoperfusion',\n",
       "   'coronary artery disease',\n",
       "   'acute lung injury',\n",
       "   'injury',\n",
       "   'respiratory distress',\n",
       "   'respiratory distress',\n",
       "   'sedation',\n",
       "   'sedation',\n",
       "   'infusion',\n",
       "   'sedation',\n",
       "   'blood glucose',\n",
       "   'blood glucose']},\n",
       " {'pmid': 23229350,\n",
       "  'sentence': 'from day 0 to day 21 after Mycobacterium tuberculli injection, respectively * p < 0.05; ** p < 0.01; *** p < 0.001, compared to arthritic control Table 2 Effect of E. hirta and Prednisolone (Pred) on Con A-induced IL-2 and IFN-Î³ productions from splenocytes in Mycobacterium tuberculli-induced inflammatory arthritic rats Treatment Dose (mg/kg) IL-2 (pg/ml) IFN-Î³ (pg/ml) Arthritic control (AC) - 235.98 Â± 15.23 165.95 Â± 13.87 E. hirta 25 225.12 Â± 14.76** 154.76 Â± 11.07** E. hirta 50 207.76 Â± 13.87** 134.76 Â± 11.01** E. hirta 100 189.98 Â± 12.65 *** 110.64 Â± 10.98*** E. hirta 200 157.84 Â± 14.32 *** 98.54 Â± 10.76*** Prednisolone (Pred) 5 131.08 Â± 13.31*** 87.65 Â± 10.61*** Normal control (NC) - 78.12 Â± 12.04 31.87 Â± 10.12 Each value indicates the mean Â± SEM of six animals AC arthritic control, NC normal control; E. hirta (25, 50, 100 and 200 mg/kg) and prednisolone (5 mg/kg) were given p.o.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pred', 'ac', 'prednisolone'],\n",
       "  'reaction': ['injection']},\n",
       " {'pmid': 23288351,\n",
       "  'sentence': 'Key summary points--Current strategies to minimize the steroid-related adverse effects in pediatric renal graft recipients include steroid withdrawal, early or late after transplantation, or complete steroid avoidance--Early steroid withdrawal or avoidance is generally used following the induction therapy with mono- or polyclonal antibodies, while in late steroid withdrawal induction therapy was generally not used- Elimination of steroids (early or late) does not increase the risk of acute rejection and does not deteriorate long-term renal graft function- Early steroid withdrawal is possible in patients at high immunological risk using a combination of polyclonal antibody induction, tacrolimus, and mycophenolate mofetil- All protocols of steroid minimization showed relevant clinical benefits, however the growth-related benefit was limited to pre-pubertal patients in all but one of the studies- Adverse events of steroid withdrawal occurred in a higher incidence of post-transplant bone marrow suppression Key research points - There is no clear evidence of the impact of steroid withdrawal on the risk of recurrence of primary glomerulonephritis after renal transplantation in children, therefore further evaluation of this important issue should be performed in prospective trials- There is limited pediatric data on the risk of anti-HLA/donor-specific antibody production in steroid-free patients after renal transplantation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tacrolimus'],\n",
       "  'reaction': ['glomerulonephritis']},\n",
       " {'pmid': 23449933,\n",
       "  'sentence': 'This model showed that: (i) the combination of five genetic alterations (CDK4, hTERT, sh-p53, KRAS(V12), and c-MYC) is sufficient for full tumorigenic conversion of HBECs; (ii) genetically identical clones of transformed HBECs exhibit pronounced differences in tumor growth, histology, and differentiation; (iii) HBECs from different individuals vary in their sensitivity to transformation by these oncogenic manipulations; (iv) high levels of KRAS(V12) are required for full malignant transformation of HBECs, however, prior loss of p53 function is required to prevent oncogene-induced senescence; (v) overexpression of c-MYC greatly enhances malignancy but only in the context of sh-p53+KRAS(V12); (vi) growth of parental HBECs in serum-containing medium induces differentiation, whereas growth of oncogenically manipulated HBECs in serum increases in vivo tumorigenicity, decreases tumor latency, produces more undifferentiated tumors, and induces epithelial-to-mesenchymal transition (EMT); (vii) oncogenic transformation of HBECs leads to increased sensitivity to standard chemotherapy doublets; (viii) an mRNA signature derived by comparing tumorigenic versus nontumorigenic clones was predictive of outcome in patients with lung cancer.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth',\n",
       "   'histology',\n",
       "   'malignant transformation',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'chemotherapy']},\n",
       " {'pmid': 23456774,\n",
       "  'sentence': 'We summarize our \"top ten list\" of papers that are likely to change the care of the anticoagulated population and improve their outcomes: (1) Patient self-management of their vitamin K antagonist and self monitoring can decrease thromboembolic events; (2) restarting warfarin after gastrointestinal bleeding may decrease mortality; (3) rivaroxaban is effective in the treatment of pulmonary embolism; either (4) apixaban or (5) low-dose aspirin prevented recurrent venous thromboembolic disease after a standard course of therapy; (6) warfarin prevents thrombotic complications up to at least 90 days after bioprosthetic aortic valve replacement; (7) the relative risk reduction of apixaban compared to warfarin is similar across CHADS2 scores, but the absolute risk reduction is higher in high-risk patients; (8) adherence to a warfarin dose-adjustment algorithm improved time in the therapeutic range and thromboembolic outcomes in the RE-LY trial; (9) warfarin had little benefit (if any) over aspirin in patients with decreased ejection fraction and sinus rhythm; (10) adding clopidogrel to aspirin in patients with lacunar infarcts did not reduce the risk of recurrent stroke and increased bleeding.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rivaroxaban', 'clopidogrel', 'apixaban'],\n",
       "  'reaction': ['pulmonary embolism',\n",
       "   'embolism',\n",
       "   'aortic valve replacement',\n",
       "   'ejection fraction',\n",
       "   'ejection fraction',\n",
       "   'sinus rhythm']},\n",
       " {'pmid': 23495004,\n",
       "  'sentence': 'Prominent in the current stage of antiviral drug development are: (i) for human immunodeficiency virus (HIV), the use of fixed-dose combinations (FDCs), the most recent example being Stribild(TM); (ii) for hepatitis C virus (HCV), the pleiade of direct-acting antivirals (DAAs) that should be formulated in the most appropriate combinations so as to obtain a cure of the infection; (iii)-(v) new strategies (i.e., AIC316, AIC246, and FV-100) for the treatment of herpesvirus infections: herpes simplex virus (HSV), cytomegalovirus (CMV), and varicella-zoster virus (VZV), respectively; (vi) the role of a new tenofovir prodrug, tenofovir alafenamide (TAF) (GS-7340) for the treatment of HIV infections; (vii) the potential use of poxvirus inhibitors (CMX001 and ST-246); (viii) the usefulness of new influenza virus inhibitors (peramivir and laninamivir octanoate); (ix) the position of the hepatitis B virus (HBV) inhibitors [lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF)]; and (x) the potential of new compounds such as FGI-103, FGI-104, FGI-106, dUY11, and LJ-001 for the treatment of filoviruses (i.e., Ebola).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['entecavir', 'telbivudine', 'lamivudine'],\n",
       "  'reaction': ['immunodeficiency',\n",
       "   'hepatitis',\n",
       "   'hepatitis c',\n",
       "   'infection',\n",
       "   'herpes simplex',\n",
       "   'influenza',\n",
       "   'hepatitis',\n",
       "   'hepatitis b']},\n",
       " {'pmid': 23548386,\n",
       "  'sentence': 'Independent predictors of lethal outcome in patients with acute decompensation of CHF were low systolic arterial pressure at admission (odds ratio [OR] 1.03, 95% confidence interval [CI] 1.01 to 1.05 per each 1 mm Hg of blood pressure lowering), elevation of urea content (OR 1.29, 95%CI 1.11 to 1.47 per each 1 mmol/L of elevation), potassium (OR 2.09, 95%CI 1.08 to 4.38 per 1 mmol/L of elevation) and creatinine (OR 1.01, 95%CI 1.01 to 1.03 per 1 mmol/L of elevation), lowering of glomerular filtration rate (OR 1.29, 95%CI 1.18 to 1.41 per 1 ml/min/1,73 m2 of lowering), left ventricular dilatation (OR 9.53, 95%CI 1.44 to 38.17; =0.043), pulmonary hypertension according to echocardiography data (=0.007), scarry changes according to electrocardiography data (OR 3.00, 95%CI 1.00 to 10.58; p=0.05), lack of therapy with acetylsalicylic acid (OR 6.21, 95%CI 1.62 to 22.73; =0.009) and -adrenoblockers (OR 6.99, 95%CI 1.39 to 14.49; =0,005) at ambulatory stage.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate',\n",
       "   'left ventricular dilatation',\n",
       "   'pulmonary hypertension',\n",
       "   'hypertension']},\n",
       " {'pmid': 23624331,\n",
       "  'sentence': 'Supraphysiological O2 concentrations, mechanical ventilation, and inflammation significantly contribute to the development of bronchopulmonary dysplasia (BPD).Exposure of newborn mice to hyperoxia causes inflammation and impaired alveolarization similar to that seen in infants with BPD.Previously, we demonstrated that pulmonary cyclooxygenase-2 (COX-2) protein expression is increased in hyperoxia-exposed newborn mice.The present studies were designed to define the role of COX-2 in newborn hyperoxic lung injury.We tested the hypothesis that attenuation of COX-2 activity would reduce hyperoxia-induced inflammation and improve alveolarization.Newborn C3H/HeN micewere injected daily with vehicle, aspirin (nonselective COX-2 inhibitor), or celecoxib (selective COX-2 inhibitor) for the first 7 days of life.Additional studies utilized wild-type (C57Bl/6, COX-2(+/+)), heterozygous (COX-2(+/-)), and homozygous (COX-2(-/-)) transgenic mice.Micewere exposed to room air (21% O2) or hyperoxia (85% O2) for 14 days.Aspirin-injected and COX-2(-/-) pups had reduced levels of monocyte chemoattractant protein (MCP-1) in bronchoalveolar lavage fluid (BAL).Both aspirin and celecoxib treatment reduced macrophage numbers in the alveolar walls and air spaces.Aspirin and celecoxib treatment attenuated hyperoxia-induced COX activity, including altered levels of prostaglandin (PG)D2 metabolites.Decreased COX activity, however, did not prevent hyperoxia-induced lung developmental deficits.Our data suggest thatincreased COX-2 activity may contribute to proinflammatory responses, including macrophage chemotaxis, during exposure to hyperoxia.Modulation of COX-2 activity may be a useful therapeutic target to limit hyperoxia-induced inflammation in preterm infants at risk of developing BPD.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['celecoxib'],\n",
       "  'reaction': ['mechanical ventilation',\n",
       "   'inflammation',\n",
       "   'bronchopulmonary dysplasia',\n",
       "   'dysplasia',\n",
       "   'hyperoxia',\n",
       "   'inflammation',\n",
       "   'inflammation',\n",
       "   'hyperoxia',\n",
       "   'inflammation']},\n",
       " {'pmid': 23645742,\n",
       "  'sentence': 'The results from western blotting also showed that quercetin reduced the protein levels of MMP-2, -7, -9 and -10, vascular endothelial growth factor (VEGF), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÎºB) p65, inductible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), urokinase-type plasminogen activator (uPA), phosphatidylinositide-3 kinases (PI3K), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IKBÎ±), IKB-Î±/Î², phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor kinase, alpha/beta (p-IKKÎ±/Î²), focal adhesion kinase (FAK), son of sevenless homolog-1 (SOS1), growth factor receptor-bound protein-2 (GRB2), mitogen-activated protein kinase kinase kinase-3 (MEKK3), MEKK7, extracellular-signal-regulated kinase 1/2 (ERK1/2), p-ERK1/2, c-Jun N-terminal kinase 1/2 (JNK1/2), p38, p-p38, Jun proto-oncogene (c-JUN) and p-c-JUN but it did not affect Ras homolog gene family, member A (RhoA), Protein kinase C (PKC) and rat sarcoma viral oncogene homolog (RAS) in SAS cells.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['polypeptide'],\n",
       "  'reaction': ['growth', 'adhesion', 'growth', 'sarcoma']},\n",
       " {'pmid': 23883553,\n",
       "  'sentence': 'Review of previous clinical trials found the following: (1) GIIG increased in size by 3-5 mm per year when observed or treated with surgery alone; (2) after pathological diagnosis, the survival rate was increased by early aggressive tumor removal at an earlier stage compared to observation alone; (3) although the prognosis after total tumor removal was significantly better than that after partial tumor removal, half of the patients relapsed within 5 years; (4) comparing postoperative early radiotherapy (RT) and non-early RT after relapse, early RT prolonged progression-free survival (PFS) but did not affect overall survival (OS); (5) local RT of 45 to 64.8 Gy did not impact PFS or OS; (6) in patients with residual tumors, RT combined with chemotherapy (procarbazine plus lomustine plus vincristine) prolonged PFS compared with RT alone but did not affect OS; and (7) poor prognostic factors included astrocytoma, non-total tumor removal, age â‰¥40 years, largest tumor diameter â‰¥4-6 cm, tumor crossing the midline, and neurological deficit.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lomustine'],\n",
       "  'reaction': ['surgery', 'radiotherapy', 'chemotherapy', 'astrocytoma']},\n",
       " {'pmid': 23908602,\n",
       "  'sentence': 'The evidence is assessed as: probable for an estimated average requirement of 0.66 g good-quality protein/kg body weight (BW)/day based on nitrogen balance studies, suggestive for a relationship between increased all-cause mortality risk and long-term low-carbohydrate-high-protein (LCHP) diets; but inconclusive for a relationship between all-cause mortality risk and protein intake per se; suggestive for an inverse relationship between cardiovascular mortality and vegetable protein intake; inconclusive for relationships between cancer mortality and cancer diseases, respectively, and protein intake; inconclusive for a relationship between cardiovascular diseases and total protein intake; suggestive for an inverse relationship between blood pressure (BP) and vegetable protein; probable to convincing for an inverse relationship between soya protein intake and LDL cholesterol; inconclusive for a relationship between protein intake and bone health, energy intake, BW control, body composition, renal function, and risk of kidney stones, respectively; suggestive for a relationship between increased risk of type 2 diabetes (T2D) and long-term LCHP-high-fat diets; inconclusive for impact of physical training on protein requirement; and suggestive for effect of physical training on whole-body protein retention.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight', 'blood pressure', 'energy']},\n",
       " {'pmid': 23979493,\n",
       "  'sentence': 'According to the experimental studies, the deepest impression on the antischistosomal properties of mefloquine can be summarized as following points: (1) single dose of mefloquine possesses potential effect against three major species of schistosomes (Schistosoma mansoni, Schistosoma haematobium, and Schistosoma japonicum) infecting humans; (2) the drug displays similar effects against developing stages of juvenile and adult schistosomes, which are superior to that of artemisinins and praziquantel; (3) in vitro mefloquine exerts direct killing effect on juvenile and adult schistosomes, while in vivo, the efficacy of the drug is independent to host immune response, (4) mefloquine causes extensive and severe morphological, histopathological, and ultrastructural damage to adult and juvenile schistosomes, particularly, the worm tegument, musculature, gut, and vitelline glands of female worms are the key sites attacked by the drug; (5) combined treatment with mefloquine and praziquantel, or artemisinins shows synergistic effect against schistosome in experimental therapy,while in initially clinical trial, mefloquine in combination with artesunate also exhibits higher cure rates against schistosomiasis hematobia and schistosomiasis mansoni, and (6) several mefloquine-related arylmethanols exhibit potential effect against schistosomes in vivo, which is a useful clue helpful for development of new antischistosomal compound.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['praziquantel'],\n",
       "  'reaction': ['schistosomiasis', 'schistosomiasis']},\n",
       " {'pmid': 24070654,\n",
       "  'sentence': 'In this second part of \"Dancing with antivirals as chemical formulae\" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. AntonÃ­n HolÃ½\\'s legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['acyclovir',\n",
       "   'elvitegravir',\n",
       "   'oseltamivir',\n",
       "   'dolutegravir',\n",
       "   'zanamivir',\n",
       "   'darunavir',\n",
       "   'raltegravir'],\n",
       "  'reaction': ['influenza', 'influenza', 'infection']},\n",
       " {'pmid': 24156429,\n",
       "  'sentence': 'The results indicated that: (1) after Raji and Ramos cells were treated with PCI-32765 (0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 Âµmol/L) alone and bortezomib (10, 20, 30, 40, 50, 60, 80 nmol/L) alone and their combination for 48 h, the cell proliferation and vitality were inhibited in a dose-dependent manner and both had synergistic effect; (2) Raji and Ramos cells were treated with PCI-32765 (2.0 Âµmol/L) and bortezomib (20 nmol/L) alone and their combination for 8, 12, 24, 36, 48 and 72 h, the cell proliferation and vitality were inhibited in a time-dependent manner, the two drugs displayed a synergistic effects; (3) the Raji and Ramos cells were treated with PCI-32765 (2.0 Âµmol/L) and bortezomib (20 nmol/L) alone and their combination for 48 h, all these treatments could induce significant apoptosis of Raji and Ramos cells.In Raji cell experiment, the cell apoptosis rate in the control group, PCI-32765 group, bortezomib group and PCI-32765 and bortezomib combination group were 10.34 Â± 0.53%, 24.26 Â± 0.91%, 43.66 Â± 1.08% and 74.06 Â± 0.72% respectively, and the differences was statistically significant among the different groups (P < 0.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['bortezomib'],\n",
       "  'reaction': ['apoptosis', 'apoptosis']},\n",
       " {'pmid': 24251461,\n",
       "  'sentence': 'Here we offer 10 key lessons to assist with the care of patients with HFpEF: (1) Know the difference between diastolic dysfunction, diastolic heart failure, and HFpEF; (2) diagnosing HFpEF is challenging, so be thorough and consider invasive hemodynamic testing to confirm the diagnosis; (3) a normal B-type natriuretic peptide does not exclude the diagnosis of HFpEF; (4) elevated pulmonary artery systolic pressure on echocardiography in the presence of a normal ejection fraction should prompt consideration of HFpEF; (5) use dynamic testing in evaluating the possibility of HFpEF in patients with unexplained dyspnea or exercise tolerance; (6) all patients with HFpEF should be systematically evaluated for the presence of coronary artery disease; (7) use targeted treatment for HFpEF patients based on their phenotypic classification; (8) treat HFpEF patients now by treating their comorbidities; (9) understand the importance of heart rate in HFpEF- lower is not always better; and (10) do not forget to consider rare diseases (\"zebras\") as causes for HFpEF when evaluating and treating patients.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['diastolic dysfunction',\n",
       "   'ejection fraction',\n",
       "   'ejection fraction',\n",
       "   'exercise tolerance',\n",
       "   'coronary artery disease',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 24251996,\n",
       "  'sentence': 'In PubMed, eight clinical trials about the therapy of micronutrients on SSc patients were searched out using medical subject headings terms (SSc: \"scleroderma, localized\", \"scleroderma, systemic\", \"scleroderma, diffuse\" and \"scleroderma, limited\"; vitamins \"vitamin A\", \"thiamin\", \"riboflavin\", \"niacin\", \"pantothenic acid\", \"vitamin B 6\", \"biotin\", \"folic acid\", \"vitamin B 12\", \"inositol\", \"choline\", \"ascorbic acid\", \"vitamin D\", \"vitamin E\", \"tocopherols\", \"vitamin K\" and \"vitamin P\"; and minerals: \"calcium\", \"magnesium\", \"potassium\", \"sodium\", \"phosphorus\", \"sulfur\", \"chlorine\", \"iron\", \"copper\", \"iodine\", \"zinc\", \"selenium\", \"manganese\", \"molybdenum\", \"cobalt\", \"chromium\", \"tin\", \"vanadium\", \"silicon\", \"nickel\" and \"fluorine\").',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium',\n",
       "   'selenium',\n",
       "   'chromium',\n",
       "   'sodium',\n",
       "   'vanadium',\n",
       "   'magnesium',\n",
       "   'calcium'],\n",
       "  'reaction': ['scleroderma',\n",
       "   'scleroderma',\n",
       "   'scleroderma',\n",
       "   'scleroderma',\n",
       "   'vitamin a',\n",
       "   'vitamin d',\n",
       "   'manganese']},\n",
       " {'pmid': 24268281,\n",
       "  'sentence': 'The following results were obtained: (i) The microstructure of the DLC layer after the deposition was amorphous and thermal annealing had no marked effect on the structure, (ii) formation of oxygen containing SiOx and Ti[O,C] layers were detected at the Si/Ti and Ti/DLC interfaces with the help of transmission electron microscope (TEM), (iii) thermal post-treatments increased the polar fraction of the surface energy, (iv) cyclic voltammetry (CV) measurements showed that the DLC films had wide water windows and were stable in contact with dilute sulphuric acid and phosphate buffered saline (PBS) solutions, (v) use of Ti interlayer between Pt(Ir) microwire and DLC layer was crucial for the electrodes to survive the electrochemical measurements without the loss of adhesion of the DLC layer, (vi) DLC electrodes with small exposed Pt areas were an order of magnitude more sensitive towards dopamine than Pt electrodes and (vii) thermal post-treatments did not markedly change the electrochemical behavior of the electrodes despite the significant increase in the polar nature of the surfaces.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['energy', 'adhesion']},\n",
       " {'pmid': 24271323,\n",
       "  'sentence': \"Myeloperoxidase-ANCA-positive hypertrophic pachymeningitis was characterized by: (i) an elderly female predominance; (ii) 82% of patients diagnosed with granulomatosis with polyangiitis (previously known as Wegener's granulomatosis) according to Watts' algorithm; (iii) a high frequency of patients with lesions limited to the dura mater and upper airways, developing headaches, chronic sinusitis, otitis media or mastoiditis; (iv) a low frequency of patients with the 'classical or generalized form' of granulomatosis with polyangiitis involving the entire upper and lower airways and kidney, or progressing to generalized disease, in contrast to proteinase 3-ANCA-positive hypertrophic pachymeningitis; (v) less severe neurological damage according to the modified Rankin Scale and low disease activity according to the Birmingham Vasculitis Activity Score compared with proteinase 3-ANCA-positive hypertrophic pachymeningitis; (vi) increased levels of CXCL10, CXCL8 and interleukin 6 in cerebrospinal fluids, and increased numbers of T cells, neutrophils, eosinophils, plasma cells and monocytes/macrophages in autopsied or biopsied dura mater with pachymeningitis, suggesting TH1-predominant granulomatous lesions in hypertrophic pachymeningitis, as previously reported in pulmonary or renal lesions of granulomatosis with polyangiitis; and (vii) greater efficacy of combination therapy with prednisolone and cyclophosphamide compared with monotherapy with prednisolone.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['prednisolone'],\n",
       "  'reaction': ['pachymeningitis',\n",
       "   'elderly',\n",
       "   'granulomatosis with polyangiitis',\n",
       "   'chronic sinusitis',\n",
       "   'sinusitis',\n",
       "   'otitis media',\n",
       "   'mastoiditis',\n",
       "   'granulomatosis with polyangiitis',\n",
       "   'pachymeningitis',\n",
       "   'vasculitis',\n",
       "   'pachymeningitis',\n",
       "   'plasma cells',\n",
       "   'pachymeningitis',\n",
       "   'pachymeningitis',\n",
       "   'granulomatosis with polyangiitis']},\n",
       " {'pmid': 24319213,\n",
       "  'sentence': 'Hundreds of studies over the last 4 decades have produced evidence to support the following: (1) risk stratification allows the identification of a subset of patients who may be safely managed as outpatients given the right health care environment; (2) antibacterial prophylaxis for high-risk patients who remain neutropenic for â‰¥7 days prevents infections and decreases mortality; (3) the empirical management of febrile neutropenia with a single antipseudomonal beta-lactam results in the same outcome and less toxicity than combination therapy using aminoglycosides; (4) vancomycin should not be used routinely empirically either as part of the initial regimen or for persistent fever, but rather should be added when a pathogen that requires its use is isolated; (5) empirical antifungal therapy should be added after 4 days of persistent fever in patients at high risk for invasive fungal infection (IFI); the details of the characterization as high risk and the choice of agent remain debatable; and (6) preemptive antifungal therapy in which the initiation of antifungals is postponed and triggered by the presence, in addition to fever, of other clinical findings, computed tomography (CT) results, and serological tests for fungal infection is an acceptable strategy in a subset of patients.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vancomycin'],\n",
       "  'reaction': ['prophylaxis',\n",
       "   'febrile neutropenia',\n",
       "   'neutropenia',\n",
       "   'fungal infection',\n",
       "   'infection',\n",
       "   'fungal infection',\n",
       "   'infection']},\n",
       " {'pmid': 24326015,\n",
       "  'sentence': 'The successful examples of immunoprophylaxis and therapy against cancers include: (i) targeted therapy using monoclonal antibodies (Nat Rev Cancer 12:278-287, 2012); (ii) allogeneic hematopoietic stem cell transplantion to elicit graft-versus-cancer effect against a variety of hematopoietic malignancies (Blood 112:4371-4383, 2008); (iii) vaccination for preventing cancers with clear viral etiology such as hepatocellular carcinoma and cervical cancer (Cancer J Clin 57:7-28, 2007; NEJM 336:1855-1859, 1997); (iv) T cell checkpoint blockade against inhibitory pathways including targeting CTLA-4 and PD-1 inhibitory molecules for the treatment of melanoma and other solid tumors (NEJM 363:711-723, 2010; NEJM 366:2443-2454, 2012; NEJM 369:122-133, 2013; NEJM 366:2455-2465, 2012); (v) antigen-pulsed autologous dendritic cell vaccination against prostate cancer (NEJM 363:411-422, 2010); and (vi) the transfer of T cells including those genetically engineered with chimeric antigen receptors allowing targeting of B cell neoplasms (NEJM 365:725-733, 2011; NEJM 368:1509-1518, 2013; Blood 118:4817-4828, 2013; Sci Transl Med 5:177ra138, 2013).This article provides an overview on the exciting and expanding immunological arsenals against cancer, and discusses critical remaining unanswered questions of cancer immunology.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rev'],\n",
       "  'reaction': ['hepatocellular carcinoma', 'prostate cancer']},\n",
       " {'pmid': 24445293,\n",
       "  'sentence': \"Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, RÃ¸der MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study\",\n",
       "  'text_type': 'title',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['prostate cancer', 'prostate cancer']},\n",
       " {'pmid': 24488810,\n",
       "  'sentence': 'We consider the following aspects of CD34+ SFCs: A) The confusing terms applied to this cell type, often combining the prefix CD34 with numerous names, including fibroblasts, fibrocytes, dendrocytes, keratocytes, telocytes and stromal, dendritic, adventitial, supraadventitial, perivascular, paravascular and delimiting cells; B) Changes in their immunophenotype, e.g., loss of CD34 expression and gain of other markers, such as those defining mesenchymal and derivate cells (myofibroblasts, osteoblasts, chondroblasts, adipocytes); C) Morphology (elongated or triangular cell body and thin, moniliform, bipolar or multipolar cytoplasmic processes), immunohistochemistry (co-expression of and changes in molecular expression) and structure (characteristics of nucleus and cytoplasmic organelles, and points of contact and junctions in quiescent and activated stages by light and electron microscopy); D) Location and distribution in the vessels (adventitia or external layer), in the tissues (connective, adipose, blood, muscle and nervous) and in the organs and systems (skin, oral cavity and oropharynx, respiratory, digestive, urinary, male, female, endocrine and lymphoid systems, serosal and synovial membranes, heart, eye and meninges); E) Origin from the mesoderm and cranial neural crest in the embryo, and from stem cells (themselves or other cells) and/or peripheral blood pluripotent stem cells (circulating progenitor cells) in post-natal life; F) Functions, such as synthesis of different molecules, progenitor of mesenchymal cells, immunomodulation, parenchymal regulation (growth, maturation and differentiation of adjacent cells), induction of angiogenesis, scaffolding support of other cells and phagocytic properties.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['growth']},\n",
       " {'pmid': 24586796,\n",
       "  'sentence': 'We found that: 1) MF approaches are more efficient than the MB method when nonlinear components are present, while the reverse situation holds in presence of high dimensional embedding spaces; 2) the CE method is the least powerful in detecting age-related trends; 3) the association of HP complexity on age suggests an impairment of cardiac regulation and response to STAND; 4) the relation of SAP complexity on age indicates a gradual increase of sympathetic activity and a reduced responsiveness of vasomotor control to STAND; 5) the association from SAP to HP on age during STAND reveals a progressive inefficiency of baroreflex; 6) the reduced connection from HP to SAP with age might be linked to the progressive exploitation of Frank-Starling mechanism at REST and to the progressive increase of peripheral resistances during STAND; 7) at REST the diminished association from RESP to HP with age suggests a vagal withdrawal and a gradual uncoupling between respiratory activity and heart; 8) the weakened connection from RESP to SAP with age might be related to the progressive increase of left ventricular thickness and vascular stiffness and to the gradual decrease of respiratory sinus arrhythmia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['sinus arrhythmia', 'arrhythmia']},\n",
       " {'pmid': 24599206,\n",
       "  'sentence': 'â¤ Negative results on culture still pose a real challenge in the diagnosis of periprosthetic joint infection.â¤ There are numerous reasons for the inability to isolate the infecting organism from the affected joint, the most important of which is the administration of antibiotics prior to obtaining culture samples.â¤ For patients suspected of having a periprosthetic joint infection, antibiotics should not be given until the diagnosis is confirmed or aspiration of the joint should be delayed for at least two weeks after the last dose of antibiotics.â¤ Other strategies that can be used to enhance the likelihood of obtaining a positive result on culture include expeditious transport of culture samples, placement of a tissue or fluid sample in the appropriate medium, implant sonication, and prolonging the incubation period of the samples to two or three weeks.â¤ In patients in whom the prerevision aspiration has not yielded an infecting organism, yet the clinical picture is consistent with periprosthetic joint infection, a minimum of three to five tissue culture samples are recommended at the time of revision surgery.â¤ Biomarkers and molecular techniques, such as polymerase chain reaction identification of bacterial DNA, may play an increasing role in the future in the diagnosis of periprosthetic joint infection, when standardized techniques have not identified an infecting organism.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['infection',\n",
       "   'aspiration',\n",
       "   'aspiration',\n",
       "   'infection',\n",
       "   'infection']},\n",
       " {'pmid': 24613419,\n",
       "  'sentence': 'Microcirculatory responses to acetylcholine [Ach, an endothelium-dependent vasodilator; 10(-8)M - *123.3Â±7.5% (C), 119.5Â±1.3% (EC), *98.1Â±3.2% (F) and 133.6Â±17.2% (EF); 10(-6)M - *133.0Â±4.1% (C), 135.6Â±4.3% (EC), *103.4Â±4.3% (F) and 134.1Â±5.9% (EF); 10(-4)M - *167.2Â±5.0% (C), 162.8Â±5.4% (EC), *123.8Â±6.3% (F) and 140.8Â±5.0% (EF)] and to sodium nitroprusside [SNP, an endothelium-independent vasodilator; 10(-8)M - 118.8Â±6.8% (C), 114.0Â±5.0% (EC), 100.2Â±2.9% (F), 104.9Â±4.4% (EF); 10(-6)M - 140.6Â±11.7% (C), 141.7Â±5.5% (EC), 125.0Â±4.7% (F), 138.3Â±2.8% (EF); 10(-4)M - 150.4Â±10.9% (C), 147.9Â±6.5% (EC), 139.2Â±7.3% (F), 155.9Â±4.7% (EF)] and macromolecular permeability increase induced by 30 min ischemia/reperfusion (I/R) procedure [14.4Â±3.5 (C), 30.0Â±1.9 (EC), *112.0Â±8.8 (F) and *22.4Â±0.9 leaks/cm(2) (EF)] have shown that endothelium-dependent vasodilatation was significantly reduced and I/R induced macromolecular permeability augmented in sedentary fructose (F) subgroup and both improved after AET.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['vasodilatation']},\n",
       " {'pmid': 24679929,\n",
       "  'sentence': 'Risk factors associated with achieving reproductive targets depended on (1) increased metabolic activity of the liver (increased glutamate dehydrogenase at calving and increased Î³-glutamyl transpeptidase in wk 4), (2) a competent immune system (increased neutrophils in wk 1; decreased Î±1-acid glycoprotein in wk 1, 2, and 3), (3) an endocrine system that was capable of responding by producing sufficient triiodothyronine in wk 2 and increased insulin-like growth factor I in wk 3 and 4, (4) a lower negative energy balance status (decreased nonesterified fatty acid concentration in wk 1; decreased Î²-hydroxybutyrate concentration in wk 2; BCS loss between calving and d 28 pp <0.5), (5) good reproductive tract health [normal uterine scan at d 45 pp; clear vaginal mucus discharge at first ovulation and at d 45 pp; resumed ovarian cyclicity by the end of the voluntary waiting period (â‰¥ d 35 pp)], and (6) adequate diet (to ensure increased glutathione peroxidase in wk 2 and 3 and increased magnesium in wk 4).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine', 'magnesium'],\n",
       "  'reaction': ['insulin-like growth factor',\n",
       "   'insulin-like growth factor',\n",
       "   'growth',\n",
       "   'energy',\n",
       "   'discharge']},\n",
       " {'pmid': 24754479,\n",
       "  'sentence': 'The most important revisions are the following: (1) ongoing efficient treatment at confirmed pregnancy may, with a few exceptions, be continued; (2) if treatment is initiated during pregnancy, the recommended first-line therapy is essentially the same as for non-pregnant women; (3) raltegravir may be added to achieve rapid reduction in HIV RNA; (4) vaginal delivery is recommended if at > 34 gestational weeks and HIV RNA is < 50 copies/ml and no obstetric contraindications exist; (5) if HIV RNA is < 50 copies/ml and delivery is at > 34 gestational weeks, intravenous zidovudine is not recommended regardless of the delivery mode; (6) if HIV RNA is > 50 copies/ml close to delivery, it is recommended that the mother should undergo a planned caesarean section, intravenous zidovudine, and oral nevirapine, and the infant should receive single-dose nevirapine at 48-72 h of age and post-exposure prophylaxis with 2 drugs; (7) if delivery is preterm at < 34 gestational weeks, a caesarean section delivery should if possible be performed, with intravenous zidovudine and oral nevirapine given to the mother, and single-dose nevirapine given to the infant at 48-72 h of age, as well as post-exposure prophylaxis with 2 additional drugs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['zidovudine', 'raltegravir'],\n",
       "  'reaction': ['pregnancy',\n",
       "   'pregnancy',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'caesarean section',\n",
       "   'infant',\n",
       "   'prophylaxis',\n",
       "   'delivery',\n",
       "   'caesarean section',\n",
       "   'delivery',\n",
       "   'infant',\n",
       "   'prophylaxis']},\n",
       " {'pmid': 24825433,\n",
       "  'sentence': 'Our hypothesis was verified by CAMK1 functional regulation subnetwork containing positive regulation of calcium ion transport via voltage gated calcium channel, cell proliferation, DNA repair, exocytosis, I-kappaB kinase/NF-kappaB cascade, immunoglobulin-mediated immune response, mast cell activation, natural killer cell-mediated cytotoxicity directed against tumor cell target, protein ubiquitination, sodium ion transport, survival gene product activity, T cell-mediated cytotoxicity, transcription, transcription from RNA polymerase II promoter, transcription initiation from RNA polymerase II promoter, transcription via serum response element binding, exit from mitosis, ubiquitin ligase activity during mitotic cell cycle, regulation of angiogenesis, apoptosis, cell growth, cell proliferation, cyclin-dependent protein kinase activity, gene expression, insulin secretion, steroid biosynthesis, transcription from RNA polymerase II promoter, transcription from RNA polymerase III promoter, cell cycle, cell migration, DNA recombination, and protein metabolism; also by CAMK1 negative functional regulation subnetwork including negative regulation of apoptosis, cell proliferation, centriole replication, fatty acid biosynthesis, lipoprotein lipase activity, MAPK activity, progression through cell cycle, transcription, transcription from RNA polymerase II promoter, cell growth, phosphorylation, and ubiquitin ligase activity during mitotic cell cycle in HCC.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium', 'calcium'],\n",
       "  'reaction': ['apoptosis',\n",
       "   'growth',\n",
       "   'apoptosis',\n",
       "   'lipase',\n",
       "   'lipase',\n",
       "   'growth']},\n",
       " {'pmid': 24973132,\n",
       "  'sentence': 'Maternal education (adjusted odds ratio [aOR]CS = 0.65; aORAPOs = 0.79) and history of syphilis (aORCS = 0.28; aORAPOs = 0.61), as well as paternal age (aORCS = 0.62; aORAPOs = 0.86) and education (aORCS = 0.66; aORAPOs = 0.86) were negatively associated with CS and APOs, but maternal unmarried status (aORCS = 1.95; aORAPOs = 2.61), inadequate antenatal care (ANC) (aORCS = 3.61; aORAPOs = 1.79), more sexual partners (aORCS = 1.51; aORAPOs = 1.39), every week of delay in treatment (aORCS = 2.82; aORAPOs = 1.27), higher baseline titers of nontreponemal antibodies (aORCS = 5.65; aORAPOs = 1.47), early syphilis (aORCS = 23.24; aORAPOs = 26.95), and non-penicillin treatment (aORCS = 3.00; aORAPOs = 2.16), as well as paternal history of cocaine use (aORCS = 2.70; aORAPOs = 2.44) and positive (aORCS = 4.14; aORAPOs = 1.50) or unknown (aORCS = 2.37; aORAPOs = 2.06) status of syphilis increased the risk of CS and APOs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['syphilis', 'syphilis', 'syphilis']},\n",
       " {'pmid': 25039193,\n",
       "  'sentence': 'Serotonin and dopamine, which are characterized by weak negative correlation in the right rear temporal region of ordinary person group, are characterized by strong negative correlation in the other encephalic regions and the whole encephalic (ordinary person group except the right rear temporal region: the range of [r] is [0.82, 0.92], P < 0.01)/(depression patients group:the range of [r] is [0.88, 0.94], P < 0.01); acetylcholine and norepinephrine, in the whole and various encephalic region are characterized by middle negative correlation(ordinary person group:the range of [r] is [0.39, 0.76], P < 0.01 or P < 0.05)/(depression patients group: the range of [Ir] is [0.56, 0.64], P < 0.01); depression neurotransmitters and excited neurotransmitters are characterized by middle strong negative correlation (ordinary person group: the range of [r] is [0.57, 0.80], P < 0.01)/(depression patients group: the range of [r] is [0.68, 0.78], P < 0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['depression', 'depression', 'depression', 'depression']},\n",
       " {'pmid': 25129838,\n",
       "  'sentence': 'Various medical conditions, disorders, and syndromes exhibit predictable-in-time diurnal and 24\\xa0h\\xa0patterning in the signs, symptoms, and grave nonfatal and fatal events, e.g., respiratory ones of viral and allergic rhinorrhea, reversible (asthma) and non-reversible (bronchitis and emphysema) chronic obstructive pulmonary disease, cystic fibrosis, high altitude pulmonary edema, and decompression sickness; cardiac ones of atrial premature beats and tachycardia, paroxysmal atrial fibrillation, 3rd degree atrial-ventricular block, paroxysmal supraventricular tachycardia, ventricular premature beats, ventricular tachyarrhythmia, symptomatic and non-symptomatic angina pectoris, Prinzmetal vasospastic variant angina, acute (non-fatal and fatal) incidents of myocardial infarction, sudden cardiac arrest, in-bed sudden death syndrome of type-1 diabetes, acute cardiogenic pulmonary edema, and heart failure; vascular and circulatory system ones of hypertension, acute orthostatic postprandial, micturition, and defecation hypotension/syncope, intermittent claudication, venous insufficiency, standing occupation leg edema, arterial and venous branch occlusion of the eye, menopausal hot flash, sickle cell syndrome, abdominal, aortic, and thoracic dissections, pulmonary thromboembolism, and deep venous thrombosis, and cerebrovascular transient ischemic attack and hemorrhagic and ischemic stroke.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['menopausal', 'cardiac'],\n",
       "  'reaction': ['asthma',\n",
       "   'bronchitis',\n",
       "   'emphysema',\n",
       "   'cystic fibrosis',\n",
       "   'fibrosis',\n",
       "   'tachycardia',\n",
       "   'atrial fibrillation',\n",
       "   'supraventricular tachycardia',\n",
       "   'tachycardia',\n",
       "   'ventricular tachyarrhythmia',\n",
       "   'tachyarrhythmia',\n",
       "   'angina pectoris',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'cardiac arrest',\n",
       "   'sudden death',\n",
       "   'death',\n",
       "   'hypertension',\n",
       "   'intermittent claudication',\n",
       "   'venous thrombosis',\n",
       "   'thrombosis']},\n",
       " {'pmid': 25294267,\n",
       "  'sentence': 'The key findings are: a) rabeprazole, the only PPI that had few studies in this field, is effective in the prevention of gastric ulcers; b) famotidine could also be effective in the prevention of complications by AAS; c) the new competitive inhibitors of the acid potassium pump are effective (as much as PPIs) on the recurrence of peptic ulcers by ASA; d) early endoscop (<8 h) in non-variceal upper gastrointestinal bleeding seems to offer no better results than those made in the first 24 h; e) endoscopic therapy in Forrest 1a ulcers does not obliterate the bleeding artery in 30% of cases and is the cause of bleeding recurrence; f) alternative therapies with glue or clotting products are being increasingly used in endoscopic therapy of gastrointestinal bleeding; g) liberal administration of blood in the GI bleeding is associated with poor prognosis; h) lesions of the small intestine are frequent cause of gastrointestinal bleeding when upper endoscopy shows no positive stigmata; and i) capsule endoscopy studies have high performance in gastrointestinal bleeding of obscure origin, if performed early in the first two days after the beginning of the bleeding episode.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium', 'rabeprazole', 'famotidine'],\n",
       "  'reaction': ['endoscopy', 'endoscopy']},\n",
       " {'pmid': 25305669,\n",
       "  'sentence': 'Urea, creatinine, total cholesterol (TC), triglycerides (TG) (mg/dL), proteinuria (mg/24 h) (Sham, n = 31; Sham + NAC, n = 20; CKD, n = 74; CKD + NAC, n = 32), total AGE and pentosidine (n = 8; fluorescence arbitrary unit) and TBARS (n = 7; nmoL/mL) were higher in CKD (122 Â± 8; 0.9 Â± 0.07; 151 Â± 6; 83 Â± 4; 46 Â± 2.5; 32,620 Â± 673; 16,700 Â± 1,370; 6.6 Â± 0.5, respectively) and in CKD + NAC (91.4 Â± 5; 0.6 Â± 0.02; 126 Â± 7.5; 73 Â± 6; 51 Â± 3.5; 24,720 Â± 1,114; 10,080 Â± 748; 4.5 Â± 0.5, respectively) in comparison to Sham (41 Â± 0.9; 0.4 Â± 0.03; 76 Â± 2.7; 51.5 Â± 3; 14 Â± 0.9; 21,750 Â± 960; 5,314 Â± 129; 2.0 Â± 0.2, respectively; p < 0.001) and Sham + NAC (40 Â± 0.9; 0.3 Â± 0.02; 76 Â± 2.6; 68 Â± 4; 18.4 Â± 1.5; 20,040 Â± 700; 5,050 Â± 267; 1.8 Â± 0.2, respectively; p < 0.001).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nac', 'cholesterol'],\n",
       "  'reaction': ['proteinuria']},\n",
       " {'pmid': 25347986,\n",
       "  'sentence': 'Among 372 pathogenic bacteria, there were 95 cases with Gram-positive cocci, the percentage was 15.32 %; there were 277 cases with Gram-negative bacilli, the percentage was 59.95 %; there were 54 cases with fungus, the percentage was 14.51 %; the common Gram-positive cocci included Staphylococcus aureus, Staphylococcus haemolyticus and Staphylococcus epidermidis, with percentages of 15.32 %, 2.96 % and 4.30 % respectively; the common Gram-negative bacilli included Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae, with percentages of 23.92 %, 14.25 % and 9.95 % respectively; the highest drug resistance rates of Staphylococcus aureus were 100.00 % to penicillin, erythrocin and oxacillin, the highest drug resistance rate of Staphylococcus epidermidis was 87.50 % to erythrocin, the highest drug resistance rate of Staphylococcus haemolyticus was 100.00 % to penicillin and erythrocin, the lowest drug resistance rates of three Gram-negative bacilli were 0 % to teicoplanin and vancomycin; the highest drug resistance rates of Escherichia coli were 100.00 % to ceftriaxone and ticarcillin, and the lowest drug resistance rate was 11.32 % to ciprofloxacin; the highest drug resistance rate of Pseudomonas aeruginosa was 100.00 % to ceftriaxone, and the lowest drug resistance rate was 22.47 % to imipenem; the highest drug resistance rate of Klebsiella pneumoniae was 81.08 % to aztreonam, and the lowest drug resistance rate was 0.00 % to imipenem.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['imipenem',\n",
       "   'oxacillin',\n",
       "   'penicillin',\n",
       "   'ciprofloxacin',\n",
       "   'ticarcillin',\n",
       "   'teicoplanin',\n",
       "   'vancomycin'],\n",
       "  'reaction': ['drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance',\n",
       "   'drug resistance']},\n",
       " {'pmid': 25370778,\n",
       "  'sentence': 'Drug-induced ABDs can be classified into five different categories in terms of their pathophysiology: (1) metabolic acidosis caused by acid overload, which may occur through accumulation of acids by endogenous (e.g., lactic acidosis by biguanides, propofol-related syndrome) or exogenous (e.g., glycol-dependant drugs, such as diazepam or salicylates) mechanisms or by decreased renal acid excretion (e.g., distal renal tubular acidosis by amphotericin B, nonsteroidal anti-inflammatory drugs, vitamin D); (2) base loss: proximal renal tubular acidosis by drugs (e.g., ifosfamide, aminoglycosides, carbonic anhydrase inhibitors, antiretrovirals, oxaliplatin or cisplatin) in the context of Fanconi syndrome; (3) alkalosis resulting from acid and/or chloride loss by renal (e.g., diuretics, penicillins, aminoglycosides) or extrarenal (e.g., laxative drugs) mechanisms; (4) exogenous bicarbonate loads: milk-alkali syndrome, overshoot alkalosis after bicarbonate therapy or citrate administration; and (5) respiratory acidosis or alkalosis resulting from drug-induced depression of the respiratory center or neuromuscular impairment (e.g., anesthetics, sedatives) or hyperventilation (e.g., salicylates, epinephrine, nicotine).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['oxaliplatin', 'diazepam', 'cisplatin'],\n",
       "  'reaction': ['metabolic acidosis',\n",
       "   'acidosis',\n",
       "   'lactic acidosis',\n",
       "   'acidosis',\n",
       "   'renal tubular acidosis',\n",
       "   'acidosis',\n",
       "   'vitamin d',\n",
       "   'renal tubular acidosis',\n",
       "   'acidosis',\n",
       "   'fanconi syndrome',\n",
       "   'fanconi syndrome',\n",
       "   'alkalosis',\n",
       "   'milk-alkali syndrome',\n",
       "   'alkalosis',\n",
       "   'respiratory acidosis',\n",
       "   'acidosis',\n",
       "   'alkalosis',\n",
       "   'depression',\n",
       "   'hyperventilation',\n",
       "   'epinephrine']},\n",
       " {'pmid': 25396269,\n",
       "  'sentence': 'Serum 25(OH)D and SNPs (n = 960) related to genes with relevance for skin pigmentation (tyrosinase [TYR], TYR-related protein 1 [TYRP1], dopachrome tautomerase [DCT], oculocutaneous albinism II [OCA2], two pore segment channel 2 [TPCN2], solute carrier family 24 A4 [SLC24A4], solute carrier family 45 A2 [SLC45A2], agouti signalling peptide [ASIP], cyclic AMP-dependent transcription factor [ATF1], microphthalmia-associated transcription factor [MITF], proopiomelanocortin [POMC], cAMP-dependent protein kinase catalytic subunit beta [PRKACB], cAMP-dependent protein kinase catalytic subunit gamma [PRKACG], cAMP-dependent protein kinase type I-alpha regulatory subunit [PRKAR1A], cAMP-dependent protein kinase type II-alpha regulatory subunit [PRKAR2A], cAMP-dependent protein kinase type II-beta regulatory subunit [PRKAR2B], tubulin beta-3 chain/melanocortin receptor 1 [TUBB3/MC1R], Cadherin-1 [CDH1], catenin beta 1 [CTNNB1], Endothelin 1 [EDN1], endothelin 3 [EDN3], endothelin receptor type B [EDNRB], fibroblast growth factor 2 [FGF2], KIT, KIT ligand [KITLG], nerve growth factor [NGF], interferon regulatory factor 4 [IRF4], exocyst complex component 2 [EXOC2], and tumor protein 53 [TP53]) were analyzed in a cohort of participants of the Ludwigshafen Risk and Cardiovascular Health Study (n = 2970).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['growth', 'growth']},\n",
       " {'pmid': 25397904,\n",
       "  'sentence': \"For this same outcome, comparison of desloratadine versus placebo in the intermediate term (5 mg) (RR 37.00, 95% CI 2.31 to 593.70) and in the short term (20 mg) (RR 15.97, 95% CI 1.04 to 245.04)favoured desloratadine, but no differences were seen between 5 mg and 10 mg for short-term treatment.Levocetirizine 20 mg per day (short-term) was more effective for complete suppression of urticaria compared with placebo (RR 20.87,95% CI 1.37 to 317.60), and at 5 mg was effective in the intermediate term (RR 52.88, 95% CI 3.31 to 843.81) but not in the shortterm, nor was 10 mg effective in the short term.Rupatadine at 10 mg and 20 mg in the intermediate term achieved a 'good or excellent response' compared with placebo (RR 1.35,95% CI 1.03 to 1.77).Loratadine (10 mg) versus placebo (RR 1.86, 95% CI 0.91 to 3.79) and loratadine (10 mg) versus cetirizine (10 mg) (RR 1.05, 95%CI 0.76 to 1.43) over short-term and intermediate-term treatment showed no significant difference for 'good or excellent response' or for complete suppression of urticaria, respectively.Loratadine (10 mg) versus desloratadine (5 mg) (intermediate-term) showed no statistically significant difference for complete suppression of urticaria (RR 0.91, 95% CI 0.78 to 1.06) or for 'good or excellent response' (RR 1.04, 95% CI 0.64 to 1.71).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['desloratadine', 'loratadine'],\n",
       "  'reaction': ['urticaria', 'urticaria', 'urticaria']},\n",
       " {'pmid': 25397904,\n",
       "  'sentence': \"For loratadine(10 mg) versus mizolastine (10 mg) (intermediate-term), no statistically significant difference was seen for complete suppression of urticaria (RR 0.86, 95% CI 0.64 to 1.16) or for 'good or excellent response' (RR 0.88, 95% CI 0.55 to 1.42).Loratadine (10mg) versus emedastine (2mg) (intermediate-term) showed no statistically significant difference for complete suppression(RR 1.04, 95% CI 0.78 to 1.39) or for 'good or excellent response' (RR 1.09, 95% CI 0.96 to 1.24); the quality of the evidence was moderate for this comparison.No difference in short-term treatment was noted between loratadine (10mg) and hydroxyzine (25mg) in terms of complete suppression(RR 1.00, 95% CI 0.32 to 3.10).When desloratadine (5 to 20 mg) was compared with levocetirizine (5 to 20 mg), levocetirizine appeared to be the more effective (P value < 0.02).In a comparison of fexofenadine versus cetirizine, more participants in the cetirizine group showed complete suppression of urticaria(P value < 0.001).Adverse events leading to withdrawals were not significantly different in the following comparisons: cetirizine versus placebo at 10 mg and 20 mg (RR 3.00, 95% CI 0.68 to 13.22); desloratadine 5 mg versus placebo (RR 1.46, 95% CI 0.42 to 5.10); loratadine 10 mg versus mizolastine 10 mg (RR 0.38, 95% CI 0.04 to 3.60); loratadine 10mg versus emedastine 2mg (RR 1.09, 95%CI 0.07 to 17.14);cetirizine 10 mg versus hydroxyzine 25 mg (RR 0.78, 95% CI 0.25 to 2.45); and hydroxyzine 25 mg versus placebo (RR 3.64, 95%CI 0.77 to 17.23), all intermediate term.No difference was seen between loratadine 10 mg versus mizolastine 10 mg in the proportion of participants with at least 50%improvement in quality of life (RR 3.21, 95% CI 0.32 to 32.33).Authors' conclusions Although the results of our review indicate that at standard doses of treatment, several antihistamines are effective when compared with placebo, all results were gathered from a few studies or, in some cases, from single-study estimates.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['desloratadine', 'loratadine'],\n",
       "  'reaction': ['urticaria', 'urticaria', 'quality of life']},\n",
       " {'pmid': 25403379,\n",
       "  'sentence': 'This paper reviews the rich experiences of advanced schistosomiasis research and control in China, including that the epidemiology researches confirm there is a family aggregation of advanced schistosomiasis and advanced schistosomiasis patients have no significance to the schistosomiasis transmission in transmission-interrupted areas but still are an infection source in endemic areas; pathogenic mechanism researches verify that genetic factors and immunoregulation play important roles in the disease developing process; ultrasound image examinations are used not only in the diagnosis and differential diagnosis of advanced schistosomiasis but also in the guidance of treatment and evaluation of therapeutic effects and, furthermore, in the risk predictions of portal hypertension and upper gastrointestinal hemorrhage; clinical practices demonstrate that praziquantel can be used in most of advanced schistosomiasis patients, and the therapy not only can interrupt the schistosomiasis transmission somewhat but also is favorable for liver fibrosis improvement; the ascetic fluid concentration afflux is used in the therapy for obstinate ascites, and endoscopic varices ligation is used in the treatment of upper gastrointestinal bleeding, and both have good effects; hundreds and thousands of severe splenomegaly advanced schistosomiasis patients received splenectomy, and the long-term survival rate is more than 90%, most of them are basically cured from the disease and their labor force recovers, some dwarf patients begin growing and developing again, and some sterile women became fertile; the researches of traditional Chinese medicine in the treatment of liver fibrosis have made progress, such as Cordyceps sinensis showing some anti-fibrosis effect in the animal experiments and primary clinical trials; the animal experiments and epidemiological investigations indicate that schistosome infection is one of the carcinogenesis risk factors, especially for liver cancer.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['praziquantel'],\n",
       "  'reaction': ['schistosomiasis',\n",
       "   'schistosomiasis',\n",
       "   'schistosomiasis',\n",
       "   'schistosomiasis',\n",
       "   'infection',\n",
       "   'schistosomiasis',\n",
       "   'portal hypertension',\n",
       "   'hypertension',\n",
       "   'schistosomiasis',\n",
       "   'schistosomiasis',\n",
       "   'fibrosis',\n",
       "   'ascites',\n",
       "   'splenomegaly',\n",
       "   'schistosomiasis',\n",
       "   'splenectomy',\n",
       "   'fibrosis',\n",
       "   'infection']},\n",
       " {'pmid': 25560380,\n",
       "  'sentence': 'Results at 12 months showed: MACE 11.8% vs. 7.7% (P\\u2009=\\u2009not significant [ns]), composite major adverse cardiac and cerebrovascular events (MACCE) 12.4% vs. 11.5% (P\\u2009=\\u2009ns), all-cause death 2.7% vs. 8.6% (P\\u2009<\\u20090.05), cardiac death 2.7% vs. 1.9% (P\\u2009=\\u2009ns), target vessel revascularization (TVR) 9.1% vs. 6.7% (P\\u2009=\\u2009ns), acute myocardial infarction (AMI) 3.8% vs. 2.9% (P\\u2009=\\u2009ns), cerebrovascular events (CVA) 0.5% vs. 1.0% (P\\u2009=\\u2009ns); and results at 24 months showed: MACE 17.7% vs. 18.3% (P\\u2009=\\u2009ns), MACCE 21.5% vs. 26.0% (P\\u2009=\\u2009ns), all-cause death 4.3% vs. 14.4% (P\\u2009<\\u20090.01), cardiac death 3.2% vs. 1.9% (P\\u2009=\\u2009ns), TVR 14.0% vs. 16.3% (P\\u2009=\\u2009ns), AMI 5.4% vs. 5.8% (P\\u2009=\\u2009ns), CVA 3.2% vs. 2.9% (P\\u2009=\\u2009ns) for non-end-stage renal disease (ESRD) and dialysis group, respectively.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['death',\n",
       "   'cardiac death',\n",
       "   'death',\n",
       "   'acute myocardial infarction',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'death',\n",
       "   'cardiac death',\n",
       "   'death',\n",
       "   'dialysis']},\n",
       " {'pmid': 25591588,\n",
       "  'sentence': 'The hypothetical mechanisms, beginning with the strongest, are summarized as follows: (i) rs667128 alters the role of taste receptor, type 2, member 8 (TAS2R8) in taste receptor activity and taste transduction pathways (p < 0.001, false discovery rate (FDR) < 0.001; p\\xa0= 0.001, FDR = 0.012, respectively), (ii) rs619381 modulates the effect of taste receptor, type 2, member 7 (TAS2R7) on taste receptor activity and taste transduction (p < 0.001, FDR < 0.001; p\\xa0= 0.001, FDR = 0.012), (iii) rs1033583 modulates delta-like protein 1 (DLL1), regulating cell adhesion and segment specification (p < 0.001, FDR = 0.011; p\\xa0= 0.001, FDR = 0.032), (iv) rs2232580 affects the role of lipopolysaccharide binding protein (LBP) in the response to lipopolysaccharide, positive regulation of interleukin-6 production, acute inflammatory response, and in macrophage activation (0.002 â‰¤ p\\xa0â‰¤ 0.013; 0.012 â‰¤ FDR â‰¤ 0.030), and (v) rs4644 and rs4652 regulate lectin, galactoside-binding, soluble, 3 (LGALS3), affecting immunoglobulin binding (p = 0.010; FDR = 0.040).Using the ICSNPathway to analyze glioma GWAS data, 6 candidate SNPs, 5 genes (TAS2R8, TAS2R7, DLL1, LBP, and LGALS3), and 9 pathways that may contribute to the susceptibility of glioma were identified.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['adhesion', 'glioma', 'glioma']},\n",
       " {'pmid': 25657639,\n",
       "  'sentence': 'The results indicated that; (1) under normal conditions, Lucifer Yellow flows from cell to cell through gap junctions; (2) the intracellular dialysis of renin (100\\u2009nM) disrupts chemical communication - an effect enhanced by simultaneous administration of angiotensinogen (100\\u2009nM); (3) enalaprilat (10(-9)\\u2009M) administered to the cytosol together with renin reduced drastically the uncoupling action of the enzyme; (4) aliskiren (10(-8)\\u2009M) inhibited the effect of renin on chemical communication; (5) the possible role of intracellular renin independently of angiotensin II (Ang II) was evaluated including the increase of the inward calcium current elicited by the enzyme and the possible role of oxidative stress on the disruption of cell communication; (6) the possible harmful versus the beneficial effect of intracellular renin during myocardial infarction was discussed; (7) the present results indicate that intracellular renin due to internalization or in situ synthesis causes a severe impairment of chemical communication in the heart resulting in derangement of metabolic cooperation with serious consequences for heart function.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['aliskiren', 'enalaprilat', 'calcium'],\n",
       "  'reaction': ['dialysis',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'stress',\n",
       "   'renin',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'renin']},\n",
       " {'pmid': 25678369,\n",
       "  'sentence': 'The results indicated that: 1) glucose flows easily from cell-to-cell through gap junctions; 2) high glucose solution (25 mM) disrupted chemical communication between cardiac cells and abolished the intercellular diffusion of glucose; 3) the effect of high glucose solution on the cell-to-cell diffusion of glucose was drastically reduced by Bis-1 (10(-9)M) which is a PKC inhibitor; 4) intracellular dialysis of Ang II (100 nM) or increment of intracellular calcium concentration (10(-8)M) also inhibited the intercellular diffusion of glucose; 5) high glucose enhances oxidative stress in heart cells; 6) calculation of gap junction permeability (Pj) (cm/s) indicated a value of 0.74Â±0.08Ã—10(-4) cm/s (5 animals) for the controls and 0.4Â±0.001Ã—10(-5) cm/s; n=35 (5 animals) (P<0.05) for cells incubated with high glucose solution for 24h; 7) measurements of Pj for cell pairs treated with high glucose plus Bis-1 (10(-9)M) revealed no significant change of Pj (P>0.05); 8) increase of intracellular Ca(2+) concentration (10(-8)M) drastically decreased Pj (Pj=0.3Â±0.003Ã—10(-5) cm/s).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'calcium'],\n",
       "  'reaction': ['dialysis', 'stress']},\n",
       " {'pmid': 25702463,\n",
       "  'sentence': 'The reaction of the cardiac (stroke volume and cardiac output) and peripheral blood volumes in the lower and upper limbs, abdominal and neck regions in response to the tilt-test before and during two hours after exercise (30 min, heart rate = 156 +/- 8 beats/min) was determined by impedance method: It is found that: (1) at baseline distribution of blood flow in favor of the neck-region in response to the tilt-test, in spite of the decrease in cardiac output, was more efficient in athletes, that was due to a large decrease in blood flow to the lower extremities, and increased blood flow in the neck region; (2) after exercise it was established symptoms of potential orthostatic intolerance: postural hypotension and tachycardia, reduced peripheral pulse blood volume, expressed in a standing position, and reduced effectiveness of the distribution of blood flow in the direction of the neck region; (3) the abilityto effectively distribute blood flow in favor of the neck region in athletes after exercise remained elevated, which was due to a large decrease in blood flow in the abdominal region at the beginning, and in the lower limbs at the end of the recovery period.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac output',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'cardiac output',\n",
       "   'orthostatic intolerance',\n",
       "   'hypotension',\n",
       "   'tachycardia',\n",
       "   'peripheral pulse']},\n",
       " {'pmid': 25892551,\n",
       "  'sentence': 'In electrophysiological experiments with unaltered synaptic transmission (muscles paralysed by blocking the voltage-dependent sodium channel of the muscle cells with Î¼-conotoxin GIIIB), we found that: (i) a collaborative action between different AR subtypes reduced synaptic depression at a moderate activity level (40\\xa0Hz); (ii) at high activity levels (100\\xa0Hz), endogenous adenosine production in the synaptic cleft was sufficient to reduce depression through A1 -type receptors (A1 Rs) and A2 A-type receptors (A2 A Rs); (iii) when the non-metabolizable 2-chloroadenosine (CADO) agonist was used, both the quantal content and depression were reduced; (iv) the protective effect of CADO on depression was mediated by A1 Rs, whereas A2 A Rs seemed to modulate A1 Rs; (v) ARs and mAChRs absolutely depended upon each other for the modulation of evoked and spontaneous acetylcholine release in basal conditions and in experimental conditions with CADO stimulation; (vi) the purinergic and muscarinic mechanisms cooperated in the control of depression by sharing a common pathway although the purinergic control was more powerful than the muscarinic control; and (vii) the imbalance of the ARs created by using subtype-selective and non-selective inhibitory and stimulatory agents uncoupled protein kinase C from evoked transmitter release.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal', 'sodium'],\n",
       "  'reaction': ['depression',\n",
       "   'depression',\n",
       "   'depression',\n",
       "   'depression',\n",
       "   'depression']},\n",
       " {'pmid': 25954730,\n",
       "  'sentence': 'Both fasting glucose and HgbA1C were negatively correlated with HDL-cholesterol (r = -0.287, p = 0.006; r = -0.261, p = 0.012), and positively correlated with age (r = 0.202, p = 0.008; r = 0.221, p = 0.035), waist circumference (r = 0.296, p = 0.005; r = 0.304, p = 0.004), diastolic blood pressure (DBP) (r = 0.206, p = 0.050; r = 0.225, p = 0.032), aspartate transaminase (AST) (r = 0.237, p = 0.024; r = 0.368, p < 0.0001), alanine transaminase (ALT) (r = 0.296, p = 0.004; r = 0.356, p = 0.001), lipid profiles including triglyceride (r = 0.372, p < 0.001; r = 0.208, p = 0.008), LDL-cholesterol (r = 0.315, p = 0.002; r = 0.373, p < 0.0001) and total cholesterol (r = 0.310, p = 0.003; r = 0.284, p = 0.006).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['fasting', 'waist circumference', 'blood pressure']},\n",
       " {'pmid': 26081614,\n",
       "  'sentence': 'The reasons for and against elective termination should be discussed with the patient (Grade 2C) In the case of presentation beyond 32\\xa0weeks gestation, it may be reasonable to deliver the foetus prior to commencement of chemotherapy (Grade 2C) Between 24 and 32\\xa0weeks, risks of foetal chemotherapy exposure must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C) The risk-benefit ratio must be carefully considered before using any drugs in pregnancy (Grade 1C) Where AML induction chemotherapy is delivered, a standard daunorubicin, cytarabine 3\\xa0+\\xa010 schedule should be used (Grade 1B) Chemotherapy should be dosed according to actual body weight and adjustments made for weight changes during treatment (Grade 1C) Quinolones, tetracyclines and sulphonamide use should be avoided in pregnancy (Grade 1B) Amphotericin B or lipid derivatives are the antifungal of choice in pregnancy (Grade 2C) Cytomegalovirus (CMV)-negative blood products should be administered during pregnancy regardless of CMV serostatus (Grade 1B) A course of corticosteroids should be considered if delivery is anticipated between 24 and 35\\xa0weeks gestation, given over a 48-h period during the week prior to delivery (Grade 1A) Use of magnesium sulphate should be considered in the 24\\xa0h prior to delivery if this is before 30\\xa0weeks gestation (Grade 1A) Where possible, delivery should be planned for a time when the woman is at least 3\\xa0weeks post-chemotherapy to minimize risk of neonatal myelosuppression (Grade 1C) Planned delivery is easier to manage than spontaneous labour; induction of labour is usually advised (Grade 2C) Epidural analgesia should be avoided in a woman who is significantly thrombocytopenic (platelet count <80\\xa0Ã—\\xa010(9) /l) and/or neutropenic (white blood cell count <1\\xa0Ã—\\xa010(9) /l): (Grade 1C) Elective caesarean section should only be recommended for obstetric indications (Grade 2C) Antibiotics should be administered during and after premature rupture of membranes and delivery (Grade 1C).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['daunorubicin', 'magnesium', 'cytarabine'],\n",
       "  'reaction': ['chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'delivery',\n",
       "   'pregnancy',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'pregnancy',\n",
       "   'pregnancy',\n",
       "   'pregnancy',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'delivery',\n",
       "   'platelet count',\n",
       "   'platelet count',\n",
       "   'caesarean section',\n",
       "   'delivery']},\n",
       " {'pmid': 26265069,\n",
       "  'sentence': 'We performed a pooled analysis of outcomes following PCI: incidence of cardiac arrest [odds ratio (OR) of 0.91; 95% confidence interval (CI): 0.76-1.09; P = 0.3], stroke (OR of 1.71; 95% CI: 0.37-1.37; P = 0.3), cardiogenic shock (OR of 1.02; 95% CI: 0.92-1.14; P = 0.6), reinfarction (OR of 0.95; 95% CI: 0.81-1.14; P = 0.5) and mortality (OR of 1.04; 95% CI: 0.96-1.13; P = 0.3); and following CABG: incidence of atrial fibrillation (OR of 0.86; 95% CI: 0.70-1.05; P = 0.1), incidence of ventricular fibrillation (OR of 0.83; 95% CI: 0.62-1.13; P = 0.2), reinfarction (OR of 0.97; 95% CI: 0.74-1.27; P = 0.8), infection (OR of 1.04; 95% CI: 0.67-1.62; P = 0.8), length of intensive care unit stay (LIS) [standard mean differences (SMD) of -0.27; 95% CI: -0.40 to -0.14; P = 0.000], length of hospital stay (LHS) (SMD of -0.035; 95% CI: -0.12 to -0.05; P = 0.4) and mortality (OR of 0.72; 95% CI: 0.41-1.26; P = 0.2).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['cardiac arrest',\n",
       "   'cardiogenic shock',\n",
       "   'shock',\n",
       "   'atrial fibrillation',\n",
       "   'ventricular fibrillation',\n",
       "   'infection',\n",
       "   'intensive care']},\n",
       " {'pmid': 26423962,\n",
       "  'sentence': 'Compared with control group, body weight of rats in ACR group decreased by 11.3 % (P < 0.01), while in ACR + CP group body weight increased significantly by 8.3 % (P < 0.01) compared with ACR group by the end of the 4th week; gait score of rats in both ACR and ACR + CP groups increased significantly by 167 % and 100 % (P < 0.01) compared with control group, while it decreased significantly by 25.1 % (P < 0.01) in ACR + CP group compared with ACR group; the distance of hind limb splay in both ACR and ACR + CP groups increased by 76.7 % and 49.5 % (P < 0.01) compared with control group, while it decreased by 15.4 % (P < 0.01) in ACR + CP group compared with ACR group; calpain activity of spinal cord at ACR and ACR + CP groups increased significantly by 14.9 % and 10.0 % (P < 0.01) compared with control group, while it decreased 4.2 % (P < 0.01) in ACR + CP group compared with ACR group; compared with control group, the levels of light NF (NF-L), medium NF (NF-M) and heavy NF (NF-H) subunits increased by 81.2 %, 263.6 % and 22.6 % (P < 0.01) in the supernatant of ACR group in spinal cord tissue and increased by 28.4 %, 96.6 % and 10.6 % (P < 0.01) in ACR + CP group, while the levels of NF-L, NF-M and NF-H subunits decreased by 29.1 %, 45.9 % and 9.8 % (P < 0.01) in ACR + CP group compared with ACR group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight']},\n",
       " {'pmid': 26454123,\n",
       "  'sentence': 'We recommend the following: (1) perform routine screening during pregnancy for HBV infection with maternal HBsAg testing (grade 1A); (2) administer hepatitis B vaccine and HBV immunoglobulin within 12 hours of birth to all newborns of HBsAg-positive mothers or those with unknown or undocumented HBsAg status, regardless of whether maternal antiviral therapy has been given during the pregnancy (grade 1A); (3) In pregnant women with HBV infection, we suggest HBV viral load testing in the third trimester (grade 2B); (4) in pregnant women with HBV infection and viral load >6-8 log 10 copies/mL, HBV-targeted maternal antiviral therapy should be considered for the purpose of decreasing the risk of intrauterine fetal infection (grade 2B); (5) in pregnant women with HBV infection who are candidates for maternal antiviral therapy, we suggest tenofovir as a first-line agent (grade 2B); (6) we recommend that women with HBV infection be encouraged to breast-feed as long as the infant receives immunoprophylaxis at birth (HBV vaccination and hepatitis B immunoglobulin) (grade 1C); (7) for HBV infected women who have an indication for genetic testing, invasive testing (eg amniocentesis or chorionic villus sampling) may be offered-counseling should include the fact that the risk for maternal-fetal transmission may increase with HBV viral load >7 log 10 IU/mL (grade 2C); and (8) we suggest cesarean delivery not be performed for the sole indication for reduction of vertical HBV transmission (grade 2C).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['pregnancy',\n",
       "   'infection',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'pregnancy',\n",
       "   'infection',\n",
       "   'viral load',\n",
       "   'viral load',\n",
       "   'infection',\n",
       "   'viral load',\n",
       "   'viral load',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infant',\n",
       "   'hepatitis',\n",
       "   'hepatitis b',\n",
       "   'viral load',\n",
       "   'viral load',\n",
       "   'delivery']},\n",
       " {'pmid': 26611796,\n",
       "  'sentence': 'In this interdisciplinary study we discovered that: (1) normal human T cells express Kv1.1 voltage-gated potassium channel mRNA, and the Kv1.1 membrane-anchored protein channel; (2) Kv1.1 is expressed in most CD4(+)CD3(+) helper T cells (mean CD4(+)CD3(+)Kv1.1(+) T cells of 7 healthy subjects: 53.09\\xa0Â±\\xa022.17\\xa0%), but not in CD8(+)CD3(+) cytotoxic T cells (mean CD8(+)CD3(+)Kv1.1(+) T cells: 4.12\\xa0Â±\\xa03.04\\xa0%); (3) electrophysiological whole-cell recordings in normal human T cells revealed Kv currents; (4) Dendrotoxin-K (DTX-K), a highly selective Kv1.1 blocker derived from snake toxin, increases the rate of rise and decay of Kv currents in both resting and activated T cells, without affecting the peak current; (5) DTX-K by itself induces robust TNFÎ± production and secretion by normal human T cells, without elevating IFNÎ³, IL-4 and IL-10; (6) intact Ca(2+) channels are required for DTX-induced TNFÎ± secretion; (7) selective anti-Kv1.1 antibodies also induce by themselves TNFÎ± secretion; (8) DTX-K activates NFÎºB in normal human T cells via the unique non-canonical-pathway; (9) injection of Kv1.1-blocked human T cells to SCID mice, causes recruitment of resident mouse cells into the liver, alike reported after TNFÎ± injection into the brain.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['potassium'],\n",
       "  'reaction': ['injection', 'injection']},\n",
       " {'pmid': 26741817,\n",
       "  'sentence': 'Infected mice showed evident clinical changes beginning in the second week of infection (wpi) when compared to the noninfected group (NI): (1) animals in hunched postures, closed eyes, lowered ears, peeling skin, increased piloerection, prostration, and social isolation; (2) significant decrease in body weight (Inf: 26.2 Â± 2.6 g vs. NI: 34.2 Â± 2.5 g) and in chow (1.5 Â± 0.3 vs. 6.3 Â± 0.5 mg) and water (2.4 Â± 0.5 vs. 5.8 Â± 0.7 ml) intake; (3) significant decrease of spontaneous activity as locomotor parameters: distance (0.64 Â± 0.06 vs. 1.8 Â± 0.13 m), velocity (1.9 Â± 0.3 vs. 6.7 Â± 1.5 cm/sec), and exploratory behavior by frequency (1.0 Â± 0.5 vs. 5.7 Â± 1.0 events) and duration (1.4 Â± 0.3 vs. 5.1 Â± 0.5 sec in central arena region); (4) significant increase in the PR (41.7 Â± 8.7 vs. 27.6 Â± 1.9 msec) and QT intervals (39.7 Â± 2.0 vs. 27.5 Â± 4.0 msec), and a decreased cardiac frequency (505 Â± 52.8 vs. 774 Â± 17.8 msec), showing a marked sinus bradycardia and an atrioventricular block.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['infection',\n",
       "   'piloerection',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'sinus bradycardia',\n",
       "   'bradycardia',\n",
       "   'atrioventricular block']},\n",
       " {'pmid': 26770156,\n",
       "  'sentence': \"As the current article shows, boron has been proven to be an important trace mineral because it (1) is essential for the growth and maintenance of bone; (2) greatly improves wound healing; (3) beneficially impacts the body's use of estrogen, testosterone, and vitamin D; (4) boosts magnesium absorption; (5) reduces levels of inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor Î± (TNF-Î±); (6) raises levels of antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and glutathione peroxidase; (7) protects against pesticide-induced oxidative stress and heavy-metal toxicity; (8) improves the brains electrical activity, cognitive performance, and short-term memory for elders; (9) influences the formation and activity of key biomolecules, such as S-adenosyl methionine (SAM-e) and nicotinamide adenine dinucleotide (NAD(+)); (10) has demonstrated preventive and therapeutic effects in a number of cancers, such as prostate, cervical, and lung cancers, and multiple and non-Hodgkin's lymphoma; and (11) may help ameliorate the adverse effects of traditional chemotherapeutic agents.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['growth',\n",
       "   'wound',\n",
       "   'vitamin d',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'necrosis',\n",
       "   'stress',\n",
       "   'lymphoma']},\n",
       " {'pmid': 26820446,\n",
       "  'sentence': 'The various factors affecting eye growth are shown in 5 simulations: (1 - unregulated eye growth): blur feedback is rendered ineffective, as in the case of form deprivation, so there is only genetically pre-programmed eye growth, generally resulting in myopia; (2 - regulated eye growth): blur feedback regulation demonstrates the emmetropization process, with abnormally excessive or reduced eye growth leading to myopia and hyperopia, respectively; (3 - repeated near-far viewing): simulation of large-to-small change in blur size as seen in the accommodative stimulus/response function, and via IRDT as well as nearwork-induced transient myopia (NITM), leading to the development of myopia; (4 - neurochemical bulk flow and diffusion): release of dopamine from the inner plexiform layer of the retina, and the subsequent diffusion and relay of neurochemical cascade show that a decrease in dopamine results in a reduction of proteoglycan synthesis rate, which leads to myopia; (5 - Simulink model): model of genetically pre-programmed signaling and blur feedback components that allows for different input functions to simulate experimental manipulations that result in hyperopia, emmetropia, and myopia.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dopamine'],\n",
       "  'reaction': ['growth',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'myopia',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'myopia',\n",
       "   'myopia',\n",
       "   'myopia',\n",
       "   'myopia',\n",
       "   'myopia']},\n",
       " {'pmid': 26902990,\n",
       "  'sentence': 'We recommend the following: (1) that women with a diagnosis of primary CMV infection in pregnancy be advised that the risk of congenital infection is 30-50%, on average, and that the severity of infection varies widely (Best Practice); (2) for women suspected of having primary CMV infection in pregnancy, we recommend that diagnosis should be either by IgG seroconversion or with positive CMV IgM, positive IgG, and low IgG avidity (grade 1B); (3) amniocentesis is the best option as a prenatal diagnostic tool to detect fetal congenital CMV infection, performed >21 weeks of gestation and >6 weeks from maternal infection (grade 1C); (4) we do not recommend routine screening of all pregnant women for evidence of primary CMV infection at this time (grade 1B); and (5) we do not recommend antenatal treatment with ganciclovir or valacyclovir; and we recommend that any antenatal therapy, either with antivirals or CMV hyperimmune globulin, should only be offered as part of a research protocol (Best Practice).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ganciclovir', 'globulin', 'valacyclovir'],\n",
       "  'reaction': ['infection',\n",
       "   'pregnancy',\n",
       "   'congenital infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'pregnancy',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection']},\n",
       " {'pmid': 26944716,\n",
       "  'sentence': 'The results indicated that compared with optimal vitamin C supplementation, vitamin C deficiency (2.9 mg/kg diet) decreased lysozyme (LA) and acid phosphatase (ACP) activities, and complement 3 and complement 4 (C4) contents (P < 0.05), down-regulated the mRNA levels of antimicrobial peptides [liver expressed antimicrobial peptide (LEAP) 2A, LEAP-2B, hepcidin, Î²-defensin] and anti-inflammatory cytokines-related factors, interleukin (IL) 4/13A, IL-4/13B (only in head kidney), IL-10, IL-11, transforming growth factor (TGF) Î²1, TGF-Î²2, inhibitor of ÎºBÎ± and eIF4E-binding protein 1 (P < 0.05), and up-regulated pro-inflammatory cytokines-related factors, tumor necrosis factor Î±, interferon Î³2, IL-1Î², IL-6, IL-8, IL-12 P35 (only in spleen), IL-12 P40, IL-15, IL-17D, nuclear factor ÎºB p65, IÎºB kinases (IKKÎ±, IKKÎ², IKKÎ³), target of rapamycin and ribosomal protein S6 kinase 1 mRNA levels (P < 0.05) in the head kidney and spleen under injection fish of A. hydrophila, suggesting that vitamin C deficiency could decrease fish head kidney and spleen immunity and cause inflammation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['vitamin c deficiency',\n",
       "   'growth',\n",
       "   'necrosis',\n",
       "   'injection',\n",
       "   'vitamin c deficiency',\n",
       "   'inflammation']},\n",
       " {'pmid': 27015174,\n",
       "  'sentence': '(1) Dan Shen agents: tiny trends toward the improvement in different neurological outcomes (RR\\u200a=\\u200a1.16, 1.10, 1.23, 1.08, 1.12); (2) Mailuoning: a tiny trend toward improvement in the neurological outcome (RR\\u200a=\\u200a1.18); (3) Ginkgo biloba: tiny trends toward improvement in the neurological outcome (RR\\u200a=\\u200a1.18, MD\\u200a=\\u200a0.81); (4) Dengzhanhua: a tiny trend toward an improvement in neurological (RR\\u200a=\\u200a1.23); (5) Acanthopanax: a small positive (RR\\u200a=\\u200a1.17, 1.31) result on neurological improvement reported; (6) Chuanxiong-type preparations: neurological functional improved (MD\\u200a=\\u200a2.90);(7) Puerarin: no better effect on the rate of death or disability (OR\\u200a=\\u200a0.81, 95% CI 0.35-1.87); (8) Milk vetch: no better effect on the rate of death (OR\\u200a=\\u200a0.66, 95% CI: 0.11-2.83);(9) Qingkailing: rate of death reduced (OR\\u200a=\\u200a0.66, 95% CI: 0.11-2.83).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dan'],\n",
       "  'reaction': ['death', 'disability', 'death', 'death']},\n",
       " {'pmid': 27082122,\n",
       "  'sentence': 'In the present study, the entire coding sequences and flanking regions of 12\\xa0major disease\\xa0(cardiomyopathy)-related genes [namely myosin, heavy chain\\xa07, cardiac muscle,\\xa0Î²\\xa0(MYH7); myosin binding protein\\xa0C, cardiac\\xa0(MYBPC3); lamin A/C\\xa0(LMNA); troponin\\xa0I type\\xa03\\xa0(cardiac)\\xa0(TNNI3); troponin\\xa0T type\\xa02 (cardiac)\\xa0(TNNT2); actin,\\xa0Î±, cardiac muscle\\xa01\\xa0(ACTC1); tropomyosin\\xa01\\xa0(Î±)\\xa0(TPM1); sodium channel, voltage gated, type\\xa0V alpha subunit\\xa0(SCN5A); myosin, light chain\\xa02, regulatory, cardiac, slow\\xa0(MYL2); myosin, heavy chain\\xa06, cardiac muscle,\\xa0Î±\\xa0(MYH6); myosin, light chain\\xa03, alkali, ventricular, skeletal, slow\\xa0(MYL3); and protein kinase, AMP-activated, gamma\\xa02 non-catalytic subunit \\xa0(PRKAG2)] in 8\\xa0patients with dilated cardiomyopathy\\xa0(DCM) and in 8\\xa0patients with hypertrophic cardiomyopathy\\xa0(HCM) were amplified and then sequenced using the Ion Torrent Personal Genome Machine\\xa0(PGM) system.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium', 'cardiac'],\n",
       "  'reaction': ['cardiomyopathy',\n",
       "   'protein c',\n",
       "   'troponin',\n",
       "   'troponin',\n",
       "   'troponin i',\n",
       "   'troponin i',\n",
       "   'troponin',\n",
       "   'troponin',\n",
       "   'troponin t',\n",
       "   'cardiomyopathy',\n",
       "   'hypertrophic cardiomyopathy',\n",
       "   'cardiomyopathy']},\n",
       " {'pmid': 27090254,\n",
       "  'sentence': 'Pooled analysis of (R)-[11C]-verapamil PET data from two European centresM Bauer, M Feldmann, R Karch, W Wadsak, M Zeitlinger, MJ Koepp, M-C Asselin, E Pataraia, O LangerA13 In-vitro and in-vivo characterization of [18F]FE@SNAP and derivatives for the visualization of the melanin concentrating hormone receptor 1M Zeilinger, C Philippe, M Dumanic, F Pichler, J Pilz, M Hacker, W Wadsak, M MitterhauserA14 Reducing time in quality control leads to higher specific radioactivity of short-lived radiotracersL Nics, B Steiner, M Hacker, M Mitterhauser, W WadsakA15 In vitro 11C-erlotinib binding experiments in cancer cell lines with epidermal growth factor receptor mutationsA Traxl, Thomas Wanek, Kushtrim Kryeziu, Severin Mairinger, Johann Stanek, Walter Berger, Claudia Kuntner, Oliver LangerA16 7-[11C]methyl-6-bromopurine, a PET tracer to measure brain Mrp1 function: radiosynthesis and first PET evaluation in miceS Mairinger, T Wanek, A Traxl, M Krohn, J Stanek, T Filip, M Sauberer, C Kuntner, J Pahnke, O LangerA17 18F labeled azidoglucose derivatives as \"click\" agents for pretargeted PET imagingD Svatunek, C Denk, M Wilkovitsch, T Wanek, T Filip, C Kuntner-Hannes, J FrÃ¶hlich, H MikulaA18 Bioorthogonal tools for PET imaging: development of radiolabeled 1,2,4,5-TetrazinesC Denk, D Svatunek, T Wanek, S Mairinger, J Stanek, T Filip, J FrÃ¶hlich, H Mikula, C Kuntner-HannesA19 Preclinical evaluation of [18F]FE@SUPPY- a new PET-tracer for oncologyT Balber, J Singer, J Fazekas, C Rami-Mark, N BerroterÃ¡n-Infante, E Jensen-Jarolim, W Wadsak, M Hacker, H Viernstein, M MitterhauserA20 Investigation of Small [18F]-Fluoroalkylazides for Rapid Radiolabeling and In Vivo Click ChemistryC Denk, D Svatunek, B Sohr, H Mikula, J FrÃ¶hlich, T Wanek, C Kuntner-Hannes, T FilipA21 Microfluidic 68Ga-radiolabeling of PSMA-HBED-CC using a flow-through reactorS Pfaff, C Philippe, M Mitterhauser, M Hartenbach, M Hacker, W WadsakA22 Influence of 24-nor-ursodeoxycholic acid on hepatic disposition of [18F]ciprofloxacin measured with positron emission tomographyT Wanek, E Halilbasic, M Visentin, S Mairinger, B Stieger, C Kuntner, M Trauner, O LangerA23 Automated 18F-flumazenil production using chemically resistant disposable cassettesP Lam, M Aistleitner, R Eichinger, C ArtnerA24 Similarities and differences in the synthesis and quality control of 177Lu-DOTA-TATE, 177Lu -HA-DOTA-TATE and 177Lu-DOTA-PSMA (PSMA-617)H Eidherr, C Vraka, A Haug, M Mitterhauser, L Nics, M Hartenbach, M Hacker, W WadsakA25 68Ga- and 177Lu-labelling of PSMA-617H Kvaternik, R MÃ¼ller, D Hausberger, C Zink, RM AignerA26 Radiolabelling of liposomes with 67Ga and biodistribution studies after administration by an aerosol inhalation systemU CossÃ­o, M Asensio, A Montes, S Akhtar, Y te Welscher, R van Nostrum, V GÃ³mez-Vallejo, J LlopA27 Fully automated quantification of DaTscan SPECT: Integration of age and gender differencesF VandeVyver, T Barclay, N Lippens, M TrochA28 Lesion-to-background ratio in co-registered 18F-FET PET/MR imaging - is it a valuable tool to differentiate between low grade and high grade brain tumor?L Hehenwarter, B Egger, J Holzmannhofer, M Rodrigues-Radischat, C PirichA29 [11C]-methionine PET in gliomas - a retrospective data analysis of 166 patientsN PÃ¶tsch, I Rausch, D Wilhelm, M Weber, J Furtner, G Karanikas, A WÃ¶hrer, M Mitterhauser, M Hacker, T Traub-WeidingerA30 18F-Fluorocholine versus 18F-Fluorodeoxyglucose for PET/CT imaging in patients with relapsed or progressive multiple myeloma: a pilot studyT Cassou-Mounat, S Balogova, V Nataf, M Calzada, V Huchet, K Kerrou, J-Y Devaux, M Mohty, L Garderet, J-N TalbotA31 Prognostic benefit of additional SPECT/CT in sentinel lymph node mapping of breast cancer patientsS Stanzel, G Pregartner, T Schwarz, V Bjelic-Radisic, B Liegl-Atzwanger, R AignerA32 Evaluation of diagnostic value of TOF-18F-FDG PET/CT in patients with suspected pancreatic cancerS Stanzel, F Quehenberger, RM AignerA33 New quantification method for diagnosis of primary hyperpatahyroidism lesions and differential diagnosis vs thyropid nodular disease in dynamic scintigraphyA KoljeviÄ‡ MarkoviÄ‡, Milica JankoviÄ‡, V Miler JerkoviÄ‡, M PaskaÅ¡, G PupiÄ‡, R DÅ¾odiÄ‡, D PopoviÄ‡A34 A rare case of diffuse pancreatic involvement in patient with merkel cell carcinoma detected by 18F-FDGMC Fornito, D FamiliariA35 TSH-stimulated 18F-FDG PET/CT in the diagnosis of recurrent/metastatic radioiodine-negative differentiated thyroid carcinomas in patients with various thyroglobuline levelsP Koranda, H PolzerovÃ¡, I MetelkovÃ¡, L HenzlovÃ¡, R FormÃ¡nek, E BuriÃ¡nkovÃ¡, M KamÃ­nekA36 Breast Dose from lactation following I131 treatmentWH Thomson, C LewisA37 A new concept for performing SeHCAT studies with the gamma cameraWH Thomson, J O\\'Brien, G James, A NotghiA38 Whole body F-18-FDG-PET and tuberculosis: sensitivity compared to x-ray-CTH Huber, I StelzmÃ¼ller, R Wunn, M Mandl, F Fellner, B Lamprecht, M GabrielA39 Emerging role 18F-FDG PET-CT in the diagnosis and follow-up of the infection in heartware ventricular assist system (HVAD)MC Fornito, G LeonardiA40 Validation of Poisson resampling softwareWH Thomson, J O\\'Brien, G JamesA41 Protection of PET nuclear medicine personnel: problems in satisfying dose limit requirementsJ HudzietzovÃ¡, J Sabol, M FÃ¼lÃ¶p.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ciprofloxacin'],\n",
       "  'reaction': ['growth',\n",
       "   'investigation',\n",
       "   'breast cancer',\n",
       "   'tuberculosis',\n",
       "   'infection']},\n",
       " {'pmid': 27096953,\n",
       "  'sentence': 'In this paper we demonstrate that: i) blockade of the calcium-activated potassium channel KCa3.1 with TRAM-34 has co-adjuvant effects with TMZ, reducing GL261 glioma cell migration, invasion and colony forming activity, increasing apoptosis, and forcing cells to pass the G2/M cell cycle phase, likely through cdc2 de-phosphorylation; ii) KCa3.1 silencing potentiates the inhibitory effect of TMZ on glioma cell viability; iii) the combination of TMZ/TRAM-34 attenuates the toxic effects of glioma conditioned medium on neuronal cultures, through a microglia dependent mechanism since the effect is abolished by clodronate-induced microglia killing; iv) TMZ/TRAM-34 co-treatment increases the number of apoptotic tumor cells, and the mean survival time in a syngeneic mouse glioma model (C57BL6 mice implanted with GL261 cells); v) TMZ/TRAM-34 co-treatment reduces cell viability of GBM cells and cancer stem cells (CSC) freshly isolated from patients.Taken together, these data suggest a new therapeutic approach for malignant glioma, targeting both glioma cell proliferating and migration, and demonstrate that TMZ/TRAM-34 co-treatment affects both glioma cells and infiltrating microglia, resulting in an overall reduction of tumor cell progression.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium', 'potassium'],\n",
       "  'reaction': ['glioma',\n",
       "   'apoptosis',\n",
       "   'glioma',\n",
       "   'glioma',\n",
       "   'glioma',\n",
       "   'glioma',\n",
       "   'glioma',\n",
       "   'glioma']},\n",
       " {'pmid': 27153341,\n",
       "  'sentence': 'In this Account, we introduce our recent successful efforts in phage-based supramolecular chemistry, by integrating the unique nanofiber-like phage structure and powerful peptide display techniques into the fields of chemistry, materials science, and medicine: (1) successfully synthesized and assembled silica, hydroxyapatite, and gold nanoparticles using phage templates to form novel functional materials; (2) chemically introduced azo units onto the phage to form photoresponsive functional azo-phage nanofibers via a diazotization reaction between aromatic amino groups and the tyrosine residues genetically displayed on phage surfaces; (3) assembled phage into 2D films for studying the effects of both biochemical (the peptide sequences displayed on the phages) and biophysical (the topographies of the phage films) cues on the proliferation and differentiation of mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) and identified peptides and topographies that can induce their osteogenic differentiation; (4) discovered that phage could induce angiogenesis and osteogenesis for MSC-based vascularized bone regeneration; (5) identified novel breast cancer cell-targeting and MSC-targeting peptides and used them to significantly improve the efficiency of targeted cancer therapy and MSC-based gene delivery, respectively; (6) employed engineered phage as a probe to achieve ultrasensitive detection of biomarkers from serum of human patients for disease diagnosis; and (7) constructed centimeter-scale 3D multilayered phage assemblies with the potential application as scaffolds for bone regeneration and functional device fabrication.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['breast cancer', 'delivery']},\n",
       " {'pmid': 27184278,\n",
       "  'sentence': 'These studies reported the following significant risk factors for malnutrition: age (OR: 1.038; P = 0.045), frailty in institutionalized persons (Î²: 0.22; P = 0.036), excessive polypharmacy (Î²: -0.62; P = 0.001), general health decline including physical function (OR: 1.793; P = 0.008), Parkinson disease (OR: 2.450; P = 0.047), constipation (OR: 2.490; P = 0.015), poor (OR: 3.30; P value not given) or moderate (Î²: -0.27; P = 0.016) self-reported health status, cognitive decline (OR: 1.844; P = 0.001), dementia (OR: 2.139; P = 0.001), eating dependencies (OR: 2.257; P = 0.001), loss of interest in life (Î²: -0.58; P = 0.017), poor appetite (Î²: -1.52; P = 0.000), basal oral dysphagia (OR: 2.72; P = 0.010), signs of impaired efficacy of swallowing (OR: 2.73; P = 0.015), and institutionalization (Î²: -1.89; P < 0.001).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['malnutrition', 'constipation', 'dementia', 'dysphagia']},\n",
       " {'pmid': 27228700,\n",
       "  'sentence': 'In terms of fructose load in rats simultaneously with the increase of body weight and the development of biochemical disorders that are characteristic for the metabolic syndrome, there comes a marked progressive increase in intravascular platelet activity [reduction of the number of discocytes from 81.0 Â± 0.1 to 61.3 Â± 0.2%, increase in the number of reactive platelets from 19.0 Â± 0.1 to 38.7 Â± 0.2%, an increase in the number of freely moving in the blood of small units from 2.4 Â± 0.0 to 14.6 Â± 0.1 per 100 free platelets, and of medium and large units (from 4 or more cells) from 0.1 Â± 0.03 to 2.3 Â± 0.06 per 100 free platelets], largely due to the increase (p < 0.01) of the synthesis of thromboxane B2 (from 145.9 Â± 0.2 to 232.6 Â± 0.7 pg/ml), endothelin-4 (from 6.9 Â± 0.2 to 12.5 Â± 0.4 pg/ml) and reduction (p < 0.01) of the generation of 6-keto-prostaglandin F1Î± (from 75.9 Â± 0.2 to 62.3 Â± 0.4 pg/ml), and the total amount of nitric oxide metabolites (from 27.9 Â± 0.3 to 23.2 Â± 0.1 mmol/l).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['weight', 'weight']},\n",
       " {'pmid': 27258489,\n",
       "  'sentence': 'The prevalence of cardiovascular comorbidities (odds ratio (OR): [95% CI] 1.90 [1.70, 2.14]; P\\u200a<\\u200a0.00001), cerebrovascular comorbidities (OR 1.44 [1.29, 1.60]; P\\u200a<\\u200a0.00001), obesity (OR 1.51 [1.14, 2.01]; P\\u200a<\\u200a0.00001), hypertension (OR 1.66 [1.47, 1.88]; P\\u200a<\\u200a0.00001, diabetes (OR 1.25 [1.08, 1.44]; P\\u200a<\\u200a0.00001), other metabolic and endocrine comorbidities (OR 1.60 [1.40, 1.83]; P\\u200a<\\u200a0.00001), psychiatric and neurological comorbidities (OR 1.62 [1.44, 1.82]; P\\u200a<\\u200a0.00001), gut and urinary comorbidities (OR 1.91 [1.47, 2.49]; P\\u200a<\\u200a0.00001),), cancer (OR 1.17 [1.10, 1.25]; P\\u200a<\\u200a0.00001), and respiratory comorbidities (OR 5.60 [4.22, 7.44]; P\\u200a<\\u200a0.00001) were significantly higher in the asthma patients in comparison with nonasthma controls.Asthma is associated with significantly higher comorbidities including cardio-/cerebrovascular diseases, obesity, hypertension, diabetes, psychiatric and neurological comorbidities, gut and urinary conditions, cancer, and respiratory problems other than asthma.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['obesity',\n",
       "   'hypertension',\n",
       "   'asthma',\n",
       "   'obesity',\n",
       "   'hypertension',\n",
       "   'asthma']},\n",
       " {'pmid': 27281742,\n",
       "  'sentence': \"Since the first antiviral drug, idoxuridine, was approved in 1963, 90 antiviral drugs categorized into 13 functional groups have been formally approved for the treatment of the following 9 human infectious diseases: (i) HIV infections (protease inhibitors, integrase inhibitors, entry inhibitors, nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus (HBV) infections (lamivudine, interferons, nucleoside analogues, and acyclic nucleoside phosphonate analogues), (iii) hepatitis C virus (HCV) infections (ribavirin, interferons, NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors), (iv) herpesvirus infections (5-substituted 2'-deoxyuridine analogues, entry inhibitors, nucleoside analogues, pyrophosphate analogues, and acyclic guanosine analogues), (v) influenza virus infections (ribavirin, matrix 2 protein inhibitors, RNA polymerase inhibitors, and neuraminidase inhibitors), (vi) human cytomegalovirus infections (acyclic guanosine analogues, acyclic nucleoside phosphonate analogues, pyrophosphate analogues, and oligonucleotides), (vii) varicella-zoster virus infections (acyclic guanosine analogues, nucleoside analogues, 5-substituted 2'-deoxyuridine analogues, and antibodies), (viii) respiratory syncytial virus infections (ribavirin and antibodies), and (ix) external anogenital warts caused by human papillomavirus infections (imiquimod, sinecatechins, and podofilox).\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['imiquimod', 'lamivudine', 'idoxuridine'],\n",
       "  'reaction': ['hepatitis',\n",
       "   'hepatitis b',\n",
       "   'hepatitis',\n",
       "   'hepatitis c',\n",
       "   'influenza',\n",
       "   'anogenital warts']},\n",
       " {'pmid': 27368044,\n",
       "  'sentence': 'We tested: (i) copeptin, a surrogate marker for antidiuretic hormone and a stress marker; (ii) ischemia-modified albumin, an ischemia/hypoxia marker; (iii) brain-natriuretic peptide (BNP), a marker of heart failure, and (iv) ultrasensitive-cardiac troponin-I (cTnI), a marker of myocardial ischemia.We found that copeptin and cardiac biomarkers were higher in IPE versus DCS and controls: (i) copeptin: 68% of IPE patients had a high level versus 25% of DCS patients (P\\u200a<\\u200a0.05) (mean\\u200aÂ±\\u200astandard-deviation: IPE: 53\\u200aÂ±\\u200a61\\u200apmol/L; DCS: 15\\u200aÂ±\\u200a17; controls: 6\\u200aÂ±\\u200a3; IPE versus DCS or controls: P\\u200a<\\u200a0.05); (ii) ischemia-modified albumin: 68% of IPE patients had a high level versus 16% of DCS patients (P\\u200a<\\u200a0.05) (IPE: 123\\u200aÂ±\\u200a25 arbitrary-units; DCS: 84\\u200aÂ±\\u200a25; controls: 94\\u200aÂ±\\u200a7; IPE versus DCS or controls: P\\u200a<\\u200a0.05); (iii) BNP: 53% of IPE patients had a high level, DCS patients having normal values (P\\u200a<\\u200a0.05) (IPE: 383\\u200aÂ±\\u200a394\\u200ang/L; DCS: 37\\u200aÂ±\\u200a28; controls: 19\\u200aÂ±\\u200a15; IPE versus DCS or controls: P\\u200a<\\u200a0.01); (iv) cTnI: 63% of IPE patients had a high level, DCS patients having normal values (P\\u200a<\\u200a0.05) (IPE: 0.66\\u200aÂ±\\u200a1.50\\u200aÎ¼g/L; DCS: 0.0061\\u200aÂ±\\u200a0.0040; controls: 0.0090\\u200aÂ±\\u200a0.01; IPE versus DCS or controls: P\\u200a<\\u200a0.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'cardiac'],\n",
       "  'reaction': ['stress']},\n",
       " {'pmid': 27399105,\n",
       "  'sentence': 'The present study had 2 objectives, first, to investigate possible relationships between increased gestational weight gain and demographic, clinical, paraclinical, genetic, and bioimpedance (BIA) characteristics of Romanian mothers, and second, to identify the influence of predictors (maternal and newborns characteristics) on our outcome birth weight (BW).We performed a cross-sectional study on 309 mothers and 309 newborns from Romania, divided into 2 groups: Group I-141 mothers with high gestational weight gain (GWG) and Group II-168 mothers with normal GWG, that is, control group.The groups were evaluated regarding demographic, anthropometric (body mass index [BMI], middle upper arm circumference, tricipital skinfold thickness, weight, height [H]), clinical, paraclinical, genetic (interleukin 6 [IL-6]: IL-6 -174G>C and IL-6 -572C>G gene polymorphisms), and BIA parameters.We noticed that fat mass (FM), muscle mass (MM), bone mass (BM), total body water (TBW), basal metabolism rate (BMR) and metabolic age (P\\u200a<\\u200a0.001), anthropometric parameters (middle upper arm circumference, tricipital skinfold thickness; P\\u200a<\\u200a0.001/P = 0.001) and hypertension (odds ratio = 4.65, 95% confidence interval: 1.27-17.03) were higher in mothers with high GWG.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['basal'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'mass',\n",
       "   'muscle mass',\n",
       "   'mass',\n",
       "   'mass',\n",
       "   'hypertension']},\n",
       " {'pmid': 27471206,\n",
       "  'sentence': 'We examined whether a quantitative measure of increased lung attenuation on computed tomography (CT) detects lung injury, inflammation and extracellular matrix remodelling in community-dwelling adults sampled without regard to respiratory symptoms or smoking.We measured high attenuation areas (HAA; percentage of lung voxels between -600 and -250 Hounsfield Units) on cardiac CT scans of adults enrolled in the Multi-Ethnic Study of Atherosclerosis.HAA was associated with higher serum matrix metalloproteinase-7 (mean adjusted difference 6.3% per HAA doubling, 95% CI 1.3-11.5), higher interleukin-6 (mean adjusted difference 8.8%, 95% CI 4.8-13.0), lower forced vital capacity (FVC) (mean adjusted difference -82\\u2005mL, 95% CI -119--44), lower 6-min walk distance (mean adjusted difference -40\\u2005m, 95% CI -1--80), higher odds of interstitial lung abnormalities at 9.5\\u2005years (adjusted OR 1.95, 95% CI 1.43-2.65), and higher all cause-mortality rate over 12.2\\u2005years (HR 1.58, 95% CI 1.39-1.79).High attenuation areas are associated with biomarkers of inflammation and extracellular matrix remodelling, reduced lung function, interstitial lung abnormalities, and a higher risk of death among community-dwelling adults.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['injury',\n",
       "   'inflammation',\n",
       "   'forced vital capacity',\n",
       "   'forced vital capacity',\n",
       "   'vital capacity',\n",
       "   'inflammation',\n",
       "   'death']},\n",
       " {'pmid': 27539038,\n",
       "  'sentence': 'Palonosetron(Palo)is a second-generation 5-hydroxytryptamine 3 receptor antagonist(5-HT3RA)effective in suppressing chemotherapy-induced nausea and vomiting in both acute and delayed phases.Most studies have reported Palo as an effective antiemetic for cisplatin(CDDP)chemotherapy(â‰¥50mg/m2)administered on an intermittent basis.To assess the antiemetic efficacy of Palo, we performed a retrospective study in 16 patients with lung cancer who received Palo with split-dose CDDP, ifosfamide, and irinotecan(CPT-11)triple combination(CIC)therapy at Sapporo Minami-Sanjo Hospital between October 2010 and January 2012.T he CIC regimen consisted of CPT-11(50-60mg/m2)administered on days 1, 8, and 15, in addition to CDDP(15-20mg/m2)and ifosfamide(1,500mg/kg)for 4 consecutive days.On day 1, ramosetron was replaced with Palo in patients who had insufficient antiemetic control in accordance with guidelines on the management of highly emetogenic chemotherapy(HEC).There was a lower incidence of grade 1 or higher nausea(62.5%)in patients in the Palo-combination group than in those in the non-Palo-combination group(87.5%).No incidence of grade 3 or higher nausea was reported in either group.On the fifth day of chemotherapy, the incidence of nausea was significantly lower in the Palo-combination group(43.8%)than in the non-Palo-combination group(81.3%)(p<0.05).In addition, there was a significant decrease in the number of days of incidence and a significant increase in the number of days since the last episode was observed in the Palo-combination group.These results suggest that Palo, in particular, decreases the incidence of nausea and extends the number of days since its occurrence; moreover, it is effective in accelerating recovery.In conclusion, this study suggests that Palo exhibits excellent antiemetic efficacy in patients administered split doses of CDDP.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['palonosetron', 'cisplatin', 'irinotecan'],\n",
       "  'reaction': ['nausea',\n",
       "   'vomiting',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'nausea',\n",
       "   'nausea',\n",
       "   'chemotherapy',\n",
       "   'nausea',\n",
       "   'nausea']},\n",
       " {'pmid': 27545826,\n",
       "  'sentence': 'The results indicated that: 1) renin (100nM) dialyzed into smooth muscle cells, increased the inward calcium current; 2) verapamil (10-9M) administered to the bath inhibited the effect of renin on the inward calcium current; 3) concurrently with the increase of calcium current a depolarization of 6.8+/-2.1mV (n=16)(P<0.05) was found in cells dialyzed with renin; 4) intracellular dialysis of renin (100nM) into smooth muscle cells isolated from mesenteric arteries of normal Wystar Kyoto rats showed no significant change on calcium current; 5) aliskiren (10-9M) dialyzed into the cell together with renin (100nM) abolished the effect of the enzyme on the calcium current in SHR; 6) Ang II (100nM) dialyzed into the smooth muscle cell from mesenteric artery of SHR in absence of renin, decreased the calcium current-an effect greatly reduced by valsartan (10-9M) added to the cytosol; 7) administration of renin (100nM) plus angiotensinogen (100nM) into the cytosol of muscles cells from SHR rats reduced the inward calcium current; 8) extracellular administration of Ang II (100nM) increased the inward calcium current in mesenteric arteries of SHR.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['verapamil', 'valsartan', 'calcium', 'aliskiren'],\n",
       "  'reaction': ['renin',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'dialysis',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'renin',\n",
       "   'renin']},\n",
       " {'pmid': 27604617,\n",
       "  'sentence': 'Dean, Nova L. Panebianco, Patricia S. HenwoodA20 Ultrasonographic diagnosis of tracheal compressionOliviero Fochi, Moreno Favarato, Ezio BonanomiA21 The role of ultrasound in the detection of lung infiltrates in critically ill patients: a pilot studyMarijana GrgiÄ‡ MediÄ‡, Ivan TomiÄ‡, Radovan RadoniÄ‡A22 The SAFER Lasso; a novel approach using point-of-care ultrasound to evaluate patients with abdominal complaints in the emergency departmentYoungrock Ha, Hongchuen TohA23 Awareness and use of clinician-performed ultrasound among clinical clerkship facultyElizabeth Harmon, Wilma Chan, Cameron Baston, Gail Morrison, Frances Shofer, Nova Panebianco, Anthony J. DeanA24 Clinical outcomes in the use of lung ultrasound for the diagnosis of pediatric pneumoniasAngela Hua, Sharon Kim, James TsungA25 Effectiveness of ultrasound in hypotensive patientsIsa Gunaydin, Zeynep Kekec, Mehmet Oguzhan AyA26 Moderate-to-severe left ventricular ejection fraction related to short-term mortality of patients with post-cardiac arrest syndrome after out-of-hospital cardiac arrestJinjoo Kim, Jinhyun Kim, Gyoosung Choi, Dowon ShimA27 Usefulness of abdominal ultrasound for acute pyelonephritis diagnosis after kidney transplantationJi-Han LeeA28 Lung ultrasound for assessing fluid tolerance in severe preeclampsiaJana Ambrozic, Katja Prokselj, Miha LucovnikA29 Optic nerve sheath ultrasound in severe preeclampsiaGabrijela Brzan Simenc, Jana Ambrozic, Miha LucovnikA30 Focused echocardiography monitoring in the postoperative period for non-cardiac patientsAsta MaÄiulienÄ—, Almantas Maleckas, Algimantas KriÅ¡Äiukaitis, Vytautas MaÄiulis, Andrius MacasA31 POCUS-guided paediatric upper limb fracture reduction: algorithm, tricks, and tipsSharad MohiteA32 Point-of-care lung ultrasound: a good diagnostic tool for pneumonia in a septic patientZoltan Narancsik, Hugon MoÅ¾inaA33 A case of undergraduate POCUS (r)evolutionSara NikoliÄ‡, Jan Hansel, Rok PetrovÄiÄ, Una MrÅ¡iÄ‡, Gregor ProsenA34 The Graz Summer School for ultrasound: from first contact to bedside application: three-and-a-half-day undergraduate ultrasound training: rÃ©sumÃ© after two years of continuous developmentSimon Orlob, Markus Lerchbaumer, Niklas SchÃ¶negger, Reinhard KaufmannA35 Usefulness of point-of-care ultrasound in the emergency room in a patient with acute abdominal painAlberto Oviedo-GarcÃ­a, Margarita Algaba-Montes, Mayra Patricio-BordomÃ¡sA36 Use of bedside ultrasound in a critically ill patient.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['ejection fraction',\n",
       "   'ejection fraction',\n",
       "   'pyelonephritis',\n",
       "   'upper limb fracture',\n",
       "   'limb fracture',\n",
       "   'fracture',\n",
       "   'fracture reduction',\n",
       "   'pneumonia']},\n",
       " {'pmid': 27604617,\n",
       "  'sentence': \"A case reportAlberto Oviedo-GarcÃ­a, Margarita Algaba-Montes, Mayra Patricio-BordomÃ¡sA37 Diagnostic yield of clinical echocardiography for the emergency physicianAlberto Oviedo-GarcÃ­a, Margarita Algaba-Montes, Mayra Patricio-BordomÃ¡sA38 Focused cardiac ultrasound in early diagnosis of type A aortic dissection with atypical presentationChun-I Pan, Hsiu-Yung Pan, Chien-Hung WuA39 Detection of imperforated hymen by point-of-care ultrasoundHsiu-yung Pan, Chia-Te KungA40 Developing a point-of-care ultrasound curriculum for pediatric nurse practitioners practicing in the pediatric emergency departmentSarah Pasquale, Stephanie J. Doniger, Sharon Yellin, Gerardo ChiricoloA41 Use of transthoracic echocardiography in emergency setting: patient with mitral valve abscessMaja Potisek, Borut DrnovÅ¡ek, BoÅ¡tjan LeskovarA42 A young man with syncopeFatemeh Rasooli, Maryam BahreiniA43 Work-related repetitive use injuries in ultrasound fellowsKristine Robinson, Clara Kraft, Benjamin Moser, Stephen Davis, Shelley Layman, Yusef Sayeed, Joseph MinardiA44 Lung ultrasonography in the evaluation of pneumonia in childrenIrmina Sefic Pasic, Amra Dzananovic, Anes Pasic, Sandra Vegar ZubovicA45 Central venous catheter placement with the ultrasound aid: two years' experience of the Interventional unit, Division of Intensive Care Medicine, KBC ZagrebAna Godan Hauptman, Marijana Grgic Medic, Ivan Tomic, Ana Vujaklija Brajkovic, Jaksa Babel, Marina Peklic, Radovan RadonicA46 Duplicitas casui: two patients admitted due to acute liver failureVedran Radonic, Ivan Tomic, Luka Bielen, Marijana Grgic MedicA47 A pilot survey on an understanding of Bedside Point-of-Care Ultrasound (POCUS) among medical doctors in internal medicine: exposure, perceptions, interest, and barriers to trainingPeh Wee MingA48 Unusual case of defecation syncopeNur hafiza Yezid, Fatahul Laham MohammedA49 A case report of massive pulmonary embolism; a multidisciplinary approachZainal Abidin Huda, Wan Nasarudin Wan Ismail, W.Yus Haniff W.Isa, Hashairi Fauzi, Praveena Seeva, Mohd Zulfakar Mazlan.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['aortic dissection',\n",
       "   'pneumonia',\n",
       "   'catheter placement',\n",
       "   'intensive care',\n",
       "   'pulmonary embolism',\n",
       "   'embolism']},\n",
       " {'pmid': 27640333,\n",
       "  'sentence': 'The results indicated that compared with optimal vitamin C supplementation, vitamin C deficiency (2.9\\xa0mg/kg diet) (1) increased reactive oxygen species, malondialdehyde and protein carbonyl (PC) contents (P\\xa0<\\xa00.05), decreased the copper/zinc superoxide dismutase, manganese superoxide dismutase, catalase, glutathione peroxidase and glutathione reductase activities and mRNA levels (P\\xa0<\\xa00.05), and glutathione and vitamin C contents (P\\xa0<\\xa00.05), down-regulated NF-E2-related factor 2 mRNA level (P\\xa0<\\xa00.05), and up-regulated Kelch-like ECH-associating protein (Keap) 1a (rather than Keap1b) mRNA level (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency induced oxidative injury in fish gill; (2) up-regulated caspase-3, -7, -8, -9, Fas ligand, B-cell lymphoma protein 2 associated X protein, apoptotic protease activating factor-1 mRNA levels (P\\xa0<\\xa00.05), and down-regulated inhibitor of apoptosis protein and B-cell lymphoma-2 (rather than myeloid cell leukemia-1) mRNA level (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency aggravated cell apoptosis in fish gill; (3) up-regulated pore-forming TJs Claudin-12, 15a, -15b, and related signaling molecules myosin light chain kinase, p38 mitogen-activated protein kinase (rather than c-Jun N-terminal kinases) mRNA levels (P\\xa0<\\xa00.05), and down-regulated barrier-forming TJs Occludin, zonula occludens (ZO) 1, ZO-2, Claudin-c, -3c, -7a, -7b mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency disrupted tight junctional complexes in fish gill; (4) decreased lysozyme and acid phosphatase (ACP) activities, and complement 3 (C3), C4 and IgM contents (P\\xa0<\\xa00.05), down-regulated the mRNA levels of antimicrobial peptides liver expressed antimicrobial peptide (LEAP) 2A, LEAP-2B, Hepcidin, Î²-defensin mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency decrease fish gill immune function; (5) down-regulated the mRNA levels of anti-inflammatory cytokines-related factors interleukin 10 (IL-10), IL-11, transforming growth factor (TGF) Î²1, TGF-Î²2, inhibitor of ÎºBa and eIF4E-binding protein 1 (4E-BP1) (rather than 4E-BP2) (P\\xa0<\\xa00.05), and up-regulated pro-inflammatory cytokines-related factors interferon Î³2, IL-1Î², IL-6, IL-8, IL-12 P35, IL-12 P40, nuclear factor ÎºB (NF-ÎºB) p65 (rather than NF-ÎºB p52), IÎºB kinases (IKK) (only IKKÎ± and IKKÎ³), target of rapamycin and ribosomal protein S6 kinase 1 mRNA levels (P\\xa0<\\xa00.05) in the gill of grass carp under infection of F.\\xa0columnare, suggesting that vitamin C deficiency aggravated fish gill inflammation.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['vitamin c deficiency',\n",
       "   'manganese',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'injury',\n",
       "   'b-cell lymphoma',\n",
       "   'lymphoma',\n",
       "   'apoptosis',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'apoptosis',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'growth',\n",
       "   'infection',\n",
       "   'vitamin c deficiency',\n",
       "   'inflammation']},\n",
       " {'pmid': 27647081,\n",
       "  'sentence': 'Mitomycin C (MMC) as an intravesical chemotherapeutic agent is a well-known option for treatment of nonmuscle invasive bladder cancer (NMIBC) recurrence; it is probably the most commonly used agent given its low rate of side effects and its efficacy.Both the American Urologic Association (AUA) and European Association of Urology (EAU) consider MMC as a standard treatment for immediate single-dose postoperative treatment and for adjuvant therapy in low and intermediate-risk NMIBC.Despite the popularity of this agent in the treatment of NMIBCs, many questions regarding the optimal approach to MMC therapy remain unanswered and the schedule widely used is empirical.Nevertheless, even when the current optimal approaches to MMC administration are used, a large proportion of NMIBCs recur.This apparent treatment resistance might be overcome by an optimization of standard MMC therapy or with a combination of MMC with other agents that have different mechanisms of action.Strategies to enhance passive delivery of MMC have been well studied and multiple measures are recommended for implementation of use in routine clinical practice.A modified scheme of instillation seems to be an easy and inexpensive alternative to increase efficacy of intravesical MMC and to also use this agent with an ablative intent.Enhancing tumor response with a sequential therapy is another option that has been investigated, mostly for chemo-immunotherapy wherein the different mechanisms of action of Bacillus of Calmette and GuerÃ¬n (BCG) and MMC are combined to achieve a higher response.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['mitomycin'],\n",
       "  'reaction': ['bladder cancer', 'adjuvant therapy', 'delivery']},\n",
       " {'pmid': 27693201,\n",
       "  'sentence': 'Meanwhile, compared with the optimal choline group, choline deficiency decreased the activities of lysozyme and acid phosphatase, contents of complement 3 and IgM in the intestine, downregulated the mRNA levels of antimicrobial peptides (liver-expressed antimicrobial peptide (LEAP) 2A and defensin-3 in the PI and MI, LEAP-2B and hepcidin in the PI, MI and DI), anti-inflammatory cytokines (interleukin (IL) 10 and transforming growth factor Î²2 in the PI, MI and DI), and signaling molecule IÎºB in the PI, MI and DI; while upregulated the mRNA levels of pro-inflammatory cytokines (IL-6a and tumor necrosis factor Î± in the MI and DI, interferon Î³2b in the PI and MI, IL-1Î² and IL-6b in the PI, MI and DI), and signaling molecules (Toll-like receptor 4 in the MI, myeloid differentiation primary response 88 in the PI and MI, Janus kinase 3 and tyrosine kinase 2 in the MI and DI, nuclear factor kappa B (NF-ÎºB), signal transducers and activators of transcription (STAT) 4 and STAT5 in the PI, MI and DI) of juvenile Jian carp, further indicating that choline deficiency caused inflammation and immunity depression in the intestine of fish.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['growth', 'necrosis', 'inflammation', 'depression']},\n",
       " {'pmid': 27831505,\n",
       "  'sentence': 'This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intra-tumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triple-negative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['breast cancer',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'chemotherapy',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'supportive care',\n",
       "   'quality of life']},\n",
       " {'pmid': 27872452,\n",
       "  'sentence': 'In this article, we discuss the following key messages for clinical practice derived from these recommendations: 1) biopsy should be performed if possible to confirm new diagnosis or relapse; 2) glucocorticoid therapy is an extremely important adjunct to the management of AAV, but it is also responsible for the majority of adverse effects; the dose should be tapered to 7.5 to 10 mg/d at 3 to 5 months; 3) cyclophosphamide or rituximab are the mainstay of remission induction; 4) patients with major relapse should be treated like those with new disease, but rituximab is the preferred option in those patients who relapse after prior cyclophosphamide; 5) minor relapse should not be treated with glucocorticoid alone, and a change in immunosuppressive regimen should be considered; 6) rituximab can be used not only for remission induction but also for maintenance; 7) maintenance therapy should continue for at least 2 years, after which gradual taper could be considered; 8) while ANCA are extremely useful for diagnosis and rising ANCA levels seem to be associated with relapse, serial monitoring should not guide treatment decisions; 9) monitoring of AAV patients should be holistic with a structured assessment tool and monitoring for effects related to the vasculitis as well as treatment; 10) management should be either at or in conjunction with an expert center; and 11) patients should be involved in decision making and have access to educational resources.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rituximab'],\n",
       "  'reaction': ['biopsy', 'vasculitis']},\n",
       " {'pmid': 28133294,\n",
       "  'sentence': 'A 63-year-old man underwent low anterior resection for rectal cancer.A synchronous liver metastasis located in segment 8 was 12 cm in diameter and unresectable due to its proximity to the inferior vena cava(IVC).The postoperative pathological findings revealed a T3(SS), N0, M1(liver)Stage IV tumor, and wild type K-RAS was expressed.We chose FOLFIRI plus cetuximab(Cmab)for first-line chemotherapy.After 6 courses, we changed the molecular target drug from Cmab to bevacizumab( Bmab)because the liver metastasis remained unresectable.The patient had long-term stable disease(SD)for approximately 30 months with the FOLFIRI-based regimen.We then changed the regimen to mFOLFOX6 plus Bmab for second-line, Cmab for third-line, and trifluridine/tipiracil hydrochloride for fourth-line chemotherapy to treat progressive disease(PD).After treatment with these chemotherapies, the patient wished to continue treatment.We restarted FOLFIRI plus Bmab for fifth-line chemotherapy as his general condition was still good.Consequently, his tumor markers levels decreased with stabilization of the disease on CT scans, and he continued therapy for 6 months while maintaining a good quality of life.This case suggested that rechallenge with anti-cancer agents could be effective and improve the prognosis of colorectal cancer patients after using all key drugs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cetuximab', 'bevacizumab'],\n",
       "  'reaction': ['metastasis',\n",
       "   'metastasis',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'condition',\n",
       "   'colorectal cancer']},\n",
       " {'pmid': 28133357,\n",
       "  'sentence': 'A 72-year-old man was admitted to our hospital department in September 2014 because of a positive fecal occult blood test.Colonoscopy showed a type 2 tumor in half of the AV 15 cm rectosigmoid colon.Histology of the biopsy indicated a moderately differentiated adenocarcinoma, and the RAS gene test found wild type.On CT examination, there were multiple liver lung metastases and a 30mm diameter tumor with pancreatic duct extension to the pancreatic body.A PET-CT examination had a high SUVmax at the same site.Because of the location of the tumor EUS-FNA was not used.However, the possibility of pancreatic body cancer could not be denied after the CT examination.Treatment by radical resection was impossible because of the spread of the cancer so we selected chemotherapy.Undeniable pancreatic metastasis of rectal cancer, pancreatic cancer was used as a prognostic factor as double cancer of rectal cancer and pancreatic cancer, from that UGT1A1 test side effects appearance was a low-risk decision, was selected FOLFIRINOX in the treatment regimen.After 25 cycles, the pancreatic body tumor and liver metastases and also the primary tumor were reduced, the multiple lung metastases disappeared, and disease control was good.Side effects were diarrhea on the day of administration of irinotecan, but this was controllable by administering oral loperamide when starting the infusion.Grade 3 or more peripheral neuropathy has not developed, and this regimen is continuing.Pancreatic cancer is a solid cancer with a poor prognosis; if you do not reach the tissue diagnosis of metastatic pancreatic cancer, was a case in which no choice but to select a regimen to carcinoma of the prognostic.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['irinotecan'],\n",
       "  'reaction': ['occult blood',\n",
       "   'biopsy',\n",
       "   'adenocarcinoma',\n",
       "   'metastasis',\n",
       "   'rectal cancer',\n",
       "   'rectal cancer']},\n",
       " {'pmid': 28223674,\n",
       "  'sentence': 'We report a case of a patient treated with everolimus and exemestane combination therapy for bone metastasis after breast surgery.The patient, a 58-year-old woman, consulted our department for back pain in October 2014.S he was diagnosed with left breast cancer when she was 41 years old.She had received Bt+Ax for left breast cancer and administered tamoxifen for 5 years.We decided on everolimus and exemestane combination therapy after observing an abnormal uptake in the 7th to 8th thoracic vertebrae on a PET-CT scan.The pain was controlled using oxycodone and fentanyl orally disintegrating tablet with zoledronic acid.After receiving treatment, the patient experienced pruritus and a Grade 2 rash, but they were managed with antihistamine administration and the treatment was continued.Four months later, the abnormal uptake on the right thoracic vertebrae shrunk; the pain almost disappeared, and oxycodone and fentanyl orally disintegrating tablet were discontinued.Subsequently, exemestane was used alone.Six months later, the range of abnormal uptake on the thoracic vertebrae progressed, and the disease was evaluated as PD.Four months later, everolimus and exemestane combination therapy was resumed, and the abnormal uptake on the thoracic vertebrae almost disappeared as observed on a PET scan.The effectiveness of the treatment was evaluated as CR because other local recurrence and new metastases were not found.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['exemestane', 'everolimus', 'tamoxifen'],\n",
       "  'reaction': ['metastasis',\n",
       "   'back pain',\n",
       "   'pain',\n",
       "   'breast cancer',\n",
       "   'breast cancer',\n",
       "   'pain',\n",
       "   'pruritus',\n",
       "   'rash',\n",
       "   'pain']},\n",
       " {'pmid': 28790262,\n",
       "  'sentence': 'The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0.02; c 2 test).In addition, the mean area under the curve of the chronological changes in the grade of nausea tended to be lower in the aprepitant group than in the fosaprepitant group.In both groups, 3 cases(30%)of vomiting were observed.However, the incidence of continued daily vomiting tended to be lower in the aprepitant group than in the fosaprepitant group.These results suggest that aprepitant is more effective than fosaprepitant for nausea induced by TPF.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['docetaxel',\n",
       "   'fosaprepitant',\n",
       "   'cisplatin',\n",
       "   'aprepitant',\n",
       "   '5-fluorouracil'],\n",
       "  'reaction': ['nausea',\n",
       "   'chemotherapy',\n",
       "   'nausea',\n",
       "   'nausea',\n",
       "   'nausea',\n",
       "   'vomiting',\n",
       "   'vomiting',\n",
       "   'nausea']},\n",
       " {'pmid': 28839660,\n",
       "  'sentence': \"The evidence for dietary interventions in this area is reviewed and the following recommendations made: â– Assessment of nutritional status is an essential part of the investigation of all patients with IBD and deficiency should be actively sought.â– Any patient with macro- or micronutrient deficiency should be referred for dietetic assessment.â– Micronutrient deficiency (most frequently iron, vitamin B12, folate and magnesium) should be replaced aggressively, parenterally if necessary.â– Significant improvement in gastrointestinal symptoms can be achieved by low-residue diets (for stricturing disease) and (always under dietetic supervision) management of lactose and other intolerances.â– Irritable bowel syndrome symptoms in patients with IBD can respond to low fermentable oligo-, di-, monosaccharide and polyol (FODMAP) diets, again this must be done under dietetic supervision.â– Active Crohn's disease can be treated by exclusive enteral nutrition (elemental/polymeric/altered fat formulations all have equivalent efficacy).â– Enteral nutrition can maintain remission in Crohn's disease and in this context can be given alongside normal oral intake.â– Nutritional support does not have an established role in the treatment of active ulcerative colitis, other than in the management of malnutrition.â– Total parenteral nutrition should not be used unless intestinal failure occurs.â– There is insufficient evidence to support the routine use of Î©3 fish oil, prebiotics and glutamine in the treatment of active IBD.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium'],\n",
       "  'reaction': ['investigation',\n",
       "   'vitamin b12',\n",
       "   'enteral nutrition',\n",
       "   'colitis',\n",
       "   'parenteral nutrition']},\n",
       " {'pmid': 28849302,\n",
       "  'sentence': 'There were significant differences between groups concerning: Lower Respiratory Tract Infections (CG\\xa0=\\xa029.4%; EG\\xa0=\\xa010.7%; IG\\xa0=\\xa03.8%; E + IG\\xa0=\\xa00.0%; p\\xa0=\\xa00.014); acute otitis media (CG\\xa0=\\xa032.4%; EG\\xa0=\\xa07.1%; IG\\xa0=\\xa011.5%; E + IG\\xa0=\\xa07.7%; p\\xa0=\\xa00.014); medical consultations (CG\\xa0=\\xa070.6%; EG\\xa0=\\xa042.9%; IG\\xa0=\\xa038.5%; E + IG\\xa0=\\xa030.8%; p\\xa0=\\xa00.021); antibiotics (CG\\xa0=\\xa044.1%; EG\\xa0=\\xa07.1%; IG\\xa0=\\xa023.1%; E + IG\\xa0=\\xa015.4%; p\\xa0=\\xa00.006); days missed from day-care (CG\\xa0=\\xa055\\xa0days; EG\\xa0=\\xa022\\xa0days; IG\\xa0=\\xa014\\xa0days; E + IG\\xa0=\\xa06\\xa0days; p\\xa0=\\xa00.020); days missed from employment (CG\\xa0=\\xa031\\xa0days; EG\\xa0=\\xa020\\xa0days; IG\\xa0=\\xa05\\xa0days; E + IG\\xa0=\\xa01\\xa0day; p\\xa0=\\xa00.021); and nasal clearance techniques (CG\\xa0=\\xa041.4%; EG\\xa0=\\xa078.6%; IG\\xa0=\\xa057.7%; E + IG\\xa0=\\xa084.6%; p\\xa0=\\xa00.011).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['otitis media']},\n",
       " {'pmid': 28856354,\n",
       "  'sentence': 'Mean (standard error) severity weight for urinary tract infection was 0.23% (0.08%); blood transfusion, 0.28% (0.09%); pneumonia, 0.55% (0.15%); hospital readmission, 0.59% (0.23%); wound dehiscence, 0.64% (0.17%); deep vein thrombosis, 0.64% (0.19%); superficial surgical-site infection, 0.68% (0.23%); return to operating room, 0.91% (0.29%); progressive renal insufficiency, 0.93% (0.27%); graft/prosthesis/flap failure, 1.20% (0.34%); unplanned intubation, 1.38% (0.53%); deep surgical-site infection, 1.45% (0.38%); failure to wean from ventilator, 1.45% (0.48%); organ/space surgical-site infection, 1.76% (0.46%); sepsis without shock, 1.77% (0.42%); peripheral nerve injury, 1.83% (0.47%); pulmonary embolism, 2.99% (0.76%); acute renal failure, 3.95% (0.85%); myocardial infarction, 4.16% (0.98%); septic shock, 7.17% (1.36%); stroke, 8.73% (1.74%); cardiac arrest requiring cardiopulmonary resuscitation, 9.97% (2.46%); and coma, 15.14% (3.04%).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'urinary tract infection',\n",
       "   'infection',\n",
       "   'transfusion',\n",
       "   'pneumonia',\n",
       "   'wound',\n",
       "   'wound dehiscence',\n",
       "   'deep vein thrombosis',\n",
       "   'thrombosis',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'infection',\n",
       "   'sepsis',\n",
       "   'shock',\n",
       "   'peripheral nerve injury',\n",
       "   'nerve injury',\n",
       "   'injury',\n",
       "   'pulmonary embolism',\n",
       "   'embolism',\n",
       "   'renal failure',\n",
       "   'myocardial infarction',\n",
       "   'infarction',\n",
       "   'septic shock',\n",
       "   'shock',\n",
       "   'cardiac arrest',\n",
       "   'resuscitation',\n",
       "   'coma']},\n",
       " {'pmid': 28877835,\n",
       "  'sentence': 'Results The senile plaques and neurofibrillar tangles in the cerebrum and cerebellum were dissolved or disappeared in LZ-H and LZ-M groups.Decrease of amyloid angiopathy was found in LZ-H and LZ-M groups.The immature neurons appeared more in hippocampus and dentate nucleus of LZ-H and LZ-M groups than those in AD model and donepezil hydrochloride groups(hippcampus:F=1.738,P=0.016;dentate nucleus:F=1.924,P=0.026),and these immature neurons differentiated to be neurons.More Purkinje cells loss occurred in AD model mice than that in LZ-H and LZ-M groups(F=9.46,P=0.007;F=9.46,P=0.010).The LZ-H and LZ-M groups had more new neuron stem cells grown up in cerebellum.Electromicroscopic examination showed the hippocampal neurons in LZ-H and LZ-M group were integrated,the nuclear membrane was intact,and the mitochondria in the cytoplasm,endoplasmic reticulum,Golgi bodies,microtubules,and synapses were also complete.The microglial cell showed no abnormality.No toxicity appeared in the pathological specimens of mice treated with ganoderma lucidum preparation.Conclusion The ganoderma lucidum preparation can dissolve and decline or dismiss the senile plaques and neurofibrillar tangles in the brain of AD mice and also reduce the amyloid angiopathy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['donepezil'],\n",
       "  'reaction': ['angiopathy', 'angiopathy']},\n",
       " {'pmid': 28901111,\n",
       "  'sentence': 'Alkaloids and flavonoids in flowers, flower buds, stems, leaves, and bulbs of Fritillaria thunbergii were identified by LC-LTQ-Orbitrap MSn.Alkaloids were identified by ACQUITY UPLC BEH Câ‚â‚ˆï¼ˆ2.1 mmÃ—50 mm, 1.7 Î¼m ) chromatographic column with a mobile phase of 10 mmolâ€¢Lâ»Â¹ ammonium formate-acetonitrile and gradient elution in positive MS scan mode.Meanwhile, flavonoids were analyzed by Agilent-Zorbax SB Câ‚â‚ˆ (4.6 mmÃ—250 mm, 5 Î¼m) chromatographic column with a mobile phase of 0.2% acetic acid-acetonitrile and gradient elution in negative MS scan mode.Combined with literature reports, chemical constituents were identified and determined by accurate molecular weights and fragment ion peaks in the ESI-MS/MS spectra based on high resolution mass spectrometer.In all parts of F.thunbergii, 37 alkaloids including 7 alkaloids (zhebeininoside, peimisine, peimine, peiminine, ebeiedinone/puqiedinone, ebeiedine/ puqiedine, peimisine-N-oxide) were simultaneously analyzed.Moreover, 16 flavonoids including quercetin, kaempferol and their glycosides were identified.The results indicated that the aerial parts had the similar alkaloids as the bulbs on the whole.Meanwhile, it had a series of flavonoids undetected in the bulbs.Our results provided the scientific basis for the development and utilization of aerial parts of F.thunbergii.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ammonium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 29049200,\n",
       "  'sentence': 'At the best of our knowledge, no such study has been carried out in a large Italian series and, in this study, we aimed to investigate the prevalence of both subclinical atherosclerosis and history of cardiovascular events (CVEs), in patients consecutively admitted from January 1, 2015 to December 31, 2015 to Rheumatology Units throughout the whole Italy.Centers members of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) were invited to enrol patients consecutively admitted from January 1, 2015 to December 31, 2015 and satisfying American College of Rheumatology/ European League Against Rheumatism criteria for RA and to investigate each of them for: traditional cardiovascular risk factors: sex, age, smoking habit, total cholesterol, triglycerides, glycaemia, high blood pressure, metabolic syndrome (MS), type 2 diabetes (T2D); RA features: disease duration as assessed from the first symptom, disease activity as evaluated by DAS28, radiographic damage as assessed by hands and feet x-ray, and previous joint surgery; prevalence of both subclinical atherosclerosis and history of CVEs.Eight centers participated to the study.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['blood pressure', 'joint surgery', 'surgery']},\n",
       " {'pmid': 29125102,\n",
       "  'sentence': \"Objective To investigate the role of methylprednisolone (MP) in treatment of spinal cord injured (SCI) with bone marrow mesenchymal stem cells (BMSCs) transplantation in rats and its effect on the expressions of tumor necrosis factor-Î±(TNF-Î±) and interleukin-1Î²(IL-1Î²) at the local tissues.Methods Forty male Sprague-Dawley(SD) rats were used to establish the models of SCI according to the modified Allen's contusion method and then divided into four groups (n=10 in each group) by using random numbers table:MP group,BMSCs group,BMSCs+MP group,and control group.MP was intravenously administrated immediately after SCI.BMSCs labeled by 5-bromo-2-deoxyuridine(BrdU)were transplanted into the injured sites of spinal cord after two hours of SCI.On the 1 st,7 th,and 14th days after SCI,when functional outcome measurements were evaluated by the Basso-Beattie-Bresnahan (BBB) score.On the 14th day after treatment,the spine cord tissues were harvested for the TNF-Î±/IL-1Î² immunohistochemistry,and Tunel staining method was used to detect cell apoptosis rate.BrdU-positive BMSCs were examined in BMSCs group and BMSCs+MP group.Results Functional recovery of hind limb in MP+BMSCs group was the best among the four group.On the 1 st day after injury,the BBB scores showed no significant difference among four group(Ï‡\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['methylprednisolone'],\n",
       "  'reaction': ['necrosis', 'contusion', 'apoptosis', 'injury']},\n",
       " {'pmid': 29125113,\n",
       "  'sentence': \"Objective To explore the efficacy and safety of ultrasound-guided cervical root block (CRB) in patients undergoing minimally invasive parathyroidectomy (MIP).Methods We enrolled 35 patients with hyperparathyroidism undergoing MIP in Peking Union Medical College Hospital.C4-7 nerve roots were identified in ultrasound imaging by the shape of the transverse process.A 50 mm insulated needle was gently introduced by an in-plane approach toward the posterior edge of the nerve root located at the inside of the posterior tubercle.After careful aspiration,a total of 3-4 ml of a mixture of 0.5% ropivacaine and 1% lidocaine was slowly injected.The superficial block was administered at the midpoint of the posterior border of the sternocleidomastoid by injecting 5-6 ml of the same mixture.The patients were administrated with dexmedetomidine during the surgery.All patients were assessed for sensory following the procedure and for pain after the surgery.Results Totally 35 patients successfully received MIP under ultrasound-guided CRB plus superficial block.There was no conversion to general anesthesia,no toxic reaction of local anesthetics,and no intravertebral injection.Hoarseness occurred in 6 patients (17.1%) and Horner syndrome occurred in 3 patients (8.6%).The median cold sensory visual analogue scale score was 1.2 [0,5] points at 10 minutes after the procedure.Patient's satisfaction score was 9.5 points.Conclusion Ultrasound-guided CRB plus superficial block can achieve accurate and safe anesthesia,and it provides lasting analgesic effect during and after MIP.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['lidocaine', 'ropivacaine'],\n",
       "  'reaction': ['parathyroidectomy',\n",
       "   'hyperparathyroidism',\n",
       "   'aspiration',\n",
       "   'pain',\n",
       "   'visual analogue scale']},\n",
       " {'pmid': 29130360,\n",
       "  'sentence': 'Abbreviations Atg autophagy related BECN1 Beclin 1 CALCOCO2 calcium binding and coiled-coil domain 2 Cry5B crystal toxin 5B Daf abnormal dauer formation DKF-1 D kinase family-1 EPG-7 Ectopic P Granules-7 FuDR fluorodeoxyuridine GFP green fluorescent protein HLH-30 Helix Loop Helix-30 Imd immune deficiency ins-18 INSulin related-18; LET-363, LEThal-363 lgg-1 LC3, GABARAP and GATE-16 family-1 MAPK mitogen-activated protein kinase MATH the meprin and TRAF homology MTOR mechanistic target of rapamycin NBR1 neighbor of BRCA1 gene 1 NFKB nuclear factor of kappa light polypeptide gene enhancer in B cells NOD nucleotide-binding oligomerization domain containing OPTN optineurin PAMPs pathogen-associated molecular patterns Park2 Parkinson disease (autosomal recessive, juvenile) 2, parkin pdr-1 Parkinson disease related PFTs pore-forming toxins PGRP peptidoglycan-recognition proteins PIK3C3 phosphatidylinositol 3- kinase catalytic subunit type 3 pink-1 PINK (PTEN-I induced kinase) homolog PRKD protein kinase D; PLC, phospholipase C PRKN parkin RBR E3 ubiquitin protein ligase PRRs pattern-recognition receptors PtdIns3P phosphatidylinositol-3-phosphate rab-5 RAB family-5 RB1CC1 RB1-inducible coiled-coil 1 RNAi RNA interference sqst SeQueSTosome related SQSTM1 sequestosome 1 TBK1 TANK-binding kinase 1 TFEB transcription factor EB TGFB/TGF-Î² transforming growth factor beta TLRs toll-like receptors unc-51 UNCoordinated-51 VPS vacuolar protein sorting; VSV, vesicular stomatitis virus VSV-G VSV surface glycoprotein G Wipi2 WD repeat domain, phosphoinositide interacting 2.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['polypeptide', 'calcium'],\n",
       "  'reaction': ['growth', 'stomatitis']},\n",
       " {'pmid': 29140729,\n",
       "  'sentence': 'Abbreviations Inducible nitric oxide synthase (INOS), neutrophil cytosolic factor 1 (p47phox), adrenomedullin (ADM), atrial natriuretic peptide (ANP), osteopontin (OPN/SPP1), angiotensin converting enzyme (ACE), monocyte chemotactic protein 1 (MCP-1), cytochrome b-245 beta polypeptide (gp91phox), intercellular adhesion molecule 1 (ICAM-1), transforming growth factor beta 1 (TGF-Î²1), connective tissue growth factor (CTGF), endothelin-1 (ET-1), cytochrome B-245, alpha polypeptide (p22phox), endothelin receptor type B (ETB/EDNRB), brain natriuretic peptide (BNP), endothelin receptor type A (ETA/EDNRA), matrix metallopeptidase 13 (MMP13), type I collagen (Col1a1), matrix metallopeptidase 2 (MMP2), TIMP metallopeptidase inhibitor 1 (TIMP1), Type III collagen (Col3a1), interleukin 1 beta (IL-1Î²), beta myocin heavy chain (Î²-MHC), endothelin converting enzyme 1 (ECE1) matrix metallopeptidase 14 (MMP14), angiotensinogen (AGT), angiotensin II receptor Type 1 (AT1R), cytochrome C oxidase I (COX1), fms-like tyrosine kinase 1 (FLT1), TIMP metallopeptidase inhibitor 2 (TIMP2), phospholamban (PLN), vascular cell adhesion molecule 1 (VCAM1), extracellular matrix (ECM).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'polypeptide'],\n",
       "  'reaction': ['angiotensin converting enzyme',\n",
       "   'adhesion',\n",
       "   'growth',\n",
       "   'growth',\n",
       "   'brain natriuretic peptide',\n",
       "   'brain natriuretic peptide',\n",
       "   'adhesion']},\n",
       " {'pmid': 29171745,\n",
       "  'sentence': 'During the course of our follow up, we have discovered additional instances of possible duplication as follows: \\n [5] Gastroenterology and Hepatology (Accepted 6 Aug 2014, Accepted ms online 28 Aug 2014, Published 23 Feb 2015) doi:10.1111/jgh.12723: Figure 1d AMPK is similar to Figure 2A AMPK in [1], Figure 3a iNOS is similar to Figure 2A LKB1 in [1] \\n [6] Acta Pharmacologica Sinica (Received 4 Mar 2014, Accepted 28 July 2014, Published 17 Nov 2014) doi: 10.1038/aps.2014.88: Figure 1 A and B bar charts are similar to Figure 1 A and B bar charts in [1], Figure 1E AMPK is similar to Figure 2A AMPK in [1], Figure 1E p-AMPK is similar to Figure 2A P-AMPK in [1], Figure 1E bar chart is similar to the Figure 2A bar chart in [1] \\n [7] Asian Pac J Cancer Prev (Published Jan 2014) doi: 10.7314/APJCP.2014.15.2.677: Figure 3A GAPDH is similar to Figure 2A AMPK in [1] and p27 kip1 is similar to Figure 2A P-AMPK in [1] \\n[8] Clinical and Experimental Hypertension (Received 15 Sep 2015, Accepted 24 Nov 2015, Published 5 May 2016) doi: 10.3109/10641963.2015.1131288: Figure 2A LKB1 and P-AMPK are similar to Figure 2A LKB1 and P-AMPK in [1], Figure 2B P-AMPK and AMPK are similar to Figure 2B P-AMPK and AMPK in [1], Figure 2A and B bar charts appear similar in both articles.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pac', 'prev'],\n",
       "  'reaction': ['hypertension']},\n",
       " {'pmid': 29172257,\n",
       "  'sentence': 'The proportion of MTA1 overexpression with 95% confidence interval (95% CI) was 0.53(95%CI: 0.43-0.62) in NSCLC\\npatients; 0.47(95%CI: 0.40-0.55) in age <60 years and 0.52(95%CI: 0.34-0.70) in age â‰¥60 years; 0.5(95%CI: 0.41-\\n0.62) in males and 0.51(95%CI: 0.39-0.62) in females; 0.59(95%CI: 0.48-0.69) in squamous cell carcinoma (SC) and\\n0.57(95%CI: 0.46-0.67) in adenocarcinoma (AC); 0.39(95%CI: 0.23-0.56) in well-differentiated tumors, 0.44(95%CI:\\n0.37-0.51) in moderately differentiated tumors and 0.55(95%CI: 0.37-0.51) in poorly differentiated tumors; 0.48(95%CI:\\n0.36-0.60) in clinical grade (III-IV) NSCLC and 0.75 (95%CI: 0.69-0.81) in clinical grade (I-II) NSCLC; 0.58(95%CI:\\n0.45-0.71) in T Stage (T1/T2) NSCLC; 0.68(95%CI: 0.49-0.82) in NSCLC patients with lymph node positivity and\\n0.51(95%CI: 0.43-0.58) in NSCLC patients with lymph node negativity.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['squamous cell carcinoma', 'adenocarcinoma']},\n",
       " {'pmid': 29189886,\n",
       "  'sentence': 'The results showed that taraxasterol decreased liver and kidney coefficients (p\\u2009<\\u20090.001), serum calcium (p\\u2009<\\u20090.01) level, serum alanine aminotransferase (p\\u2009<\\u20090.001), aspartate aminotransferase (p\\u2009<\\u20090.001), lactate dehydrogenase (p\\u2009<\\u20090.05) activities, urine magnesium (p\\u2009<\\u20090.05) and oxalate (p\\u2009<\\u20090.001) levels, number of crystal deposits (p\\u2009<\\u20090.001), score of crystal deposits (p\\u2009<\\u20090.01), score of histopathological damages (p\\u2009<\\u20090.001) and score of inflammation (p\\u2009<\\u20090.01) in kidney sections, while increased urine pH (p\\u2009<\\u20090.01), calcium (p\\u2009<\\u20090.001) and citrate (p\\u2009<\\u20090.05), serum magnesium (p\\u2009<\\u20090.001) and albumin (p\\u2009<\\u20090.01) levels, superoxide dismutase and glutathione peroxidase in serum (p\\u2009<\\u20090.01), kidney (p\\u2009<\\u20090.05 and p\\u2009<\\u20090.001, respectively) and liver (p\\u2009<\\u20090.01 and p\\u2009<\\u20090.001, respectively) tissue homogenates in treated urolithiatic rats in comparison to the control urolithiatic rats.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['magnesium', 'calcium'],\n",
       "  'reaction': ['alanine aminotransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'aspartate aminotransferase',\n",
       "   'inflammation']},\n",
       " {'pmid': 29199166,\n",
       "  'sentence': 'For the medication groups for which sufficient data were obtained (Figure 1), a systematic literature review in English was conducted using the keywords \"gastroesophageal reflux\" [MeSH Terms] and \"anti-inflammatory agents, non-steroidal\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"acetylsalicylic acid\" [MeSH Terms], \"gastroesophageal reflux\" [All Fields] and \"estrogenic agents\" [All Fields], \"gastroesophageal reflux\" [All Fields] and \"progesterones\" [All Fields], \"gastroesophageal reflux\" [All Fields] and \"hormone replacement therapy\" [All Fields], \"gastroesophageal reflux\" [MeSH Terms] and \"diphosphonates\" [MeSH Terms] OR \"diphosphonates\" [All Fields], \"calcium channel blockers\" [MeSH Terms] and \"gastroesophageal reflux\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"nitrates\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"antidepressive agents\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"benzodiazepines\" [MeSH Terms] and \"hypnotic drugs\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"cholinergic antagonists\" [MeSH Terms], \"gastroesophageal reflux\" [MeSH Terms] and \"theophylline\" [MeSH Terms], and \"gastroesophageal reflux [MeSH Terms] AND \"anti-asthmatic agents\" [MeSH Terms].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['hormone replacement therapy']},\n",
       " {'pmid': 29292200,\n",
       "  'sentence': 'Results indicated that the optimal Met-Met supplementation: (1) increased fish growth performance, intestinal lysozyme (LZ) and acid phosphatase (ACP) activities, complement (C3 and C4) and immunoglobulin M (IgM) contents, up-regulated hepcidin, liver expressed antimicrobial peptide 2A (LEAP-2A), LEAP-2B, Î²-defensin-1 and Mucin2 mRNA levels; (2) down-regulated tumour necrosis factor Î± (TNF-Î±), interferon Î³2 (IFN-Î³2), interleukin 1Î² (IL-1Î²), IL-8 [only in the distal intestine (DI)], IL-12p35, IL-12p40 and IL-15 (not IL-17D) mRNA levels partially related to the down-regulation of IÎºB kinase Î² (IKKÎ²) and IKKÎ³ (rather than IKKÎ±), nuclear factor kappa B (NF-ÎºB) p65 and c-Rel (rather than NF-ÎºB p52) mRNA levels and the up-regulation of inhibitor of ÎºBÎ± (IÎºBÎ±) mRNA levels; (3) up-regulated IL-4/13A, IL-4/13B, IL-6, IL-10, IL-11 and transforming growth factor (TGF)-Î²1 (not TGF-Î²2) mRNA levels partially associated with the target of rapamycin (TOR) signalling pathway [TOR/ribosomal protein S6 kinases 1 (S6K1), eIF4E-binding proteins (4E-BP)] in three intestinal segments of juvenile grass carp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'immunoglobulin'],\n",
       "  'reaction': ['growth', 'tumour necrosis', 'necrosis', 'growth']},\n",
       " {'pmid': 29362312,\n",
       "  'sentence': 'We report a case of synchronous and unilateral breast cancers in a 51-year-old female.A focal asymmetric right breast density was detected on breast cancer screening mammography.Ultrasonography showed a low echoic mass, 9mm in diameter, in the B area, and a second low echoic mass in the CD area of her right breast.A core needle biopsy of the B area mass led to a diagnosis of an invasive lobular carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), and negative for HER2/neu.One -percent of the tumor cells were Ki-67 positive.Her preoperative diagnosis was Stage I (T1N0M0).She underwent muscle-preserving mastectomy plus sentinel lymph node biopsy.The pathological diagnosis from the resected surgical specimen was invasive lobular carcinoma(B area), positive for ER, and negative for PgR and HER2/neu protein expression.From this, she was additionally diagnosed with non-invasive ductal carcinoma(CD area)that was posi- tive for ER, and negative for PgR and HER2/neu protein expression.The surgical margins were negative, and there were no sentinel lymph node metastases.These tumors were independent.She was given adjuvant endocrine therapy.Two years and 6 months after surgery, the patient was doing well and without metastases.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['breast cancer',\n",
       "   'mass',\n",
       "   'mass',\n",
       "   'biopsy',\n",
       "   'mass',\n",
       "   'progesterone',\n",
       "   'mastectomy',\n",
       "   'surgery']},\n",
       " {'pmid': 29362313,\n",
       "  'sentence': 'We report an elderly patient with locally advanced breast cancer who received long-term fulvestrant therapy.The patient was a 75-year-old woman who presented with a right breast lump.She noticed the tumor 4 years and 6 months ago, but she had not visited any hospital.However, her daughter brought her to our hospital.The tumor was 73mm in diameter.A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma, positive for estrogen receptor(ER)and progesterone receptor(PgR), and negative for HER2/neu.The Ki-67 positive cell index was 20%.We performed a whole- body checkup, and confirmed the diagnosis as T4cN1M0, Stage III B.She initiated endocrine therapy by letrozole(2.5 mg/ day).After 1 year and 6months, tumor marker levels increased.We changed the endocrine therapy to fulvestrant(500mg/ month).For the next 2 years and 6 months, this therapy was effective.Her axillary lymph node metastases disappeared and tumor size decreased(60%).She underwent muscle-preserving mastectomy plus axillary lymph node dissection.The pathological diagnosis from the resected surgical specimen was confirmed as invasive ductal carcinoma, positive for ER and PgR, and negative for HER2/neu protein expression.The surgical margins were negative, and there was no metastasis in the lymph nodes.She was administered adjuvant endocrine therapy.Four years after surgery, she was well without metastasis.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine', 'letrozole', 'fulvestrant'],\n",
       "  'reaction': ['elderly',\n",
       "   'breast cancer',\n",
       "   'biopsy',\n",
       "   'progesterone',\n",
       "   'mastectomy',\n",
       "   'metastasis',\n",
       "   'surgery',\n",
       "   'metastasis']},\n",
       " {'pmid': 29368965,\n",
       "  'sentence': 'A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACEI = angiotensin-converting enzyme inhibitor; ADVANCE = Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BCR-QR = bromocriptine quick release; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CHD = coronary heart disease; CKD = chronic kidney disease; CVD = cardiovascular disease; DASH = Dietary Approaches to Stop Hypertension; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density lipoprotein cholesterol; IMPROVE-IT = Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LDL-C = low-density lipoprotein cholesterol; LDL-P = low-density lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium glucose cotransporter-2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione; VADT = Veterans Affairs Diabetes Trial.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'calcium', 'cholesterol', 'sodium'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'apolipoprotein b',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'blood pressure',\n",
       "   'chronic kidney disease',\n",
       "   'hypertension',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate',\n",
       "   'blood glucose',\n",
       "   'blood glucose']},\n",
       " {'pmid': 29394550,\n",
       "  'sentence': 'A 63-year-old man presented with the chief complaint of an unpleasant feeling in the chest after a meal.Esophagogastroduodenoscopy revealed interminglement of ulcer infiltration type lesions and protruding lesions in the lower esophagus.A large type 1 protruding lesion was located mainly in the esophagogastric junction(EGJ)and it progressed towards the stomach.A hypertrophic and protruding lesion on the lower esophageal wall and a 6 cm tumor in the major axis of the fornix were observed on thoracic and abdominal CT, and an endocrine cell carcinoma or basaloid carcinoma were suggested after biopsy.Finally, we diagnosed a basaloid carcinoma after immunohistochemistry analysis.We administered 4 courses of TS-1 plus CDDP as pre-operative chemotherapy.Because of a significant reduction in tumor size, approximately 5 months after first presentation, we performed esophageal resection by right thoracotomy and laparotomy, and reconstructive surgery for the thoracic gastric duct.The pathological diagnosis was basaloid carcinoma with multiple foci of squamous cell carcinoma.After surgery, we continued chemotherapy with TS-1 plus CDDP, which was previously effective, but a liver metastasis appeared 8 months later.We discontinued chemotherapy because of a prominent decline in platelets.Because of the clinical symptoms, we diagnosed secondary thrombotic thrombocytopenic purpura accompanied by a malignant tumor.We implemented plasma exchange and steroid pulse therapy, but this patient experienced no therapeutic effect and died.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['endocrine'],\n",
       "  'reaction': ['ulcer',\n",
       "   'thoracotomy',\n",
       "   'laparotomy',\n",
       "   'surgery',\n",
       "   'surgery',\n",
       "   'chemotherapy',\n",
       "   'metastasis',\n",
       "   'chemotherapy',\n",
       "   'thrombotic thrombocytopenic purpura',\n",
       "   'thrombocytopenic purpura',\n",
       "   'purpura']},\n",
       " {'pmid': 29429506,\n",
       "  'sentence': \"Eleven Â« hot topics Â» were analyzed: i/lowering cholesterol level but not blood blessure has a significant impact on cardiovascular morbi-mortality in cardiovascular intermediate risk patients; ii/the Â« treat to treat target Â» is efficient in psoriatic arthritis; iii/ a genotype/ phenotype correlation favors the separation of ileal Crohn's disease, colonic Crohn's disease and ulcerative colitis; iv/ tocilizumab treatment (anti-IL-6 monoclonal antibody ) is very efficient in giant cell arteritis and slightly efficient in systemic sclerosis; v/ combination therapy using methotrexate plus steroids compared with steroids alone becomes the Â« gold standard Â» treatment for juvenile dermatomyositis; vi/ dupilumab treatment (antibody blocking IL-4 and IL-13 receptors) is not only efficient in atopic dermatitis but also in asthma; vii/ think of eosinophilic oesophagitis in a patient with atopic dermatitis and dypshagia or food impaction; viii/ genetic A2 protein dysfunction induces NF-kB hyperactivation and an autoinflammatory disorder with features similar to Behcet's disease; ix/ no new biotherapies have shown high efficacy in systemic lupus erythematosus; x/ nanoparticles loaded with autoantigens induce Tregs and Bregs and may be a promising therapeutic option to treat auto-immune disease in the future; xi/ ipilimumab treatment (anti-CTLA4 antibody, immune checkpoint inhibitor) may induce complete remission in acute myeloid leukemia patients relapsing after haematological stem cell transplantation.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['dupilumab',\n",
       "   'ipilimumab',\n",
       "   'methotrexate',\n",
       "   'tocilizumab',\n",
       "   'cholesterol'],\n",
       "  'reaction': ['arthritis',\n",
       "   'colitis',\n",
       "   'arteritis',\n",
       "   'dermatomyositis',\n",
       "   'dermatitis',\n",
       "   'dermatitis',\n",
       "   'asthma',\n",
       "   'eosinophilic oesophagitis',\n",
       "   'oesophagitis',\n",
       "   'dermatitis',\n",
       "   'dermatitis',\n",
       "   'systemic lupus erythematosus']},\n",
       " {'pmid': 29483431,\n",
       "  'sentence': 'We report 2 cases of prolonged survival achieved with surgical resection and multidisciplinary therapy for acinar cell carcinoma of the pancreas with liver metastases.Case 1: The patient was a 55-year-old woman.She presented with upper right abdominal pain and anemia.We diagnosed a tumor originating from the pancreas and multiple liver metastases.To avoid death caused by bleeding from the tumor, we performed pancreaticoduodenectomy and right-hemi hepatectomy, and a rapid diagnosis of acinar cell carcinoma of the pancreas was confirmed intraoperatively.After the hospital discharge, we administered hepatic intra-arterial chemotherapy and performed microwave ablation for the remnant liver metastases.Additionally, systemic chemotherapy with gemcitabine was administered; however, multiple metastases of the lung and liver became uncontrollable and she died 2 and half years postoperatively.Case 2: The patient was a 42-year-old woman.Through a medical checkup, gastric varix and elevated tumor markers were detected.The examination revealed a tumor at the tail of the pancreas and liver metastasis.We performed distal pancreatomy and partial liver resection.The pathological diagnosis was acinar cell carcinoma and liver metastasis.We administered adjuvant chemotherapy by using gemcitabine and achieved 5 years of relapse-free survival.The prognosis of ACC is better than that for PDAC.However, prognosis of unresectable cases is still unfavorable.Therapeutic strategies including aggressive surgical resection for metastatic ACC are worthy of consideration.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['gemcitabine'],\n",
       "  'reaction': ['abdominal pain',\n",
       "   'pain',\n",
       "   'death',\n",
       "   'pancreaticoduodenectomy',\n",
       "   'hepatectomy',\n",
       "   'discharge',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy',\n",
       "   'chemotherapy']},\n",
       " {'pmid': 29498024,\n",
       "  'sentence': 'Cardiomyopathies (Cs) are a heterogeneous group of myocardial diseases with structural and/or functional abnormalities.The aetiology is due to genetic-family substrate in most cases, however, the correct and detailed analysis of morphofunctional abnormalities (severity and distribution of hypertrophy, ventricular dilatation, ventricular dysfunction) and tissue characteristics (myocardial fibrosis, myocardial infiltration) are a crucial element for a definite diagnosis.Among the different diagnostic imaging modalities applied in clinical practice (echocardiography, nuclear medicine), cardiac magnetic resonance (CMR) has emerged as a non-invasive diagnostic tool having high ability to quantify systolic function and tissue abnormalities that represent the substrates of many Cs.The main added value of CMR is the ability to identify cardiomyopathies with respect to ischemic heart disease and, above all, to discriminate the major types of cardiomyopathies based on morpho-functional presentation patterns and the presence and location of myocardial fibrosis.Many CMR elements allow increasing diagnostic accuracy but CMR data should be integrated with an appropriate clinical and instrumental context.Computed Tomographic (CT) scan technology has showed a complementary role in patients having Cs and HF.In this chapter, the diagnostic, pathophysiologic and prognostic value of CMR and CT in heart failure due to the most common cardiomyopathies will be discussed.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['hypertrophy',\n",
       "   'ventricular dysfunction',\n",
       "   'myocardial fibrosis',\n",
       "   'fibrosis']},\n",
       " {'pmid': 29608324,\n",
       "  'sentence': 'During transplantation, patients receive components that are ABO-compatible with both the donor graft and recipient; this practice can strain group O red blood cell (RBC) inventories.1 In addition, there are risks for acute hemolysis at the time of infusion and in the early post-transplant period.1,2 In ABO major-incompatible bone marrow HSCTs, which contain significant quantities of donor RBCs that are ABOi with recipient plasma, it is common to perform a RBC depletion of the bone marrow in an effort to minimize hemolysis at the time of infusion.2 Furthermore, patients with high-titer ABO antibodies may undergo a prophylactic, pre-transplant plasma exchange to further reduce the risk of acute hemolysis, delayed RBC engraftment, and pure RBC aplasia.2-4 ABO minor-incompatible HSCTs, in which donor plasma is ABOi with the recipient, have less risk for hemolysis at the time of infusion but can result in transient hemolysis approximately 10-21 days post-transplant, especially in patients undergoing nonmyeloablative HSCT and/or patients who have not received methotrexate for graft-versus-host-disease (GVHD) prophylaxis.1-4 In these patients, viable donor B-lymphocytes in the graft may expand and produce ABO antibodies capable of hemolyzing patient RBCs.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['methotrexate'],\n",
       "  'reaction': ['infusion', 'infusion']},\n",
       " {'pmid': 29627983,\n",
       "  'sentence': 'Fish oil could also improve HFD-induced imbalance of lipid metabolism in blood, liver, and adipose tissues including the significant decreases in plasma and liver total cholesterol (TC) (plasma-HFD, 113 Â± 33.6 mg/dL; HFD+FO, 50.0 Â± 5.95 mg/dL, p < 0.05; liver-HFD, 102 Â± 13.0 mg/g liver; [corrected] HFD+FO, 86.6 Â± 7.81 mg/g liver, [corrected] p < 0.05), blood, liver, and adipose triglyceride (TG) (blood-HFD, 52.5 Â± 20.4 mg/dL; HFD+FO, 29.8 Â± 4.30 mg/dL, p < 0.05; liver-HFD, 56.2 Â± 10.0 mg/g liver; [corrected] HFD+FO, 30.3 Â± 5.28 mg/g liver, [corrected] p < 0.05; adipose-HFD, 614 Â± 73.2 mg/g liver, [corrected] HFD+FO, 409 Â± 334 mg/g of adipose tissue, [corrected] p < 0.05), and low density (HFD, 79.8 Â± 40.9 mg/dL; HFD+FO, 16.6 Â± 5.47 mg/dL, p < 0.05) and very-low-density (HFD, 49.7 Â± 33.3 mg/dL; HFD+FO, 10.4 Â± 3.45 mg/dL, p < 0.05) lipoprotein and the significant increases in fecal TC (HFD, 12.2 Â± 0.67 mg/g feces; [corrected] HFD+FO, 16.3 Â± 2.04 mg/g feces, [corrected] < 0.05) and TG (HFD, 2.09 Â± 0.10 mg/g feces; [corrected] HFD+FO, 2.38 Â± 0.22 mg/g feces, [corrected] p < 0.05) and lipoprotein lipase activity of adipose tissues (HFD, 16.6 Â± 3.64 Î¼M p-nitrophenol; HFD+FO, 24.5 Â± 4.19 Î¼M p-nitrophenol, p < 0.05).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['lipase', 'lipase']},\n",
       " {'pmid': 29631831,\n",
       "  'sentence': 'Based on medication class, the highest and lowest cost medications were antiallergy agents (Zaditor [ketotifen], Vasocon [naphazoline]), antibiotic ophthalmic solutions (Vigamox [moxifloxacin], generic ciprofloxacin), oral antibiotics (Cipro [ciprofloxacin], generic cephalexin), antibiotic ophthalmic ointments (generic erythromycin, Tobrex [tobramycin]), antiviral treatment (Valtrex [oral valacyclovir], Viroptic [topical trifluridine]), blepharitis treatment (Zithromax [oral azithromycin], generic oral tetracycline), beta-adrenergic inhibitors (Timoptic [topical timolol], generic topical timolol), topical prostaglandin analogues (Xalatan [latanoprost], generic travoprost), oral carbonic anhydrase inhibitors (methazolamide, acetazolamide), topical carbonic anhydrase solutions (Trusopt preservative-free [dorzolamide], Azopt [brinzolamide]), topical alpha-adrenergic agonists (Alphagan [brimonidine], generic brimonidine), topical muscarinic agonists (Isopto carpine [pilocarpine], Diocarpine [pilocarpine]), topical combination glaucoma agents (Cosopt [dorzolamide-timolol], generic dorzolamide-timolol), topical lubricants (Lacri-lube, Isopto tears), topical nonsteroidal anti-inflammatory drugs (Acuvail [ketorolac], Ilevro [nepafenac]), and steroids (Durezol [difluprednate], Pred mild [prednisolone]).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tobramycin',\n",
       "   'valacyclovir',\n",
       "   'ketorolac',\n",
       "   'tetracycline',\n",
       "   'ketotifen',\n",
       "   'brinzolamide',\n",
       "   'ciprofloxacin',\n",
       "   'methazolamide',\n",
       "   'latanoprost',\n",
       "   'azithromycin',\n",
       "   'moxifloxacin',\n",
       "   'acetazolamide',\n",
       "   'travoprost',\n",
       "   'trifluridine',\n",
       "   'pred',\n",
       "   'prednisolone',\n",
       "   'dorzolamide',\n",
       "   'naphazoline',\n",
       "   'timolol',\n",
       "   'erythromycin',\n",
       "   'nepafenac'],\n",
       "  'reaction': ['blepharitis', 'glaucoma']},\n",
       " {'pmid': 29665497,\n",
       "  'sentence': 'Histological changes in the nasal mucosa were evaluated by hematoxylin and eosin (H & E) and Periodic Acid-Schiff (PAS) staining; cytokine levels in serum were measured with enzyme-linked immunosorbent assays (ELISAs);the mRNA expression levels of IFN-Î³, IL-17 and Foxp3 in the spleen determined by quantitative real-time RT-PCR (qRT-PCR); the proportions of Th1, Th2, Th17, Treg and TIM3\\u202f+\\u202fIFN-Î³\\u202f+\\u202fTh1 cells in the spleen were assessed with flow cytometry; TIM1, TIM3 and IL-33 expression levels in the nasal mucosa were evaluated with immunofluorescence staining(IF).R848 alleviated the nasal allergic symptoms; reduced eosinophil cell infiltration, goblet cell hyperplasia in the nasal mucosa; reduced IL-13, IL-17, IL-25 and IL-33 levels in serum; upregulated the relative mRNA expression of IFN-Î³ and Foxp3, and downregulated the relative mRNA expression of IL-17 in the spleen; decreased Th2, Th17 and TIM3\\u202f+\\u202fIFN-Î³\\u202f+\\u202fTh1 cells ratios, increased the proportion of Th1 and Treg cells in the spleen; suppressed TIM1 and TIM3,but increased IL-33 expression in the nasal mucosa in OVA-induced AR mice.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['nasal'],\n",
       "  'reaction': ['flow cytometry', 'hyperplasia']},\n",
       " {'pmid': 29708668,\n",
       "  'sentence': 'To screen new tuberculosis diagnostic antigens and vaccine candidates,we predicted the epitopes of Mycobacterium tuberculosis latent infection-associated protein Rv2004 cby means of bioinformatics.The homology between Rv2004 cprotein and human protein sequences was analyzed with BLAST method.The second structures,hydrophilicity,antigenicity,flexibility and surface probability of the protein were analyzed to predict B cell epitopes and T cell epitopes by Protean software of DNAStar software package.The Th epitopes were predicted by RANKPEP and SYFPEITHI supermotif method,the CTL epitopes were predicted by means of combination analyses of SYFPEITHI supermotif method,BIMAS quantitative motif method and NetCTL prediction method.The peptide sequences with higher scores were chosen as the candidate epitopes.Blast analysis showed that Rv2004 cprotein had low homology with human protein.This protein had abundant secondary structures through analysis of DNAStar software,the peptide segments with high index of hydrophilicity,antigenicity,surface probability and flexibility were widely distributed and were consistent with segments having beta turn or irregular coil.Ten candidates of B cell epitopes were predicted.The Th epitopes of Rv2004 cprotein were located after the 200 th amino acid.Of 37 Th cell epitopes predicted,there were more epitopes of HLA-DRB1*0401and HLA-DRB1*0701phenotypes,and the MHC restrictive types of some Th cell epitopes exist cross overlap.Of 10 CTL epitopes predicted,there were more number and higher score of HLA-A2 restricted epitopes.Therefore MycobacteriumtuberculosisRv2004 cprotein is a protein antigen with T cell and B cell epitopes,and is expected to be a new target protein candidate for tuberculosis diagnosis and vaccine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide'],\n",
       "  'reaction': ['tuberculosis', 'tuberculosis', 'tuberculosis']},\n",
       " {'pmid': 29709152,\n",
       "  'sentence': 'This study aims to investigate the role of calreticulin in(CRT)pressure overload induced cardiac hypertrophy.In our study,cardiac hypertrophy was induced by left ventricular pressure overload in male SD rats subjected to transverse aortic constriction(TAC)operation.Expression of gene and protein of calreticulin,markers of cardiac hypertrophy and endoplasmic reticulum stress(ERS)were measured with real-time qPCR and Western blot respectively.Meanwhile,atorvastatin(a known ERS inhibitor)and calreticulin-specific small interference ribonucleic acid(siRNA)were used to inhibit the expression of ERS and calreticulin respectively.The experimental data demonstrated that the gene and protein levels of calreticulin,hypertrophic and ERS markers were increased significantly in the heart tissues of TAC rat models after 4weeks.Moreover,atorvastatin administration improved the cardiac function and reduced the expression of calreticulin and ERS markers in TAC rats.In addition,cultured primary neonatal rat cardiomyocytes(NCMs)were treated with norepinephrine(NE),angiotensionâ…¡(Angâ…¡)or isoprenaline(ISO)to induce hypertrophic phenotype and ERS.The expression of hypertrophic markers was reduced in NCMs transfected with calreticulin-siRNA.The results suggested that calreticulin might be a promising target for the treatment of cardiac hypertrophy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'atorvastatin', 'cardiac'],\n",
       "  'reaction': ['cardiac hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'cardiac hypertrophy',\n",
       "   'hypertrophy',\n",
       "   'stress',\n",
       "   'cardiac hypertrophy',\n",
       "   'hypertrophy']},\n",
       " {'pmid': 29714943,\n",
       "  'sentence': 'With silk fibroin and vancomycin(VCM)as carrier and drug model,respectively,we prepared silk fibroin microspheres(SFM)with different concentration using the water-in-oil emulsion solvent diffusion method.We further developed VCM loaded calcium sulfate hemihydrates(CSH)/SFM artificial bone composites.In this study,surface morphology of the materials was observed using scanning electron microscope(SEM).Structure of the materials was studied with Fourier transform infrared spectroscopy(FTIR).Antibacterial activity of the materials was validated with the inhibition zone test.Drug release property of materials was evaluated using ultraviolet/visible spectrophotometry.Mechanical property of the materials was tested using computer-controlled electronic universal testing machine.The results showed that silk fibroin concentration had no significant effect on molecular conformation and antibacterial property of the SFM.The average diameter of SFM increased and the release rate decreased gradually as the silk fibroin concentration increased.The release rate decreased and the compressive fracture work increased as the silk fibroin concentration increased when adding SFM to CSH.This composite had partly corrected the disadvantages of CSH including the high brittleness and initial burst release.The research would have a good application foreground in the clinical treatment of infectious bone defect.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['vancomycin', 'calcium'],\n",
       "  'reaction': ['fracture']},\n",
       " {'pmid': 29714977,\n",
       "  'sentence': 'In order to solve the problem of high cytotoxicity in vitro of nano-silver antibacterial gel,and the problem of large nano-silver particle size and size distribution,this study prepared nano-silver antibacterial gel with better biocompatibility and good antibacterial effect by using physical cross-linking method and using poloxamer as dispersant when prepared nano-silver.In this study,nano-silver was prepared by photo-initiator method and by adding poloxamer as a dispersant,and then UV-visible absorption spectrum test and scanning electron microscopy(SEM)test were carried out using prepared nano-silver mixture and particles after drying respectively.The gel was prepared through adjusting its pH value by using sodium bicarbonate,and then pH value test,SEM test for cross-section of gel,swelling ratio test,viscosity test,inhibition zone test and in vitro cytotoxicity test were carried out.The test results showed that the maximum absorption wavelength of prepared nano-silver,using poloxamer as dispersant and ultra-pure water as solvent,was 414 nm,and the average nano-silver size was about 60 nm.The prepared nano-silver using poloxamer as dispersant had smaller particle diameter and narrower particle size distribution than those using PVP as dispersant.Similarly,the prepared nano-silver using ultra-pure water as solvent also had smaller particle diameter and narrower particle size distribution than those using distilled water as solvent.The pH value of the prepared gel was between 5.8~6.1.The dried gel section had many holes.The water absorption of gel was fine and the viscosity of gel was fit to coat on the gauze.In addition,the prepared gel with nano-silver had greater ability to inhibit Escherichia coli and Staphyloccocus aureus at the concentrations of 24,18 and 12Î¼g/mL.And the biocompatibility of the prepared gel with nano-silver was good when the concentration below 24Î¼g/mL.Based on the above features,the nano-silver antibacterial gel could be used in the treatment of burn or other wounds.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['swelling']},\n",
       " {'pmid': 29714981,\n",
       "  'sentence': 'The new mechanisms of automaticity controlled by the calcium and membrane clocks in sinoatrial node are helpful to revealing the sinus arrhythmia,but the present calcium dynamic model is only on the single cell level.In the present study,a central and peripheral single cell model was developed,and by exponentially changing the cell membrane capacitance,size,conductance and gap junction from the center to the periphery,a two-dimensional inhomogeneous sinus and atrial model was created on the basis of the anatomical structure.Five-point difference and finite element methods were used to process the internal grids and the borders.Irregular borders were defined by creating segment trial functions.Quantitative experiments suggested the consistency of the central and peripheral action potentials with related reports in amplitude,cycle length,maximum diastolic potential and upstroke velocity.Functions of the calcium and membrane clocks on the leading pacemaker site and upstroke velocity as well as the effects of the atrial premature beat on the sinus automaticity were also in good agreement with those in other studies.The developed model is helpful for deeply studying relative roles of the calcium and membrane clocks in automaticity and the relations with electrical activities in atrium.At the same time it will lay the foundation for building three-dimensional sinus and atrial organic models.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['sinus arrhythmia', 'arrhythmia']},\n",
       " {'pmid': 29724305,\n",
       "  'sentence': 'Methods Totally 60 patients undergoing VATS lobectomy were enrolled in this single-center randomized controlled study.The patients were equally randomized into lidocaine continuous pumping group(lidocaine group) and control group by computer-based random numbers.The patients had double-lumen catheter intubation,and total intravenous anesthesia was administrated intraoperatively.In the lidocaine group,patients continuously received intravenous pumping of lidocaine [2 mg/(kgdh) ] after a loading doses(1 mg/kg) until the end of the operation.We recorded the basic characteristics,preoperative examination,intraoperative medications,and postoperative recovery of both groups.Results The basic characteristics and preoperative examination findings were comparable between these two groups(all P>0.05).Compared with the control group,the intraoperative sufentanil consumption significantly decreased in the lidocaine group [(32.3Â±7.5) Î¼g vs.(40.9Â±10.2) Î¼g,P<0.001].Significantly more patients were given esmolol intraoperatively in the control group to lower heart rate(P=0.010).The incidence of postoperative nausea within 24 hours was significantly lower in the lidocaine group(P=0.045).There was no significant difference between the two groups in postoperative recovery(all P>0.05).Conclusion Intravenous continuous pumping of lidocaine during operation can reduce opioids consumption and lower the incidence of postoperative nausea without extra adverse or toxic reaction in patients undergoing VATS lobectomy.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sufentanil', 'lidocaine', 'esmolol'],\n",
       "  'reaction': ['heart rate', 'heart rate', 'nausea', 'nausea']},\n",
       " {'pmid': 29886470,\n",
       "  'sentence': 'Results: There was no statistical significance in sex, age, height, body mass, initial diagnosis and re-diagnosis interval between the 2 groups (P>0.05); the total efficiency after ORS III and ORS I \\u2028treatment were 79.59% and 62.96%, respectively, with no statistical significance (Ï‡2=2.483, P>0.05); the HUTT negative conversion rate after ORS III and ORS I treatment were 51.02% and 48.16%, respectively, with no statistical significance (Ï‡2=0.058, P>0.05); before treatment, the serum sodium [(140.20Â±2.26) mmol/L vs (138.39Â±2.72) mmol/L; t=2.856, P<0.05] in the ORS III group was higher than that in the ORS I group, the serum phosphorus [(1.46Â±0.19) mmol/L \\u2028vs (1.65Â±0.29) mmol/L; t=3.146, P<0.05] in the ORS III group was lower than that in the ORS I \\u2028group; after treatment, the serum sodium [(140.31Â±2.01) mmol/L vs (138.88Â±2.08) mmol/L; \\u2028t=2.692, P<0.05] and serum calcium [(2.31Â±0.09) mmol/L vs (2.24Â±0.11) mmol/L; t=2.696, P<0.05] in the ORS III group were higher than those in the ORS I group, the serum phosphorus [(1.45Â±0.16) mmol/L vs (1.61Â±0.25) mmol/L; t=3.128, P<0.05] in the ORS III group was lower than that in the ORS I group; after ORS III treatment, there was no statistical significance in serum electrolytes between HUTT positive group and HUTT negative group (P>0.05); after ORS I treatment, the serum calcium [(2.29Â±0.10) mmol/L vs (2.19Â±0.10) mmol/L; t=2.501, P<0.05] and serum phosphorus [(1.71Â±0.24) mmol/L vs (1.50Â±0.21) mmol/L; t=2.392, P<0.05] in HUTT positive group were higher than those in HUTT negative group.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium', 'sodium'],\n",
       "  'reaction': ['mass']},\n",
       " {'pmid': 30158417,\n",
       "  'sentence': 'A 54-year-old man who was undergoing a routine hemodialysis for chronic renal failure presented with cold symptoms and was prescribed antibiotics.As no symptomatic improvement was achieved, he was referred to the Department of Internal Medicine in our hospital, where computed tomographic scan findings raised the suspicion of lung cancer.He was then referred to the Department of Surgery.A bronchoscopy detected a tumor, which obstructed the right upper lobe bronchus, and the patient was diagnosed with squamous cell carcinoma.Based on the mediastinal lymph node enlargement that extended into the contralateral hilar region, the stage was determined to be III B(c-T3N3M0), and we initiated chemotherapy.The regimen was CBDCA plus PTX.The carboplatin dose area under the curve(AUC)was 4(100 mg at a glomerular filtration rate of 0)for the first course, AUC 5 for the second course, and AUC 6 for the third to sixth courses, and the PTX dose was 200mg/m2.Only mild adverse events were noted, and the patient achieved a partial response after 6 treatment courses.Only a few reports have described chemotherapies administered to patients with lung cancer on hemodialysis, and as such, evidence of useful drugs is not yet available.This makes it difficult to select the most appropriate treatment for such patients.We report our experience with this patient, with a relevant literature review.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['carboplatin'],\n",
       "  'reaction': ['renal failure',\n",
       "   'bronchoscopy',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate']},\n",
       " {'pmid': 30187438,\n",
       "  'sentence': 'The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the \"gold standard\" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['intensive care']},\n",
       " {'pmid': 30231727,\n",
       "  'sentence': 'Using both published and unpublished adaptive design clinical trials, we have selected and reviewed examples of clinical trials with different design adaptations to discuss the ethical obstacles presented and often successfully resolved by these approaches, including (1) confirmatory trials for treatments widely accepted on the basis of uncontrolled case series or open-label trials (clinical equipoise and \"justice\" in the sense of which trial groups will \"receive the benefits of research and bear its burdens\") (infantile hemangioma/propranolol); (2) interim results analysis by unblinded data monitoring committees (\"withholding information necessary to make a considered judgment\" [\"respect for persons\"] versus compromising the trial\\'s scientific basis) (BIG 1-98); (3) adaptations involving sample size reassessment or dose adjustment via dropping or adding treatment arms, allowing fewer subjects to produce statistically significant results, fewer subjects treated with ineffective/toxic doses, and more subjects given doses showing tolerance and treatment activity (\"beneficence\" or \"protecting from harm and making efforts to secure wellbeing\") (ECMO, Neuromyelitis Optica); (4) adaptive randomization inferential problems balanced against ethical benefits (trastuzumab vs taxane in advanced gastric cancer; ADVENT); (5) more efficient allocation of societal resources for research, in both public and commercial realms, versus uncertain regulatory acceptance (indicaterol; VALOR); and (6) platform, umbrella, and basket trials offering additional efficiencies (I-SPY II, BATTLE, Lung-MAP).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['trastuzumab'],\n",
       "  'reaction': ['gastric cancer']},\n",
       " {'pmid': 30290714,\n",
       "  'sentence': \"Abbreviations: AD: Alzheimer disease; AEC: airway epithelial cells; BALF: bronchoalveolar lavage fluid; AKT: AKT serine/threonine kinase; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CDKN1A: cyclin dependent kinase inhibitor 1A; CDKN2A: cyclin dependent kinase inhibitor 2A; COPD: chronic obstructive pulmonary disease; CS: cigarette smoke; CSE: CS extract; CXCL1: C-X-C motif chemokine ligand 1; CXCL8: C-X-C motif chemokine ligand 8; HBEC: human bronchial epithelial cells; 4-HNE: 4-hydroxynonenal; IL: interleukin; KO: knockout; LF: lung fibroblasts; LPS: lipopolysaccharide; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; 8-OHdG: 8-hydroxy-2'-deoxyguanosine; OPTN: optineurin; PRKN: parkin RBR E3 ubiquitin protein ligase; PCD: programmed cell death; PFD: pirfenidone; PIK3C: phosphatidylinositol-4:5-bisphosphate 3-kinase catalytic subunit; PINK1: PTEN induced putative kinase 1; PTEN: phosphatase and tensin homolog; RA: rheumatoid arthritis; ROS: reactive oxygen species; SA-GLB1/Î²-Gal: senescence-associated-galactosidase, beta 1; SASP: senescence-associated secretory phenotype; SNP: single nucleotide polymorphism; TNF: tumor necrosis factor.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['cell death',\n",
       "   'death',\n",
       "   'rheumatoid arthritis',\n",
       "   'arthritis',\n",
       "   'necrosis']},\n",
       " {'pmid': 30335591,\n",
       "  'sentence': \"Abbreviations: ALS: amyotrophic lateral sclerosis; AR: androgen receptor; ATG: autophagy related; AV: autophagic vacuole; BAG3: BCL2-associated athanogene 3; BECN1: beclin 1, autophagy related; CASA: chaperone-assisted selective autophagy; CTSB: cathepsin b; DAPI: 4',6-diamidino-2-phenylindole; DMEM: Dulbecco's modified Eagle's medium; EGFP: enhanced green fluorescent protein; fALS, familial amyotrophic lateral sclerosis; FRA: filter retardation assay; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLA: galactosidase, alpha; HD: Huntington disease; hIPSCs: human induced pluripotent stem cells; HSPA8: heat shock protein A8; HSPB8: heat shock protein B8; IF: immunofluorescence analysis; LAMP1: lysosomal-associated membrane protein 1; LAMP2A: lysosomal-associated membrane protein 2A; LGALS3: lectin, galactose binding, soluble 3; LLOMe: L-leucyl-L-leucine methyl ester; LMP: lysosomal membrane permeabilization; Lys: lysosomes; MAP1LC3B: microtubule-associated protein 1 light chain 3 beta; MCOLN1: mucolipin 1; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; NDs: neurodegenerative diseases; NSC34: neuroblastoma x spinal cord 34; PBS: phosphate-buffered saline; PD: Parkinson disease; polyQ: polyglutamine; PPARGC1A: peroxisome proliferative activated receptor, gamma, coactivator 1 alpha; PPP3CB: protein phosphatase 3, catalytic subunit, beta isoform; RT-qPCR: real-time quantitative polymerase chain reaction; SBMA: spinal and bulbar muscular atrophy; SCAs: spinocerebellar ataxias; siRNA: small interfering RNA; SLC2A8: solute carrier family 2, (facilitated glucose transporter), member 8; smNPCs: small molecules neural progenitors cells; SOD1: superoxide dismutase 1; SQSTM1/p62: sequestosome 1; STED: stimulated emission depletion; STUB1: STIP1 homology and U-box containing protein 1; TARDBP/TDP-43: TAR DNA binding protein; TFEB: transcription factor EB; TPP1: tripeptidyl peptidase I; TREH: trehalase (brush-border membrane glycoprotein); WB: western blotting; ZKSCAN3: zinc finger with KRAB and SCAN domains 3.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['amyotrophic lateral sclerosis',\n",
       "   'amyotrophic lateral sclerosis',\n",
       "   'shock',\n",
       "   'shock',\n",
       "   'neuroblastoma',\n",
       "   'atrophy']},\n",
       " {'pmid': 30339843,\n",
       "  'sentence': \"The results were analysed by the Duncan's multiple-range test (P\\u202f<\\u202f0.05), indicating that compared with the control group (27\\u202fÎ¼g/kg diet), dietary DON levels up to 318\\u202fÎ¼g/kg diet: (1) decreased lysozyme (LZ) and acid phosphatase (ACP) activities, as well as complement 3 (C3), C4 and immunoglobulin M (IgM) content in the proximal intestine (PI), middle intestine (MI) and distal intestine (DI) of juvenile grass carp (P\\u202f<\\u202f0.05); (2) down-regulated the mRNA levels of anti-microbial substance: liver expressed antimicrobial peptide (LEAP) -2A, LEAP-2B, hepcidin, Î²-defensin-1 and mucin2 in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05); (3) up-regulated the mRNA levels of pro-inflammatory cytokines [interleukin 1Î² (IL-1Î²), tumour necrosis factor Î± (TNF-Î±), interferon Î³2 (INF-Î³2), IL-6 (only in PI), IL-8, IL-12p35, IL-12p40, IL-15 and IL-17D] in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05), which might be partly related to nuclear factor kappa B (NF-ÎºB) signalling [IÎºB kinase Î² (IKKÎ²) and IKKÎ³/inhibitor of ÎºBÎ± (IÎºBÎ±)/NF-ÎºB (p65 and c-Rel)]; and (4) down-regulated the mRNA levels of anti-inflammatory cytokines [IL-10, IL-11, IL-4/13A (not IL-4/13B), transforming growth factor Î²1 (TGF-Î²1) (not TGF-Î²2)] in the PI, MI and DI of juvenile grass carp (P\\u202f<\\u202f0.05), which might be partly related to target of rapamycin (TOR) signalling [TOR/ribosomal protein S6 kinases 1 (S6K1) and eIF4E-binding proteins (4E-BP)].\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'immunoglobulin'],\n",
       "  'reaction': ['tumour necrosis', 'necrosis', 'growth']},\n",
       " {'pmid': 30407304,\n",
       "  'sentence': 'Patients with CHF were older (73.3 vs 64.7 years, P\\u200a<.001), less likely to be women (37.4% vs 42%, P\\u200a=\\u200a.007), had higher CHA2DS2-VASc score (3.8\\u200aÂ±\\u200a1.7 vs 2.6\\u200aÂ±\\u200a1.8, P\\u200a<.001), more often had permanent AF (53.0% vs 13.4%, P\\u200a<.001), chronic obstructive pulmonary disease (16.7% vs 4.9%, P\\u200a<.001), coronary artery disease (64.3% vs 29.8%, P\\u200a<.001), peripheral vascular disease (65.3% vs 31.4%, P\\u200a<.001), chronic kidney disease (43.1% vs 10.0%, P\\u200a<.001), liver fibrosis (5.7% vs 2.6%, P\\u200a<.001), neoplasm (9.6% vs 7.3%, P\\u200a=\\u200a.05), history of composite of stroke, transient ischemic attack or systemic embolization (16.2% vs 10.7%, P\\u200a<.001), pacemaker (27.4% vs 22.1%, P\\u200a=\\u200a.004), implantable cardioverter-defibrillator (22.7% vs 0.8%, P\\u200a<.001) or transaortic valve implantation (4.0% vs 0.8%, P\\u200a<.001), cardiac resynchronization therapy (8.7% vs 0.3%, P\\u200a<.001), composite of kidney transplantation, hemodialysis or creatinine level\\u200a>\\u200a2.26\\u200amg/dL (3.6% vs 0.8%, P\\u200a<.001) and had less often hypertension (69.4% vs 72.5%, P\\u200a=\\u200a.05).Patients with AF and CHF had a higher thromboembolic risk and had more concomitant diseases.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'concomitant'],\n",
       "  'reaction': ['coronary artery disease',\n",
       "   'chronic kidney disease',\n",
       "   'fibrosis',\n",
       "   'neoplasm',\n",
       "   'hypertension']},\n",
       " {'pmid': 30472582,\n",
       "  'sentence': 'The validation proved that the method was suitable for the quantitative analysis of a wide panel of androgens (testosterone, T (3.3\\u2009pM-13 nM); androstenedione, A4 (3.3\\u2009pM-13 nM); 5Î±-androstanedione, DHA4 (13\\u2009pM-13 nM); dehydroepiandrosterone, DHEA (67\\u2009pM-133 nM); dihydrotestosterone, DHT (33\\u2009pM-33 nM); 11-ketodihydrotestosterone, 11KDHT (13\\u2009pM-13nM); 11-ketotestosterone, 11KT (33\\u2009pM-6.7\\u2009nM); 11Î²-hydroxyandrostenedione, 11bOHA4 (33\\u2009pM-13 nM); 11Î²-hydroxytestosterone, 11OHT (13\\u2009pM-33 nM)), as well as estrogens (estrone, E1 (3.3\\u2009pM-13 nM)), progestagens (17Î±-hydroxypregnenolone, 17OHP5 (32\\u2009pM-127\\u2009nM); 17Î±-hydroxyprogesterone, 17OHP4 (67\\u2009pM-133 nM); progesterone, P4 (3.3\\u2009pM-13 nM); pregnenolone, P5 (6.6 pM-13 nM)), and glucocorticoids (cortisol, F (33\\u2009pM-134\\u2009nM); cortisone E (66 pM-131 nM); corticosterone, B (33\\u2009pM-67\\u2009nM); 11-deoxycortisol, S (33\\u2009pM-66 nM); 21-hydroxyprogesterone, 21OHP4 (32\\u2009pM-13 nM)).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['pregnenolone'],\n",
       "  'reaction': ['androgens',\n",
       "   'dehydroepiandrosterone',\n",
       "   'progesterone',\n",
       "   'glucocorticoids',\n",
       "   'cortisol']},\n",
       " {'pmid': 30477805,\n",
       "  'sentence': \"A total of 3,415 (5.14%) had depression, 670 (1.0%) had rheumatoid arthritis, 640 (0.96%) had anxiety, 545 (0.82%) had a migraine disorder, 440 (0.66%) used steroids, 385 (0.58%) had malignant hypertension, 280 (0.42%) had systemic lupus erythematosus, 250 (0.38%) had cocaine abuse, 215 (0.32%) had hypertensive heart or renal disease, 130 (0.19%) had coronary spasm, 105 (0.16%) had fibromuscular dysplasia, 85 (0.13%) had Crohn's disease, 75 (0.11%) had celiac disease, 60 (0.09%) had adult autosomal dominant polycystic kidney disease, 60 (0.09%) had hormone replacement therapy, 55 (0.08%) had sarcoidosis, 55 (0.08%) had amphetamine abuse, 15 (0.02%) had granulomatosis polyangiitis, 10 (0.02%) had Î±1-antitrypsin deficiency, 10 (0.02%) had Marfan syndrome, 10 (0.02%) had Ehlers-Danlos syndrome, 10 (0.02%) had Kawasaki disease, 10 (0.02%) had polyarteritis nodosa, and 5 (0.01%) had multiparity.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cocaine'],\n",
       "  'reaction': ['depression',\n",
       "   'rheumatoid arthritis',\n",
       "   'arthritis',\n",
       "   'anxiety',\n",
       "   'migraine',\n",
       "   'malignant hypertension',\n",
       "   'hypertension',\n",
       "   'systemic lupus erythematosus',\n",
       "   'fibromuscular dysplasia',\n",
       "   'dysplasia',\n",
       "   'hormone replacement therapy',\n",
       "   'sarcoidosis',\n",
       "   'ehlers-danlos syndrome',\n",
       "   'polyarteritis nodosa']},\n",
       " {'pmid': 30543935,\n",
       "  'sentence': 'The results showed that dietary gossypol (1) could aggravate enteritis and damage the structure of intestinal epithelial cells, (2) decreased the lysozyme (LZ) and Acid phosphatase (ACP) activities, complement 3 (C3), C4 and immunoglobulin M (IgM) contents, and it down-regulated the Hepcidin (rather than distal intestine (DI)), immunoglobulin Z (IgZ), liver-expressed antimicrobial peptide (LEAP)-2B, Mucin2 and Î²-defensin-1 mRNA levels in the proximal intestine (PI), mid intestine (MI) and DI, (3) up-regulated intestinal pro-inflammatory cytokines tumor necrosis factor Î± (TNF-Î±), interferon Î³2 (IFN-Î³2), interleukin 1Î² (IL-1Î²), IL-6 (only in PI), IL-8 and IL-12p35 mRNA levels partly related to nuclear factor kappa B (NF-ÎºB) signalling, and (4) down-regulated the mRNA levels of anti-inflammatory cytokines such as transforming growth factor (TGF)-Î²1, TGF-Î²2, interleukin 4/13A (IL-4/13A) (except IL-4/13B), IL-10 and IL-11 partly relating to target of rapamycin (TOR) signalling in the intestines of on-growing grass carp.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'immunoglobulin'],\n",
       "  'reaction': ['enteritis', 'necrosis', 'growth']},\n",
       " {'pmid': 30632020,\n",
       "  'sentence': \"The article Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, written by Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E. Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer, Andrea Stefek, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, Cornelia Liedtke, Calvin Chao, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher's internet portal (currently SpringerLink) on June 29, 2017 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on January 6, 2019 to Â© The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['chemotherapy', 'breast cancer']},\n",
       " {'pmid': 30681394,\n",
       "  'sentence': 'Abbreviations: ACTB/Î²-actin: actin, beta; ATG14: autophagy related 14; ATG16L1: autophagy related 16-like 1 (S. cerevisiae); ATP6V0D1/2: ATPase, H+\\xa0transporting, lysosomal V0 subunit D1/2; AIM2: absent in melanoma 2; BMDM: bone marrow-derived macrophage; CASP1: caspase 1; CGD: chronic granulomatous disease; CSF1/M-CSF: colony stimulating factor 1 (macrophage); CTSB: cathepsin B; DSS: dextran sodium sulfate; IL1B: interleukin 1 beta; IL6: interleukin 6; IRGM: immunity-related GTPase family M member; KO: knockout; LAMP1: lysosomal-associated membrane protein 1; LC3: microtubule-associated protein 1 light chain 3; LPS: lipo-polysaccaride; NLRP3: NLR family, pyrin domain containing 3; PYCARD/ASC: PYD and CARD domain containing; SNARE: soluble N-ethylmaleimide-sensitive factor attachment protein receptor; SNAP29: synaptosomal-associated protein 29; SQSTM1/p62: sequestosome 1; STX17: syntaxin 17; TLR: toll-like receptor; TNF: tumor necrosis factor ; TOMM20: translocase of outer mitochondrial membrane 20; ULK1: unc-51 like kinase 1; VAMP8: vesicle-associated membrane protein 8; WT: wild type; 3-MA: 3-methyladenine.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['necrosis']},\n",
       " {'pmid': 30742570,\n",
       "  'sentence': 'A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['peptide', 'calcium', 'cholesterol'],\n",
       "  'reaction': ['blood pressure',\n",
       "   'apolipoprotein b',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'blood pressure',\n",
       "   'chronic kidney disease',\n",
       "   'diabetic ketoacidosis',\n",
       "   'ketoacidosis',\n",
       "   'glomerular filtration rate',\n",
       "   'glomerular filtration rate',\n",
       "   'blood glucose',\n",
       "   'blood glucose']},\n",
       " {'pmid': 30868823,\n",
       "  'sentence': 'The aim of this paper was to investigate the inhibitory effect of extract of Coptidis Rhizoma(ECR) on invasion of Candida albicans hyphae in vitro.XTT reduction method was used to evaluate the metabolic activity of C.albicans.The colony edge growth of C.albicans was observed by solid medium.The growth of C.albicans hyphae was determined on semi-solid medium.The morphology and viability changes of C.albicans hyphae were assessed by scanning electron microscope and fluorescence microscope.qRT-PCR method was used to detect the ALS3 and SSA1 expression of C.albicans invasin genes.The results showed that the metabolic viability by XTT method detected that the activity of C.albicans was gradually decreased under the intervention of 64,128 and 256 mgÂ·L-1 of ECR respectively.128,256 mgÂ·L-1 of ECR significantly inhibited colony folds and wrinkles on solid medium and the hyphal invasion in semi-solid medium.Scanning electron microscopy and fluorescence microscopy showed that 128,256 mgÂ·L-1 of ECR could inhibit the formation of C.albicans hyphae.qRT-PCR results showed that the expression of invasin gene ALS3 and SSA1 was down-regulated,and especially 256 mgÂ·L-1 of ECR could down-regulate the two genes expression by 4.8,1.68 times respectively.This study showed that ECR can affect the invasiveness of C.albicans by inhibiting the growth of hyphae and the expression of invasin.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth', 'growth', 'growth']},\n",
       " {'pmid': 30868824,\n",
       "  'sentence': 'In this study,transcriptomics technique was used to investigate the mechanism of action of Aconiti Lateralis Radix Praeparata on acute heart failure rats induced by propafenone hydrochloride.First,rats were randomly divided into normal group,model group and administration group(1.25,2.5,5 gÂ·kg-1).A rat with acute heart failure was constructed by intravenous femoral administration of proparone hydrochloride.The changes of heart rate,+dp/dtmaxand-dp/dtmaxat 5,10,20,30 and 60 min were recorded.Then another group of rats were given the same drug delivery method.In another group of animals,serum TNF-Î± could be determined by ELISA with the same dosage method.High-throughput sequencing technology was used to detect all gene expression differences in cardiac tissue samples of rats with acute heart failure.Through functional annotation and enrichment analysis,gene expression signaling pathways of rats with acute heart failure and rats with post-administration heart failure were screened out.The results showed that heart rate and LV+dp/dtmaxand LV-dp/dtmaxwere significantly decreased in the model group(P<0.05),while heart rate and LV+dp/dtmax and LV-dp/dtmaxwere significantly increased in the drug group(P<0.05,P<0.01).Moreover,ANP,BNP and TNF-Î± in acute heart failure rats was significantly decreased in high-dose aconite decoction group(P<0.05).Transcriptomics analysis showed that the mechanism of action was mainly related to activation of PI3 K-AKT signaling pathway and Jak-STAT pathway.Compared with the model group,aconite decoction up-regulated the expression of phosphatidylinostol 3-kinase(PI3 K),lysophosphatidic acid(LAP3),Bcl-3 and STAT genes,and down-regulated the expression of integrin(ITGA),nuclear orphan receptor(Nur77) genes.It could be concluded that the mechanism of aconite in treating acute heart failure rats may be related to the regulation of the PI3 k-Akt/Jak-STAT pathway.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'propafenone'],\n",
       "  'reaction': ['heart rate',\n",
       "   'heart rate',\n",
       "   'delivery',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'heart rate',\n",
       "   'heart rate']},\n",
       " {'pmid': 30868825,\n",
       "  'sentence': 'This study aims to observe the intervention effects of Chinese herbal medicine of supplementing Qi and activating blood circulation on chronic intermittent hypoxia(CIH) composite insulin resistance(IR) mediated atherosclerosis(AS) mice model,and to observe the mechanism of SREBP-1 c signaling molecule.IR Apo E-/-mice model was induced by high-fat diet combined with STZ injection.Then the mice were treated with hypoxic animal incubator for 8 h per day and 8 weeks to establish a CIH+IR-ApoE-/-mouse model.Model mice were randomly and averagely divided into normoxic control group(NC),model group(CIH) and SREBPs inhibitor group(betulin),atorvastatin group(WM),TCM low-dose group(TCM-L),TCM middle-dose group(TCM-M) and TCM high-dose group(TCM-H) group.Chinese herbal medicine of supplementing Qi and activating blood circulation including ginsenosides combined with ligustrazine(TMP) were used as intervention drugs.The study observed the effect of drugs on IR,serum lipid,inflammation,stress,AS and SREBP-1 c related molecules.The results showed that fasting blood glucose in TCM-H group decreased compared with other experimental groups(P<0.05).HDL-C level in betulin group,WM group,TCM-H group was higher than that in CIH group(P<0.05).LDL-C level in TCM-M group,TCM-H group is lower than that in CIH group(P<0.05).The level of CRP in CIH group was higher than that in other groups(P<0.05).The level of SOD in TCM-H group was higher than that in CIH group(P<0.05).NC group and CIH group showed obvious AS aortic plaque,while betulin group,WM group,TCM-H group showed reduction in AS plaque(P<0.05).For descending aorta,AS plaque in CIH group was multiple and large,while less and smaller in WM group and TCM-H(P<0.05).The expression of SREBP-1 c and FAS in aorta and skeletal muscle in TCM-H group was lower than that in CIH group(P<0.05).In aorta,the expression of TNF-Î± and CD106(VCAM-1) was lower in TCM-H group than that in CIH group(P<0.05).In aorta,skeletal muscle and liver,the level of p-IRS-1 in TCM-H group was significantly higher than that in CIH group(P<0.05).In aorta and liver,the expression of HIF-1Î± in TCM-H group was lower than that in CIH group(P<0.05).The study demonstrated that combination ginsenosides with TMP could improve IR and serum lipid level and inhibit inflammation and oxidative stress as well as ultimately alleviate AS to some extent.And the mechanism of its interventional effects might be related to the inhibition of CIH-induced upregulation of SREBP-1 c related molecules.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['atorvastatin'],\n",
       "  'reaction': ['hypoxia',\n",
       "   'insulin resistance',\n",
       "   'inflammation',\n",
       "   'stress',\n",
       "   'fasting',\n",
       "   'blood glucose',\n",
       "   'blood glucose',\n",
       "   'inflammation',\n",
       "   'stress']},\n",
       " {'pmid': 30868827,\n",
       "  'sentence': 'In order to find the endogenous potential biomarkers of in vitro hepatic injury caused by NCTD-Na and elucidate the mechanism of hepatic injury of NCTD-Na,ultra-high performance liquid chromatography coupled quadrupole time-of-flight mass spectrometry(UPLC-Q-TOF-MS/MS) was used for lipidomics detection.Multivariate statistical analysis was used to study the endogenous lipid metabolic changes of human normal liver cells LO2 injury after the treatment with sodium norcantharidate(NCTD-Na).The results showed that the half maximal inhibitory concentration(IC50) of NCTD-Na was 0.034 mmolÂ·L-1.A total of 280 differential metabolites were found between the control group and the low-dose group,with VIP > 2.0 and P<0.05.At the same time,a total of 273 differential metabolites were found between the control group and the high-dose group,with VIP > 2.0 and P<0.05.Cell metabolite profiles showed clear separation among control group,the low-dose group and the high-dose group,and 111 differential metabolites were found,with VIP > 2.0,P<0.05,RSD<30% and in a dose-dependent manner.It was found that most of the above differential metabolites were lipid metabolites after the analysis of simple preparnation methods and database search.A total of 32 potential biomarkers were identified,including 3 phosphatidylcholine(PC),5 lysophosphatidylcholine(Lyso PC),3 ceramide(Cer),1 sphingomyelin(SM),1 phosphatidylethanolamine(PE),10 lysophosphatidylethanolamine(LysoPE),4 diacylglycerol(DG),1 Phosphatidic acid(PA),1 lysophosphatidic acid(Lyso PA),1 phosphatidyl glycerol(PG),1 fatty acid hydroxy fatty acid(FAHFA) and 1 phosphatidylserine(PS).The changes of PCs,Cers,SM,PE and DGs were closely related liver protection,DNA methylation and self-repair in hepatocytes,apoptosis,methylation and detoxification of carcinogens,as well as lipid peroxides production process.Also,they had impact on the proliferation of hepatocytes,differentiation and gene transcription disorders.Cells stimulated by NCTD-Na could promote the production of PA as well as the synthesis and catabolism of FAHFA in a variety of ways.The levels of Lyso PCs,LysoPEs and Lyso PA were correlated with PCs,PE and PA;PE and PS might have valgus during apoptosis,triggering phagocytosis.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['injury',\n",
       "   'injury',\n",
       "   'mass',\n",
       "   'injury',\n",
       "   'apoptosis',\n",
       "   'detoxification',\n",
       "   'apoptosis',\n",
       "   'phagocytosis']},\n",
       " {'pmid': 30868829,\n",
       "  'sentence': 'To observe the clinical curative effect of Qingying Tang in the treatment of psoriatic blood-heat syndrome and explore its intrinsic mechanism.In this study,we collected 72 patients with blood-heat syndrome psoriasis admitted to our dermatology clinic from January 2016 to December 2017 and divided into control group and observation group according to the random number table method,36 cases in each group.The patients in control group were given with Acitretin Capsules orally,10 mg/time,twice a day.The patients in observation group were given with Qingying Tang orally,150 mL/time,twice a day.The treatment period was 12 weeks in both groups.The traditional Chinese medicine(TCM) syndrome scores before and after treatment,psoriasis area and severity index(PASI) score,dermatology life quality index(DLQI) score,and the clinical efficacy of the two groups were compared between the two groups;flow cytometry was used to detect peripheral blood Th17 cell percentages before and after treatment in both groups;serum interleukin(IL)-17,IL-23,IL-22,and IL-21 levels in both groups before and after treatment were measured by ELISA;the expression levels of STAT3 and RORÎ³t before and after treatment in patients were measured by using skin lesion immunohistochemical method.The results showed that the TCM symptoms were improved significantly in both groups(P<0.05),and the effect in observation group was significantly better than that in the control group(P<0.05).PASI and DLQI scores were decreased significantly after treatment in both groups(P<0.05),and the scores in observation group were significantly lower than those in the control group(P<0.05).The curative effect of the observation group was significantly higher than that of the control group(P<0.05).After treatment,the percentage of Th17 cells,as well as IL-17,IL-23,IL-22 and IL-21 levels in peripheral blood were significantly decreased in both groups(P<0.05),and the levels in observation group were significantly lower than those in the control group(P<0.05).The expression levels of STAT3 and RORÎ³t in both groups were significantly lower than those before treatment(P<0.01),and the levels in observation group were significantly lower than those in the control group(P<0.05).All of the results indicted that Qingying Tang can effectively improve the skin lesions and TCM syndrome in patients with psoriasis and blood-heat syndrome,and improve patient health quality,which may be related to regulation of peripheral blood IL-23/Th17.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['acitretin'],\n",
       "  'reaction': ['psoriasis',\n",
       "   'psoriasis',\n",
       "   'flow cytometry',\n",
       "   'skin lesion',\n",
       "   'psoriasis']},\n",
       " {'pmid': 30868831,\n",
       "  'sentence': 'To systemically evaluate the efficacy and safety of Jintiange Capsules in the treatment of postmenopausal osteoporosis(PMOP).Seven literature databases were retrieved systematically,and two reviewers independently searched and screened studies,extracted data,and included all the randomized controlled trials on Jintiange Capsules in the treatment of PMOP.Interventions included comparison of Jintiange Capsules with placebo and routine treatment,and the studies on Jintiange Capsules combined with routine treatment versus conventional treatment were also included.The evaluation indicators of the study included at least one of the followings:fracture,quality of life,daily living ability,clinical symptoms,death,adverse events/adverse reactions,bone density,and bone metabolism indexes.The original study quality evaluation was conducted by following the Cochrane Handbook standard and statistical analysis was performed by using Rev Man 5.2.A total of 7 randomized controlled trials were included and the study quality was low.Meta-analysis showed that as compared with conventional treatment alone,Jintiange Capsules combined with conventional treatment showed more obvious effects in pain relief(MD=-0.98,95% CI[-1.55,-0.41],P=0.000 8),increasing blood calcium levels(MD=0.05,95% CI[0.02,0.09],P=0.003) and lowering serum alkaline phosphatase levels(MD=-12.92,95% CI[-24.09,-1.75],P=0.02).In addition,the Chinese patent medicine alone or in combination with conventional treatment was relatively safe.In conclusion,Jintiange Capsules has a certain effect in treating PMOP,but the quality of evidence is low.It is necessary to conduct well designed randomized controlled trials and select recognized evaluation indicators,especially the end outcomes in order to further improve the clinical evidence.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['rev', 'calcium'],\n",
       "  'reaction': ['osteoporosis',\n",
       "   'fracture',\n",
       "   'quality of life',\n",
       "   'death',\n",
       "   'bone density',\n",
       "   'pain',\n",
       "   'blood calcium',\n",
       "   'blood calcium']},\n",
       " {'pmid': 30868832,\n",
       "  'sentence': 'To explore the regularity of traditional Chinese medicine(TCM) prescriptions for cardio-cerebrovascular diseases,the core drug groups with common therapeutic effects on cerebrovascular diseases represented by stroke and cardiovascular diseases represented by coronary artery disease were extracted,and their consistency and difference in the treatment of different diseases were analyzed.A total of 388 Chinese patent medicines were collected for the treatment of cerebrovascular diseases,cardiovascular diseases and cardio-cerebrovascular diseases.The dominant and recessive patterns of Chinese patent medicines in clinical use were found by \"frequency analysis\",\"compatibility analysis\" and \"network analysis\" respectively.According to the findings of the three parts,Salviae Miltiorrhizae Radix et Rhizoma,Chuanxiong Rhizoma,Carthami Flos and Astragali Radix have a high frequency of use in the treatment of brain disease,heart disease and both,with frequent combined medication.Data mining confirmed the core drug combinations for the treatment of cerebral and cardiac vascular diseases,so as to reveal the similarities and differences in the drug use of Chinese medicine for these diseases,and provide a basis for the rational use of traditional Chinese medicine in clinical practice.This analysis also defines a new direction for the future development of prescription combinations for different indications of cerebral and cardiac diseases.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac'],\n",
       "  'reaction': ['coronary artery disease']},\n",
       " {'pmid': 30916067,\n",
       "  'sentence': \"Ab initio calculations, in combination with the fit of experimental data, predict that the single-ion magnetic ground state is highly anisotropic () and consists of a quasi-doublet with a Î”Tb/kB = 3.22 K gap, well separated from the next excited state, while the gap for the Tb2 dimer is Î”2Tb/kB = 2.58 K. Static magnetization and heat capacity measurements show that, magnetically, the system can be modeled as dimers of non-Kramers Tb ions, coupled by an antiferromagnetic intradimer interaction J'*/kB = -1.6 K. Dipolar interactions couple the Tb ions in the dimer with their first neighbour ions along the chain, with J''*/kB = -0.15 K, and with the surrounding ions out of the chain, with maximum J'''*/kB = -0.03 K. Ac susceptibility measurements in H = 0 performed down to 50 mK temperatures have enabled us to observe slow relaxation of magnetization, with an Orbach-like activation energy of U/kB = 1.1 K. It is assigned to the sluggish response of the 3D spin system due to a short-range ordering, possibly enhanced by the presence of disorder caused by defects in the polymeric chains.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['ac'],\n",
       "  'reaction': ['energy']},\n",
       " {'pmid': 30951392,\n",
       "  'sentence': 'Abbreviations: AICD: activation induced cell death; AIM2: absent in melanoma 2; ALPL/HOPS: alkaline phosphatase, biomineralization associated; AMA: anti-mitochondrial antibodies; AMFR: autocrine motility factor receptor; ATG: autophagy-related; BCL2L13: BCL2 like 13; BNIP3: BCL2 interacting protein 3; BNIP3L/NIX: BCL2 interacting protein 3 like; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CARD: caspase recruitment domain containing; CASP1: caspase 1; CD: Crohn disease; CGAS: cyclic GMP-AMP synthase; CXCL1: C-X-C motif chemokine ligand 1; DEN: diethylnitrosamine; DLAT/PDC-E2: dihydrolipoamide S-acetyltransferase; DNM1L/Drp1: dynamin 1 like; ESCRT: endosomal sorting complexes required for transport; FKBP8: FKBP prolyl isomerase 8; FUNDC1: Fun14 domain containing 1; GABARAP: GABA type A receptor-associated protein; HMGB1: high mobility group box 1; HPIV3: human parainfluenza virus type 3; IBD: inflammatory bowel diseases; IEC: intestinal epithelial cell; IFN: interferon; IL1B/IL-1Î²: interleukin 1 beta; iNK: invariant natural killer; IRGM: immunity related GTPase M; LIR: LC3-interacting region; LPS: lipopolysaccharide; LRRK2: leucine rich repeat kinase 2; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MARCH5: membrane associated ring-CH-type finger 5; MAVS: mitochondrial antiviral signaling protein; MDV: mitochondria-derived vesicle; MFN1: mitofusin 1; MHC: major histocompatibility complex; MIF: macrophage migration inhibitory factor; mtAP: mitochondrial antigen presentation; mtDNA: mitochondrial DNA; MTOR: mechanistic target of rapamycin kinase; mtROS: mitochondrial ROS; MUL1: mitochondrial E3 ubiquitin protein ligase 1; NBR1: NBR1 autophagy cargo receptor; NFKB/NF-Ä¸B: nuclear factor kappa B subunit; NK: natural killer; NLR: NOD-like receptor; NLRC4: NLR family CARD domain containing 4; NLRP3: NLR family pyrin domain containing 3; OGDH: oxoglutarate dehydrogenase; OMM: outer mitochondrial membrane; OPTN: optineurin; ox: oxidized; PARK7: Parkinsonism associated deglycase; PBC: primary biliary cirrhosis; PEX13: peroxisomal biogenesis factor 13; PHB/PHB1: prohibitin; PHB2: prohibitin 2; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PINK1: PTEN induced kinase 1; PLEKHM1: pleckstrin homology and RUN domain containing M1; PRKN/PARK2: parkin RBR E3 ubiquitin protein ligase; RAB: member RAS oncogene family; RHEB: Ras homolog: mTORC1 binding; RIPK2: receptor interacting serine/threonine kinase 2; RLR: DDX58/RIG-I like receptor; ROS: reactive oxygen species; SBD: small bile ducts; SLC2A1/GLUT1: solute carrier family 2 member 1; SLE: systemic lupus erythematosus; SMURF1: SMAD specific E3 ubiquitin protein ligase 1; SQSTM1/p62: sequestosome 1; TAX1BP1: Tax1 binding protein 1; TCR: T cell receptor; TFAM: transcription factor A: mitochondrial; Th17: T helper 17; TLR9: toll like receptor 9; TMEM173/STING: transmembrane protein 173; TNF/TNF-Î±: tumor necrosis factor; Ub: ubiquitin; UC: ulcerative colitis; ULK1: unc-51 like autophagy activating kinase 1; WIPI: WD repeat domain: phosphoinositide interacting; ZFYVE1/DFCP1: zinc finger FYVE-type containing 1.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['calcium'],\n",
       "  'reaction': ['cell death',\n",
       "   'death',\n",
       "   'mobility',\n",
       "   'parkinsonism',\n",
       "   'biliary cirrhosis',\n",
       "   'systemic lupus erythematosus',\n",
       "   'necrosis',\n",
       "   'colitis']},\n",
       " {'pmid': 30966844,\n",
       "  'sentence': 'Abbreviation: AIDS: Acquired Immunodeficiency Syndrome; ATF6: Activating Transcription Factor 6; ATG6: Autophagy-specific Gene 6; BAG3: BCL Associated Athanogene 3; Bak: BCL-2-Anatagonist/Killer1; Bax; BCL-2: Associated X protein; Bcl-2: B cell Lymphoma 2x; BiP: Chaperon immunoglobulin heavy chain binding Protein; CARD: Caspase Recruitment Domain; cART: combination Antiretroviral Therapy; CCR5: C-C Chemokine Receptor type 5; CD4: Cluster of Differentiation 4; CHOP: C/EBP homologous protein; CXCR4: C-X-C Chemokine Receptor Type 4; Cyto c: Cytochrome C; DCs: Dendritic Cells; EDEM1: ER-degradation enhancing-a-mannosidase-like protein 1; ENV: Envelope; ER: Endoplasmic Reticulum; FasR: Fas Receptor;G2: Gap 2; G2/M: Gap2/Mitosis; GFAP: Glial Fibrillary Acidic Protein; GP120: Glycoprotein120; GP41: Glycoprotein41; HAND: HIV Associated Neurodegenerative Disease; HEK: Human Embryonic Kidney; HeLa: Human Cervical Epithelial Carcinoma; HIV: Human Immunodeficiency Virus; IPS-1: IFN-Î² promoter stimulator 1; IRE-1: Inositol Requiring Enzyme 1; IRGM: Immunity Related GTPase Family M protein; LAMP2A: Lysosome Associated Membrane Protein 2A; LC3: Microtubule Associated Light Chain 3; MDA5: Melanoma Differentiation Associated gene 5; MEF: Mouse Embryonic Fibroblast; MMP: Mitochondrial Membrane Permeabilization; Nef: Negative Regulatory Factor; OASIS: Old Astrocyte Specifically Induced Substrate; PAMP: Pathogen-Associated Molecular Pattern; PERK: Pancreatic Endoplasmic Reticulum Kinase; PRR: Pattern Recognition Receptor; Puma: P53 Upregulated Modulator of Apoptosis; RIG-I: Retinoic acid-Inducible Gene-I; Tat: Transactivator Protein of HIV; TLR: Toll-like receptor; ULK1: Unc51 Like Autophagy Activating Kinase 1; UPR: Unfolded Protein Response; Vpr: Viral Protein Regulatory; XBP1: X-Box Binding Protein 1.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['acquired immunodeficiency syndrome',\n",
       "   'immunodeficiency',\n",
       "   'lymphoma',\n",
       "   'immunodeficiency',\n",
       "   'apoptosis']},\n",
       " {'pmid': 30989987,\n",
       "  'sentence': 'The aim of this study was to observe the effect of baicalin on the growth state of attention deficit hyperactivity disorder animal model and its regulation on Ca MKâ…¡and ERK1/2.In the present study,a total of 40 SHR rats were randomly divided into model group,methylphenidate hydrochloride group,and low,medium,and high dose baicalin groups,with 8 rats in each group.Eight WKYrats were selected as a normal control group.The methylphenidate hydrochloride group(0.07 gÂ·L~(-1))and the low(3.33 gÂ·L~(-1)),medium(6.67 gÂ·L~(-1)),and high dose(10 gÂ·L~(-1))baicalin groups received corresponding drugs by gavage administration according to the body weight(0.015 m LÂ·g~(-1)),while the normal group and the model group received the same volume of normal saline by gavage.Thegavage administration lasted for 4 weeks,twice a day.The body weight of the rats and the amount of remaining feed were weighed daily,and the growth state of the rats was statistically evaluated weekly.Percoll density gradient centrifugation was used to prepare brain synaptosomes and an electron microscope was used to observe their structures.The Ca MKâ…¡and ERK1/2 protein and mRNA expression levels were detected with Western blot and Real-time PCR methods,respectively.RESULTS: showed that baicalin did not affect the normal eating and weight gain of rats,and the weight gain of rats was even more significant than that in the normal group(P<0.05).In the study of its effects on Ca MKâ…¡and ERK1/2 protein expression in rat synaptosomes,the expression of both proteins in each drug-administered group was higher than that in the model group(P<0.05);besides,the expression levels of Ca MKâ…¡and ERK1/2 protein were significantly increased in both baicalin high dose group and the methylphenidate hydrochloride group(P<0.05).The relative expression of Ca MKâ…¡and ERK1/2 mRNA in synaptosome was detected by PCR.The results showed that medium and high doses of baicalin and methylphenidate hydrochloride significantly increased the relative expression of Ca MKâ…¡and ERK1/2 mRNA in synaptosomes of SHR rats(P<0.05).In conclusion,baicalin does not affect the normal growth and development of SHR rats,so it is safe for administration.Both baicalin and methylphenidate hydrochloride could up-regulate the relative expression of Ca MKâ…¡and ERK1/2 in mRNA and protein,and the pharmacodynamic stability of baicalin is in a dose-dependent manner to certain extent.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'growth']},\n",
       " {'pmid': 30989988,\n",
       "  'sentence': 'To investigate the effect of Yunkang Oral Liquid on preventing lipopolysaccharide(LPS)-induced abortion and regulating immune tolerance in mice,sixty normal ICR mice were randomly divided into normal group,model group,Yunkang Oral Liquid high,middle and low dose groups and progesterone group.Abortion model was established by tail vain injection of LPS(0.1Î¼g/mouse)on the 7th day of pregnancy.Since the first day of pregnancy,the same volume of distilled water,Yunkang Oral Liquid at the dose of 36,18 and 9 m LÂ·kg~(-1)Â·d~(-1),and progesterone at the dose of 0.038 gÂ·kg~(-1)Â·d~(-1)were given in corresponding groups.The mice were sacrificed at the 9th day of pregnancy,and the embryo loss of each group was calculated.The levels of Th1 type cytokines(TNF-Î±,IFN-Î³)and Th2 type cytokines(IL-4,IL-10)in uterus homogenate were detected by ELISA.HE staining was performed to examine the histopathological changes in the decidua.The expression levels of CD14,F4/80 in macrophages of uterus were detected by immunohistochemistry.Western blot was used to investigate the protein expression of TLR4,MyD88 and NF-ÎºB in uterine decidua.In our study,all Yunkang Oral Liquid groups could significantly reduce the embryo absorption rate of mice,while high dose group can significantly increase the levels of IL-10 and IL-4;both medium and high dose groups can significantly decrease TNF-Î±,and IFN-Î³levelsin the uterus of model mice,reduce the protein expression of NF-ÎºB,MyD88 and TLR4 in uterine decidua tissue.Various treatment groups could reduce the counts of F4/80,CD14 macrophages and decrease expression area in uterine tissue.Our results showed that Yunkang Oral Liquid could prevent LPS-induced abortion,and the mechanism may be associated with inhibiting the TLR4/MyD88/NF-ÎºB signaling pathway and regulating the balance of Th1/Th2 immune factors,which could improve the endometrial receptivity of mice,and promote the development of decidua and implantation of embryo.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['abortion',\n",
       "   'abortion',\n",
       "   'progesterone',\n",
       "   'injection',\n",
       "   'pregnancy',\n",
       "   'progesterone',\n",
       "   'pregnancy',\n",
       "   'macrophages',\n",
       "   'macrophages',\n",
       "   'abortion',\n",
       "   'abortion']},\n",
       " {'pmid': 30989990,\n",
       "  'sentence': 'The study was aimed to investigate the protective effect and pharmacodynamic difference of the ethanol extracts of Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus on the drug-induced liver injury induced by acetaminophen.The cell activations of LO2 cells treated by Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extracts were tested by CCK-8 essay.The effects of ethanol extracts on cell survival rate,the activities of ALT and AST in culture medium were detected based on the injury model of LO2 cells induced by APAP.Further,in purpose to observe the protective effect of Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extracts on a mouse model of liver injury induced by intraperitoneal injectionof acetaminophen was established.Mice were randomly divided into control group,model group,positive drug group and Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extracts administration groups.The activities of ALT and AST in the serum and the levels of MDA,SOD,GSH and GSH-PX in the liver homogenate of the mice were detected by commercial kits.The HEstaining was used to observe the histopathological changes of liver tissue in each group and the TUNEL staining was used to observe the hepatocyte apoptosis.The results showed that the ethanol extracts at less than 1 gÂ·L~(-1)did not affect the activity of LO2 cell.Compared with the model group,the cell survival rates of the Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extract administration groups was significantly increased;the ALT and AST in the culture medium were distinct decreased(P<0.05 or P<0.01).The survival rate of Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extract from different batches were similar,while that of the Schisandrea Sphenatherae Fructus ethanol extract from different batches were quite different(P<0.05or P<0.01).Further,animal experiments showed that Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extract administration groups could markedly inhibit the increase of ALT and AST levels in serum(P<0.01),decrease MDA content significantly(P<0.01),and increase GSH,GSH-PX and SOD activity significantly(P<0.01).Among them,compared with other groups,Schisandrae Sphenantherae Fructus ethanol extract-2 group showed the best effect(P<0.05 or P<0.01)while Schisandrae Sphenantherae Fructus ethanol extract-1 showed a poor effect(P<0.05 or P<0.01).In conclusion,both Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extracts have protective effect on APAP-induced drug-induced liver injury and there was a certain difference in the efficacy between Schisandrae Sphenantherae Fructus and Schisandrae Chinensis Fructus ethanol extracts from different habitats.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['medium'],\n",
       "  'reaction': ['drug-induced liver injury',\n",
       "   'liver injury',\n",
       "   'injury',\n",
       "   'injury',\n",
       "   'liver injury',\n",
       "   'injury',\n",
       "   'drug-induced liver injury',\n",
       "   'liver injury',\n",
       "   'injury']},\n",
       " {'pmid': 30989991,\n",
       "  'sentence': 'The aim of this paper was to observe the changes of EPO in rats with chronic renal failure and low immunity induced by adenine and to investigate the reversal effect of Yougui Yin(YGY)and exogenous EPO.SD rats were randomly divided into normal control group(n=20)and adenine-model group(n=90).The adenine-model group rats were given with adenine 150 mgÂ·kg~(-1)for 14days by gavage administration,and then randomly divided into 8 groups as follows:model group(n=20),YGY groups(10,20,40 gÂ·kg~(-1),10 in each group),rh EPO group(500,1 000,1 500 IUÂ·kg~(-1),10 in each group),and Guilu Erxian Gao 10 gÂ·kg~(-1)group(positive control group,n=10).From the 15th day,every group except normal control group received 150 mgÂ·kg~(-1)adenine by gavage administration once every two days to maintain the model.Meanwhile,the rats in each YGY group and Guilu Erxian Gao group received corresponding drugs by gavage administration once a day for 30 days.The rats in rh EPO groups were subcutaneously injected with rh E-PO once every 3 days for 30 days.On day 46,rats were anesthetized to take blood and then sacrificed.The serum levels of creatinine,urea,glandular hormone,immunoglobulin,complement and interleukin,the proportion of T cells in the spleen,the killing rate of NKcells and the proliferative capacity of spleen cells were measured.Western blot was used to detect the key proteins in JAK2-STAT5 and NF-ÎºB pathways mediated by EPO in kidney and spleen.As compared with the normal control group,the serum levels of CREA and UREA were increased significantly and the serum levels of ACTH,T and T3 were decreased significantly in the model group rats,indicating that the functions of kidney,adrenal gland,gonad and thyroid in rats were decreased.At the same time,the serum levels of Ig A,Ig G,Ig M,C3,C4,IL-2 and IL-6 were significantly decreased,the proportion of CD4~+,CD4~+/CD8~+T cell subsets,the killing rate of NK cell and the proliferation ability of spleen lymphocyte in spleen of the model group rats were significantly declined,indicating that the immune function of model group rats was decreased,and the model of kidney deficiency immunodeficiency was successfully constructed.As compared with the model group,both YGY and rh EPO significantly reduced serum levels of CREA and UREA,significantly increased serum levels of ACTH,T,T3,T4,Ig A,Ig G,Ig M,C3,C4,IL-2,and IL-6,increased the proportion of CD4~+,CD4~+/CD8~+T cell subsets,the killing rate of NK cell and the proliferation ability of spleen lymphocyte in spleen.YGY could significantly increase the content of EPO in serum.Both YGY and rh EPO could regulate the expression of EPOR,p-JAK2/JAK2,STAT5,NF-ÎºB p50,NF-ÎºB p65 and NF-ÎºB IÎºB of EPO-mediated JAK2-STAT5 and NF-ÎºB pathways in kidney and spleen.EPO is an important factor in the chronic renal failure and low immunity induced by adenine in rats.Exogenous EPO and YGY have significant reversal effects for the model rats.The mechanism of YGY may be related to the up-regulation of EPO in serum and regulating the expression of key proteins in EPO-mediated JAK2-STAT5 and NF-ÎºB pathways in kidney and spleen.The mechanism of exogenous EPO may be related to regulating the expression of the key proteins in EPO-mediated JAK2-STAT5 and NF-ÎºB pathways in kidney and spleen.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin'],\n",
       "  'reaction': ['renal failure', 'immunodeficiency', 'renal failure']},\n",
       " {'pmid': 30990357,\n",
       "  'sentence': 'Abbreviations: 3-MA: 3-methyladenine; AKT/protein kinase B: thymoma viral proto-oncogene; AKT1: thymoma viral proto-oncogene 1; ATG: AuTophaGy-related; ATF6: activating transcription factor 6; BAX: BCL2-associated X protein; BBC3/PUMA: BCL2 binding component 3; BCL2: B cell leukemia/lymphoma 2; BNIP3L: BCL2/adenovirus E1B interacting protein 3-like; CASP3: caspase 3; CASP8: caspase 8; CASP9: caspase 9; CL: cardiolipin; CTSB: cathepsin B; CTSD: cathepsin D; DDIT3/CHOP: DNA-damage inducible transcript 3; DNM1L/DRP1: dynamin 1-like; DRAM1: DNA-damage regulated autophagy modulator 1; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; EIF2S1/eIF2Î±: eukaryotic translation initiation factor 2, subunit alpha; ERN1/IRE1Î±: endoplasmic reticulum to nucleus signaling 1; ESCs: embryonic stem cells; KRT8/TROMA-1: cytokeratin 8; LAMP2A: lysosomal-associated membrane protein 2A; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NANOG: Nanog homeobox; NAO: 10-N-nonyl acridine orange; NFE2L2/NRF2: nuclear factor, erythroid derived 2, like 2; OPA1: OPA1, mitochondrial dynamin like GTPase; P19dCs: P19 differentiated cells; P19SCs: P19 stem cells; POU5F1/OCT4: POU domain, class 5, transcription factor 1; PtdIns3K: phosphatidylinositol 3-kinase; RA: retinoic acid; ROS: reactive oxygen species; RPS6KB1/p70S6K: ribosomal protein S6 kinase, polypeptide 1; SCs: stem cells; SOD: superoxide dismutase; SHC1-1/p66SHC: src homology 2 domain-containing transforming protein C1, 66 kDa isoform; SOX2: SRY (sex determining region Y)-box 2; SQSTM1/p62: sequestosome 1; SPTAN1/Î±II-spectrin: spectrin alpha, non-erythrocytic 1; TOMM20: translocase of outer mitochondrial membrane 20; TRP53/p53: transformation related protein 53; TUBB3/betaIII-tubulin: tubulin, beta 3 class III; UPR: unfolded protein response; UPS: ubiquitin-proteasome system.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['polypeptide'],\n",
       "  'reaction': ['thymoma', 'thymoma']},\n",
       " {'pmid': 31041449,\n",
       "  'sentence': 'Meta-analysis of 8 eligible studies revealed that a PD significantly reduced body weight [weighted mean difference (WMD)\\xa0=\\xa0-2.17\\xa0kg; 95% CI: -3.48, -0.87\\xa0kg], waist circumference (WMD\\xa0=\\xa0-2.90\\xa0cm; 95% CI: -4.51, -1.28 cm), body mass index (in kg/m2) (WMD\\xa0=\\xa0-1.15; 95% CI: -1.68, -0.62), body fat percentage (WMD\\xa0=\\xa0-1.38%; 95% CI: -2.08%, -0.67%), systolic (WMD\\xa0=\\xa0-4.24\\xa0mm Hg; 95% CI: -7.11, -1.38 mm Hg) and diastolic (WMD\\xa0=\\xa0-2.95\\xa0mm Hg; 95% CI: -4.72, -1.18 mm Hg) blood pressure, and circulating concentrations of total cholesterol (WMD\\xa0=\\xa0-0.22\\xa0mg/dL; 95% CI: -0.42, -0.03 mg/dL), TGs (WMD\\xa0=\\xa0-0.23\\xa0mg/dL; 95% CI: -0.46, -0.01 mg/dL), LDL cholesterol (WMD\\xa0=\\xa0-0.13\\xa0mg/dL; 95% CI: -0.25, -0.01 mg/dL), and C-reactive protein (CRP) (WMD\\xa0=\\xa0-0.41\\xa0mg/L; 95% CI: -0.81, -0.008 mg/L) and also significantly increased HDL cholesterol (WMD\\xa0=\\xa00.05\\xa0mg/dL; 95% CI: 0.005, 0.10 mg/dL).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'waist circumference',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'blood pressure',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein']},\n",
       " {'pmid': 31165401,\n",
       "  'sentence': 'Probiotic supplementation significantly decreased weight (SMD -\\u20090.30; 95% CI, -\\u20090.53, -\\u20090.07; P\\u2009=\\u20090.01), body mass index (BMI) (SMD -\\u20090.29; 95% CI, -\\u20090.54, -\\u20090.03; P\\u2009=\\u20090.02), fasting plasma glucose (FPG) (SMD -\\u20090.26; 95% CI, -\\u20090.45, -\\u20090.07; P\\u2009<\\u20090.001), insulin (SMD -\\u20090.52; 95% CI, -\\u20090.81, -\\u20090.24; P\\u2009<\\u20090.001), homeostatic model assessment for insulin resistance (HOMA-IR) (SMD -\\u20090.53; 95% CI, -\\u20090.79, -\\u20090.26; P\\u2009<\\u20090.001), triglycerides (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), VLDL-cholesterol (SMD -\\u20090.69; 95% CI, -\\u20090.99, -\\u20090.39; P\\u2009<\\u20090.001), C-reactive protein (CRP) (SMD -\\u20091.26; 95% CI, -\\u20092.14, -\\u20090.37; P\\u2009<\\u20090.001), malondialdehyde (MDA) (SMD -\\u20090.90; 95% CI, -\\u20091.16, -\\u20090.63; P\\u2009<\\u20090.001), hirsutism (SMD -\\u20090.58; 95% CI, -\\u20091.01, -\\u20090.16; P\\u2009<\\u20090.001), and total testosterone levels (SMD -\\u20090.58; 95% CI, -\\u20090.82, -\\u20090.34; P\\u2009<\\u20090.001), and also increased the quantitative insulin sensitivity check index (QUICKI) (SMD 0.41; 95% CI, 0.11, 0.70; P\\u2009<\\u20090.01), nitric oxide (NO) (SMD 0.33; 95% CI 0.08, 0.59; P\\u2009=\\u20090.01), total antioxidant capacity (TAC) (SMD 0.64; 95% CI, 0.38, 0.90; P\\u2009<\\u20090.001), glutathione (GSH) (SMD 0.26; 95% CI, 0.01, 0.52; P\\u2009=\\u20090.04), and sex hormone binding globulin (SHBG) levels (SMD 0.46; 95% CI, 0.08, 0.85; P\\u2009=\\u20090.01).',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['tac', 'globulin'],\n",
       "  'reaction': ['weight',\n",
       "   'weight',\n",
       "   'body mass index',\n",
       "   'body mass index',\n",
       "   'mass',\n",
       "   'fasting',\n",
       "   'insulin resistance',\n",
       "   'c-reactive protein',\n",
       "   'c-reactive protein',\n",
       "   'hirsutism']},\n",
       " {'pmid': 31210979,\n",
       "  'sentence': 'The purpose of this paper is to determine the prevalence of metal-on-metal (MoM) total hip replacement (THR) in European registries, to assess the incidence of revision surgery and to describe the national follow-up guidelines for patients with MoM THR including resurfacings.Eleven registries of the Network of Orthopaedic Registries of Europe (NORE) participated totalling 54\\u2009434 resurfacings and 58\\u2009498 large stemmed MoM THRs.The resurfacings and stemmed large head MoM had higher pooled revision rates at five years than the standard total hip arthroplasties (THA): 6.0%, 95% confidence interval (CI) 5.3 to 6.8 for resurfacings; 6.9%, 95% CI 4.4 to 9.4 for stemmed large head MoM; and 3.0%, 95% CI 2.5 to 3.6 for conventional THA.The resurfacings and stemmed large head MoM had higher pooled revision rates at ten years than the standard THAs: 12.1%, 95% CI 11.0 to 13.3 for resurfacings; 15.5%, 95% CI 9.0 to 22 for stemmed large head MoM; and 5.1%, 95% CI 3.8 to 6.4 for conventional THA.Although every national registry reports slightly different protocols for follow-up, these mostly consist of annual assessments of cobalt and chromium levels in blood and MRI (MARS) imaging.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['chromium'],\n",
       "  'reaction': ['surgery']},\n",
       " {'pmid': 31240929,\n",
       "  'sentence': 'Compared with the HFD group, BITC or PEITC decreased the final body weight of mice in a dose-dependent manner [39.0 Â± 3.1 (HFD), 34.4 Â± 3.2 (BITC-L), 32.4 Â± 2.8 (BITC-H), 36.2 Â± 4.4 (PEITC-L), and 32.8 Â± 2.9 (PEITC-H) g, p < 0.05], relative weight of epididymal fat [5.7 Â± 0.4 (HFD), 4.7 Â± 0.7 (BITC-L), 3.7 Â± 0.3 (BITC-H), 4.4 Â± 1.0 (PEITC-L), and 3.2 Â± 0.6 (PEITC-H) %, p < 0.05], hepatic triglycerides [98.4 Â± 6.0 (HFD), 81.0 Â± 8.9 (BITC-L), 63.5 Â± 5.6 (BITC-H), 69.3 Â± 5.6 (PEITC-L), and 49.4 Â± 2.9 (PEITC-H) mg/g, p < 0.05], and plasma total cholesterol [140 Â± 21.3 (HFD), 109 Â± 5.6 (BITC-L), 101 Â± 11.3 (BITC-H), 126 Â± 8.3 (PEITC-L), and 91.8 Â± 12.7 (PEITC-H) mg/dL, p < 0.05].',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cholesterol'],\n",
       "  'reaction': ['weight', 'weight', 'weight', 'weight']},\n",
       " {'pmid': 31247320,\n",
       "  'sentence': 'The results indicated that, compared with the control group (0% PA), PA did the following: (1) suppressed fish growth performance (percentage weight gain and feed efficiency) and reduced their ability to resist enteritis; (2) decreased fish intestinal antimicrobial ability by reducing intestinal lysozyme (LZ) activities, the contents of complement 3 (C3), C4 and immunoglobulin M (IgM), and downregulating the mRNA levels of hepcidin, liver-expressed antimicrobial peptide 2A (LEAP-2A), LEAP-2B, and Î²-defensin-1; and (3) aggravated fish intestinal inflammation responses by upregulating the mRNA levels of pro-inflammatory cytokines including tumour necrosis factor Î± (TNF-Î±), interleukin 1Î² (IL-1Î²) (except in the DI), interferon Î³2 (IFN-Î³2), IL-8, IL-12p40, IL-15 (except in the DI) and IL-17D, which is partly related to the nuclear factor kappa B (NF-ÎºB) signalling pathway, whereas downregulating the mRNA levels of anti-inflammatory cytokines including transforming growth factor Î²1 (TGF-Î²1), IL-4/13A, IL-4/13B, IL-10 and IL-11, which is partially associated with the target of rapamycin (TOR) signalling pathway.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['immunoglobulin', 'peptide'],\n",
       "  'reaction': ['growth',\n",
       "   'weight',\n",
       "   'weight',\n",
       "   'enteritis',\n",
       "   'inflammation',\n",
       "   'tumour necrosis',\n",
       "   'necrosis',\n",
       "   'growth']},\n",
       " {'pmid': 31282320,\n",
       "  'sentence': 'Objective To investigate the effects of simvastatin on diabetic neuropathic pain and systematic inflammation in diabetic rats and explore their molecular mechanisms.Methods Totally 24 rats were equally randomized into the normal+vehicle(NV)group,diabetic+vehicle(DV)group,and diabetic+simvastatin(DS)group using the random number table.Streptozotocin(STZ)was used to establish the rat models of diabetes.Blood glucose,body mass,paw withdrawal mechanical threshold(PWMT),and paw withdrawal thermal latency(PWTL)in each group were observed on days 7,14,21,and 28 after STZ injection.On day 28 after STZ injection,rats were sacrificed,and the lumbar spinal dorsal horn and serum were collected.Western blotting was used to detect the expression of receptor for advanced glycation end products(RAGE)and the phosphorylation levels of protein kinase B(AKT),extracellular signal-regulated kinase(ERK),p38,and c-Jun N-terminal kinase(JNK)in the spinal dorsal horn of rats in each group.Enzyme-linked immunosorbent assay was performed to determine the serum concentrations of oxidized low density lipoprotein(ox-LDL)and interleukin-1Î²(IL-1Î²).Results On days 14,21 and 28 after STZ injection,the PWMT in DV group were(8.6 Â± 0.8),(7.1 Â± 1.6),and(7.8 Â± 0.8)g respectively,which were significantly lower than (12.0 Â± 0.9)(',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['simvastatin'],\n",
       "  'reaction': ['pain',\n",
       "   'inflammation',\n",
       "   'mass',\n",
       "   'injection',\n",
       "   'low density lipoprotein',\n",
       "   'low density lipoprotein',\n",
       "   'injection']},\n",
       " {'pmid': 31484614,\n",
       "  'sentence': 'Results These seven patients included two males and 5 females aged 22 to 77 years(mean,49 years).Headache was the most common symptom.The magnetic resonance imaging of SFT/HPC showed irregularly contoured masses and dural tail sign was observed at the periphery of the lesion in 4 cases.The major axis of the tumor ranged from 1.8 cm to 10 cm(mean,4 cm).The tumors were located in the mater in 6 cases and in the spinal meninx in 1 case.The tumors were surgically removed in all cases.Under light microscope,the tumors were formed by long round,oval or spindle cells,with rich branching vascular pattern and varying quantity of collagenous fibers bands in both sparse areas and dense areas.According the WHO classification,2 cases were in WHO grade â… ,2 cases in WHO grade â…¡,and 3 cases in WHO grade â…¢.Immunohistochemistry of the paraffin-embedded tissues in all cases showed positive immunoreativity for CD34 and vimentin in all seven cases,along with positive signal transducer and activator of transcription 6 in 4 cases,negative epithelial membrane antigen and S-100 in 7 cases,and negative progestational hormone and somatostatin receptor 2 in 6 cases.The Ki-67 index ranged from 1% to 15%.Five patients with follow-up data(including 1 current case)were alive,while 2 patients were lost to follow-up.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['somatostatin'],\n",
       "  'reaction': ['magnetic resonance imaging']},\n",
       " {'pmid': 31499086,\n",
       "  'sentence': 'The results showed that (1) pain stimulation enhanced OXT mRNA expression in the SON at 10\\u202fmin (268.1\\u202fÂ±\\u202f39.2%, p\\u202f<\\u202f0.001) and 20 min (135.4Â±37.9%, p\\u202f<\\u202f0.05) treatment and did not change in the PAG; (2) OXT level increase in SON perfusion liquid during pain stimulation [236.7Â±22.1% at 10 min (p\\u202f<\\u202f0.001), 223.1Â±12.4% at 20 min (p<0.001), 56.1\\u202fÂ±\\u202f15.7% at 30\\u202fmin (p\\u202f<\\u202f0.01) and 11.2Â±14.2% at 40 min] was earlier than that in PAG perfusion liquid [17.8Â±9.7% at 10 min, 375.6Â±35.1% at 20 min (p\\u202f<\\u202f 0.001), 123.2Â±17.7% at 30 min (p\\u202f<\\u202f 0.001) and 52.7Â±22.4% at 40 min (p\\u202f<\\u202f0.05)]; (3) SON excitation (L-glutamate sodium microinjection) induced OXT level increase in PAG perfusion liquid in a dose-dependent manner; (4) the bilateral SON cauterization completely controlled and the right SON cauterization partly reversed the pain stimulation induced-OXT concentration increase in PAG perfusion liquid.',\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['sodium'],\n",
       "  'reaction': ['pain', 'pain', 'pain']},\n",
       " {'pmid': 31634096,\n",
       "  'sentence': \"The key findings include: (1) Vancomycin or fidaxomicin are the first-line treatment for initial Clostridioides difficile infection; (2) Unnecessary supplemental oxygen is linked to increased mortality; aim for a target oxygen saturation of 90%-94% in most hospitalized patients; (3) Stigmatizing language in medical records impacts physician trainees' attitudes and pain management practices; (4) Consider ablation for atrial fibrillation in patients with heart failure; (5) Patients with opioid use disorder should be offered buprenorphine or methadone therapy; (6) Apixaban is safe and may be preferable over warfarin in patients with atrial fibrillation and end-stage kidney disease; (7) It is probably safe to discontinue antimethicillin-resistant Staphylococcus aureus (MRSA) coverage in patients with hospital-acquired pneumonia who are improving and have negative cultures; (8) Selected patients with left-sided endocarditis (excluding MRSA) may switch from intravenous (IV) to oral antibiotics if they are clinically stable after 10 days; (9) Oral antibiotics may be equivalent to IV antibiotics in patients with joint and soft tissue infections; (10) A history-electrocardiogram-age-risk factors-troponin (HEART) score â‰¥4 is a reliable threshold for determining the patients who are at risk for short-term major adverse cardiac events and may warrant further evaluation.\",\n",
       "  'text_type': 'abstract',\n",
       "  'drug_entities': ['cardiac', 'apixaban', 'vancomycin', 'fidaxomicin'],\n",
       "  'reaction': ['infection',\n",
       "   'oxygen saturation',\n",
       "   'oxygen saturation',\n",
       "   'pain',\n",
       "   'pain management',\n",
       "   'atrial fibrillation',\n",
       "   'atrial fibrillation',\n",
       "   'pneumonia',\n",
       "   'endocarditis']}]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sent_counter.long_sents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "number sentences: 2738336\n",
      "long sentences: 459\n",
      "short sentences: 3227\n",
      "many brackets: 110\n",
      "many punctuations 28\n"
     ]
    }
   ],
   "source": [
    "print(\"number sentences:\", sent_counter.total)\n",
    "print(\"long sentences:\", len(sent_counter.long_sents))\n",
    "print(\"short sentences:\", len(sent_counter.short_sents))\n",
    "print(\"many brackets:\", len(sent_counter.many_brackets))\n",
    "print(\"many punctuations\", len(sent_counter.many_punctuations))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "##### Token Number #####\n",
      "range\t\tnumber\n",
      "<= 3\t\t 255\n",
      "4 - 6\t\t 7707\n",
      "7 - 12\t\t 153397\n",
      "13 - 20\t\t 635435\n",
      "21 - 50\t\t 1704329\n",
      "51 - 100\t 225569\n",
      "101 - 200\t 11198\n",
      ">= 201\t\t 446\n"
     ]
    }
   ],
   "source": [
    "max_3_token = 0\n",
    "range_4_to_6 = 0\n",
    "range_7_to_12 = 0\n",
    "range_13_to_20 = 0\n",
    "range_21_to_50 = 0\n",
    "range_51_to_100 = 0\n",
    "range_101_to_200 = 0\n",
    "min_201 = 0\n",
    "\n",
    "for sent_token, count in sent_counter.lengths.items():\n",
    "    \n",
    "    if int(sent_token) <= 3:\n",
    "        max_3_token += count\n",
    "    if 4 <= int(sent_token) <= 6:\n",
    "        range_4_to_6 += count\n",
    "    if 7 <= int(sent_token) <= 12:\n",
    "        range_7_to_12 += count\n",
    "    if 13 <= int(sent_token) <= 20:\n",
    "        range_13_to_20 += count\n",
    "    if 21 <= int(sent_token) <= 50:\n",
    "        range_21_to_50 += count\n",
    "    if 51 <= int(sent_token) <= 100:\n",
    "        range_51_to_100 += count\n",
    "    if 101 <= int(sent_token) <= 200:\n",
    "        range_101_to_200 += count\n",
    "    if  int(sent_token) >= 201:\n",
    "        min_201 += count\n",
    "print(\"##### Token Number #####\")\n",
    "print(\"range\\t\\tnumber\")\n",
    "print(\"<= 3\\t\\t\", max_3_token)\n",
    "print(\"4 - 6\\t\\t\", range_4_to_6)\n",
    "print(\"7 - 12\\t\\t\", range_7_to_12)\n",
    "print(\"13 - 20\\t\\t\", range_13_to_20)\n",
    "print(\"21 - 50\\t\\t\", range_21_to_50)\n",
    "print(\"51 - 100\\t\", range_51_to_100)\n",
    "print(\"101 - 200\\t\", range_101_to_200)\n",
    "print(\">= 201\\t\\t\", min_201)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#### Bracket Number ####\n",
      "range\t\tnumber\n",
      "10 - 20\t\t 52911\n",
      "21-50\t\t 3372\n",
      ">= 50\t\t 94\n"
     ]
    }
   ],
   "source": [
    "range_10_to_20 = 0\n",
    "range_21_to_50 = 0\n",
    "min_51 = 0\n",
    "\n",
    "for brack_num, count in sent_counter.brackets.items():\n",
    "    \n",
    "    if 10 <= int(brack_num) <= 20:\n",
    "        range_10_to_20 += count\n",
    "    if 21 <= int(brack_num) <= 50:\n",
    "        range_21_to_50 += count\n",
    "    if int(brack_num) >= 51:\n",
    "        min_51 += count\n",
    "\n",
    "print(\"#### Bracket Number ####\")\n",
    "print(\"range\\t\\tnumber\")\n",
    "print(\"10 - 20\\t\\t\", range_10_to_20)\n",
    "print(\"21-50\\t\\t\", range_21_to_50)\n",
    "print(\">= 50\\t\\t\", min_51)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#### Punctuation Number ####\n",
      "range\t\tnumber\n",
      "10 - 20\t\t 25643\n",
      "21-50\t\t 1162\n",
      "51-100\t\t 1162\n",
      ">= 101\t\t 28\n"
     ]
    }
   ],
   "source": [
    "range_10_to_20 = 0\n",
    "range_21_to_50 = 0\n",
    "range_51_to_100 = 0\n",
    "min_101 = 0\n",
    "\n",
    "for punc_num, count in sent_counter.punctuation_marks.items():\n",
    "    \n",
    "    if 10 <= int(punc_num) <= 20:\n",
    "        range_10_to_20 += count\n",
    "    if 21 <= int(punc_num) <= 50:\n",
    "        range_21_to_50 += count\n",
    "    if 51 <= int(punc_num) <= 100:\n",
    "        range_51_to_100 += count\n",
    "    if int(punc_num) >= 101:\n",
    "        min_101 += count\n",
    "\n",
    "print(\"#### Punctuation Number ####\")\n",
    "print(\"range\\t\\tnumber\")\n",
    "print(\"10 - 20\\t\\t\", range_10_to_20)\n",
    "print(\"21-50\\t\\t\", range_21_to_50)\n",
    "print(\"51-100\\t\\t\", range_21_to_50)\n",
    "print(\">= 101\\t\\t\", min_101)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "count_ttype = Counter()\n",
    "\n",
    "for index in range(1, 1016):\n",
    "    s_i = str(index)\n",
    "    zeros = \"0\" * (4 - len(s_i))\n",
    "    tagged_sent_file = f\"tagged_pubmed20n{zeros + s_i}.json\"\n",
    "    file_path = os.path.join(tagged_sent_path, tagged_sent_file)\n",
    "    with open(file_path, \"r\") as json_file:\n",
    "        file_data = json.load(json_file)\n",
    "    for sent_data in file_data:\n",
    "        count_ttype[sent_data[\"text_type\"]] += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Counter({'abstract': 2201386, 'title': 536950})"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "count_ttype"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2738336"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sum(count_ttype.values())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "unexpected EOF while parsing (<ipython-input-16-9cffd789f2e2>, line 5)",
     "output_type": "error",
     "traceback": [
      "\u001b[0;36m  File \u001b[0;32m\"<ipython-input-16-9cffd789f2e2>\"\u001b[0;36m, line \u001b[0;32m5\u001b[0m\n\u001b[0;31m    \u001b[0m\n\u001b[0m    ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m unexpected EOF while parsing\n"
     ]
    }
   ],
   "source": [
    "kb_path = os.path.join(\"data\", \"knowledge_base\")\n",
    "kb_file = os.path.join(kb_path, \"rel_drug_react_triple_occ_all.json\")\n",
    "#with open()\n",
    "    "
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
